<s> O None
Inhibition I None
of I None
monoamine I GENE-Y
oxidase O GENE-Y
type O GENE-Y
A O GENE-Y
, I None
but I None
not I None
type I None
B I None
, I None
is I None
an I None
effective I None
means I None
of I None
inducing I None
anticonvulsant I None
activity I None
in I None
the I None
kindling I None
model I None
of I None
epilepsy I None
. I None
<eof> I None

<s> O None
The I None
anticonvulsant I None
activity I None
of I None
inhibitors I None
of I None
monoamine I GENE-N
oxidase O GENE-N
( I None
MAO I GENE-N
) I None
was I None
reported I None
early I None
after I None
the I None
development I None
of I None
irreversible I None
MAO I GENE-N
inhibitors I None
such I None
as I None
tranylcypromine I CHEMICAL
, I None
but I None
was I None
never I None
clinically I None
used I None
because I None
of I None
the I None
adverse I None
effects I None
of I None
these I None
compounds I None
. I None
<eof> I None

<s> O None
The I None
more I None
recently I None
developed I None
reversible I None
MAO I GENE-N
inhibitors I None
with I None
selectivity I None
for I None
either I None
the I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
or I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
isoenzyme I None
forms I None
have I None
not I None
been I None
studied I None
extensively I None
in I None
animal I None
models I None
of I None
epilepsy I None
, I None
so I None
it I None
is I None
not I None
known I None
which I None
type I None
of I None
MAO I GENE-N
inhibitor I None
is I None
particularly I None
effective I None
in I None
this I None
respect I None
. I None
<eof> I None

<s> O None
We I None
compared I None
the I None
following I None
drugs I None
in I None
the I None
kindling I None
model I None
of I None
epilepsy I None
: I None
1 I None
) I None
L I CHEMICAL
- O CHEMICAL
deprenyl O CHEMICAL
( I None
selegiline I CHEMICAL
) I None
, I None
i I None
. I None
e I None
. I None
, I None
an I None
irreversible I None
inhibitor I None
of I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
, I None
which I None
, I None
however I None
, I None
also I None
inhibits I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
at I None
higher I None
doses I None
, I None
2 I None
) I None
the I None
novel I None
reversible I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
inhibitor I None
LU I CHEMICAL
53439 O CHEMICAL
( I None
3 I CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
dimethyl O CHEMICAL
- O CHEMICAL
7 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
isopropyl O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
, O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
thiadiazol O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
yl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
methoxy O CHEMICAL
- O CHEMICAL
coumarin O CHEMICAL
) I None
, I None
which I None
is I None
much I None
more I None
selective I None
for I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
than I None
L I CHEMICAL
- O CHEMICAL
deprenyl O CHEMICAL
, I None
3 I None
) I None
the I None
novel I None
reversible I None
and I None
highly I None
selective I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
inhibitor I None
LU I CHEMICAL
43839 O CHEMICAL
( I None
esuprone I CHEMICAL
; I None
7 I CHEMICAL
- O CHEMICAL
hydroxy O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
dimethylcoumarin O CHEMICAL
ethanesulfonate O CHEMICAL
) I None
, I None
and I None
4 I None
) I None
the I None
irreversible I None
nonselective I None
MAO I GENE-N
inhibitor I None
tranylcypromine I CHEMICAL
. I None
<eof> I None

<s> O None
Esuprone I CHEMICAL
proved I None
to I None
be I None
an I None
effective I None
anticonvulsant I None
in I None
the I None
kindling I None
model I None
with I None
a I None
similar I None
potency I None
as I None
L I CHEMICAL
- O CHEMICAL
deprenyl O CHEMICAL
. I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
esuprone I CHEMICAL
and I None
L I CHEMICAL
- O CHEMICAL
deprenyl O CHEMICAL
, I None
the I None
selective I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
inhibitor I None
LU I CHEMICAL
53439 O CHEMICAL
was I None
not I None
effective I None
in I None
the I None
kindling I None
model I None
; I None
this I None
substantiates I None
the I None
previous I None
notion I None
that I None
the I None
anticonvulsant I None
activity I None
of I None
L I CHEMICAL
- O CHEMICAL
deprenyl O CHEMICAL
is I None
not I None
related I None
to I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
inhibition I None
, I None
but I None
to I None
other I None
effects I None
of I None
this I None
drug I None
, I None
such I None
as I None
inhibition I None
of I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
. I None
<eof> I None

<s> O None
Drugs I None
inhibiting I None
both I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
and I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
to I None
a I None
similar I None
extent I None
( I None
tranylcypromine I CHEMICAL
) I None
or I None
combinations I None
of I None
selective I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
and I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
inhibitors I None
( I None
esuprone I CHEMICAL
plus I None
LU I CHEMICAL
53439 O CHEMICAL
) I None
had I None
no I None
advantage I None
over I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
inhibition I None
alone I None
, I None
but I None
were I None
less I None
well I None
tolerated I None
. I None
<eof> I None

<s> O None
The I None
data I None
thus I None
suggest I None
that I None
selective I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
inhibitors I None
such I None
as I None
esuprone I CHEMICAL
may I None
be I None
an I None
interesting I None
new I None
approach I None
for I None
the I None
treatment I None
of I None
epilepsy I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
mCPP I CHEMICAL
on I None
the I None
extracellular I None
concentrations I None
of I None
serotonin I CHEMICAL
and I None
dopamine I CHEMICAL
in I None
rat I None
brain I None
. I None
<eof> I None

<s> O None
Intravenous I None
administration I None
of I None
m I CHEMICAL
- O CHEMICAL
chloro O CHEMICAL
- O CHEMICAL
phenylpiperazine O CHEMICAL
( I None
mCPP I CHEMICAL
) I None
( I None
0 I None
. I None
25 I None
or I None
2 I None
. I None
5 I None
mg I None
/ I None
kg I None
) I None
induced I None
a I None
marked I None
and I None
dose I None
- I None
related I None
increase I None
in I None
extracellular I None
concentrations I None
of I None
serotonin I None
in I None
hippocampus I None
( I None
300 I None
- I None
1 I None
, I None
400 I None
% I None
of I None
baseline I None
) I None
as I None
measured I None
using I None
in I None
vivo I None
microdialysis I None
in I None
awake I None
male I None
Wistar I None
rats I None
of I None
the I None
spontaneously I None
hypertensive I None
( I None
SH I None
) I None
strain I None
. I None
<eof> I None

<s> O None
Indicating I None
that I None
the I None
effect I None
of I None
mCPP I CHEMICAL
was I None
caused I None
by I None
a I None
reversal I None
of I None
the I None
serotonin I CHEMICAL
transporter I None
, I None
it I None
was I None
antagonized I None
by I None
pretreatment I None
with I None
the I None
serotonin I CHEMICAL
re I None
- I None
uptake I None
inhibitor I None
citalopram I CHEMICAL
( I None
10 I None
mg I None
/ I None
kg I None
) I None
but I None
was I None
unaffected I None
by I None
local I None
administration I None
of I None
the I None
sodium I GENE-N
channel O GENE-N
blocker I None
tetrodotoxin I CHEMICAL
( I None
TTX I CHEMICAL
; I None
1 I None
microns I None
) I None
. I None
<eof> I None

<s> O None
mCPP I CHEMICAL
was I None
also I None
shown I None
to I None
induce I None
an I None
increase I None
in I None
extracellular I None
concentrations I None
of I None
dopamine I CHEMICAL
in I None
the I None
nucleus I None
accumbens I None
and I None
the I None
striatum I None
of I None
SH I None
rats I None
and I None
in I None
the I None
nucleus I None
accumbens I None
of I None
rats I None
of I None
the I None
Sprague I None
- I None
Dawley I None
( I None
SD I None
) I None
strain I None
; I None
this I None
effect I None
of I None
mCPP I CHEMICAL
was I None
, I None
however I None
, I None
much I None
weaker I None
( I None
125 I None
- I None
170 I None
% I None
of I None
baseline I None
) I None
than I None
the I None
effect I None
on I None
serotonin I CHEMICAL
; I None
moreover I None
, I None
it I None
seems I None
to I None
be I None
TTX I CHEMICAL
- I None
sensitive I None
. I None
<eof> I None

<s> O None
In I None
anesthetized I None
SD I None
rats I None
, I None
mCPP I CHEMICAL
induced I None
a I None
moderate I None
reduction I None
of I None
nigral I None
dopamine I None
cell I None
firing I None
rate I None
; I None
supporting I None
the I None
assumption I None
that I None
this I None
effect I None
is I None
secondary I None
to I None
the I None
observed I None
increase I None
in I None
dopamine I CHEMICAL
release I None
, I None
it I None
was I None
blocked I None
by I None
pretreatment I None
either I None
with I None
the I None
dopamine I CHEMICAL
synthesis I None
inhibitor I None
alpha I CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
- O CHEMICAL
para O CHEMICAL
- O CHEMICAL
tyrosine O CHEMICAL
or I None
with I None
the I None
dopamine I GENE-Y
D2 O GENE-Y
receptor O GENE-Y
antagonist I None
haloperidol I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
the I None
results I None
suggest I None
that I None
mCPP I CHEMICAL
induces I None
a I None
marked I None
, I None
TTX I CHEMICAL
- I None
insensitive I None
increase I None
in I None
serotonin I CHEMICAL
release I None
in I None
rat I None
brain I None
, I None
but I None
only I None
a I None
modest I None
and I None
TTX I CHEMICAL
- I None
sensitive I None
increase I None
in I None
the I None
extracellular I None
levels I None
of I None
dopamine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
human I GENE-Y
NADH O GENE-Y
: O GENE-Y
ubiquinone O GENE-Y
oxidoreductase O GENE-Y
NDUFS5 O GENE-Y
( O GENE-Y
15 O GENE-Y
kDa O GENE-Y
) O GENE-Y
subunit O GENE-Y
: I None
cDNA I None
cloning I None
, I None
chromosomal I None
localization I None
, I None
tissue I None
distribution I None
and I None
the I None
absence I None
of I None
mutations I None
in I None
isolated I None
complex I GENE-N
I O GENE-N
- I None
deficient I None
patients I None
. I None
<eof> I None

<s> O None
We I None
have I None
cloned I None
the I None
cDNA I None
of I None
the I None
NDUFS5 I GENE-Y
subunit O GENE-Y
( O GENE-Y
15 O GENE-Y
kDa O GENE-Y
) O GENE-Y
of I None
the I None
human I GENE-N
mitochondrial O GENE-N
respiratory O GENE-N
chain O GENE-N
complex O GENE-N
NADH O GENE-N
: O GENE-N
ubiquinone O GENE-N
oxidoreductase O GENE-N
( O GENE-N
complex O GENE-N
I O GENE-N
) O GENE-N
. I None
<eof> I None

<s> O None
The I None
open I None
reading I None
frame I None
consists I None
of I None
321 I None
base I None
- I None
pairs I None
, I None
coding I None
for I None
106 I None
amino I CHEMICAL
acids O CHEMICAL
, I None
with I None
a I None
calculated I None
molecular I None
mass I None
of I None
12 I None
. I None
5 I None
kDa I None
. I None
<eof> I None

<s> O None
There I None
is I None
an I None
81 I None
. I None
0 I None
% I None
identity I None
with I None
the I None
bovine I None
equivalent I None
on I None
cDNA I None
level I None
and I None
74 I None
. I None
5 I None
% I None
identity I None
on I None
amino I CHEMICAL
acid O CHEMICAL
basis I None
. I None
<eof> I None

<s> O None
PCR I None
analysis I None
of I None
rodent I None
- I None
human I None
somatic I None
cell I None
hybrids I None
revealed I None
that I None
the I None
human I GENE-Y
NDUFS5 O GENE-Y
gene I None
maps I None
to I None
chromosome I None
1 I None
. I None
<eof> I None

<s> O None
The I None
NDUFS5 I GENE-Y
mRNA I None
is I None
expressed I None
ubiquitously I None
in I None
human I None
tissues I None
, I None
with I None
a I None
relative I None
higher I None
expression I None
in I None
human I None
heart I None
, I None
skeletal I None
muscle I None
, I None
liver I None
, I None
kidney I None
and I None
fetal I None
heart I None
. I None
<eof> I None

<s> O None
A I None
mutation I None
detection I None
study I None
of I None
twenty I None
isolated I None
enzymatic I None
complex I GENE-N
I O GENE-N
- I None
deficient I None
patients I None
revealed I None
no I None
mutations I None
, I None
nor I None
polymorphisms I None
. I None
<eof> I None

<s> O None
Participation I None
of I None
beta I GENE-N
- O GENE-N
adrenergic O GENE-N
receptors O GENE-N
on I None
macrophages I None
in I None
modulation I None
of I None
LPS I None
- I None
induced I None
cytokine I GENE-N
release I None
. I None
<eof> I None

<s> O None
For I None
several I None
years I None
it I None
is I None
known I None
that I None
beta I GENE-N
- O GENE-N
adrenergic O GENE-N
receptor O GENE-N
agonists I None
have I None
anti I None
- I None
inflammatory I None
effects I None
. I None
<eof> I None

<s> O None
However I None
, I None
little I None
is I None
known I None
about I None
the I None
role I None
of I None
beta I GENE-N
- O GENE-N
adrenergic O GENE-N
receptors O GENE-N
on I None
macrophages I None
in I None
the I None
modulation I None
of I None
cytokine I GENE-N
production I None
by I None
beta I None
- I None
agonists I None
during I None
inflammation I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
the I None
presence I None
of I None
beta I GENE-N
- O GENE-N
receptors O GENE-N
on I None
PMA I None
- I None
differentiated I None
U937 I None
human I None
macrophages I None
, I None
and I None
the I None
participation I None
of I None
these I None
receptors I None
in I None
the I None
modulation I None
of I None
LPS I None
- I None
mediated I None
cytokine I GENE-N
production I None
by I None
beta I None
- I None
agonists I None
was I None
investigated I None
. I None
<eof> I None

<s> O None
Total I None
beta I GENE-N
- O GENE-N
receptor O GENE-N
expression I None
on I None
undifferentiated I None
( I None
monocyte I None
) I None
and I None
PMA I None
- I None
differentiated I None
U937 I None
cells I None
was I None
established I None
using I None
receptor I None
binding I None
studies I None
on I None
membrane I None
fractions I None
with I None
a I None
radio I None
ligand I None
. I None
<eof> I None

<s> O None
The I None
expression I None
of I None
beta I GENE-N
- O GENE-N
receptors O GENE-N
proved I None
to I None
be I None
significantly I None
lower I None
on I None
monocytes I None
than I None
on I None
macrophages I None
, I None
additionally I None
a I None
predominant I None
expression I None
of I None
beta I GENE-Y
2 O GENE-Y
- O GENE-Y
receptors O GENE-Y
was I None
found I None
. I None
<eof> I None

<s> O None
Production I None
of I None
the I None
cytokines I GENE-N
TNF I GENE-Y
- O GENE-Y
alpha O GENE-Y
, I None
IL I GENE-Y
- O GENE-Y
6 O GENE-Y
, I None
and I None
IL I GENE-Y
- O GENE-Y
10 O GENE-Y
by I None
LPS I None
- I None
stimulated I None
differentiated I None
U937 I None
cells I None
was I None
measured I None
in I None
time I None
. I None
<eof> I None

<s> O None
Peak I None
concentrations I None
for I None
TNF I GENE-Y
- O GENE-Y
alpha O GENE-Y
, I None
IL I GENE-Y
- O GENE-Y
6 O GENE-Y
and I None
IL I GENE-Y
- O GENE-Y
10 O GENE-Y
occurred I None
at I None
3 I None
, I None
12 I None
and I None
9 I None
hrs I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
When I None
differentiated I None
U937 I None
cells I None
were I None
incubated I None
with I None
both I None
LPS I None
and I None
the I None
beta I None
- I None
agonist I None
clenbuterol I CHEMICAL
the I None
production I None
of I None
TNF I GENE-Y
- O GENE-Y
alpha O GENE-Y
and I None
IL I GENE-Y
- O GENE-Y
6 O GENE-Y
was I None
significantly I None
reduced I None
. I None
<eof> I None

<s> O None
However I None
the I None
production I None
of I None
IL I GENE-Y
- O GENE-Y
10 O GENE-Y
was I None
increased I None
. I None
<eof> I None

<s> O None
To I None
study I None
the I None
mechanism I None
of I None
modulation I None
of I None
cytokine I GENE-N
production I None
in I None
more I None
detail I None
, I None
U937 I None
macrophages I None
were I None
incubated I None
with I None
LPS I None
/ I None
clenbuterol I CHEMICAL
in I None
combination I None
with I None
selective I None
beta I None
1 I None
- I None
and I None
beta I None
2 I None
- I None
antagonists I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicated I None
that I None
the I None
beta I None
2 I None
- I None
and I None
not I None
the I None
beta I None
1 I None
- I None
receptor I None
is I None
involved I None
in I None
the I None
anti I None
- I None
inflammatory I None
activity I None
of I None
clenbuterol I CHEMICAL
. I None
<eof> I None

<s> O None
Androgen I CHEMICAL
antagonistic I None
effect I None
of I None
estramustine I CHEMICAL
phosphate O CHEMICAL
( I None
EMP I CHEMICAL
) I None
metabolites I None
on I None
wild I None
- I None
type I None
and I None
mutated I None
androgen I GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
Estramustine I CHEMICAL
phosphate O CHEMICAL
is I None
used I None
frequently I None
, I None
alone I None
or I None
in I None
combination I None
with I None
other I None
antitumor I None
agents I None
, I None
for I None
the I None
treatment I None
of I None
hormone I None
- I None
refractory I None
prostate I None
cancer I None
. I None
<eof> I None

<s> O None
Estramustine I CHEMICAL
phosphate O CHEMICAL
is I None
metabolically I None
activated I None
in I None
vivo I None
, I None
and I None
its I None
metabolites I None
, I None
estramustine I CHEMICAL
, I None
estromustine I CHEMICAL
, I None
estrone I CHEMICAL
, I None
and I None
beta I CHEMICAL
- O CHEMICAL
estradiol O CHEMICAL
inhibit I None
the I None
assembly I None
of I None
microtubules I None
[ I None
for I None
review I None
see I None
: I None
Kreis I None
W I None
, I None
In I None
: I None
Concepts I None
, I None
Mechanisms I None
, I None
and I None
New I None
Targets I None
for I None
Chemotherapy I None
( I None
Ed I None
. I None
Muggia I None
FM I None
) I None
, I None
pp I None
. I None
163 I None
- I None
184 I None
. I None
Kluwer I None
Academic I None
Publishers I None
, I None
Boston I None
, I None
1995 I None
] I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
, I None
by I None
displacement I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
methyltrienolone O CHEMICAL
in I None
the I None
presence I None
of I None
2 I None
. I None
5 I None
mM I None
of I None
triamcinolone I CHEMICAL
acetonide O CHEMICAL
, I None
the I None
binding I None
of I None
estramustine I CHEMICAL
phosphate O CHEMICAL
and I None
its I None
metabolites I None
, I None
estramustine I CHEMICAL
, I None
estromustine I CHEMICAL
, I None
estrone I CHEMICAL
, I None
and I None
beta I CHEMICAL
- O CHEMICAL
estradiol O CHEMICAL
, I None
as I None
well I None
as I None
other I None
antiandrogen I None
agents I None
including I None
alpha I CHEMICAL
- O CHEMICAL
estradiol O CHEMICAL
, I None
bicalutamide I CHEMICAL
, I None
and I None
hydroxyflutamide I CHEMICAL
, I None
to I None
the I None
mutated I None
androgen I GENE-Y
receptor O GENE-Y
( I None
m I None
- I None
AR I GENE-Y
) I None
in I None
LNCaP I None
cells I None
and I None
to I None
the I None
wild I None
- I None
type I None
androgen I GENE-Y
receptor O GENE-Y
in I None
wild I None
- I None
type I None
AR I GENE-Y
cDNA I None
expression I None
plasmid I None
( I None
w I None
- I None
pAR0 I None
) I None
cDNA I None
- I None
transfected I None
HeLa I None
cells I None
. I None
<eof> I None

<s> O None
Analogous I None
to I None
the I None
antiandrogens I None
, I None
bicalutamide I CHEMICAL
and I None
hydroxyflutamide I CHEMICAL
, I None
binding I None
of I None
estramustine I CHEMICAL
phosphate O CHEMICAL
metabolites I None
to I None
the I None
androgen I GENE-Y
receptor O GENE-Y
was I None
observed I None
. I None
<eof> I None

<s> O None
The I None
EC50 I None
values I None
( I None
in I None
microM I None
) I None
were I None
: I None
estramustine I CHEMICAL
phosphate O CHEMICAL
, I None
> I None
10 I None
; I None
estramustine I CHEMICAL
, I None
3 I None
. I None
129 I None
+ I None
/ I None
- I None
0 I None
. I None
312 I None
; I None
estromustine I CHEMICAL
; I None
2 I None
. I None
612 I None
+ I None
/ I None
- I None
0 I None
. I None
584 I None
; I None
estrone I CHEMICAL
, I None
0 I None
. I None
800 I None
+ I None
/ I None
- I None
0 I None
. I None
090 I None
; I None
alpha I CHEMICAL
- O CHEMICAL
estradiol O CHEMICAL
, I None
1 I None
. I None
051 I None
+ I None
/ I None
- I None
0 I None
. I None
096 I None
; I None
beta I CHEMICAL
- O CHEMICAL
estradiol O CHEMICAL
, I None
0 I None
. I None
523 I None
+ I None
/ I None
- I None
0 I None
. I None
028 I None
; I None
bicalutamide I CHEMICAL
, I None
4 I None
. I None
920 I None
+ I None
/ I None
- I None
0 I None
. I None
361 I None
; I None
and I None
hydroxyflutamide I CHEMICAL
, I None
0 I None
. I None
254 I None
+ I None
/ I None
- I None
0 I None
. I None
012 I None
. I None
<eof> I None

<s> O None
The I None
transactivation I None
assay I None
demonstrated I None
that I None
, I None
analogous I None
to I None
bicalutamide I CHEMICAL
, I None
estramustine I CHEMICAL
could I None
not I None
induce I None
luciferase I None
activity I None
in I None
either I None
w I None
- I None
pAR0 I None
or I None
m I None
- I None
pARL I None
transfected I None
HeLa I None
cells I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
a I None
strong I None
induction I None
of I None
the I None
reporter I None
activity I None
by I None
dihydrotestosterone I CHEMICAL
was I None
observed I None
. I None
<eof> I None

<s> O None
Down I None
- I None
regulation I None
of I None
prostate I GENE-Y
- O GENE-Y
specific O GENE-Y
antigen O GENE-Y
( I None
PSA I GENE-Y
) I None
expression I None
, I None
an I None
AR I GENE-Y
- I None
target I None
gene I None
, I None
by I None
estramustine I CHEMICAL
and I None
bicalutamide I CHEMICAL
was I None
accompanied I None
by I None
the I None
blockade I None
of I None
the I None
mutated I None
androgen I GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
Exposure I None
of I None
LNCaP I None
cells I None
to I None
estramustine I CHEMICAL
for I None
24 I None
hr I None
caused I None
transcriptional I None
inhibition I None
of I None
PSA I GENE-Y
in I None
a I None
concentration I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
The I None
levels I None
of I None
PSA I GENE-Y
mRNA I None
decreased I None
56 I None
and I None
90 I None
% I None
when I None
LNCaP I None
cells I None
were I None
treated I None
with I None
5 I None
and I None
10 I None
microM I None
of I None
estramustine I CHEMICAL
, I None
respectively I None
( I None
IC50 I None
= I None
10 I None
. I None
97 I None
+ I None
/ I None
- I None
1 I None
. I None
68 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
Binding I None
of I None
hydroxyflutamide I CHEMICAL
to I None
m I None
- I None
AR I GENE-Y
in I None
LNCaP I None
cells I None
resulted I None
in I None
a I None
concentration I None
- I None
dependent I None
stimulation I None
of I None
PSA I GENE-Y
expression I None
, I None
suggesting I None
that I None
hydroxyflutamide I CHEMICAL
acted I None
as I None
an I None
agonist I None
of I None
the I None
m I None
- I None
AR I GENE-Y
. I None
<eof> I None

<s> O None
Our I None
data I None
indicate I None
that I None
estramustine I CHEMICAL
phosphate O CHEMICAL
metabolites I None
perform I None
as I None
androgen I CHEMICAL
antagonists I None
of I None
AR I GENE-Y
, I None
an I None
additional I None
mechanism I None
involved I None
in I None
the I None
therapeutic I None
effect I None
of I None
estramustine I CHEMICAL
phosphate O CHEMICAL
in I None
patients I None
with I None
prostate I None
cancer I None
. I None
<eof> I None

<s> O None
Determinants I None
of I None
specificity I None
for I None
aflatoxin I CHEMICAL
B1 O CHEMICAL
- O CHEMICAL
8 O CHEMICAL
, O CHEMICAL
9 O CHEMICAL
- O CHEMICAL
epoxide O CHEMICAL
in I None
alpha I GENE-N
- O GENE-N
class O GENE-N
glutathione O GENE-N
S O GENE-N
- O GENE-N
transferases O GENE-N
. I None
<eof> I None

<s> O None
We I None
have I None
used I None
homology I None
modelling I None
, I None
based I None
on I None
the I None
crystal I None
structure I None
of I None
the I None
human I GENE-Y
glutathione O GENE-Y
S O GENE-Y
- O GENE-Y
transferase O GENE-Y
( O GENE-Y
GST O GENE-Y
) O GENE-Y
A1 O GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
to I None
obtain I None
the I None
three I None
- I None
dimensional I None
structures I None
of I None
rat I GENE-Y
GSTA3 O GENE-Y
and I None
rat I GENE-Y
GSTA5 O GENE-Y
subunits I None
bound I None
to I None
S I CHEMICAL
- O CHEMICAL
aflatoxinyl O CHEMICAL
- O CHEMICAL
glutathione O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
resulting I None
models I None
highlight I None
two I None
residues I None
, I None
at I None
positions I None
208 I None
and I None
108 I None
, I None
that I None
could I None
be I None
important I None
for I None
determining I None
, I None
either I None
directly I None
or I None
indirectly I None
, I None
substrate I None
specificity I None
for I None
aflatoxin I CHEMICAL
- O CHEMICAL
exo O CHEMICAL
- O CHEMICAL
8 O CHEMICAL
, O CHEMICAL
9 O CHEMICAL
- O CHEMICAL
epoxide O CHEMICAL
among I None
the I None
Alpha I GENE-N
- O GENE-N
class O GENE-N
GSTs O GENE-N
. I None
<eof> I None

<s> O None
Residues I None
at I None
these I None
positions I None
were I None
mutated I None
in I None
human I GENE-Y
GSTA1 O GENE-Y
- O GENE-Y
1 O GENE-Y
( I None
Met I None
- I None
208 I None
, I None
Leu I None
- I None
108 I None
) I None
, I None
rat I GENE-Y
GSTA3 O GENE-Y
- O GENE-Y
3 O GENE-Y
( I None
Glu I None
- I None
208 I None
, I None
His I None
- I None
108 I None
) I None
and I None
rat I GENE-Y
GSTA5 O GENE-Y
- O GENE-Y
5 O GENE-Y
( I None
Asp I None
- I None
208 I None
, I None
Tyr I None
- I None
108 I None
) I None
: I None
in I None
the I None
active I None
rat I GENE-Y
GSTA5 O GENE-Y
- O GENE-Y
5 O GENE-Y
to I None
those I None
in I None
the I None
inactive I None
GSTA1 I GENE-Y
- O GENE-Y
1 O GENE-Y
; I None
and I None
in I None
the I None
inactive I None
human I GENE-Y
GSTA1 O GENE-Y
- O GENE-Y
1 O GENE-Y
and I None
rat I GENE-Y
GSTA3 O GENE-Y
- O GENE-Y
3 O GENE-Y
to I None
those I None
in I None
the I None
active I None
rat I GENE-Y
GSTA5 O GENE-Y
- O GENE-Y
5 O GENE-Y
. I None
<eof> I None

<s> O None
These I None
studies I None
show I None
clearly I None
that I None
, I None
in I None
all I None
three I None
GSTs I GENE-N
, I None
an I None
aspartate I None
residue I None
at I None
position I None
208 I None
is I None
a I None
prerequisite I None
for I None
high I None
activity I None
in I None
aflatoxin I CHEMICAL
- O CHEMICAL
exo O CHEMICAL
- O CHEMICAL
8 O CHEMICAL
, O CHEMICAL
9 O CHEMICAL
- O CHEMICAL
epoxide O CHEMICAL
conjugation I None
, I None
although I None
this I None
alone I None
is I None
not I None
sufficient I None
; I None
other I None
residues I None
in I None
the I None
vicinity I None
, I None
particularly I None
residues I None
103 I None
- I None
112 I None
, I None
are I None
important I None
, I None
perhaps I None
for I None
the I None
optimal I None
orientation I None
of I None
the I None
aflatoxin I CHEMICAL
- O CHEMICAL
exo O CHEMICAL
- O CHEMICAL
8 O CHEMICAL
, O CHEMICAL
9 O CHEMICAL
- O CHEMICAL
epoxide O CHEMICAL
in I None
the I None
active I None
site I None
for I None
catalysis I None
to I None
occur I None
. I None
<eof> I None

<s> O None
Static I None
Laue I None
diffraction I None
studies I None
on I None
acetylcholinesterase I GENE-Y
. I None
<eof> I None

<s> O None
Acetylcholinesterase I GENE-Y
( I None
AChE I GENE-Y
) I None
is I None
one I None
of I None
nature I None
' I None
s I None
fastest I None
enzymes I None
, I None
despite I None
the I None
fact I None
that I None
its I None
three I None
- I None
dimensional I None
structure I None
reveals I None
its I None
active I None
site I None
to I None
be I None
deeply I None
sequestered I None
within I None
the I None
molecule I None
. I None
<eof> I None

<s> O None
This I None
raises I None
questions I None
with I None
respect I None
to I None
traffic I None
of I None
substrate I None
to I None
, I None
and I None
products I None
from I None
, I None
the I None
active I None
site I None
, I None
which I None
may I None
be I None
investigated I None
by I None
time I None
- I None
resolved I None
crystallography I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
address I None
one I None
aspect I None
of I None
the I None
feasibility I None
of I None
performing I None
time I None
- I None
resolved I None
studies I None
on I None
AChE I GENE-Y
, I None
a I None
data I None
set I None
has I None
been I None
collected I None
using I None
the I None
Laue I None
technique I None
on I None
a I None
trigonal I None
crystal I None
of I None
Torpedo I GENE-Y
californica O GENE-Y
AChE O GENE-Y
soaked I None
with I None
the I None
reversible I None
inhibitor I None
edrophonium I CHEMICAL
, I None
using I None
a I None
total I None
X I None
- I None
ray I None
exposure I None
time I None
of I None
24 I None
ms I None
. I None
<eof> I None

<s> O None
Electron I None
- I None
density I None
maps I None
obtained I None
from I None
the I None
Laue I None
data I None
, I None
which I None
are I None
of I None
surprisingly I None
good I None
quality I None
compared I None
with I None
similar I None
maps I None
from I None
monochromatic I None
data I None
, I None
show I None
essentially I None
the I None
same I None
features I None
. I None
<eof> I None

<s> O None
They I None
clearly I None
reveal I None
the I None
bound I None
ligand I None
, I None
as I None
well I None
as I None
a I None
structural I None
change I None
in I None
the I None
conformation I None
of I None
the I None
active I None
- I None
site I None
Ser200 I None
induced I None
upon I None
binding I None
. I None
<eof> I None

<s> O None
YAP1 I GENE-Y
confers I None
resistance I None
to I None
the I None
fatty I GENE-N
acid O GENE-N
synthase O GENE-N
inhibitor I None
cerulenin I CHEMICAL
through I None
the I None
transporter I GENE-Y
Flr1p O GENE-Y
in I None
Saccharomyces I None
cerevisiae I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
utilized I None
a I None
genetic I None
approach I None
to I None
identify I None
genes I None
which I None
render I None
yeast I None
cells I None
resistant I None
to I None
cerulenin I CHEMICAL
( I None
Cer I CHEMICAL
) I None
, I None
a I None
potent I None
and I None
noncompetitive I None
inhibitor I None
of I None
fatty I GENE-N
acid O GENE-N
synthase O GENE-N
( I None
FAS I GENE-N
) I None
. I None
<eof> I None

<s> O None
Overexpression I None
of I None
the I None
yeast I None
transcription I None
factor I None
Yap1p I GENE-Y
was I None
found I None
to I None
confer I None
Cer I CHEMICAL
resistance I None
( I None
CerR I None
) I None
. I None
<eof> I None

<s> O None
This I None
resistance I None
was I None
shown I None
to I None
be I None
less I None
pronounced I None
in I None
a I None
strain I None
deleted I None
for I None
YCF1 I GENE-Y
, I None
a I None
multidrug I None
resistance I None
ABC I GENE-N
transporter O GENE-N
, I None
supporting I None
previous I None
observations I None
that I None
implicated I None
YCF1 I GENE-Y
in I None
mediating I None
CerR I None
. I None
<eof> I None

<s> O None
However I None
, I None
isolation I None
of I None
YAP1 I GENE-Y
as I None
a I None
high I None
- I None
copy I None
CerR I None
gene I None
in I None
a I None
ycf1delta I GENE-Y
strain I None
suggested I None
that I None
YAP1 I GENE-Y
- I None
induced I None
CerR I None
was I None
mediated I None
by I None
additional I None
downstream I None
effectors I None
. I None
<eof> I None

<s> O None
Overexpression I None
of I None
neither I None
glutathione I GENE-Y
reductase O GENE-Y
nor I None
a I None
predicted I None
aryl I GENE-N
alcohol O GENE-N
dehydrogenase O GENE-N
( I None
the I None
products I None
of I None
two I None
YAP1 I GENE-Y
- I None
regulated I None
genes I None
involved I None
in I None
detoxification I None
) I None
conferred I None
CerR I None
. I None
<eof> I None

<s> O None
Overexpression I None
of I None
ATR1 I GENE-Y
, I None
another I None
YAP1 I GENE-Y
- I None
regulated I None
gene I None
previously I None
implicated I None
in I None
conferring I None
resistance I None
to I None
a I None
number I None
of I None
cytotoxic I None
drugs I None
, I None
was I None
also I None
incapable I None
of I None
making I None
cells I None
resistant I None
to I None
Cer I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
overexpression I None
of I None
Flr1p I GENE-Y
, I None
a I None
yeast I None
transporter I None
of I None
the I None
major I None
facilitator I None
superfamily I None
which I None
is I None
also I None
under I None
the I None
control I None
of I None
YAP1 I GENE-Y
, I None
was I None
sufficient I None
to I None
confer I None
CerR I None
in I None
an I None
otherwise I None
wild I None
- I None
type I None
background I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
CerR I None
was I None
markedly I None
diminished I None
in I None
a I None
strain I None
deleted I None
for I None
FLR1 I GENE-Y
. I None
<eof> I None

<s> O None
These I None
findings I None
implicate I None
members I None
of I None
both I None
of I None
the I None
transporter I None
superfamilies I None
involved I None
in I None
multiple I None
drug I None
resistance I None
( I None
MDR I None
) I None
in I None
the I None
acquisition I None
of I None
CerR I None
in I None
yeast I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
our I None
studies I None
indicate I None
that I None
yeast I None
may I None
be I None
a I None
useful I None
model I None
system I None
in I None
which I None
to I None
investigate I None
the I None
role I None
of I None
FAS I GENE-N
in I None
cancer I None
biology I None
and I None
the I None
effects I None
of I None
Cer I CHEMICAL
on I None
eukaryotic I None
cell I None
growth I None
. I None
<eof> I None

<s> O None
Mortality I None
risk I None
in I None
men I None
is I None
associated I None
with I None
a I None
common I None
mutation I None
in I None
the I None
methylene I GENE-Y
- O GENE-Y
tetrahydrofolate O GENE-Y
reductase O GENE-Y
gene I None
( I None
MTHFR I GENE-Y
) I None
. I None
<eof> I None

<s> O None
An I None
elevated I None
level I None
of I None
homocysteine I CHEMICAL
in I None
plasma I None
is I None
associated I None
with I None
the I None
occurrence I None
of I None
cardiovascular I None
disease I None
. I None
<eof> I None

<s> O None
A I None
common I None
ala I None
- I None
to I None
- I None
val I None
mutation I None
in I None
the I None
methylenetetrahydrofolate I GENE-Y
reductase O GENE-Y
gene O GENE-Y
( I None
MTHFR I GENE-Y
) I None
is I None
associated I None
with I None
an I None
elevated I None
level I None
of I None
plasma I None
homocysteine I CHEMICAL
. I None
<eof> I None

<s> O None
We I None
studied I None
the I None
possible I None
detrimental I None
effects I None
of I None
the I None
MTHFR I GENE-Y
mutation I None
on I None
mortality I None
. I None
<eof> I None

<s> O None
Within I None
a I None
population I None
- I None
based I None
study I None
in I None
the I None
city I None
of I None
Leiden I None
, I None
the I None
Netherlands I None
, I None
we I None
first I None
compared I None
the I None
MTHFR I GENE-Y
genotype I None
distribution I None
among I None
365 I None
elderly I None
subjects I None
aged I None
85 I None
years I None
and I None
over I None
born I None
in I None
Leiden I None
, I None
and I None
250 I None
young I None
subjects I None
aged I None
18 I None
to I None
40 I None
years I None
whose I None
families I None
originated I None
from I None
the I None
same I None
geographical I None
region I None
. I None
<eof> I None

<s> O None
Second I None
, I None
the I None
complete I None
cohort I None
of I None
666 I None
subjects I None
aged I None
85 I None
years I None
and I None
over I None
was I None
followed I None
over I None
a I None
period I None
of I None
10 I None
years I None
for I None
all I None
- I None
cause I None
and I None
cause I None
- I None
specific I None
mortality I None
and I None
stratified I None
according I None
to I None
MTHFR I GENE-Y
genotype I None
. I None
<eof> I None

<s> O None
The I None
frequency I None
of I None
the I None
MTHFR I GENE-Y
mutation I None
was I None
significantly I None
lower I None
in I None
the I None
elderly I None
than I None
in I None
the I None
young I None
( I None
0 I None
. I None
30 I None
and I None
0 I None
. I None
36 I None
, I None
respectively I None
; I None
P I None
= I None
0 I None
. I None
03 I None
) I None
. I None
<eof> I None

<s> O None
The I None
difference I None
in I None
genotype I None
distribution I None
was I None
only I None
present I None
in I None
men I None
. I None
<eof> I None

<s> O None
The I None
estimated I None
mortality I None
risk I None
up I None
to I None
85 I None
years I None
in I None
men I None
carrying I None
the I None
vallval I None
genotype I None
was I None
3 I None
. I None
7 I None
( I None
95 I None
% I None
confidence I None
interval I None
( I None
CI I None
) I None
, I None
1 I None
. I None
3 I None
- I None
10 I None
. I None
9 I None
) I None
. I None
<eof> I None

<s> O None
Over I None
the I None
age I None
of I None
85 I None
, I None
mortality I None
in I None
men I None
with I None
the I None
vallval I None
genotype I None
was I None
increased I None
2 I None
. I None
0 I None
- I None
fold I None
( I None
95 I None
% I None
CI I None
, I None
1 I None
. I None
1 I None
- I None
3 I None
. I None
9 I None
) I None
and I None
appeared I None
to I None
be I None
attributable I None
to I None
cancer I None
rather I None
than I None
cardiovascular I None
causes I None
of I None
death I None
. I None
<eof> I None

<s> O None
Among I None
women I None
aged I None
85 I None
years I None
and I None
over I None
, I None
no I None
deleterious I None
effect I None
of I None
the I None
MTHFR I GENE-Y
mutation I None
was I None
observed I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
the I None
MTHFR I GENE-Y
mutation I None
is I None
associated I None
with I None
increased I None
mortality I None
in I None
men I None
in I None
middle I None
and I None
old I None
age I None
, I None
but I None
not I None
in I None
women I None
. I None
<eof> I None

<s> O None
The I None
NDUFA1 I GENE-Y
gene I None
product I None
( I None
MWFE I GENE-Y
protein I None
) I None
is I None
essential I None
for I None
activity I None
of I None
complex I GENE-N
I O GENE-N
in I None
mammalian I None
mitochondria I None
. I None
<eof> I None

<s> O None
The I None
MWFE I GENE-Y
polypeptide I None
of I None
mammalian I GENE-N
complex O GENE-N
I O GENE-N
( I None
the I None
proton I None
- I None
translocating I None
NADH I GENE-N
- O GENE-N
quinone O GENE-N
oxidoreductase O GENE-N
) I None
is I None
70 I None
amino I CHEMICAL
acids O CHEMICAL
long I None
, I None
and I None
it I None
is I None
predicted I None
to I None
be I None
a I None
membrane I None
protein I None
. I None
<eof> I None

<s> O None
The I None
NDUFA1 I GENE-Y
gene I None
encoding I None
the I None
MWFE I GENE-Y
polypeptide I None
is I None
located I None
on I None
the I None
X I None
chromosome I None
. I None
<eof> I None

<s> O None
This I None
polypeptide I None
is I None
1 I None
of I None
approximately I None
28 I None
" I None
accessory I None
proteins I None
" I None
identified I None
in I None
complex I GENE-N
I O GENE-N
, I None
which I None
is I None
composed I None
of I None
42 I None
unlike I None
subunits I None
. I None
<eof> I None

<s> O None
It I None
was I None
considered I None
accessory I None
, I None
because I None
it I None
is I None
not I None
one I None
of I None
the I None
14 I None
polypeptides I None
making I None
up I None
the I None
core I None
complex I GENE-N
I O GENE-N
; I None
a I None
homologous I None
set I None
of I None
14 I None
polypeptides I None
can I None
make I None
a I None
fully I None
functional I None
proton I None
- I None
translocating I None
NADH I GENE-N
- O GENE-N
quinone O GENE-N
oxidoreductase O GENE-N
in I None
prokaryotes I None
. I None
<eof> I None

<s> O None
One I None
MWFE I GENE-Y
mutant I None
has I None
been I None
identified I None
and I None
isolated I None
from I None
a I None
collection I None
of I None
respiration I None
- I None
deficient I None
Chinese I None
hamster I None
cell I None
mutants I None
. I None
<eof> I None

<s> O None
The I None
CCL16 I None
- I None
B2 I None
mutant I None
has I None
suffered I None
a I None
deletion I None
that I None
would I None
produce I None
a I None
truncated I None
and I None
abnormal I None
MWFE I GENE-Y
protein I None
. I None
<eof> I None

<s> O None
In I None
these I None
mutant I None
cells I None
, I None
complex I GENE-N
I O GENE-N
activity I None
is I None
reduced I None
severely I None
( I None
< I None
10 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Complementation I None
with I None
hamster I GENE-Y
NDUFA1 O GENE-Y
cDNA I None
restored I None
the I None
rotenone I CHEMICAL
- I None
sensitive I None
complex I GENE-N
I O GENE-N
activity I None
of I None
these I None
mutant I None
cells I None
to I None
approximately I None
100 I None
% I None
of I None
the I None
parent I None
cell I None
activity I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
it I None
is I None
established I None
that I None
the I None
MWFE I GENE-Y
polypeptide I None
is I None
absolutely I None
essential I None
for I None
an I None
active I None
complex I GENE-N
I O GENE-N
in I None
mammals I None
. I None
<eof> I None

<s> O None
Synthesis I None
of I None
thrombin I GENE-Y
- I None
inhibiting I None
heparin I None
mimetics I None
without I None
side I None
effects I None
. I None
<eof> I None

<s> O None
Unwanted I None
side I None
effects I None
of I None
pharmacologically I None
active I None
compounds I None
can I None
usually I None
be I None
eliminated I None
by I None
structural I None
modifications I None
. I None
<eof> I None

<s> O None
But I None
the I None
complex I None
heterogeneous I None
structure I None
of I None
the I None
polysaccharide I None
heparin I None
has I None
limited I None
this I None
approach I None
to I None
fragmentation I None
, I None
leading I None
to I None
slightly I None
better I None
- I None
tolerated I None
heparin I None
preparations I None
of I None
low I None
molecular I None
mass I None
. I None
<eof> I None

<s> O None
Despite I None
this I None
improvement I None
, I None
heparin I None
- I None
induced I None
thrombocytopaenia I None
( I None
HIT I None
) I None
, I None
related I None
to I None
an I None
interaction I None
with I None
platelet I GENE-Y
factor O GENE-Y
4 O GENE-Y
( I None
PF4 I GENE-Y
) I None
and I None
, I None
to I None
a I None
lesser I None
extent I None
, I None
haemorrhages I None
, I None
remain I None
significant I None
side I None
effects I None
of I None
heparinotherapy I None
. I None
<eof> I None

<s> O None
Breakthroughs I None
in I None
oligosaccharide I None
chemistry I None
made I None
possible I None
the I None
total I None
synthesis I None
of I None
the I None
pentasaccharide I None
antithrombin I GENE-Y
- I None
binding I None
site I None
of I None
heparin I None
. I None
<eof> I None

<s> O None
This I None
pentasaccharide I None
represents I None
a I None
new I None
family I None
of I None
potential I None
antithrombotic I None
drugs I None
, I None
devoid I None
of I None
thrombin I GENE-Y
inhibitory I None
properties I None
, I None
and I None
free I None
of I None
undesired I None
interactions I None
with I None
blood I None
and I None
vessel I None
components I None
. I None
<eof> I None

<s> O None
To I None
obtain I None
more I None
potent I None
and I None
well I None
- I None
tolerated I None
antithrombotic I None
drugs I None
, I None
we I None
wished I None
to I None
synthesize I None
heparin I None
mimetics I None
able I None
to I None
inhibit I None
thrombin I GENE-Y
, I None
that I None
is I None
, I None
longer I None
oligosaccharides I None
. I None
<eof> I None

<s> O None
Like I None
thrombin I GENE-Y
inhibition I None
, I None
undesired I None
interactions I None
are I None
directly I None
correlated I None
to I None
the I None
charge I None
and I None
the I None
size I None
of I None
the I None
molecules I None
, I None
so I None
we I None
had I None
to I None
design I None
structures I None
that I None
were I None
able I None
to I None
discriminate I None
between I None
thrombin I GENE-Y
and I None
other I None
proteins I None
, I None
particularly I None
PF4 I GENE-Y
. I None
<eof> I None

<s> O None
Here I None
we I None
describe I None
the I None
use I None
of I None
multistep I None
converging I None
synthesis I None
to I None
obtain I None
sulphated I None
oligosaccharides I None
that I None
meet I None
these I None
requirements I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
candesartan I CHEMICAL
and I None
cilazapril I CHEMICAL
on I None
rats I None
with I None
myocardial I None
infarction I None
assessed I None
by I None
echocardiography I None
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
this I None
study I None
was I None
to I None
compare I None
the I None
angiotensin I GENE-N
II O GENE-N
type O GENE-N
1 O GENE-N
receptor O GENE-N
antagonist I None
candesartan I CHEMICAL
cilexitil O CHEMICAL
( I None
candesartan I CHEMICAL
) I None
and I None
the I None
angiotensin I GENE-Y
- O GENE-Y
converting O GENE-Y
enzyme O GENE-Y
inhibitor I None
cilazapril I CHEMICAL
on I None
cardiac I None
function I None
, I None
assessed I None
by I None
Doppler I None
echocardiography I None
and I None
cardiac I None
gene I None
expression I None
associated I None
with I None
cardiac I None
remodeling I None
, I None
in I None
rats I None
with I None
myocardial I None
infarction I None
. I None
<eof> I None

<s> O None
Candesartan I CHEMICAL
or I None
cilazapril I CHEMICAL
was I None
administered I None
after I None
myocardial I None
infarction I None
. I None
<eof> I None

<s> O None
At I None
1 I None
and I None
4 I None
weeks I None
after I None
myocardial I None
infarction I None
, I None
cardiac I None
function I None
and I None
mRNA I None
expression I None
in I None
noninfarcted I None
myocardium I None
were I None
analyzed I None
. I None
<eof> I None

<s> O None
Candesartan I CHEMICAL
and I None
cilazapril I CHEMICAL
equally I None
prevented I None
increases I None
in I None
hypertrophy I None
in I None
noninfarcted I None
myocardium I None
, I None
left I None
ventricular I None
dilatation I None
, I None
and I None
ejection I None
fraction I None
at I None
4 I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
E I None
- I None
wave I None
/ I None
A I None
- I None
wave I None
velocity I None
ratio I None
and I None
the I None
rate I None
of I None
E I None
- I None
wave I None
deceleration I None
, I None
measures I None
of I None
diastolic I None
function I None
, I None
increased I None
to I None
9 I None
. I None
2 I None
+ I None
/ I None
- I None
0 I None
. I None
6 I None
and I None
26 I None
. I None
3 I None
+ I None
/ I None
- I None
2 I None
. I None
<eof> I None

<s> O None
6 I None
m I None
/ I None
s2 I None
at I None
1 I None
week I None
after I None
myocardial I None
infarction I None
. I None
<eof> I None

<s> O None
Candesartan I CHEMICAL
and I None
cilazapril I CHEMICAL
, I None
administered I None
at I None
a I None
dose I None
of I None
1 I None
mg I None
/ I None
kg I None
per I None
day I None
, I None
prevented I None
increases I None
in I None
E I None
- I None
wave I None
/ I None
A I None
- I None
wave I None
velocity I None
ratio I None
and I None
E I None
- I None
wave I None
deceleration I None
at I None
1 I None
and I None
4 I None
weeks I None
. I None
<eof> I None

<s> O None
Candesartan I CHEMICAL
and I None
cilazapril I CHEMICAL
significantly I None
suppressed I None
increased I None
mRNA I None
expression I None
of I None
beta I GENE-Y
- O GENE-Y
myosin O GENE-Y
heavy O GENE-Y
chain O GENE-Y
, I None
alpha I GENE-Y
- O GENE-Y
skeletal O GENE-Y
actin O GENE-Y
, I None
and I None
atrial I GENE-Y
natriuretic O GENE-Y
peptide O GENE-Y
in I None
noninfarcted I None
ventricle I None
at I None
1 I None
and I None
4 I None
weeks I None
and I None
expression I None
of I None
collagen I GENE-N
I O GENE-N
and O GENE-N
III O GENE-N
at I None
4 I None
weeks I None
to I None
a I None
similar I None
extent I None
. I None
<eof> I None

<s> O None
When I None
given I None
at I None
a I None
dose I None
of I None
10 I None
mg I None
/ I None
kg I None
per I None
day I None
, I None
both I None
candesartan I CHEMICAL
and I None
cilazapril I CHEMICAL
prevented I None
cardiac I None
dysfunction I None
and I None
gene I None
expression I None
to I None
the I None
same I None
extent I None
as I None
when I None
given I None
at I None
1 I None
mg I None
/ I None
kg I None
per I None
day I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
Doppler I None
echocardiography I None
showed I None
that I None
candesartan I CHEMICAL
and I None
cilazapril I CHEMICAL
equally I None
improved I None
systolic I None
and I None
diastolic I None
function I None
and I None
that I None
ventricular I None
remodeling I None
accompanied I None
modulation I None
of I None
cardiac I None
gene I None
expression I None
. I None
<eof> I None

<s> O None
Genetic I None
causes I None
of I None
mild I None
hyperhomocysteinemia I None
in I None
patients I None
with I None
premature I None
occlusive I None
coronary I None
artery I None
diseases I None
. I None
<eof> I None

<s> O None
Elevated I None
plasma I None
homocysteine I CHEMICAL
is I None
increasingly I None
being I None
recognized I None
as I None
a I None
risk I None
factor I None
for I None
coronary I None
artery I None
disease I None
( I None
CAD I None
) I None
. I None
<eof> I None

<s> O None
Although I None
there I None
is I None
general I None
agreement I None
on I None
the I None
importance I None
of I None
micronutrients I None
and I None
genetic I None
predisposition I None
to I None
elevated I None
plasma I None
homocysteine I CHEMICAL
, I None
the I None
exact I None
influence I None
of I None
the I None
known I None
prevalent I None
mutations I None
in I None
genes I None
which I None
regulate I None
homocysteine I CHEMICAL
metabolism I None
is I None
not I None
clear I None
. I None
<eof> I None

<s> O None
We I None
studied I None
376 I None
cases I None
of I None
individuals I None
with I None
premature I None
CAD I None
with I None
respect I None
to I None
their I None
fasting I None
and I None
post I None
- I None
methionine I CHEMICAL
load I None
( I None
PML I None
) I None
total I None
homocysteine I CHEMICAL
( I None
tHcy I CHEMICAL
) I None
concentrations I None
. I None
<eof> I None

<s> O None
We I None
also I None
determined I None
the I None
presence I None
or I None
absence I None
of I None
the I None
T833C I GENE-N
and I None
G919A I GENE-N
mutations I None
of I None
the I None
cystathionine I GENE-Y
- O GENE-Y
beta O GENE-Y
- O GENE-Y
synthase O GENE-Y
( I None
CBS I GENE-Y
) I None
gene I None
, I None
the I None
C677T I GENE-N
mutation I None
of I None
the I None
methylene I GENE-Y
tetrahydrofolate O GENE-Y
reductase O GENE-Y
( I None
MTHFR I GENE-Y
) I None
gene I None
, I None
and I None
the I None
A2756G I GENE-N
transition I None
of I None
the I None
B12 I None
dependent I None
methionine I GENE-Y
synthase O GENE-Y
( I None
MS I GENE-Y
) I None
gene I None
. I None
<eof> I None

<s> O None
Our I None
objectives I None
were I None
therefore I None
both I None
to I None
confirm I None
the I None
relationship I None
of I None
plasma I None
homocysteine I CHEMICAL
with I None
premature I None
CAD I None
and I None
to I None
examine I None
the I None
importance I None
of I None
genetic I None
influence I None
on I None
both I None
fasting I None
and I None
PML I None
homocysteine I CHEMICAL
. I None
<eof> I None

<s> O None
Approximately I None
32 I None
% I None
of I None
the I None
CAD I None
patients I None
had I None
fasting I None
hyperhomocysteinemia I None
and I None
16 I None
% I None
had I None
PML I None
hyperhomocysteinemia I None
. I None
<eof> I None

<s> O None
Of I None
these I None
, I None
8 I None
. I None
5 I None
% I None
had I None
both I None
forms I None
of I None
hyperhomocysteinemia I None
( I None
combined I None
hyperhomocysteinemia I None
) I None
. I None
<eof> I None

<s> O None
The I None
T133C I GENE-N
mutation I None
in I None
the I None
CBS I GENE-Y
gene I None
and I None
the I None
thermolabile I None
C677T I GENE-N
mutation I None
in I None
the I None
MTHFR I GENE-Y
gene I None
seem I None
to I None
play I None
an I None
important I None
role I None
in I None
the I None
subset I None
of I None
individuals I None
with I None
combined I None
hyperhomocysteinemia I None
. I None
<eof> I None

<s> O None
The I None
A2756G I GENE-N
transition I None
in I None
the I None
MS I GENE-Y
gene I None
is I None
not I None
associated I None
with I None
elevated I None
plasma I None
tHcy I CHEMICAL
. I None
<eof> I None

<s> O None
Many I None
cases I None
( I None
47 I None
% I None
) I None
of I None
hyperhomocysteinemia I None
are I None
not I None
associated I None
with I None
micronutrient I None
deficiencies I None
, I None
impaired I None
renal I None
function I None
, I None
and I None
/ I None
or I None
currently I None
known I None
genetic I None
mutations I None
. I None
<eof> I None

<s> O None
Further I None
work I None
is I None
needed I None
to I None
study I None
whether I None
unknown I None
mutations I None
, I None
particularly I None
those I None
residing I None
in I None
the I None
intronic I None
sequences I None
of I None
the I None
genes I None
involved I None
in I None
homocysteine I CHEMICAL
metabolism I None
, I None
other I None
environmental I None
factors I None
, I None
or I None
interaction I None
of I None
gene I None
, I None
nutrient I None
, I None
and I None
environmental I None
factors I None
may I None
be I None
the I None
cause I None
of I None
currently I None
unexplained I None
cases I None
of I None
mild I None
hyperhomocysteinemia I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
bis I CHEMICAL
( O CHEMICAL
7 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
tacrine O CHEMICAL
, I None
a I None
novel I None
anti I None
- I None
Alzheimer I None
' I None
s I None
agent I None
, I None
on I None
rat I GENE-Y
brain O GENE-Y
AChE O GENE-Y
. I None
<eof> I None

<s> O None
The I None
anticholinesterase I None
effects I None
of I None
bis I CHEMICAL
( O CHEMICAL
7 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
tacrine O CHEMICAL
were I None
compared I None
with I None
tacrine I CHEMICAL
in I None
vitro I None
and I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Based I None
on I None
IC50 I None
ratios I None
, I None
the I None
dimeric I None
analog I None
bis I CHEMICAL
( O CHEMICAL
7 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
tacrine O CHEMICAL
was I None
, I None
in I None
a I None
reversible I None
manner I None
, I None
up I None
to I None
150 I None
- I None
fold I None
more I None
potent I None
and I None
250 I None
- I None
fold I None
more I None
selective I None
than I None
tacrine I CHEMICAL
for I None
acetylcholinesterase I GENE-Y
( I None
AChE I GENE-Y
) I None
over I None
butyrylcholinesterase I GENE-Y
( I None
BChE I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Following I None
a I None
single I None
oral I None
administration I None
, I None
both I None
bis I CHEMICAL
( O CHEMICAL
7 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
tacrine O CHEMICAL
and I None
tacrine I CHEMICAL
produced I None
dose I None
- I None
dependent I None
inhibitions I None
of I None
AChE I GENE-Y
in I None
rat I None
brain I None
, I None
but I None
bis I CHEMICAL
( O CHEMICAL
7 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
tacrine O CHEMICAL
exhibited I None
higher I None
efficacy I None
and I None
AChE I GENE-Y
/ I None
BChE I GENE-Y
selectivity I None
than I None
tacrine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
anti I None
- I None
AChE I GENE-Y
efficacy I None
of I None
bis I CHEMICAL
( O CHEMICAL
7 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
tacrine O CHEMICAL
was I None
quite I None
similar I None
following I None
an I None
oral I None
or I None
i I None
. I None
p I None
. I None
administration I None
, I None
but I None
tacrine I CHEMICAL
showed I None
much I None
lower I None
efficacy I None
when I None
administered I None
orally I None
than I None
when I None
given I None
i I None
. I None
p I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
bis I CHEMICAL
( O CHEMICAL
7 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
tacrine O CHEMICAL
, I None
a I None
highly I None
potent I None
and I None
selective I None
inhibitor I None
of I None
AChE I GENE-Y
, I None
can I None
probably I None
be I None
used I None
as I None
an I None
improved I None
drug I None
in I None
the I None
palliative I None
treatment I None
of I None
AD I None
. I None
<eof> I None

<s> O None
Fibroblast I GENE-Y
growth O GENE-Y
factor O GENE-Y
- O GENE-Y
10 O GENE-Y
. I None
<eof> I None

<s> O None
A I None
second I None
candidate I None
stromal I None
to I None
epithelial I None
cell I None
andromedin I None
in I None
prostate I None
. I None
<eof> I None

<s> O None
Fibroblast I GENE-Y
growth O GENE-Y
factor O GENE-Y
( O GENE-Y
FGF O GENE-Y
) O GENE-Y
- O GENE-Y
10 O GENE-Y
, I None
a I None
homologue I None
of I None
FGF I GENE-Y
- O GENE-Y
7 O GENE-Y
, I None
is I None
expressed I None
significantly I None
in I None
normal I None
rat I None
prostate I None
tissue I None
, I None
well I None
differentiated I None
rat I None
prostate I None
tumors I None
with I None
an I None
epithelial I None
and I None
stromal I None
compartment I None
and I None
only I None
in I None
derived I None
prostate I None
stromal I None
cells I None
in I None
culture I None
. I None
<eof> I None

<s> O None
Similar I None
to I None
FGF I GENE-Y
- O GENE-Y
7 O GENE-Y
, I None
recombinant I None
rat I GENE-Y
FGF O GENE-Y
- O GENE-Y
10 O GENE-Y
was I None
a I None
specific I None
mitogen I None
for I None
prostate I None
epithelial I None
cells I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
FGF I GENE-Y
- O GENE-Y
7 O GENE-Y
which I None
is I None
widely I None
expressed I None
among I None
stromal I None
cells I None
in I None
tissues I None
, I None
the I None
expression I None
of I None
FGF I GENE-Y
- O GENE-Y
10 O GENE-Y
correlated I None
with I None
the I None
presence I None
of I None
stromal I None
cells I None
of I None
muscle I None
origin I None
. I None
<eof> I None

<s> O None
Radioreceptor I None
binding I None
assays I None
and I None
covalent I None
cross I None
- I None
linking I None
analysis I None
revealed I None
that I None
FGF I GENE-Y
- O GENE-Y
10 O GENE-Y
binds I None
with I None
an I None
affinity I None
equal I None
to I None
FGF I GENE-Y
- O GENE-Y
7 O GENE-Y
to I None
resident I None
epithelial I None
cell I None
receptor I None
, I None
FGFR2IIIb I GENE-Y
, I None
but I None
unlike I None
FGF I GENE-Y
- O GENE-Y
7 O GENE-Y
also I None
binds I None
the I None
IIIb I GENE-Y
splice O GENE-Y
variant O GENE-Y
of O GENE-Y
FGFR1 O GENE-Y
. I None
<eof> I None

<s> O None
Analysis I None
of I None
mRNA I None
expression I None
by I None
RNase I None
protection I None
revealed I None
that I None
, I None
similar I None
to I None
FGF I GENE-Y
- O GENE-Y
7 O GENE-Y
, I None
the I None
expression I None
of I None
FGF I GENE-Y
- O GENE-Y
10 O GENE-Y
was I None
responsive I None
to I None
androgen I CHEMICAL
in I None
stromal I None
cells I None
from I None
normal I None
prostate I None
and I None
non I None
- I None
malignant I None
differentiated I None
tumors I None
. I None
<eof> I None

<s> O None
Although I None
FGF I GENE-Y
- O GENE-Y
10 O GENE-Y
cDNA I None
exhibits I None
a I None
signal I None
sequence I None
for I None
secretion I None
, I None
cultured I None
stromal I None
cells I None
exhibit I None
strictly I None
a I None
cell I None
- I None
associated I None
FGF I GENE-Y
- O GENE-Y
10 O GENE-Y
antigen I None
that I None
correlates I None
with I None
an I None
alternately I None
translated I None
intracellular I None
isoform I None
. I None
<eof> I None

<s> O None
FGF I GENE-Y
- O GENE-Y
10 O GENE-Y
requires I None
1 I None
. I None
4 I None
times I None
higher I None
NaCl I CHEMICAL
for I None
elution I None
from I None
immobilized I None
heparin I None
than I None
does I None
FGF I GENE-Y
- O GENE-Y
7 O GENE-Y
and I None
binds I None
to I None
four I None
times I None
the I None
number I None
of I None
sites I None
on I None
the I None
pericellular I None
matrix I None
of I None
epithelial I None
cells I None
. I None
<eof> I None

<s> O None
The I None
results I None
show I None
that I None
prostate I None
stromal I None
cell I None
- I None
derived I None
FGF I GENE-Y
- O GENE-Y
10 O GENE-Y
, I None
like I None
FGF I GENE-Y
- O GENE-Y
7 O GENE-Y
, I None
exhibits I None
the I None
properties I None
of I None
an I None
andromedin I None
which I None
may I None
indirectly I None
mediate I None
control I None
of I None
epithelial I None
cell I None
growth I None
and I None
function I None
by I None
androgen I CHEMICAL
. I None
<eof> I None

<s> O None
Although I None
FGF I GENE-Y
- O GENE-Y
10 O GENE-Y
and I None
FGF I GENE-Y
- O GENE-Y
7 O GENE-Y
bind I None
and I None
activate I None
the I None
same I None
resident I None
epithelial I GENE-N
cell O GENE-N
receptor O GENE-N
( I None
FGFR2IIIb I GENE-Y
) I None
, I None
differences I None
in I None
cell I None
type I None
of I None
origin I None
, I None
compartmentation I None
by I None
alternate I None
translation I None
, I None
the I None
affinity I None
for I None
FGFR1IIIb I GENE-Y
, I None
and I None
access I None
to I None
FGFR I GENE-N
by I None
differential I None
interaction I None
with I None
pericellular I None
matrix I None
heparan I None
sulfate I CHEMICAL
suggest I None
they I None
may I None
play I None
both I None
independent I None
and I None
compensatory I None
roles I None
in I None
prostate I None
homeostasis I None
. I None
<eof> I None

<s> O None
Pre I None
- I None
or I None
post I None
- I None
training I None
injection I None
of I None
buspirone I CHEMICAL
impaired I None
retention I None
in I None
the I None
inhibitory I None
avoidance I None
task I None
: I None
involvement I None
of I None
amygdala I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
receptors I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
investigated I None
the I None
effect I None
of I None
buspirone I CHEMICAL
on I None
memory I None
formation I None
in I None
an I None
aversive I None
learning I None
task I None
. I None
<eof> I None

<s> O None
Male I None
Wistar I None
rats I None
were I None
trained I None
on I None
the I None
inhibitory I None
avoidance I None
task I None
and I None
tested I None
for I None
retention I None
1 I None
day I None
after I None
training I None
. I None
<eof> I None

<s> O None
They I None
received I None
peripheral I None
or I None
intra I None
- I None
amygdala I None
administration I None
of I None
buspirone I CHEMICAL
or I None
other I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
drugs I None
either I None
before I None
or I None
after I None
training I None
. I None
<eof> I None

<s> O None
Results I None
indicated I None
that I None
pretraining I None
systemic I None
injections I None
of I None
buspirone I CHEMICAL
caused I None
a I None
dose I None
- I None
dependent I None
retention I None
deficit I None
; I None
5 I None
. I None
<eof> I None

<s> O None
0 I None
mg I None
/ I None
kg I None
had I None
a I None
marked I None
effect I None
and I None
1 I None
. I None
0 I None
mg I None
/ I None
kg I None
had I None
no I None
effect I None
. I None
<eof> I None

<s> O None
Post I None
- I None
training I None
injections I None
of I None
the I None
drug I None
caused I None
a I None
time I None
- I None
dependent I None
retention I None
deficit I None
, I None
which I None
was I None
not I None
due I None
to I None
a I None
state I None
- I None
dependent I None
effect I None
on I None
retrieval I None
. I None
<eof> I None

<s> O None
When I None
training I None
in I None
the I None
inhibitory I None
avoidance I None
task I None
was I None
divided I None
into I None
a I None
context I None
- I None
training I None
phase I None
and I None
a I None
shock I None
- I None
training I None
phase I None
, I None
buspirone I CHEMICAL
impaired I None
retention I None
only I None
when I None
administered I None
in I None
the I None
shock I None
- I None
training I None
phase I None
, I None
suggesting I None
that I None
the I None
drug I None
influenced I None
memory I None
processing I None
of I None
affective I None
events I None
. I None
<eof> I None

<s> O None
Further I None
results I None
indicated I None
that I None
post I None
- I None
training I None
intra I None
- I None
amygdala I None
infusion I None
of I None
buspirone I CHEMICAL
or I None
the I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
agonist I None
8 I CHEMICAL
- O CHEMICAL
hydroxy O CHEMICAL
- O CHEMICAL
di O CHEMICAL
- O CHEMICAL
n O CHEMICAL
- O CHEMICAL
propylaminotetralin O CHEMICAL
( I None
8 I CHEMICAL
- O CHEMICAL
OH O CHEMICAL
- O CHEMICAL
DPAT O CHEMICAL
) I None
caused I None
a I None
time I None
- I None
dependent I None
and I None
dose I None
- I None
dependent I None
retention I None
deficit I None
. I None
<eof> I None

<s> O None
Post I None
- I None
training I None
intra I None
- I None
amygdala I None
infusion I None
of I None
the I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
antagonist I None
WAY100635 I CHEMICAL
( I None
N I CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
methoxyphenyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
piperazinyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
N O CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
pyridyl O CHEMICAL
) O CHEMICAL
cyclohexane O CHEMICAL
carboxamine O CHEMICAL
maleate O CHEMICAL
) I None
attenuated I None
the I None
memory I None
- I None
impairing I None
effects I None
of I None
buspirone I CHEMICAL
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
buspirone I CHEMICAL
may I None
modulate I None
memory I None
storage I None
processes I None
in I None
the I None
inhibitory I None
avoidance I None
task I None
through I None
an I None
action I None
on I None
amygdaloid I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
receptors I None
. I None
<eof> I None

<s> O None
Selective I None
inhibition I None
of I None
cyclooxygenase I GENE-Y
2 O GENE-Y
spares I None
renal I None
function I None
and I None
prostaglandin I CHEMICAL
synthesis I None
in I None
cirrhotic I None
rats I None
with I None
ascites I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
& I None
AIMS I None
: I None
The I None
critical I None
role I None
of I None
cyclooxygenase I GENE-N
( I None
COX I GENE-N
) I None
products I None
in I None
maintenance I None
of I None
renal I None
function I None
in I None
cirrhosis I None
with I None
ascites I None
discourages I None
the I None
use I None
of I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
in I None
this I None
disease I None
. I None
<eof> I None

<s> O None
The I None
recent I None
development I None
of I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
opens I None
new I None
avenues I None
for I None
the I None
use I None
of I None
these I None
compounds I None
in I None
decompensated I None
cirrhosis I None
. I None
<eof> I None

<s> O None
The I None
current I None
study I None
evaluates I None
the I None
effects I None
of I None
a I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
( I None
SC I CHEMICAL
- O CHEMICAL
236 O CHEMICAL
) I None
on I None
renal I None
function I None
in I None
cirrhotic I None
rats I None
with I None
ascites I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
In I None
protocol I None
1 I None
, I None
urine I None
volume I None
, I None
urinary I None
excretion I None
of I None
sodium I CHEMICAL
and I None
prostaglandins I CHEMICAL
, I None
glomerular I None
filtration I None
rate I None
, I None
and I None
renal I None
plasma I None
flow I None
were I None
measured I None
before I None
and I None
after I None
administration I None
of I None
SC I CHEMICAL
- O CHEMICAL
236 O CHEMICAL
( I None
n I None
= I None
12 I None
) I None
or I None
ketorolac I CHEMICAL
( I None
n I None
= I None
10 I None
) I None
to I None
rats I None
with I None
cirrhosis I None
. I None
<eof> I None

<s> O None
Protocol I None
2 I None
was I None
aimed I None
at I None
assessing I None
the I None
effects I None
of I None
COX I GENE-N
inhibitors I None
on I None
renal I None
water I None
metabolism I None
in I None
28 I None
cirrhotic I None
rats I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Administration I None
of I None
SC I CHEMICAL
- O CHEMICAL
236 O CHEMICAL
to I None
cirrhotic I None
animals I None
did I None
not I None
produce I None
significant I None
renal I None
effects I None
, I None
whereas I None
administration I None
of I None
the I None
nonselective I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
/ I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
, I None
ketorolac I CHEMICAL
, I None
resulted I None
in I None
a I None
marked I None
reduction I None
in I None
urine I None
volume I None
, I None
urinary I None
excretion I None
of I None
prostaglandins I CHEMICAL
, I None
and I None
glomerular I None
filtration I None
rate I None
and I None
in I None
a I None
significant I None
impairment I None
in I None
renal I None
water I None
metabolism I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
These I None
findings I None
indicate I None
that I None
SC I CHEMICAL
- O CHEMICAL
236 O CHEMICAL
does I None
not I None
significantly I None
impair I None
renal I None
function I None
in I None
rats I None
with I None
cirrhosis I None
. I None
<eof> I None

<s> O None
[ I None
Pharmacodynamic I None
and I None
pharmacokinetic I None
aspects I None
of I None
the I None
non I None
- I None
inflammatory I None
non I None
- I None
steroidal I CHEMICAL
agent I None
meloxicam I CHEMICAL
in I None
dogs I None
] I None
. I None
<eof> I None

<s> O None
The I None
pharmacodynamics I None
of I None
non I None
- I None
steroidal I CHEMICAL
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
are I None
for I None
the I None
most I None
part I None
well I None
- I None
understood I None
. I None
<eof> I None

<s> O None
All I None
NSAIDs I None
inhibit I None
the I None
enzyme I None
cyclooxygenase I GENE-N
( I None
COX I GENE-N
) I None
, I None
and I None
for I None
this I None
reason I None
prostaglandin I CHEMICAL
synthesis I None
. I None
<eof> I None

<s> O None
Two I None
isoforms I None
of I None
COX I GENE-N
could I None
be I None
isolated I None
. I None
<eof> I None

<s> O None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
is I None
detectable I None
in I None
most I None
tissues I None
on I None
a I None
constant I None
level I None
and I None
is I None
responsible I None
for I None
the I None
synthesis I None
of I None
prostaglandins I CHEMICAL
with I None
cytoprotective I None
effects I None
. I None
<eof> I None

<s> O None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
is I None
induced I None
through I None
inflammation I None
and I None
supports I None
the I None
inflammatory I None
process I None
by I None
producing I None
pro I None
- I None
inflammatory I None
prostaglandins I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
desired I None
effects I None
of I None
NSAIDs I None
are I None
related I None
to I None
inhibition I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
, I None
whereas I None
inhibition I None
of I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
has I None
been I None
linked I None
to I None
the I None
typical I None
side I None
- I None
effects I None
of I None
NSAIDs I None
, I None
especially I None
in I None
the I None
stomach I None
and I None
kidney I None
. I None
<eof> I None

<s> O None
The I None
great I None
differences I None
between I None
effects I None
and I None
side I None
- I None
effects I None
in I None
the I None
numerous I None
substances I None
can I None
be I None
explained I None
because I None
of I None
different I None
interactions I None
of I None
the I None
NSAIDs I None
on I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
and I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
In I None
various I None
test I None
systems I None
meloxicam I CHEMICAL
has I None
been I None
shown I None
to I None
be I None
a I None
preferential I None
inhibitor I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
There I None
are I None
also I None
large I None
differences I None
between I None
the I None
individual I None
NSAIDs I None
with I None
regard I None
to I None
pharmacokinetics I None
. I None
<eof> I None

<s> O None
Meloxicam I CHEMICAL
is I None
completely I None
absorbed I None
from I None
the I None
gastrointestinal I None
tract I None
and I None
has I None
an I None
elimination I None
half I None
- I None
life I None
of I None
24 I None
hours I None
in I None
the I None
dog I None
. I None
<eof> I None

<s> O None
It I None
is I None
excreted I None
in I None
faeces I None
and I None
urine I None
. I None
<eof> I None

<s> O None
The I None
metabolites I None
, I None
detectable I None
in I None
urine I None
are I None
biologically I None
inactive I None
and I None
do I None
not I None
influence I None
the I None
prostaglandin I CHEMICAL
synthesis I None
in I None
the I None
kidney I None
. I None
<eof> I None

<s> O None
In I None
the I None
underlying I None
study I None
, I None
plasma I None
concentration I None
of I None
meloxicam I CHEMICAL
was I None
determined I None
after I None
a I None
subcutaneous I None
injection I None
of I None
0 I None
. I None
2 I None
mg I None
/ I None
kg I None
b I None
. I None
<eof> I None

<s> O None
w I None
. I None
<eof> I None

<s> O None
( I None
day I None
1 I None
) I None
followed I None
by I None
oral I None
treatment I None
of I None
0 I None
. I None
1 I None
mg I None
/ I None
kg I None
b I None
. I None
<eof> I None

<s> O None
w I None
. I None
<eof> I None

<s> O None
( I None
days I None
2 I None
- I None
14 I None
) I None
. I None
<eof> I None

<s> O None
The I None
results I None
confirm I None
the I None
recommended I None
dosage I None
regime I None
of I None
meloxicam I CHEMICAL
with I None
its I None
initial I None
loading I None
dose I None
and I None
the I None
subsequent I None
maintenance I None
dose I None
. I None
<eof> I None

<s> O None
This I None
dosing I None
regime I None
results I None
in I None
a I None
very I None
favourable I None
curve I None
of I None
concentrations I None
with I None
a I None
very I None
rapidly I None
attained I None
steady I None
state I None
after I None
roughly I None
two I None
days I None
, I None
without I None
accumulation I None
even I None
in I None
long I None
- I None
term I None
treatment I None
. I None
<eof> I None

<s> O None
In I None
vitro I None
activities I None
of I None
the I None
potent I None
, I None
broad I None
- I None
spectrum I None
carbapenem I CHEMICAL
MK I CHEMICAL
- O CHEMICAL
0826 O CHEMICAL
( I None
L I CHEMICAL
- O CHEMICAL
749 O CHEMICAL
, O CHEMICAL
345 O CHEMICAL
) I None
against I None
broad I GENE-N
- O GENE-N
spectrum O GENE-N
beta O GENE-N
- O GENE-N
lactamase O GENE-N
- I None
and I None
extended I GENE-N
- O GENE-N
spectrum O GENE-N
beta O GENE-N
- O GENE-N
lactamase O GENE-N
- I None
producing I None
Klebsiella I None
pneumoniae I None
and I None
Escherichia I None
coli I None
clinical I None
isolates I None
. I None
<eof> I None

<s> O None
An I None
important I None
mechanism I None
of I None
bacterial I None
resistance I None
to I None
beta I None
- I None
lactam I None
antibiotics I None
is I None
inactivation I None
by I None
beta I GENE-N
- O GENE-N
lactam O GENE-N
- O GENE-N
hydrolyzing O GENE-N
enzymes O GENE-N
( I None
beta I GENE-N
- O GENE-N
lactamases O GENE-N
) I None
. I None
<eof> I None

<s> O None
The I None
evolution I None
of I None
the I None
extended I GENE-N
- O GENE-N
spectrum O GENE-N
beta O GENE-N
- O GENE-N
lactamases O GENE-N
( I None
ESBLs I GENE-N
) I None
is I None
associated I None
with I None
extensive I None
use I None
of I None
beta I None
- I None
lactam I None
antibiotics I None
, I None
particularly I None
cephalosporins I CHEMICAL
, I None
and I None
is I None
a I None
serious I None
threat I None
to I None
therapeutic I None
efficacy I None
. I None
<eof> I None

<s> O None
ESBLs I GENE-N
and I None
broad I GENE-N
- O GENE-N
spectrum O GENE-N
beta O GENE-N
- O GENE-N
lactamases O GENE-N
( I None
BDSBLs I GENE-N
) I None
are I None
plasmid I None
- I None
mediated I None
class I None
A I None
enzymes I None
produced I None
by I None
gram I None
- I None
negative I None
pathogens I None
, I None
principally I None
Escherichia I None
coli I None
and I None
Klebsiella I None
pneumoniae I None
. I None
<eof> I None

<s> O None
MK I CHEMICAL
- O CHEMICAL
0826 O CHEMICAL
was I None
highly I None
potent I None
against I None
all I None
ESBL I GENE-N
- I None
and I None
BDSBL I GENE-N
- I None
producing I None
K I None
. I None
pneumoniae I None
and I None
E I None
. I None
coli I None
clinical I None
isolates I None
tested I None
( I None
MIC I None
range I None
, I None
0 I None
. I None
008 I None
to I None
0 I None
. I None
12 I None
microgram I None
/ I None
ml I None
) I None
. I None
<eof> I None

<s> O None
In I None
E I None
. I None
coli I None
, I None
this I None
activity I None
was I None
associated I None
with I None
high I None
- I None
affinity I None
binding I None
to I None
penicillin I GENE-N
- O GENE-N
binding O GENE-N
proteins O GENE-N
2 O GENE-N
and O GENE-N
3 O GENE-N
. I None
<eof> I None

<s> O None
When I None
the I None
inoculum I None
level I None
was I None
increased I None
10 I None
- I None
fold I None
, I None
increasing I None
the I None
amount I None
of I None
beta I GENE-N
- O GENE-N
lactamase O GENE-N
present I None
, I None
the I None
MK I CHEMICAL
- O CHEMICAL
0826 O CHEMICAL
MIC I None
range I None
increased I None
to I None
0 I None
. I None
008 I None
to I None
1 I None
microgram I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
By I None
comparison I None
, I None
similar I None
observations I None
were I None
made I None
with I None
meropenem I CHEMICAL
while I None
imipenem I CHEMICAL
MICs I None
were I None
usually I None
less I None
affected I None
. I None
<eof> I None

<s> O None
Not I None
surprisingly I None
, I None
MIC I None
increases I None
with I None
noncarbapenem I None
beta I None
- I None
lactams I None
were I None
generally I None
substantially I None
greater I None
, I None
resulting I None
in I None
resistance I None
in I None
many I None
cases I None
. I None
<eof> I None

<s> O None
E I None
. I None
coli I None
strains I None
that I None
produce I None
chromosomal I None
( I None
Bush I None
group I None
1 I None
) I None
beta I GENE-Y
- O GENE-Y
lactamase O GENE-Y
served I None
as I None
controls I None
. I None
<eof> I None

<s> O None
All I None
three I None
carbapenems I CHEMICAL
were I None
subject I None
to I None
an I None
inoculum I None
effect I None
with I None
the I None
majority I None
of I None
the I None
BDSBL I GENE-N
- I None
and I None
ESBL I GENE-N
- I None
producers I None
but I None
not I None
the I None
Bush I None
group I None
1 I None
strains I None
, I None
implying I None
some I None
effect I None
of I None
the I None
plasmid I None
- I None
borne I None
enzymes I None
on I None
potency I None
. I None
<eof> I None

<s> O None
Importantly I None
, I None
MK I CHEMICAL
- O CHEMICAL
0826 O CHEMICAL
MICs I None
remained I None
at I None
or I None
below I None
1 I None
microgram I None
/ I None
ml I None
under I None
all I None
test I None
conditions I None
. I None
<eof> I None

<s> O None
Molecular I None
cloning I None
and I None
characterization I None
of I None
a I None
new I None
multispecific I None
organic I GENE-N
anion O GENE-N
transporter O GENE-N
from I None
rat I None
brain I None
. I None
<eof> I None

<s> O None
A I None
cDNA I None
encoding I None
the I None
new I None
member I None
of I None
the I None
multispecific I None
organic I GENE-N
anion O GENE-N
transporter O GENE-N
family O GENE-N
, I None
OAT3 I GENE-Y
, I None
was I None
isolated I None
by I None
the I None
reverse I None
transcription I None
- I None
polymerase I None
chain I None
reaction I None
cloning I None
method I None
. I None
<eof> I None

<s> O None
Degenerate I None
primers I None
were I None
designed I None
based I None
on I None
the I None
sequences I None
conserved I None
among I None
OAT1 I GENE-Y
, I None
OAT2 I GENE-Y
, I None
and I None
organic I GENE-Y
cation O GENE-Y
transporter O GENE-Y
1 O GENE-Y
( I None
OCT1 I GENE-Y
) I None
, I None
and I None
reverse I None
transcription I None
- I None
polymerase I None
chain I None
reaction I None
was I None
performed I None
using I None
rat I None
brain I None
poly I None
( I None
A I None
) I None
+ I None
RNA I None
. I None
<eof> I None

<s> O None
The I None
536 I None
- I None
amino I CHEMICAL
acid O CHEMICAL
protein I None
sequence I None
encoded I None
by I None
OAT3 I GENE-Y
showed I None
49 I None
, I None
39 I None
, I None
and I None
36 I None
% I None
identity I None
to I None
those I None
of I None
OAT1 I GENE-Y
, I None
OAT2 I GENE-Y
, I None
and I None
OCT1 I GENE-Y
, I None
respectively I None
. I None
<eof> I None

<s> O None
Northern I None
blot I None
analysis I None
revealed I None
that I None
rat I GENE-Y
OAT3 O GENE-Y
mRNA I None
is I None
expressed I None
in I None
the I None
liver I None
, I None
brain I None
, I None
kidney I None
, I None
and I None
eye I None
. I None
<eof> I None

<s> O None
When I None
expressed I None
in I None
Xenopus I None
laevis I None
oocytes I None
, I None
OAT3 I GENE-Y
mediated I None
the I None
uptake I None
of I None
organic I None
anions I None
, I None
such I None
as I None
p I CHEMICAL
- O CHEMICAL
aminohippurate O CHEMICAL
( I None
Km I None
= I None
65 I None
microM I None
) I None
, I None
ochratoxin I CHEMICAL
A O CHEMICAL
( I None
Km I None
= I None
0 I None
. I None
74 I None
microM I None
) I None
, I None
and I None
estrone I CHEMICAL
sulfate O CHEMICAL
( I None
Km I None
= I None
2 I None
. I None
3 I None
microM I None
) I None
and I None
a I None
cationic I None
compound I None
, I None
cimetidine I CHEMICAL
. I None
<eof> I None

<s> O None
OAT3 I GENE-Y
- I None
mediated I None
uptake I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
estrone O CHEMICAL
sulfate O CHEMICAL
was I None
sodium I CHEMICAL
- I None
independent I None
. I None
<eof> I None

<s> O None
para I CHEMICAL
- O CHEMICAL
Aminohippuric O CHEMICAL
acid O CHEMICAL
, I None
estrone I CHEMICAL
sulfate O CHEMICAL
or I None
ochratoxin I CHEMICAL
A O CHEMICAL
did I None
not I None
show I None
any I None
trans I None
- I None
stimulatory I None
effect I None
on I None
either I None
influx I None
or I None
efflux I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
estrone O CHEMICAL
sulfate O CHEMICAL
via I None
OAT3 I GENE-Y
. I None
<eof> I None

<s> O None
Organic I None
anions I None
such I None
as I None
sulfobromophthalein I CHEMICAL
, I None
probenecid I CHEMICAL
, I None
indocyanine I CHEMICAL
green O CHEMICAL
, I None
bumetanide I CHEMICAL
, I None
piroxicam I CHEMICAL
, I None
furosemide I CHEMICAL
, I None
azidodeoxythymidine I CHEMICAL
, I None
4 I CHEMICAL
, O CHEMICAL
4 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
diisothiocyanostilbene O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
3 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
disulfonic O CHEMICAL
acid O CHEMICAL
, I None
and I None
benzylpenicillin I CHEMICAL
inhibited I None
OAT3 I GENE-Y
- I None
mediated I None
estrone I CHEMICAL
sulfate O CHEMICAL
uptake I None
, I None
while I None
ouabain I CHEMICAL
and I None
digoxin I CHEMICAL
did I None
not I None
. I None
<eof> I None

<s> O None
Organic I None
cations I None
such I None
as I None
tetraethylammonium I CHEMICAL
, I None
guanidine I CHEMICAL
, I None
verapamil I CHEMICAL
, I None
and I None
quinidine I CHEMICAL
did I None
not I None
interact I None
with I None
OAT3 I GENE-Y
. I None
<eof> I None

<s> O None
Acidic I None
metabolites I None
of I None
neurotransmitters I None
derived I None
from I None
dopamine I CHEMICAL
, I None
epinephrine I CHEMICAL
, I None
norepinephrine I CHEMICAL
, I None
and I None
serotonin I CHEMICAL
inhibited I None
the I None
uptake I None
of I None
estrone I CHEMICAL
sulfate O CHEMICAL
via I None
OAT3 I GENE-Y
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
an I None
important I None
role I None
of I None
OAT3 I GENE-Y
in I None
the I None
excretion I None
/ I None
detoxification I None
of I None
endogenous I None
and I None
exogenous I None
organic I None
anions I None
, I None
especially I None
from I None
the I None
brain I None
. I None
<eof> I None

<s> O None
Influence I None
of I None
halothane I CHEMICAL
on I None
phospholipase I GENE-Y
A2 O GENE-Y
and I None
enzymatic I None
methylations I None
in I None
the I None
rat I None
retinal I None
membranes I None
. I None
<eof> I None

<s> O None
Phospholipase I GENE-Y
A2 O GENE-Y
( I None
PLA2 I GENE-Y
) I None
and I None
phospholipid I GENE-N
methylases O GENE-N
( I None
PLM I GENE-N
) I None
play I None
significant I None
roles I None
in I None
transmitter I None
release I None
and I None
membrane I None
signal I None
transduction I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Previous I None
studies I None
have I None
indicated I None
that I None
PLMs I GENE-N
occur I None
in I None
the I None
rat I None
brain I None
synaptosomal I None
and I None
retinal I None
membranes I None
, I None
and I None
they I None
are I None
activated I None
under I None
halothane I CHEMICAL
anesthesia I None
. I None
<eof> I None

<s> O None
The I None
influence I None
of I None
halothane I CHEMICAL
on I None
PLA2 I GENE-Y
is I None
not I None
known I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
we I None
have I None
investigated I None
the I None
effect I None
of I None
halothane I CHEMICAL
on I None
retinal I None
PLA2 I GENE-Y
activity I None
. I None
<eof> I None

<s> O None
Rat I None
retinal I None
sonicates I None
were I None
assayed I None
for I None
PLA2 I GENE-Y
activity I None
using I None
1 I CHEMICAL
- O CHEMICAL
palmitoyl O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
[ O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
14C O CHEMICAL
] O CHEMICAL
arachidonyl O CHEMICAL
- O CHEMICAL
phosphatidylethanolamine O CHEMICAL
( I None
PE I CHEMICAL
, I None
2 I None
. I None
2 I None
nmol I None
) I None
in I None
Tris I None
buffer I None
( I None
10 I None
mM I None
, I None
pH I None
7 I None
. I None
4 I None
) I None
at I None
37 I None
degrees I None
C I None
with I None
and I None
without I None
halothane I CHEMICAL
( I None
0 I None
. I None
25 I None
- I None
2 I None
. I None
0 I None
mM I None
) I None
in I None
the I None
assay I None
medium I None
. I None
<eof> I None

<s> O None
These I None
studies I None
gave I None
the I None
following I None
results I None
: I None
( I None
1 I None
) I None
Rat I None
retinal I None
sonicates I None
contained I None
PLA2 I GENE-Y
activity I None
of I None
4 I None
. I None
2 I None
+ I None
/ I None
- I None
0 I None
. I None
8 I None
pmol I None
PE I CHEMICAL
hydrolyzed I None
/ I None
100 I None
ng I None
protein I None
/ I None
hr I None
; I None
( I None
2 I None
) I None
Halothane I CHEMICAL
( I None
0 I None
. I None
25 I None
- I None
2 I None
. I None
0 I None
mM I None
) I None
increased I None
PLA2 I GENE-Y
activity I None
by I None
20 I None
to I None
150 I None
% I None
depending I None
upon I None
concentration I None
; I None
( I None
3 I None
) I None
The I None
lower I None
concentration I None
of I None
halothane I CHEMICAL
( I None
0 I None
. I None
25 I None
mM I None
) I None
exhibited I None
high I None
activation I None
of I None
PLA2 I GENE-Y
( I None
150 I None
% I None
) I None
; I None
( I None
4 I None
) I None
High I None
concentrations I None
of I None
halothane I CHEMICAL
( I None
1 I None
. I None
0 I None
- I None
2 I None
. I None
0 I None
mM I None
) I None
caused I None
a I None
low I None
degree I None
of I None
activation I None
of I None
PLA2 I GENE-Y
( I None
20 I None
% I None
) I None
; I None
and I None
( I None
5 I None
) I None
During I None
phospholipid I None
methylation I None
of I None
retinal I None
membranes I None
with I None
S I CHEMICAL
- O CHEMICAL
adenosyl O CHEMICAL
- O CHEMICAL
L O CHEMICAL
- O CHEMICAL
methionine O CHEMICAL
in I None
the I None
presence I None
of I None
halothane I CHEMICAL
, I None
increased I None
amounts I None
of I None
fatty I CHEMICAL
acid O CHEMICAL
methyl O CHEMICAL
esters O CHEMICAL
( I None
FAME I None
) I None
were I None
formed I None
. I None
<eof> I None

<s> O None
This I None
increase I None
in I None
FAME I None
( I None
45 I None
% I None
) I None
was I None
possibly I None
due I None
to I None
the I None
hydrolysis I None
of I None
phospholipids I None
by I None
activated I None
PLA2 I GENE-Y
, I None
liberating I None
fatty I CHEMICAL
acids O CHEMICAL
which I None
were I None
methylated I None
. I None
<eof> I None

<s> O None
This I None
increase I None
in I None
FAME I None
( I None
45 I None
% I None
) I None
was I None
inhibited I None
by I None
mepacrine I CHEMICAL
( I None
quinacrine I CHEMICAL
) I None
( I None
10 I None
microM I None
) I None
, I None
an I None
inhibitor I None
of I None
PLA2 I GENE-Y
. I None
<eof> I None

<s> O None
These I None
observations I None
suggest I None
that I None
the I None
release I None
of I None
retinal I None
transmitters I None
( I None
dopamine I CHEMICAL
, I None
acetylcholine I CHEMICAL
and I None
others I None
) I None
is I None
affected I None
during I None
halothane I CHEMICAL
anesthesia I None
, I None
due I None
to I None
activation I None
of I None
PLA2 I GENE-Y
and I None
enhanced I None
fusogenic I None
activity I None
of I None
vesicular I None
membranes I None
with I None
plasma I None
membrane I None
and I None
depletion I None
of I None
vesicles I None
. I None
<eof> I None

<s> O None
Atypical I None
teratoid I None
/ I None
rhabdoid I None
tumor I None
of I None
the I None
CNS I None
: I None
cytopathology I None
and I None
immunohistochemistry I None
of I None
insulin I GENE-Y
- O GENE-Y
like O GENE-Y
growth O GENE-Y
factor O GENE-Y
- O GENE-Y
II O GENE-Y
, I None
insulin I GENE-Y
- O GENE-Y
like O GENE-Y
growth O GENE-Y
factor O GENE-Y
receptor O GENE-Y
type O GENE-Y
1 O GENE-Y
, I None
cathepsin I GENE-Y
D O GENE-Y
, I None
and I None
Ki I GENE-Y
- O GENE-Y
67 O GENE-Y
. I None
<eof> I None

<s> O None
Insulin I GENE-Y
- O GENE-Y
like O GENE-Y
growth O GENE-Y
factor O GENE-Y
( O GENE-Y
IGF O GENE-Y
) O GENE-Y
- O GENE-Y
II O GENE-Y
is I None
a I None
potent I None
growth I None
factor I None
, I None
normally I None
controlled I None
by I None
a I None
number I None
of I None
other I None
factors I None
, I None
including I None
IGF I GENE-N
binding O GENE-N
proteins O GENE-N
and I None
IGF I GENE-N
binding O GENE-N
protein O GENE-N
proteases O GENE-N
. I None
<eof> I None

<s> O None
In I None
general I None
, I None
the I None
latter I None
increase I None
the I None
bioavailability I None
of I None
IGF I GENE-N
by I None
cleaving I None
IGF I GENE-N
binding O GENE-N
proteins O GENE-N
. I None
<eof> I None

<s> O None
Cathepsin I GENE-Y
D O GENE-Y
( I None
an I None
IGF I GENE-N
binding O GENE-N
protein O GENE-N
protease O GENE-N
) I None
was I None
also I None
implicated I None
in I None
tumor I None
invasion I None
. I None
<eof> I None

<s> O None
Although I None
IGF I GENE-Y
- O GENE-Y
II O GENE-Y
was I None
implicated I None
in I None
the I None
pathogeneses I None
of I None
various I None
childhood I None
neoplasms I None
, I None
its I None
significance I None
in I None
the I None
pathogenesis I None
of I None
atypical I None
teratoid I None
/ I None
rhabdoid I None
tumor I None
of I None
the I None
central I None
nervous I None
system I None
( I None
ATRT I None
- I None
CNS I None
) I None
was I None
not I None
studied I None
to I None
date I None
. I None
<eof> I None

<s> O None
We I None
present I None
clinicopathologic I None
features I None
of I None
two I None
cases I None
of I None
ATRT I None
- I None
CNS I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
formalin I CHEMICAL
- I None
fixed I None
, I None
paraffin I None
- I None
embedded I None
tissue I None
sections I None
were I None
stained I None
immunohistochemically I None
for I None
IGF I GENE-Y
- O GENE-Y
II O GENE-Y
, I None
IGF I GENE-Y
receptor O GENE-Y
type O GENE-Y
1 O GENE-Y
, I None
cathepsin I GENE-Y
D O GENE-Y
, I None
and I None
Ki I GENE-Y
- O GENE-Y
67 O GENE-Y
. I None
<eof> I None

<s> O None
Both I None
tumors I None
demonstrated I None
diffuse I None
strong I None
cytoplasmic I None
positivity I None
for I None
IGF I GENE-Y
- O GENE-Y
II O GENE-Y
, I None
diffuse I None
cytoplasmic I None
and I None
focal I None
membranous I None
positivity I None
for I None
IGF I GENE-Y
receptor O GENE-Y
type O GENE-Y
I O GENE-Y
, I None
and I None
diffuse I None
cytoplasmic I None
positivity I None
for I None
cathepsin I GENE-Y
D O GENE-Y
. I None
<eof> I None

<s> O None
The I None
Ki I GENE-Y
- O GENE-Y
67 O GENE-Y
labeling I None
indices I None
were I None
10 I None
. I None
0 I None
% I None
and I None
1 I None
. I None
4 I None
% I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
ATRT I None
- I None
CNS I None
cells I None
express I None
both I None
IGF I GENE-Y
- O GENE-Y
II O GENE-Y
and I None
IGF I GENE-Y
receptor O GENE-Y
type O GENE-Y
1 O GENE-Y
, I None
supporting I None
the I None
hypothesis I None
that I None
autocrine I None
/ I None
paracrine I None
stimulation I None
of I None
cell I None
growth I None
by I None
IGF I GENE-Y
- O GENE-Y
II O GENE-Y
might I None
be I None
one I None
mechanism I None
involved I None
in I None
ATRT I None
- I None
CNS I None
tumorigenesis I None
. I None
<eof> I None

<s> O None
Cathepsin I GENE-Y
D O GENE-Y
expressed I None
by I None
the I None
tumor I None
cells I None
might I None
also I None
be I None
involved I None
in I None
both I None
tumor I None
cell I None
invasion I None
and I None
growth I None
. I None
<eof> I None

<s> O None
The I None
exact I None
pathogenesis I None
of I None
ATRT I None
- I None
CNS I None
remains I None
to I None
be I None
elucidated I None
. I None
<eof> I None

<s> O None
Is I None
phentermine I CHEMICAL
an I None
inhibitor I None
of I None
monoamine I GENE-N
oxidase O GENE-N
? I None
<eof> I None

<s> O None
A I None
critical I None
appraisal I None
. I None
<eof> I None

<s> O None
Phentermine I CHEMICAL
produces I None
a I None
spectrum I None
of I None
concentration I None
- I None
dependent I None
biochemical I None
effects I None
. I None
<eof> I None

<s> O None
It I None
interacts I None
with I None
NE I GENE-Y
transporters O GENE-Y
at I None
0 I None
. I None
1 I None
microM I None
, I None
DA I GENE-Y
transporters O GENE-Y
at I None
about I None
1 I None
microM I None
, I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
transporters O GENE-Y
at I None
15 I None
microM I None
and I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
at I None
about I None
100 I None
microM I None
. I None
<eof> I None

<s> O None
When I None
administered I None
at I None
typical I None
anorectic I None
doses I None
, I None
phentermine I CHEMICAL
primarily I None
interacts I None
with I None
DA I GENE-N
and O GENE-N
NE O GENE-N
transporters O GENE-N
and I None
does I None
not I None
produce I None
biochemical I None
or I None
neurochemical I None
effects I None
which I None
would I None
occur I None
if I None
it I None
were I None
inhibiting I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
. I None
<eof> I None

<s> O None
Some I None
other I None
explanation I None
other I None
than I None
MAO I GENE-N
inhibition I None
must I None
be I None
sought I None
to I None
explain I None
how I None
oral I None
phentermine I CHEMICAL
increases I None
platelet I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
, I None
since I None
platelet I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
does I None
not I None
metabolize I None
platelet I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
, I None
and I None
since I None
amphetamine I CHEMICAL
- I None
type I None
drugs I None
are I None
even I None
weaker I None
inhibitors I None
of I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
than I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
. I None
<eof> I None

<s> O None
Clinical I None
studies I None
in I None
humans I None
have I None
shown I None
that I None
amphetamine I CHEMICAL
, I None
which I None
is I None
a I None
more I None
potent I None
inhibitor I None
of I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
than I None
phentermine I CHEMICAL
, I None
does I None
not I None
inhibit I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
at I None
therapeutic I None
doses I None
. I None
<eof> I None

<s> O None
Neither I None
phentermine I CHEMICAL
alone I None
, I None
fluoxetine I CHEMICAL
alone I None
or I None
their I None
combined I None
use I None
have I None
been I None
associated I None
with I None
cardiac I None
valvulopathy I None
, I None
and I None
clinical I None
experience I None
has I None
shown I None
their I None
combined I None
use I None
to I None
be I None
free I None
of I None
significant I None
adverse I None
effects I None
. I None
<eof> I None

<s> O None
Viewed I None
collectively I None
, I None
there I None
appears I None
to I None
be I None
no I None
data I None
to I None
support I None
the I None
hypothesis I None
that I None
phentermine I CHEMICAL
inhibits I None
MAO I GENE-N
at I None
typical I None
therapeutic I None
doses I None
. I None
<eof> I None

<s> O None
Identification I None
of I None
a I None
nuclear I GENE-N
receptor O GENE-N
for I None
bile I CHEMICAL
acids O CHEMICAL
. I None
<eof> I None

<s> O None
Bile I CHEMICAL
acids O CHEMICAL
are I None
essential I None
for I None
the I None
solubilization I None
and I None
transport I None
of I None
dietary I None
lipids I None
and I None
are I None
the I None
major I None
products I None
of I None
cholesterol I CHEMICAL
catabolism I None
. I None
<eof> I None

<s> O None
Results I None
presented I None
here I None
show I None
that I None
bile I CHEMICAL
acids O CHEMICAL
are I None
physiological I None
ligands I None
for I None
the I None
farnesoid I GENE-Y
X O GENE-Y
receptor O GENE-Y
( I None
FXR I GENE-Y
) I None
, I None
an I None
orphan I GENE-N
nuclear O GENE-N
receptor O GENE-N
. I None
<eof> I None

<s> O None
When I None
bound I None
to I None
bile I None
acids I None
, I None
FXR I GENE-Y
repressed I None
transcription I None
of I None
the I None
gene I None
encoding I None
cholesterol I GENE-Y
7alpha O GENE-Y
- O GENE-Y
hydroxylase O GENE-Y
, I None
which I None
is I None
the I None
rate I None
- I None
limiting I None
enzyme I None
in I None
bile I CHEMICAL
acid O CHEMICAL
synthesis I None
, I None
and I None
activated I None
the I None
gene I None
encoding I None
intestinal I GENE-Y
bile O GENE-Y
acid O GENE-Y
- O GENE-Y
binding O GENE-Y
protein O GENE-Y
, I None
which I None
is I None
a I None
candidate I None
bile I GENE-N
acid O GENE-N
transporter O GENE-N
. I None
<eof> I None

<s> O None
These I None
results I None
demonstrate I None
a I None
mechanism I None
by I None
which I None
bile I CHEMICAL
acids O CHEMICAL
transcriptionally I None
regulate I None
their I None
biosynthesis I None
and I None
enterohepatic I None
transport I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
cPLA2 I GENE-Y
translocation I None
and I None
leukotriene I CHEMICAL
C4 O CHEMICAL
secretion I None
by I None
fluticasone I CHEMICAL
propionate O CHEMICAL
in I None
exogenously I None
activated I None
human I None
eosinophils I None
. I None
<eof> I None

<s> O None
We I None
examined I None
the I None
effect I None
of I None
the I None
highly I None
lipophilic I None
corticosteroid I None
, I None
fluticasone I CHEMICAL
propionate O CHEMICAL
( I None
FP I CHEMICAL
) I None
, I None
in I None
causing I None
( I None
1 I None
) I None
inhibition I None
of I None
nuclear I None
translocation I None
of I None
cytosolic I GENE-Y
phospholipase O GENE-Y
A2 O GENE-Y
( I None
cPLA2 I GENE-Y
) I None
, I None
and I None
( I None
2 I None
) I None
blockade I None
of I None
leukotriene I CHEMICAL
C4 O CHEMICAL
( I None
LTC4 I CHEMICAL
) I None
synthesis I None
in I None
isolated I None
human I None
eosinophils I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
Eosinophils I None
were I None
isolated I None
from I None
peripheral I None
blood I None
, I None
treated I None
with I None
either I None
buffer I None
or I None
10 I None
( I None
- I None
) I None
10 I None
M I None
to I None
10 I None
( I None
- I None
) I None
6 I None
M I None
FP I CHEMICAL
in I None
the I None
presence I None
of I None
10 I None
pg I None
/ I None
ml I None
human I GENE-Y
recombinant O GENE-Y
interleukin O GENE-Y
- O GENE-Y
5 O GENE-Y
( I None
rhIL I GENE-Y
- O GENE-Y
5 O GENE-Y
) I None
and I None
activated I None
with I None
formyl I CHEMICAL
- O CHEMICAL
met O CHEMICAL
- O CHEMICAL
leu O CHEMICAL
- O CHEMICAL
phe O CHEMICAL
( I None
FMLP I CHEMICAL
) I None
+ I None
cytochalasin I CHEMICAL
B O CHEMICAL
( I None
CB I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
At I None
24 I None
h I None
, I None
stimulated I None
LTC4 I CHEMICAL
secretion I None
from I None
eosinophils I None
was I None
unchanged I None
; I None
however I None
, I None
when I None
corrected I None
for I None
cell I None
viability I None
, I None
LTC4 I CHEMICAL
secretion I None
decreased I None
from I None
1 I None
, I None
429 I None
+ I None
/ I None
- I None
327 I None
pg I None
/ I None
10 I None
( I None
6 I None
) I None
cells I None
to I None
762 I None
+ I None
/ I None
- I None
113 I None
pg I None
/ I None
10 I None
( I None
6 I None
) I None
cells I None
for I None
eosinophils I None
treated I None
for I None
48 I None
h I None
with I None
> I None
/ I None
= I None
10 I None
( I None
- I None
) I None
8 I None
M I None
FP I CHEMICAL
( I None
p I None
< I None
0 I None
. I None
003 I None
) I None
. I None
<eof> I None

<s> O None
FMLP I CHEMICAL
/ I None
CB I CHEMICAL
- I None
stimulated I None
translocation I None
of I None
cPLA2 I GENE-Y
to I None
the I None
nuclear I None
envelope I None
assessed I None
by I None
specific I None
immunohistochemical I None
staining I None
also I None
was I None
blocked I None
by I None
FP I CHEMICAL
. I None
<eof> I None

<s> O None
By I None
contrast I None
, I None
membrane I None
expression I None
of I None
annexin I GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
which I None
was I None
not I None
minimal I None
at I None
30 I None
min I None
, I None
was I None
substantial I None
at I None
48 I None
h I None
for I None
eosinophils I None
treated I None
with I None
> I None
10 I None
( I None
- I None
) I None
10 I None
M I None
FP I CHEMICAL
, I None
and I None
inhibition I None
of I None
LTC4 I CHEMICAL
synthesis I None
was I None
reversed I None
by I None
exogenous I None
arachidonic I CHEMICAL
acid O CHEMICAL
( I None
AA I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
We I None
find I None
that I None
FP I CHEMICAL
causes I None
a I None
decrease I None
in I None
stimulated I None
eosinophil I None
secretion I None
of I None
LTC4 I CHEMICAL
that I None
is I None
regulated I None
by I None
phospholipase I GENE-Y
A2 O GENE-Y
( I None
PLA2 I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
LTC4 I CHEMICAL
synthesis I None
precedes I None
the I None
global I None
cytotoxic I None
effects I None
of I None
FP I CHEMICAL
as I None
indicated I None
by I None
the I None
simultaneous I None
upregulation I None
of I None
annexin I GENE-Y
- O GENE-Y
1 O GENE-Y
expression I None
. I None
<eof> I None

<s> O None
Inhibited I None
stimulated I None
secretion I None
corresponds I None
to I None
inhibited I None
translocation I None
of I None
cPLA2 I GENE-Y
to I None
the I None
nuclear I None
envelope I None
during I None
cellular I None
activation I None
. I None
<eof> I None

<s> O None
Hyperammonemia I None
: I None
regulation I None
of I None
argininosuccinate I GENE-Y
synthetase O GENE-Y
and I None
argininosuccinate I GENE-Y
lyase O GENE-Y
genes I None
in I None
aggregating I None
cell I None
cultures I None
of I None
fetal I None
rat I None
brain I None
. I None
<eof> I None

<s> O None
Hyperammonemia I None
in I None
the I None
brain I None
leads I None
to I None
poorly I None
understood I None
alterations I None
of I None
nitric I CHEMICAL
oxide O CHEMICAL
( I None
NO I CHEMICAL
) I None
synthesis I None
. I None
<eof> I None

<s> O None
Arginine I CHEMICAL
, I None
the I None
substrate I None
of I None
nitric I GENE-N
oxide O GENE-N
synthases O GENE-N
, I None
might I None
be I None
recycled I None
from I None
the I None
citrulline I CHEMICAL
produced I None
with I None
NO I CHEMICAL
by I None
argininosuccinate I GENE-Y
synthetase O GENE-Y
( I None
AS I GENE-Y
) I None
and I None
argininosuccinate I GENE-Y
lyase O GENE-Y
( I None
AL I GENE-Y
) I None
. I None
<eof> I None

<s> O None
The I None
regulation I None
of I None
AS I GENE-Y
and I None
AL I GENE-Y
genes I None
during I None
hyperammonemia I None
is I None
unknown I None
in I None
the I None
brain I None
. I None
<eof> I None

<s> O None
We I None
used I None
brain I None
cell I None
aggregates I None
cultured I None
from I None
dissociated I None
telencephalic I None
cortex I None
of I None
rat I None
embryos I None
to I None
analyze I None
the I None
regulation I None
of I None
AS I GENE-Y
and I None
AL I GENE-Y
genes I None
in I None
hyperammonemia I None
. I None
<eof> I None

<s> O None
Using I None
RNase I None
protection I None
assay I None
and I None
non I None
- I None
radioactive I None
in I None
situ I None
hybridization I None
on I None
aggregate I None
cryosections I None
, I None
we I None
show I None
that I None
both I None
AS I GENE-Y
and I None
AL I GENE-Y
genes I None
are I None
induced I None
in I None
astrocytes I None
but I None
not I None
in I None
neurons I None
of I None
aggregates I None
exposed I None
to I None
5 I None
mM I None
NH4Cl I CHEMICAL
. I None
<eof> I None

<s> O None
Our I None
work I None
suggests I None
that I None
the I None
hyperammonemic I None
brain I None
might I None
increase I None
its I None
recycling I None
of I None
citrulline I CHEMICAL
to I None
arginine I CHEMICAL
. I None
<eof> I None

<s> O None
Reduced I None
satiating I None
effect I None
of I None
d I CHEMICAL
- O CHEMICAL
fenfluramine O CHEMICAL
in I None
serotonin I CHEMICAL
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
2C O GENE-Y
) O GENE-Y
receptor I None
mutant I None
mice I None
. I None
<eof> I None

<s> O None
RATIONALE I None
: I None
d I CHEMICAL
- O CHEMICAL
Fenfluramine O CHEMICAL
stimulates I None
the I None
release I None
of I None
serotonin I CHEMICAL
( I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
) I None
and I None
is I None
a I None
potent I None
inhibitor I None
of I None
the I None
re I None
- I None
uptake I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
into I None
nerve I None
terminals I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
d I CHEMICAL
- O CHEMICAL
fenfluramine O CHEMICAL
suppresses I None
food I None
intake I None
in I None
both I None
animals I None
and I None
humans I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
We I None
have I None
investigated I None
the I None
role I None
of I None
the I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
receptor I None
in I None
mediating I None
the I None
effect I None
of I None
d I CHEMICAL
- O CHEMICAL
fenfluramine O CHEMICAL
on I None
mouse I None
food I None
intake I None
and I None
the I None
behavioural I None
satiety I None
sequence I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Mutant I None
mice I None
lacking I None
serotonin I CHEMICAL
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
receptors I None
and I None
wild I None
- I None
type I None
animals I None
were I None
habituated I None
to I None
a I None
daily I None
presentation I None
of I None
wet I None
mash I None
. I None
<eof> I None

<s> O None
Animals I None
were I None
non I None
- I None
deprived I None
and I None
received I None
d I CHEMICAL
- O CHEMICAL
fenfluramine O CHEMICAL
( I None
3 I None
- I None
30 I None
mg I None
/ I None
kg I None
) I None
30 I None
min I None
prior I None
to I None
being I None
assessed I None
for I None
the I None
presence I None
of I None
stereotypy I None
and I None
presented I None
with I None
wet I None
mash I None
. I None
<eof> I None

<s> O None
The I None
behaviour I None
of I None
animals I None
was I None
observed I None
for I None
the I None
subsequent I None
40 I None
min I None
and I None
food I None
intake I None
was I None
recorded I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
d I CHEMICAL
- O CHEMICAL
Fenfluramine O CHEMICAL
dose I None
- I None
dependently I None
inhibited I None
the I None
consumption I None
of I None
a I None
palatable I None
wet I None
mash I None
by I None
the I None
mice I None
. I None
<eof> I None

<s> O None
d I CHEMICAL
- O CHEMICAL
Fenfluramine O CHEMICAL
( I None
3 I None
mg I None
/ I None
kg I None
) I None
significantly I None
reduced I None
the I None
amount I None
of I None
wet I None
mash I None
consumed I None
by I None
wild I None
- I None
type I None
mice I None
and I None
induced I None
a I None
temporal I None
advance I None
in I None
the I None
behavioural I None
satiety I None
sequence I None
consistent I None
with I None
an I None
enhancement I None
of I None
satiety I None
. I None
<eof> I None

<s> O None
Mutant I None
mice I None
were I None
less I None
sensitive I None
to I None
the I None
satiating I None
effects I None
of I None
3 I None
mg I None
/ I None
kg I None
d I CHEMICAL
- O CHEMICAL
fenfluramine O CHEMICAL
. I None
<eof> I None

<s> O None
Hence I None
, I None
this I None
dose I None
of I None
d I CHEMICAL
- O CHEMICAL
fenfluramine O CHEMICAL
had I None
a I None
reduced I None
effect I None
on I None
both I None
food I None
consumption I None
and I None
the I None
behavioural I None
satiety I None
sequence I None
in I None
the I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
mutant I None
mice I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
mutant I None
mice I None
showed I None
an I None
increased I None
sensitivity I None
to I None
the I None
stereotypy I None
induced I None
by I None
high I None
doses I None
of I None
d I CHEMICAL
- O CHEMICAL
fenfluramine O CHEMICAL
( I None
10 I None
, I None
30 I None
mg I None
/ I None
kg I None
) I None
compared I None
to I None
that I None
of I None
wild I None
- I None
type I None
littermates I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
These I None
data I None
demonstrate I None
a I None
role I None
for I None
the I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
receptor I None
in I None
mediating I None
d I CHEMICAL
- O CHEMICAL
fenfluramine O CHEMICAL
- I None
induced I None
satiety I None
. I None
<eof> I None

<s> O None
Role I None
of I None
acetylcholinesterase I None
( I None
AChE I None
) I None
secreted I None
by I None
parasitic I None
nematodes I None
on I None
the I None
growth I None
of I None
the I None
cell I None
line I None
from I None
epithelial I None
origin I None
HT29 I None
- I None
D4 I None
. I None
<eof> I None

<s> O None
The I None
excretory I None
- I None
secretory I None
( I None
E I None
- I None
S I None
) I None
products I None
of I None
the I None
parasitic I None
nematodes I None
Trichostrongylus I None
colubriformis I None
and I None
Nematodirus I None
battus I None
were I None
found I None
to I None
modify I None
the I None
in I None
vitro I None
proliferation I None
of I None
the I None
tumorous I None
colic I None
HT29 I None
- I None
D4 I None
cell I None
line I None
of I None
epithelial I None
origin I None
. I None
<eof> I None

<s> O None
A I None
characteristic I None
feature I None
of I None
these I None
E I None
- I None
S I None
products I None
is I None
the I None
presence I None
of I None
a I None
high I None
level I None
of I None
acetylcholinesterase I GENE-N
( I None
AChE I GENE-N
) I None
activity I None
, I None
the I None
biological I None
significance I None
of I None
which I None
remains I None
unclear I None
. I None
<eof> I None

<s> O None
To I None
determine I None
a I None
possible I None
role I None
of I None
AChE I GENE-N
on I None
cell I None
growth I None
, I None
the I None
enzyme I None
was I None
purified I None
from I None
E I None
- I None
S I None
products I None
using I None
edrophonium I CHEMICAL
chloride O CHEMICAL
. I None
<eof> I None

<s> O None
Purity I None
was I None
confirmed I None
by I None
polyacrylamide I None
gel I None
electrophoresis I None
, I None
using I None
silver I None
and I None
Karnovsky I None
stains I None
, I None
before I None
assessing I None
its I None
effects I None
on I None
cell I None
proliferation I None
. I None
<eof> I None

<s> O None
The I None
purified I None
AChE I GENE-N
was I None
incorporated I None
at I None
different I None
concentrations I None
in I None
a I None
culture I None
medium I None
of I None
HT29 I None
- I None
D4 I None
cells I None
. I None
<eof> I None

<s> O None
A I None
mitogenic I None
effect I None
was I None
shown I None
for I None
low I None
concentrations I None
( I None
0 I None
. I None
1 I None
- I None
14 I None
units I None
) I None
. I None
<eof> I None

<s> O None
By I None
contrast I None
, I None
an I None
inhibitory I None
effect I None
was I None
noted I None
at I None
high I None
concentrations I None
( I None
35 I None
- I None
1400 I None
units I None
) I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
polyclonal I None
antibodies I None
were I None
prepared I None
and I None
depletion I None
of I None
AChE I GENE-N
in I None
E I None
- I None
S I None
products I None
by I None
immunoprecipitation I None
or I None
affinity I None
chromatography I None
resulted I None
in I None
a I None
partial I None
or I None
total I None
disappearance I None
of I None
the I None
stimulatory I None
effect I None
of I None
cell I None
growth I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
the I None
results I None
form I None
this I None
in I None
vitro I None
study I None
suggest I None
a I None
modulatory I None
role I None
for I None
AChE I GENE-N
secreted I None
by I None
nematode I None
parasites I None
on I None
the I None
proliferation I None
of I None
epithelial I None
cells I None
of I None
the I None
host I None
. I None
<eof> I None

<s> O None
Methimazole I CHEMICAL
and I None
propylthiouracil I CHEMICAL
increase I None
cellular I None
thyroid I GENE-Y
peroxidase O GENE-Y
activity I None
and I None
thyroid I GENE-Y
peroxidase O GENE-Y
mRNA I None
in I None
cultured I None
porcine I None
thyroid I None
follicles I None
. I None
<eof> I None

<s> O None
Methimazole I CHEMICAL
( I None
MMI I CHEMICAL
) I None
and I None
propylthiouracil I CHEMICAL
( I None
PTU I CHEMICAL
) I None
are I None
common I None
antithyroid I None
drugs I None
for I None
treating I None
hyperthyroidism I None
because I None
the I None
2 I None
drugs I None
inhibit I None
thyroid I GENE-Y
peroxidase O GENE-Y
( I None
TPO I GENE-Y
) I None
- I None
catalyzed I None
thyroid I None
hormone I None
formation I None
. I None
<eof> I None

<s> O None
We I None
studied I None
whether I None
the I None
2 I None
drugs I None
actually I None
inhibit I None
cellular I None
TPO I GENE-Y
activity I None
in I None
cultured I None
porcine I None
follicles I None
. I None
<eof> I None

<s> O None
Porcine I None
follicles I None
were I None
cultured I None
in I None
the I None
presence I None
of I None
1 I None
mU I None
/ I None
mL I None
thyrotropin I CHEMICAL
( I None
TSH I CHEMICAL
) I None
for I None
7 I None
days I None
. I None
<eof> I None

<s> O None
Then I None
follicles I None
were I None
exposed I None
to I None
MMI I CHEMICAL
or I None
PTU I CHEMICAL
in I None
the I None
presence I None
of I None
0 I None
. I None
1 I None
microM I None
Kl I None
for I None
2 I None
days I None
. I None
<eof> I None

<s> O None
TPO I GENE-Y
activity I None
was I None
measured I None
in I None
the I None
100 I None
, I None
000 I None
x I None
g I None
- I None
pellet I None
of I None
the I None
thyroid I None
sonicate I None
by I None
the I None
guaiacol I CHEMICAL
oxidation I None
method I None
. I None
<eof> I None

<s> O None
Exposure I None
to I None
MMI I CHEMICAL
( I None
1 I None
microM I None
and I None
10 I None
microM I None
) I None
or I None
PTU I CHEMICAL
( I None
10 I None
microM I None
and I None
100 I None
microM I None
) I None
for I None
2 I None
days I None
caused I None
a I None
significant I None
increase I None
in I None
cellular I None
TPO I GENE-Y
activity I None
; I None
100 I None
microM I None
MMI I CHEMICAL
inhibited I None
cellular I None
TPO I GENE-Y
activity I None
. I None
<eof> I None

<s> O None
The I None
presence I None
of I None
cyclic I CHEMICAL
adenosine O CHEMICAL
monophosphate O CHEMICAL
( I None
cAMP I CHEMICAL
) I None
- I None
generating I None
system I None
( I None
forskolin I CHEMICAL
) I None
in I None
TSH I None
- I None
free I None
medium I None
increased I None
MMI I CHEMICAL
- I None
mediated I None
TPO I GENE-Y
activity I None
. I None
<eof> I None

<s> O None
Cyclohexamide I CHEMICAL
inhibited I None
MMI I CHEMICAL
- I None
mediated I None
TPO I GENE-Y
activation I None
, I None
indicating I None
that I None
new I None
protein I None
synthesis I None
is I None
required I None
for I None
increased I None
TPO I GENE-Y
activity I None
. I None
<eof> I None

<s> O None
Reverse I None
transcriptase I None
- I None
polymerase I None
chain I None
reaction I None
( I None
RT I None
- I None
PCR I None
) I None
showed I None
an I None
increase I None
in I None
TPO I GENE-Y
mRNA I None
by I None
PTU I CHEMICAL
or I None
MMI I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
MMI I CHEMICAL
and I None
PTU I CHEMICAL
at I None
therapeutic I None
concentrations I None
can I None
increase I None
TPO I GENE-Y
mRNA I None
and I None
cellular I None
TPO I GENE-Y
activity I None
, I None
although I None
the I None
2 I None
drugs I None
inhibit I None
the I None
TPO I GENE-Y
- I None
H2O2 I CHEMICAL
- I None
mediated I None
catalytic I None
reaction I None
. I None
<eof> I None

<s> O None
Structure I None
of I None
acetylcholinesterase I GENE-Y
complexed I None
with I None
E2020 I CHEMICAL
( I None
Aricept I CHEMICAL
) I None
: I None
implications I None
for I None
the I None
design I None
of I None
new I None
anti I None
- I None
Alzheimer I None
drugs I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Several I None
cholinesterase I GENE-Y
inhibitors I None
are I None
either I None
being I None
utilized I None
for I None
symptomatic I None
treatment I None
of I None
Alzheimer I None
' I None
s I None
disease I None
or I None
are I None
in I None
advanced I None
clinical I None
trials I None
. I None
<eof> I None

<s> O None
E2020 I None
, I None
marketed I None
as I None
Aricept I CHEMICAL
, I None
is I None
a I None
member I None
of I None
a I None
large I None
family I None
of I None
N I CHEMICAL
- O CHEMICAL
benzylpiperidine O CHEMICAL
- I None
based I None
acetylcholinesterase I GENE-Y
( I None
AChE I GENE-Y
) I None
inhibitors I None
developed I None
, I None
synthesized I None
and I None
evaluated I None
by I None
the I None
Eisai I None
Company I None
in I None
Japan I None
. I None
<eof> I None

<s> O None
These I None
inhibitors I None
were I None
designed I None
on I None
the I None
basis I None
of I None
QSAR I None
studies I None
, I None
prior I None
to I None
elucidation I None
of I None
the I None
three I None
- I None
dimensional I None
structure I None
of I None
Torpedo I GENE-Y
californica O GENE-Y
AChE O GENE-Y
( I None
TcAChE I GENE-Y
) I None
. I None
<eof> I None

<s> O None
It I None
significantly I None
enhances I None
performance I None
in I None
animal I None
models I None
of I None
cholinergic I None
hypofunction I None
and I None
has I None
a I None
high I None
affinity I None
for I None
AChE I GENE-Y
, I None
binding I None
to I None
both I None
electric I GENE-N
eel O GENE-N
and O GENE-N
mouse O GENE-N
AChE O GENE-N
in I None
the I None
nanomolar I None
range I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Our I None
experimental I None
structure I None
of I None
the I None
E2020 I CHEMICAL
- I None
TcAChE I GENE-Y
complex I None
pinpoints I None
specific I None
interactions I None
responsible I None
for I None
the I None
high I None
affinity I None
and I None
selectivity I None
demonstrated I None
previously I None
. I None
<eof> I None

<s> O None
It I None
shows I None
that I None
E2020 I CHEMICAL
has I None
a I None
unique I None
orientation I None
along I None
the I None
active I None
- I None
site I None
gorge I None
, I None
extending I None
from I None
the I None
anionic I None
subsite I None
of I None
the I None
active I None
site I None
, I None
at I None
the I None
bottom I None
, I None
to I None
the I None
peripheral I None
anionic I None
site I None
, I None
at I None
the I None
top I None
, I None
via I None
aromatic I None
stacking I None
interactions I None
with I None
conserved I None
aromatic I CHEMICAL
acid O CHEMICAL
residues I None
. I None
<eof> I None

<s> O None
E2020 I CHEMICAL
does I None
not I None
, I None
however I None
, I None
interact I None
directly I None
with I None
either I None
the I None
catalytic I None
triad I None
or I None
the I None
' I None
oxyanion I None
hole I None
' I None
, I None
but I None
only I None
indirectly I None
via I None
solvent I None
molecules I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Our I None
study I None
shows I None
, I None
a I None
posteriori I None
, I None
that I None
the I None
design I None
of I None
E2020 I CHEMICAL
took I None
advantage I None
of I None
several I None
important I None
features I None
of I None
the I None
active I None
- I None
site I None
gorge I None
of I None
AChE I GENE-Y
to I None
produce I None
a I None
drug I None
with I None
both I None
high I None
affinity I None
for I None
AChE I GENE-Y
and I None
a I None
high I None
degree I None
of I None
selectivity I None
for I None
AChE I GENE-Y
versus I None
butyrylcholinesterase I GENE-Y
( I None
BChE I GENE-Y
) I None
. I None
<eof> I None

<s> O None
It I None
also I None
delineates I None
voids I None
within I None
the I None
gorge I None
that I None
are I None
not I None
occupied I None
by I None
E2020 I CHEMICAL
and I None
could I None
provide I None
sites I None
for I None
potential I None
modification I None
of I None
E2020 I CHEMICAL
to I None
produce I None
drugs I None
with I None
improved I None
pharmacological I None
profiles I None
. I None
<eof> I None

<s> O None
Maturation I None
of I None
neuromuscular I None
transmission I None
during I None
early I None
development I None
in I None
zebrafish I None
. I None
<eof> I None

<s> O None
We I None
have I None
examined I None
the I None
rapid I None
development I None
of I None
synaptic I None
transmission I None
at I None
the I None
neuromuscular I None
junction I None
( I None
NMJ I None
) I None
in I None
zebrafish I None
embryos I None
and I None
larvae I None
by I None
patch I None
- I None
clamp I None
recording I None
of I None
spontaneous I None
miniature I None
endplate I None
currents I None
( I None
mEPCs I None
) I None
and I None
single I None
acetylcholine I GENE-N
receptor O GENE-N
( I None
AChR I GENE-N
) I None
channels I None
. I None
<eof> I None

<s> O None
Embryonic I None
( I None
24 I None
- I None
36 I None
h I None
) I None
mEPCs I None
recorded I None
in I None
vivo I None
were I None
small I None
in I None
amplitude I None
( I None
< I None
50 I None
pA I None
) I None
. I None
<eof> I None

<s> O None
The I None
rate I None
of I None
mEPCs I None
increased I None
in I None
larvae I None
( I None
3 I None
. I None
5 I None
- I None
fold I None
increase I None
measured I None
by I None
6 I None
days I None
) I None
, I None
and I None
these I None
mEPCs I None
were I None
mostly I None
of I None
larger I None
amplitude I None
( I None
10 I None
- I None
fold I None
on I None
average I None
) I None
with I None
( I None
< I None
/ I None
= I None
5 I None
- I None
fold I None
) I None
faster I None
kinetics I None
. I None
<eof> I None

<s> O None
Intracellular I None
labeling I None
with I None
Lucifer I None
yellow I None
indicated I None
extensive I None
coupling I None
between I None
muscle I None
cells I None
in I None
both I None
embryos I None
and I None
larvae I None
( I None
< I None
/ I None
= I None
10 I None
days I None
) I None
. I None
<eof> I None

<s> O None
Blocking I None
acetylcholinesterase I None
( I None
AChE I None
) I None
with I None
eserine I None
had I None
no I None
effect I None
on I None
mEPC I None
kinetics I None
in I None
embryos I None
at I None
1 I None
day I None
and I None
only I None
partially I None
slowed I None
( I None
by I None
approximately I None
1 I None
/ I None
2 I None
) I None
the I None
decay I None
rate I None
in I None
larvae I None
at I None
6 I None
days I None
. I None
<eof> I None

<s> O None
In I None
acutely I None
dissociated I None
muscle I None
cells I None
, I None
we I None
observed I None
the I None
same I None
two I None
types I None
of I None
AChR I None
with I None
conductances I None
of I None
45 I None
and I None
60 I None
pS I None
and I None
with I None
similar I None
, I None
brief I None
( I None
< I None
0 I None
. I None
5 I None
ms I None
) I None
mean I None
open I None
times I None
in I None
both I None
embryos I None
and I None
larvae I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
AChR I None
properties I None
are I None
set I None
early I None
during I None
development I None
at I None
these I None
early I None
stages I None
; I None
functional I None
maturation I None
of I None
the I None
NMJ I None
is I None
only I None
partly I None
shaped I None
by I None
expression I None
of I None
AChE I None
and I None
may I None
also I None
depend I None
on I None
postsynaptic I None
AChR I None
clustering I None
and I None
presynaptic I None
maturation I None
. I None
<eof> I None

<s> O None
Multiple I None
mechanisms I None
of I None
action I None
: I None
the I None
pharmacological I None
profile I None
of I None
budipine I CHEMICAL
. I None
<eof> I None

<s> O None
Four I None
major I None
components I None
of I None
the I None
mechanism I None
of I None
action I None
have I None
been I None
identified I None
for I None
the I None
antiparkinsonian I None
drug I None
budipine I CHEMICAL
up I None
to I None
now I None
. I None
<eof> I None

<s> O None
1 I None
) I None
The I None
primary I None
action I None
of I None
budipine I CHEMICAL
is I None
an I None
indirect I None
dopaminergic I None
effect I None
as I None
shown I None
by I None
facilitation I None
of I None
dopamine I CHEMICAL
( I None
DA I CHEMICAL
) I None
release I None
, I None
inhibition I None
of I None
monoamine I GENE-Y
oxidase O GENE-Y
type O GENE-Y
B O GENE-Y
( I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
) I None
and I None
of I None
DA I CHEMICAL
( I None
re I None
) I None
up I None
- I None
take I None
and I None
stimulation I None
of I None
aromatic I GENE-Y
L O GENE-Y
- O GENE-Y
amino O GENE-Y
acid O GENE-Y
decarboxylase O GENE-Y
( I None
AADC I GENE-Y
) I None
, I None
which I None
in I None
sum I None
might I None
be I None
responsible I None
for I None
enhancing I None
the I None
endogenous I None
dopaminergic I None
activity I None
. I None
<eof> I None

<s> O None
2 I None
) I None
Radioligand I None
and I None
functional I None
studies I None
at I None
the I None
N I GENE-N
- O GENE-N
methyl O GENE-N
- O GENE-N
D O GENE-N
- O GENE-N
aspartate O GENE-N
( O GENE-N
NMDA O GENE-N
) O GENE-N
type O GENE-N
glutamate O GENE-N
receptor O GENE-N
characterize I None
budipine I CHEMICAL
as I None
a I None
low I None
- I None
affinity I None
, I None
uncompetitive I None
antagonist I None
with I None
fast I None
kinetics I None
and I None
moderate I None
voltage I None
- I None
dependency I None
at I None
the I None
phencyclidine I CHEMICAL
( I None
PCP I CHEMICAL
) I None
binding I None
site I None
, I None
comparable I None
to I None
that I None
observed I None
with I None
amantadine I CHEMICAL
, I None
thereby I None
counteracting I None
an I None
increased I None
excitatory I None
glutamatergic I None
activity I None
. I None
<eof> I None

<s> O None
3 I None
) I None
The I None
antimuscarinic I None
action I None
of I None
budipine I CHEMICAL
, I None
verified I None
by I None
functional I None
and I None
binding I None
studies I None
at I None
native I None
muscarinic I GENE-N
M1 O GENE-N
- O GENE-N
M3 O GENE-N
and I None
human I GENE-N
recombinant O GENE-N
m1 O GENE-N
- O GENE-N
m5 O GENE-N
receptor O GENE-N
subtypes I None
in I None
vitro I None
, I None
is I None
up I None
to I None
125 I None
- I None
fold I None
weaker I None
than I None
that I None
of I None
biperiden I CHEMICAL
and I None
corresponds I None
to I None
its I None
approximately I None
100 I None
- I None
fold I None
lower I None
potency I None
to I None
cause I None
experimentally I None
- I None
induced I None
peripheral I None
antimuscarinic I None
effects I None
and I None
explains I None
only I None
part I None
of I None
its I None
high I None
potency I None
, I None
which I None
equals I None
biperiden I CHEMICAL
, I None
to I None
suppress I None
cholinergically I None
evoked I None
tremor I None
. I None
<eof> I None

<s> O None
4 I None
) I None
An I None
additional I None
inhibition I None
of I None
striatal I None
gamma I CHEMICAL
- O CHEMICAL
aminobutyric O CHEMICAL
acid O CHEMICAL
( I None
GABA I CHEMICAL
) I None
release I None
by I None
budipine I CHEMICAL
may I None
be I None
beneficial I None
to I None
suppress I None
an I None
increased I None
striatal I None
GABAergic I None
output I None
activity I None
. I None
<eof> I None

<s> O None
The I None
contribution I None
of I None
other I None
observed I None
effects I None
to I None
the I None
therapeutic I None
action I None
of I None
budipine I CHEMICAL
, I None
i I None
. I None
e I None
. I None
weak I None
stimulation I None
of I None
noradrenaline I CHEMICAL
and I None
serotonin I CHEMICAL
release I None
, I None
binding I None
to I None
brain I GENE-Y
sigma1 O GENE-Y
receptors O GENE-Y
and I None
blockade I None
of I None
histamine I GENE-Y
H1 O GENE-Y
receptors O GENE-Y
, I None
is I None
not I None
yet I None
clear I None
. I None
<eof> I None

<s> O None
By I None
means I None
of I None
these I None
multiple I None
mechanisms I None
, I None
budipine I CHEMICAL
might I None
correct I None
the I None
imbalance I None
of I None
striatal I None
output I None
pathways I None
by I None
restoring I None
DA I CHEMICAL
levels I None
in I None
the I None
striatum I None
, I None
and I None
positively I None
influence I None
the I None
secondary I None
changes I None
in I None
other I None
transmitter I None
systems I None
( I None
glutamate I CHEMICAL
, I None
acetylcholine I CHEMICAL
, I None
GABA I CHEMICAL
) I None
observed I None
in I None
Parkinson I None
' I None
s I None
disease I None
. I None
<eof> I None

<s> O None
Disparate I None
actions I None
of I None
mifepristone I CHEMICAL
( I None
RU I CHEMICAL
486 O CHEMICAL
) I None
on I None
glands I None
and I None
stroma I None
in I None
the I None
primate I None
endometrium I None
. I None
<eof> I None

<s> O None
Besides I None
being I None
an I None
antiprogestin I None
, I None
mifepristone I CHEMICAL
( I None
RU I CHEMICAL
486 O CHEMICAL
) I None
was I None
recently I None
shown I None
to I None
antagonize I None
oestrogen I CHEMICAL
- I None
dependent I None
growth I None
in I None
the I None
endometrium I None
. I None
<eof> I None

<s> O None
To I None
explore I None
the I None
molecular I None
mechanisms I None
for I None
this I None
phenomenon I None
, I None
we I None
investigated I None
whether I None
or I None
not I None
the I None
morphological I None
effects I None
of I None
mifepristone I CHEMICAL
are I None
mediated I None
by I None
the I None
progesterone I GENE-Y
receptor O GENE-Y
( I None
PR I GENE-Y
) I None
and I None
whether I None
mifepristone I CHEMICAL
has I None
disparate I None
effects I None
on I None
the I None
glandular I None
epithelium I None
and I None
stroma I None
. I None
<eof> I None

<s> O None
Six I None
groups I None
of I None
hypogonadal I None
, I None
oestrogen I CHEMICAL
- I None
primed I None
cynomolgus I None
monkeys I None
were I None
treated I None
for I None
2 I None
weeks I None
with I None
: I None
vehicle I None
only I None
( I None
group I None
I I None
) I None
; I None
mifepristone I CHEMICAL
( I None
group I None
II I None
) I None
; I None
mifepristone I CHEMICAL
plus I None
progesterone I None
at I None
0 I None
. I None
2 I None
mg I None
/ I None
kg I None
( I None
group I None
III I None
) I None
, I None
1 I None
. I None
0 I None
mg I None
/ I None
kg I None
( I None
group I None
IV I None
) I None
or I None
5 I None
. I None
0 I None
mg I None
/ I None
kg I None
( I None
group I None
V I None
) I None
; I None
and I None
progesterone I CHEMICAL
only I None
( I None
5 I None
. I None
0 I None
mg I None
/ I None
kg I None
) I None
( I None
group I None
VI I None
) I None
. I None
<eof> I None

<s> O None
Histomorphological I None
evaluation I None
showed I None
strikingly I None
compacted I None
stroma I None
in I None
the I None
mifepristone I CHEMICAL
- I None
exposed I None
endometria I None
( I None
group I None
II I None
) I None
, I None
which I None
was I None
partially I None
reversible I None
by I None
additional I None
progesterone I CHEMICAL
treatment I None
( I None
groups I None
III I None
- I None
V I None
) I None
. I None
<eof> I None

<s> O None
Glandular I None
proliferation I None
( I None
pseudostratification I None
, I None
glandular I None
mitoses I None
) I None
in I None
mifepristone I CHEMICAL
- I None
treated I None
monkeys I None
was I None
not I None
significantly I None
different I None
from I None
that I None
in I None
vehicle I None
( I None
oestradiol I CHEMICAL
) I None
- I None
treated I None
monkeys I None
, I None
but I None
was I None
inhibited I None
by I None
progesterone I CHEMICAL
- I None
only I None
treatment I None
. I None
<eof> I None

<s> O None
Cells I None
containing I None
vacuoles I None
were I None
scarce I None
in I None
the I None
mifepristone I CHEMICAL
- I None
exposed I None
endometrium I None
, I None
but I None
detected I None
frequently I None
in I None
progesterone I CHEMICAL
- I None
exposed I None
endometria I None
, I None
indicating I None
the I None
strong I None
antisecretory I None
effect I None
of I None
mifepristone I CHEMICAL
on I None
glands I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
oestrogen I CHEMICAL
- I None
dependent I None
oedema I None
in I None
the I None
stroma I None
is I None
antagonized I None
by I None
mifepristone I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
reversal I None
of I None
this I None
effect I None
by I None
progesterone I CHEMICAL
suggests I None
a I None
PR I GENE-Y
- I None
mediated I None
mechanism I None
. I None
<eof> I None

<s> O None
In I None
glands I None
, I None
mifepristone I CHEMICAL
is I None
antiprogestogenic I None
, I None
but I None
not I None
antioestrogenic I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
stromal I None
cells I None
may I None
be I None
the I None
target I None
of I None
antiprogestin I None
- I None
induced I None
inhibition I None
of I None
oedema I None
and I None
endometrial I None
growth I None
. I None
<eof> I None

<s> O None
An I None
Arg I CHEMICAL
/ I None
Ser I CHEMICAL
substitution I None
in I None
the I None
second I None
epidermal I GENE-N
growth O GENE-N
factor O GENE-N
- O GENE-N
like O GENE-N
module O GENE-N
of I None
factor I GENE-Y
IX O GENE-Y
introduces I None
an I None
O I CHEMICAL
- I None
linked I None
carbohydrate I CHEMICAL
and I None
markedly I None
impairs I None
activation I None
by I None
factor I GENE-Y
XIa O GENE-Y
and I None
factor I GENE-Y
VIIa O GENE-Y
/ I None
Tissue I GENE-Y
factor O GENE-Y
and I None
catalytic I None
efficiency I None
of I None
factor I GENE-Y
IXa O GENE-Y
. I None
<eof> I None

<s> O None
Factor I GENE-Y
IXR94S O GENE-Y
is I None
a I None
naturally I None
occurring I None
hemophilia I None
B I None
defect I None
, I None
which I None
results I None
from I None
an I None
Arg I GENE-N
94 O GENE-N
to O GENE-N
Ser O GENE-N
mutation I None
in I None
the I None
second I None
epidermal I GENE-N
growth O GENE-N
factor O GENE-N
( O GENE-N
EGF O GENE-N
) O GENE-N
- O GENE-N
like O GENE-N
module O GENE-N
of I None
factor I GENE-Y
IX O GENE-Y
. I None
<eof> I None

<s> O None
Recombinant I None
factor I GENE-Y
IXR94S O GENE-Y
was I None
activated I None
by I None
factor I GENE-Y
XIa O GENE-Y
/ I None
calcium I CHEMICAL
with I None
an I None
approximately I None
50 I None
- I None
fold I None
reduced I None
rate I None
and I None
by I None
factor I GENE-Y
VIIa O GENE-Y
/ I None
tissue I GENE-Y
factor O GENE-Y
/ I None
phospholipid I None
/ I None
calcium I CHEMICAL
with I None
an I None
approximately I None
20 I None
- I None
fold I None
reduced I None
rate I None
compared I None
with I None
wild I None
- I None
type I None
factor I GENE-Y
IX O GENE-Y
. I None
<eof> I None

<s> O None
The I None
apparent I None
molecular I None
mass I None
of I None
the I None
light I None
chain I None
of I None
factor I GENE-Y
IXaR94S O GENE-Y
was I None
approximately I None
6 I None
kD I None
higher I None
than I None
that I None
of I None
plasma I None
or I None
wild I None
- I None
type I None
factor I GENE-Y
IX O GENE-Y
, I None
which I None
was I None
not I None
corrected I None
by I None
N I GENE-Y
- O GENE-Y
glycosidase O GENE-Y
F O GENE-Y
digestion I None
. I None
<eof> I None

<s> O None
This I None
result I None
indicated I None
the I None
presence I None
of I None
additional I None
O I CHEMICAL
- I None
linked I None
carbohydrate I CHEMICAL
in I None
the I None
mutant I None
light I None
chain I None
, I None
probably I None
at I None
new I None
Ser I CHEMICAL
94 I None
. I None
<eof> I None

<s> O None
The I None
initial I None
rate I None
of I None
activation I None
of I None
factor I GENE-Y
X O GENE-Y
by I None
factor I GENE-Y
IXaR94S O GENE-Y
in I None
the I None
presence I None
of I None
polylysine I None
was I None
7 I None
% I None
+ I None
/ I None
- I None
1 I None
% I None
of I None
the I None
initial I None
rate I None
of I None
activation I None
of I None
factor I GENE-Y
X O GENE-Y
by I None
plasma I None
factor I GENE-Y
IXa O GENE-Y
, I None
and I None
the I None
kc I None
/ I None
Km I None
for I None
activation I None
of I None
factor I GENE-Y
X O GENE-Y
by I None
factor I GENE-Y
IXaR94S O GENE-Y
/ I None
factor I GENE-Y
VIIIa O GENE-Y
/ I None
phospholipid I None
/ I None
calcium I CHEMICAL
was I None
4 I None
% I None
+ I None
/ I None
- I None
1 I None
% I None
of I None
the I None
kc I None
/ I None
Km I None
for I None
activation I None
of I None
factor I GENE-Y
X O GENE-Y
by I None
plasma I None
factor I GENE-Y
IXa O GENE-Y
/ I None
factor I GENE-Y
VIIIa O GENE-Y
/ I None
phospholipid I None
/ I None
calcium I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
reduced I None
efficiency I None
of I None
activation I None
of I None
factor I GENE-Y
X O GENE-Y
by I None
factor I GENE-Y
IXaR94S O GENE-Y
in I None
the I None
tenase I GENE-N
enzyme O GENE-N
complex O GENE-N
was I None
due I None
to I None
a I None
58 I None
- I None
fold I None
+ I None
/ I None
- I None
12 I None
- I None
fold I None
decrease I None
in I None
kcat I None
with I None
little I None
effect I None
on I None
Km I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
the I None
R94S I GENE-N
mutation I None
had I None
introduced I None
an I None
O I CHEMICAL
- I None
linked I None
carbohydrate I CHEMICAL
, I None
which I None
markedly I None
impaired I None
both I None
activation I None
by I None
factor I GENE-Y
XIa O GENE-Y
and I None
turnover I None
of I None
factor I GENE-Y
X O GENE-Y
in I None
the I None
tenase I GENE-N
enzyme O GENE-N
complex O GENE-N
. I None
<eof> I None

<s> O None
Expression I None
of I None
multiple I None
alpha1 I GENE-N
- O GENE-N
adrenoceptors O GENE-N
on I None
vascular I None
smooth I None
muscle I None
: I None
correlation I None
with I None
the I None
regulation I None
of I None
contraction I None
. I None
<eof> I None

<s> O None
Previous I None
work I None
has I None
shown I None
that I None
the I None
genes I None
encoding I None
each I None
alpha1 I GENE-N
- O GENE-N
adrenoceptor O GENE-N
subtype I None
are I None
coexpressed I None
throughout I None
the I None
peripheral I None
vascular I None
system I None
. I None
<eof> I None

<s> O None
We I None
have I None
evaluated I None
subtype I None
- I None
selective I None
antibodies I None
as I None
tools I None
to I None
determine I None
the I None
extent I None
of I None
protein I None
expression I None
in I None
arteries I None
. I None
<eof> I None

<s> O None
The I None
alpha1A I GENE-N
- O GENE-N
, O GENE-N
alpha1B O GENE-N
- O GENE-N
, O GENE-N
and O GENE-N
alpha1D O GENE-N
- O GENE-N
adrenoceptors O GENE-N
were I None
detected I None
in I None
the I None
medial I None
layer I None
of I None
the I None
aorta I None
, I None
caudal I None
, I None
femoral I None
, I None
iliac I None
, I None
renal I None
, I None
superior I None
mesenteric I None
, I None
and I None
mesenteric I None
resistance I None
arteries I None
. I None
<eof> I None

<s> O None
In I None
Rat1 I None
fibroblasts I None
expressing I None
each I None
subtype I None
, I None
immunoreactivity I None
was I None
noted I None
both I None
on I None
the I None
cell I None
surface I None
and I None
in I None
a I None
perinuclear I None
orientation I None
. I None
<eof> I None

<s> O None
Intense I None
alpha1B I GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
immunostaining I None
was I None
similarly I None
localized I None
in I None
cultured I None
femoral I None
and I None
renal I None
vascular I None
smooth I None
muscle I None
cells I None
. I None
<eof> I None

<s> O None
Although I None
the I None
cellular I None
localization I None
appeared I None
to I None
be I None
the I None
same I None
, I None
immunoreactivity I None
obtained I None
with I None
alpha1A I GENE-N
- O GENE-N
and O GENE-N
alpha1D O GENE-N
- O GENE-N
adrenoceptors O GENE-N
was I None
much I None
less I None
intense I None
than I None
that I None
with I None
the I None
alpha1B I GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
. I None
<eof> I None

<s> O None
The I None
alpha1A I GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
selective I None
agonist I None
A I CHEMICAL
- O CHEMICAL
61603 O CHEMICAL
was I None
22 I None
- I None
fold I None
more I None
potent I None
in I None
activating I None
renal I None
artery I None
contraction I None
when I None
compared I None
with I None
the I None
femoral I None
artery I None
. I None
<eof> I None

<s> O None
The I None
expression I None
of I None
each I None
alpha1 I GENE-N
- O GENE-N
adrenoceptor O GENE-N
was I None
significantly I None
decreased I None
by I None
in I None
vivo I None
application I None
of I None
antisense I None
oligonucleotides I CHEMICAL
targeted I None
against I None
each I None
subtype I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
the I None
expression I None
of I None
only I None
one I None
, I None
the I None
alpha1A I None
in I None
renal I None
and I None
the I None
alpha1D I None
in I None
femoral I None
arteries I None
, I None
reduced I None
the I None
contractile I None
response I None
to I None
naphazoline I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
results I None
show I None
: I None
1 I None
) I None
subtype I None
- I None
selective I None
antibodies I None
can I None
be I None
used I None
in I None
tissues I None
and I None
cell I None
culture I None
to I None
localize I None
the I None
alpha1 I GENE-N
- O GENE-N
adrenoceptor O GENE-N
subtypes I None
, I None
2 I None
) I None
in I None
addition I None
to I None
expression I None
on I None
the I None
cell I None
surface I None
, I None
the I None
alpha1 I GENE-N
- O GENE-N
adrenoceptors O GENE-N
are I None
expressed I None
intracellularly I None
, I None
and I None
3 I None
) I None
despite I None
expression I None
of I None
all I None
adrenoceptors I GENE-N
, I None
a I None
single I None
subtype I None
mediates I None
the I None
contractile I None
response I None
in I None
the I None
femoral I None
and I None
renal I None
arteries I None
. I None
<eof> I None

<s> O None
Probing I None
the I None
structural I None
changes I None
in I None
the I None
light I GENE-Y
chain O GENE-Y
of O GENE-Y
human O GENE-Y
coagulation O GENE-Y
factor O GENE-Y
VIIa O GENE-Y
due I None
to I None
tissue I GENE-Y
factor O GENE-Y
association I None
. I None
<eof> I None

<s> O None
The I None
crystallographic I None
structure I None
of I None
human I GENE-Y
coagulation O GENE-Y
factor O GENE-Y
VIIa O GENE-Y
/ I None
tissue I GENE-Y
factor O GENE-Y
complex I None
bound I None
with I None
calcium I CHEMICAL
ions I None
was I None
used I None
to I None
model I None
the I None
solution I None
structure I None
of I None
the I None
light I GENE-Y
chain O GENE-Y
of O GENE-Y
factor O GENE-Y
VIIa O GENE-Y
( I None
residues I None
1 I None
- I None
142 I None
) I None
in I None
the I None
absence I None
of I None
tissue I GENE-Y
factor O GENE-Y
. I None
<eof> I None

<s> O None
The I None
Amber I None
force I None
field I None
in I None
conjunction I None
with I None
the I None
particle I None
mesh I None
Ewald I None
summation I None
method I None
to I None
accommodate I None
long I None
- I None
range I None
electrostatic I None
interactions I None
was I None
used I None
in I None
the I None
trajectory I None
calculations I None
. I None
<eof> I None

<s> O None
The I None
estimated I None
TF I GENE-Y
- I None
free I None
solution I None
structure I None
was I None
then I None
compared I None
with I None
the I None
crystal I None
structure I None
of I None
factor I GENE-Y
VIIa O GENE-Y
/ I None
tissue I GENE-Y
factor O GENE-Y
complex I None
to I None
estimate I None
the I None
restructuring I None
of I None
factor I GENE-Y
VIIa O GENE-Y
due I None
to I None
tissue I GENE-Y
factor O GENE-Y
binding I None
. I None
<eof> I None

<s> O None
The I None
solution I None
structure I None
of I None
the I None
light I GENE-Y
chain O GENE-Y
of O GENE-Y
factor O GENE-Y
VIIa O GENE-Y
in I None
the I None
absence I None
of I None
tissue I GENE-Y
factor O GENE-Y
is I None
predicted I None
to I None
be I None
an I None
extended I None
domain I None
structure I None
similar I None
to I None
that I None
of I None
the I None
tissue I GENE-Y
factor O GENE-Y
- I None
bound I None
crystal I None
. I None
<eof> I None

<s> O None
Removal I None
of I None
the I None
EGF1 I GENE-N
- I None
bound I None
calcium I CHEMICAL
ion I None
is I None
shown I None
by I None
simulation I None
to I None
lead I None
to I None
minor I None
structural I None
changes I None
within I None
the I None
EGF1 I GENE-N
domain O GENE-N
, I None
but I None
also I None
leads I None
to I None
substantial I None
relative I None
reorientation I None
of I None
the I None
Gla I GENE-N
and O GENE-N
EGF1 O GENE-N
domains O GENE-N
. I None
<eof> I None

<s> O None
A I None
noncatalytic I None
tetrahydrofolate I GENE-N
tight O GENE-N
binding O GENE-N
site O GENE-N
is I None
on I None
the I None
small I None
domain I None
of I None
10 I GENE-Y
- O GENE-Y
formyltetrahydrofolate O GENE-Y
dehydrogenase O GENE-Y
. I None
<eof> I None

<s> O None
10 I GENE-Y
- O GENE-Y
Formyltetrahydrofolate O GENE-Y
dehydrogenase O GENE-Y
has I None
previously I None
been I None
identified I None
as I None
a I None
tight I None
binding I None
protein I None
of I None
the I None
polyglutamate I CHEMICAL
forms I None
of I None
tetrahydrofolate I CHEMICAL
( I None
R I None
. I None
J I None
. I None
Cook I None
and I None
C I None
. I None
Wagner I None
, I None
Biochemistry I None
21 I None
, I None
4427 I None
- I None
4434 I None
, I None
1982 I None
) I None
. I None
<eof> I None

<s> O None
Each I None
subunit I None
contains I None
two I None
independently I None
folded I None
domains I None
connected I None
by I None
a I None
linking I None
peptide I None
. I None
<eof> I None

<s> O None
By I None
using I None
the I None
stable I None
substrate I None
and I None
product I None
analogs I None
10 I CHEMICAL
- O CHEMICAL
formyl O CHEMICAL
5 O CHEMICAL
, O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
dideazafolate O CHEMICAL
and I None
5 I CHEMICAL
, O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
dideazafolate O CHEMICAL
, I None
respectively I None
, I None
we I None
have I None
determined I None
that I None
the I None
tight I GENE-N
binding O GENE-N
folate O GENE-N
site O GENE-N
is I None
separate I None
from I None
the I None
catalytic I None
site I None
and I None
that I None
it I None
is I None
located I None
on I None
the I None
N I CHEMICAL
- I None
terminal I None
domain I None
of I None
the I None
protein I None
. I None
<eof> I None

<s> O None
This I None
was I None
achieved I None
by I None
cross I None
- I None
linking I None
10 I CHEMICAL
- O CHEMICAL
formyl O CHEMICAL
5 O CHEMICAL
, O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
dideazafolate O CHEMICAL
to I None
the I None
dehydrogenase I GENE-N
through I None
the I None
carboxyl I None
group I None
of I None
the I None
substrate I None
analog I None
. I None
<eof> I None

<s> O None
The I None
cross I None
- I None
linked I None
substrate I None
analog I None
was I None
converted I None
to I None
the I None
cross I None
- I None
linked I None
product I None
complex I None
by I None
adding I None
either I None
NADP I CHEMICAL
+ O CHEMICAL
or I None
2 I CHEMICAL
- O CHEMICAL
mercaptoethanol O CHEMICAL
, I None
proving I None
that I None
the I None
10 I CHEMICAL
- O CHEMICAL
formyl O CHEMICAL
5 O CHEMICAL
, O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
dideazafolate O CHEMICAL
was I None
bound I None
at I None
the I None
active I None
site I None
. I None
<eof> I None

<s> O None
With I None
the I None
active I None
site I None
cross I None
- I None
linked I None
to I None
5 I CHEMICAL
, O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
dideazafolate O CHEMICAL
and I None
not I None
available I None
for I None
binding I None
, I None
the I None
enzyme I None
still I None
bound I None
5 I CHEMICAL
, O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
dideazafolate O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
3H O CHEMICAL
] O CHEMICAL
tetraglutamate O CHEMICAL
tightly I None
but I None
noncovalently I None
. I None
<eof> I None

<s> O None
Separation I None
of I None
the I None
large I None
and I None
small I None
domains I None
by I None
limited I None
proteolysis I None
showed I None
that I None
the I None
tightly I None
bound I None
5 I CHEMICAL
, O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
dideazafolate O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
3H O CHEMICAL
] O CHEMICAL
tetraglutamate O CHEMICAL
was I None
located I None
on I None
the I None
small I None
domain I None
. I None
<eof> I None

<s> O None
The I None
location I None
of I None
the I None
cross I None
- I None
linked I None
10 I CHEMICAL
- O CHEMICAL
formyl O CHEMICAL
5 O CHEMICAL
, O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
dideazafolate O CHEMICAL
at I None
the I None
active I None
site I None
was I None
determined I None
by I None
amino I CHEMICAL
acid O CHEMICAL
sequencing I None
of I None
an I None
isolated I None
tryptic I None
peptide I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
tumor I GENE-Y
necrosis O GENE-Y
factor O GENE-Y
alpha O GENE-Y
- I None
stimulated I None
aromatase I GENE-Y
activity I None
by I None
microtubule I None
- I None
stabilizing I None
agents I None
, I None
paclitaxel I CHEMICAL
and I None
2 I CHEMICAL
- O CHEMICAL
methoxyestradiol O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
aromatase I GENE-Y
enzyme I None
, I None
which I None
converts I None
androstenedione I CHEMICAL
to I None
oestrone I CHEMICAL
, I None
regulates I None
the I None
availability I None
of I None
oestrogen I CHEMICAL
to I None
support I None
the I None
growth I None
of I None
hormone I None
- I None
dependent I None
breast I None
tumours I None
. I None
<eof> I None

<s> O None
Cytokines I GENE-N
, I None
such I None
as I None
interleukin I GENE-Y
6 O GENE-Y
( I None
IL I GENE-Y
- O GENE-Y
6 O GENE-Y
) I None
and I None
tumour I GENE-Y
necrosis O GENE-Y
factor O GENE-Y
alpha O GENE-Y
( I None
TNFalpha I GENE-Y
) I None
or I None
prostaglandin I CHEMICAL
E O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
( I None
PGE I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
) I None
, I None
can I None
stimulate I None
aromatase I GENE-Y
activity I None
. I None
<eof> I None

<s> O None
These I None
factors I None
may I None
originate I None
from I None
cells I None
of I None
the I None
immune I None
system I None
that I None
infiltrate I None
breast I None
tumours I None
. I None
<eof> I None

<s> O None
Paclitaxel I CHEMICAL
, I None
which I None
is I None
used I None
in I None
the I None
treatment I None
of I None
breast I None
cancer I None
, I None
stabilizes I None
microtubules I None
and I None
has I None
previously I None
been I None
shown I None
to I None
rapidly I None
down I None
- I None
regulate I None
TNF I GENE-N
- O GENE-N
receptors O GENE-N
on I None
human I None
macrophages I None
. I None
<eof> I None

<s> O None
The I None
endogenous I None
oestrogen I CHEMICAL
metabolite I None
, I None
2 I CHEMICAL
- O CHEMICAL
methoxyestradiol O CHEMICAL
( I None
2 I CHEMICAL
- O CHEMICAL
meOE2 O CHEMICAL
) I None
, I None
also I None
acts I None
to I None
stabilize I None
microtubules I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
have I None
examined I None
the I None
ability I None
of I None
paclitaxel I CHEMICAL
or I None
2 I CHEMICAL
- O CHEMICAL
meOE2 O CHEMICAL
to I None
antagonise I None
TNFalpha I GENE-Y
- I None
stimulated I None
aromatase I GENE-Y
activity I None
in I None
stromal I None
fibroblasts I None
derived I None
from I None
normal I None
or I None
malignant I None
breast I None
tissues I None
. I None
<eof> I None

<s> O None
Paclitaxel I CHEMICAL
inhibited I None
basal I None
and I None
TNFalpha I GENE-Y
- I None
stimulated I None
aromatase I GENE-Y
activities I None
by I None
88 I None
% I None
and I None
91 I None
% I None
respectively I None
. I None
<eof> I None

<s> O None
2 I CHEMICAL
- O CHEMICAL
MeOE2 O CHEMICAL
also I None
reduced I None
basal I None
and I None
TNFalpha I GENE-Y
- I None
stimulated I None
aromatase I GENE-Y
activities I None
by I None
46 I None
% I None
and I None
56 I None
% I None
respectively I None
. I None
<eof> I None

<s> O None
Both I None
paclitaxel I CHEMICAL
and I None
2 I CHEMICAL
- O CHEMICAL
meOE2 O CHEMICAL
also I None
inhibited I None
stimulation I None
of I None
aromatase I GENE-Y
activity I None
by I None
IL I GENE-Y
- O GENE-Y
6 O GENE-Y
plus I None
its I None
soluble I None
receptor I None
and I None
PGE I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
16alpha I None
- I None
hydroxylated I None
derivative I None
of I None
2 I None
- I None
meoE2 I None
and I None
2 I None
- I None
meOE3 I None
, I None
which I None
does I None
not I None
bind I None
to I None
microtubules I None
, I None
was I None
less I None
effective I None
at I None
inhibiting I None
TNFalpha I GENE-Y
- I None
stimulated I None
aromatase I GENE-Y
activity I None
. I None
<eof> I None

<s> O None
Increased I None
2 I CHEMICAL
- O CHEMICAL
hydroxylation O CHEMICAL
of O CHEMICAL
oestrogens O CHEMICAL
, I None
and I None
subsequent I None
formation I None
of I None
their I None
2 I CHEMICAL
- O CHEMICAL
methoxy O CHEMICAL
derivatives I None
, I None
may I None
be I None
associated I None
with I None
a I None
reduced I None
risk I None
of I None
breast I None
cancer I None
. I None
<eof> I None

<s> O None
It I None
is I None
possible I None
that I None
the I None
pathway I None
of I None
oestrogen I CHEMICAL
metabolism I None
may I None
influence I None
the I None
ability I None
of I None
stromal I None
cells I None
to I None
respond I None
to I None
cytokine I GENE-N
stimulation I None
. I None
<eof> I None

<s> O None
Insulin I GENE-Y
resistance I None
and I None
thrombosis I None
: I None
a I None
cardiologist I None
' I None
s I None
view I None
. I None
<eof> I None

<s> O None
Atherogenesis I None
in I None
the I None
vasculature I None
is I None
accelerated I None
by I None
changes I None
in I None
the I None
dynamic I None
equilibrium I None
between I None
endogenous I None
tissue I GENE-Y
plasminogen O GENE-Y
activator O GENE-Y
and I None
plasminogen I GENE-Y
activator O GENE-Y
inhibitor O GENE-Y
- O GENE-Y
1 O GENE-Y
( I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
. I None
<eof> I None

<s> O None
Increased I None
expression I None
of I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
decreased I None
expression I None
of I None
tissue I GENE-N
plasminogen O GENE-N
activator O GENE-N
, I None
or I None
both I None
can I None
lead I None
to I None
decreased I None
fibrinolytic I None
activity I None
and I None
predispose I None
to I None
thrombosis I None
. I None
<eof> I None

<s> O None
Increased I None
concentrations I None
of I None
insulin I GENE-Y
( I None
and I None
proinsulin I GENE-Y
) I None
in I None
the I None
plasma I None
increase I None
plasma I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
although I None
the I None
mechanisms I None
of I None
this I None
effect I None
are I None
not I None
known I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
it I None
has I None
been I None
observed I None
that I None
basal I None
fibrinolytic I None
activity I None
is I None
decreased I None
in I None
patients I None
with I None
type I None
2 I None
diabetes I None
; I None
this I None
may I None
accelerate I None
atherosclerosis I None
by I None
exposing I None
vascular I None
luminal I None
wall I None
surfaces I None
to I None
persistent I None
and I None
recurrent I None
thrombi I None
. I None
<eof> I None

<s> O None
Abnormalities I None
in I None
the I None
vessel I None
wall I None
appear I None
to I None
contribute I None
to I None
the I None
increased I None
risk I None
. I None
<eof> I None

<s> O None
There I None
is I None
also I None
evidence I None
that I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
content I None
is I None
increased I None
in I None
atherosclerotic I None
lesions I None
of I None
patients I None
with I None
type I None
2 I None
diabetes I None
, I None
suggesting I None
that I None
interventions I None
to I None
reduce I None
insulin I GENE-Y
resistance I None
and I None
improve I None
glycemic I None
control I None
may I None
improve I None
the I None
fibrinolytic I None
response I None
. I None
<eof> I None

<s> O None
Clinical I None
studies I None
in I None
patients I None
with I None
polycystic I None
ovary I None
syndrome I None
( I None
characterized I None
by I None
insulin I GENE-Y
resistance I None
, I None
hyperinsulinemia I None
, I None
ovarian I None
androgen I None
overproduction I None
, I None
and I None
impaired I None
fibrinolytic I None
capacity I None
) I None
demonstrated I None
that I None
treatment I None
with I None
troglitazone I CHEMICAL
, I None
an I None
insulin I GENE-Y
- I None
sensitizing I None
agent I None
, I None
can I None
markedly I None
reduce I None
blood I None
levels I None
of I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
. I None
<eof> I None

<s> O None
There I None
is I None
also I None
clinical I None
evidence I None
that I None
these I None
agents I None
may I None
contribute I None
to I None
regression I None
of I None
intimal I None
medial I None
thickness I None
in I None
patients I None
with I None
type I None
2 I None
diabetes I None
, I None
providing I None
further I None
indication I None
that I None
antidiabetic I None
interventions I None
may I None
help I None
inhibit I None
the I None
progression I None
of I None
early I None
atherosclerotic I None
lesions I None
. I None
<eof> I None

<s> O None
An I None
estrogen I GENE-Y
receptor O GENE-Y
basis I None
for I None
raloxifene I CHEMICAL
action I None
in I None
bone I None
. I None
<eof> I None

<s> O None
Although I None
controversy I None
remains I None
regarding I None
direct I None
effects I None
of I None
estrogen I CHEMICAL
on I None
bone I None
, I None
in I None
vivo I None
data I None
clearly I None
show I None
that I None
estrogens I CHEMICAL
suppress I None
bone I None
turnover I None
, I None
resulting I None
in I None
decreased I None
bone I None
resorption I None
and I None
formation I None
activity I None
. I None
<eof> I None

<s> O None
Selective I None
estrogen I GENE-Y
receptor O GENE-Y
modulators I None
( I None
SERMs I None
) I None
, I None
such I None
as I None
raloxifene I CHEMICAL
, I None
produce I None
effects I None
on I None
bone I None
which I None
are I None
very I None
similar I None
to I None
those I None
of I None
estrogen I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
vitro I None
, I None
both I None
raloxifene I CHEMICAL
and I None
estrogen I CHEMICAL
inhibit I None
mammalian I None
osteoclast I None
differentiation I None
and I None
bone I None
resorption I None
activity I None
, I None
but I None
only I None
in I None
the I None
presence I None
of I None
IL I GENE-Y
- O GENE-Y
6 O GENE-Y
. I None
<eof> I None

<s> O None
Data I None
from I None
a I None
number I None
of I None
ovariectomized I None
rat I None
model I None
manipulations I None
( I None
i I None
. I None
e I None
. I None
hypophysectomy I None
, I None
low I None
calcium I CHEMICAL
diet I None
and I None
drug I None
combinations I None
) I None
demonstrate I None
a I None
strong I None
parallel I None
between I None
the I None
antiosteopenic I None
effects I None
of I None
raloxifene I CHEMICAL
and I None
estrogen I CHEMICAL
. I None
<eof> I None

<s> O None
A I None
characteristic I None
action I None
of I None
estrogens I CHEMICAL
on I None
the I None
skeleton I None
is I None
inhibition I None
of I None
longitudinal I None
bone I None
growth I None
, I None
an I None
effect I None
which I None
is I None
not I None
observed I None
with I None
other I None
resorption I None
inhibitors I None
, I None
including I None
calcitonin I GENE-Y
and I None
bisphosphonates I CHEMICAL
. I None
<eof> I None

<s> O None
Consistent I None
with I None
an I None
estrogen I CHEMICAL
- I None
like I None
mechanism I None
on I None
bone I None
, I None
raloxifene I CHEMICAL
inhibits I None
longitudinal I None
bone I None
growth I None
in I None
growing I None
rats I None
. I None
<eof> I None

<s> O None
In I None
addition I None
to I None
the I None
overall I None
similarity I None
of I None
the I None
bone I None
activity I None
profile I None
in I None
animals I None
, I None
estrogen I CHEMICAL
and I None
raloxifene I CHEMICAL
also I None
produce I None
similar I None
effects I None
on I None
various I None
signaling I None
pathways I None
relative I None
to I None
the I None
antiosteopenic I None
effect I None
of I None
these I None
two I None
agents I None
. I None
<eof> I None

<s> O None
For I None
example I None
, I None
IL I GENE-Y
- O GENE-Y
6 O GENE-Y
, I None
a I None
cytokine I GENE-N
involved I None
in I None
high I None
turnover I None
bone I None
resorption I None
following I None
estrogen I CHEMICAL
deficiency I None
in I None
rats I None
, I None
is I None
suppressed I None
by I None
both I None
raloxifene I CHEMICAL
and I None
estrogen I CHEMICAL
. I None
<eof> I None

<s> O None
Raloxifene I CHEMICAL
and I None
estrogen I CHEMICAL
also I None
produce I None
a I None
similar I None
activation I None
of I None
TGF I GENE-Y
- O GENE-Y
beta3 O GENE-Y
( I None
a I None
cytokine I GENE-N
associated I None
with I None
inhibition I None
of I None
osteoclast I None
differentiation I None
and I None
activity I None
) I None
in I None
ovariectomized I None
rats I None
. I None
<eof> I None

<s> O None
Like I None
17beta I CHEMICAL
- O CHEMICAL
estradiol O CHEMICAL
, I None
raloxifene I CHEMICAL
binds I None
with I None
high I None
affinity I None
to I None
both I None
estrogen I GENE-Y
receptor O GENE-Y
- O GENE-Y
alpha O GENE-Y
( I None
ER I GENE-Y
alpha O GENE-Y
) I None
and I None
estrogen I GENE-Y
receptor O GENE-Y
- O GENE-Y
beta O GENE-Y
( I None
ER I GENE-Y
beta O GENE-Y
) I None
. I None
<eof> I None

<s> O None
Crystal I None
structure I None
analyses I None
have I None
shown I None
that I None
17beta I CHEMICAL
- O CHEMICAL
estradiol O CHEMICAL
and I None
raloxifene I CHEMICAL
bind I None
to I None
ER I GENE-N
alpha O GENE-N
with I None
small I None
, I None
but I None
important I None
, I None
differences I None
in I None
three I None
dimensional I None
structure I None
. I None
<eof> I None

<s> O None
These I None
subtle I None
differences I None
in I None
the I None
conformation I None
of I None
the I None
ligand I None
: I None
receptor I None
complex I None
are I None
likely I None
the I None
basis I None
for I None
the I None
key I None
pharmacological I None
differences I None
between I None
estrogens I CHEMICAL
and I None
the I None
various I None
SERMs I None
( I None
i I None
. I None
e I None
. I None
raloxifene I CHEMICAL
vs I None
tamoxifen I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Raloxifene I CHEMICAL
also I None
produces I None
estrogen I CHEMICAL
- I None
like I None
effects I None
on I None
serum I None
cholesterol I CHEMICAL
metabolism I None
and I None
the I None
vasculature I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
while I None
raloxifene I CHEMICAL
exhibits I None
a I None
complete I None
estrogen I CHEMICAL
antagonist I None
in I None
mammary I None
tissue I None
and I None
the I None
uterus I None
, I None
it I None
produces I None
beneficial I None
effects I None
on I None
the I None
cardiovascular I None
system I None
and I None
prevents I None
bone I None
loss I None
via I None
an I None
estrogen I CHEMICAL
receptor I None
mediated I None
mechanism I None
. I None
<eof> I None

<s> O None
Discovery I None
of I None
novel I None
peptidic I None
dopamine I GENE-Y
transporter O GENE-Y
ligands I None
by I None
screening I None
a I None
positional I None
scanning I None
combinatorial I None
hexapeptide I None
library I None
. I None
<eof> I None

<s> O None
The I None
acute I None
reinforcing I None
effects I None
of I None
cocaine I None
are I None
thought I None
by I None
some I None
to I None
result I None
from I None
cocaine I CHEMICAL
binding I None
to I None
the I None
dopamine I GENE-Y
( O GENE-Y
DA O GENE-Y
) O GENE-Y
transporter O GENE-Y
, I None
which I None
inhibits I None
DA I CHEMICAL
uptake I None
and I None
increases I None
synaptic I None
DA I CHEMICAL
levels I None
in I None
the I None
mesolimbic I None
system I None
. I None
<eof> I None

<s> O None
Other I None
data I None
suggest I None
that I None
neurotransmitters I None
other I None
than I None
DA I CHEMICAL
contribute I None
to I None
cocaine I None
reinforcement I None
and I None
addiction I None
. I None
<eof> I None

<s> O None
These I None
considerations I None
illustrate I None
the I None
need I None
to I None
have I None
additional I None
research I None
tools I None
with I None
which I None
to I None
test I None
the I None
" I None
DA I CHEMICAL
hypothesis I None
. I None
" I None
One I None
strategy I None
is I None
to I None
identify I None
drugs I None
which I None
bind I None
to I None
the I None
DA I GENE-Y
transporter O GENE-Y
( I None
DAT I GENE-Y
ligands I None
) I None
but I None
which I None
do I None
not I None
inhibit I None
DA I CHEMICAL
uptake I None
as I None
effectively I None
as I None
cocaine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
purpose I None
of I None
the I None
present I None
study I None
was I None
to I None
identify I None
members I None
of I None
a I None
novel I None
structural I None
class I None
of I None
DAT I GENE-Y
ligands I None
and I None
to I None
characterize I None
their I None
interactions I None
at I None
the I None
DA I GENE-Y
transporter O GENE-Y
. I None
<eof> I None

<s> O None
A I None
positional I None
scanning I None
hexapeptide I None
D I CHEMICAL
- O CHEMICAL
amino O CHEMICAL
acid O CHEMICAL
library I None
was I None
screened I None
for I None
inhibition I None
of I None
[ I CHEMICAL
( O CHEMICAL
125 O CHEMICAL
) O CHEMICAL
I O CHEMICAL
] O CHEMICAL
RTI O CHEMICAL
- O CHEMICAL
55 O CHEMICAL
binding I None
to I None
rat I GENE-Y
caudate O GENE-Y
DA O GENE-Y
transporters O GENE-Y
. I None
<eof> I None

<s> O None
Based I None
on I None
the I None
results I None
, I None
12 I None
peptides I None
were I None
synthesized I None
. I None
<eof> I None

<s> O None
All I None
12 I None
peptides I None
inhibited I None
[ I CHEMICAL
( O CHEMICAL
125 O CHEMICAL
) O CHEMICAL
I O CHEMICAL
] O CHEMICAL
RTI O CHEMICAL
- O CHEMICAL
55 O CHEMICAL
binding I None
to I None
DA I GENE-Y
transporters O GENE-Y
with I None
IC I None
( I None
50 I None
) I None
values I None
, I None
which I None
ranged I None
from I None
1 I None
. I None
8 I None
microM I None
to I None
12 I None
microM I None
. I None
<eof> I None

<s> O None
The I None
two I None
most I None
potent I None
peptides I None
( I None
TPI I None
- I None
669 I None
- I None
1 I None
and I None
TPI I None
- I None
669 I None
- I None
4 I None
) I None
were I None
prepared I None
in I None
larger I None
quantities I None
and I None
were I None
characterized I None
further I None
for I None
activity I None
at I None
the I None
DAT I GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
transporter O GENE-Y
. I None
<eof> I None

<s> O None
Both I None
peptides I None
inhibited I None
DA I CHEMICAL
and I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
uptake I None
and I None
transporter I None
binding I None
with I None
IC I None
( I None
50 I None
) I None
/ I None
K I None
( I None
i I None
) I None
values I None
in I None
the I None
low I None
micromolar I None
range I None
. I None
<eof> I None

<s> O None
In I None
vivo I None
microdialysis I None
studies I None
demonstrated I None
that I None
both I None
peptides I None
increase I None
extracellular I None
DA I CHEMICAL
and I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
in I None
the I None
nucleus I None
accumbens I None
of I None
rats I None
. I None
<eof> I None

<s> O None
These I None
data I None
demonstrate I None
that I None
peptides I None
can I None
function I None
as I None
inhibitors I None
of I None
biogenic I None
amine I None
transport I None
. I None
<eof> I None

<s> O None
Future I None
work I None
will I None
focus I None
on I None
developing I None
more I None
potent I None
and I None
selective I None
peptides I None
. I None
<eof> I None

<s> O None
Published I None
1999 I None
Wiley I None
- I None
Liss I None
, I None
Inc I None
. I None
<eof> I None

<s> O None
Role I None
of I None
edrophonium I CHEMICAL
in I None
prevention I None
of I None
the I None
re I None
- I None
inhibition I None
of I None
acetylcholinesterase I GENE-Y
by I None
phosphorylated I None
oxime I CHEMICAL
. I None
<eof> I None

<s> O None
We I None
examined I None
the I None
role I None
of I None
edrophonium I CHEMICAL
in I None
the I None
acceleration I None
phenomenon I None
using I None
mouse I None
wild I None
- I None
type I None
and I None
mutant I None
D74N I GENE-N
AChE I GENE-Y
inhibited I None
with I None
7 I CHEMICAL
- O CHEMICAL
( O CHEMICAL
O O CHEMICAL
, O CHEMICAL
O O CHEMICAL
- O CHEMICAL
diethyl O CHEMICAL
- O CHEMICAL
phosphinyloxy O CHEMICAL
) O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
methylquinolinium O CHEMICAL
methylsulfate O CHEMICAL
( I None
DEPQ I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
With I None
DEPQ I CHEMICAL
- I None
inhibited I None
wild I None
- I None
type I None
mouse I GENE-Y
acetylcholinesterase O GENE-Y
( I None
AChE I GENE-Y
) I None
, I None
the I None
reactivation I None
kinetic I None
profile I None
demonstrated I None
one I None
- I None
phase I None
exponential I None
association I None
only I None
when I None
2 I CHEMICAL
- O CHEMICAL
[ O CHEMICAL
hydroxyimino O CHEMICAL
methyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
methylpyridinium O CHEMICAL
chloride O CHEMICAL
( I None
2 I CHEMICAL
- O CHEMICAL
PAM O CHEMICAL
) I None
and I None
1 I CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
hydroxy O CHEMICAL
- O CHEMICAL
iminomethyl O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
pyridinium O CHEMICAL
) O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
carboxy O CHEMICAL
- O CHEMICAL
aminopyridi O CHEMICAL
nium O CHEMICAL
) O CHEMICAL
- O CHEMICAL
dimethyl O CHEMICAL
ether O CHEMICAL
hydrochloride O CHEMICAL
( I None
HI I CHEMICAL
- O CHEMICAL
6 O CHEMICAL
) I None
were I None
used I None
as I None
reactivators I None
. I None
<eof> I None

<s> O None
When I None
1 I CHEMICAL
, O CHEMICAL
1 O CHEMICAL
[ O CHEMICAL
oxybis O CHEMICAL
- O CHEMICAL
methylene O CHEMICAL
) O CHEMICAL
bis O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
hydroxyimino O CHEMICAL
) O CHEMICAL
methyl O CHEMICAL
] O CHEMICAL
pyridinium O CHEMICAL
dichloride O CHEMICAL
( I None
LuH6 I CHEMICAL
) I None
and I None
1 I CHEMICAL
, O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
trimethylene O CHEMICAL
bis O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
hydroxyimino O CHEMICAL
methyl O CHEMICAL
) O CHEMICAL
pyridinium O CHEMICAL
dichloride O CHEMICAL
( I None
TMB4 I CHEMICAL
) I None
were I None
used I None
, I None
the I None
reactivation I None
kinetic I None
profile I None
was I None
biphasic I None
in I None
nature I None
. I None
<eof> I None

<s> O None
Edrophonium I CHEMICAL
had I None
no I None
effect I None
on I None
reactivation I None
by I None
2 I CHEMICAL
- O CHEMICAL
PAM O CHEMICAL
and I None
HI I CHEMICAL
- O CHEMICAL
6 O CHEMICAL
, I None
but I None
significantly I None
accelerated I None
LuH6 I CHEMICAL
- I None
and I None
TMB4 I CHEMICAL
- I None
induced I None
reactivation I None
of I None
DEPQ I CHEMICAL
- I None
inhibited I None
wild I None
- I None
type I None
mouse I GENE-Y
AChE O GENE-Y
. I None
<eof> I None

<s> O None
Comparison I None
of I None
the I None
initial I None
and I None
overall I None
reactivation I None
rate I None
constants I None
with I None
five I None
oximes I CHEMICAL
indicated I None
that I None
acceleration I None
by I None
edrophonium I CHEMICAL
may I None
be I None
due I None
to I None
the I None
prevention I None
of I None
re I None
- I None
inhibition I None
of I None
the I None
reactivated I None
enzyme I None
by I None
the I None
phosphorylated I CHEMICAL
oxime O CHEMICAL
( I None
POX I None
) I None
produced I None
during I None
the I None
reactivation I None
. I None
<eof> I None

<s> O None
With I None
LuH6 I CHEMICAL
and I None
TMB4 I CHEMICAL
, I None
about I None
2 I None
. I None
5 I None
- I None
fold I None
increase I None
in I None
the I None
reactivation I None
rate I None
constants I None
was I None
observed I None
in I None
the I None
presence I None
of I None
edrophonium I CHEMICAL
, I None
but I None
little I None
or I None
no I None
effect I None
was I None
observed I None
with I None
the I None
other I None
three I None
oximes I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
initial I None
reactivation I None
rate I None
constants I None
were I None
5 I None
. I None
4 I None
- I None
and I None
4 I None
. I None
2 I None
- I None
fold I None
of I None
the I None
overall I None
rate I None
constants I None
with I None
LuH6 I CHEMICAL
and I None
TMB4 I CHEMICAL
as I None
reactivators I None
respectively I None
, I None
however I None
, I None
very I None
little I None
change I None
was I None
found I None
between I None
the I None
initial I None
and I None
overall I None
rate I None
constants I None
with I None
the I None
other I None
three I None
oximes I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
experiments I None
with I None
D74N I GENE-N
AChE I GENE-Y
, I None
for I None
which I None
the I None
inhibition I None
potency I None
of I None
charged I None
organophosphate I CHEMICAL
( I None
OP I None
) I None
was I None
two I None
to I None
three I None
orders I None
less I None
than I None
wild I None
- I None
type I None
enzyme I None
, I None
edrophonium I CHEMICAL
had I None
no I None
effect I None
on I None
the I None
reactivation I None
by I None
LuH6 I CHEMICAL
and I None
TMB4 I CHEMICAL
and I None
the I None
time I None
courses I None
of I None
reactivation I None
were I None
monophasic I None
. I None
<eof> I None

<s> O None
The I None
data I None
from I None
mutant I None
enzyme I None
substantiate I None
the I None
involvement I None
of I None
edrophonium I CHEMICAL
in I None
protecting I None
POX I None
re I None
- I None
inhibition I None
of I None
reactivated I None
enzyme I None
formed I None
during I None
the I None
reactivation I None
of I None
OP I None
- I None
inhibited I None
AChE I GENE-Y
. I None
<eof> I None

<s> O None
Synergistic I None
antiallodynic I None
effects I None
of I None
spinal I None
morphine I CHEMICAL
with I None
ketorolac I CHEMICAL
and I None
selective I None
COX1 I GENE-Y
- I None
and I None
COX2 I GENE-Y
- I None
inhibitors I None
in I None
nerve I None
- I None
injured I None
rats I None
. I None
<eof> I None

<s> O None
The I None
possible I None
role I None
of I None
spinal I None
prostanoids I CHEMICAL
in I None
the I None
tactile I None
allodynia I None
and I None
thermal I None
hyperalgesia I None
associated I None
with I None
an I None
experimental I None
model I None
of I None
neuropathic I None
pain I None
was I None
investigated I None
. I None
<eof> I None

<s> O None
Neuropathic I None
pain I None
was I None
induced I None
by I None
tight I None
ligation I None
of I None
the I None
L5 I None
and I None
L6 I None
spinal I None
nerves I None
. I None
<eof> I None

<s> O None
Tactile I None
allodynia I None
was I None
assessed I None
7 I None
days I None
after I None
the I None
surgery I None
by I None
measuring I None
hindpaw I None
withdrawal I None
threshold I None
to I None
probing I None
with I None
von I None
Frey I None
filaments I None
. I None
<eof> I None

<s> O None
Thermal I None
hyperalgesia I None
and I None
nociception I None
were I None
determined I None
by I None
the I None
52 I None
degrees I None
C I None
warm I None
- I None
water I None
tail I None
- I None
flick I None
test I None
and I None
by I None
applying I None
radiant I None
heat I None
to I None
the I None
plantar I None
aspect I None
of I None
the I None
hindpaw I None
ipsilateral I None
to I None
the I None
ligation I None
. I None
<eof> I None

<s> O None
Minimal I None
antiallodynic I None
effect I None
was I None
produced I None
by I None
intrathecal I None
( I None
i I None
. I None
th I None
. I None
) I None
administration I None
of I None
ketorolac I CHEMICAL
or I None
morphine I CHEMICAL
up I None
to I None
the I None
highest I None
testable I None
dose I None
( I None
100 I None
microg I None
) I None
or I None
by I None
the I None
( I CHEMICAL
R O CHEMICAL
) O CHEMICAL
- O CHEMICAL
or O CHEMICAL
( O CHEMICAL
S O CHEMICAL
) O CHEMICAL
- O CHEMICAL
enantiomers O CHEMICAL
of O CHEMICAL
ketorolac O CHEMICAL
( I None
up I None
to I None
6 I None
microg I None
) I None
when I None
administered I None
alone I None
. I None
<eof> I None

<s> O None
However I None
, I None
i I None
. I None
th I None
. I None
administration I None
of I None
a I None
fixed I None
ratio I None
( I None
1 I None
: I None
1 I None
) I None
of I None
morphine I CHEMICAL
plus I None
racemic I CHEMICAL
ketorolac O CHEMICAL
or I None
of I None
morphine I CHEMICAL
plus I None
the I None
( I CHEMICAL
S O CHEMICAL
) O CHEMICAL
- O CHEMICAL
enantiomer O CHEMICAL
of O CHEMICAL
ketorolac O CHEMICAL
( I None
S I CHEMICAL
- O CHEMICAL
ketorolac O CHEMICAL
) I None
produced I None
a I None
dose I None
- I None
and I None
time I None
- I None
related I None
antiallodynic I None
effect I None
: I None
ED50 I None
114 I None
+ I None
/ I None
- I None
35 I None
. I None
9 I None
microg I None
( I None
total I None
dose I None
) I None
for I None
morphine I CHEMICAL
plus I None
ketorolac I CHEMICAL
and I None
70 I None
. I None
5 I None
+ I None
/ I None
- I None
21 I None
. I None
0 I None
microg I None
( I None
total I None
dose I None
) I None
for I None
morphine I CHEMICAL
plus I None
S I CHEMICAL
- O CHEMICAL
ketorolac O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
combination I None
of I None
i I None
. I None
th I None
. I None
morphine I CHEMICAL
plus I None
the I None
( I CHEMICAL
R O CHEMICAL
) O CHEMICAL
- O CHEMICAL
enantiomer O CHEMICAL
of O CHEMICAL
ketorolac O CHEMICAL
( I None
R I CHEMICAL
- O CHEMICAL
ketorolac O CHEMICAL
) I None
( I None
up I None
to I None
200 I None
microg I None
total I None
dose I None
) I None
was I None
without I None
effect I None
. I None
<eof> I None

<s> O None
Similar I None
antiallodynic I None
activity I None
was I None
obtained I None
for I None
the I None
co I None
- I None
administration I None
of I None
i I None
. I None
th I None
. I None
morphine I CHEMICAL
and I None
intravenous I None
( I None
i I None
. I None
v I None
. I None
) I None
racemic I CHEMICAL
ketorolac O CHEMICAL
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
investigate I None
the I None
role I None
of I None
cyclooxygenase I GENE-N
( I None
COX I GENE-N
) I None
isozymes I None
, I None
relatively I None
selective I None
COX1 I GENE-Y
( I None
piroxicam I CHEMICAL
) I None
and I None
COX2 I GENE-Y
N I CHEMICAL
- O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
cyclohexyloxy O CHEMICAL
- O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
nitrophenyl O CHEMICAL
] O CHEMICAL
metanesulfonamide O CHEMICAL
( I None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
) I None
inhibitors I None
were I None
administered I None
i I None
. I None
th I None
. I None
<eof> I None

<s> O None
( I None
60 I None
microg I None
) I None
alone I None
or I None
together I None
with I None
i I None
. I None
th I None
. I None
morphine I CHEMICAL
. I None
<eof> I None

<s> O None
Piroxicam I CHEMICAL
, I None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
, I None
morphine I CHEMICAL
and I None
vehicle I None
( I None
90 I None
% I None
DMSO I CHEMICAL
) I None
were I None
without I None
significant I None
antiallodynic I None
effect I None
when I None
administered I None
alone I None
, I None
but I None
moderate I None
antiallodynic I None
effects I None
were I None
produced I None
by I None
i I None
. I None
th I None
. I None
administration I None
of I None
fixed I None
ratio I None
( I None
1 I None
: I None
1 I None
) I None
combinations I None
of I None
morphine I CHEMICAL
with I None
60 I None
microg I None
each I None
( I None
highest I None
soluble I None
dose I None
) I None
of I None
piroxicam I CHEMICAL
( I None
% I None
MPE I None
= I None
40 I None
. I None
8 I None
+ I None
/ I None
- I None
10 I None
. I None
2 I None
) I None
or I None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
( I None
% I None
MPE I None
= I None
32 I None
. I None
4 I None
+ I None
/ I None
- I None
9 I None
. I None
5 I None
) I None
. I None
<eof> I None

<s> O None
Further I None
, I None
the I None
combined I None
i I None
. I None
th I None
. I None
administration I None
of I None
morphine I CHEMICAL
, I None
piroxicam I CHEMICAL
and I None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
in I None
fixed I None
1 I None
: I None
1 I None
: I None
1 I None
ratio I None
( I None
60 I None
microg I None
each I None
) I None
resulted I None
in I None
a I None
supraadditive I None
antiallodynic I None
effect I None
( I None
% I None
MPE I None
= I None
70 I None
. I None
4 I None
+ I None
/ I None
- I None
10 I None
. I None
8 I None
) I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
morphine I CHEMICAL
, I None
but I None
not I None
ketorolac I CHEMICAL
, I None
given I None
i I None
. I None
th I None
. I None
produced I None
dose I None
- I None
dependent I None
anti I None
nociception I None
in I None
either I None
the I None
tail I None
- I None
flick I None
or I None
the I None
paw I None
- I None
flick I None
tests I None
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
was I None
no I None
synergy I None
between I None
morphine I CHEMICAL
and I None
ketorolac I CHEMICAL
against I None
thermal I None
nociception I None
in I None
either I None
of I None
the I None
tests I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
spinal I None
prostanoids I None
produced I None
via I None
both I None
COX1 I GENE-Y
and I None
COX2 I GENE-Y
pathways I None
may I None
play I None
a I None
role I None
in I None
neuropathic I None
pain I None
states I None
and I None
suggest I None
the I None
clinical I None
utility I None
of I None
opioid I None
plus I None
COX I GENE-N
- I None
inhibitor I None
combination I None
therapy I None
. I None
<eof> I None

<s> O None
Desipramine I CHEMICAL
treatment I None
decreases I None
3H I CHEMICAL
- O CHEMICAL
nisoxetine O CHEMICAL
binding I None
and I None
norepinephrine I GENE-Y
transporter O GENE-Y
mRNA I None
in I None
SK I None
- I None
N I None
- I None
SHSY5Y I None
cells I None
. I None
<eof> I None

<s> O None
The I None
antidepressant I None
desipramine I CHEMICAL
has I None
been I None
shown I None
to I None
decrease I None
synaptic I None
membrane I None
concentrations I None
of I None
the I None
norepinephrine I GENE-Y
re O GENE-Y
- O GENE-Y
uptake O GENE-Y
transporter O GENE-Y
( I None
NET I GENE-Y
) I None
in I None
vivo I None
and I None
in I None
vitro I None
, I None
on I None
both I None
an I None
acute I None
and I None
a I None
chronic I None
basis I None
. I None
<eof> I None

<s> O None
The I None
possible I None
contribution I None
of I None
decreased I None
NET I GENE-Y
synthesis I None
to I None
the I None
chronic I None
downregulation I None
of I None
the I None
NETs I GENE-Y
has I None
not I None
been I None
definitively I None
established I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
treated I None
SK I None
- I None
N I None
- I None
SHSY5Y I None
cells I None
with I None
100 I None
nM I None
desipramine I CHEMICAL
for I None
24 I None
or I None
72 I None
h I None
, I None
and I None
measured I None
3H I CHEMICAL
- O CHEMICAL
nisoxetine O CHEMICAL
binding I None
( I None
as I None
an I None
estimate I None
of I None
NETs I GENE-Y
) I None
and I None
NET I GENE-Y
mRNA I None
by I None
quantitative I None
reverse I None
transcription I None
polymerase I None
chain I None
reaction I None
. I None
<eof> I None

<s> O None
Similar I None
to I None
what I None
has I None
been I None
reported I None
previously I None
, I None
membrane I None
3H I CHEMICAL
- O CHEMICAL
nisoxetine O CHEMICAL
binding I None
was I None
significantly I None
decreased I None
at I None
both I None
24 I None
and I None
72 I None
h I None
( I None
approximately I None
50 I None
% I None
at I None
both I None
time I None
points I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
a I None
significant I None
decrease I None
( I None
64 I None
+ I None
/ I None
- I None
8 I None
% I None
of I None
paired I None
control I None
) I None
of I None
NET I GENE-Y
mRNA I None
was I None
observed I None
only I None
at I None
the I None
72 I None
- I None
h I None
time I None
point I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
decreased I None
NET I GENE-Y
synthesis I None
may I None
contribute I None
to I None
the I None
chronic I None
, I None
but I None
not I None
acute I None
, I None
effect I None
of I None
desipramine I CHEMICAL
to I None
downregulate I None
the I None
NET I GENE-Y
. I None
<eof> I None

<s> O None
Antitumor I None
activity I None
of I None
ZD1694 I CHEMICAL
( I None
tomudex I CHEMICAL
) I None
against I None
human I None
head I None
and I None
neck I None
cancer I None
in I None
nude I None
mouse I None
models I None
: I None
role I None
of I None
dosing I None
schedule I None
and I None
plasma I None
thymidine I CHEMICAL
. I None
<eof> I None

<s> O None
We I None
studied I None
the I None
antitumor I None
activity I None
and I None
toxicity I None
of I None
ZD1694 I CHEMICAL
( I None
tomudex I CHEMICAL
) I None
, I None
a I None
specific I None
inhibitor I None
of I None
thymidylate I GENE-Y
synthase O GENE-Y
( I None
TS I GENE-Y
) I None
, I None
in I None
nude I None
mice I None
bearing I None
human I None
head I None
and I None
neck I None
squamous I None
cell I None
carcinoma I None
A253 I None
and I None
FaDu I None
xenografts I None
. I None
<eof> I None

<s> O None
Mice I None
were I None
treated I None
by I None
single I None
i I None
. I None
v I None
. I None
push I None
( I None
i I None
. I None
v I None
. I None
x I None
1 I None
) I None
, I None
i I None
. I None
v I None
. I None
push I None
once I None
a I None
week I None
for I None
3 I None
weeks I None
( I None
weekly I None
x I None
3 I None
) I None
, I None
and I None
i I None
. I None
v I None
. I None
push I None
once I None
a I None
day I None
for I None
5 I None
days I None
( I None
daily I None
x I None
5 I None
) I None
, I None
and I None
the I None
maximum I None
tolerated I None
doses I None
( I None
MTDs I None
) I None
of I None
ZD1694 I CHEMICAL
were I None
300 I None
mg I None
/ I None
kg I None
, I None
60 I None
mg I None
/ I None
kg I None
/ I None
week I None
, I None
and I None
30 I None
mg I None
/ I None
kg I None
/ I None
day I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
ZD1694 I CHEMICAL
was I None
moderately I None
active I None
against I None
both I None
A253 I None
and I None
FaDu I None
xenografts I None
. I None
<eof> I None

<s> O None
Antitumor I None
activity I None
was I None
schedule I None
- I None
dependent I None
in I None
both I None
tumors I None
: I None
weekly I None
x I None
3 I None
> I None
or I None
= I None
i I None
. I None
v I None
. I None
x I None
1 I None
> I None
> I None
daily I None
x I None
5 I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
rank I None
order I None
of I None
toxicity I None
was I None
daily I None
x I None
5 I None
> I None
> I None
weekly I None
x I None
3 I None
> I None
or I None
= I None
i I None
. I None
v I None
. I None
x I None
1 I None
. I None
<eof> I None

<s> O None
ZD1694 I CHEMICAL
at I None
the I None
MTD I None
produced I None
20 I None
% I None
complete I None
tumor I None
regression I None
and I None
20 I None
% I None
partial I None
tumor I None
regression I None
( I None
PR I None
) I None
with I None
i I None
. I None
v I None
. I None
x I None
1 I None
and I None
weekly I None
x I None
3 I None
schedules I None
and I None
12 I None
- I None
day I None
tumor I None
growth I None
delay I None
with I None
daily I None
x I None
5 I None
schedule I None
against I None
FaDu I None
xenografts I None
. I None
<eof> I None

<s> O None
No I None
complete I None
tumor I None
regression I None
was I None
achieved I None
with I None
ZD1694 I CHEMICAL
with I None
any I None
schedule I None
against I None
A253 I None
; I None
a I None
20 I None
% I None
PR I None
, I None
40 I None
% I None
PR I None
, I None
and I None
10 I None
- I None
day I None
tumor I None
growth I None
delay I None
were I None
observed I None
with I None
i I None
. I None
v I None
. I None
x I None
1 I None
, I None
weekly I None
x I None
3 I None
, I None
and I None
daily I None
x I None
5 I None
schedules I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
data I None
indicate I None
that I None
ZD1694 I CHEMICAL
was I None
slightly I None
more I None
effective I None
against I None
FaDu I None
than I None
against I None
A253 I None
. I None
<eof> I None

<s> O None
Of I None
interest I None
and I None
potential I None
clinical I None
importance I None
was I None
the I None
observation I None
that I None
ZD1694 I CHEMICAL
was I None
still I None
active I None
at I None
doses I None
lower I None
than I None
the I None
MTD I None
( I None
> I None
or I None
= I None
1 I None
/ I None
3 I None
MTD I None
) I None
, I None
which I None
showed I None
a I None
high I None
therapeutic I None
index I None
and I None
wide I None
safety I None
margin I None
. I None
<eof> I None

<s> O None
Study I None
of I None
ZD1694 I CHEMICAL
compared I None
with I None
5 I CHEMICAL
- O CHEMICAL
fluorouracil O CHEMICAL
and I None
5 I CHEMICAL
- O CHEMICAL
fluoro O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
deoxyuridine O CHEMICAL
at I None
the I None
MTD I None
revealed I None
that I None
the I None
antitumor I None
activity I None
of I None
ZD1694 I CHEMICAL
was I None
comparable I None
with I None
or I None
superior I None
to I None
5 I CHEMICAL
- O CHEMICAL
fluorouracil O CHEMICAL
and I None
5 I CHEMICAL
- O CHEMICAL
fluoro O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
deoxyuridine O CHEMICAL
against I None
both I None
A253 I None
and I None
FaDu I None
xenografts I None
, I None
with I None
less I None
toxicity I None
. I None
<eof> I None

<s> O None
High I None
plasma I None
thymidine I CHEMICAL
in I None
mouse I None
relative I None
to I None
human I None
( I None
approximately I None
1 I None
. I None
3 I None
microM I None
and I None
< I None
0 I None
. I None
1 I None
microM I None
, I None
respectively I None
) I None
may I None
complicate I None
the I None
study I None
of I None
antitumor I None
activity I None
and I None
toxicity I None
of I None
TS I GENE-Y
inhibitors I None
with I None
human I None
tumor I None
xenografts I None
grown I None
in I None
the I None
mouse I None
. I None
<eof> I None

<s> O None
To I None
test I None
this I None
hypothesis I None
, I None
we I None
preadministered I None
methoxypolyethyleneglycol I GENE-Y
- O GENE-Y
conjugated O GENE-Y
thymidine O GENE-Y
phosphorylase O GENE-Y
( I None
MPEG I GENE-Y
- O GENE-Y
TPase O GENE-Y
; I None
2500 I None
units I None
/ I None
kg I None
/ I None
dose I None
) I None
to I None
reduce I None
mouse I None
plasma I None
thymidine I CHEMICAL
, I None
then I None
treated I None
with I None
various I None
doses I None
of I None
ZD1694 I CHEMICAL
using I None
the I None
daily I None
x I None
5 I None
or I None
i I None
. I None
v I None
. I None
x I None
1 I None
schedules I None
in I None
the I None
A253 I None
tumor I None
model I None
. I None
<eof> I None

<s> O None
MPEG I GENE-Y
- O GENE-Y
TPase O GENE-Y
significantly I None
increased I None
the I None
toxicity I None
of I None
ZD1694 I CHEMICAL
; I None
the I None
MTD I None
of I None
ZD1694 I CHEMICAL
plus I None
MPEG I GENE-Y
- O GENE-Y
TPase O GENE-Y
was I None
reduced I None
3 I None
- I None
and I None
10 I None
- I None
fold I None
compared I None
with I None
ZD1694 I CHEMICAL
alone I None
for I None
i I None
. I None
v I None
x I None
1 I None
and I None
daily I None
x I None
5 I None
schedules I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
However I None
, I None
preadministration I None
of I None
MPEG I GENE-Y
- O GENE-Y
TPase O GENE-Y
did I None
not I None
potentiate I None
the I None
antitumor I None
activity I None
of I None
ZD1694 I CHEMICAL
with I None
either I None
schedule I None
. I None
<eof> I None

<s> O None
The I None
data I None
indicate I None
that I None
the I None
study I None
of I None
TS I GENE-Y
inhibitors I None
in I None
rodent I None
models I None
may I None
not I None
be I None
suitable I None
for I None
predicting I None
a I None
safe I None
dose I None
for I None
clinical I None
study I None
. I None
<eof> I None

<s> O None
However I None
, I None
rodent I None
models I None
, I None
particularly I None
human I None
tumor I None
xenografts I None
, I None
are I None
still I None
useful I None
models I None
for I None
evaluation I None
of I None
antitumor I None
activity I None
and I None
schedule I None
selection I None
for I None
TS I GENE-Y
inhibitors I None
. I None
<eof> I None

<s> O None
Crystal I None
structure I None
of I None
human I GENE-Y
quinone O GENE-Y
reductase O GENE-Y
type O GENE-Y
2 O GENE-Y
, I None
a I None
metalloflavoprotein I None
. I None
<eof> I None

<s> O None
In I None
mammals I None
, I None
two I None
separate I None
but I None
homologous I None
cytosolic I None
quinone I GENE-N
reductases O GENE-N
have I None
been I None
identified I None
: I None
NAD I GENE-Y
( O GENE-Y
P O GENE-Y
) O GENE-Y
H O GENE-Y
: O GENE-Y
quinone O GENE-Y
oxidoreductase O GENE-Y
type O GENE-Y
1 O GENE-Y
( I None
QR1 I GENE-Y
) I None
( I None
EC I GENE-N
1 O GENE-N
. O GENE-N
6 O GENE-N
. O GENE-N
99 O GENE-N
. O GENE-N
2 O GENE-N
) I None
and I None
quinone I GENE-Y
reductase O GENE-Y
type O GENE-Y
2 O GENE-Y
( I None
QR2 I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Although I None
QR1 I GENE-Y
and I None
QR2 I GENE-Y
are I None
nearly I None
50 I None
% I None
identical I None
in I None
protein I None
sequence I None
, I None
they I None
display I None
markedly I None
different I None
catalytic I None
properties I None
and I None
substrate I None
specificities I None
. I None
<eof> I None

<s> O None
We I None
report I None
here I None
two I None
crystal I None
structures I None
of I None
QR2 I GENE-Y
: I None
in I None
its I None
native I None
form I None
and I None
bound I None
to I None
menadione I CHEMICAL
( I None
vitamin I CHEMICAL
K O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
) I None
, I None
a I None
physiological I None
substrate I None
. I None
<eof> I None

<s> O None
Phases I None
were I None
obtained I None
by I None
molecular I None
replacement I None
, I None
using I None
our I None
previously I None
determined I None
rat I GENE-Y
QR1 O GENE-Y
structure I None
as I None
the I None
search I None
model I None
. I None
<eof> I None

<s> O None
QR2 I GENE-Y
shares I None
the I None
overall I None
fold I None
of I None
the I None
major I None
catalytic I None
domain I None
of I None
QR1 I GENE-Y
, I None
but I None
lacks I None
the I None
smaller I None
C I CHEMICAL
- I None
terminal I None
domain I None
. I None
<eof> I None

<s> O None
The I None
FAD I GENE-N
binding O GENE-N
sites O GENE-N
of I None
QR1 I GENE-Y
and I None
QR2 I GENE-Y
are I None
very I None
similar I None
, I None
but I None
their I None
hydride I None
donor I None
binding I None
sites I None
are I None
considerably I None
different I None
. I None
<eof> I None

<s> O None
Unexpectedly I None
, I None
we I None
found I None
that I None
QR2 I GENE-Y
contains I None
a I None
specific I None
metal I None
binding I None
site I None
, I None
which I None
is I None
not I None
present I None
in I None
QR1 I GENE-Y
. I None
<eof> I None

<s> O None
Two I None
histidine I CHEMICAL
nitrogens O CHEMICAL
, I None
one I None
cysteine I CHEMICAL
thiol O CHEMICAL
, I None
and I None
a I None
main I None
chain I None
carbonyl I CHEMICAL
group I None
are I None
involved I None
in I None
metal I None
coordination I None
. I None
<eof> I None

<s> O None
The I None
metal I None
binding I None
site I None
is I None
solvent I None
- I None
accessible I None
, I None
and I None
is I None
separated I None
from I None
the I None
FAD I None
cofactor I None
by I None
a I None
distance I None
of I None
about I None
13 I None
A I None
. I None
<eof> I None

<s> O None
Direct I None
effects I None
of I None
ephedrine I CHEMICAL
isomers I None
on I None
human I GENE-N
beta O GENE-N
- O GENE-N
adrenergic O GENE-N
receptor O GENE-N
subtypes I None
. I None
<eof> I None

<s> O None
Ephedrine I CHEMICAL
and I None
its I None
alkaloids I None
are I None
used I None
for I None
the I None
treatment I None
of I None
asthma I None
, I None
nasal I None
congestion I None
, I None
and I None
obesity I None
. I None
<eof> I None

<s> O None
Ephedrine I CHEMICAL
, I None
with I None
two I None
chiral I None
centers I None
, I None
exists I None
as I None
four I None
isomers I None
that I None
exhibit I None
direct I None
and I None
indirect I None
effects I None
on I None
both I None
alpha I GENE-N
- O GENE-N
and O GENE-N
beta O GENE-N
- O GENE-N
adrenergic O GENE-N
receptors O GENE-N
( I None
AR I GENE-N
) I None
. I None
<eof> I None

<s> O None
Our I None
main I None
goal I None
was I None
to I None
study I None
the I None
direct I None
effects I None
of I None
the I None
ephedrine I CHEMICAL
isomers I None
on I None
human I GENE-N
beta1 O GENE-N
- O GENE-N
, O GENE-N
beta2 O GENE-N
- O GENE-N
, O GENE-N
and O GENE-N
beta3 O GENE-N
- O GENE-N
AR O GENE-N
expressed I None
in I None
Chinese I None
hamster I None
ovary I None
cells I None
. I None
<eof> I None

<s> O None
Previous I None
work I None
indicated I None
that I None
the I None
ephedrine I CHEMICAL
isomers I None
are I None
inactive I None
as I None
agonists I None
and I None
that I None
1R I CHEMICAL
, O CHEMICAL
2S O CHEMICAL
- O CHEMICAL
ephedrine O CHEMICAL
is I None
more I None
potent I None
than I None
the I None
1S I None
, I None
2R I None
- I None
isomer I None
as I None
an I None
antagonist I None
of I None
catecholamine I CHEMICAL
- I None
induced I None
lipolysis I None
in I None
rat I None
adipose I None
tissue I None
( I None
Lee I None
et I None
al I None
. I None
, I None
J I None
Pharmacol I None
Exp I None
Ther I None
190 I None
: I None
249 I None
- I None
259 I None
, I None
1974 I None
) I None
. I None
<eof> I None

<s> O None
Stimulation I None
of I None
adenylyl I GENE-N
cyclase O GENE-N
, I None
associated I None
with I None
cyclic I CHEMICAL
AMP O CHEMICAL
accumulations I None
, I None
was I None
measured I None
by I None
a I None
luciferase I None
reporter I None
gene I None
assay I None
. I None
<eof> I None

<s> O None
On I None
human I GENE-Y
beta1 O GENE-Y
- O GENE-Y
AR O GENE-Y
, I None
the I None
rank I None
order I None
of I None
potency I None
( I None
EC50 I None
values I None
, I None
maximal I None
response I None
relative I None
to I None
isoproterenol I None
= I None
100 I None
% I None
) I None
was I None
1R I CHEMICAL
, O CHEMICAL
2S O CHEMICAL
- O CHEMICAL
ephedrine O CHEMICAL
( I None
0 I None
. I None
5 I None
microM I None
, I None
68 I None
% I None
) I None
> I None
1S I CHEMICAL
, O CHEMICAL
2R O CHEMICAL
- O CHEMICAL
ephedrine O CHEMICAL
( I None
72 I None
microM I None
, I None
66 I None
% I None
) I None
> I None
1S I CHEMICAL
, O CHEMICAL
2S O CHEMICAL
- O CHEMICAL
pseudoephedrine O CHEMICAL
( I None
309 I None
microM I None
, I None
53 I None
% I None
) I None
= I None
1R I CHEMICAL
, O CHEMICAL
2R O CHEMICAL
- O CHEMICAL
pseudoephedrine O CHEMICAL
( I None
1122 I None
microM I None
, I None
53 I None
% I None
) I None
. I None
<eof> I None

<s> O None
On I None
human I GENE-Y
beta2 O GENE-Y
- O GENE-Y
AR O GENE-Y
, I None
the I None
rank I None
order I None
of I None
potency I None
was I None
1R I CHEMICAL
, O CHEMICAL
2S O CHEMICAL
- O CHEMICAL
ephedrine O CHEMICAL
( I None
0 I None
. I None
36 I None
microM I None
, I None
78 I None
% I None
) I None
> I None
1R I CHEMICAL
, O CHEMICAL
2R O CHEMICAL
- O CHEMICAL
pseudoephedrine O CHEMICAL
( I None
7 I None
microM I None
, I None
50 I None
% I None
) I None
> I None
or I None
= I None
1S I CHEMICAL
, O CHEMICAL
2S O CHEMICAL
- O CHEMICAL
pseudoephedrine O CHEMICAL
( I None
10 I None
microM I None
, I None
47 I None
% I None
) I None
> I None
1S I CHEMICAL
, O CHEMICAL
2R O CHEMICAL
- O CHEMICAL
ephedrine O CHEMICAL
( I None
106 I None
microM I None
, I None
22 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Only I None
1R I CHEMICAL
, O CHEMICAL
2S O CHEMICAL
- O CHEMICAL
ephedrine O CHEMICAL
showed I None
significant I None
agonist I None
activity I None
on I None
human I GENE-Y
beta3 O GENE-Y
- O GENE-Y
AR O GENE-Y
with I None
an I None
EC50 I None
= I None
45 I None
betaM I None
and I None
a I None
maximal I None
response I None
of I None
31 I None
% I None
. I None
<eof> I None

<s> O None
Our I None
studies I None
demonstrated I None
that I None
( I None
a I None
) I None
stereoselective I None
and I None
rank I None
order I None
differences I None
exist I None
among I None
the I None
direct I None
effects I None
of I None
ephedrine I CHEMICAL
isomers I None
; I None
( I None
b I None
) I None
1R I CHEMICAL
, O CHEMICAL
2S O CHEMICAL
- O CHEMICAL
ephedrine O CHEMICAL
is I None
the I None
most I None
potent I None
of I None
the I None
four I None
ephedrine I CHEMICAL
isomers I None
on I None
all I None
three I None
human I GENE-N
beta O GENE-N
- O GENE-N
AR O GENE-N
; I None
and I None
( I None
c I None
) I None
1R I CHEMICAL
, O CHEMICAL
2S O CHEMICAL
- O CHEMICAL
ephedrine O CHEMICAL
was I None
nearly I None
equipotent I None
as I None
a I None
beta1 I GENE-N
- O GENE-N
/ O GENE-N
beta2 O GENE-N
- O GENE-N
AR O GENE-N
agonist I None
and I None
the I None
only I None
isomer I None
possessing I None
weak I None
partial I None
agonist I None
activity I None
on I None
beta3 I GENE-Y
- O GENE-Y
AR O GENE-Y
. I None
<eof> I None

<s> O None
Marimastat I CHEMICAL
inhibits I None
elastin I GENE-Y
degradation I None
and I None
matrix I GENE-Y
metalloproteinase O GENE-Y
2 O GENE-Y
activity I None
in I None
a I None
model I None
of I None
aneurysm I None
disease I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Abdominal I None
aortic I None
aneurysms I None
are I None
characterized I None
by I None
degradation I None
of I None
the I None
extracellular I None
matrix I None
, I None
with I None
a I None
reduction I None
in I None
the I None
elastin I None
concentration I None
of I None
the I None
arterial I None
media I None
. I None
<eof> I None

<s> O None
These I None
changes I None
have I None
been I None
linked I None
to I None
increased I None
levels I None
of I None
endogenous I None
metalloproteinases I GENE-N
( I None
MMPs I GENE-N
) I None
within I None
the I None
aorta I None
, I None
particularly I None
MMP I GENE-Y
- O GENE-Y
2 O GENE-Y
and I None
MMP I GENE-Y
- O GENE-Y
9 O GENE-Y
. I None
<eof> I None

<s> O None
This I None
provides I None
a I None
potential I None
therapeutic I None
target I None
for I None
pharmacological I None
agents I None
aimed I None
at I None
reducing I None
the I None
growth I None
rate I None
of I None
small I None
aneurysms I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
the I None
ability I None
of I None
marimastat I CHEMICAL
( I None
an I None
MMP I GENE-N
inhibitor I None
) I None
to I None
reduce I None
matrix I None
degradation I None
was I None
assessed I None
in I None
a I None
previously I None
described I None
model I None
of I None
aneurysm I None
disease I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Porcine I None
aortic I None
segments I None
( I None
n I None
= I None
12 I None
) I None
were I None
preincubated I None
in I None
exogenous I None
pancreatic I GENE-N
elastase O GENE-N
for I None
24 I None
h I None
before I None
culture I None
in I None
standard I None
conditions I None
for I None
13 I None
days I None
with I None
marimastat I CHEMICAL
10 I None
( I None
- I None
5 I None
) I None
, I None
10 I None
( I None
- I None
6 I None
) I None
and I None
10 I None
( I None
- I None
7 I None
) I None
mol I None
/ I None
l I None
. I None
<eof> I None

<s> O None
Control I None
segments I None
were I None
cultured I None
both I None
without I None
marimastat I CHEMICAL
and I None
without I None
elastase I GENE-N
. I None
<eof> I None

<s> O None
At I None
the I None
termination I None
of I None
culture I None
, I None
MMPs I GENE-N
were I None
extracted I None
from I None
the I None
tissue I None
and I None
quantified I None
by I None
substrate I None
gel I None
enzymography I None
. I None
<eof> I None

<s> O None
The I None
volume I None
fractions I None
of I None
elastin I GENE-Y
and I None
collagen I GENE-N
were I None
determined I None
by I None
stereological I None
analysis I None
of I None
sections I None
stained I None
with I None
Miller I None
' I None
s I None
elastin I GENE-Y
and I None
van I CHEMICAL
Gieson O CHEMICAL
' O CHEMICAL
s O CHEMICAL
stain O CHEMICAL
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Stereological I None
analysis I None
demonstrated I None
preservation I None
of I None
elastin I GENE-Y
in I None
aorta I None
treated I None
with I None
marimastat I CHEMICAL
at I None
10 I None
( I None
- I None
6 I None
) I None
and I None
10 I None
( I None
- I None
5 I None
) I None
mol I None
/ I None
l I None
; I None
this I None
was I None
significant I None
at I None
the I None
latter I None
concentration I None
( I None
P I None
= I None
0 I None
. I None
007 I None
) I None
. I None
<eof> I None

<s> O None
This I None
was I None
accompanied I None
by I None
a I None
significant I None
reduction I None
in I None
active I None
MMP I GENE-Y
- O GENE-Y
2 O GENE-Y
activity I None
in I None
the I None
samples I None
treated I None
with I None
marimastat I CHEMICAL
10 I None
( I None
- I None
5 I None
) I None
mol I None
/ I None
l I None
( I None
P I None
< I None
0 I None
. I None
01 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Marimastat I CHEMICAL
significantly I None
inhibited I None
elastin I None
degradation I None
and I None
active I None
MMP I GENE-Y
- O GENE-Y
2 O GENE-Y
production I None
within I None
aortic I None
organ I None
cultures I None
. I None
<eof> I None

<s> O None
[ I None
The I None
relation I None
between I None
metabolism I None
of I None
biopterin I CHEMICAL
and I None
dystonia I None
- I None
parkinsonism I None
] I None
. I None
<eof> I None

<s> O None
Tetrahydrobiopterin I CHEMICAL
( I None
BH4 I CHEMICAL
) I None
is I None
an I None
essential I None
cofactor I None
for I None
tyrosine I GENE-Y
hydroxylase O GENE-Y
. I None
<eof> I None

<s> O None
BH4 I CHEMICAL
can I None
be I None
synthesized I None
from I None
GTP I CHEMICAL
through I None
three I None
enzymatic I None
reactions I None
. I None
<eof> I None

<s> O None
The I None
rate I None
- I None
limiting I None
step I None
of I None
the I None
BH4 I CHEMICAL
synthesis I None
is I None
catalyzed I None
by I None
GTP I GENE-Y
cyclohydrolase O GENE-Y
I O GENE-Y
( I None
GCH I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
we I None
found I None
that I None
GCH I GENE-Y
is I None
a I None
causative I None
gene I None
for I None
hereditary I None
progressive I None
dystonia I None
/ I None
dopa I None
- I None
responsive I None
dystonia I None
( I None
HPD I None
/ I None
DRD I None
) I None
. I None
<eof> I None

<s> O None
However I None
, I None
several I None
problems I None
still I None
remain I None
to I None
be I None
solved I None
. I None
<eof> I None

<s> O None
The I None
first I None
concern I None
is I None
the I None
presence I None
of I None
asymptomatic I None
carriers I None
in I None
the I None
disease I None
. I None
<eof> I None

<s> O None
The I None
difference I None
between I None
symptomatic I None
and I None
asymptomatic I None
carriers I None
is I None
unknown I None
. I None
<eof> I None

<s> O None
Second I None
, I None
we I None
cannot I None
find I None
any I None
mutation I None
in I None
the I None
coding I None
region I None
of I None
the I None
GCH I GENE-Y
gene I None
in I None
about I None
40 I None
% I None
of I None
the I None
patients I None
. I None
<eof> I None

<s> O None
What I None
kind I None
of I None
mutation I None
would I None
be I None
present I None
in I None
these I None
patients I None
. I None
<eof> I None

<s> O None
The I None
last I None
concern I None
is I None
the I None
molecular I None
mechanism I None
how I None
the I None
enzymatic I None
activity I None
is I None
decreased I None
to I None
less I None
than I None
20 I None
% I None
of I None
normal I None
values I None
. I None
<eof> I None

<s> O None
Further I None
studies I None
are I None
required I None
to I None
solve I None
the I None
questions I None
. I None
<eof> I None

<s> O None
Use I None
of I None
a I None
PPAR I GENE-Y
gamma O GENE-Y
- I None
specific I None
monoclonal I None
antibody I None
to I None
demonstrate I None
thiazolidinediones I CHEMICAL
induce I None
PPAR I GENE-Y
gamma O GENE-Y
receptor I None
expression I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
Troglitazone I CHEMICAL
and I None
rosiglitazone I CHEMICAL
( I None
BRL49653 I CHEMICAL
) I None
, I None
members I None
of I None
the I None
thiazolidinedione I CHEMICAL
( I None
TZD I CHEMICAL
) I None
class I None
of I None
antidiabetic I None
drugs I None
, I None
are I None
peroxisome I GENE-Y
proliferator O GENE-Y
- O GENE-Y
activated O GENE-Y
receptor O GENE-Y
gamma O GENE-Y
( I None
PPARgamma I GENE-Y
) I None
ligands I None
that I None
induce I None
adipocyte I None
differentiation I None
and I None
increase I None
the I None
expression I None
of I None
PPARgamma I GENE-Y
protein I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
report I None
the I None
characterization I None
of I None
a I None
PPARgamma I GENE-Y
specific I None
monoclonal I None
antibody I None
( I None
MAb I None
) I None
, I None
PgammaA53 I None
. I None
25 I None
, I None
and I None
its I None
use I None
to I None
monitor I None
PPARgamma I GENE-Y
expression I None
in I None
the I None
noncommitted I None
pluripotent I None
murine I None
mesenchymal I None
stem I None
cell I None
line I None
, I None
C3H10T1 I None
/ I None
2 I None
, I None
treated I None
with I None
TZDs I None
. I None
<eof> I None

<s> O None
MAb I None
PgammaA53 I None
. I None
25 I None
was I None
raised I None
against I None
a I None
region I None
in I None
the I None
N I CHEMICAL
- I None
terminal I None
domain I None
of I None
human I GENE-Y
PPARgamma O GENE-Y
shared I None
by I None
splice I None
variants I None
PPARgamma1 I GENE-Y
and I None
PPARgamma2 I GENE-Y
. I None
<eof> I None

<s> O None
It I None
recognizes I None
immunizing I None
antigen I None
in I None
enzyme I None
- I None
linked I None
immunoadsorbent I None
assay I None
( I None
ELISA I None
) I None
, I None
and I None
does I None
not I None
cross I None
- I None
react I None
with I None
the I None
N I CHEMICAL
- I None
terminal I None
domains I None
of I None
PPARalpha I GENE-Y
or I None
PPARdelta I GENE-Y
. I None
<eof> I None

<s> O None
In I None
Western I None
blotting I None
, I None
PgammaA53 I None
. I None
25 I None
reacts I None
with I None
the I None
immunizing I None
antigen I None
as I None
well I None
as I None
distinct I None
protein I None
bands I None
corresponding I None
to I None
the I None
molecular I None
weight I None
of I None
full I None
length I None
PPARgamma I GENE-Y
from I None
C3H10T1 I None
/ I None
2 I None
cells I None
and I None
rat I None
tissue I None
lysates I None
. I None
<eof> I None

<s> O None
In I None
fluorescent I None
microscopy I None
, I None
PgammaA53 I None
. I None
25 I None
immunostains I None
nuclei I None
of I None
C3H10T1 I None
/ I None
2 I None
cells I None
treated I None
with I None
PPARgamma I GENE-Y
ligands I None
. I None
<eof> I None

<s> O None
The I None
fluorescence I None
intensity I None
of I None
the I None
treated I None
cells I None
is I None
TZD I CHEMICAL
dose I None
- I None
dependent I None
, I None
and I None
correlates I None
with I None
lipid I None
accumulation I None
consistent I None
with I None
adipogenesis I None
. I None
<eof> I None

<s> O None
Based I None
on I None
these I None
results I None
, I None
we I None
propose I None
that I None
MAb I None
PgammaA53 I None
. I None
25 I None
will I None
be I None
a I None
useful I None
tool I None
for I None
elucidating I None
the I None
role I None
of I None
PPARgamma I GENE-Y
in I None
fatty I CHEMICAL
acid O CHEMICAL
metabolism I None
and I None
adipocyte I None
differentiation I None
. I None
<eof> I None

<s> O None
Increased I None
cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
expression I None
in I None
human I None
pancreatic I None
carcinomas I None
and I None
cell I None
lines I None
: I None
growth I None
inhibition I None
by I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
. I None
<eof> I None

<s> O None
Cyclooxygenase I GENE-Y
( O GENE-Y
COX O GENE-Y
) O GENE-Y
- O GENE-Y
2 O GENE-Y
mRNA I None
and I None
protein I None
expression I None
were I None
found I None
to I None
be I None
frequently I None
elevated I None
in I None
human I None
pancreatic I None
adenocarcinomas I None
and I None
cell I None
lines I None
derived I None
from I None
such I None
tumors I None
. I None
<eof> I None

<s> O None
Immunohistochemistry I None
demonstrated I None
cytoplasmic I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
expression I None
in I None
14 I None
of I None
21 I None
( I None
67 I None
% I None
) I None
pancreatic I None
carcinomas I None
. I None
<eof> I None

<s> O None
The I None
level I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
mRNA I None
was I None
found I None
to I None
be I None
elevated I None
in I None
carcinomas I None
, I None
relative I None
to I None
histologically I None
normal I None
pancreas I None
from I None
a I None
healthy I None
individual I None
, I None
as I None
assessed I None
by I None
reverse I None
transcription I None
- I None
PCR I None
. I None
<eof> I None

<s> O None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
protein I None
expression I None
was I None
detected I None
by I None
the I None
Western I None
blot I None
assay I None
in I None
three I None
of I None
five I None
pancreatic I None
carcinoma I None
cell I None
lines I None
( I None
BxPC I None
- I None
3 I None
, I None
Capan I None
- I None
1 I None
, I None
and I None
MDAPanc I None
- I None
3 I None
) I None
, I None
whereas I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
protein I None
was I None
detected I None
in I None
two I None
of I None
the I None
five I None
cell I None
lines I None
( I None
BxPC I None
- I None
3 I None
and I None
Capan I None
- I None
1 I None
) I None
. I None
<eof> I None

<s> O None
Increased I None
levels I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
mRNA I None
were I None
found I None
in I None
four I None
of I None
five I None
cell I None
lines I None
, I None
and I None
only I None
in I None
PANC I None
- I None
1 I None
cells I None
was I None
the I None
low I None
level I None
of I None
transcript I None
comparable I None
to I None
that I None
in I None
the I None
normal I None
pancreas I None
. I None
<eof> I None

<s> O None
The I None
level I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
mRNA I None
was I None
positively I None
correlated I None
with I None
the I None
differentiation I None
status I None
of I None
the I None
tumor I None
of I None
origin I None
for I None
each I None
cell I None
line I None
, I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
protein I None
expression I None
was I None
up I None
- I None
regulated I None
by I None
epidermal I GENE-Y
growth O GENE-Y
factor O GENE-Y
when I None
the I None
cells I None
were I None
grown I None
in I None
absence I None
of I None
serum I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
two I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
, I None
sulindac I CHEMICAL
sulfide O CHEMICAL
and I None
NS398 I CHEMICAL
, I None
produced I None
a I None
dose I None
- I None
dependent I None
inhibition I None
of I None
cell I None
proliferation I None
in I None
all I None
pancreatic I None
cell I None
lines I None
tested I None
. I None
<eof> I None

<s> O None
No I None
correlation I None
was I None
found I None
between I None
the I None
level I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
or I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
expression I None
and I None
the I None
extent I None
of I None
growth I None
inhibition I None
. I None
<eof> I None

<s> O None
Treatment I None
of I None
BxPC I None
- I None
3 I None
cells I None
with I None
sulindac I CHEMICAL
sulfide O CHEMICAL
and I None
NS398 I CHEMICAL
resulted I None
in I None
an I None
induction I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
expression I None
. I None
<eof> I None

<s> O None
Our I None
findings I None
indicate I None
that I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
up I None
- I None
regulation I None
is I None
a I None
frequent I None
event I None
in I None
pancreatic I None
cancers I None
and I None
suggest I None
that I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
may I None
be I None
useful I None
in I None
the I None
chemoprevention I None
and I None
therapy I None
of I None
pancreatic I None
carcinoma I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
ATM I GENE-Y
and I None
ATR I GENE-Y
kinase I GENE-N
activities I None
by I None
the I None
radiosensitizing I None
agent I None
, I None
caffeine I CHEMICAL
. I None
<eof> I None

<s> O None
Caffeine I CHEMICAL
exposure I None
sensitizes I None
tumor I None
cells I None
to I None
ionizing I None
radiation I None
and I None
other I None
genotoxic I None
agents I None
. I None
<eof> I None

<s> O None
The I None
radiosensitizing I None
effects I None
of I None
caffeine I CHEMICAL
are I None
associated I None
with I None
the I None
disruption I None
of I None
multiple I None
DNA I None
damage I None
- I None
responsive I None
cell I None
cycle I None
checkpoints I None
. I None
<eof> I None

<s> O None
The I None
similarity I None
of I None
these I None
checkpoint I None
defects I None
to I None
those I None
seen I None
in I None
ataxia I None
- I None
telangiectasia I None
( I None
A I None
- I None
T I None
) I None
suggested I None
that I None
caffeine I CHEMICAL
might I None
inhibit I None
one I None
or I None
more I None
components I None
in I None
an I None
A I GENE-Y
- O GENE-Y
T O GENE-Y
mutated O GENE-Y
( I None
ATM I GENE-Y
) I None
- I None
dependent I None
checkpoint I None
pathway I None
in I None
DNA I None
- I None
damaged I None
cells I None
. I None
<eof> I None

<s> O None
We I None
now I None
show I None
that I None
caffeine I CHEMICAL
inhibits I None
the I None
catalytic I None
activity I None
of I None
both I None
ATM I GENE-Y
and I None
the I None
related I None
kinase I GENE-N
, I None
ATM I GENE-Y
and O GENE-Y
Rad3 O GENE-Y
- O GENE-Y
related O GENE-Y
( I None
ATR I GENE-Y
) I None
, I None
at I None
drug I None
concentrations I None
similar I None
to I None
those I None
that I None
induce I None
radiosensitization I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
like I None
ATM I GENE-Y
- I None
deficient I None
cells I None
, I None
caffeine I CHEMICAL
- I None
treated I None
A549 I None
lung I None
carcinoma I None
cells I None
irradiated I None
in I None
G2 I None
fail I None
to I None
arrest I None
progression I None
into I None
mitosis I None
, I None
and I None
S I None
- I None
phase I None
- I None
irradiated I None
cells I None
exhibit I None
radioresistant I None
DNA I None
synthesis I None
. I None
<eof> I None

<s> O None
Similar I None
concentrations I None
of I None
caffeine I CHEMICAL
also I None
inhibit I None
gamma I None
- I None
and I None
UV I None
radiation I None
- I None
induced I None
phosphorylation I None
of I None
p53 I GENE-N
on I None
Ser15 I None
, I None
a I None
modification I None
that I None
may I None
be I None
directly I None
mediated I None
by I None
the I None
ATM I GENE-Y
and I None
ATR I GENE-Y
kinases I GENE-N
. I None
<eof> I None

<s> O None
DNA I None
- I None
dependent I None
protein I None
kinase I GENE-N
, I None
another I None
ATM I GENE-N
- O GENE-N
related O GENE-N
protein O GENE-N
involved I None
in I None
DNA I None
damage I None
repair I None
, I None
was I None
resistant I None
to I None
the I None
inhibitory I None
effects I None
of I None
caffeine I CHEMICAL
. I None
<eof> I None

<s> O None
Likewise I None
, I None
the I None
catalytic I None
activity I None
of I None
the I None
G2 I None
checkpoint I GENE-N
kinase O GENE-N
, I None
hChk1 I GENE-Y
, I None
was I None
only I None
marginally I None
suppressed I None
by I None
caffeine I CHEMICAL
but I None
was I None
inhibited I None
potently I None
by I None
the I None
structurally I None
distinct I None
radiosensitizer I None
, I None
UCN I CHEMICAL
- O CHEMICAL
01 O CHEMICAL
. I None
<eof> I None

<s> O None
These I None
data I None
suggest I None
that I None
the I None
radiosensitizing I None
effects I None
of I None
caffeine I CHEMICAL
are I None
related I None
to I None
inhibition I None
of I None
the I None
protein I GENE-N
kinase O GENE-N
activities I None
of I None
ATM I GENE-Y
and I None
ATR I GENE-Y
and I None
that I None
both I None
proteins I None
are I None
relevant I None
targets I None
for I None
the I None
development I None
of I None
novel I None
anticancer I None
agents I None
. I None
<eof> I None

<s> O None
Stimulation I None
by I None
transforming I GENE-Y
growth O GENE-Y
factor O GENE-Y
- O GENE-Y
alpha O GENE-Y
of I None
DNA I None
synthesis I None
and I None
proliferation I None
of I None
adult I None
rat I None
hepatocytes I None
in I None
primary I None
cultures I None
: I None
modulation I None
by I None
alpha I GENE-N
- O GENE-N
and O GENE-N
beta O GENE-N
- O GENE-N
adrenoceptor O GENE-N
agonists I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
the I None
effects I None
of I None
transforming I GENE-Y
growth O GENE-Y
factor O GENE-Y
alpha O GENE-Y
( I None
TGF I GENE-Y
- O GENE-Y
alpha O GENE-Y
) I None
on I None
DNA I None
synthesis I None
and I None
proliferation I None
in I None
primary I None
cultures I None
of I None
adult I None
rat I None
hepatocytes I None
and I None
examined I None
the I None
influence I None
of I None
alpha I GENE-N
and O GENE-N
beta O GENE-N
adrenoceptor O GENE-N
agonists I None
on I None
the I None
TGF I GENE-Y
- O GENE-Y
alpha O GENE-Y
- I None
induced I None
responses I None
. I None
<eof> I None

<s> O None
TGF I GENE-Y
- O GENE-Y
alpha O GENE-Y
( I None
1 I None
. I None
0 I None
ng I None
/ I None
ml I None
) I None
produced I None
a I None
4 I None
. I None
1 I None
- I None
fold I None
elevation I None
of I None
DNA I None
synthesis I None
during I None
3 I None
h I None
of I None
culture I None
and I None
a I None
1 I None
. I None
2 I None
- I None
fold I None
increase I None
in I None
the I None
nucleus I None
number I None
( I None
proliferation I None
) I None
during I None
4 I None
h I None
of I None
culture I None
at I None
a I None
cell I None
density I None
of I None
3 I None
. I None
3 I None
x I None
10 I None
( I None
4 I None
) I None
cells I None
/ I None
cm I None
( I None
2 I None
) I None
. I None
<eof> I None

<s> O None
The I None
TGF I GENE-Y
- O GENE-Y
alpha O GENE-Y
- I None
induced I None
hepatocyte I None
DNA I None
synthesis I None
and I None
proliferation I None
were I None
dose I None
- I None
dependent I None
at I None
EC I None
( I None
50 I None
) I None
values I None
of I None
0 I None
. I None
36 I None
ng I None
/ I None
ml I None
and I None
0 I None
. I None
45 I None
ng I None
/ I None
ml I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Hepatocyte I None
DNA I None
synthesis I None
and I None
proliferation I None
induced I None
by I None
1 I None
. I None
0 I None
ng I None
/ I None
ml I None
TGF I GENE-Y
- O GENE-Y
alpha O GENE-Y
did I None
not I None
reduce I None
even I None
at I None
higher I None
initial I None
plating I None
densities I None
( I None
5 I None
. I None
0 I None
x I None
10 I None
( I None
4 I None
) I None
and I None
1 I None
. I None
0 I None
x I None
10 I None
( I None
5 I None
) I None
cells I None
/ I None
cm I None
( I None
2 I None
) I None
) I None
. I None
<eof> I None

<s> O None
Increasing I None
concentrations I None
of I None
the I None
beta I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
adrenoceptor O GENE-Y
agonist I None
metaproterenol I CHEMICAL
( I None
10 I None
( I None
- I None
7 I None
) I None
- I None
10 I None
( I None
- I None
6 I None
) I None
M I None
) I None
markedly I None
reduced I None
the I None
proliferative I None
effects I None
of I None
TGF I GENE-Y
- O GENE-Y
alpha O GENE-Y
, I None
whereas I None
those I None
of I None
the I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
adrenoceptor O GENE-N
agonist I None
5 I CHEMICAL
- O CHEMICAL
bromo O CHEMICAL
- O CHEMICAL
6 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
imidazolin O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
yl O CHEMICAL
- O CHEMICAL
amino O CHEMICAL
] O CHEMICAL
- O CHEMICAL
quinoxaline O CHEMICAL
( I None
UK I CHEMICAL
- O CHEMICAL
14304 O CHEMICAL
; I None
10 I None
( I None
- I None
6 I None
) I None
- I None
10 I None
( I None
- I None
5 I None
) I None
M I None
) I None
and I None
the I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
adrenoceptor O GENE-N
agonist I None
phenylephrine I CHEMICAL
( I None
10 I None
( I None
- I None
7 I None
) I None
- I None
10 I None
( I None
- I None
6 I None
) I None
M I None
) I None
significantly I None
potentiated I None
the I None
TGF I GENE-Y
- O GENE-Y
alpha O GENE-Y
action I None
. I None
<eof> I None

<s> O None
The I None
proliferative I None
effects I None
of I None
TGF I GENE-Y
- O GENE-Y
alpha O GENE-Y
( I None
1 I None
. I None
0 I None
ng I None
/ I None
ml I None
) I None
were I None
not I None
affected I None
significantly I None
by I None
a I None
monoclonal I None
antiepidermal I GENE-Y
growth O GENE-Y
factor O GENE-Y
receptor O GENE-Y
antibody I None
( I None
1 I None
- I None
100 I None
ng I None
/ I None
ml I None
) I None
and I None
were I None
almost I None
completely I None
blocked I None
by I None
specific I None
inhibitors I None
of I None
signal I None
transducers I None
such I None
as I None
genistein I CHEMICAL
( I None
10 I None
( I None
- I None
5 I None
) I None
M I None
) I None
, I None
1 I CHEMICAL
- O CHEMICAL
6 O CHEMICAL
[ O CHEMICAL
[ O CHEMICAL
17beta O CHEMICAL
- O CHEMICAL
3methoxyestra O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
, O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
( O CHEMICAL
10 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
trien O CHEMICAL
- O CHEMICAL
17 O CHEMICAL
- O CHEMICAL
yl O CHEMICAL
] O CHEMICAL
amino O CHEMICAL
] O CHEMICAL
hexyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
1H O CHEMICAL
- O CHEMICAL
pyrrol2 O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
dione O CHEMICAL
( I None
U I CHEMICAL
- O CHEMICAL
73122 O CHEMICAL
; I None
0 I None
( I None
- I None
5 I None
) I None
M I None
) I None
, I None
wortmannin I CHEMICAL
( I None
5 I None
x I None
10 I None
( I None
- I None
7 I None
) I None
M I None
) I None
, I None
sphingosine I CHEMICAL
( I None
5 I None
x I None
10 I None
( I None
- I None
6 I None
) I None
M I None
) I None
, I None
2 I CHEMICAL
' O CHEMICAL
- O CHEMICAL
amino O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
methoxyflavone O CHEMICAL
( I None
PD98059 I CHEMICAL
; I None
5 I None
x I None
10 I None
( I None
- I None
5 I None
) I None
M I None
) I None
, I None
and I None
rapamycin I CHEMICAL
( I None
10 I None
ng I None
/ I None
ml I None
) I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
among I None
the I None
elements I None
that I None
link I None
signals I None
of I None
cell I None
surface I None
receptor I None
to I None
the I None
nucleus I None
, I None
the I None
proliferative I None
action I None
of I None
TGF I GENE-Y
- O GENE-Y
alpha O GENE-Y
is I None
mediated I None
, I None
at I None
least I None
, I None
by I None
tyrosine I GENE-N
kinase O GENE-N
, I None
phospholipase I GENE-N
C O GENE-N
, I None
phosphatidylinositol I GENE-N
3 O GENE-N
- O GENE-N
kinase O GENE-N
, I None
protein I GENE-N
kinase O GENE-N
C O GENE-N
, I None
mitogen I GENE-N
- O GENE-N
activated O GENE-N
protein O GENE-N
kinase O GENE-N
kinase O GENE-N
, I None
and I None
ribosomal I GENE-N
protein O GENE-N
p70 O GENE-N
S6 O GENE-N
kinase O GENE-N
. I None
<eof> I None

<s> O None
Cell I None
culture I None
conditions I None
determine I None
apolipoprotein I GENE-Y
CIII O GENE-Y
secretion I None
and I None
regulation I None
by I None
fibrates I None
in I None
human I None
hepatoma I None
HepG2 I None
cells I None
. I None
<eof> I None

<s> O None
Fibrates I CHEMICAL
are I None
widely I None
used I None
drugs I None
which I None
lower I None
triglycerides I CHEMICAL
and I None
increase I None
HDL I GENE-N
concentrations I None
in I None
serum I None
. I None
<eof> I None

<s> O None
Recent I None
findings I None
from I None
our I None
laboratory I None
have I None
shown I None
that I None
fibrates I CHEMICAL
repress I None
apolipoprotein I GENE-Y
( O GENE-Y
apo O GENE-Y
) O GENE-Y
CIII O GENE-Y
gene I None
expression I None
, I None
an I None
effect I None
that I None
explains I None
partially I None
the I None
triglyceride I CHEMICAL
- I None
lowering I None
activity I None
of I None
these I None
drugs I None
. I None
<eof> I None

<s> O None
The I None
goal I None
of I None
the I None
present I None
study I None
was I None
to I None
compare I None
the I None
effect I None
of I None
various I None
fibrates I CHEMICAL
on I None
apo I GENE-Y
CIII O GENE-Y
gene I None
expression I None
in I None
the I None
human I None
hepatoblastoma I None
cell I None
line I None
HepG2 I None
. I None
<eof> I None

<s> O None
First I None
, I None
we I None
demonstrate I None
that I None
the I None
level I None
of I None
apo I GENE-Y
CIII O GENE-Y
secretion I None
by I None
HepG2 I None
cells I None
is I None
controlled I None
by I None
serum I None
factors I None
whereas I None
apo I GENE-Y
CIII O GENE-Y
mRNA I None
levels I None
are I None
not I None
and I None
even I None
increase I None
under I None
conditions I None
when I None
apo I GENE-Y
CIII O GENE-Y
secretion I None
dramatically I None
decreases I None
. I None
<eof> I None

<s> O None
Twelve I None
different I None
fetal I None
calf I None
serum I None
batches I None
were I None
tested I None
during I None
this I None
study I None
and I None
apo I GENE-Y
CIII O GENE-Y
secretion I None
in I None
cell I None
medium I None
could I None
only I None
be I None
detected I None
with I None
three I None
of I None
them I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
serum I None
on I None
apolipoprotein I GENE-N
secretion I None
was I None
more I None
pronounced I None
for I None
apo I GENE-Y
CIII O GENE-Y
whereas I None
other I None
apolipoproteins I GENE-N
( I None
apo I GENE-Y
E O GENE-Y
, I None
apo I GENE-Y
B O GENE-Y
, I None
apo I GENE-Y
AII O GENE-Y
and I None
apo I GENE-Y
AI O GENE-Y
) I None
were I None
affected I None
to I None
a I None
lesser I None
extent I None
. I None
<eof> I None

<s> O None
Under I None
serum I None
conditions I None
allowing I None
apo I GENE-Y
CIII O GENE-Y
secretion I None
, I None
treatment I None
with I None
the I None
peroxisome I GENE-Y
- O GENE-Y
proliferator O GENE-Y
activated O GENE-Y
receptor O GENE-Y
( O GENE-Y
PPAR O GENE-Y
) O GENE-Y
alpha O GENE-Y
activators I None
fenofibrate I CHEMICAL
, I None
gemfibrozil I CHEMICAL
and I None
Wy I CHEMICAL
- O CHEMICAL
14643 O CHEMICAL
result I None
in I None
a I None
marked I None
lowering I None
of I None
apo I GENE-Y
CIII O GENE-Y
secretion I None
and I None
gene I None
expression I None
, I None
this I None
effect I None
being I None
most I None
pronounced I None
with I None
Wy I CHEMICAL
- O CHEMICAL
14643 O CHEMICAL
. I None
<eof> I None

<s> O None
Comparison I None
of I None
the I None
activity I None
of I None
a I None
PPARgamma I GENE-Y
- I None
specific I None
ligand I None
, I None
the I None
antidiabetic I None
thiazolidinedione I CHEMICAL
, I None
BRL I CHEMICAL
- O CHEMICAL
49653 O CHEMICAL
and I None
a I None
PPARalpha I GENE-Y
ligand I None
Wy I CHEMICAL
- O CHEMICAL
14643 O CHEMICAL
showed I None
a I None
marked I None
decrease I None
of I None
apo I GENE-Y
CIII O GENE-Y
secretion I None
and I None
gene I None
expression I None
after I None
activation I None
of I None
PPARalpha I GENE-Y
but I None
not I None
PPARgamma I GENE-Y
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
fibrates I CHEMICAL
down I None
- I None
regulate I None
apo I GENE-Y
CIII O GENE-Y
gene I None
expression I None
in I None
human I None
HepG2 I None
cells I None
, I None
most I None
likely I None
via I None
PPARalpha I GENE-Y
but I None
not I None
via I None
PPARgamma I GENE-Y
. I None
<eof> I None

<s> O None
However I None
, I None
these I None
effects I None
are I None
only I None
observed I None
in I None
HepG2 I None
cells I None
cultured I None
under I None
appropriate I None
conditions I None
. I None
<eof> I None

<s> O None
Variations I None
of I None
progesterone I GENE-Y
receptor O GENE-Y
and I None
c I GENE-Y
- O GENE-Y
fos O GENE-Y
gene I None
expression I None
in I None
the I None
rat I None
uterus I None
after I None
treatment I None
with I None
norethisterone I CHEMICAL
and I None
its I None
A I None
- I None
ring I None
reduced I None
metabolites I None
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
suggested I None
that I None
some I None
contraceptive I None
derivatives I None
of I None
19 I CHEMICAL
- O CHEMICAL
nor O CHEMICAL
- O CHEMICAL
testosterone O CHEMICAL
possess I None
estrogenic I None
activity I None
that I None
may I None
facilitate I None
the I None
development I None
of I None
breast I None
cancer I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
work I None
was I None
to I None
investigate I None
the I None
estrogenic I None
properties I None
of I None
norethisterone I CHEMICAL
( I None
NET I CHEMICAL
) I None
and I None
its I None
A I None
- I None
ring I None
- I None
reduced I None
derivatives I None
by I None
determining I None
progesterone I GENE-Y
receptor O GENE-Y
( I None
PR I GENE-Y
) I None
and I None
c I GENE-Y
- O GENE-Y
fos O GENE-Y
mRNA I None
content I None
of I None
two I None
estrogen I CHEMICAL
- I None
regulated I None
genes I None
in I None
the I None
uterus I None
of I None
ovariectomized I None
rats I None
. I None
<eof> I None

<s> O None
mRNA I None
content I None
was I None
evaluated I None
by I None
Northern I None
blot I None
1 I None
- I None
6 I None
h I None
after I None
17 I CHEMICAL
beta O CHEMICAL
- O CHEMICAL
estradiol O CHEMICAL
administration I None
. I None
<eof> I None

<s> O None
The I None
highest I None
PR I GENE-Y
and I None
c I GENE-Y
- O GENE-Y
fos O GENE-Y
mRNA I None
content I None
was I None
observed I None
3 I None
h I None
and I None
2 I None
h I None
after I None
17 I CHEMICAL
beta O CHEMICAL
- O CHEMICAL
estradiol O CHEMICAL
administration I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
NET I CHEMICAL
did I None
not I None
modify I None
either I None
PR I GENE-Y
or I None
c I GENE-Y
- O GENE-Y
fos O GENE-Y
mRNA I None
content I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
5 I CHEMICAL
alpha O CHEMICAL
- O CHEMICAL
and O CHEMICAL
3 O CHEMICAL
beta O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
alpha O CHEMICAL
- O CHEMICAL
NET O CHEMICAL
significantly I None
increased I None
mRNA I None
content I None
of I None
both I None
genes I None
. I None
<eof> I None

<s> O None
The I None
increase I None
in I None
c I GENE-Y
- O GENE-Y
fos O GENE-Y
mRNA I None
content I None
induced I None
by I None
these I None
reduced I None
compounds I None
was I None
lower I None
than I None
that I None
found I None
with I None
estradiol I CHEMICAL
treatment I None
. I None
<eof> I None

<s> O None
The I None
overall I None
results I None
indicate I None
that I None
NET I CHEMICAL
administration I None
can I None
indirectly I None
induce I None
estrogenic I None
effects I None
through I None
the I None
action I None
of I None
its I None
5 I CHEMICAL
alpha O CHEMICAL
- O CHEMICAL
dihydro O CHEMICAL
and I None
3 I CHEMICAL
beta O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
alpha O CHEMICAL
- O CHEMICAL
tetrahydro O CHEMICAL
derivatives I None
. I None
<eof> I None

<s> O None
Involvement I None
of I None
bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
and I None
p21waf1 I GENE-Y
proteins I None
in I None
response I None
of I None
human I None
breast I None
cancer I None
cell I None
clones I None
to I None
Tomudex I CHEMICAL
. I None
<eof> I None

<s> O None
Mechanisms I None
of I None
resistance I None
to I None
Tomudex I CHEMICAL
include I None
increased I None
thymidylate I GENE-Y
synthase O GENE-Y
activity I None
, I None
as I None
well I None
as I None
reduced I None
intracellular I None
drug I None
uptake I None
and I None
polyglutamation I None
. I None
<eof> I None

<s> O None
However I None
, I None
little I None
is I None
known I None
about I None
other I None
mechanisms I None
of I None
resistance I None
, I None
such I None
as I None
a I None
possible I None
protection I None
against I None
Tomudex I CHEMICAL
- I None
induced I None
apoptosis I None
mediated I None
by I None
bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
We I None
transfected I None
the I None
MDA I None
- I None
MB I None
- I None
435 I None
human I None
breast I None
cancer I None
cell I None
line I None
, I None
which I None
is I None
characterized I None
by I None
a I None
mutated I None
p53 I GENE-Y
gene I None
, I None
with I None
cDNA I None
of I None
the I None
bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
gene I None
and I None
generated I None
two I None
clones I None
( I None
MDA I None
- I None
bcl4 I GENE-Y
and I None
MDA I None
- I None
bcl7 I GENE-N
) I None
characterized I None
by I None
bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
expression I None
twofold I None
and I None
fourfold I None
that I None
observed I None
in I None
the I None
control I None
cell I None
clone I None
( I None
MDAneo I None
) I None
. I None
<eof> I None

<s> O None
A I None
concomitant I None
overexpression I None
of I None
p21wafl I GENE-Y
was I None
also I None
detected I None
in I None
the I None
MDA I None
- I None
bcl7 I GENE-N
clone I None
. I None
<eof> I None

<s> O None
The I None
MDA I None
- I None
bcl4 I GENE-Y
clone I None
was I None
three I None
times I None
more I None
resistant I None
to I None
a I None
24 I None
- I None
h I None
Tomudex I CHEMICAL
exposure I None
than I None
the I None
MDAneo I None
clone I None
, I None
whereas I None
the I None
MDA I None
- I None
bcl7 I GENE-N
clone I None
was I None
as I None
sensitive I None
to I None
Tomudex I CHEMICAL
as I None
the I None
control I None
cell I None
clone I None
. I None
<eof> I None

<s> O None
A I None
lower I None
sensitivity I None
of I None
the I None
MDA I None
- I None
bcl4 I GENE-Y
clone I None
than I None
MDAneo I None
and I None
MDA I None
- I None
bcl7 I GENE-N
clones I None
to I None
5 I CHEMICAL
- O CHEMICAL
fluorouracil O CHEMICAL
and I None
gemcitabine I CHEMICAL
was I None
also I None
observed I None
. I None
<eof> I None

<s> O None
No I None
significant I None
difference I None
was I None
noted I None
in I None
the I None
susceptibility I None
of I None
clones I None
to I None
fludarabine I CHEMICAL
and I None
methothrexate I CHEMICAL
. I None
<eof> I None

<s> O None
Basal I None
levels I None
of I None
thymidylate I GENE-Y
synthase O GENE-Y
activity I None
were I None
superimposable I None
in I None
the I None
three I None
clones I None
. I None
<eof> I None

<s> O None
Tomudex I CHEMICAL
induced I None
a I None
marked I None
accumulation I None
of I None
cells I None
in I None
the I None
S I None
phase I None
in I None
all I None
the I None
clones I None
. I None
<eof> I None

<s> O None
However I None
, I None
an I None
apoptotic I None
hypodiploid I None
DNA I None
peak I None
and I None
the I None
characteristic I None
nuclear I None
morphology I None
of I None
apoptosis I None
were I None
observed I None
only I None
in I None
the I None
MDA I None
- I None
bcl7 I GENE-N
clone I None
after I None
exposure I None
to I None
Tomudex I CHEMICAL
. I None
<eof> I None

<s> O None
No I None
difference I None
in I None
the I None
treatment I None
- I None
induced I None
modulation I None
of I None
proteins I None
involved I None
in I None
cell I None
cycle I None
progression I None
( I None
cyclin I GENE-Y
A O GENE-Y
, I None
cdk2 I GENE-Y
, I None
pRB I GENE-Y
, I None
E2F I GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
and I None
apoptosis I None
( I None
bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
, I None
bax I GENE-Y
) I None
was I None
observed I None
in I None
the I None
three I None
clones I None
. I None
<eof> I None

<s> O None
The I None
only I None
exception I None
was I None
that I None
the I None
expression I None
of I None
p21wafl I GENE-Y
in I None
the I None
MDA I None
- I None
bcl4 I GENE-Y
clone I None
was I None
inducible I None
at I None
a I None
Tomudex I CHEMICAL
concentration I None
much I None
higher I None
than I None
that I None
required I None
to I None
induce I None
the I None
protein I None
in I None
the I None
other I None
clones I None
. I None
<eof> I None

<s> O None
Overall I None
, I None
the I None
results I None
indicate I None
that I None
bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
and I None
p21wafl I GENE-Y
proteins I None
concur I None
in I None
determining I None
the I None
cellular I None
profile I None
of I None
sensitivity I None
/ I None
resistance I None
to I None
Tomudex I CHEMICAL
. I None
<eof> I None

<s> O None
Suppression I None
of I None
Delta I CHEMICAL
( O CHEMICAL
5 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
androstenediol O CHEMICAL
- I None
induced I None
androgen I GENE-Y
receptor O GENE-Y
transactivation I None
by I None
selective I None
steroids I CHEMICAL
in I None
human I None
prostate I None
cancer I None
cells I None
. I None
<eof> I None

<s> O None
Our I None
earlier I None
report I None
suggested I None
that I None
androst I CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
ene O CHEMICAL
- O CHEMICAL
3beta O CHEMICAL
, O CHEMICAL
7beta O CHEMICAL
- O CHEMICAL
diol O CHEMICAL
( I None
Delta I CHEMICAL
( O CHEMICAL
5 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
androstenediol O CHEMICAL
or I None
Adiol I CHEMICAL
) I None
is I None
a I None
natural I None
hormone I None
with I None
androgenic I None
activity I None
and I None
that I None
two I None
potent I None
antiandrogens I None
, I None
hydroxyflutamide I CHEMICAL
( I None
Eulexin I CHEMICAL
) I None
and I None
bicalutamide I CHEMICAL
( I None
Casodex I CHEMICAL
) I None
, I None
fail I None
to I None
block I None
completely I None
the I None
Adiol I CHEMICAL
- I None
induced I None
androgen I GENE-Y
receptor O GENE-Y
( I None
AR I GENE-Y
) I None
transactivation I None
in I None
prostate I None
cancer I None
cells I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
report I None
the I None
development I None
of I None
a I None
reporter I None
assay I None
to I None
screen I None
several I None
selective I None
steroids I CHEMICAL
with I None
anti I None
- I None
Adiol I CHEMICAL
activity I None
. I None
<eof> I None

<s> O None
Among I None
22 I None
derivatives I None
/ I None
metabolites I None
of I None
dehydroepiandrosterone I CHEMICAL
, I None
we I None
found I None
4 I None
steroids I CHEMICAL
[ I None
no I None
. I None
4 I CHEMICAL
, O CHEMICAL
1 O CHEMICAL
, O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
( O CHEMICAL
10 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
estratriene O CHEMICAL
- O CHEMICAL
17alpha O CHEMICAL
- O CHEMICAL
ethynyl O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
17beta O CHEMICAL
- O CHEMICAL
diol O CHEMICAL
; I None
no I None
. I None
6 I CHEMICAL
, O CHEMICAL
17alpha O CHEMICAL
- O CHEMICAL
ethynyl O CHEMICAL
- O CHEMICAL
androstene O CHEMICAL
- O CHEMICAL
diol O CHEMICAL
; I None
no I None
. I None
8 I CHEMICAL
, O CHEMICAL
3beta O CHEMICAL
, O CHEMICAL
17beta O CHEMICAL
- O CHEMICAL
dihydroxy O CHEMICAL
- O CHEMICAL
androst O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
ene O CHEMICAL
- O CHEMICAL
16 O CHEMICAL
- O CHEMICAL
one O CHEMICAL
; I None
and I None
no I None
. I None
10 I CHEMICAL
, O CHEMICAL
3beta O CHEMICAL
- O CHEMICAL
methylcarbonate O CHEMICAL
- O CHEMICAL
androst O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
ene O CHEMICAL
- O CHEMICAL
7 O CHEMICAL
, O CHEMICAL
17 O CHEMICAL
- O CHEMICAL
dione O CHEMICAL
] I None
that I None
have I None
no I None
androgenic I None
activity I None
and I None
could I None
also I None
block I None
the I None
Adiol I CHEMICAL
- I None
induced I None
AR I GENE-Y
transactivation I None
in I None
prostate I None
cancer I None
PC I None
- I None
3 I None
cells I None
. I None
<eof> I None

<s> O None
Interestingly I None
, I None
these I None
compounds I None
, I None
in I None
combination I None
with I None
hydroxyflutamide I CHEMICAL
, I None
further I None
suppressed I None
the I None
Adiol I CHEMICAL
- I None
induced I None
AR I GENE-Y
transactivation I None
. I None
<eof> I None

<s> O None
Reporter I None
assays I None
further I None
showed I None
that I None
these I None
four I None
anti I None
- I None
Adiol I CHEMICAL
steroids I CHEMICAL
have I None
relatively I None
lower I None
glucocorticoid I None
, I None
progesterone I CHEMICAL
, I None
and I None
estrogenic I None
activity I None
. I None
<eof> I None

<s> O None
Together I None
, I None
these I None
data I None
suggest I None
some I None
selective I None
steroids I CHEMICAL
might I None
have I None
anti I None
- I None
Adiol I CHEMICAL
activity I None
, I None
which I None
may I None
have I None
potential I None
clinical I None
application I None
in I None
the I None
battle I None
against I None
the I None
androgen I CHEMICAL
- I None
dependent I None
prostate I None
cancer I None
growth I None
. I None
<eof> I None

<s> O None
EPR I None
studies I None
on I None
the I None
photo I None
- I None
induced I None
intermediates I None
of I None
ferric I CHEMICAL
NO O CHEMICAL
complexes I None
of I None
rat I GENE-Y
neuronal O GENE-Y
nitric O GENE-Y
oxide O GENE-Y
synthase O GENE-Y
trapped I None
at I None
low I None
temperature I None
. I None
<eof> I None

<s> O None
Rat I GENE-Y
neuronal O GENE-Y
nitric O GENE-Y
oxide O GENE-Y
synthase O GENE-Y
( I None
nNOS I GENE-Y
) I None
was I None
expressed I None
in I None
Escherichia I None
coli I None
and I None
purified I None
. I None
<eof> I None

<s> O None
Although I None
the I None
nitric I CHEMICAL
oxide O CHEMICAL
( I None
NO I CHEMICAL
) I None
complex I None
of I None
the I None
ferric I CHEMICAL
heme O CHEMICAL
was I None
EPR I None
- I None
silent I None
, I None
photo I None
- I None
illumination I None
at I None
5 I None
K I None
to I None
the I None
NO I CHEMICAL
complex I None
of I None
the I None
ferric I CHEMICAL
nNOS I GENE-Y
in I None
the I None
substrate I None
- I None
free I None
form I None
produced I None
a I None
new I None
high I None
spin I None
EPR I None
signal I None
similar I None
to I None
that I None
of I None
the I None
ferric I CHEMICAL
heme O CHEMICAL
of I None
N I CHEMICAL
( O CHEMICAL
omega O CHEMICAL
) O CHEMICAL
- O CHEMICAL
nitro O CHEMICAL
- O CHEMICAL
L O CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
- I None
bound I None
nNOS I GENE-Y
, I None
suggesting I None
that I None
the I None
photo I None
- I None
dissociated I None
NO I CHEMICAL
might I None
move I None
away I None
from I None
the I None
heme I None
. I None
<eof> I None

<s> O None
Low I None
photo I None
- I None
dissociability I None
of I None
NO I CHEMICAL
in I None
this I None
complex I None
indicated I None
less I None
restricted I None
movement I None
of I None
the I None
dissociated I None
NO I CHEMICAL
in I None
the I None
distal I None
region I None
of I None
the I None
heme I None
, I None
which I None
might I None
result I None
in I None
the I None
rapid I None
rebinding I None
of I None
the I None
NO I CHEMICAL
to I None
the I None
ferric I CHEMICAL
heme O CHEMICAL
at I None
5 I None
K I None
. I None
<eof> I None

<s> O None
In I None
the I None
presence I None
of I None
substrate I None
L I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
, I None
derivatives I None
, I None
or I None
product I None
L I CHEMICAL
- O CHEMICAL
citrulline O CHEMICAL
, I None
the I None
photo I None
- I None
products I None
from I None
the I None
ferric I CHEMICAL
NO O CHEMICAL
complexes I None
exhibited I None
large I None
novel I None
EPR I None
signals I None
with I None
a I None
spin I None
- I None
coupled I None
interaction I None
between I None
the I None
ferric I CHEMICAL
heme O CHEMICAL
( I None
S I None
= I None
5 I None
/ I None
2 I None
) I None
and I None
the I None
photolyzed I None
NO I CHEMICAL
( I None
S I None
= I None
1 I None
/ I None
2 I None
) I None
, I None
suggesting I None
a I None
stereochemically I None
restricted I None
interaction I None
between I None
the I None
photo I None
- I None
dissociated I None
NO I CHEMICAL
and I None
the I None
guanidino I CHEMICAL
- I None
or I None
the I None
ureido I CHEMICAL
- I None
group I None
of I None
the I None
substrate I None
analogues I None
at I None
the I None
distal I None
heme I None
region I None
of I None
nNOS I GENE-Y
. I None
<eof> I None

<s> O None
The I None
photo I None
- I None
product I None
from I None
the I None
NO I CHEMICAL
complex I None
produced I None
from I None
citrulline I CHEMICAL
- I None
bound I None
nNOS I GENE-Y
might I None
be I None
the I None
same I None
intermediate I None
species I None
as I None
that I None
formed I None
in I None
the I None
last I None
step I None
of I None
the I None
catalytic I None
cycle I None
. I None
<eof> I None

<s> O None
Raloxifene I CHEMICAL
: I None
a I None
selective I None
estrogen I GENE-Y
receptor O GENE-Y
modulator I None
. I None
<eof> I None

<s> O None
Raloxifene I CHEMICAL
is I None
a I None
selective I None
estrogen I GENE-Y
receptor O GENE-Y
modulator I None
that I None
produces I None
both I None
estrogen I CHEMICAL
- I None
agonistic I None
effects I None
on I None
bone I None
and I None
lipid I None
metabolism I None
and I None
estrogen I CHEMICAL
- I None
antagonistic I None
effects I None
on I None
uterine I None
endometrium I None
and I None
breast I None
tissue I None
. I None
<eof> I None

<s> O None
Because I None
of I None
its I None
tissue I None
selectivity I None
, I None
raloxifene I CHEMICAL
may I None
have I None
fewer I None
side I None
effects I None
than I None
are I None
typically I None
observed I None
with I None
estrogen I CHEMICAL
therapy I None
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
adverse I None
effects I None
of I None
raloxifene I CHEMICAL
are I None
hot I None
flushes I None
and I None
leg I None
cramps I None
. I None
<eof> I None

<s> O None
The I None
drug I None
is I None
also I None
associated I None
with I None
an I None
increased I None
risk I None
of I None
thromboembolic I None
events I None
. I None
<eof> I None

<s> O None
The I None
beneficial I None
estrogenic I None
activities I None
of I None
raloxifene I CHEMICAL
include I None
a I None
lowering I None
of I None
total I None
and I None
low I GENE-N
- O GENE-N
density O GENE-N
lipoprotein O GENE-N
cholesterol I CHEMICAL
levels I None
and I None
an I None
augmentation I None
of I None
bone I None
mineral I None
density I None
. I None
<eof> I None

<s> O None
Raloxifene I CHEMICAL
has I None
been I None
labeled I None
by I None
the I None
U I None
. I None
S I None
. I None
<eof> I None

<s> O None
Food I None
and I None
Drug I None
Administration I None
for I None
the I None
prevention I None
of I None
osteoporosis I None
. I None
<eof> I None

<s> O None
However I None
, I None
its I None
effects I None
on I None
fracture I None
risk I None
and I None
its I None
ability I None
to I None
protect I None
against I None
cardiovascular I None
disease I None
have I None
yet I None
to I None
be I None
determined I None
. I None
<eof> I None

<s> O None
Studies I None
are I None
also I None
being I None
conducted I None
to I None
determine I None
its I None
impact I None
on I None
breast I None
and I None
endometrial I None
cancer I None
reduction I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
the I None
human I GENE-Y
ether O GENE-Y
- O GENE-Y
a O GENE-Y
- O GENE-Y
go O GENE-Y
- O GENE-Y
go O GENE-Y
- O GENE-Y
related O GENE-Y
gene O GENE-Y
( O GENE-Y
HERG O GENE-Y
) O GENE-Y
potassium O GENE-Y
channel O GENE-Y
by I None
cisapride I CHEMICAL
: I None
affinity I None
for I None
open I None
and I None
inactivated I None
states I None
. I None
<eof> I None

<s> O None
1 I None
Cisapride I CHEMICAL
is I None
a I None
prokinetic I None
agent I None
which I None
has I None
been I None
associated I None
with I None
QT I None
prolongation I None
, I None
torsades I None
de I None
pointes I None
and I None
cardiac I None
arrest I None
. I None
<eof> I None

<s> O None
The I None
cellular I None
mechanism I None
for I None
these I None
observations I None
is I None
high I None
affinity I None
blockade I None
of I None
IKr I GENE-N
( I None
encoded I None
by I None
HERG I GENE-Y
) I None
. I None
<eof> I None

<s> O None
2 I None
In I None
a I None
chronic I None
transfection I None
model I None
using I None
CHO I None
- I None
K1 I None
cells I None
, I None
cisapride I CHEMICAL
inhibited I None
HERG I GENE-Y
tail I None
currents I None
after I None
a I None
step I None
to I None
+ I None
25 I None
mV I None
with I None
similar I None
potency I None
at I None
room I None
and I None
physiological I None
temperatures I None
( I None
IC50 I None
16 I None
. I None
4 I None
nM I None
at I None
20 I None
- I None
22 I None
degrees I None
C I None
and I None
23 I None
. I None
6 I None
nM I None
at I None
37 I None
degrees I None
C I None
) I None
. I None
<eof> I None

<s> O None
3 I None
Channel I None
inhibition I None
exhibited I None
time I None
- I None
, I None
voltage I None
- I None
and I None
frequency I None
- I None
dependence I None
. I None
<eof> I None

<s> O None
In I None
an I None
envelope I None
of I None
tails I None
test I None
, I None
channel I None
blockade I None
increased I None
from I None
27 I None
+ I None
/ I None
- I None
8 I None
% I None
after I None
a I None
120 I None
ms I None
depolarizing I None
step I None
to I None
50 I None
+ I None
/ I None
- I None
4 I None
% I None
after I None
a I None
1 I None
. I None
0 I None
s I None
step I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggested I None
affinity I None
for I None
open I None
and I None
/ I None
or I None
inactivated I None
channel I None
states I None
. I None
<eof> I None

<s> O None
4 I None
Inactivation I None
was I None
significantly I None
accelerated I None
by I None
cisapride I CHEMICAL
in I None
a I None
concentration I None
- I None
dependent I None
manner I None
and I None
there I None
was I None
a I None
small I None
( I None
- I None
7 I None
mV I None
) I None
shift I None
in I None
the I None
voltage I None
dependence I None
of I None
steady I None
state I None
inactivation I None
. I None
<eof> I None

<s> O None
5 I None
Channel I None
blockade I None
by I None
cisapride I CHEMICAL
was I None
modulated I None
by I None
[ I None
K I CHEMICAL
+ O CHEMICAL
] I None
o I None
, I None
with I None
a I None
26 I None
% I None
reduction I None
in I None
the I None
potency I None
of I None
channel I None
blockade I None
when I None
[ I None
K I CHEMICAL
+ O CHEMICAL
] I None
o I None
was I None
increased I None
from I None
1 I None
to I None
10 I None
mM I None
. I None
<eof> I None

<s> O None
6 I None
In I None
conclusion I None
, I None
HERG I GENE-Y
channel I None
inhibition I None
by I None
cisapride I CHEMICAL
exhibits I None
features I None
consistent I None
with I None
open I None
and I None
inactivated I None
state I None
binding I None
and I None
is I None
sensitive I None
to I None
external I None
potassium I CHEMICAL
concentration I None
. I None
<eof> I None

<s> O None
These I None
features I None
may I None
have I None
significant I None
clinical I None
implications I None
with I None
regard I None
to I None
the I None
mechanism I None
and I None
treatment I None
of I None
cisapride I CHEMICAL
- I None
induced I None
proarrhythmia I None
. I None
<eof> I None

<s> O None
Modification I None
of I None
dopamine I GENE-Y
D2 O GENE-Y
receptor O GENE-Y
activity I None
by I None
pergolide I CHEMICAL
in I None
Parkinson I None
' I None
s I None
disease I None
: I None
an I None
in I None
vivo I None
study I None
by I None
PET I None
. I None
<eof> I None

<s> O None
It I None
is I None
well I None
known I None
that I None
chronic I None
administration I None
of I None
pergolide I CHEMICAL
and I None
other I None
dopamine I CHEMICAL
agonists I None
may I None
induce I None
a I None
downregulation I None
of I None
dopamine I GENE-Y
D2 O GENE-Y
receptors O GENE-Y
in I None
the I None
rat I None
model I None
of I None
Parkinson I None
' I None
s I None
disease I None
( I None
PD I None
) I None
. I None
<eof> I None

<s> O None
To I None
our I None
knowledge I None
, I None
this I None
effect I None
has I None
not I None
been I None
demonstrated I None
in I None
vivo I None
in I None
patients I None
with I None
PD I None
. I None
<eof> I None

<s> O None
At I None
present I None
, I None
the I None
status I None
of I None
striatal I None
dopamine I GENE-Y
D2 O GENE-Y
receptors O GENE-Y
can I None
be I None
studied I None
with I None
use I None
of I None
positron I None
emission I None
tomographic I None
( I None
PET I None
) I None
technology I None
. I None
<eof> I None

<s> O None
Five I None
patients I None
with I None
PD I None
chronically I None
treated I None
with I None
levodopa I CHEMICAL
were I None
studied I None
with I None
use I None
of I None
PET I None
and I None
[ I CHEMICAL
11C O CHEMICAL
] O CHEMICAL
- O CHEMICAL
raclopride O CHEMICAL
before I None
and I None
after I None
6 I None
months I None
of I None
pergolide I CHEMICAL
treatment I None
( I None
dose I None
range I None
= I None
4 I None
. I None
5 I None
- I None
7 I None
. I None
5 I None
mg I None
/ I None
d I None
) I None
. I None
<eof> I None

<s> O None
We I None
found I None
a I None
slight I None
reduction I None
in I None
the I None
specific I None
striatal I None
[ I CHEMICAL
11C O CHEMICAL
] O CHEMICAL
- O CHEMICAL
raclopride O CHEMICAL
uptake I None
index I None
( I None
mean I None
reduction I None
14 I None
% I None
in I None
putamen I None
and I None
9 I None
% I None
in I None
caudate I None
) I None
after I None
pergolide I CHEMICAL
treatment I None
. I None
<eof> I None

<s> O None
This I None
reduction I None
appears I None
to I None
be I None
related I None
to I None
downregulation I None
of I None
the I None
receptor I None
, I None
although I None
competitive I None
binding I None
of I None
pergolide I CHEMICAL
at I None
the I None
D2 I GENE-Y
receptor O GENE-Y
cannot I None
be I None
excluded I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
the I None
novel I None
antipsychotic I None
ziprasidone I CHEMICAL
with I None
clozapine I CHEMICAL
and I None
olanzapine I CHEMICAL
: I None
inhibition I None
of I None
dorsal I None
raphe I None
cell I None
firing I None
and I None
the I None
role I None
of I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
receptor O GENE-Y
activation I None
. I None
<eof> I None

<s> O None
Ziprasidone I CHEMICAL
is I None
a I None
novel I None
antipsychotic I None
agent I None
which I None
binds I None
with I None
high I None
affinity I None
to I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
receptors O GENE-Y
( I None
Ki I None
= I None
3 I None
. I None
4 I None
nM I None
) I None
, I None
in I None
addition I None
to I None
5 I GENE-Y
- O GENE-Y
HT1D O GENE-Y
, I None
5 I GENE-Y
- O GENE-Y
HT2 O GENE-Y
, I None
and I None
D2 I GENE-Y
sites I None
. I None
<eof> I None

<s> O None
While I None
it I None
is I None
an I None
antagonist I None
at I None
these I None
latter I None
receptors I None
, I None
ziprasidone I CHEMICAL
behaves I None
as I None
a I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
agonist I None
in I None
vitro I None
in I None
adenylate I GENE-N
cyclase O GENE-N
measurements I None
. I None
<eof> I None

<s> O None
The I None
goal I None
of I None
the I None
present I None
study I None
was I None
to I None
examine I None
the I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
properties I None
of I None
ziprasidone I CHEMICAL
in I None
vivo I None
using I None
as I None
a I None
marker I None
of I None
central I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
activity I None
the I None
inhibition I None
of I None
firing I None
of I None
serotonin I CHEMICAL
- I None
containing I None
neurons I None
in I None
the I None
dorsal I None
raphe I None
nucleus I None
. I None
<eof> I None

<s> O None
In I None
anesthetized I None
rats I None
, I None
ziprasidone I CHEMICAL
dose I None
- I None
dependently I None
slowed I None
raphe I None
unit I None
activity I None
( I None
ED50 I None
= I None
300 I None
micrograms I None
/ I None
kg I None
i I None
. I None
v I None
. I None
) I None
as I None
did I None
the I None
atypical I None
antipsychotics I None
clozapine I CHEMICAL
( I None
ED50 I None
= I None
250 I None
micrograms I None
/ I None
kg I None
i I None
. I None
v I None
. I None
) I None
and I None
olanzapine I CHEMICAL
( I None
ED50 I None
= I None
1000 I None
micrograms I None
/ I None
kg I None
i I None
. I None
v I None
. I None
) I None
. I None
<eof> I None

<s> O None
Pretreatment I None
with I None
the I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
antagonist I None
WAY I CHEMICAL
- O CHEMICAL
100 O CHEMICAL
, O CHEMICAL
635 O CHEMICAL
( I None
10 I None
micrograms I None
/ I None
kg I None
i I None
. I None
v I None
. I None
) I None
prevented I None
the I None
ziprasidone I CHEMICAL
- I None
induced I None
inhibition I None
; I None
the I None
same I None
dose I None
of I None
WAY I CHEMICAL
- O CHEMICAL
100 O CHEMICAL
, O CHEMICAL
635 O CHEMICAL
had I None
little I None
effect I None
on I None
the I None
inhibition I None
produced I None
by I None
clozapine I CHEMICAL
and I None
olanzapine I CHEMICAL
. I None
<eof> I None

<s> O None
Because I None
all I None
three I None
agents I None
also I None
bind I None
to I None
alpha I GENE-N
1 O GENE-N
receptors O GENE-N
, I None
antagonists I None
of I None
which I None
inhibit I None
serotonin I CHEMICAL
neuronal I None
firing I None
, I None
this I None
aspect I None
of I None
their I None
pharmacology I None
was I None
assessed I None
with I None
desipramine I CHEMICAL
( I None
DMI I CHEMICAL
) I None
, I None
a I None
NE I CHEMICAL
re I None
- I None
uptake I None
blocker I None
previously I None
shown I None
to I None
reverse I None
the I None
effects I None
of I None
alpha I None
1 I None
antagonists I None
on I None
raphe I None
unit I None
activity I None
. I None
<eof> I None

<s> O None
DMI I CHEMICAL
( I None
5 I None
mg I None
/ I None
kg I None
i I None
. I None
v I None
. I None
) I None
failed I None
to I None
reverse I None
the I None
inhibitory I None
effect I None
of I None
ziprasidone I CHEMICAL
but I None
produced I None
nearly I None
complete I None
reversal I None
of I None
that I None
of I None
clozapine I CHEMICAL
and I None
olanzapine I CHEMICAL
. I None
<eof> I None

<s> O None
These I None
profiles I None
suggest I None
a I None
mechanism I None
of I None
action I None
for I None
each I None
agent I None
, I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
agonism I None
for I None
ziprasidone I CHEMICAL
and I None
alpha I None
1 I None
antagonism I None
for I None
clozapine I CHEMICAL
and I None
olanzapine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
agonist I None
activity I None
reported I None
here I None
clearly I None
distinguishes I None
ziprasidone I CHEMICAL
from I None
currently I None
available I None
antipsychotic I None
agents I None
and I None
suggests I None
that I None
this I None
property I None
may I None
play I None
a I None
significant I None
role I None
in I None
its I None
pharmacologic I None
actions I None
. I None
<eof> I None

<s> O None
CCK I GENE-Y
- I None
mediated I None
response I None
in I None
the I None
activation I None
of I None
5 I GENE-N
- O GENE-N
HT O GENE-N
receptor O GENE-N
types I None
in I None
the I None
guinea I None
- I None
pig I None
ileum I None
. I None
<eof> I None

<s> O None
The I None
possible I None
interaction I None
between I None
cholecystokinin I GENE-Y
( I None
CCK I GENE-Y
) I None
and I None
5 I CHEMICAL
- O CHEMICAL
hydroxytryptamine O CHEMICAL
( I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
) I None
was I None
evaluated I None
in I None
vitro I None
in I None
the I None
longitudinal I None
muscle I None
- I None
myenteric I None
plexus I None
of I None
the I None
guinea I None
- I None
pig I None
ileum I None
. I None
<eof> I None

<s> O None
Devazepide I CHEMICAL
and I None
L I CHEMICAL
- O CHEMICAL
365 O CHEMICAL
, O CHEMICAL
260 O CHEMICAL
were I None
used I None
to I None
block I None
CCKA I GENE-N
and O GENE-N
CCK O GENE-N
( O GENE-N
B O GENE-N
) O GENE-N
receptors O GENE-N
and I None
ondansetron I CHEMICAL
and I None
tropisetron I CHEMICAL
to I None
block I None
5 I GENE-Y
- O GENE-Y
HT3 O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT4 O GENE-Y
receptors I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
CCK I GENE-N
receptor O GENE-N
antagonists I None
blocked I None
, I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
, I None
the I None
response I None
to I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
and I None
to I None
the I None
selective I None
agonists I None
at I None
5 I GENE-Y
- O GENE-Y
HT3 O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT4 O GENE-Y
receptors I None
, I None
2 I CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
hydroxytryptamine O CHEMICAL
( I None
2 I CHEMICAL
- O CHEMICAL
Me O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
HT O CHEMICAL
) I None
and I None
5 I CHEMICAL
- O CHEMICAL
methoxytryptamine O CHEMICAL
( I None
5 I CHEMICAL
- O CHEMICAL
MeOT O CHEMICAL
) I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
blockade I None
was I None
almost I None
complete I None
on I None
the I None
first I None
phase I None
of I None
the I None
concentration I None
response I None
curve I None
to I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
and I None
for I None
all I None
the I None
concentrations I None
of I None
5 I CHEMICAL
- O CHEMICAL
MeOT O CHEMICAL
tested I None
. I None
<eof> I None

<s> O None
In I None
the I None
2 I CHEMICAL
- O CHEMICAL
Me O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
HT O CHEMICAL
- I None
induced I None
contractile I None
response I None
there I None
was I None
a I None
component I None
with I None
the I None
same I None
sensitivity I None
to I None
devazepide I CHEMICAL
and I None
to I None
the I None
selective I None
NK1 I GENE-Y
receptor I None
antagonist I None
, I None
GR I CHEMICAL
82334 O CHEMICAL
, I None
and I None
another I None
resistant I None
component I None
that I None
was I None
abolished I None
by I None
atropine I CHEMICAL
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
blockade I None
of I None
the I None
NK1 I GENE-Y
receptor I None
did I None
not I None
produce I None
a I None
significant I None
increase I None
in I None
the I None
inhibition I None
obtained I None
when I None
atropine I CHEMICAL
or I None
devazepide I CHEMICAL
were I None
separately I None
tested I None
on I None
the I None
5 I CHEMICAL
- O CHEMICAL
MeOT O CHEMICAL
- I None
induced I None
response I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
CCK I GENE-Y
is I None
involved I None
in I None
the I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
- I None
induced I None
contractile I None
response I None
, I None
particularly I None
in I None
the I None
response I None
induced I None
by I None
5 I GENE-Y
- O GENE-Y
HT4 O GENE-Y
receptor I None
stimulation I None
. I None
<eof> I None

<s> O None
Pharmacological I None
plasticity I None
of I None
cardiac I None
ATP I GENE-N
- O GENE-N
sensitive O GENE-N
potassium O GENE-N
channels O GENE-N
toward I None
diazoxide I CHEMICAL
revealed I None
by I None
ADP I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
pharmacological I None
phenotype I None
of I None
ATP I GENE-N
- O GENE-N
sensitive O GENE-N
potassium O GENE-N
( O GENE-N
K O GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
) O GENE-N
channels O GENE-N
is I None
defined I None
by I None
their I None
tissue I None
- I None
specific I None
regulatory I None
subunit I None
, I None
the I None
sulfonylurea I GENE-N
receptor O GENE-N
( I None
SUR I GENE-N
) I None
, I None
which I None
associates I None
with I None
the I None
pore I GENE-N
- O GENE-N
forming O GENE-N
channel O GENE-N
core O GENE-N
, I None
Kir6 I GENE-Y
. O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
The I None
potassium I GENE-N
channel O GENE-N
opener I None
diazoxide I CHEMICAL
has I None
hyperglycemic I None
and I None
hypotensive I None
properties I None
that I None
stem I None
from I None
its I None
ability I None
to I None
open I None
K I GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
channels O GENE-N
in I None
pancreas I None
and I None
smooth I None
muscle I None
. I None
<eof> I None

<s> O None
Diazoxide I CHEMICAL
is I None
believed I None
not I None
to I None
have I None
any I None
significant I None
action I None
on I None
cardiac I GENE-N
sarcolemmal O GENE-N
K O GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
channels O GENE-N
. I None
<eof> I None

<s> O None
Yet I None
, I None
diazoxide I CHEMICAL
can I None
be I None
cardioprotective I None
in I None
ischemia I None
and I None
has I None
been I None
found I None
to I None
bind I None
to I None
the I None
presumed I None
cardiac I GENE-N
sarcolemmal O GENE-N
K O GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
channel O GENE-N
- I None
regulatory I None
subunit I None
, I None
SUR2A I GENE-Y
. I None
<eof> I None

<s> O None
Here I None
, I None
in I None
excised I None
patches I None
, I None
diazoxide I CHEMICAL
( I None
300 I None
microM I None
) I None
activated I None
pancreatic I None
SUR1 I GENE-Y
/ I None
Kir6 I GENE-Y
. O GENE-Y
2 O GENE-Y
currents I None
and I None
had I None
little I None
effect I None
on I None
native I None
or I None
recombinant I None
cardiac I None
SUR2A I GENE-Y
/ I None
Kir6 I GENE-Y
. O GENE-Y
2 O GENE-Y
currents I None
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
the I None
presence I None
of I None
cytoplasmic I None
ADP I CHEMICAL
( I None
100 I None
microM I None
) I None
, I None
SUR2A I GENE-Y
/ I None
Kir6 I GENE-Y
. O GENE-Y
2 O GENE-Y
channels I None
became I None
as I None
sensitive I None
to I None
diazoxide I CHEMICAL
as I None
SUR1 I GENE-Y
/ I None
Kir6 I GENE-Y
. O GENE-Y
2 O GENE-Y
channels I None
. I None
<eof> I None

<s> O None
This I None
effect I None
involved I None
specific I None
interactions I None
between I None
MgADP I CHEMICAL
and I None
SUR I GENE-N
, I None
as I None
it I None
required I None
Mg I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
, I None
but I None
not I None
ATP I CHEMICAL
, I None
and I None
was I None
abolished I None
by I None
point I None
mutations I None
in I None
the I None
second I None
nucleotide I GENE-N
- O GENE-N
binding O GENE-N
domain O GENE-N
of I None
SUR I GENE-N
, I None
which I None
impaired I None
channel I None
activation I None
by I None
MgADP I CHEMICAL
. I None
<eof> I None

<s> O None
At I None
the I None
whole I None
- I None
cell I None
level I None
, I None
in I None
cardiomyocytes I None
treated I None
with I None
oligomycin I None
to I None
block I None
mitochondrial I None
function I None
, I None
diazoxide I CHEMICAL
could I None
also I None
activate I None
K I CHEMICAL
( I None
ATP I CHEMICAL
) I None
currents I None
only I None
after I None
cytosolic I None
ADP I CHEMICAL
had I None
been I None
raised I None
by I None
a I None
creatine I GENE-N
kinase O GENE-N
inhibitor I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
ADP I CHEMICAL
serves I None
as I None
a I None
cofactor I None
to I None
define I None
the I None
responsiveness I None
of I None
cardiac I None
K I GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
channels O GENE-N
toward I None
diazoxide I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
present I None
demonstration I None
of I None
a I None
pharmacological I None
plasticity I None
of I None
K I GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
channels O GENE-N
identifies I None
a I None
mechanism I None
for I None
the I None
control I None
of I None
channel I None
activity I None
in I None
cardiac I None
cells I None
depending I None
on I None
the I None
cellular I None
ADP I CHEMICAL
levels I None
, I None
which I None
are I None
elevated I None
under I None
ischemia I None
. I None
<eof> I None

<s> O None
A I None
review I None
of I None
the I None
preclinical I None
and I None
clinical I None
data I None
of I None
newer I None
intranasal I None
steroids I CHEMICAL
used I None
in I None
the I None
treatment I None
of I None
allergic I None
rhinitis I None
. I None
<eof> I None

<s> O None
The I None
anti I None
- I None
inflammatory I None
activity I None
of I None
corticosteroids I CHEMICAL
has I None
prompted I None
the I None
exploration I None
of I None
their I None
use I None
in I None
the I None
treatment I None
of I None
allergic I None
rhinitis I None
. I None
<eof> I None

<s> O None
The I None
development I None
of I None
intranasal I None
steroids I CHEMICAL
has I None
resulted I None
in I None
several I None
agents I None
with I None
quick I None
actions I None
, I None
localized I None
effects I None
, I None
and I None
great I None
efficacy I None
in I None
the I None
treatment I None
of I None
seasonal I None
allergic I None
rhinitis I None
and I None
the I None
prophylactic I None
management I None
of I None
perennial I None
rhinitis I None
. I None
<eof> I None

<s> O None
This I None
article I None
presents I None
a I None
concise I None
review I None
of I None
the I None
preclinical I None
and I None
clinical I None
evidence I None
with I None
these I None
new I None
agents I None
and I None
provides I None
data I None
- I None
based I None
guidance I None
for I None
the I None
selection I None
of I None
optimal I None
agents I None
. I None
<eof> I None

<s> O None
The I None
survey I None
reveals I None
that I None
mometasone I CHEMICAL
furoate O CHEMICAL
, I None
a I None
new I None
inhaled I None
steroid I CHEMICAL
with I None
topical I None
activity I None
, I None
has I None
the I None
greatest I None
binding I None
affinity I None
for I None
the I None
glucocorticoid I GENE-Y
receptor O GENE-Y
, I None
followed I None
by I None
fluticasone I CHEMICAL
propionate O CHEMICAL
, I None
budesonide I CHEMICAL
, I None
triamcinolone I CHEMICAL
acetonide O CHEMICAL
, I None
and I None
dexamethasone I CHEMICAL
. I None
<eof> I None

<s> O None
Mometasone I CHEMICAL
furoate O CHEMICAL
also I None
has I None
strong I None
anti I None
- I None
inflammatory I None
activity I None
, I None
with I None
IL I GENE-Y
- O GENE-Y
4 O GENE-Y
and I None
IL I GENE-Y
- O GENE-Y
5 O GENE-Y
inhibition I None
activities I None
equivalent I None
to I None
those I None
of I None
fluticasone I CHEMICAL
propionate O CHEMICAL
. I None
<eof> I None

<s> O None
Clinically I None
, I None
both I None
mometasone I CHEMICAL
furoate O CHEMICAL
and I None
fluticasone I CHEMICAL
propionate O CHEMICAL
appear I None
to I None
be I None
well I None
tolerated I None
, I None
to I None
have I None
quick I None
onsets I None
of I None
action I None
, I None
and I None
to I None
be I None
equivalent I None
in I None
efficacy I None
in I None
the I None
treatment I None
of I None
seasonal I None
allergic I None
and I None
perennial I None
rhinitis I None
. I None
<eof> I None

<s> O None
Of I None
the I None
intranasal I None
steroids I CHEMICAL
currently I None
available I None
, I None
mometasone I CHEMICAL
furoate O CHEMICAL
has I None
been I None
shown I None
to I None
have I None
the I None
least I None
systemic I None
availability I None
and I None
, I None
consequently I None
, I None
is I None
expected I None
to I None
have I None
the I None
fewest I None
systemic I None
side I None
effects I None
. I None
<eof> I None

<s> O None
Some I None
suppression I None
of I None
overnight I None
cortisol I CHEMICAL
levels I None
has I None
been I None
reported I None
with I None
fluticasone I CHEMICAL
propionate O CHEMICAL
( I None
indicative I None
of I None
hypothalamic I None
- I None
pituitary I None
- I None
adrenal I None
axis I None
suppression I None
) I None
. I None
<eof> I None

<s> O None
A I None
novel I None
mutation I None
of I None
delta I GENE-Y
- O GENE-Y
aminolaevulinate O GENE-Y
dehydratase O GENE-Y
in I None
a I None
healthy I None
child I None
with I None
12 I None
% I None
erythrocyte I None
enzyme I None
activity I None
. I None
<eof> I None

<s> O None
Cloning I None
, I None
expression I None
and I None
phenotype I None
studies I None
of I None
the I None
defective I None
gene I None
for I None
delta I GENE-Y
- O GENE-Y
aminolaevulinate O GENE-Y
dehydratase O GENE-Y
( I None
ALAD I GENE-Y
) I None
in I None
a I None
family I None
with I None
an I None
asymptomatic I None
girl I None
who I None
had I None
ALAD I GENE-Y
deficiency I None
were I None
carried I None
out I None
. I None
<eof> I None

<s> O None
The I None
proband I None
was I None
identified I None
by I None
neonatal I None
ALAD I GENE-Y
screening I None
, I None
and I None
had I None
erythrocyte I None
ALAD I GENE-Y
activity I None
at I None
12 I None
% I None
of I None
the I None
normal I None
control I None
. I None
<eof> I None

<s> O None
She I None
was I None
heterozygous I None
for I None
ALAD I GENE-Y
deficiency I None
, I None
which I None
was I None
inherited I None
from I None
her I None
father I None
. I None
<eof> I None

<s> O None
Nucleotide I CHEMICAL
sequence I None
analysis I None
of I None
the I None
cloned I None
ALAD I GENE-Y
cDNA I None
revealed I None
C36 I GENE-N
to O GENE-N
G O GENE-N
and I None
T168 I GENE-N
to O GENE-N
C O GENE-N
mutations I None
on I None
the I None
same I None
allele I None
. I None
<eof> I None

<s> O None
The I None
former I None
mutation I None
resulted I None
in I None
F12L I GENE-N
substitution I None
, I None
whereas I None
the I None
latter I None
was I None
a I None
silent I None
mutation I None
. I None
<eof> I None

<s> O None
All I None
family I None
members I None
who I None
had I None
decreased I None
ALAD I GENE-Y
activity I None
had I None
the I None
same I None
mutation I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
the I None
mutant I None
ALAD I GENE-Y
cDNA I None
in I None
Chinese I None
hamster I None
ovary I None
cells I None
produced I None
an I None
ALAD I GENE-Y
protein I None
without I None
significant I None
enzyme I None
activity I None
. I None
<eof> I None

<s> O None
Additionally I None
, I None
the I None
mutant I None
ALAD I GENE-Y
cDNA I None
which I None
encodes I None
F12L I GENE-N
substitution I None
produced I None
an I None
aberrant I None
migration I None
pattern I None
in I None
polyacrylamide I None
gel I None
electrophoresis I None
under I None
denaturing I None
conditions I None
. I None
<eof> I None

<s> O None
This I None
finding I None
probably I None
reflects I None
an I None
abnormal I None
folding I None
of I None
the I None
F12L I GENE-N
protein I None
, I None
since I None
the I None
mutation I None
occurred I None
in I None
the I None
alpha1 I None
helix I None
of I None
the I None
N I CHEMICAL
- I None
terminal I None
arm I None
of I None
the I None
enzyme I None
, I None
which I None
is I None
involved I None
in I None
the I None
extensive I None
quaternary I None
interactions I None
among I None
the I None
subunits I None
. I None
<eof> I None

<s> O None
This I None
is I None
also I None
the I None
first I None
report I None
of I None
ALAD I GENE-Y
gene I None
mutation I None
in I None
an I None
asymptomatic I None
subject I None
. I None
<eof> I None

<s> O None
Tamsulosin I CHEMICAL
: I None
assessment I None
of I None
affinityof I None
( I CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
- O CHEMICAL
P O CHEMICAL
razosin O CHEMICAL
binding I None
to I None
two I None
alpha I GENE-N
- O GENE-N
1 O GENE-N
- O GENE-N
adrenoceptor O GENE-N
subtypes I None
in I None
the I None
canine I None
aorta I None
. I None
<eof> I None

<s> O None
This I None
study I None
was I None
performed I None
to I None
assess I None
the I None
affinity I None
of I None
tamsulosin I CHEMICAL
to I None
the I None
alpha I None
( I None
1L I None
) I None
- I None
in I None
addition I None
to I None
alpha I GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
( I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
AR O GENE-N
) I None
subtypes I None
coexisting I None
in I None
the I None
canine I None
aorta I None
using I None
the I None
radioligand I None
binding I None
assay I None
. I None
<eof> I None

<s> O None
The I None
antagonistic I None
effects I None
of I None
this I None
drug I None
on I None
contraction I None
of I None
the I None
rat I None
aorta I None
were I None
also I None
assessed I None
, I None
and I None
the I None
results I None
were I None
compared I None
with I None
those I None
obtained I None
with I None
prazosin I CHEMICAL
, I None
amosulalol I CHEMICAL
, I None
labetalol I CHEMICAL
, I None
ketanserin I CHEMICAL
, I None
clonidine I CHEMICAL
and I None
propranolol I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
pKi I None
value I None
of I None
tamsulosin I CHEMICAL
to I None
the I None
alpha I None
( I None
1L I None
) I None
- I None
subtype I None
was I None
lower I None
than I None
those I None
of I None
prazosin I CHEMICAL
and I None
HV I CHEMICAL
- O CHEMICAL
723 O CHEMICAL
, I None
but I None
higher I None
than I None
those I None
of I None
amosulalol I CHEMICAL
, I None
ketanserin I CHEMICAL
and I None
labetalol I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
pKi I None
value I None
of I None
tamsulosin I CHEMICAL
for I None
the I None
alpha I GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
- I None
subtype I None
in I None
the I None
canine I None
aorta I None
was I None
similar I None
to I None
that I None
of I None
prazosin I CHEMICAL
. I None
<eof> I None

<s> O None
However I None
, I None
this I None
drug I None
showed I None
a I None
higher I None
pKi I None
value I None
than I None
amosulalol I CHEMICAL
, I None
HV I CHEMICAL
- O CHEMICAL
723 O CHEMICAL
, I None
labetalol I CHEMICAL
and I None
ketanserin I CHEMICAL
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
the I None
order I None
of I None
inhibition I None
potencies I None
for I None
contraction I None
of I None
the I None
rat I None
aorta I None
by I None
phenylephrine I CHEMICAL
was I None
as I None
follows I None
: I None
prazosin I CHEMICAL
> I None
tamsulosin I CHEMICAL
> I None
amosulalol I CHEMICAL
> I None
HV I CHEMICAL
- O CHEMICAL
723 O CHEMICAL
> I None
labetalol I CHEMICAL
> I None
ketanserin I CHEMICAL
> I None
clonidine I CHEMICAL
> I None
propranolol I CHEMICAL
. I None
<eof> I None

<s> O None
Thus I None
, I None
although I None
the I None
affinity I None
of I None
tamsulosin I CHEMICAL
to I None
the I None
alpha I GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
- O GENE-Y
AR O GENE-Y
subtype I None
in I None
the I None
canine I None
aorta I None
was I None
as I None
high I None
as I None
that I None
in I None
the I None
bovine I None
prostate I None
reported I None
in I None
our I None
previous I None
study I None
, I None
the I None
affinity I None
( I None
pKi I None
7 I None
. I None
87 I None
) I None
of I None
this I None
drug I None
to I None
alpha I GENE-Y
( O GENE-Y
1L O GENE-Y
) O GENE-Y
- O GENE-Y
AR O GENE-Y
in I None
the I None
canine I None
aorta I None
was I None
lower I None
than I None
that I None
( I None
pKi I None
8 I None
. I None
99 I None
) I None
in I None
the I None
bovine I None
prostate I None
. I None
<eof> I None

<s> O None
These I None
observations I None
suggested I None
that I None
the I None
pharmacological I None
potencies I None
of I None
tamsulosin I CHEMICAL
in I None
the I None
aorta I None
and I None
prostate I None
may I None
be I None
different I None
. I None
<eof> I None

<s> O None
In I None
vitro I None
characterization I None
of I None
the I None
erythrocyte I None
distribution I None
of I None
methazolamide I CHEMICAL
: I None
a I None
model I None
of I None
erythrocyte I None
transport I None
and I None
binding I None
kinetics I None
. I None
<eof> I None

<s> O None
The I None
rate I None
and I None
extent I None
of I None
binding I None
of I None
methazolamide I CHEMICAL
to I None
human I None
erythrocytes I None
was I None
studied I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
All I None
experiments I None
were I None
carried I None
out I None
at I None
physiological I None
temperature I None
( I None
37 I None
C I None
) I None
and I None
pH I None
( I None
7 I None
. I None
4 I None
) I None
. I None
<eof> I None

<s> O None
Methazolamide I CHEMICAL
( I None
MTZ I CHEMICAL
) I None
buffer I None
concentrations I None
were I None
analyzed I None
by I None
HPLC I None
. I None
<eof> I None

<s> O None
Distributional I None
equilibrium I None
between I None
buffer I None
and I None
washed I None
red I None
blood I None
cells I None
was I None
achieved I None
after I None
1 I None
hr I None
. I None
<eof> I None

<s> O None
Results I None
of I None
equilibrium I None
studies I None
were I None
consistent I None
with I None
two I None
classes I None
of I None
binding I None
sites I None
for I None
MTZ I CHEMICAL
within I None
the I None
erythrocyte I None
: I None
a I None
low I None
affinity I None
, I None
high I None
capacity I None
site I None
( I None
CA I GENE-N
- I None
I I None
) I None
and I None
a I None
high I None
affinity I None
, I None
low I None
capacity I None
site I None
( I None
CA I GENE-N
- I None
II I None
) I None
. I None
<eof> I None

<s> O None
A I None
two I None
- I None
binding I None
site I None
model I None
was I None
fitted I None
to I None
experimental I None
data I None
generating I None
estimates I None
for I None
binding I None
parameters I None
Ka1 I None
( I None
0 I None
. I None
0017 I None
+ I None
/ I None
- I None
0 I None
. I None
00022 I None
microM I None
- I None
1 I None
) I None
nM1 I None
( I None
636 I None
+ I None
/ I None
- I None
5 I None
. I None
23 I None
microM I None
) I None
, I None
Ka2 I None
( I None
0 I None
. I None
46 I None
+ I None
/ I None
- I None
0 I None
. I None
0083 I None
microM I None
- I None
1 I None
) I None
, I None
and I None
nM2 I None
( I None
80 I None
. I None
9 I None
+ I None
/ I None
- I None
0 I None
. I None
389 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
Based I None
upon I None
these I None
findings I None
, I None
kinetic I None
studies I None
were I None
performed I None
in I None
order I None
to I None
characterize I None
the I None
rate I None
of I None
drug I None
distribution I None
. I None
<eof> I None

<s> O None
The I None
rate I None
of I None
erythrocyte I None
uptake I None
of I None
MTZ I CHEMICAL
was I None
mathematically I None
modeled I None
using I None
a I None
series I None
of I None
differential I None
equations I None
describing I None
drug I None
diffusion I None
across I None
the I None
red I None
blood I None
cell I None
membrane I None
and I None
subsequent I None
complexation I None
with I None
intracellular I None
binding I None
sites I None
. I None
<eof> I None

<s> O None
The I None
model I None
assumed I None
that I None
penetration I None
of I None
MTZ I CHEMICAL
into I None
the I None
red I None
blood I None
cells I None
was I None
passive I None
but I None
drug I None
binding I None
to I None
the I None
carbonic I GENE-N
anhydrase O GENE-N
isozymes I None
was I None
not I None
instantaneous I None
. I None
<eof> I None

<s> O None
Using I None
a I None
novel I None
curve I None
fitting I None
technique I None
, I None
parameter I None
estimates I None
of I None
RBC I None
membrane I None
permeability I None
( I None
0 I None
. I None
0102 I None
+ I None
/ I None
- I None
0 I None
. I None
000618 I None
cm I None
/ I None
min I None
) I None
, I None
and I None
binding I None
rate I None
constants I None
k I None
- I None
1 I None
( I None
0 I None
. I None
254 I None
+ I None
/ I None
- I None
0 I None
. I None
0213 I None
min I None
- I None
1 I None
) I None
, I None
k1 I None
( I None
0 I None
. I None
0022 I None
+ I None
/ I None
- I None
0 I None
. I None
00020 I None
ml I None
/ I None
microgram I None
- I None
min I None
) I None
, I None
k I None
- I None
2 I None
( I None
1 I None
. I None
59 I None
+ I None
/ I None
- I None
0 I None
. I None
0358 I None
min I None
- I None
1 I None
) I None
, I None
and I None
k2 I None
( I None
3 I None
. I None
1 I None
+ I None
/ I None
- I None
0 I None
. I None
035 I None
ml I None
/ I None
microgram I None
- I None
min I None
) I None
were I None
obtained I None
. I None
<eof> I None

<s> O None
The I None
model I None
characterized I None
the I None
observed I None
biphasic I None
decline I None
of I None
MTZ I CHEMICAL
buffer I None
concentrations I None
over I None
time I None
and I None
may I None
help I None
explain I None
the I None
prolonged I None
residence I None
of I None
MTZ I CHEMICAL
in I None
vivo I None
. I None
<eof> I None

<s> O None
Radioimmunotherapy I None
of I None
relapsed I None
non I None
- I None
Hodgkin I None
' I None
s I None
lymphoma I None
with I None
zevalin I CHEMICAL
, I None
a I None
90Y I CHEMICAL
- I None
labeled I None
anti I None
- I None
CD20 I GENE-Y
monoclonal I None
antibody I None
. I None
<eof> I None

<s> O None
Approximately I None
55 I None
, I None
400 I None
new I None
cases I None
of I None
non I None
- I None
Hodgkin I None
' I None
s I None
lymphoma I None
( I None
NHL I None
) I None
are I None
diagnosed I None
each I None
year I None
, I None
with I None
the I None
overall I None
prevalence I None
of I None
the I None
disease I None
now I None
estimated I None
to I None
be I None
243 I None
, I None
000 I None
. I None
<eof> I None

<s> O None
Until I None
recently I None
, I None
treatment I None
alternatives I None
for I None
advanced I None
disease I None
included I None
chemotherapy I None
with I None
or I None
without I None
external I None
beam I None
radiation I None
. I None
<eof> I None

<s> O None
Based I None
on I None
the I None
results I None
of I None
several I None
clinical I None
trials I None
, I None
the I None
chimeric I None
monoclonal I None
antibody I None
Rituximab I None
has I None
now I None
been I None
approved I None
by I None
the I None
United I None
States I None
Food I None
and I None
Drug I None
Administration I None
as I None
a I None
treatment I None
for I None
patients I None
with I None
relapsed I None
or I None
refractory I None
, I None
low I None
- I None
grade I None
or I None
follicular I None
, I None
B I None
- I None
cell I None
NHL I None
. I None
<eof> I None

<s> O None
Several I None
other I None
monoclonal I None
antibodies I None
in I None
conjugated I None
and I None
unconjugated I None
forms I None
have I None
been I None
evaluated I None
in I None
the I None
treatment I None
of I None
NHL I None
. I None
<eof> I None

<s> O None
Ibritumomab I None
, I None
the I None
murine I None
counterpart I None
to I None
Rituximab I None
, I None
radiolabeled I None
with I None
90Y I CHEMICAL
( I None
Zevalin I CHEMICAL
) I None
, I None
is I None
presently I None
being I None
evaluated I None
in I None
clinical I None
trials I None
. I None
<eof> I None

<s> O None
The I None
success I None
of I None
radioimmunotherapy I None
is I None
dependent I None
upon I None
the I None
appropriate I None
choice I None
of I None
antibody I None
, I None
isotope I None
, I None
and I None
chelator I None
- I None
linker I None
. I None
<eof> I None

<s> O None
The I None
Ibritumomab I None
antibody I None
targets I None
the I None
CD20 I GENE-Y
antigen I None
. I None
<eof> I None

<s> O None
The I None
antibody I None
is I None
covalently I None
bound I None
to I None
the I None
chelator I None
- I None
linker I None
tiuxetan I CHEMICAL
( I None
MX I CHEMICAL
- O CHEMICAL
DTPA O CHEMICAL
) I None
, I None
which I None
tightly I None
chelates I None
the I None
isotope I None
90Y I CHEMICAL
. I None
<eof> I None

<s> O None
To I None
date I None
, I None
two I None
Phase I None
I I None
/ I None
II I None
Zevalin I CHEMICAL
clinical I None
trials I None
have I None
been I None
completed I None
in I None
patients I None
with I None
low I None
- I None
grade I None
, I None
intermediate I None
- I None
grade I None
, I None
and I None
mantle I None
cell I None
NHL I None
. I None
<eof> I None

<s> O None
The I None
overall I None
response I None
rate I None
was I None
64 I None
% I None
in I None
the I None
first I None
trial I None
and I None
67 I None
% I None
in I None
the I None
later I None
trial I None
. I None
<eof> I None

<s> O None
Phase I None
II I None
and I None
III I None
trials I None
are I None
ongoing I None
. I None
<eof> I None

<s> O None
Reduction I None
of I None
oral I None
ethanol I CHEMICAL
self I None
- I None
administration I None
in I None
rats I None
by I None
monoamine I GENE-N
oxidase O GENE-N
inhibitors I None
. I None
<eof> I None

<s> O None
Evidence I None
for I None
a I None
role I None
of I None
dopamine I CHEMICAL
and I None
serotonin I CHEMICAL
in I None
the I None
control I None
of I None
ethanol I CHEMICAL
intake I None
in I None
animals I None
suggests I None
that I None
monoamine I GENE-N
oxidase O GENE-N
( I None
MAO I GENE-N
) I None
inhibitors I None
, I None
which I None
increase I None
the I None
synaptic I None
availability I None
of I None
serotonin I CHEMICAL
and I None
dopamine I CHEMICAL
by I None
blocking I None
their I None
metabolism I None
, I None
might I None
have I None
efficacy I None
in I None
the I None
treatment I None
of I None
alcohol I CHEMICAL
dependence I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
the I None
present I None
study I None
was I None
, I None
therefore I None
, I None
to I None
evaluate I None
several I None
MAO I GENE-N
inhibitors I None
for I None
their I None
capacity I None
to I None
affect I None
ethanol I CHEMICAL
self I None
- I None
administration I None
in I None
rats I None
trained I None
to I None
self I None
- I None
administer I None
ethanol I CHEMICAL
( I None
10 I None
% I None
v I None
/ I None
v I None
) I None
orally I None
in I None
a I None
free I None
- I None
choice I None
two I None
- I None
lever I None
operant I None
task I None
. I None
<eof> I None

<s> O None
The I None
nonselective I None
and I None
irreversible I None
MAO I GENE-N
inhibitors I None
, I None
phenelzine I CHEMICAL
( I None
3 I None
- I None
10 I None
mg I None
/ I None
kg I None
) I None
, I None
tranylcypromine I CHEMICAL
( I None
1 I None
- I None
3 I None
mg I None
/ I None
kg I None
) I None
, I None
and I None
nialamide I CHEMICAL
( I None
30 I None
mg I None
/ I None
kg I None
) I None
, I None
decreased I None
rates I None
of I None
responding I None
maintained I None
by I None
ethanol I CHEMICAL
reinforcement I None
. I None
<eof> I None

<s> O None
The I None
reversible I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
inhibitor I None
, I None
befloxatone I CHEMICAL
( I None
0 I None
. I None
3 I None
- I None
3 I None
mg I None
/ I None
kg I None
) I None
, I None
and I None
the I None
irreversible I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
inhibitor I None
, I None
clorgyline I CHEMICAL
( I None
10 I None
- I None
30 I None
mg I None
/ I None
kg I None
) I None
, I None
also I None
reduced I None
ethanol I CHEMICAL
self I None
- I None
administration I None
. I None
<eof> I None

<s> O None
However I None
, I None
befloxatone I CHEMICAL
- I None
induced I None
effects I None
leveled I None
off I None
at I None
a I None
50 I None
% I None
decrease I None
. I None
<eof> I None

<s> O None
The I None
irreversible I None
MAO I GENE-Y
- O GENE-Y
B O GENE-Y
inhibitors I None
, I None
pargyline I CHEMICAL
( I None
30 I None
mg I None
/ I None
kg I None
) I None
and I None
l I CHEMICAL
- O CHEMICAL
deprenyl O CHEMICAL
( I None
3 I None
- I None
10 I None
mg I None
/ I None
kg I None
) I None
also I None
decreased I None
responding I None
maintained I None
by I None
ethanol I CHEMICAL
reinforcement I None
; I None
these I None
results I None
are I None
consistent I None
with I None
previous I None
findings I None
that I None
both I None
drugs I None
decreased I None
ethanol I CHEMICAL
intake I None
in I None
mice I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
the I None
present I None
results I None
showing I None
that I None
several I None
MAO I GENE-N
inhibitors I None
decreased I None
ethanol I CHEMICAL
self I None
- I None
administration I None
in I None
rats I None
are I None
consistent I None
with I None
previous I None
findings I None
that I None
synaptic I None
levels I None
of I None
serotonin I CHEMICAL
and I None
dopamine I CHEMICAL
play I None
a I None
critical I None
role I None
in I None
the I None
control I None
of I None
ethanol I CHEMICAL
self I None
- I None
administration I None
. I None
<eof> I None

<s> O None
Regulation I None
of I None
gene I None
expression I None
by I None
activation I None
of I None
the I None
peroxisome I GENE-Y
proliferator O GENE-Y
- O GENE-Y
activated O GENE-Y
receptor O GENE-Y
gamma O GENE-Y
with I None
rosiglitazone I CHEMICAL
( I None
BRL I CHEMICAL
49653 O CHEMICAL
) I None
in I None
human I None
adipocytes I None
. I None
<eof> I None

<s> O None
To I None
better I None
define I None
the I None
mechanism I None
of I None
action I None
of I None
the I None
thiazolidinediones I CHEMICAL
, I None
we I None
incubated I None
freshly I None
isolated I None
human I None
adipocytes I None
with I None
rosiglitazone I CHEMICAL
and I None
investigated I None
the I None
changes I None
in I None
mRNA I None
expression I None
of I None
genes I None
encoding I None
key I None
proteins I None
of I None
adipose I None
tissue I None
functions I None
. I None
<eof> I None

<s> O None
Rosiglitazone I CHEMICAL
( I None
10 I None
( I None
- I None
6 I None
) I None
M I None
, I None
4 I None
h I None
) I None
increased I None
p85alphaphosphatidylinositol I GENE-Y
3 O GENE-Y
- O GENE-Y
kinase O GENE-Y
( I None
p85alphaPI I GENE-Y
- O GENE-Y
3K O GENE-Y
) I None
and I None
uncoupling I GENE-Y
protein O GENE-Y
- O GENE-Y
2 O GENE-Y
mRNA I None
levels I None
and I None
decreased I None
leptin I GENE-Y
expression I None
. I None
<eof> I None

<s> O None
The I None
mRNA I None
levels I None
of I None
insulin I GENE-Y
receptor O GENE-Y
, I None
IRS I GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
Glut I GENE-Y
4 O GENE-Y
, I None
lipoprotein I GENE-Y
lipase O GENE-Y
, I None
hormone I GENE-Y
- O GENE-Y
sensitive O GENE-Y
lipase O GENE-Y
, I None
acylation I GENE-Y
- O GENE-Y
stimulating O GENE-Y
protein O GENE-Y
, I None
fatty I GENE-Y
acid O GENE-Y
transport O GENE-Y
protein O GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
angiotensinogen I GENE-Y
, I None
plasminogen I GENE-Y
activator O GENE-Y
inhibitor O GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
and I None
PPARgamma1 I GENE-N
and O GENE-N
gamma2 O GENE-N
were I None
not I None
modified I None
by I None
rosiglitazone I CHEMICAL
treatment I None
. I None
<eof> I None

<s> O None
Activation I None
of I None
RXR I GENE-N
, I None
the I None
partner I None
of I None
PPARgamma I GENE-Y
, I None
in I None
the I None
presence I None
of I None
rosiglitazone I CHEMICAL
, I None
increased I None
further I None
p85alphaPI I GENE-Y
- O GENE-Y
3K O GENE-Y
and I None
UCP2 I GENE-Y
mRNA I None
levels I None
and I None
produced I None
a I None
significant I None
augmentation I None
of I None
Glut I GENE-Y
4 O GENE-Y
expression I None
. I None
<eof> I None

<s> O None
Because I None
p85alphaPI I GENE-Y
- O GENE-Y
3K O GENE-Y
is I None
a I None
major I None
component I None
of I None
insulin I GENE-Y
action I None
, I None
the I None
induction I None
of I None
its I None
expression I None
might I None
explain I None
, I None
at I None
least I None
in I None
part I None
, I None
the I None
insulin I GENE-Y
- I None
sensitizing I None
effect I None
of I None
the I None
thiazolidinediones I CHEMICAL
. I None
<eof> I None

<s> O None
Effect I None
of I None
specific I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibition I None
in I None
osteoarthritis I None
of I None
the I None
knee I None
: I None
a I None
6 I None
week I None
double I None
blind I None
, I None
placebo I None
controlled I None
pilot I None
study I None
of I None
rofecoxib I CHEMICAL
. I None
<eof> I None

<s> O None
Rofecoxib I CHEMICAL
Osteoarthritis I None
Pilot I None
Study I None
Group I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
To I None
determine I None
the I None
efficacy I None
and I None
safety I None
of I None
the I None
cyclooxygenase I GENE-Y
2 O GENE-Y
( I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
specific I None
inhibitor I None
, I None
rofecoxib I CHEMICAL
in I None
patients I None
with I None
osteoarthritis I None
( I None
OA I None
) I None
of I None
the I None
knee I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Rofecoxib I CHEMICAL
, I None
25 I None
mg I None
or I None
125 I None
mg I None
once I None
daily I None
, I None
was I None
compared I None
with I None
placebo I None
in I None
a I None
6 I None
week I None
, I None
double I None
blind I None
, I None
parallel I None
group I None
, I None
randomized I None
, I None
multicenter I None
study I None
of I None
219 I None
patients I None
with I None
knee I None
OA I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Both I None
doses I None
of I None
rofecoxib I CHEMICAL
produced I None
clinically I None
significant I None
improvement I None
as I None
assessed I None
by I None
primary I None
( I None
e I None
. I None
g I None
. I None
, I None
WOMAC I None
Pain I None
Subscale I None
0 I None
- I None
100 I None
mm I None
, I None
decrease I None
from I None
baseline I None
: I None
placebo I None
: I None
7 I None
. I None
1 I None
mm I None
; I None
rofecoxib I CHEMICAL
25 I None
mg I None
: I None
28 I None
. I None
1 I None
mm I None
, I None
rofecoxib I CHEMICAL
125 I None
mg I None
: I None
28 I None
. I None
0 I None
mm I None
; I None
p I None
< I None
0 I None
. I None
001 I None
rofecoxib I CHEMICAL
vs I None
placebo I None
) I None
and I None
secondary I None
efficacy I None
( I None
p I None
< I None
0 I None
. I None
05 I None
) I None
criteria I None
compared I None
with I None
placebo I None
. I None
<eof> I None

<s> O None
Clinical I None
improvement I None
with I None
the I None
25 I None
mg I None
dose I None
was I None
similar I None
to I None
that I None
with I None
the I None
125 I None
mg I None
dose I None
. I None
<eof> I None

<s> O None
Both I None
rofecoxib I CHEMICAL
doses I None
were I None
generally I None
well I None
tolerated I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Specific I None
inhibition I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
by I None
25 I None
and I None
125 I None
mg I None
rofecoxib I CHEMICAL
, I None
administered I None
once I None
daily I None
, I None
resulted I None
in I None
clinically I None
meaningful I None
improvements I None
in I None
patients I None
with I None
OA I None
. I None
<eof> I None

<s> O None
This I None
study I None
confirms I None
that I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
derived I None
prostanoids I CHEMICAL
are I None
important I None
clinical I None
mediators I None
of I None
pain I None
and I None
other I None
symptoms I None
of I None
knee I None
OA I None
and I None
that I None
inhibition I None
of I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
is I None
not I None
required I None
to I None
provide I None
clinical I None
benefit I None
. I None
<eof> I None

<s> O None
Decreased I None
intracellular I None
proteolysis I None
correlates I None
with I None
the I None
maintenance I None
of I None
a I None
specific I None
isoenzyme I None
of I None
cytochrome I GENE-N
P O GENE-N
- O GENE-N
450 O GENE-N
. I None
<eof> I None

<s> O None
The I None
rates I None
of I None
intracellular I None
protein I None
degradation I None
, I None
of I None
identically I None
labelled I None
populations I None
of I None
proteins I None
, I None
were I None
compared I None
in I None
hepatocytes I None
cultured I None
at I None
37 I None
degrees I None
( I None
on I None
an I None
adsorbed I None
collagen I None
layer I None
) I None
and I None
in I None
cells I None
preserved I None
on I None
gelatin I None
gels I None
at I None
10 I None
degrees I None
C I None
. I None
<eof> I None

<s> O None
The I None
half I None
- I None
lives I None
of I None
the I None
long I None
- I None
lived I None
proteins I None
were I None
35 I None
. I None
4 I None
+ I None
/ I None
- I None
8 I None
. I None
6 I None
h I None
( I None
N I None
= I None
4 I None
) I None
and I None
692 I None
. I None
9 I None
+ I None
/ I None
- I None
216 I None
. I None
9 I None
h I None
( I None
N I None
= I None
4 I None
) I None
respectively I None
. I None
<eof> I None

<s> O None
Proteolysis I None
was I None
substantially I None
decreased I None
at I None
10 I None
degrees I None
C I None
but I None
the I None
rate I None
of I None
decrease I None
remained I None
constant I None
. I None
<eof> I None

<s> O None
Hepatocytes I None
rapidly I None
removed I None
resorufin I CHEMICAL
from I None
the I None
culture I None
medium I None
. I None
<eof> I None

<s> O None
The I None
resorufin I CHEMICAL
was I None
not I None
being I None
conjugated I None
or I None
accumulated I None
within I None
the I None
cells I None
. I None
<eof> I None

<s> O None
Dicumarol I CHEMICAL
, I None
a I None
potent I None
inhibitor I None
of I None
quinone I GENE-N
oxidoreductase O GENE-N
, I None
at I None
high I None
concentration I None
( I None
500 I None
microm I None
) I None
caused I None
only I None
a I None
72 I None
% I None
decrease I None
in I None
the I None
utilization I None
of I None
resorufin I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
microsomal I None
detoxifying I None
enzyme I None
, I None
cytochrome I GENE-Y
P O GENE-Y
- O GENE-Y
450 O GENE-Y
1A1 O GENE-Y
remained I None
at I None
a I None
constant I None
level I None
in I None
the I None
preserved I None
hepatocyte I None
monolayers I None
. I None
<eof> I None

<s> O None
The I None
results I None
of I None
this I None
study I None
strongly I None
favour I None
storing I None
hepatocytes I None
at I None
10 I None
degrees I None
C I None
rather I None
than I None
at I None
4 I None
degrees I None
or I None
37 I None
degrees I None
C I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
rofecoxib I CHEMICAL
and I None
celecoxib I CHEMICAL
, I None
two I None
cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
, I None
in I None
postoperative I None
dental I None
pain I None
: I None
a I None
randomized I None
, I None
placebo I None
- I None
and I None
active I None
- I None
comparator I None
- I None
controlled I None
clinical I None
trial I None
. I None
<eof> I None

<s> O None
Pain I None
is I None
a I None
common I None
complaint I None
, I None
often I None
occurring I None
in I None
conjunction I None
with I None
inflammation I None
. I None
<eof> I None

<s> O None
Nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
are I None
the I None
most I None
commonly I None
used I None
analgesic I None
agents I None
in I None
ambulatory I None
patients I None
. I None
<eof> I None

<s> O None
In I None
recent I None
studies I None
, I None
the I None
cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
( I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
inhibitor I None
rofecoxib I CHEMICAL
demonstrated I None
analgesic I None
effects I None
similar I None
to I None
those I None
of I None
NSAIDs I None
in I None
the I None
treatment I None
of I None
acute I None
pain I None
and I None
primary I None
dysmenorrhea I None
. I None
<eof> I None

<s> O None
The I None
present I None
randomized I None
, I None
single I None
- I None
dose I None
, I None
double I None
- I None
blind I None
, I None
double I None
- I None
dummy I None
, I None
placebo I None
- I None
and I None
active I None
- I None
comparator I None
- I None
controlled I None
, I None
parallel I None
- I None
group I None
study I None
was I None
undertaken I None
to I None
compare I None
the I None
analgesic I None
efficacy I None
of I None
the I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
rofecoxib I CHEMICAL
50 I None
mg I None
and I None
celecoxib I CHEMICAL
200 I None
mg I None
with I None
that I None
of I None
ibuprofen I CHEMICAL
400 I None
mg I None
and I None
placebo I None
in I None
patients I None
with I None
postoperative I None
dental I None
pain I None
. I None
<eof> I None

<s> O None
Two I None
hundred I None
and I None
seventy I None
- I None
two I None
patients I None
experiencing I None
pain I None
after I None
the I None
removal I None
of I None
> I None
or I None
= I None
2 I None
third I None
molars I None
were I None
randomized I None
according I None
to I None
pain I None
severity I None
( I None
moderate I None
vs I None
severe I None
) I None
to I None
receive I None
a I None
single I None
dose I None
of I None
placebo I None
( I None
n I None
= I None
45 I None
) I None
, I None
rofecoxib I CHEMICAL
50 I None
mg I None
( I None
n I None
= I None
90 I None
) I None
, I None
celecoxib I CHEMICAL
200 I None
mg I None
( I None
n I None
= I None
91 I None
) I None
, I None
or I None
ibuprofen I CHEMICAL
400 I None
mg I None
( I None
n I None
= I None
46 I None
) I None
. I None
<eof> I None

<s> O None
Using I None
a I None
patient I None
diary I None
, I None
patients I None
recorded I None
pain I None
intensity I None
, I None
pain I None
relief I None
, I None
and I None
global I None
evaluations I None
throughout I None
the I None
24 I None
- I None
hour I None
period I None
after I None
dosing I None
. I None
<eof> I None

<s> O None
The I None
overall I None
analgesic I None
effect I None
, I None
onset I None
of I None
action I None
, I None
peak I None
effect I None
, I None
and I None
duration I None
of I None
effect I None
were I None
evaluated I None
, I None
with I None
the I None
primary I None
end I None
point I None
being I None
total I None
pain I None
relief I None
over I None
8 I None
hours I None
( I None
TOPAR8 I None
) I None
. I None
<eof> I None

<s> O None
The I None
safety I None
profile I None
was I None
assessed I None
on I None
the I None
basis I None
of I None
physical I None
findings I None
, I None
laboratory I None
results I None
, I None
and I None
spontaneous I None
reports I None
of I None
adverse I None
experiences I None
. I None
<eof> I None

<s> O None
The I None
results I None
showed I None
that I None
compared I None
with I None
celecoxib I CHEMICAL
, I None
rofecoxib I CHEMICAL
had I None
superior I None
analgesic I None
effects I None
on I None
all I None
measures I None
of I None
analgesic I None
efficacy I None
, I None
including I None
overall I None
analgesic I None
effect I None
( I None
TOPAR8 I None
, I None
18 I None
. I None
3 I None
vs I None
. I None
12 I None
. I None
5 I None
; I None
P I None
< I None
0 I None
. I None
001 I None
) I None
, I None
time I None
to I None
onset I None
of I None
effect I None
( I None
30 I None
vs I None
. I None
60 I None
minutes I None
; I None
P I None
= I None
0 I None
. I None
003 I None
) I None
, I None
peak I None
pain I None
relief I None
( I None
score I None
, I None
2 I None
. I None
8 I None
vs I None
2 I None
. I None
3 I None
; I None
P I None
< I None
0 I None
. I None
05 I None
) I None
, I None
and I None
duration I None
of I None
effect I None
( I None
> I None
24 I None
vs I None
. I None
5 I None
. I None
1 I None
hours I None
; I None
P I None
< I None
0 I None
. I None
001 I None
) I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
rofecoxib I CHEMICAL
' O CHEMICAL
s O CHEMICAL
analgesic I None
efficacy I None
was I None
similar I None
to I None
that I None
of I None
ibuprofen I CHEMICAL
( I None
TOPAR8 I None
, I None
18 I None
. I None
3 I None
vs I None
. I None
17 I None
. I None
0 I None
; I None
P I None
= I None
0 I None
. I None
460 I None
) I None
, I None
but I None
the I None
duration I None
was I None
longer I None
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
; I None
with I None
ibuprofen I CHEMICAL
, I None
the I None
time I None
to I None
on I None
set I None
was I None
24 I None
minutes I None
, I None
peak I None
pain I None
relief I None
score I None
was I None
2 I None
. I None
9 I None
, I None
and I None
duration I None
of I None
analgesic I None
effect I None
was I None
8 I None
. I None
9 I None
hours I None
. I None
<eof> I None

<s> O None
The I None
safety I None
profile I None
was I None
similar I None
across I None
all I None
treatment I None
groups I None
. I None
<eof> I None

<s> O None
Thus I None
rofecoxib I CHEMICAL
provided I None
analgesic I None
efficacy I None
superior I None
to I None
that I None
of I None
celecoxib I CHEMICAL
and I None
comparable I None
to I None
that I None
of I None
ibuprofen I None
in I None
the I None
treatment I None
of I None
patients I None
with I None
acute I None
postoperative I None
dental I None
pain I None
. I None
<eof> I None

<s> O None
Natriuretic I None
response I None
to I None
increased I None
pressure I None
is I None
preserved I None
with I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
. I None
<eof> I None

<s> O None
Elevation I None
of I None
renal I None
interstitial I None
hydrostatic I None
pressure I None
( I None
RIHP I None
) I None
by I None
direct I None
renal I None
interstitial I None
volume I None
expansion I None
increases I None
sodium I CHEMICAL
excretion I None
. I None
<eof> I None

<s> O None
This I None
natriuretic I None
response I None
is I None
blunted I None
by I None
the I None
nonspecific I None
inhibition I None
of I None
the I None
cyclooxygenase I GENE-N
( I None
COX I GENE-N
) I None
enzymes I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
tested I None
the I None
hypothesis I None
that I None
the I None
natriuretic I None
response I None
to I None
increased I None
RIHP I None
during I None
direct I None
renal I None
interstitial I None
volume I None
expansion I None
is I None
dependent I None
on I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
but I None
not I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
RIHP I None
and I None
fractional I None
excretion I None
of I None
sodium I CHEMICAL
( I None
FE I None
( I None
Na I None
) I None
) I None
were I None
measured I None
before I None
and I None
after I None
direct I None
renal I None
interstitial I None
volume I None
expansion I None
in I None
control I None
rats I None
( I None
n I None
= I None
7 I None
) I None
, I None
rats I None
infused I None
with I None
the I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
inhibitor I None
piroxicam I CHEMICAL
( I None
n I None
= I None
6 I None
, I None
1 I None
. I None
5 I None
mg I None
/ I None
kg I None
) I None
, I None
and I None
rats I None
infused I None
with I None
the I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
( I None
n I None
= I None
5 I None
, I None
1 I None
. I None
5 I None
mg I None
/ I None
kg I None
) I None
and I None
meloxicam I CHEMICAL
( I None
n I None
= I None
6 I None
, I None
0 I None
. I None
3 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
In I None
control I None
animals I None
, I None
direct I None
renal I None
interstitial I None
volume I None
expansion I None
significantly I None
increased I None
RIHP I None
( I None
Delta2 I None
. I None
3 I None
+ I None
/ I None
- I None
0 I None
. I None
5 I None
mm I None
Hg I None
, I None
P I None
< I None
0 I None
. I None
05 I None
) I None
and I None
FE I None
( I None
Na I None
) I None
( I None
Delta1 I None
. I None
1 I None
+ I None
/ I None
- I None
0 I None
. I None
3 I None
% I None
, I None
P I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
Likewise I None
, I None
in I None
animals I None
infused I None
with I None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
or I None
meloxicam I CHEMICAL
, I None
direct I None
renal I None
interstitial I None
volume I None
expansion I None
significantly I None
increased I None
RIHP I None
( I None
Delta1 I None
. I None
8 I None
+ I None
/ I None
- I None
0 I None
. I None
6 I None
mm I None
Hg I None
, I None
P I None
< I None
0 I None
. I None
05 I None
, I None
and I None
Delta1 I None
. I None
7 I None
+ I None
/ I None
- I None
0 I None
. I None
3 I None
mm I None
Hg I None
, I None
P I None
< I None
0 I None
. I None
05 I None
) I None
and I None
FE I None
( I None
Na I None
) I None
( I None
Delta1 I None
. I None
5 I None
+ I None
/ I None
- I None
0 I None
. I None
4 I None
% I None
, I None
P I None
< I None
0 I None
. I None
05 I None
, I None
and I None
Delta1 I None
. I None
1 I None
+ I None
/ I None
- I None
0 I None
. I None
3 I None
% I None
, I None
P I None
< I None
0 I None
. I None
05 I None
) I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
infusion I None
of I None
piroxicam I CHEMICAL
significantly I None
blunted I None
the I None
natriuretic I None
response I None
to I None
direct I None
renal I None
interstitial I None
volume I None
expansion I None
( I None
DeltaFE I None
( I None
Na I None
) I None
0 I None
. I None
3 I None
+ I None
/ I None
- I None
0 I None
. I None
2 I None
% I None
) I None
, I None
even I None
though I None
RIHP I None
was I None
increased I None
( I None
Delta1 I None
. I None
9 I None
+ I None
/ I None
- I None
0 I None
. I None
6 I None
mm I None
Hg I None
, I None
P I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
Infusion I None
of I None
piroxicam I CHEMICAL
but I None
not I None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
or I None
meloxicam I CHEMICAL
blunted I None
the I None
natriuretic I None
response I None
to I None
increased I None
renal I None
interstitial I None
hydrostatic I None
pressure I None
, I None
suggesting I None
that I None
the I None
natriuretic I None
response I None
to I None
increased I None
blood I None
pressure I None
may I None
be I None
preserved I None
during I None
inhibition I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
Functional I None
significance I None
of I None
globotriaosyl I CHEMICAL
ceramide O CHEMICAL
in I None
interferon I GENE-N
- O GENE-N
alpha O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
/ O GENE-N
type O GENE-N
1 O GENE-N
interferon O GENE-N
receptor O GENE-N
- I None
mediated I None
antiviral I None
activity I None
. I None
<eof> I None

<s> O None
The I None
N I CHEMICAL
- I None
terminus I None
of I None
the I None
type I GENE-Y
1 O GENE-Y
interferon O GENE-Y
receptor O GENE-Y
subunit O GENE-Y
, I None
IFNAR1 I GENE-Y
, I None
has I None
high I None
amino I CHEMICAL
acid O CHEMICAL
sequence I None
similarity I None
to I None
the I None
receptor I None
binding I None
B I GENE-N
subunit O GENE-N
of O GENE-N
the O GENE-N
Escherichia O GENE-N
coli O GENE-N
- O GENE-N
derived O GENE-N
verotoxin O GENE-N
1 O GENE-N
, O GENE-N
VT1 O GENE-N
. I None
<eof> I None

<s> O None
The I None
glycolipid I None
, I None
globotriaosyl I CHEMICAL
ceramide O CHEMICAL
( I None
Gb I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
: I None
Gal I CHEMICAL
alpha O CHEMICAL
( O CHEMICAL
1 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
- O CHEMICAL
> O CHEMICAL
4 O CHEMICAL
Gal O CHEMICAL
beta O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
- O CHEMICAL
> O CHEMICAL
4 O CHEMICAL
Glu O CHEMICAL
beta O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
- O CHEMICAL
> O CHEMICAL
1 O CHEMICAL
Cer O CHEMICAL
) I None
is I None
the I None
specific I None
cell I None
receptor I None
for I None
VT1 I GENE-N
. I None
<eof> I None

<s> O None
Gb I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
- I None
deficient I None
variant I None
cells I None
selected I None
for I None
VT I GENE-N
resistance I None
are I None
cross I None
- I None
resistant I None
to I None
interferon I GENE-N
- O GENE-N
alpha O GENE-N
( I None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
) I None
- I None
mediated I None
antiproliferative I None
activity I None
. I None
<eof> I None

<s> O None
The I None
association I None
of I None
eIFNAR1 I GENE-Y
with I None
Gal I CHEMICAL
alpha O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
- O CHEMICAL
> O CHEMICAL
4 O CHEMICAL
Gal O CHEMICAL
containing I None
glycolipids I None
has I None
been I None
previously I None
shown I None
to I None
be I None
important I None
for I None
the I None
receptor I None
- I None
mediated I None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
signal I None
transduction I None
for I None
growth I None
inhibition I None
. I None
<eof> I None

<s> O None
The I None
crucial I None
role I None
of I None
Gb I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
for I None
the I None
signal I None
transduction I None
of I None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
- I None
mediated I None
antiviral I None
activity I None
is I None
now I None
reported I None
. I None
<eof> I None

<s> O None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
- I None
mediated I None
antiviral I None
activity I None
, I None
nuclear I None
translocation I None
of I None
activated I None
Stat1 I GENE-N
, I None
and I None
increased I None
expression I None
of I None
PKR I GENE-Y
were I None
defective I None
in I None
Gb I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
- I None
deficient I None
vero I None
mutant I None
cells I None
, I None
although I None
the I None
surface I None
expression I None
of I None
IFNAR1 I GENE-N
was I None
unaltered I None
. I None
<eof> I None

<s> O None
The I None
VT1B I GENE-N
subunit I None
was I None
found I None
to I None
inhibit I None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
- I None
mediated I None
antiviral I None
activity I None
, I None
Stat1 I GENE-N
nuclear I None
translocation I None
and I None
PKR I GENE-Y
upregulation I None
. I None
<eof> I None

<s> O None
Unlike I None
VT1 I GENE-N
cytotoxicity I None
, I None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
- I None
induced I None
Stat1 I GENE-N
nuclear I None
translocation I None
was I None
not I None
inhibited I None
when I None
RME I None
was I None
prevented I None
, I None
suggesting I None
that I None
the I None
accessory I None
function I None
of I None
Gb I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
occurs I None
at I None
the I None
plasma I None
membrane I None
. I None
<eof> I None

<s> O None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
antiviral I None
activity I None
was I None
also I None
studied I None
in I None
Gb I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
- I None
positive I None
MRC I None
- I None
5 I None
cells I None
, I None
which I None
are I None
resistant I None
to I None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
growth I None
inhibition I None
, I None
partially I None
resistant I None
to I None
VT1 I GENE-N
but I None
still I None
remain I None
fully I None
sensitive I None
to I None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
antiviral I None
activity I None
, I None
and I None
two I None
astrocytoma I None
cell I None
lines I None
expressing I None
different I None
Gb I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
fatty I None
acid I None
isoforms I None
. I None
<eof> I None

<s> O None
In I None
both I None
systems I None
, I None
long I CHEMICAL
chain O CHEMICAL
fatty O CHEMICAL
acid O CHEMICAL
- I None
containing I None
Gb I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
isoforms I None
, I None
which I None
are I None
less I None
effective I None
to I None
mediate I None
VT1 I GENE-N
cytotoxicity I None
, I None
were I None
found I None
to I None
correlate I None
with I None
higher I None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
- I None
mediated I None
antiviral I None
activity I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
Gb I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
synthesis I None
in I None
toto I None
prevented I None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
antiviral I None
activity I None
in I None
all I None
cells I None
. I None
<eof> I None

<s> O None
We I None
propose I None
that I None
the I None
long I None
chain I None
Gb I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
fatty I None
isoforms I None
preferentially I None
remain I None
in I None
the I None
plasma I None
membrane I None
, I None
and I None
by I None
associating I None
with I None
IFNAR1 I GENE-N
, I None
mediate I None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
antiviral I None
signaling I None
, I None
whereas I None
short I None
chain I None
Gb I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
fatty I CHEMICAL
acid O CHEMICAL
isoforms I None
are I None
preferentially I None
internalized I None
to I None
mediate I None
VT1 I GENE-N
cytotoxicity I None
and I None
IFNAR1 I GENE-N
- I None
dependent I None
IFN I GENE-N
- O GENE-N
alpha O GENE-N
growth I None
inhibition I None
. I None
<eof> I None

<s> O None
Overexpression I None
of I None
the I None
Na I GENE-Y
( O GENE-Y
+ O GENE-Y
) O GENE-Y
/ O GENE-Y
K O GENE-Y
( O GENE-Y
+ O GENE-Y
) O GENE-Y
/ O GENE-Y
Cl O GENE-Y
( O GENE-Y
- O GENE-Y
) O GENE-Y
cotransporter O GENE-Y
gene I None
induces I None
cell I None
proliferation I None
and I None
phenotypic I None
transformation I None
in I None
mouse I None
fibroblasts I None
. I None
<eof> I None

<s> O None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
Cl O GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
cotransporter O GENE-N
activity I None
is I None
stimulated I None
in I None
early I None
G I None
( I None
1 I None
) I None
phase I None
of I None
the I None
cell I None
cycle I None
and I None
this I None
stimulation I None
was I None
shown I None
to I None
be I None
an I None
essential I None
event I None
in I None
fibroblast I None
cell I None
proliferation I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
elucidate I None
further I None
the I None
role I None
of I None
the I None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
Cl O GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
cotransporter O GENE-N
in I None
cell I None
proliferation I None
, I None
we I None
overexpressed I None
the I None
gene I None
encoding I None
the I None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
Cl O GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
cotransporter O GENE-N
in I None
mouse I None
fibroblasts I None
, I None
and I None
analyzed I None
cellular I None
phenotypic I None
changes I None
. I None
<eof> I None

<s> O None
Mouse I None
Balb I None
/ I None
c I None
3T3 I None
cells I None
were I None
stably I None
transfected I None
with I None
the I None
cDNA I None
of I None
the I None
shark I GENE-Y
rectal O GENE-Y
gland O GENE-Y
Na O GENE-Y
( O GENE-Y
+ O GENE-Y
) O GENE-Y
/ O GENE-Y
K O GENE-Y
( O GENE-Y
+ O GENE-Y
) O GENE-Y
/ O GENE-Y
Cl O GENE-Y
( O GENE-Y
- O GENE-Y
) O GENE-Y
cotransporter O GENE-Y
gene I None
( I None
NKCC1 I GENE-Y
) I None
, I None
and I None
expressed I None
in I None
a I None
mammalian I None
vector I None
under I None
the I None
cytomegalovirus I None
promoter I None
( I None
Balb I None
/ I None
c I None
- I None
NKCC1 I GENE-Y
cells I None
) I None
. I None
<eof> I None

<s> O None
The I None
transfected I None
cells I None
exhibited I None
up I None
to I None
10 I None
- I None
fold I None
greater I None
bumetanide I CHEMICAL
- I None
sensitive I None
Rb I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
influx I None
compared I None
to I None
the I None
control I None
cells I None
. I None
<eof> I None

<s> O None
The I None
Balb I None
/ I None
c I None
- I None
NKCC1 I GENE-Y
cells I None
have I None
acquired I None
a I None
typical I None
transformation I None
phenotype I None
indicated I None
by I None
: I None
( I None
1 I None
) I None
Loss I None
of I None
contact I None
inhibition I None
exhibited I None
by I None
growth I None
to I None
a I None
higher I None
cell I None
density I None
in I None
confluent I None
cultures I None
, I None
and I None
formation I None
of I None
cell I None
foci I None
; I None
( I None
2 I None
) I None
proliferation I None
in I None
low I None
serum I None
concentrations I None
; I None
and I None
( I None
3 I None
) I None
formation I None
of I None
cell I None
colonies I None
in I None
soft I None
agar I None
. I None
<eof> I None

<s> O None
The I None
control I None
cells I None
transfected I None
with I None
the I None
NKCC1 I GENE-Y
gene I None
inserted I None
in I None
the I None
opposite I None
orientation I None
in I None
the I None
vector I None
retained I None
their I None
normal I None
phenotype I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
the I None
two I None
specific I None
inhibitors I None
of I None
the I None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
Cl O GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
cotransporter O GENE-N
activity I None
; I None
bumetanide I CHEMICAL
and I None
furosemide I CHEMICAL
inhibited I None
the I None
clonogenic I None
efficiency I None
in I None
the I None
NKCC1 I GENE-Y
transfected I None
cells I None
. I None
<eof> I None

<s> O None
These I None
control I None
experiments I None
indicate I None
that I None
the I None
apparent I None
transformation I None
phenotype I None
acquired I None
by I None
the I None
Balb I None
/ I None
c I None
- I None
NKCC1 I GENE-Y
cells I None
was I None
not I None
merely I None
associated I None
with I None
the I None
process I None
of I None
transfection I None
and I None
selecting I None
for I None
the I None
neomycin I CHEMICAL
- I None
resistant I None
clones I None
, I None
but I None
rather I None
with I None
the I None
overexpression I None
of I None
the I None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
Cl O GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
cotransporter O GENE-N
gene I None
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
ascertain I None
that I None
the I None
regulated I None
and I None
normal I None
expression I None
of I None
the I None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
Cl O GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
cotransporter O GENE-N
control I None
cell I None
proliferation I None
, I None
the I None
effect I None
of I None
bumetanide I CHEMICAL
a I None
specific I None
inhibitor I None
of I None
the I None
cotransporter I None
, I None
was I None
tested I None
on I None
Balb I None
/ I None
c I None
3T3 I None
cell I None
proliferation I None
, I None
induced I None
by I None
fibroblasts I GENE-N
growth O GENE-N
factor O GENE-N
( I None
FGF I GENE-N
) I None
and I None
fetal I None
calf I None
serum I None
( I None
FCS I None
) I None
. I None
<eof> I None

<s> O None
Bumetanide I CHEMICAL
inhibited I None
synchronized I None
Balb I None
/ I None
c I None
3T3 I None
cell I None
exit I None
from I None
the I None
G I None
( I None
0 I None
) I None
/ I None
G I None
( I None
1 I None
) I None
arrest I None
and I None
entering I None
S I None
- I None
phase I None
. I None
<eof> I None

<s> O None
The I None
inhibition I None
was I None
reversible I None
, I None
as I None
removal I None
of I None
bumetanide I CHEMICAL
completely I None
released I None
cell I None
proliferation I None
. I None
<eof> I None

<s> O None
Taken I None
together I None
, I None
these I None
results I None
propose I None
that I None
the I None
NKCC1 I GENE-Y
gene I None
is I None
involved I None
in I None
the I None
control I None
of I None
normal I None
cell I None
proliferation I None
, I None
while I None
its I None
overexpression I None
results I None
in I None
apparent I None
cell I None
transformation I None
, I None
in I None
a I None
manner I None
similar I None
to I None
some I None
protooncogenes I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
chronic I None
antidepressant I None
treatments I None
on I None
serotonin I GENE-Y
transporter O GENE-Y
function I None
, I None
density I None
, I None
and I None
mRNA I None
level I None
. I None
<eof> I None

<s> O None
To I None
investigate I None
functional I None
changes I None
in I None
the I None
brain I GENE-Y
serotonin O GENE-Y
transporter O GENE-Y
( I None
SERT I GENE-Y
) I None
after I None
chronic I None
antidepressant I None
treatment I None
, I None
several I None
techniques I None
were I None
used I None
to I None
assess I None
SERT I GENE-Y
activity I None
, I None
density I None
, I None
or I None
its I None
mRNA I None
content I None
. I None
<eof> I None

<s> O None
Rats I None
were I None
treated I None
by I None
osmotic I None
minipump I None
for I None
21 I None
d I None
with I None
the I None
selective I None
serotonin I CHEMICAL
reuptake I None
inhibitors I None
( I None
SSRIs I None
) I None
paroxetine I CHEMICAL
or I None
sertraline I CHEMICAL
, I None
the I None
selective I None
norepinephrine I CHEMICAL
reuptake I None
inhibitor I None
desipramine I CHEMICAL
( I None
DMI I CHEMICAL
) I None
, I None
or I None
the I None
monoamine I CHEMICAL
oxidase I None
inhibitor I None
phenelzine I CHEMICAL
. I None
<eof> I None

<s> O None
High I None
- I None
speed I None
in I None
vivo I None
electrochemical I None
recordings I None
were I None
used I None
to I None
assess I None
the I None
ability I None
of I None
the I None
SSRI I None
fluvoxamine I CHEMICAL
to I None
modulate I None
the I None
clearance I None
of I None
locally I None
applied I None
serotonin I CHEMICAL
in I None
the I None
CA3 I None
region I None
of I None
hippocampus I None
in I None
drug I None
- I None
or I None
vehicle I None
- I None
treated I None
rats I None
. I None
<eof> I None

<s> O None
Fluvoxamine I CHEMICAL
decreased I None
the I None
clearance I None
of I None
serotonin I CHEMICAL
in I None
rats I None
treated I None
with I None
vehicle I None
, I None
DMI I CHEMICAL
, I None
or I None
phenelzine I CHEMICAL
but I None
had I None
no I None
effect I None
on I None
the I None
clearance I None
of I None
serotonin I CHEMICAL
in I None
SSRI I None
- I None
treated I None
rats I None
. I None
<eof> I None

<s> O None
SERT I GENE-Y
density I None
in I None
the I None
CA3 I None
region I None
of I None
the I None
hippocampus I None
of I None
the I None
same I None
rats I None
, I None
assessed I None
by I None
quantitative I None
autoradiography I None
with I None
tritiated I None
cyanoimipramine I CHEMICAL
( I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
CN O CHEMICAL
- O CHEMICAL
IMI O CHEMICAL
) I None
, I None
was I None
decreased I None
by I None
80 I None
- I None
90 I None
% I None
in I None
SSRI I None
- I None
treated I None
rats I None
but I None
not I None
in I None
those I None
treated I None
with I None
phenelzine I CHEMICAL
or I None
DMI I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
serotonin I CHEMICAL
content I None
of I None
the I None
hippocampus I None
was I None
unaffected I None
by I None
paroxetine I CHEMICAL
or I None
sertraline I CHEMICAL
treatment I None
, I None
ruling I None
out I None
neurotoxicity I None
as I None
a I None
possible I None
explanation I None
for I None
the I None
SSRI I None
- I None
induced I None
decrease I None
in I None
SERT I GENE-Y
binding I None
and I None
alteration I None
in I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
clearance I None
. I None
<eof> I None

<s> O None
Levels I None
of I None
mRNA I None
for I None
the I None
SERT I GENE-Y
in I None
the I None
raphe I None
nucleus I None
were I None
also I None
unaltered I None
by I None
chronic I None
paroxetine I CHEMICAL
treatment I None
. I None
<eof> I None

<s> O None
Based I None
on I None
these I None
results I None
, I None
it I None
appears I None
that I None
the I None
SERT I GENE-Y
is I None
downregulated I None
by I None
chronic I None
administration I None
of I None
SSRIs I None
but I None
not I None
other I None
types I None
of I None
antidepressants I None
; I None
furthermore I None
, I None
the I None
downregulation I None
is I None
not I None
caused I None
by I None
decreases I None
in I None
SERT I GENE-Y
gene I None
expression I None
. I None
<eof> I None

<s> O None
A I None
novel I None
mutation I None
of I None
the I None
erythroid I GENE-N
- O GENE-N
specific O GENE-N
gamma O GENE-N
- O GENE-N
Aminolevulinate O GENE-N
synthase O GENE-N
gene I None
in I None
a I None
patient I None
with I None
non I None
- I None
inherited I None
pyridoxine I CHEMICAL
- I None
responsive I None
sideroblastic I None
anemia I None
. I None
<eof> I None

<s> O None
A I None
novel I None
missense I None
mutation I None
, I None
G663A I GENE-N
, I None
in I None
exon I None
5 I None
of I None
the I None
erythroid I GENE-Y
- O GENE-Y
specific O GENE-Y
delta O GENE-Y
- O GENE-Y
aminolevulinate O GENE-Y
synthase O GENE-Y
gene I None
( I None
ALAS2 I GENE-Y
) I None
was I None
identified I None
in I None
a I None
Japanese I None
male I None
with I None
pyridoxine I CHEMICAL
- I None
responsive I None
sideroblastic I None
anemia I None
. I None
<eof> I None

<s> O None
Activity I None
of I None
the I None
mutant I None
delta I GENE-Y
- O GENE-Y
aminolevulinate O GENE-Y
synthase O GENE-Y
protein I None
expressed I None
in I None
vitro I None
was I None
15 I None
. I None
1 I None
% I None
compared I None
with I None
the I None
normal I None
control I None
, I None
but I None
was I None
increased I None
up I None
to I None
34 I None
. I None
5 I None
% I None
by I None
the I None
addition I None
of I None
pyridoxal I CHEMICAL
5 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
phosphate O CHEMICAL
, I None
consistent I None
with I None
the I None
clinical I None
response I None
of I None
the I None
patient I None
to I None
pyridoxine I CHEMICAL
treatment I None
. I None
<eof> I None

<s> O None
The I None
same I None
mutation I None
was I None
also I None
detected I None
in I None
genomic I None
DNa I None
from I None
the I None
oral I None
mucosal I None
membrane I None
of I None
the I None
patiet I None
; I None
however I None
, I None
it I None
was I None
not I None
detected I None
in I None
other I None
family I None
member I None
. I None
<eof> I None

<s> O None
These I None
findings I None
suggest I None
that I None
this I None
G663A I GENE-N
mutation I None
is I None
responsible I None
for I None
sideroblastic I None
anemia I None
in I None
the I None
proband I None
, I None
and I None
may I None
be I None
an I None
index I None
mutation I None
in I None
this I None
pedigree I None
. I None
<eof> I None

<s> O None
Adverse I None
upper I None
gastrointestinal I None
effects I None
of I None
rofecoxib I CHEMICAL
compared I None
with I None
NSAIDs I None
. I None
<eof> I None

<s> O None
CONTEXT I None
: I None
Nonsteroidal I None
anti I None
- I None
inflammatory I None
drug I None
( I None
NSAID I None
) I None
- I None
induced I None
gastrointestinal I None
( I None
GI I None
) I None
toxic I None
effects I None
, I None
such I None
as I None
upper I None
GI I None
tract I None
perforations I None
, I None
symptomatic I None
gastroduodenal I None
ulcers I None
, I None
and I None
upper I None
GI I None
tract I None
bleeding I None
( I None
PUBs I None
) I None
, I None
are I None
thought I None
to I None
be I None
attributable I None
to I None
cyclooxygenase I GENE-Y
1 O GENE-Y
( I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
inhibition I None
. I None
<eof> I None

<s> O None
Rofecoxib I CHEMICAL
specifically I None
inhibits I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
and I None
has I None
demonstrated I None
a I None
low I None
potential I None
for I None
causing I None
upper I None
GI I None
injury I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
To I None
compare I None
the I None
incidence I None
of I None
PUBs I None
in I None
patients I None
with I None
osteoarthritis I None
treated I None
with I None
rofecoxib I CHEMICAL
vs I None
NSAIDs I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
Prespecified I None
analysis I None
of I None
all I None
8 I None
double I None
- I None
blind I None
, I None
randomized I None
phase I None
2b I None
/ I None
3 I None
rofecoxib I CHEMICAL
osteoarthritis I None
trials I None
conducted I None
from I None
December I None
1996 I None
through I None
March I None
1998 I None
, I None
including I None
one I None
6 I None
- I None
week I None
dose I None
- I None
ranging I None
study I None
, I None
two I None
6 I None
- I None
week I None
efficacy I None
studies I None
vs I None
ibuprofen I CHEMICAL
and I None
placebo I None
, I None
two I None
1 I None
- I None
year I None
efficacy I None
studies I None
vs I None
diclofenac I None
, I None
two I None
6 I None
- I None
month I None
endoscopy I None
studies I None
vs I None
ibuprofen I CHEMICAL
and I None
placebo I None
, I None
and I None
one I None
6 I None
- I None
week I None
efficacy I None
study I None
vs I None
nabumetone I CHEMICAL
and I None
placebo I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
Multinational I None
sites I None
. I None
<eof> I None

<s> O None
Participants I None
Osteoarthritis I None
patients I None
( I None
N I None
= I None
5435 I None
; I None
mean I None
age I None
, I None
63 I None
years I None
[ I None
range I None
, I None
38 I None
- I None
94 I None
years I None
] I None
; I None
72 I None
. I None
9 I None
% I None
women I None
) I None
. I None
<eof> I None

<s> O None
INTERVENTIONS I None
: I None
Rofecoxib I CHEMICAL
, I None
12 I None
. I None
5 I None
, I None
25 I None
, I None
or I None
50 I None
mg I None
/ I None
d I None
( I None
n I None
= I None
1209 I None
, I None
1603 I None
, I None
and I None
545 I None
, I None
respectively I None
, I None
combined I None
) I None
vs I None
ibuprofen I CHEMICAL
, I None
800 I None
mg I None
3 I None
times I None
per I None
day I None
( I None
n I None
= I None
847 I None
) I None
, I None
diclofenac I CHEMICAL
, I None
50 I None
mg I None
3 I None
times I None
per I None
day I None
( I None
n I None
= I None
590 I None
) I None
; I None
or I None
nabumetone I CHEMICAL
, I None
1500 I None
mg I None
/ I None
d I None
( I None
n I None
= I None
127 I None
) I None
( I None
combined I None
) I None
. I None
<eof> I None

<s> O None
MAIN I None
OUTCOME I None
MEASURE I None
: I None
Cumulative I None
incidence I None
of I None
PUBs I None
for I None
rofecoxib I CHEMICAL
vs I None
NSAIDs I None
, I None
based I None
on I None
survival I None
analysis I None
of I None
time I None
to I None
first I None
PUB I None
diagnosis I None
, I None
using I None
PUBs I None
that I None
met I None
pre I None
- I None
specified I None
criteria I None
judged I None
by I None
a I None
blinded I None
, I None
external I None
adjudication I None
committee I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
The I None
incidence I None
of I None
PUBs I None
over I None
12 I None
months I None
was I None
significantly I None
lower I None
with I None
rofecoxib I CHEMICAL
vs I None
NSAIDs I None
( I None
12 I None
- I None
month I None
cumulative I None
incidence I None
, I None
1 I None
. I None
3 I None
% I None
vs I None
1 I None
. I None
8 I None
% I None
; I None
P I None
= I None
. I None
046 I None
; I None
rate I None
per I None
100 I None
patient I None
- I None
years I None
, I None
1 I None
. I None
33 I None
vs I None
2 I None
. I None
60 I None
; I None
relative I None
risk I None
, I None
0 I None
. I None
51 I None
; I None
95 I None
% I None
confidence I None
interval I None
, I None
0 I None
. I None
26 I None
- I None
1 I None
. I None
00 I None
) I None
. I None
<eof> I None

<s> O None
The I None
cumulative I None
incidence I None
of I None
dyspeptic I None
GI I None
adverse I None
experiences I None
was I None
also I None
lower I None
with I None
rofecoxib I CHEMICAL
vs I None
NSAIDS I None
over I None
6 I None
months I None
( I None
23 I None
. I None
5 I None
% I None
vs I None
25 I None
. I None
5 I None
% I None
; I None
P I None
= I None
. I None
02 I None
) I None
, I None
after I None
which I None
the I None
incidence I None
rates I None
converged I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
In I None
a I None
combined I None
analysis I None
of I None
8 I None
trials I None
of I None
patients I None
with I None
osteoarthritis I None
, I None
treatment I None
with I None
rofecoxib I CHEMICAL
was I None
associated I None
with I None
a I None
significantly I None
lower I None
incidence I None
of I None
PUBs I None
than I None
treatment I None
with I None
NSAIDs I None
. I None
<eof> I None

<s> O None
Preferential I None
cerebrospinal I None
fluid I None
acetylcholinesterase I GENE-Y
inhibition I None
by I None
rivastigmine I CHEMICAL
in I None
humans I None
. I None
<eof> I None

<s> O None
This I None
study I None
sought I None
to I None
examine I None
the I None
feasibility I None
of I None
prolonged I None
assessment I None
of I None
acetylcholinesterase I GENE-Y
( I None
AChE I GENE-Y
) I None
activity I None
in I None
the I None
cerebrospinal I None
fluid I None
( I None
CSF I None
) I None
of I None
volunteers I None
and I None
to I None
test I None
the I None
hypothesis I None
that I None
rivastigmine I CHEMICAL
( I None
ENA I CHEMICAL
- O CHEMICAL
713 O CHEMICAL
; I None
Exelon I CHEMICAL
, I None
Novartis I None
Pharma I None
AG I None
, I None
Basel I None
, I None
Switzerland I None
) I None
selectively I None
inhibits I None
AChE I GENE-Y
in I None
CSF I None
in I None
humans I None
at I None
a I None
dose I None
producing I None
minimal I None
inhibition I None
of I None
the I None
peripheral I None
enzyme I None
. I None
<eof> I None

<s> O None
Lumbar I None
CSF I None
samples I None
were I None
collected I None
continuously I None
( I None
0 I None
. I None
1 I None
mL I None
x I None
min I None
( I None
- I None
1 I None
) I None
) I None
for I None
49 I None
hours I None
from I None
eight I None
healthy I None
volunteers I None
who I None
took I None
either I None
placebo I None
or I None
a I None
single I None
oral I None
dose I None
of I None
rivastigmine I CHEMICAL
( I None
3 I None
mg I None
) I None
. I None
<eof> I None

<s> O None
CSF I None
specimens I None
and I None
samples I None
of I None
blood I None
cells I None
and I None
blood I None
plasma I None
were I None
analyzed I None
at I None
intervals I None
for I None
rivastigmine I CHEMICAL
and I None
its I None
metabolite I None
NAP I CHEMICAL
226 O CHEMICAL
- O CHEMICAL
90 O CHEMICAL
( I None
[ I CHEMICAL
- O CHEMICAL
] O CHEMICAL
[ O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
[ O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
dimethylaminolethyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
phenol O CHEMICAL
] O CHEMICAL
) I None
, I None
erythrocyte I None
AChE I GENE-Y
activity I None
, I None
CSF I None
AChE I GENE-Y
activity I None
, I None
and I None
plasma I None
and I None
CSF I None
butyrylcholinesterase I GENE-Y
( I None
BuChE I GENE-Y
) I None
activity I None
. I None
<eof> I None

<s> O None
Safety I None
evaluations I None
were I None
performed I None
23 I None
hours I None
after I None
drug I None
dosing I None
and I None
at I None
the I None
end I None
of I None
the I None
study I None
. I None
<eof> I None

<s> O None
Evaluable I None
data I None
were I None
obtained I None
from I None
six I None
subjects I None
. I None
<eof> I None

<s> O None
The I None
mean I None
time I None
to I None
maximal I None
rivastigmine I CHEMICAL
plasma I None
concentration I None
( I None
tmax I None
) I None
was I None
0 I None
. I None
83 I None
+ I None
/ I None
- I None
0 I None
. I None
26 I None
hours I None
, I None
the I None
mean I None
maximal I None
plasma I None
concentration I None
( I None
Cmax I None
) I None
was I None
4 I None
. I None
88 I None
+ I None
/ I None
- I None
3 I None
. I None
82 I None
ng I None
x I None
mL I None
( I None
- I None
1 I None
) I None
, I None
the I None
mean I None
plasma I None
area I None
under I None
the I None
concentration I None
versus I None
time I None
curve I None
( I None
AUC0 I None
- I None
infinity I None
) I None
was I None
7 I None
. I None
43 I None
+ I None
/ I None
- I None
4 I None
. I None
74 I None
ng I None
x I None
hr I None
x I None
mL I None
( I None
- I None
1 I None
) I None
, I None
and I None
the I None
mean I None
plasma I None
t1 I None
/ I None
2 I None
was I None
0 I None
. I None
85 I None
+ I None
/ I None
- I None
0 I None
. I None
115 I None
hours I None
. I None
<eof> I None

<s> O None
The I None
concentration I None
of I None
rivastigmine I CHEMICAL
in I None
CSF I None
was I None
lower I None
than I None
the I None
quantification I None
limit I None
for I None
assay I None
( I None
0 I None
. I None
65 I None
ng I None
x I None
mL I None
( I None
- I None
1 I None
) I None
) I None
, I None
but I None
NAP I CHEMICAL
226 O CHEMICAL
- O CHEMICAL
90 O CHEMICAL
reached I None
a I None
mean I None
Cmax I None
of I None
3 I None
. I None
14 I None
+ I None
/ I None
- I None
0 I None
. I None
57 I None
ng I None
x I None
mL I None
( I None
- I None
1 I None
) I None
. I None
<eof> I None

<s> O None
Only I None
minimal I None
inhibition I None
of I None
erythrocyte I None
AChE I GENE-Y
activity I None
( I None
approximately I None
3 I None
% I None
) I None
was I None
observed I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
AChE I GENE-Y
in I None
the I None
CSF I None
after I None
rivastigmine I CHEMICAL
administration I None
was I None
significantly I None
greater I None
than I None
after I None
placebo I None
for I None
up I None
to I None
8 I None
. I None
4 I None
hours I None
after I None
the I None
dose I None
and I None
was I None
maximal I None
( I None
40 I None
% I None
) I None
at I None
2 I None
. I None
4 I None
hours I None
. I None
<eof> I None

<s> O None
Plasma I None
BuChE I GENE-Y
activity I None
was I None
significantly I None
lower I None
after I None
rivastigmine I CHEMICAL
than I None
after I None
placebo I None
, I None
but I None
this I None
was I None
not I None
clinically I None
relevant I None
. I None
<eof> I None

<s> O None
BuChE I GENE-Y
activity I None
in I None
CSF I None
was I None
significantly I None
lower I None
after I None
rivastigmine I CHEMICAL
than I None
after I None
placebo I None
for I None
up I None
to I None
3 I None
. I None
6 I None
hours I None
after I None
dosing I None
, I None
but I None
this I None
difference I None
was I None
not I None
sustained I None
. I None
<eof> I None

<s> O None
This I None
study I None
confirms I None
the I None
feasibility I None
of I None
using I None
continuous I None
measurement I None
of I None
AChE I GENE-Y
activity I None
in I None
CSF I None
over I None
prolonged I None
periods I None
, I None
that I None
rivastigmine I CHEMICAL
markedly I None
inhibits I None
CSF I None
AChE I GENE-Y
after I None
a I None
single I None
oral I None
dose I None
of I None
3 I None
mg I None
, I None
and I None
that I None
the I None
inhibition I None
of I None
central I None
AChE I GENE-Y
is I None
substantially I None
greater I None
than I None
that I None
of I None
peripheral I None
AChE I GENE-Y
or I None
BuChE I GENE-Y
. I None
<eof> I None

<s> O None
Identification I None
of I None
amino I CHEMICAL
acids O CHEMICAL
in I None
the I None
factor I GENE-N
XI O GENE-N
apple O GENE-N
3 O GENE-N
domain O GENE-N
required I None
for I None
activation I None
of I None
factor I GENE-Y
IX O GENE-Y
. I None
<eof> I None

<s> O None
Activated I GENE-Y
coagulation O GENE-Y
factor O GENE-Y
XI O GENE-Y
( I None
factor I GENE-Y
XIa O GENE-Y
) I None
proteolytically I None
cleaves I None
its I None
substrate I None
, I None
factor I GENE-Y
IX O GENE-Y
, I None
in I None
an I None
interaction I None
requiring I None
the I None
factor I GENE-N
XI O GENE-N
A3 O GENE-N
domain O GENE-N
( I None
Sun I None
, I None
Y I None
. I None
, I None
and I None
Gailani I None
, I None
D I None
. I None
( I None
1996 I None
) I None
J I None
. I None
Biol I None
. I None
Chem I None
. I None
271 I None
, I None
29023 I None
- I None
29028 I None
) I None
. I None
<eof> I None

<s> O None
To I None
identify I None
key I None
amino I CHEMICAL
acids O CHEMICAL
involved I None
in I None
factor I GENE-Y
IX O GENE-Y
activation I None
, I None
recombinant I None
factor I GENE-Y
XIa O GENE-Y
proteins I None
containing I None
alanine I CHEMICAL
substitutions I None
for I None
wild I None
- I None
type I None
sequence I None
were I None
expressed I None
in I None
293 I None
fibroblasts I None
and I None
tested I None
in I None
a I None
plasma I None
clotting I None
assay I None
. I None
<eof> I None

<s> O None
Substitutions I None
for I None
Ile I None
( I None
183 I None
) I None
- I None
Val I None
( I None
191 I None
) I None
and I None
Ser I None
( I None
195 I None
) I None
- I None
Ile I None
( I None
197 I None
) I None
at I None
the I None
N I CHEMICAL
terminus I None
and I None
for I None
Ser I None
( I None
258 I None
) I None
- I None
Ser I None
( I None
264 I None
) I None
at I None
the I None
C I CHEMICAL
terminus I None
of I None
the I None
A3 I GENE-N
domain O GENE-N
markedly I None
decreased I None
factor I GENE-Y
XI O GENE-Y
coagulant I None
activity I None
. I None
<eof> I None

<s> O None
The I None
plasma I GENE-N
protease O GENE-N
prekallikrein I GENE-Y
is I None
structurally I None
homologous I None
to I None
factor I GENE-Y
XI O GENE-Y
, I None
but I None
activated I None
factor I GENE-Y
IX O GENE-Y
poorly I None
. I None
<eof> I None

<s> O None
A I None
chimeric I None
factor I GENE-Y
XIa O GENE-Y
molecule I None
with I None
the I None
A3 I GENE-N
domain O GENE-N
replaced I None
with I None
A3 I None
from I None
prekallikrein I GENE-Y
( I None
FXI I GENE-Y
/ I None
PKA3 I GENE-N
) I None
activated I GENE-Y
factor O GENE-Y
IX O GENE-Y
with I None
a I None
K I None
( I None
m I None
) I None
35 I None
- I None
fold I None
greater I None
than I None
that I None
of I None
wild I None
- I None
type I None
factor I GENE-Y
XI O GENE-Y
. I None
<eof> I None

<s> O None
FXI I GENE-Y
/ I None
PKA3 I GENE-N
was I None
used I None
as I None
a I None
template I None
for I None
a I None
series I None
of I None
proteins I None
in I None
which I None
prekallikrein I GENE-Y
A3 I None
sequence I None
was I None
replaced I None
with I None
factor I GENE-Y
XI O GENE-Y
sequence I None
to I None
restore I None
factor I GENE-Y
IX O GENE-Y
activation I None
. I None
<eof> I None

<s> O None
Clotting I None
and I None
kinetics I None
studies I None
using I None
these I None
chimeras I None
confirmed I None
the I None
results I None
obtained I None
with I None
alanine I CHEMICAL
mutants I None
. I None
<eof> I None

<s> O None
Amino I CHEMICAL
acids O CHEMICAL
between I None
Ile I None
( I None
183 I None
) I None
and I None
Val I None
( I None
191 I None
) I None
are I None
necessary I None
for I None
proper I None
factor I GENE-Y
IX O GENE-Y
activation I None
, I None
but I None
additional I None
sequence I None
between I None
Ser I None
( I None
195 I None
) I None
and I None
Ile I None
( I None
197 I None
) I None
or I None
between I None
Phe I None
( I None
260 I None
) I None
and I None
Ser I None
( I None
265 I None
) I None
is I None
required I None
for I None
complete I None
restoration I None
of I None
activation I None
. I None
<eof> I None

<s> O None
Pharmacological I None
profile I None
of I None
LF I CHEMICAL
16 O CHEMICAL
- O CHEMICAL
0687 O CHEMICAL
, I None
a I None
new I None
potent I None
non I None
- I None
peptide I None
bradykinin I GENE-N
B2 O GENE-N
receptor O GENE-N
antagonist I None
. I None
<eof> I None

<s> O None
LF I CHEMICAL
16 O CHEMICAL
- O CHEMICAL
0687 O CHEMICAL
( I None
1 I CHEMICAL
- O CHEMICAL
[ O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
dichloro O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
[ O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
dimethylquinolin O CHEMICAL
- O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
yl O CHEMICAL
) O CHEMICAL
oxy O CHEMICAL
] O CHEMICAL
methyl O CHEMICAL
] O CHEMICAL
phenyl O CHEMICAL
] O CHEMICAL
sulfonyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
N O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
aminoimethyl O CHEMICAL
) O CHEMICAL
phenyl O CHEMICAL
] O CHEMICAL
carbonylamino O CHEMICAL
] O CHEMICAL
propyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
( O CHEMICAL
S O CHEMICAL
) O CHEMICAL
- O CHEMICAL
pyrrolidinecarboxamide O CHEMICAL
) I None
has I None
been I None
selected I None
from I None
a I None
large I None
- I None
scale I None
medicinal I None
chemistry I None
program I None
for I None
further I None
development I None
. I None
<eof> I None

<s> O None
In I None
competition I None
binding I None
studies I None
using I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
bradykinin O CHEMICAL
( I None
BK I CHEMICAL
) I None
, I None
LF I CHEMICAL
16 O CHEMICAL
- O CHEMICAL
0687 O CHEMICAL
bound I None
to I None
the I None
human I None
, I None
rat I None
and I None
guinea I None
- I None
pig I None
recombinant I None
B2 I GENE-N
receptor O GENE-N
expressed I None
in I None
CHO I None
cells I None
giving I None
K I None
( I None
i I None
) I None
values I None
of I None
0 I None
. I None
67 I None
nM I None
, I None
1 I None
. I None
74 I None
nM I None
and I None
1 I None
. I None
37 I None
nM I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
It I None
also I None
bound I None
to I None
the I None
native I None
BK I GENE-N
B2 O GENE-N
receptor O GENE-N
from I None
human I None
umbilical I None
vein I None
( I None
HUV I None
) I None
, I None
rat I None
uterus I None
( I None
RU I None
) I None
and I None
guinea I None
- I None
pig I None
ileum I None
( I None
GPI I None
) I None
giving I None
K I None
( I None
i I None
) I None
values I None
of I None
0 I None
. I None
89 I None
nM I None
, I None
0 I None
. I None
28 I None
nM I None
and I None
0 I None
. I None
98 I None
nM I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
It I None
inhibited I None
BK I None
- I None
induced I None
IP1 I None
, I None
IP2 I None
and I None
IP3 I None
formation I None
in I None
INT407 I None
cells I None
yielding I None
pK I None
( I None
B I None
) I None
values I None
of I None
8 I None
. I None
5 I None
, I None
8 I None
. I None
6 I None
and I None
8 I None
. I None
7 I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
In I None
isolated I None
organs I None
experiments I None
, I None
LF I CHEMICAL
16 O CHEMICAL
- O CHEMICAL
0687 O CHEMICAL
behaved I None
as I None
a I None
competitive I None
antagonist I None
of I None
BK I None
- I None
mediated I None
contractions I None
giving I None
pA2 I None
values I None
of I None
9 I None
. I None
1 I None
in I None
HUV I None
, I None
7 I None
. I None
7 I None
in I None
RU I None
and I None
9 I None
. I None
1 I None
in I None
GPI I None
. I None
<eof> I None

<s> O None
Binding I None
and I None
functional I None
studies I None
performed I None
over I None
40 I None
different I None
receptors I None
revealed I None
that I None
LF I CHEMICAL
16 O CHEMICAL
- O CHEMICAL
0687 O CHEMICAL
was I None
selective I None
for I None
the I None
BK I GENE-N
B2 O GENE-N
receptor O GENE-N
. I None
<eof> I None

<s> O None
A I None
continuous I None
intravenous I None
infusion I None
of I None
LF I CHEMICAL
16 O CHEMICAL
- O CHEMICAL
0687 O CHEMICAL
antagonized I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
and I None
with I None
a I None
rapid I None
onset I None
of I None
action I None
BK I None
- I None
induced I None
hypotensive I None
response I None
. I None
<eof> I None

<s> O None
Subcutaneous I None
administration I None
of I None
LF I CHEMICAL
16 O CHEMICAL
- O CHEMICAL
0687 O CHEMICAL
at I None
1 I None
. I None
1 I None
micromol I None
/ I None
kg I None
to I None
rats I None
markedly I None
reduced I None
BK I CHEMICAL
- I None
induced I None
edema I None
of I None
the I None
stomach I None
( I None
- I None
69 I None
% I None
) I None
, I None
duodenum I None
( I None
- I None
65 I None
% I None
) I None
and I None
pancreas I None
( I None
- I None
56 I None
% I None
) I None
. I None
<eof> I None

<s> O None
Vasopeptidase I GENE-N
inhibition I None
with I None
omapatrilat I CHEMICAL
improves I None
cardiac I None
geometry I None
and I None
survival I None
in I None
cardiomyopathic I None
hamsters I None
more I None
than I None
does I None
ACE I GENE-Y
inhibition I None
with I None
captopril I CHEMICAL
. I None
<eof> I None

<s> O None
Vasopeptidase I GENE-N
inhibitors I None
are I None
single I None
molecules I None
that I None
inhibit I None
neutral I GENE-Y
endopeptidase O GENE-Y
( I None
NEP I GENE-Y
) I None
and I None
angiotensin I GENE-Y
- O GENE-Y
converting O GENE-Y
enzyme O GENE-Y
( I None
ACE I GENE-Y
) I None
simultaneously I None
. I None
<eof> I None

<s> O None
Omapatrilat I CHEMICAL
, I None
the I None
first I None
in I None
this I None
new I None
class I None
of I None
cardiovascular I None
agents I None
, I None
potentiates I None
vasodilatory I None
and I None
cardioprotective I None
peptides I None
and I None
represses I None
angiotensin I GENE-Y
II O GENE-Y
. I None
<eof> I None

<s> O None
This I None
study I None
compared I None
the I None
effects I None
of I None
omapatrilat I CHEMICAL
with I None
those I None
of I None
a I None
pure I None
ACE I GENE-Y
inhibitor I None
on I None
cardiac I None
geometry I None
and I None
survival I None
in I None
animals I None
with I None
heart I None
failure I None
. I None
<eof> I None

<s> O None
BIO I None
TO I None
- I None
2 I None
cardiomyopathic I None
hamsters I None
( I None
CMHs I None
) I None
in I None
the I None
early I None
stages I None
of I None
dilated I None
heart I None
failure I None
were I None
treated I None
with I None
vehicle I None
or I None
maximal I None
ACE I GENE-Y
inhibitory I None
doses I None
of I None
captopril I CHEMICAL
( I None
750 I None
micromol I None
/ I None
kg I None
/ I None
day I None
) I None
or I None
omapatrilat I CHEMICAL
( I None
200 I None
micromol I None
/ I None
kg I None
/ I None
day I None
) I None
. I None
<eof> I None

<s> O None
Prolonged I None
vasopeptidase I GENE-N
inhibition I None
increased I None
median I None
survival I None
time I None
after I None
the I None
start I None
of I None
treatment I None
by I None
99 I None
and I None
31 I None
% I None
compared I None
with I None
vehicle I None
and I None
captopril I CHEMICAL
, I None
respectively I None
( I None
median I None
survival I None
times I None
: I None
146 I None
, I None
221 I None
, I None
and I None
290 I None
days I None
with I None
vehicle I None
, I None
captopril I CHEMICAL
, I None
and I None
omapatrilat I CHEMICAL
, I None
respectively I None
; I None
p I None
< I None
0 I None
. I None
001 I None
for I None
all I None
comparisons I None
) I None
. I None
<eof> I None

<s> O None
In I None
similar I None
CMHs I None
, I None
captopril I CHEMICAL
or I None
omapatrilat I CHEMICAL
administered I None
for I None
2 I None
months I None
significantly I None
( I None
p I None
< I None
0 I None
. I None
05 I None
) I None
decreased I None
heart I None
weight I None
, I None
pulmonary I None
congestion I None
( I None
lung I None
weight I None
) I None
, I None
and I None
left I None
ventricular I None
( I None
LV I None
) I None
chamber I None
volume I None
compared I None
with I None
vehicle I None
. I None
<eof> I None

<s> O None
Omapatrilat I CHEMICAL
significantly I None
increased I None
LV I None
mass I None
- I None
to I None
- I None
volume I None
ratio I None
compared I None
with I None
vehicle I None
and I None
captopril I CHEMICAL
. I None
<eof> I None

<s> O None
Omapatrilat I CHEMICAL
, I None
but I None
not I None
captopril I CHEMICAL
, I None
significantly I None
increased I None
urinary I None
atrial I GENE-N
natriuretic O GENE-N
peptide O GENE-N
excretion I None
, I None
indicating I None
NEP I GENE-Y
inhibition I None
. I None
<eof> I None

<s> O None
Thus I None
vasopeptidase I GENE-N
inhibition I None
with I None
omapatrilat I CHEMICAL
was I None
more I None
effective I None
than I None
ACE I GENE-Y
inhibition I None
with I None
captopril I CHEMICAL
in I None
preventing I None
changes I None
in I None
LV I None
geometry I None
and I None
premature I None
mortality I None
in I None
hamsters I None
with I None
dilated I None
heart I None
failure I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
etonogestrel I CHEMICAL
on I None
VEGF I GENE-Y
, I None
oestrogen I CHEMICAL
and I None
progesterone I GENE-Y
receptor O GENE-Y
immunoreactivity I None
and I None
endothelial I None
cell I None
number I None
in I None
human I None
endometrium I None
. I None
<eof> I None

<s> O None
Contraceptive I None
use I None
often I None
leads I None
to I None
disrupted I None
endometrial I None
bleeding I None
patterns I None
in I None
women I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
two I None
different I None
contraceptive I None
regimes I None
( I None
Mircette I CHEMICAL
, I None
a I None
monophasic I None
oral I None
contraceptive I None
and I None
Implanon I CHEMICAL
, I None
a I None
long I None
- I None
acting I None
gestagen I CHEMICAL
) I None
were I None
used I None
and I None
their I None
effects I None
on I None
the I None
immunoreactivity I None
of I None
vascular I GENE-Y
endothelial O GENE-Y
growth O GENE-Y
factor O GENE-Y
( I None
VEGF I GENE-Y
) I None
, I None
oestrogen I GENE-Y
receptor O GENE-Y
( I None
ER I GENE-Y
) I None
, I None
progesterone I GENE-Y
receptor O GENE-Y
( I None
PR I GENE-Y
) I None
and I None
endothelial I None
cell I None
number I None
were I None
determined I None
. I None
<eof> I None

<s> O None
During I None
the I None
untreated I None
normal I None
cycle I None
, I None
there I None
was I None
a I None
significant I None
increase I None
( I None
P I None
= I None
0 I None
. I None
005 I None
) I None
in I None
glandular I None
VEGF I GENE-Y
immunoreactivity I None
and I None
a I None
significant I None
decrease I None
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
in I None
PR I GENE-Y
immunoreactivity I None
in I None
the I None
mid I None
- I None
and I None
late I None
secretory I None
phases I None
compared I None
with I None
the I None
proliferative I None
phase I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
significant I None
positive I None
correlation I None
( I None
gamma I None
= I None
0 I None
. I None
38 I None
, I None
P I None
= I None
0 I None
. I None
046 I None
) I None
between I None
stromal I None
VEGF I GENE-Y
immunoreactivity I None
and I None
endothelial I None
cell I None
number I None
. I None
<eof> I None

<s> O None
This I None
correlation I None
was I None
also I None
apparent I None
during I None
treatment I None
with I None
Implanon I CHEMICAL
, I None
but I None
not I None
with I None
Mircette I CHEMICAL
. I None
<eof> I None

<s> O None
Disrupted I None
bleeding I None
patterns I None
were I None
associated I None
with I None
Implanon I CHEMICAL
and I None
, I None
to I None
a I None
lesser I None
extent I None
, I None
with I None
Mircette I CHEMICAL
. I None
<eof> I None

<s> O None
Both I None
contraceptives I None
significantly I None
reduced I None
glandular I None
VEGF I GENE-Y
immunoreactivity I None
. I None
<eof> I None

<s> O None
Implanon I CHEMICAL
significantly I None
increased I None
( I None
P I None
= I None
0 I None
. I None
016 I None
) I None
glandular I None
PR I GENE-Y
staining I None
, I None
but I None
Mircette I CHEMICAL
significantly I None
reduced I None
( I None
P I None
= I None
0 I None
. I None
027 I None
) I None
stromal I None
PR I GENE-Y
staining I None
when I None
compared I None
with I None
secretory I None
before I None
- I None
treatment I None
biopsies I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
changes I None
in I None
endothelial I None
cell I None
number I None
or I None
glandular I None
or I None
stromal I None
ER I GENE-Y
during I None
the I None
normal I None
cycle I None
, I None
or I None
with I None
use I None
of I None
either I None
contraceptive I None
. I None
<eof> I None

<s> O None
There I None
was I None
no I None
association I None
between I None
the I None
parameters I None
measured I None
with I None
bleeding I None
patterns I None
and I None
histological I None
category I None
. I None
<eof> I None

<s> O None
Agonist I None
and I None
antagonist I None
actions I None
of I None
yohimbine I CHEMICAL
as I None
compared I None
to I None
fluparoxan I CHEMICAL
at I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenergic O GENE-N
receptors O GENE-N
( I GENE-N
AR O GENE-N
) O GENE-N
s O GENE-N
, I None
serotonin I CHEMICAL
( I GENE-Y
5 O GENE-Y
- O GENE-Y
HT O GENE-Y
) O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
, I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
, I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1D O GENE-Y
) O GENE-Y
and I None
dopamine I GENE-N
D O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
and O GENE-N
D O GENE-N
( O GENE-N
3 O GENE-N
) O GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
Significance I None
for I None
the I None
modulation I None
of I None
frontocortical I None
monoaminergic I None
transmission I None
and I None
depressive I None
states I None
. I None
<eof> I None

<s> O None
Herein I None
, I None
we I None
evaluate I None
the I None
interaction I None
of I None
the I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
AR O GENE-N
antagonist O GENE-N
, I None
yohimbine I CHEMICAL
, I None
as I None
compared I None
to I None
fluparoxan I CHEMICAL
, I None
at I None
multiple I None
monoaminergic I GENE-N
receptors O GENE-N
and I None
examine I None
their I None
roles I None
in I None
the I None
modulation I None
of I None
adrenergic I None
, I None
dopaminergic I None
and I None
serotonergic I None
transmission I None
in I None
freely I None
- I None
moving I None
rats I None
. I None
<eof> I None

<s> O None
Yohimbine I CHEMICAL
displays I None
marked I None
affinity I None
at I None
human I GENE-N
( O GENE-N
h O GENE-N
) O GENE-N
alpha O GENE-N
( O GENE-N
2A O GENE-N
) O GENE-N
- O GENE-N
, O GENE-N
halpha O GENE-N
( O GENE-N
2B O GENE-N
) O GENE-N
- O GENE-N
and O GENE-N
halpha O GENE-N
( O GENE-N
2C O GENE-N
) O GENE-N
- O GENE-N
ARs O GENE-N
, I None
significant I None
affinity I None
for I None
h5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
, I None
h5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
, I None
h5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1D O GENE-Y
) O GENE-Y
, I None
and I None
hD I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
receptors O GENE-Y
and I None
weak I None
affinity I None
for I None
hD I GENE-Y
( O GENE-Y
3 O GENE-Y
) O GENE-Y
receptors O GENE-Y
. I None
<eof> I None

<s> O None
In I None
[ I None
( I CHEMICAL
35 O CHEMICAL
) O CHEMICAL
S O CHEMICAL
] I None
GTPgammaS I None
binding I None
protocols I None
, I None
yohimbine I CHEMICAL
exerts I None
antagonist I None
actions I None
at I None
halpha I GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- O GENE-Y
AR O GENE-Y
, I None
h5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
, I None
h5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1D O GENE-Y
) O GENE-Y
, I None
and I None
hD I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
sites I None
, I None
yet I None
partial I None
agonist I None
actions I None
at I None
h5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
sites I None
. I None
<eof> I None

<s> O None
In I None
vivo I None
, I None
agonist I None
actions I None
of I None
yohimbine I CHEMICAL
at I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
sites I None
are I None
revealed I None
by I None
WAY100 I CHEMICAL
, O CHEMICAL
635 O CHEMICAL
- I None
reversible I None
induction I None
of I None
hypothermia I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
In I None
guinea I None
pigs I None
, I None
antagonist I None
actions I None
of I None
yohimbine I CHEMICAL
at I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
receptors I None
are I None
revealed I None
by I None
blockade I None
of I None
hypothermia I None
evoked I None
by I None
the I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
agonist I None
, I None
GR46 I CHEMICAL
, O CHEMICAL
611 O CHEMICAL
. I None
<eof> I None

<s> O None
In I None
distinction I None
to I None
yohimbine I CHEMICAL
, I None
fluparoxan I CHEMICAL
shows I None
only I None
modest I None
partial I None
agonist I None
actions I None
at I None
h5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
sites I None
versus I None
marked I None
antagonist I None
actions I None
at I None
halpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
ARs O GENE-N
. I None
<eof> I None

<s> O None
While I None
fluparoxan I CHEMICAL
selectively I None
enhances I None
hippocampal I None
noradrenaline I CHEMICAL
( I None
NAD I CHEMICAL
) I None
turnover I None
, I None
yohimbine I CHEMICAL
also I None
enhances I None
striatal I None
dopamine I CHEMICAL
( I None
DA I CHEMICAL
) I None
turnover I None
and I None
suppresses I None
striatal I None
turnover I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
. I None
<eof> I None

<s> O None
Further I None
, I None
yohimbine I CHEMICAL
decreases I None
firing I None
of I None
serotonergic I None
neurones I None
in I None
raphe I None
nuclei I None
, I None
an I None
action I None
reversed I None
by I None
WAY100 I CHEMICAL
, O CHEMICAL
635 O CHEMICAL
. I None
<eof> I None

<s> O None
Fluparoxan I CHEMICAL
increases I None
extracellular I None
levels I None
of I None
DA I CHEMICAL
and I None
NAD I CHEMICAL
, I None
but I None
not I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
, I None
in I None
frontal I None
cortex I None
. I None
<eof> I None

<s> O None
In I None
analogy I None
, I None
yohimbine I CHEMICAL
enhances I None
FCX I None
levels I None
of I None
DA I CHEMICAL
and I None
NAD I CHEMICAL
, I None
yet I None
suppresses I None
those I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
, I None
the I None
latter I None
effect I None
being I None
antagonized I None
by I None
WAY100 I CHEMICAL
, O CHEMICAL
635 O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
induction I None
by I None
fluoxetine I None
of I None
FCX I None
levels I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
, I None
DA I CHEMICAL
, I None
and I None
NAD I CHEMICAL
is I None
potentiated I None
by I None
fluparoxan I CHEMICAL
. I None
<eof> I None

<s> O None
Yohimbine I CHEMICAL
likewise I None
facilitates I None
the I None
influence I None
of I None
fluoxetine I CHEMICAL
upon I None
DA I CHEMICAL
and I None
NAD I CHEMICAL
levels I None
, I None
but I None
not I None
those I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
the I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
AR O GENE-N
antagonist I None
properties I None
of I None
yohimbine I CHEMICAL
increase I None
DA I CHEMICAL
and I None
NAD I CHEMICAL
levels I None
both I None
alone I None
and I None
in I None
association I None
with I None
fluoxetine I None
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
contrast I None
to I None
the I None
selective I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
AR O GENE-N
antagonist I None
, I None
fluparoxan I CHEMICAL
, I None
the I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
agonist I None
actions I None
of I None
yohimbine I CHEMICAL
suppress I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
levels I None
alone I None
and I None
underlie I None
its I None
inability I None
to I None
augment I None
the I None
influence I None
of I None
fluoxetine I CHEMICAL
upon I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
Pharmacological I None
and I None
ocular I None
hypotensive I None
properties I None
of I None
topical I None
carbonic I GENE-N
anhydrase O GENE-N
inhibitors I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
time I None
gap I None
of I None
over I None
40 I None
years I None
between I None
the I None
demonstrated I None
oral I None
effectiveness I None
of I None
acetazolamide I CHEMICAL
in I None
lowering I None
the I None
intraocular I None
pressure I None
( I None
IOP I None
) I None
of I None
glaucoma I None
patients I None
and I None
the I None
introduction I None
of I None
a I None
topical I None
carbonic I GENE-N
anhydrase O GENE-N
( I None
CA I GENE-N
) I None
inhibitor I None
. I None
<eof> I None

<s> O None
This I None
is I None
due I None
to I None
the I None
fact I None
that I None
CA I GENE-Y
- O GENE-Y
II O GENE-Y
, I None
the I None
isoenzyme I None
which I None
most I None
likely I None
plays I None
an I None
important I None
role I None
in I None
the I None
production I None
of I None
aqueous I None
humor I None
in I None
humans I None
, I None
must I None
be I None
essentially I None
inhibited I None
by I None
100 I None
% I None
to I None
elicit I None
a I None
pharmacological I None
response I None
. I None
<eof> I None

<s> O None
The I None
lack I None
of I None
success I None
with I None
earlier I None
attempts I None
to I None
obtain I None
a I None
topical I None
agent I None
stems I None
from I None
an I None
inability I None
to I None
attain I None
and I None
maintain I None
a I None
sufficiently I None
high I None
intraocular I None
concentration I None
of I None
drug I None
to I None
achieve I None
the I None
required I None
inhibition I None
of I None
CA I GENE-N
. I None
<eof> I None

<s> O None
Dorzolamide I CHEMICAL
and I None
brinzolamide I CHEMICAL
are I None
two I None
topical I None
CA I GENE-N
inhibitors I None
which I None
are I None
currently I None
available I None
to I None
treat I None
ocular I None
hypertension I None
and I None
/ I None
or I None
glaucoma I None
. I None
<eof> I None

<s> O None
Dorzolamide I CHEMICAL
is I None
a I None
very I None
potent I None
inhibitor I None
of I None
CA I GENE-Y
- O GENE-Y
II O GENE-Y
and I None
its I None
site I None
of I None
action I None
is I None
local I None
within I None
the I None
eye I None
. I None
<eof> I None

<s> O None
Like I None
oral I None
CA I GENE-N
inhibitors I None
, I None
topically I None
applied I None
dorzolamide I CHEMICAL
lowers I None
IOP I None
by I None
decreasing I None
the I None
production I None
of I None
aqueous I None
humor I None
. I None
<eof> I None

<s> O None
The I None
drug I None
is I None
used I None
in I None
monotherapy I None
as I None
a I None
2 I None
% I None
solution I None
administered I None
three I None
times I None
daily I None
. I None
<eof> I None

<s> O None
Its I None
ocular I None
hypotensive I None
effect I None
is I None
comparable I None
to I None
that I None
of I None
timolol I CHEMICAL
at I None
peak I None
but I None
is I None
somewhat I None
less I None
at I None
trough I None
. I None
<eof> I None

<s> O None
The I None
IOP I None
lowering I None
effect I None
of I None
timolol I CHEMICAL
is I None
enhanced I None
by I None
the I None
twice I None
daily I None
administration I None
of I None
2 I None
% I None
dorzolamide I CHEMICAL
either I None
concomitantly I None
or I None
in I None
combination I None
. I None
<eof> I None

<s> O None
Topically I None
applied I None
dorzolamide I CHEMICAL
is I None
generally I None
well I None
tolerated I None
and I None
had I None
a I None
low I None
drop I None
- I None
out I None
rate I None
in I None
clinical I None
studies I None
. I None
<eof> I None

<s> O None
The I None
most I None
frequent I None
ocular I None
adverse I None
experience I None
is I None
burning I None
and I None
/ I None
or I None
stinging I None
. I None
<eof> I None

<s> O None
Corneal I None
and I None
lenticular I None
problems I None
have I None
generally I None
not I None
been I None
encountered I None
with I None
long I None
- I None
term I None
therapy I None
with I None
dorzolamide I CHEMICAL
. I None
<eof> I None

<s> O None
Topically I None
applied I None
dorzolamide I CHEMICAL
penetrates I None
directly I None
to I None
the I None
posterior I None
segment I None
of I None
the I None
eye I None
and I None
its I None
presence I None
is I None
consistent I None
with I None
the I None
initial I None
report I None
that I None
dorzolamide I CHEMICAL
increases I None
retinal I None
blood I None
flow I None
velocity I None
in I None
patients I None
with I None
normal I None
tension I None
glaucoma I None
. I None
<eof> I None

<s> O None
The I None
most I None
frequent I None
systemic I None
adverse I None
experience I None
is I None
a I None
transient I None
bitter I None
taste I None
. I None
<eof> I None

<s> O None
Biochemical I None
changes I None
indicative I None
of I None
the I None
systemic I None
inhibition I None
of I None
CA I GENE-N
have I None
not I None
been I None
observed I None
in I None
monotherapy I None
studies I None
lasting I None
up I None
to I None
2 I None
years I None
. I None
<eof> I None

<s> O None
This I None
is I None
in I None
harmony I None
with I None
the I None
inability I None
of I None
dorzolamide I CHEMICAL
at I None
steady I None
- I None
state I None
to I None
saturate I None
CA I GENE-N
in I None
the I None
red I None
blood I None
cell I None
and I None
the I None
failure I None
to I None
detect I None
its I None
presence I None
in I None
plasma I None
. I None
<eof> I None

<s> O None
A I None
1 I None
% I None
suspension I None
of I None
brinzolamide I CHEMICAL
is I None
comparable I None
to I None
2 I None
% I None
dorzolamide I CHEMICAL
in I None
lowering I None
IOP I None
, I None
both I None
drugs I None
being I None
administered I None
three I None
times I None
daily I None
. I None
<eof> I None

<s> O None
Although I None
brinzolamide I CHEMICAL
has I None
a I None
lower I None
incidence I None
of I None
burning I None
/ I None
stinging I None
, I None
it I None
elicits I None
more I None
blurred I None
vision I None
. I None
<eof> I None

<s> O None
Microvessel I None
density I None
and I None
endothelial I None
cell I None
proliferation I None
after I None
amifostine I CHEMICAL
( I None
Ethyol I CHEMICAL
) I None
administration I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
As I None
amifostine I CHEMICAL
is I None
rapidly I None
metabolised I None
by I None
the I None
membrane I None
- I None
bound I None
and I None
capillary I None
alkaline I GENE-N
phosphatase O GENE-N
to I None
the I None
active I None
metabolite I None
WR I CHEMICAL
- O CHEMICAL
1065 O CHEMICAL
, I None
microvessel I None
density I None
in I None
normal I None
and I None
cancer I None
tissue I None
may I None
influence I None
the I None
therapeutic I None
potential I None
of I None
the I None
pro I None
- I None
drug I None
WR I CHEMICAL
- O CHEMICAL
2721 O CHEMICAL
. I None
<eof> I None

<s> O None
Thus I None
, I None
it I None
is I None
of I None
interest I None
how I None
the I None
administration I None
of I None
amifostine I CHEMICAL
itself I None
alters I None
vascular I None
density I None
. I None
<eof> I None

<s> O None
MATERIALS I None
AND I None
METHOD I None
: I None
For I None
this I None
study I None
fertilized I None
eggs I None
were I None
used I None
and I None
0 I None
. I None
05 I None
ml I None
amifostine I CHEMICAL
( I None
25 I None
. I None
7 I None
micrograms I None
) I None
was I None
injected I None
into I None
the I None
area I None
vasculosa I None
. I None
<eof> I None

<s> O None
As I None
controls I None
untreated I None
area I None
vasculosa I None
were I None
examined I None
as I None
well I None
as I None
eggs I None
treated I None
with I None
0 I None
. I None
05 I None
ml I None
NaCl I CHEMICAL
0 I None
. I None
9 I None
% I None
, I None
48 I None
hr I None
after I None
injection I None
the I None
vascular I None
density I None
was I None
determined I None
by I None
histometrical I None
methods I None
. I None
<eof> I None

<s> O None
Applying I None
the I None
LAB I None
method I None
we I None
performed I None
immunohistochemical I None
analysis I None
of I None
the I None
proliferating I GENE-N
cell O GENE-N
nuclear O GENE-N
antigen O GENE-N
of I None
endothelial I None
cells I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
There I None
was I None
a I None
significant I None
( I None
p I None
< I None
0 I None
. I None
001 I None
) I None
difference I None
in I None
vascular I None
density I None
with I None
a I None
mean I None
microvessel I None
count I None
of I None
25 I None
. I None
08 I None
( I None
+ I None
/ I None
- I None
8 I None
. I None
45 I None
SD I None
) I None
vascular I None
intersections I None
/ I None
mm2 I None
in I None
the I None
untreated I None
control I None
, I None
30 I None
. I None
40 I None
( I None
+ I None
/ I None
- I None
12 I None
. I None
84 I None
SD I None
) I None
in I None
the I None
NaCl I CHEMICAL
control I None
and I None
53 I None
. I None
69 I None
( I None
+ I None
/ I None
- I None
24 I None
. I None
56 I None
SD I None
) I None
in I None
the I None
amifostine I CHEMICAL
treated I None
area I None
. I None
<eof> I None

<s> O None
There I None
was I None
also I None
a I None
significant I None
( I None
p I None
< I None
0 I None
. I None
001 I None
) I None
difference I None
in I None
endothelial I None
cell I None
proliferation I None
( I None
PCNA I GENE-N
) I None
between I None
untreated I None
controls I None
with I None
a I None
mean I None
PCNA I GENE-N
positivity I None
of I None
14 I None
. I None
05 I None
( I None
+ I None
/ I None
- I None
5 I None
. I None
28 I None
SD I None
) I None
and I None
amifostine I CHEMICAL
treated I None
area I None
vasculosa I None
with I None
a I None
mean I None
PCNA I GENE-N
positivity I None
of I None
32 I None
. I None
22 I None
( I None
+ I None
/ I None
- I None
18 I None
. I None
14 I None
SD I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
A I None
single I None
dose I None
administration I None
of I None
25 I None
. I None
7 I None
micrograms I None
amifostine I CHEMICAL
induces I None
endothelial I None
cell I None
proliferation I None
and I None
subsequent I None
neovascularisation I None
in I None
the I None
area I None
vasculosa I None
of I None
the I None
fertilised I None
egg I None
. I None
<eof> I None

<s> O None
Biochemically I None
based I None
design I None
of I None
cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
( I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
inhibitors I None
: I None
facile I None
conversion I None
of I None
nonsteroidal I None
antiinflammatory I None
drugs I None
to I None
potent I None
and I None
highly I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
. I None
<eof> I None

<s> O None
All I None
nonsteroidal I None
antiinflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
inhibit I None
the I None
cyclooxygenase I GENE-N
( I None
COX I GENE-N
) I None
isozymes I None
to I None
different I None
extents I None
, I None
which I None
accounts I None
for I None
their I None
anti I None
- I None
inflammatory I None
and I None
analgesic I None
activities I None
and I None
their I None
gastrointestinal I None
side I None
effects I None
. I None
<eof> I None

<s> O None
We I None
have I None
exploited I None
biochemical I None
differences I None
between I None
the I None
two I None
COX I GENE-N
enzymes I None
to I None
identify I None
a I None
strategy I None
for I None
converting I None
carboxylate I None
- I None
containing I None
NSAIDs I None
into I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
. I None
<eof> I None

<s> O None
Derivatization I None
of I None
the I None
carboxylate I None
moiety I None
in I None
moderately I None
selective I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
inhibitors I None
, I None
such I None
as I None
5 I CHEMICAL
, O CHEMICAL
8 O CHEMICAL
, O CHEMICAL
11 O CHEMICAL
, O CHEMICAL
14 O CHEMICAL
- O CHEMICAL
eicosatetraynoic O CHEMICAL
acid O CHEMICAL
( I None
ETYA I CHEMICAL
) I None
and I None
arylacetic I CHEMICAL
and I None
fenamic I CHEMICAL
acid O CHEMICAL
NSAIDs I None
, I None
exemplified I None
by I None
indomethacin I CHEMICAL
and I None
meclofenamic I CHEMICAL
acid O CHEMICAL
, I None
respectively I None
, I None
generated I None
potent I None
and I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
. I None
<eof> I None

<s> O None
In I None
the I None
indomethacin I CHEMICAL
series I None
, I None
esters I CHEMICAL
and I None
primary I CHEMICAL
and O CHEMICAL
secondary O CHEMICAL
amides O CHEMICAL
are I None
superior I None
to I None
tertiary I CHEMICAL
amides O CHEMICAL
as I None
selective I None
inhibitors I None
. I None
<eof> I None

<s> O None
Only I None
the I None
amide I CHEMICAL
derivatives I None
of I None
ETYA I CHEMICAL
and I None
meclofenamic I CHEMICAL
acid O CHEMICAL
inhibit I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
; I None
the I None
esters I CHEMICAL
are I None
either I None
inactive I None
or I None
nonselective I None
. I None
<eof> I None

<s> O None
Inhibition I None
kinetics I None
reveal I None
that I None
indomethacin I CHEMICAL
amides O CHEMICAL
behave I None
as I None
slow I None
, I None
tight I None
- I None
binding I None
inhibitors I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
and I None
that I None
selectivity I None
is I None
a I None
function I None
of I None
the I None
time I None
- I None
dependent I None
step I None
. I None
<eof> I None

<s> O None
Site I None
- I None
directed I None
mutagenesis I None
of I None
murine I GENE-Y
COX O GENE-Y
- O GENE-Y
2 O GENE-Y
indicates I None
that I None
the I None
molecular I None
basis I None
for I None
selectivity I None
differs I None
from I None
the I None
parent I None
NSAIDs I None
and I None
from I None
diarylheterocycles I None
. I None
<eof> I None

<s> O None
Selectivity I None
arises I None
from I None
novel I None
interactions I None
at I None
the I None
opening I None
and I None
at I None
the I None
apex I None
of I None
the I None
substrate I None
- I None
binding I None
site I None
. I None
<eof> I None

<s> O None
Lead I None
compounds I None
in I None
the I None
present I None
study I None
are I None
potent I None
inhibitors I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
activity I None
in I None
cultured I None
inflammatory I None
cells I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
indomethacin I CHEMICAL
amides O CHEMICAL
are I None
orally I None
active I None
, I None
nonulcerogenic I None
, I None
anti I None
- I None
inflammatory I None
agents I None
in I None
an I None
in I None
vivo I None
model I None
of I None
acute I None
inflammation I None
. I None
<eof> I None

<s> O None
Expansion I None
of I None
this I None
approach I None
can I None
be I None
envisioned I None
for I None
the I None
modification I None
of I None
all I None
carboxylic I CHEMICAL
acid O CHEMICAL
- I None
containing I None
NSAIDs I None
into I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
. I None
<eof> I None

<s> O None
The I None
antitussive I None
activity I None
of I None
delta I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
stimulation I None
in I None
guinea I None
pigs I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
the I None
activity I None
of I None
the I None
delta I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
subtype I None
- I None
selective I None
agonist I None
, I None
SB I CHEMICAL
227122 O CHEMICAL
, I None
was I None
investigated I None
in I None
a I None
guinea I None
pig I None
model I None
of I None
citric I CHEMICAL
acid O CHEMICAL
- I None
induced I None
cough I None
. I None
<eof> I None

<s> O None
Parenteral I None
administration I None
of I None
selective I None
agonists I None
of I None
the I None
delta I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
( I None
SB I CHEMICAL
227122 O CHEMICAL
) I None
, I None
mu I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
( I None
codeine I CHEMICAL
and I None
hydrocodone I CHEMICAL
) I None
, I None
and I None
kappa I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
( I None
BRL I CHEMICAL
52974 O CHEMICAL
) I None
produced I None
dose I None
- I None
related I None
inhibition I None
of I None
citric I CHEMICAL
acid O CHEMICAL
- I None
induced I None
cough I None
with I None
ED I None
( I None
50 I None
) I None
values I None
of I None
7 I None
. I None
3 I None
, I None
5 I None
. I None
2 I None
, I None
5 I None
. I None
1 I None
, I None
and I None
5 I None
. I None
3 I None
mg I None
/ I None
kg I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
The I None
nonselective I None
opioid I GENE-N
receptor O GENE-N
antagonist I None
, I None
naloxone I CHEMICAL
( I None
3 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
m I None
. I None
) I None
, I None
attenuated I None
the I None
antitussive I None
effects I None
of I None
codeine I CHEMICAL
or I None
SB I CHEMICAL
227122 O CHEMICAL
, I None
indicating I None
that I None
the I None
antitussive I None
activity I None
of I None
both I None
compounds I None
is I None
opioid I GENE-N
receptor O GENE-N
- I None
mediated I None
. I None
<eof> I None

<s> O None
The I None
delta I GENE-Y
- O GENE-Y
receptor O GENE-Y
antagonist I None
, I None
SB I CHEMICAL
244525 O CHEMICAL
( I None
10 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
p I None
. I None
) I None
, I None
inhibited I None
the I None
antitussive I None
effect I None
of I None
SB I CHEMICAL
227122 O CHEMICAL
( I None
20 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
p I None
. I None
) I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
combined I None
pretreatment I None
with I None
beta I CHEMICAL
- O CHEMICAL
funaltrexamine O CHEMICAL
( I None
mu I GENE-Y
- O GENE-Y
receptor O GENE-Y
antagonist I None
; I None
20 I None
mg I None
/ I None
kg I None
, I None
s I None
. I None
c I None
. I None
) I None
and I None
norbinaltorphimine I CHEMICAL
( I None
kappa I GENE-Y
- O GENE-Y
receptor O GENE-Y
antagonist I None
; I None
20 I None
mg I None
/ I None
kg I None
, I None
s I None
. I None
c I None
. I None
) I None
, I None
at I None
doses I None
that I None
inhibited I None
the I None
antitussive I None
activity I None
of I None
mu I GENE-N
- O GENE-N
and O GENE-N
kappa O GENE-N
- O GENE-N
receptor O GENE-N
agonists I None
, I None
respectively I None
, I None
was I None
without I None
effect I None
on I None
the I None
antitussive I None
response I None
of I None
SB I CHEMICAL
227122 O CHEMICAL
( I None
20 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
p I None
. I None
) I None
. I None
<eof> I None

<s> O None
The I None
sigma I GENE-N
- O GENE-N
receptor O GENE-N
antagonist I None
rimcazole I CHEMICAL
( I None
3 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
p I None
. I None
) I None
inhibited I None
the I None
antitussive I None
effect I None
of I None
dextromethorphan I CHEMICAL
( I None
30 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
p I None
. I None
) I None
, I None
a I None
sigma I None
- I None
receptor I None
agonist I None
, I None
but I None
not I None
that I None
of I None
SB I CHEMICAL
227122 O CHEMICAL
. I None
<eof> I None

<s> O None
These I None
studies I None
provide I None
compelling I None
evidence I None
that I None
the I None
antitussive I None
effects I None
of I None
SB I CHEMICAL
227122 O CHEMICAL
in I None
this I None
guinea I None
pig I None
cough I None
model I None
are I None
mediated I None
by I None
agonist I None
activity I None
at I None
the I None
delta I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
. I None
<eof> I None

<s> O None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
- I None
specific I None
inhibition I None
: I None
implications I None
for I None
clinical I None
practice I None
. I None
<eof> I None

<s> O None
Although I None
conventional I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
have I None
long I None
been I None
a I None
major I None
therapeutic I None
choice I None
for I None
the I None
management I None
of I None
arthritic I None
conditions I None
, I None
the I None
potential I None
adverse I None
effects I None
of I None
these I None
agents I None
sometimes I None
compromise I None
their I None
clinical I None
utility I None
. I None
<eof> I None

<s> O None
New I None
modes I None
of I None
therapy I None
have I None
recently I None
been I None
introduced I None
, I None
and I None
data I None
on I None
the I None
cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
( I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
- I None
specific I None
inhibitors I None
celecoxib I CHEMICAL
and I None
rofecoxib I CHEMICAL
suggest I None
that I None
these I None
agents I None
will I None
meet I None
the I None
need I None
for I None
safe I None
and I None
effective I None
therapeutic I None
alternatives I None
to I None
conventional I None
NSAIDs I None
. I None
<eof> I None

<s> O None
A I None
review I None
of I None
recent I None
advances I None
on I None
the I None
regulation I None
of I None
pigmentation I None
in I None
the I None
human I None
epidermis I None
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
recognised I None
that I None
the I None
active I None
transport I None
of I None
L I CHEMICAL
- O CHEMICAL
phenylalanine O CHEMICAL
and I None
its I None
autocrine I None
turnover I None
to I None
L I CHEMICAL
- O CHEMICAL
tyrosine O CHEMICAL
via I None
phenylalanine I GENE-Y
hydroxylase O GENE-Y
in I None
the I None
cytosol I None
of I None
epidermal I None
melanocytes I None
provides I None
the I None
majority I None
of I None
the I None
L I CHEMICAL
- O CHEMICAL
tyrosine O CHEMICAL
pool I None
for I None
melanogenesis I None
. I None
<eof> I None

<s> O None
In I None
this I None
context I None
, I None
it I None
has I None
been I None
shown I None
that I None
the I None
cofactor I None
6 I CHEMICAL
( O CHEMICAL
R O CHEMICAL
) O CHEMICAL
- O CHEMICAL
L O CHEMICAL
- O CHEMICAL
erythro O CHEMICAL
5 O CHEMICAL
, O CHEMICAL
6 O CHEMICAL
, O CHEMICAL
7 O CHEMICAL
, O CHEMICAL
8 O CHEMICAL
tetrahydrobiopterin O CHEMICAL
( I None
6BH4 I CHEMICAL
) I None
is I None
produced I None
de I None
novo I None
, I None
recycled I None
and I None
regulated I None
in I None
both I None
epidermal I None
melanocytes I None
and I None
keratinocytes I None
to I None
control I None
tyrosine I GENE-Y
hydroxylase O GENE-Y
, I None
phenylalanine I GENE-Y
hydroxylase O GENE-Y
and I None
tyrosinase I GENE-Y
activity I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
the I None
enzymes I None
by I None
excessive I None
6BH4 I None
levels I None
is I None
reversible I None
with I None
alpha I GENE-Y
- O GENE-Y
MSH O GENE-Y
by I None
specific I None
complex I None
formation I None
between I None
6BH4 I CHEMICAL
and I None
the I None
hormone I None
. I None
<eof> I None

<s> O None
This I None
direct I None
mechanism I None
of I None
alpha I GENE-Y
- O GENE-Y
MSH O GENE-Y
is I None
supported I None
by I None
the I None
presence I None
of I None
the I None
entire I None
POMC I GENE-Y
processing I None
system I None
in I None
the I None
melanosome I None
indicating I None
a I None
receptor I None
independent I None
control I None
of I None
eumelanogenesis I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
the I None
role I None
of I None
tyrosinase I GENE-Y
, I None
TRP I GENE-Y
- O GENE-Y
1 O GENE-Y
and I None
TRP2 I GENE-Y
is I None
discussed I None
in I None
association I None
with I None
oxidative I None
stress I None
specifically I None
related I None
to I None
hydrogen I CHEMICAL
peroxide O CHEMICAL
. I None
<eof> I None

<s> O None
These I None
recent I None
findings I None
are I None
based I None
on I None
detailed I None
investigations I None
of I None
the I None
depigmentation I None
disorder I None
vitiligo I None
and I None
Hermansky I None
- I None
Pudlak I None
syndrome I None
. I None
<eof> I None

<s> O None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
mediates I None
its I None
membrane I None
receptor I None
- I None
dependent I None
effects I None
on I None
protein I GENE-N
kinase O GENE-N
C O GENE-N
and I None
alkaline I GENE-N
phosphatase O GENE-N
via I None
phospholipase I GENE-N
A O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
and I None
cyclooxygenase I GENE-Y
- O GENE-Y
1 O GENE-Y
but I None
not I None
cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
in I None
growth I None
plate I None
chondrocytes I None
. I None
<eof> I None

<s> O None
Recent I None
studies I None
have I None
shown I None
that I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
mediates I None
its I None
effects I None
on I None
growth I None
plate I None
chondrocytes I None
via I None
membrane I None
receptors I None
. I None
<eof> I None

<s> O None
This I None
study I None
examined I None
the I None
roles I None
of I None
phospholipase I GENE-N
A O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
( I None
PLA I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
) I None
and I None
cyclooxygenase I GENE-N
( I None
Cox I GENE-N
) I None
in I None
the I None
mechanism I None
of I None
action I None
of I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
in I None
resting I None
zone I None
chondrocytes I None
in I None
order I None
to I None
determine I None
whether I None
the I None
activity I None
of I None
one I None
or I None
both I None
enzymes I None
provides I None
a I None
regulatory I None
checkpoint I None
in I None
the I None
signaling I None
pathway I None
resulting I None
in I None
increased I None
protein I GENE-N
kinase O GENE-N
C O GENE-N
( I None
PKC I GENE-N
) I None
activity I None
. I None
<eof> I None

<s> O None
We I None
also I None
determined I None
whether I None
constitutive I None
or I None
inducible I None
Cox I GENE-N
is I None
involved I None
. I None
<eof> I None

<s> O None
Cultures I None
were I None
incubated I None
with I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
for I None
90 I None
min I None
to I None
measure I None
PKC I GENE-N
or I None
for I None
24 I None
h I None
to I None
measure I None
physiological I None
responses I None
( I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
- O CHEMICAL
thymidine O CHEMICAL
incorporation I None
, I None
alkaline I GENE-N
phosphatase O GENE-N
- I None
specific I None
activity I None
, I None
[ I CHEMICAL
( O CHEMICAL
35 O CHEMICAL
) O CHEMICAL
S O CHEMICAL
] O CHEMICAL
- O CHEMICAL
sulfate O CHEMICAL
incorporation I None
) I None
. I None
<eof> I None

<s> O None
Based I None
on I None
RT I None
- I None
PCR I None
and I None
Northern I None
blot I None
analysis I None
, I None
resting I None
zone I None
chondrocytes I None
express I None
mRNAs I None
for I None
both I None
Cox I GENE-Y
- O GENE-Y
1 O GENE-Y
and I None
Cox I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
Levels I None
of I None
mRNA I None
for I None
both I None
proteins I None
were I None
unchanged I None
from I None
control I None
levels I None
after I None
a I None
24 I None
- I None
h I None
incubation I None
with I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
. I None
<eof> I None

<s> O None
To I None
examine I None
the I None
role I None
of I None
Cox I GENE-N
, I None
the I None
cultures I None
were I None
also I None
treated I None
with I None
resveratrol I CHEMICAL
( I None
a I None
specific I None
inhibitor I None
of I None
Cox I GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
, I None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
( I None
a I None
specific I None
inhibitor I None
of I None
Cox I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
, I None
or I None
indomethacin I CHEMICAL
( I None
a I None
general I None
Cox I GENE-N
inhibitor I None
) I None
. I None
<eof> I None

<s> O None
Cox I GENE-Y
- O GENE-Y
1 O GENE-Y
inhibition I None
resulted I None
in I None
effects I None
on I None
proliferation I None
, I None
differentiation I None
, I None
and I None
matrix I None
production I None
typical I None
of I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
inhibition I None
of I None
Cox I GENE-Y
- O GENE-Y
2 O GENE-Y
had I None
no I None
effect I None
, I None
indicating I None
that I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
exerts I None
its I None
effects I None
via I None
Cox I GENE-Y
- O GENE-Y
1 O GENE-Y
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
Cox I GENE-Y
- O GENE-Y
1 O GENE-Y
also I None
blocked I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
- I None
dependent I None
increases I None
in I None
PKC I GENE-N
. I None
<eof> I None

<s> O None
Activation I None
of I None
PLA I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
with I None
melittin I None
inhibited I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
- I None
dependent I None
stimulation I None
of I None
PKC I GENE-N
, I None
and I None
inhibition I None
of I None
PLA I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
with I None
quinacrine I CHEMICAL
stimulated I None
PKC I GENE-N
in I None
response I None
to I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
. I None
<eof> I None

<s> O None
Inclusion I None
of I None
resveratrol I CHEMICAL
reduced I None
the I None
melittin I None
- I None
dependent I None
inhibition I None
of I None
PLA I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
and I None
caused I None
an I None
increase I None
in I None
quinacrine I CHEMICAL
- I None
stimulated I None
PLA I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
activity I None
. I None
<eof> I None

<s> O None
Metabolism I None
of I None
arachidonic I CHEMICAL
acid O CHEMICAL
to I None
leukotrienes I CHEMICAL
is I None
not I None
involved I None
in I None
the I None
response I None
to I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
because I None
inhibition I None
of I None
lipoxygenase I GENE-N
had I None
no I None
effect I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
was I None
specific I None
because I None
24S I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
, I None
the I None
biologically I None
inactive I None
stereoisomer I None
, I None
failed I None
to I None
elicit I None
a I None
response I None
from I None
the I None
cells I None
. I None
<eof> I None

<s> O None
These I None
results I None
support I None
the I None
hypothesis I None
that I None
24R I CHEMICAL
, O CHEMICAL
25 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
OH O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
D O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
exerts I None
its I None
effects I None
via I None
more I None
than I None
one I None
signaling I None
pathway I None
and I None
that I None
these I None
pathways I None
are I None
interrelated I None
via I None
the I None
modulation I None
of I None
PLA I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
. I None
<eof> I None

<s> O None
PKC I GENE-N
regulation I None
may I None
occur I None
at I None
multiple I None
stages I None
in I None
the I None
signal I None
transduction I None
cascade I None
. I None
<eof> I None

<s> O None
Local I None
tolerance I None
, I None
pharmacokinetics I None
, I None
and I None
dynamics I None
of I None
ganirelix I CHEMICAL
( I None
Orgalutran I CHEMICAL
) I None
administration I None
by I None
Medi I None
- I None
Jector I None
compared I None
to I None
conventional I None
needle I None
injections I None
. I None
<eof> I None

<s> O None
The I None
feasibility I None
of I None
administering I None
a I None
relatively I None
high I None
dose I None
of I None
the I None
gonadotrophin I CHEMICAL
- O CHEMICAL
releasing O CHEMICAL
hormone O CHEMICAL
( I None
GnRH I CHEMICAL
) I None
antagonist I None
ganirelix I CHEMICAL
by I None
means I None
of I None
a I None
needle I None
- I None
free I None
injection I None
device I None
, I None
which I None
could I None
be I None
useful I None
in I None
the I None
long I None
- I None
term I None
treatment I None
of I None
sex I None
- I None
steroid I CHEMICAL
- I None
dependent I None
disorders I None
, I None
was I None
evaluated I None
in I None
a I None
randomized I None
, I None
crossover I None
study I None
in I None
16 I None
healthy I None
females I None
. I None
<eof> I None

<s> O None
Local I None
tolerance I None
and I None
pharmacokinetics I None
of I None
ganirelix I CHEMICAL
administered I None
by I None
MediJector I None
versus I None
conventional I None
needle I None
injections I None
were I None
compared I None
. I None
<eof> I None

<s> O None
Additionally I None
, I None
the I None
pharmacodynamic I None
effect I None
was I None
evaluated I None
. I None
<eof> I None

<s> O None
Two I None
milligrams I None
of I None
ganirelix I CHEMICAL
was I None
administered I None
s I None
. I None
c I None
. I None
once I None
daily I None
for I None
7 I None
days I None
by I None
Medi I None
- I None
Jector I None
or I None
conventional I None
needle I None
in I None
a I None
randomized I None
sequence I None
, I None
without I None
a I None
washout I None
period I None
. I None
<eof> I None

<s> O None
No I None
apparent I None
differences I None
in I None
local I None
tolerance I None
were I None
observed I None
. I None
<eof> I None

<s> O None
Most I None
injections I None
( I None
87 I None
. I None
5 I None
% I None
) I None
gave I None
either I None
no I None
or I None
only I None
a I None
mild I None
reaction I None
. I None
<eof> I None

<s> O None
Of I None
the I None
moderate I None
reactions I None
, I None
swelling I None
and I None
redness I None
were I None
reported I None
most I None
frequently I None
( I None
overall I None
4 I None
. I None
9 I None
and I None
8 I None
. I None
5 I None
% I None
per I None
injection I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
Administration I None
by I None
Medi I None
- I None
Jector I None
was I None
bioequivalent I None
to I None
conventional I None
needle I None
injection I None
with I None
respect I None
to I None
the I None
peak I None
concentration I None
and I None
area I None
under I None
the I None
curve I None
. I None
<eof> I None

<s> O None
A I None
profound I None
suppression I None
of I None
luteinizing I GENE-N
hormone O GENE-N
and I None
follicle I GENE-N
stimulating O GENE-N
hormone O GENE-N
was I None
observed I None
. I None
<eof> I None

<s> O None
Serum I None
oestradiol I CHEMICAL
and I None
progesterone I CHEMICAL
concentrations I None
were I None
relatively I None
low I None
prior I None
to I None
treatment I None
and I None
remained I None
low I None
during I None
the I None
entire I None
study I None
period I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
administration I None
of I None
a I None
relatively I None
high I None
dose I None
of I None
ganirelix I CHEMICAL
by I None
Medi I None
- I None
Jector I None
might I None
be I None
useful I None
for I None
long I None
- I None
term I None
treatment I None
of I None
sex I None
- I None
steroid I CHEMICAL
dependent I None
disorders I None
. I None
<eof> I None

<s> O None
Kinetics I None
of I None
inhibition I None
of I None
human I GENE-N
and O GENE-N
rat O GENE-N
dihydroorotate O GENE-N
dehydrogenase O GENE-N
by I None
atovaquone I CHEMICAL
, I None
lawsone I CHEMICAL
derivatives I None
, I None
brequinar I CHEMICAL
sodium O CHEMICAL
and I None
polyporic I CHEMICAL
acid O CHEMICAL
. I None
<eof> I None

<s> O None
Mitochondrially I None
- I None
bound I None
dihydroorotate I GENE-Y
dehydrogenase O GENE-Y
( I None
EC I GENE-Y
1 O GENE-Y
. O GENE-Y
3 O GENE-Y
. O GENE-Y
99 O GENE-Y
. O GENE-Y
11 O GENE-Y
) I None
catalyzes I None
the I None
fourth I None
sequential I None
step I None
in I None
the I None
de I None
novo I None
synthesis I None
of I None
uridine I CHEMICAL
monophosphate O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
enzyme I None
has I None
been I None
identified I None
as I None
or I None
surmised I None
to I None
be I None
the I None
pharmacological I None
target I None
for I None
isoxazol I CHEMICAL
, I None
triazine I CHEMICAL
, I None
cinchoninic I CHEMICAL
acid O CHEMICAL
and I None
( I CHEMICAL
naphtho O CHEMICAL
) O CHEMICAL
quinone O CHEMICAL
derivatives I None
, I None
which I None
exerted I None
antiproliferative I None
, I None
immunosuppressive I None
, I None
and I None
antiparasitic I None
effects I None
. I None
<eof> I None

<s> O None
Despite I None
this I None
broad I None
spectrum I None
of I None
biological I None
and I None
clinical I None
relevance I None
, I None
there I None
have I None
been I None
no I None
comparative I None
studies I None
on I None
drug I None
- I None
dihydroorotate I GENE-Y
dehydrogenase O GENE-Y
interactions I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
describe I None
a I None
study I None
of I None
the I None
inhibition I None
of I None
the I None
purified I None
recombinant I None
human I GENE-N
and O GENE-N
rat O GENE-N
dihydroorotate O GENE-N
dehydrogenase O GENE-N
by I None
ten I None
compounds I None
. I None
<eof> I None

<s> O None
1 I CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
Naphthoquinone O CHEMICAL
, I None
5 I CHEMICAL
, O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
hydroxy O CHEMICAL
- O CHEMICAL
naphthoquinone O CHEMICAL
and I None
the I None
natural I None
compounds I None
juglon I CHEMICAL
, I None
plumbagin I CHEMICAL
and I None
polyporic I CHEMICAL
acid O CHEMICAL
( I None
quinone I CHEMICAL
derivative I None
) I None
were I None
found I None
to I None
function I None
as I None
alternative I None
electron I None
acceptors I None
with I None
10 I None
- I None
30 I None
% I None
of I None
control I None
enzyme I None
activity I None
. I None
<eof> I None

<s> O None
The I None
human I None
and I None
rat I None
enzyme I None
activity I None
was I None
decreased I None
by I None
50 I None
% I None
by I None
the I None
natural I None
compound I None
lawsone I CHEMICAL
( I None
> I None
500 I None
and I None
49 I None
microM I None
, I None
respectively I None
) I None
and I None
by I None
the I None
derivatives I None
dichloroally I CHEMICAL
- O CHEMICAL
lawsone O CHEMICAL
( I None
67 I None
and I None
10 I None
nM I None
) I None
, I None
lapachol I CHEMICAL
( I None
618 I None
and I None
61 I None
nM I None
) I None
and I None
atovaquone I CHEMICAL
( I None
15 I None
microM I None
and I None
698 I None
nM I None
) I None
. I None
<eof> I None

<s> O None
With I None
respect I None
to I None
the I None
quinone I CHEMICAL
co I None
- I None
substrate I None
of I None
the I None
dihydroorotate I GENE-Y
dehydrogenase O GENE-Y
, I None
atovaquone I CHEMICAL
( I None
Kic I None
= I None
2 I None
. I None
7 I None
microM I None
) I None
and I None
dichloroally I CHEMICAL
- O CHEMICAL
lawsone O CHEMICAL
( I None
Kic I None
= I None
9 I None
. I None
8 I None
nM I None
) I None
were I None
shown I None
to I None
be I None
competitive I None
inhibitors I None
of I None
human I GENE-Y
dihydroorotate O GENE-Y
dehydrogenase O GENE-Y
. I None
<eof> I None

<s> O None
Atovaquone I CHEMICAL
( I None
Kic I None
= I None
60 I None
nM I None
) I None
was I None
also I None
acompetitive I None
inhibitor I None
of I None
the I None
rat I None
enzyme I None
. I None
<eof> I None

<s> O None
Dichloroally I CHEMICAL
] O CHEMICAL
- O CHEMICAL
lawsone O CHEMICAL
was I None
found I None
to I None
be I None
a I None
time I None
- I None
dependent I None
inhibitor I None
of I None
the I None
rat I None
enzyme I None
, I None
with I None
the I None
lowest I None
inhibition I None
constant I None
( I None
Ki I None
* I None
= I None
0 I None
. I None
77 I None
nM I None
) I None
determined I None
so I None
far I None
for I None
mammalian I GENE-N
dihydroorotate O GENE-N
dehydrogenases O GENE-N
. I None
<eof> I None

<s> O None
Another I None
inhibitor I None
, I None
brequinar I CHEMICAL
was I None
previously I None
reported I None
to I None
be I None
a I None
slow I None
- I None
binding I None
inhibitor I None
of I None
the I None
human I GENE-Y
dihydroorotate O GENE-Y
dehydrogenase O GENE-Y
[ I None
W I None
. I None
Knecht I None
, I None
M I None
. I None
Loffler I None
, I None
Species I None
- I None
related I None
inhibition I None
of I None
human I GENE-N
and O GENE-N
rat O GENE-N
dihyroorotate O GENE-N
dehydrogenase O GENE-N
by I None
immunosuppressive I None
isoxazol I CHEMICAL
and I None
cinchoninic I CHEMICAL
acid O CHEMICAL
derivatives I None
, I None
Biochem I None
. I None
Pharmacol I None
. I None
56 I None
( I None
1998 I None
) I None
1259 I None
- I None
1264 I None
] I None
. I None
<eof> I None

<s> O None
The I None
slow I None
binding I None
features I None
of I None
this I None
potent I None
inhibitor I None
( I None
Ki I None
* I None
= I None
1 I None
. I None
8 I None
nM I None
) I None
with I None
the I None
human I None
enzyme I None
, I None
were I None
verified I None
and I None
seen I None
to I None
be I None
one I None
of I None
the I None
reasons I None
for I None
the I None
narrow I None
therapeutic I None
window I None
( I None
efficacy I None
versus I None
toxicity I None
) I None
reported I None
from I None
clinical I None
trials I None
on I None
its I None
antiproliferative I None
and I None
immunosuppressive I None
action I None
. I None
<eof> I None

<s> O None
With I None
respect I None
to I None
the I None
substrate I None
dihydroorotate I CHEMICAL
, I None
atovaquone I CHEMICAL
was I None
an I None
uncompetitive I None
inhibitor I None
of I None
human I GENE-Y
dihydroorotate O GENE-Y
dehydrogenase O GENE-Y
( I None
Kiu I None
= I None
11 I None
. I None
6 I None
microM I None
) I None
and I None
a I None
non I None
- I None
competitive I None
inhibitor I None
of I None
the I None
rat I None
enzyme I None
( I None
Kiu I None
= I None
905 I None
/ I None
Kic I None
= I None
1 I None
, I None
012 I None
nM I None
) I None
. I None
<eof> I None

<s> O None
1 I None
. I None
5 I None
mM I None
polyporic I CHEMICAL
acid O CHEMICAL
, I None
a I None
natural I None
quinone I CHEMICAL
from I None
fungi I None
, I None
influenced I None
the I None
activity I None
of I None
the I None
human I None
enzyme I None
only I None
slightly I None
; I None
the I None
activity I None
of I None
the I None
rat I None
enzyme I None
was I None
decreased I None
by I None
30 I None
% I None
. I None
<eof> I None

<s> O None
[ I None
New I None
prospects I None
in I None
the I None
treatment I None
of I None
migraine I None
] I None
. I None
<eof> I None

<s> O None
The I None
options I None
for I None
migraine I None
treatment I None
have I None
increased I None
in I None
the I None
recent I None
years I None
and I None
will I None
expand I None
in I None
the I None
near I None
future I None
. I None
<eof> I None

<s> O None
In I None
this I None
work I None
both I None
recent I None
and I None
future I None
options I None
for I None
migraine I None
treatment I None
are I None
critically I None
reviewed I None
. I None
<eof> I None

<s> O None
Firstly I None
the I None
late I None
advances I None
in I None
the I None
symptomatic I None
treatment I None
of I None
migraine I None
, I None
including I None
the I None
new I None
5 I GENE-N
- O GENE-N
HT1B O GENE-N
/ O GENE-N
D O GENE-N
agonists I None
" I None
triptans I CHEMICAL
" I None
appeared I None
after I None
sumatriptan I CHEMICAL
, I None
are I None
reviewed I None
. I None
<eof> I None

<s> O None
Possible I None
alternative I None
, I None
such I None
as I None
selective I None
5 I GENE-Y
- O GENE-Y
HT1D O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT1F O GENE-Y
agonists I None
, I None
are I None
also I None
discussed I None
. I None
<eof> I None

<s> O None
In I None
the I None
second I None
part I None
of I None
this I None
manuscript I None
the I None
new I None
, I None
possible I None
options I None
for I None
the I None
preventive I None
treatment I None
of I None
migraine I None
comprising I None
" I None
antiepileptics I None
" I None
, I None
such I None
as I None
valproic I CHEMICAL
acid O CHEMICAL
, I None
gabapentin I CHEMICAL
and I None
topiramate I CHEMICAL
, I None
calcium I CHEMICAL
- I None
antagonists I None
, I None
such I None
as I None
cyclandelate I CHEMICAL
and I None
dotarizin I CHEMICAL
, I None
and I None
a I None
miscellany I None
, I None
including I None
riboflavin I CHEMICAL
, I None
are I None
analysed I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
possible I None
compounds I None
for I None
the I None
future I None
, I None
such I None
as I None
the I None
selective I None
inhibitors I None
of I None
neurokinin I GENE-N
receptors O GENE-N
or I None
drugs I None
acting I None
upon I None
neuronal I GENE-N
calcium O GENE-N
channels O GENE-N
, I None
are I None
commented I None
. I None
<eof> I None

<s> O None
From I None
this I None
review I None
we I None
conclude I None
that I None
while I None
there I None
have I None
been I None
relevant I None
advances I None
in I None
the I None
symptomatic I None
treatment I None
of I None
migraine I None
, I None
there I None
is I None
a I None
need I None
for I None
the I None
development I None
of I None
better I None
preventive I None
compounds I None
. I None
<eof> I None

<s> O None
Sodium I GENE-N
channel O GENE-N
blockers I None
identify I None
risk I None
for I None
sudden I None
death I None
in I None
patients I None
with I None
ST I None
- I None
segment I None
elevation I None
and I None
right I None
bundle I None
branch I None
block I None
but I None
structurally I None
normal I None
hearts I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
A I None
mutation I None
in I None
the I None
cardiac I GENE-N
sodium O GENE-N
channel O GENE-N
gene I None
( I None
SCN5A I GENE-Y
) I None
has I None
been I None
described I None
in I None
patients I None
with I None
the I None
syndrome I None
of I None
right I None
bundle I None
branch I None
block I None
, I None
ST I None
- I None
segment I None
elevation I None
in I None
leads I None
V1 I None
to I None
V3 I None
, I None
and I None
sudden I None
death I None
( I None
Brugada I None
syndrome I None
) I None
. I None
<eof> I None

<s> O None
These I None
electrocardiographic I None
manifestations I None
are I None
transient I None
in I None
many I None
patients I None
with I None
the I None
syndrome I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
examined I None
arrhythmic I None
risk I None
in I None
patients I None
with I None
overt I None
and I None
concealed I None
forms I None
of I None
the I None
disease I None
and I None
the I None
effectiveness I None
of I None
sodium I GENE-N
channel O GENE-N
blockers I None
to I None
unmask I None
the I None
syndrome I None
and I None
, I None
thus I None
, I None
identify I None
patients I None
at I None
risk I None
. I None
<eof> I None

<s> O None
METHODS I None
AND I None
RESULTS I None
: I None
The I None
effect I None
of I None
intravenous I None
ajmaline I CHEMICAL
( I None
1 I None
mg I None
/ I None
kg I None
) I None
, I None
procainamide I CHEMICAL
( I None
10 I None
mg I None
/ I None
kg I None
) I None
, I None
or I None
flecainide I CHEMICAL
( I None
2 I None
mg I None
/ I None
kg I None
) I None
on I None
the I None
ECG I None
was I None
studied I None
in I None
34 I None
patients I None
with I None
the I None
syndrome I None
and I None
transient I None
normalization I None
of I None
the I None
ECG I None
( I None
group I None
A I None
) I None
, I None
11 I None
members I None
of I None
3 I None
families I None
in I None
whom I None
a I None
SCN5A I GENE-Y
mutation I None
was I None
associated I None
with I None
the I None
syndrome I None
and I None
8 I None
members I None
in I None
whom I None
it I None
was I None
not I None
( I None
group I None
B I None
) I None
, I None
and I None
53 I None
control I None
subjects I None
( I None
group I None
C I None
) I None
. I None
<eof> I None

<s> O None
Ajmaline I CHEMICAL
, I None
procainamide I CHEMICAL
, I None
or I None
flecainide I CHEMICAL
administration I None
resulted I None
in I None
ST I None
- I None
segment I None
elevation I None
and I None
right I None
bundle I None
branch I None
block I None
in I None
all I None
patients I None
in I None
group I None
A I None
and I None
in I None
all I None
11 I None
patients I None
with I None
the I None
mutation I None
in I None
group I None
B I None
. I None
<eof> I None

<s> O None
A I None
similar I None
pattern I None
could I None
not I None
be I None
elicited I None
in I None
the I None
8 I None
patients I None
in I None
group I None
B I None
who I None
lacked I None
the I None
mutation I None
or I None
in I None
any I None
person I None
in I None
group I None
C I None
. I None
<eof> I None

<s> O None
The I None
follow I None
- I None
up I None
period I None
( I None
37 I None
+ I None
/ I None
- I None
33 I None
months I None
) I None
revealed I None
no I None
differences I None
in I None
the I None
incidence I None
of I None
arrhythmia I None
between I None
the I None
34 I None
patients I None
in I None
whom I None
the I None
phenotypic I None
manifestation I None
of I None
the I None
syndrome I None
was I None
transient I None
and I None
the I None
24 I None
patients I None
in I None
whom I None
it I None
was I None
persistent I None
( I None
log I None
- I None
rank I None
, I None
0 I None
. I None
639 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
The I None
data I None
demonstrated I None
a I None
similar I None
incidence I None
of I None
potentially I None
lethal I None
arrhythmias I None
in I None
patients I None
displaying I None
transient I None
versus I None
persistent I None
ST I None
- I None
segment I None
elevation I None
and I None
right I None
bundle I None
branch I None
block I None
, I None
as I None
well I None
as I None
the I None
effectiveness I None
of I None
sodium I GENE-N
channel O GENE-N
blockers I None
to I None
unmask I None
the I None
syndrome I None
and I None
, I None
thus I None
, I None
identify I None
patients I None
at I None
risk I None
. I None
<eof> I None

<s> O None
Determinants I None
of I None
voltage I None
- I None
dependent I None
inactivation I None
affect I None
Mibefradil I CHEMICAL
block I None
of I None
calcium I GENE-N
channels O GENE-N
. I None
<eof> I None

<s> O None
The I None
voltage I GENE-N
gated O GENE-N
calcium O GENE-N
channel O GENE-N
family I None
is I None
a I None
major I None
target I None
for I None
a I None
range I None
of I None
therapeutic I None
drugs I None
. I None
<eof> I None

<s> O None
Mibefradil I CHEMICAL
( I None
Ro I CHEMICAL
40 O CHEMICAL
- O CHEMICAL
5967 O CHEMICAL
) I None
belongs I None
to I None
a I None
new I None
chemical I None
class I None
of I None
these I None
molecules I None
which I None
differs I None
from I None
other I None
Ca2 I CHEMICAL
+ O CHEMICAL
antagonists I None
by I None
its I None
ability I None
to I None
potently I None
block I None
T I GENE-N
- O GENE-N
type O GENE-N
Ca2 O GENE-N
+ O GENE-N
channels O GENE-N
. I None
<eof> I None

<s> O None
However I None
, I None
this I None
molecule I None
has I None
also I None
been I None
shown I None
to I None
inhibit I None
other I None
Ca2 I GENE-N
+ O GENE-N
channel O GENE-N
subtypes I None
. I None
<eof> I None

<s> O None
To I None
further I None
analyze I None
the I None
mechanism I None
governing I None
the I None
Ca2 I GENE-N
+ O GENE-N
channel O GENE-N
- I None
Mibefradil I CHEMICAL
interaction I None
, I None
we I None
examined I None
the I None
effect I None
of I None
Mibefradil I CHEMICAL
on I None
various I None
recombinant I None
Ca2 I GENE-N
+ O GENE-N
channels O GENE-N
expressed I None
in I None
mammalian I None
cells I None
from I None
their I None
cloned I None
cDNAs I None
, I None
using I None
Ca2 I CHEMICAL
+ O CHEMICAL
as I None
the I None
permeant I None
ion I None
at I None
physiological I None
concentration I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
alpha1A I None
, I None
alpha1C I None
, I None
and I None
alpha1E I None
in I None
tsA I None
201 I None
cells I None
resulted I None
in I None
Ca2 I CHEMICAL
+ O CHEMICAL
currents I None
with I None
functional I None
characteristics I None
closely I None
related I None
to I None
those I None
of I None
their I None
native I None
counterparts I None
. I None
<eof> I None

<s> O None
Mibefradil I CHEMICAL
blocked I None
alpha1A I None
and I None
alpha1E I None
with I None
a I None
Kd I None
comparable I None
to I None
that I None
reported I None
for I None
T I GENE-N
- O GENE-N
type O GENE-N
channels O GENE-N
, I None
but I None
had I None
a I None
lower I None
affinity I None
( I None
approximately I None
30 I None
- I None
fold I None
) I None
for I None
alpha1C I None
. I None
<eof> I None

<s> O None
For I None
each I None
channel I None
, I None
inhibition I None
by I None
Mibefradil I CHEMICAL
was I None
consistent I None
with I None
high I None
- I None
affinity I None
binding I None
to I None
the I None
inactivated I None
state I None
. I None
<eof> I None

<s> O None
Modulation I None
of I None
the I None
voltage I None
- I None
dependent I None
inactivation I None
properties I None
by I None
the I None
nature I None
of I None
the I None
coexpressed I None
beta I None
subunit I None
or I None
the I None
alpha1 I None
splice I None
variant I None
altered I None
block I None
at I None
the I None
Mibefradil I CHEMICAL
receptor I None
site I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
we I None
conclude I None
that I None
the I None
tissue I None
and I None
sub I None
- I None
cellular I None
localization I None
of I None
calcium I GENE-N
channel O GENE-N
subunits I None
as I None
well I None
as I None
their I None
specific I None
associations I None
are I None
essential I None
parameters I None
to I None
understand I None
the I None
in I None
vivo I None
effects I None
of I None
Mibefradil I CHEMICAL
. I None
<eof> I None

<s> O None
Streptokinase I GENE-N
- I None
induced I None
platelet I None
activation I None
involves I None
antistreptokinase I None
antibodies I None
and I None
cleavage I None
of I None
protease I GENE-Y
- O GENE-Y
activated O GENE-Y
receptor O GENE-Y
- O GENE-Y
1 O GENE-Y
. I None
<eof> I None

<s> O None
Streptokinase I GENE-N
activates I None
platelets I None
, I None
limiting I None
its I None
effectiveness I None
as I None
a I None
thrombolytic I None
agent I None
. I None
<eof> I None

<s> O None
The I None
role I None
of I None
antistreptokinase I None
antibodies I None
and I None
proteases I GENE-N
in I None
streptokinase I GENE-N
- I None
induced I None
platelet I None
activation I None
was I None
investigated I None
. I None
<eof> I None

<s> O None
Streptokinase I GENE-N
induced I None
localization I None
of I None
human I GENE-N
IgG O GENE-N
to I None
the I None
platelet I None
surface I None
, I None
platelet I None
aggregation I None
, I None
and I None
thromboxane I None
A I None
( I None
2 I None
) I None
production I None
. I None
<eof> I None

<s> O None
These I None
effects I None
were I None
inhibited I None
by I None
a I None
monoclonal I None
antibody I None
to I None
the I None
platelet I None
Fc I GENE-Y
receptor O GENE-Y
, O GENE-Y
IV O GENE-Y
. O GENE-Y
3 O GENE-Y
. I None
<eof> I None

<s> O None
The I None
platelet I None
response I None
to I None
streptokinase I GENE-N
was I None
also I None
blocked I None
by I None
an I None
antibody I None
directed I None
against I None
the I None
cleavage I None
site I None
of I None
the I None
platelet I GENE-Y
thrombin O GENE-Y
receptor O GENE-Y
, I None
protease I GENE-Y
- O GENE-Y
activated O GENE-Y
receptor O GENE-Y
- O GENE-Y
1 O GENE-Y
( I None
PAR I GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
, I None
but I None
not I None
by I None
hirudin I None
or I None
an I None
active I None
site I None
thrombin I GENE-Y
inhibitor I None
, I None
Ro46 I CHEMICAL
- O CHEMICAL
6240 O CHEMICAL
. I None
<eof> I None

<s> O None
In I None
plasma I None
depleted I None
of I None
plasminogen I GENE-Y
, I None
exogenous I None
wild I None
- I None
type I None
plasminogen I GENE-Y
, I None
but I None
not I None
an I None
inactive I None
mutant I None
protein I None
, I None
S I GENE-N
( O GENE-N
741 O GENE-N
) O GENE-N
A O GENE-N
plasminogen I GENE-Y
, I None
supported I None
platelet I None
aggregation I None
, I None
suggesting I None
that I None
the I None
protease I GENE-N
cleaving I None
PAR I GENE-Y
- O GENE-Y
1 O GENE-Y
was I None
streptokinase I GENE-N
- I None
plasminogen I GENE-Y
. I None
<eof> I None

<s> O None
Streptokinase I GENE-N
- I None
plasminogen I GENE-Y
cleaved I None
a I None
synthetic I None
peptide I None
corresponding I None
to I None
PAR I GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
resulting I None
in I None
generation I None
of I None
PAR I GENE-Y
- O GENE-Y
1 O GENE-Y
tethered I None
ligand I None
sequence I None
and I None
selectively I None
reduced I None
binding I None
of I None
a I None
cleavage I None
- I None
sensitive I None
PAR I GENE-Y
- O GENE-Y
1 O GENE-Y
antibody I None
in I None
intact I None
cells I None
. I None
<eof> I None

<s> O None
A I None
combination I None
of I None
streptokinase I GENE-N
, I None
plasminogen I GENE-Y
, I None
and I None
antistreptokinase I None
antibodies I None
activated I None
human I None
erythroleukemic I None
cells I None
and I None
was I None
inhibited I None
by I None
pretreatment I None
with I None
IV I GENE-Y
. O GENE-Y
3 O GENE-Y
or I None
pretreating I None
the I None
cells I None
with I None
the I None
PAR I GENE-Y
- O GENE-Y
1 O GENE-Y
agonist I None
SFLLRN I None
, I None
suggesting I None
Fc I GENE-N
receptor O GENE-N
and I None
PAR I GENE-Y
- O GENE-Y
1 O GENE-Y
interactions I None
are I None
necessary I None
for I None
cell I None
activation I None
in I None
this I None
system I None
also I None
. I None
<eof> I None

<s> O None
Streptokinase I GENE-N
- I None
induced I None
platelet I None
activation I None
is I None
dependent I None
on I None
both I None
antistreptokinase I None
- I None
Fc I GENE-N
receptor O GENE-N
interactions I None
and I None
cleavage I None
of I None
PAR I GENE-Y
- O GENE-Y
1 O GENE-Y
. I None
<eof> I None

<s> O None
( I None
Blood I None
. I None
2000 I None
; I None
95 I None
: I None
1301 I None
- I None
1308 I None
) I None
<eof> I None

<s> O None
Polysulfated I None
heparinoids I None
selectively I None
inactivate I None
heparin I None
- I None
binding I None
angiogenesis I None
factors I None
. I None
<eof> I None

<s> O None
Angiogenesis I None
is I None
a I None
prerequisite I None
for I None
tumor I None
expansion I None
and I None
metastasis I None
. I None
<eof> I None

<s> O None
The I None
angiogenic I None
potential I None
of I None
the I None
heparin I GENE-N
- O GENE-N
binding O GENE-N
growth O GENE-N
factors O GENE-N
acidic I GENE-Y
fibroblast O GENE-Y
growth O GENE-Y
factor O GENE-Y
( I None
FGF I GENE-N
) I None
and I None
basic I GENE-Y
FGF O GENE-Y
has I None
been I None
demonstrated I None
in I None
various I None
publications I None
. I None
<eof> I None

<s> O None
We I None
studied I None
the I None
inhibitory I None
effects I None
of I None
suramin I CHEMICAL
and I None
the I None
polysulfated I None
heparinoids I None
pentosan I None
polysulfate I None
, I None
dextran I None
sulfate I CHEMICAL
, I None
and I None
fucoidan I None
on I None
the I None
action I None
of I None
FGF I GENE-N
. I None
<eof> I None

<s> O None
As I None
an I None
experimental I None
model I None
, I None
we I None
used I None
the I None
adrenal I None
cancer I None
cell I None
line I None
SW I None
13 I None
, I None
whose I None
anchorage I None
- I None
independent I None
growth I None
depends I None
on I None
the I None
presence I None
of I None
FGF I GENE-N
. I None
<eof> I None

<s> O None
The I None
polysulfated I None
heparinoids I None
inhibited I None
FGF I GENE-N
- I None
induced I None
growth I None
and I None
binding I None
to I None
the I None
receptor I None
at I None
an I None
IC50 I None
of I None
0 I None
. I None
5 I None
- I None
3 I None
micrograms I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
Suramin I CHEMICAL
inhibited I None
FGF I GENE-N
at I None
an I None
IC50 I None
of I None
100 I None
micrograms I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
The I None
polysulfated I None
heparinoids I None
exerted I None
no I None
effect I None
on I None
IGF I GENE-Y
- O GENE-Y
1 O GENE-Y
or I None
TGF I GENE-Y
alpha O GENE-Y
- I None
related I None
growth I None
. I None
<eof> I None

<s> O None
Suramin I CHEMICAL
inhibited I None
the I None
anchorage I None
- I None
independent I None
growth I None
induced I None
by I None
IGF I GENE-Y
- O GENE-Y
1 O GENE-Y
or I None
TGF I GENE-Y
alpha O GENE-Y
only I None
at I None
an I None
IC50 I None
of I None
100 I None
micrograms I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
Our I None
results I None
indicate I None
that I None
suramin I CHEMICAL
inhibits I None
growth I None
factors I None
in I None
a I None
nonselective I None
way I None
. I None
<eof> I None

<s> O None
By I None
contrast I None
, I None
polysulfated I None
heparinoids I None
exert I None
a I None
selective I None
inhibitory I None
effect I None
on I None
heparin I None
binding I None
angiogenesis I None
factors I None
at I None
an I None
IC50 I None
, I None
which I None
is I None
100 I None
times I None
below I None
the I None
IC50 I None
of I None
suramin I CHEMICAL
. I None
<eof> I None

<s> O None
Therefore I None
, I None
the I None
administration I None
of I None
polysulfated I None
heparinoids I None
might I None
become I None
a I None
novel I None
approach I None
to I None
tumor I None
therapy I None
based I None
on I None
blocking I None
angiogenesis I None
. I None
<eof> I None

<s> O None
Use I None
of I None
tranexamic I CHEMICAL
acid O CHEMICAL
for I None
an I None
effective I None
blood I None
conservation I None
strategy I None
after I None
total I None
knee I None
arthroplasty I None
. I None
<eof> I None

<s> O None
We I None
have I None
investigated I None
the I None
effect I None
of I None
treatment I None
with I None
tranexamic I CHEMICAL
acid O CHEMICAL
, I None
an I None
inhibitor I None
of I None
fibrinolysis I None
, I None
on I None
blood I None
loss I None
, I None
blood I None
transfusion I None
requirements I None
and I None
blood I None
coagulation I None
in I None
a I None
randomized I None
, I None
double I None
- I None
blind I None
, I None
placebo I None
- I None
controlled I None
study I None
of I None
42 I None
patients I None
after I None
total I None
knee I None
arthroplasty I None
. I None
<eof> I None

<s> O None
Tranexamic I CHEMICAL
acid O CHEMICAL
15 I None
mg I None
kg I None
- I None
1 I None
( I None
n I None
= I None
21 I None
) I None
or I None
an I None
equivalent I None
volume I None
of I None
normal I None
saline I None
( I None
n I None
= I None
21 I None
) I None
was I None
given I None
30 I None
min I None
before I None
surgery I None
and I None
subsequently I None
every I None
8 I None
h I None
for I None
3 I None
days I None
. I None
<eof> I None

<s> O None
Coagulation I None
and I None
fibrinolysis I None
values I None
, I None
blood I None
loss I None
and I None
blood I None
units I None
administered I None
were I None
measured I None
before I None
administration I None
of I None
tranexamic I CHEMICAL
acid O CHEMICAL
, I None
8 I None
h I None
after I None
the I None
end I None
of I None
surgery I None
and I None
at I None
24 I None
and I None
72 I None
h I None
after I None
operation I None
. I None
<eof> I None

<s> O None
Coagulation I None
profile I None
was I None
examined I None
( I None
bleeding I None
time I None
, I None
platelet I None
count I None
, I None
prothrombin I GENE-Y
time I None
( I None
PT I None
) I None
, I None
activated I None
partial I None
thromboplastin I GENE-Y
time I None
( I None
aPTT I None
) I None
, I None
plasminogen I GENE-Y
, I None
beta I GENE-Y
- O GENE-Y
thromboglobulin O GENE-Y
and I None
fibrinogen I GENE-N
) I None
. I None
<eof> I None

<s> O None
Fibrinolysis I None
was I None
evaluated I None
by I None
measurement I None
of I None
concentrations I None
of I None
D I None
- I None
dimer I None
and I None
fibrinogen I GENE-N
degradation O GENE-N
products O GENE-N
( I None
FDP I GENE-N
) I None
. I None
<eof> I None

<s> O None
Total I None
blood I None
loss I None
in I None
the I None
tranexamic I CHEMICAL
acid O CHEMICAL
group I None
was I None
678 I None
( I None
SD I None
352 I None
) I None
ml I None
compared I None
with I None
1419 I None
( I None
607 I None
) I None
ml I None
in I None
the I None
control I None
group I None
( I None
P I None
< I None
0 I None
. I None
001 I None
) I None
, I None
and I None
occurred I None
primarily I None
during I None
the I None
first I None
24 I None
h I None
after I None
surgery I None
. I None
<eof> I None

<s> O None
Thirteen I None
patients I None
received I None
1 I None
- I None
5 I None
u I None
. I None
of I None
packed I None
red I None
blood I None
cells I None
in I None
the I None
control I None
group I None
compared I None
with I None
two I None
patients I None
in I None
the I None
tranexamic I CHEMICAL
acid O CHEMICAL
group I None
, I None
who I None
received I None
3 I None
u I None
. I None
<eof> I None

<s> O None
( I None
P I None
< I None
0 I None
. I None
001 I None
) I None
. I None
<eof> I None

<s> O None
Postoperative I None
packed I None
cell I None
volume I None
values I None
were I None
higher I None
in I None
the I None
tranexamic I CHEMICAL
acid O CHEMICAL
group I None
despite I None
fewer I None
blood I None
transfusions I None
. I None
<eof> I None

<s> O None
Postoperative I None
concentrations I None
of I None
plasminogen I GENE-Y
were I None
decreased I None
significantly I None
in I None
the I None
tranexamic I CHEMICAL
acid O CHEMICAL
group I None
( I None
P I None
< I None
0 I None
. I None
001 I None
) I None
. I None
<eof> I None

<s> O None
Platelet I None
count I None
, I None
PT I None
, I None
aPTT I None
, I None
bleeding I None
time I None
, I None
beta I GENE-Y
- O GENE-Y
thromboglobulin O GENE-Y
, I None
fibrinogen I GENE-N
and I None
FDP I GENE-N
concentrations I None
did I None
not I None
differ I None
between I None
groups I None
, I None
but I None
D I None
- I None
dimer I None
concentrations I None
were I None
increased I None
in I None
the I None
control I None
group I None
. I None
<eof> I None

<s> O None
Thromboembolic I None
complications I None
occurred I None
in I None
two I None
patients I None
in I None
the I None
control I None
group I None
compared I None
with I None
none I None
in I None
the I None
tranexamic I CHEMICAL
acid O CHEMICAL
group I None
. I None
<eof> I None

<s> O None
Nitric I GENE-N
oxide O GENE-N
synthase O GENE-N
expression I None
in I None
the I None
opossum I None
superior I None
colliculus I None
: I None
a I None
histochemical I None
, I None
immunohistochemical I None
and I None
biochemical I None
study I None
. I None
<eof> I None

<s> O None
The I None
expression I None
of I None
neuronal I GENE-N
nitric O GENE-N
oxide O GENE-N
synthase O GENE-N
( I None
nNOS I GENE-N
) I None
in I None
the I None
superior I None
colliculus I None
( I None
SC I None
) I None
of I None
the I None
opossum I None
Didelphis I None
marsupialis I None
was I None
studied I None
by I None
NADPH I GENE-N
diaphorase O GENE-N
( I None
NADPH I GENE-N
- O GENE-N
d O GENE-N
) I None
histochemistry I None
and I None
nNOS I GENE-N
immunohistochemistry I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
the I None
activity I None
of I None
nNOS I GENE-Y
was I None
quantified I None
by I None
measurement I None
of I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
- O CHEMICAL
L O CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
conversion I None
to I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
- O CHEMICAL
L O CHEMICAL
- O CHEMICAL
citrulline O CHEMICAL
in I None
tissue I None
extracts I None
from I None
SC I None
superficial I None
layers I None
in I None
opossums I None
and I None
rats I None
. I None
<eof> I None

<s> O None
Our I None
results I None
show I None
that I None
the I None
number I None
of I None
NADPH I GENE-N
- O GENE-N
d O GENE-N
stained I None
cells I None
was I None
small I None
and I None
virtually I None
identical I None
in I None
stratum I None
opticum I None
( I None
SO I None
) I None
and I None
stratum I None
griseum I None
superficiale I None
( I None
SGS I None
) I None
and I None
their I None
staining I None
was I None
very I None
light I None
, I None
particularly I None
in I None
SGS I None
. I None
<eof> I None

<s> O None
Neuropil I None
staining I None
was I None
heavier I None
in I None
the I None
stratum I None
zonale I None
( I None
SZ I None
) I None
than I None
in I None
SGS I None
or I None
SO I None
. I None
<eof> I None

<s> O None
The I None
intermediate I None
and I None
deep I None
layers I None
contained I None
heavily I None
stained I None
cells I None
and I None
moderate I None
neuropil I None
staining I None
. I None
<eof> I None

<s> O None
Surprisingly I None
, I None
nNOS I GENE-N
- I None
immunoreactive I None
cells I None
were I None
far I None
more I None
numerous I None
than I None
NADPH I GENE-N
- O GENE-N
d O GENE-N
+ I None
cells I None
in I None
every I None
layer I None
. I None
<eof> I None

<s> O None
The I None
production I None
of I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
- O CHEMICAL
L O CHEMICAL
- O CHEMICAL
citrulline O CHEMICAL
from I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
- O CHEMICAL
L O CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
in I None
tissue I None
extracts I None
enriched I None
in I None
superficial I None
layers I None
indicated I None
that I None
nNOS I GENE-N
specific I None
activity I None
is I None
as I None
high I None
in I None
the I None
opossum I None
as I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Our I None
results I None
suggest I None
that I None
the I None
location I None
of I None
nNOS I GENE-N
- I None
expressing I None
neurons I None
in I None
retino I None
- I None
receptive I None
layers I None
may I None
be I None
related I None
to I None
inter I None
- I None
specific I None
differences I None
in I None
the I None
processing I None
of I None
visual I None
information I None
. I None
<eof> I None

<s> O None
Correlations I None
between I None
serotonin I CHEMICAL
level I None
and I None
single I None
- I None
cell I None
firing I None
in I None
the I None
rat I None
' I None
s I None
nucleus I None
raphe I None
magnus I None
. I None
<eof> I None

<s> O None
The I None
relation I None
between I None
serotonin I CHEMICAL
release I None
and I None
electrical I None
activity I None
was I None
examined I None
in I None
the I None
nucleus I None
raphe I None
magnus I None
of I None
rats I None
anesthetized I None
with I None
pentobarbital I CHEMICAL
. I None
<eof> I None

<s> O None
Serotonin I CHEMICAL
levels I None
were I None
monitored I None
through I None
a I None
carbon I CHEMICAL
- I None
fiber I None
microelectrode I None
by I None
fast I None
cyclic I None
voltammetry I None
( I None
usually I None
at I None
1 I None
Hz I None
) I None
. I None
<eof> I None

<s> O None
Single I None
- I None
cell I None
firing I None
was I None
recorded I None
through I None
the I None
same I None
microelectrode I None
, I None
except I None
during I None
the I None
voltammetry I None
waveform I None
and I None
associated I None
electrical I None
artifact I None
( I None
totaling I None
about I None
30 I None
ms I None
) I None
. I None
<eof> I None

<s> O None
Multi I None
- I None
barrel I None
micropipettes I None
incorporating I None
the I None
voltammetry I None
electrode I None
were I None
used I None
for I None
iontophoresis I None
of I None
drugs I None
. I None
<eof> I None

<s> O None
Cells I None
were I None
inhibited I None
, I None
excited I None
or I None
unaffected I None
by I None
noxious I None
mechanical I None
skin I None
stimulation I None
. I None
<eof> I None

<s> O None
These I None
were I None
respectively I None
designated I None
as I None
off I None
( I None
M I None
) I None
cells I None
, I None
on I None
( I None
M I None
) I None
cells I None
and I None
neutral I None
( I None
M I None
) I None
cells I None
, I None
M I None
denoting I None
mechanical I None
. I None
<eof> I None

<s> O None
During I None
3 I None
min I None
of I None
pinching I None
, I None
serotonin I CHEMICAL
slowly I None
rose I None
near I None
seven I None
of I None
14 I None
on I None
( I None
M I None
) I None
cells I None
and I None
26 I None
of I None
46 I None
off I None
( I None
M I None
) I None
cells I None
; I None
it I None
fell I None
near I None
two I None
off I None
( I None
M I None
) I None
cells I None
; I None
it I None
was I None
unchanged I None
near I None
all I None
other I None
cells I None
, I None
including I None
six I None
neutral I None
( I None
M I None
) I None
cells I None
. I None
<eof> I None

<s> O None
On I None
a I None
finer I None
spatiotemporal I None
scale I None
, I None
near I None
four I None
of I None
seven I None
on I None
( I None
M I None
) I None
cells I None
, I None
10 I None
of I None
14 I None
off I None
( I None
M I None
) I None
cells I None
and I None
0 I None
of I None
four I None
neutral I None
( I None
M I None
) I None
cells I None
, I None
average I None
serotonin I CHEMICAL
levels I None
fell I None
significantly I None
within I None
+ I None
/ I None
- I None
100 I None
ms I None
of I None
spontaneous I None
spikes I None
. I None
<eof> I None

<s> O None
Lower I None
serotonin I CHEMICAL
may I None
have I None
caused I None
the I None
higher I None
spike I None
probability I None
; I None
the I None
converse I None
is I None
theoretically I None
unlikely I None
, I None
since I None
delays I None
between I None
release I None
and I None
detection I None
are I None
estimated I None
to I None
exceed I None
100 I None
ms I None
. I None
<eof> I None

<s> O None
Increased I None
serotonin I CHEMICAL
and I None
decreased I None
firing I None
were I None
always I None
seen I None
following I None
iontophoresis I None
or I None
intravenous I None
injection I None
( I None
1 I None
mg I None
/ I None
kg I None
) I None
of I None
the I None
serotonin I CHEMICAL
re I None
- I None
uptake I None
inhibitor I None
clomipramine I CHEMICAL
( I None
n I None
= I None
7 I None
) I None
. I None
<eof> I None

<s> O None
Iontophoresis I None
of I None
+ I CHEMICAL
/ O CHEMICAL
- O CHEMICAL
propranolol O CHEMICAL
, I None
whose I None
serotonergic I None
actions I None
include I None
antagonism I None
and I None
partial I None
agonism I None
at I None
5 I GENE-N
- O GENE-N
HT1 O GENE-N
receptors I None
, I None
also I None
increased I None
serotonin I CHEMICAL
and I None
decreased I None
firing I None
( I None
n I None
= I None
4 I None
) I None
. I None
<eof> I None

<s> O None
Methiothepin I CHEMICAL
( I None
intravenous I None
, I None
1 I None
mg I None
/ I None
kg I None
) I None
, I None
whose I None
serotonergic I None
actions I None
include I None
5 I GENE-N
- O GENE-N
HT1 O GENE-N
and I None
5 I GENE-N
- O GENE-N
HT2 O GENE-N
antagonism I None
, I None
typically I None
raised I None
serotonin I CHEMICAL
levels I None
( I None
four I None
of I None
five I None
cells I None
) I None
and I None
always I None
blocked I None
inhibition I None
by I None
clomipramine I CHEMICAL
( I None
n I None
= I None
3 I None
) I None
. I None
<eof> I None

<s> O None
Iontophoresis I None
of I None
glutamate I CHEMICAL
always I None
lowered I None
serotonin I CHEMICAL
and I None
increased I None
firing I None
( I None
n I None
= I None
4 I None
) I None
. I None
<eof> I None

<s> O None
Since I None
serotonin I CHEMICAL
levels I None
and I None
firing I None
were I None
usually I None
inversely I None
correlated I None
, I None
except I None
near I None
on I None
( I None
M I None
) I None
cells I None
during I None
pinch I None
, I None
we I None
propose I None
that I None
serotonin I CHEMICAL
is I None
released I None
from I None
terminals I None
of I None
incoming I None
nociceptive I None
afferents I None
. I None
<eof> I None

<s> O None
Prior I None
neuroanatomical I None
knowledge I None
favors I None
a I None
midbrain I None
origin I None
for I None
these I None
afferents I None
, I None
while I None
some I None
of I None
the I None
drug I None
findings I None
suggest I None
that I None
their I None
terminals I None
possess I None
inhibitory I None
serotonergic I None
autoreceptors I None
, I None
possibly I None
of I None
5 I GENE-Y
- O GENE-Y
HT1b O GENE-Y
subtype I None
. I None
<eof> I None

<s> O None
The I None
released I None
serotonin I CHEMICAL
could I None
contribute I None
to I None
the I None
inhibition I None
of I None
off I None
( I None
M I None
) I None
cells I None
and I None
excitation I None
of I None
on I None
( I None
M I None
) I None
cells I None
by I None
noxious I None
stimulation I None
, I None
since I None
inhibitory I None
5 I GENE-Y
- O GENE-Y
HT1a O GENE-Y
receptors I None
and I None
excitatory I None
5 I GENE-N
- O GENE-N
HT2 O GENE-N
receptors I None
, I None
respectively I None
, I None
have I None
previously I None
been I None
shown I None
to I None
dominate I None
their I None
serotonergic I None
responses I None
. I None
<eof> I None

<s> O None
Abnormal I None
fatty I CHEMICAL
acid O CHEMICAL
pattern I None
in I None
rheumatoid I None
arthritis I None
. I None
<eof> I None

<s> O None
A I None
rationale I None
for I None
treatment I None
with I None
marine I None
and I None
botanical I None
lipids I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
To I None
assess I None
the I None
fatty I CHEMICAL
acid O CHEMICAL
pattern I None
in I None
plasma I None
and I None
synovial I None
fluid I None
( I None
SF I None
) I None
in I None
rheumatoid I None
arthritis I None
( I None
RA I None
) I None
and I None
to I None
determine I None
clinical I None
factors I None
related I None
to I None
possible I None
abnormalities I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Thirty I None
- I None
nine I None
patients I None
with I None
RA I None
were I None
included I None
. I None
<eof> I None

<s> O None
SF I None
samples I None
were I None
obtained I None
from I None
9 I None
patients I None
. I None
<eof> I None

<s> O None
Disease I None
activity I None
was I None
assessed I None
using I None
the I None
Ritchie I None
Articular I None
Index I None
and I None
erythrocyte I None
sedimentation I None
rate I None
. I None
<eof> I None

<s> O None
Fatty I CHEMICAL
acids O CHEMICAL
were I None
assayed I None
with I None
gas I None
liquid I None
chromatography I None
. I None
<eof> I None

<s> O None
RESULT I None
: I None
Decreased I None
levels I None
of I None
eicosapentaenoic I CHEMICAL
acid O CHEMICAL
( I None
p I None
< I None
0 I None
. I None
0001 I None
) I None
and I None
total I None
n3 I CHEMICAL
polyunsaturated O CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
( I None
p I None
< I None
0 I None
. I None
05 I None
) I None
were I None
observed I None
in I None
plasma I None
and I None
in I None
joint I None
fluid I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
An I None
increase I None
of I None
the I None
substrates I None
of I None
delta I GENE-Y
- O GENE-Y
5 O GENE-Y
- O GENE-Y
desaturase O GENE-Y
( I None
C20 I None
: I None
3n6 I None
and I None
C20 I None
: I None
2n6 I None
) I None
and I None
decrease I None
of I None
their I None
products I None
( I None
C20 I None
: I None
4n6 I None
and I None
C22 I None
: I None
4n6 I None
) I None
was I None
observed I None
in I None
plasma I None
total I None
lipids I None
and I None
phospholipids I None
. I None
<eof> I None

<s> O None
The I None
long I None
chain I None
mono I CHEMICAL
- O CHEMICAL
unsaturated O CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
( I None
C20 I None
: I None
1n9 I None
, I None
C22 I None
: I None
1n9 I None
, I None
C24 I None
: I None
ln9 I None
) I None
were I None
increased I None
in I None
the I None
joint I None
fluid I None
and I None
in I None
plasma I None
phospholipids I None
. I None
<eof> I None

<s> O None
Patients I None
with I None
active I None
disease I None
showed I None
a I None
mild I None
decrease I None
of I None
several I None
saturated I CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
, I None
n3 I CHEMICAL
, O CHEMICAL
and O CHEMICAL
n6 O CHEMICAL
polyunsaturated O CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
. I None
<eof> I None

<s> O None
Minor I None
abnormalities I None
or I None
no I None
changes I None
in I None
fatty I CHEMICAL
acid O CHEMICAL
profile I None
were I None
found I None
related I None
to I None
use I None
of I None
steroids I CHEMICAL
, I None
nonsteroidal I None
antiinflammatory I None
drugs I None
, I None
and I None
gold I None
salts I None
, I None
or I None
malnutrition I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
The I None
fatty I CHEMICAL
acid O CHEMICAL
pattern I None
found I None
in I None
RA I None
( I None
decreased I None
levels I None
of I None
n3 I None
polyunsaturated I CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
) I None
may I None
explain I None
the I None
beneficial I None
effect I None
of I None
fish I None
oil I None
. I None
<eof> I None

<s> O None
Changes I None
in I None
n6 I CHEMICAL
polyunsaturated O CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
suggest I None
that I None
delta I None
- I None
5 I None
desaturation I None
is I None
decreased I None
and I None
this I None
might I None
facilitate I None
the I None
antiinflammatory I None
effect I None
of I None
botanical I None
lipids I None
in I None
RA I None
. I None
<eof> I None

<s> O None
Selective I None
inhibition I None
of I None
monoamine I GENE-N
neurotransmitter O GENE-N
transporters O GENE-N
by I None
synthetic I None
local I None
anesthetics I None
. I None
<eof> I None

<s> O None
Synthetic I None
local I None
anesthetics I None
( I None
LAs I None
) I None
have I None
been I None
found I None
to I None
have I None
cocaine I CHEMICAL
- I None
like I None
characteristics I None
with I None
some I None
psychotomimetic I None
action I None
, I None
possibly I None
through I None
monoaminergic I None
neurotransmission I None
. I None
<eof> I None

<s> O None
To I None
gain I None
insight I None
into I None
the I None
relation I None
between I None
LA I None
action I None
and I None
monoamine I GENE-N
transporters O GENE-N
, I None
we I None
investigated I None
the I None
effect I None
of I None
synthetic I None
LAs I None
on I None
neurotransmitter I GENE-N
transporters O GENE-N
, I None
including I None
monoamine I GENE-N
transporters O GENE-N
. I None
<eof> I None

<s> O None
We I None
used I None
cloned I None
transporter I None
cDNAs I None
and I None
examined I None
transient I None
functional I None
expression I None
in I None
COS I None
cells I None
and I None
stable I None
expression I None
in I None
HeLa I None
cells I None
. I None
<eof> I None

<s> O None
Among I None
the I None
LAs I None
tested I None
, I None
procaine I CHEMICAL
and I None
other I None
ester I CHEMICAL
- I None
type I None
LAs I None
inhibited I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
DA O CHEMICAL
uptake I None
and I None
binding I None
of I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
beta O CHEMICAL
- O CHEMICAL
carbomethoxy O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
beta O CHEMICAL
- O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
fluorophenyl O CHEMICAL
) O CHEMICAL
tropane O CHEMICAL
( I None
CFT I CHEMICAL
) I None
, I None
a I None
cocaine I CHEMICAL
analogue I None
, I None
in I None
COS I None
cells I None
expressing I None
rat I GENE-Y
dopamine O GENE-Y
transporter O GENE-Y
( I None
DAT I GENE-Y
) I None
. I None
<eof> I None

<s> O None
The I None
inhibition I None
was I None
concentration I None
- I None
dependent I None
. I None
<eof> I None

<s> O None
The I None
inhibitory I None
effect I None
on I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
DA O CHEMICAL
uptake I None
was I None
reversible I None
and I None
not I None
dependent I None
on I None
pH I None
, I None
as I None
observed I None
in I None
HeLa I None
cells I None
stably I None
expressing I None
DAT I GENE-Y
. I None
<eof> I None

<s> O None
Procaine I CHEMICAL
also I None
inhibited I None
uptake I None
of I None
norepinephrine I CHEMICAL
( I None
NE I CHEMICAL
) I None
and I None
serotonin I CHEMICAL
( I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
) I None
by I None
the I None
norepinephrine I GENE-Y
transporter O GENE-Y
( I None
NET I GENE-Y
) I None
or I None
serotonin I GENE-Y
transporter O GENE-Y
( I None
SERT I GENE-Y
) I None
expressed I None
in I None
COS I None
cells I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
procaine I CHEMICAL
and I None
other I None
LAs I None
had I None
little I None
or I None
no I None
effect I None
on I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
GABA O CHEMICAL
and I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
glutamate O CHEMICAL
uptake I None
in I None
COS I None
cells I None
expressing I None
mouse I GENE-N
GABA O GENE-N
or O GENE-N
rat O GENE-N
glutamate O GENE-N
/ O GENE-N
aspartate O GENE-N
transporter O GENE-N
. I None
<eof> I None

<s> O None
IC50 I None
values I None
for I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
DA O CHEMICAL
uptake I None
inhibition I None
correlated I None
well I None
with I None
those I None
for I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
CFT O CHEMICAL
binding I None
inhibition I None
, I None
but I None
not I None
with I None
intrinsic I None
anesthetic I None
potency I None
. I None
<eof> I None

<s> O None
Kinetic I None
analysis I None
of I None
monoamine I CHEMICAL
uptake I None
inhibition I None
by I None
procaine I CHEMICAL
in I None
COS I None
cells I None
expressing I None
rat I GENE-Y
DAT O GENE-Y
, I None
NET I GENE-Y
or I None
SERT I GENE-Y
revealed I None
a I None
competitive I None
action I None
similar I None
to I None
that I None
of I None
cocaine I CHEMICAL
. I None
<eof> I None

<s> O None
These I None
results I None
demonstrate I None
that I None
certain I None
LAs I None
selectively I None
inhibit I None
monoamine I GENE-N
transporters O GENE-N
. I None
<eof> I None

<s> O None
This I None
might I None
contribute I None
to I None
the I None
cocaine I CHEMICAL
- I None
like I None
psychotomimetic I None
action I None
of I None
certain I None
LAs I None
. I None
<eof> I None

<s> O None
Estrogen I GENE-Y
receptor O GENE-Y
- O GENE-Y
alpha O GENE-Y
gene I None
transfer I None
into I None
bovine I None
aortic I None
endothelial I None
cells I None
induces I None
eNOS I GENE-Y
gene I None
expression I None
and I None
inhibits I None
cell I None
migration I None
. I None
<eof> I None

<s> O None
OBJECTIVES I None
: I None
It I None
has I None
been I None
suggested I None
that I None
estrogen I CHEMICAL
may I None
improve I None
endothelial I None
cell I None
function I None
to I None
delay I None
the I None
onset I None
of I None
atherosclerosis I None
in I None
pre I None
- I None
menopausal I None
females I None
, I None
though I None
its I None
mechanism I None
of I None
action I None
is I None
not I None
fully I None
understood I None
. I None
<eof> I None

<s> O None
We I None
examined I None
the I None
hypothesis I None
that I None
human I GENE-Y
estrogen O GENE-Y
receptor O GENE-Y
- O GENE-Y
alpha O GENE-Y
( I None
ER I GENE-Y
alpha O GENE-Y
) I None
gene I None
transfection I None
improves I None
the I None
endothelial I None
cell I None
function I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
A I None
replication I None
deficient I None
adenoviral I None
vector I None
was I None
used I None
to I None
transfect I None
the I None
ER I GENE-Y
alpha O GENE-Y
gene I None
into I None
bovine I None
aortic I None
endothelial I None
cells I None
( I None
BAEC I None
) I None
and I None
a I None
GFP I None
gene I None
containing I None
vector I None
was I None
used I None
as I None
control I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
the I None
eNOS I GENE-Y
gene I None
was I None
determined I None
by I None
Northern I None
blot I None
analysis I None
and I None
enzyme I None
activity I None
assay I None
; I None
cell I None
migration I None
was I None
assayed I None
using I None
a I None
Transwell I None
apparatus I None
; I None
and I None
tyrosine I CHEMICAL
phosphorylation I None
of I None
FAK I GENE-N
was I None
estimated I None
by I None
Western I None
blot I None
analysis I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
ER I GENE-Y
alpha O GENE-Y
gene I None
transfection I None
of I None
endothelial I None
cells I None
produced I None
a I None
2 I None
- I None
3 I None
- I None
fold I None
increase I None
in I None
eNOS I GENE-Y
mRNA I None
and I None
protein I None
levels I None
as I None
well I None
as I None
a I None
significant I None
increase I None
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
in I None
NOS I GENE-N
activity I None
as I None
measured I None
by I None
citrulline I None
assay I None
and I None
nitrite I CHEMICAL
accumulation I None
in I None
the I None
media I None
in I None
response I None
to I None
bradykinin I GENE-Y
stimulation I None
. I None
<eof> I None

<s> O None
Treatment I None
of I None
cells I None
with I None
estrogen I CHEMICAL
blocking I None
agent I None
ICI I CHEMICAL
182780 O CHEMICAL
inhibited I None
eNOS I GENE-Y
induction I None
in I None
response I None
to I None
ER I GENE-Y
alpha O GENE-Y
transfection I None
. I None
<eof> I None

<s> O None
ER I GENE-Y
alpha O GENE-Y
gene I None
transfection I None
significantly I None
inhibited I None
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
bFGF I GENE-Y
- I None
induced I None
chemotactic I None
migration I None
of I None
endothelial I None
cells I None
but I None
increased I None
cell I None
attachment I None
to I None
fibronectin I GENE-Y
, I None
laminin I GENE-N
, I None
and I None
type I GENE-N
I O GENE-N
and O GENE-N
IV O GENE-N
collagens O GENE-N
. I None
<eof> I None

<s> O None
ER I GENE-Y
alpha O GENE-Y
gene I None
transfer I None
also I None
inhibited I None
bFGF I GENE-Y
- I None
stimulated I None
tyrosine I CHEMICAL
phosphorylation I None
of I None
FAK I GENE-N
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
Our I None
results I None
suggest I None
that I None
the I None
atheroprotective I None
effects I None
of I None
estrogen I CHEMICAL
may I None
in I None
part I None
be I None
mediated I None
by I None
ER I GENE-Y
alpha O GENE-Y
- I None
induced I None
upregulation I None
of I None
eNOS I GENE-Y
gene I None
expression I None
and I None
maintenance I None
of I None
endothelial I None
cell I None
function I None
and I None
integrity I None
. I None
<eof> I None

<s> O None
The I None
Hsp90 I GENE-N
- I None
specific I None
inhibitor I None
geldanamycin I CHEMICAL
selectively I None
disrupts I None
kinase I GENE-N
- I None
mediated I None
signaling I None
events I None
of I None
T I None
- I None
lymphocyte I None
activation I None
. I None
<eof> I None

<s> O None
The I None
90 I GENE-N
- O GENE-N
kDa O GENE-N
heat O GENE-N
shock O GENE-N
protein O GENE-N
( I None
Hsp90 I GENE-N
) I None
is I None
the I None
most I None
abundant I None
molecular I GENE-N
chaperone O GENE-N
of I None
eukaryotic I None
cells I None
. I None
<eof> I None

<s> O None
Its I None
chaperone I None
function I None
in I None
folding I None
nascent I None
proteins I None
seems I None
to I None
be I None
restricted I None
to I None
a I None
subset I None
of I None
proteins I None
including I None
major I None
components I None
of I None
signal I None
transduction I None
pathways I None
( I None
eg I None
, I None
nuclear I GENE-N
hormone O GENE-N
receptors O GENE-N
, I None
transcription I None
factors I None
, I None
and I None
protein I GENE-N
kinases O GENE-N
) I None
. I None
<eof> I None

<s> O None
Improper I None
function I None
of I None
these I None
proteins I None
can I None
be I None
induced I None
by I None
selective I None
disruption I None
of I None
their I None
complexes I None
with I None
Hsp90 I GENE-N
using I None
the I None
benzoquinonoid I CHEMICAL
ansamycin O CHEMICAL
geldanamycin I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
demonstrate I None
that I None
geldanamycin I CHEMICAL
treatment I None
blocks I None
interleukin I GENE-Y
( O GENE-Y
IL O GENE-Y
) O GENE-Y
- O GENE-Y
2 O GENE-Y
secretion I None
, I None
IL I GENE-N
- O GENE-N
2 O GENE-N
receptor O GENE-N
expression I None
, I None
and I None
proliferation I None
of I None
stimulated I None
T I None
- I None
lymphocytes I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
geldanamycin I CHEMICAL
decreases I None
the I None
amount I None
and I None
phosphorylation I None
of I None
Lck I GENE-Y
and I None
Raf I GENE-Y
- O GENE-Y
1 O GENE-Y
kinases I GENE-N
and I None
prevents I None
activation I None
of I None
the I None
extracellular I GENE-Y
signal O GENE-Y
regulated O GENE-Y
kinase O GENE-Y
( O GENE-Y
ERK O GENE-Y
) O GENE-Y
- O GENE-Y
2 O GENE-Y
kinase I GENE-N
. I None
<eof> I None

<s> O None
Geldanamycin I CHEMICAL
also I None
disrupts I None
the I None
T I GENE-N
- O GENE-N
cell O GENE-N
receptor O GENE-N
- I None
mediated I None
activation I None
of I None
nuclear I GENE-N
factor O GENE-N
of O GENE-N
activated O GENE-N
T O GENE-N
- O GENE-N
cells O GENE-N
( I None
NF I GENE-N
- O GENE-N
AT O GENE-N
) I None
. I None
<eof> I None

<s> O None
Treatment I None
with I None
geldanamycin I CHEMICAL
, I None
however I None
, I None
does I None
not I None
affect I None
the I None
activation I None
of I None
lysophosphatide I GENE-N
acyltransferase O GENE-N
, I None
which I None
is I None
a I None
plasma I None
membrane I None
enzyme I None
coupled I None
to I None
the I None
T I GENE-N
- O GENE-N
cell O GENE-N
receptor O GENE-N
after I None
T I None
- I None
cell I None
stimulation I None
. I None
<eof> I None

<s> O None
Through I None
demonstrating I None
the I None
selective I None
inhibition I None
of I None
kinase I GENE-N
- I None
related I None
T I None
- I None
lymphocyte I None
responses I None
by I None
geldanamycin I CHEMICAL
, I None
our I None
results I None
emphasize I None
the I None
substantial I None
role I None
of I None
Hsp90 I GENE-N
- I None
kinase I GENE-N
complexes I None
in I None
T I None
- I None
cell I None
activation I None
. I None
<eof> I None

<s> O None
Prevention I None
of I None
acute I None
allograft I None
rejection I None
in I None
nonhuman I None
primate I None
lung I None
transplant I None
recipients I None
: I None
induction I None
with I None
chimeric I None
anti I None
- I None
interleukin I GENE-N
- O GENE-N
2 O GENE-N
receptor O GENE-N
monoclonal I None
antibody I None
improves I None
the I None
tolerability I None
and I None
potentiates I None
the I None
immunosuppressive I None
activity I None
of I None
a I None
regimen I None
using I None
low I None
doses I None
of I None
both I None
microemulsion I None
cyclosporine I CHEMICAL
and I None
40 I CHEMICAL
- O CHEMICAL
O O CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
hydroxyethyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
rapamycin O CHEMICAL
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
In I None
previous I None
studies I None
of I None
cynomolgus I None
monkey I None
lung I None
allograft I None
recipients I None
, I None
we I None
demonstrated I None
significant I None
immunosuppressive I None
efficacy I None
but I None
reduced I None
tolerability I None
after I None
combined I None
treatment I None
with I None
high I None
doses I None
of I None
microemulsion I None
cyclosporine I CHEMICAL
( I None
CsA I CHEMICAL
) I None
and I None
SDZ I CHEMICAL
RAD O CHEMICAL
( I None
40 I CHEMICAL
- O CHEMICAL
O O CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
hydroxyethyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
rapamycin O CHEMICAL
) I None
. I None
<eof> I None

<s> O None
The I None
current I None
study I None
was I None
designed I None
to I None
compare I None
efficacy I None
and I None
tolerability I None
of I None
a I None
combination I None
of I None
low I None
- I None
dose I None
CsA I CHEMICAL
and I None
high I None
- I None
dose I None
SDZ I CHEMICAL
RAD O CHEMICAL
( I None
CTL I None
group I None
) I None
to I None
triple I None
therapy I None
using I None
the I None
chimeric I None
anti I None
- I None
interleukin I GENE-N
- O GENE-N
2 O GENE-N
( O GENE-N
IL O GENE-N
- O GENE-N
2 O GENE-N
) O GENE-N
receptor O GENE-N
( I None
CD25 I GENE-Y
) I None
monoclonal I None
antibody I None
( I None
mAb I None
) I None
basiliximab I None
( I None
anti I None
- I None
IL I GENE-N
- O GENE-N
2 O GENE-N
receptor O GENE-N
mAb I None
) I None
for I None
induction I None
therapy I None
( I None
basiliximab I None
: I None
5 I None
mg I None
intravenously I None
on I None
days I None
0 I None
and I None
4 I None
) I None
plus I None
low I None
- I None
dose I None
CsA I CHEMICAL
and I None
low I None
- I None
dose I None
SDZ I CHEMICAL
RAD O CHEMICAL
for I None
maintenance I None
immunosuppression I None
( I None
CD25 I GENE-Y
group I None
) I None
. I None
<eof> I None

<s> O None
CsA I CHEMICAL
and I None
anti I None
- I None
IL I GENE-N
- O GENE-N
2 O GENE-N
receptor O GENE-N
mAb I None
are I None
drugs I None
that I None
reduce I None
cytokine I GENE-N
synthesis I None
and I None
block I None
IL I GENE-Y
- O GENE-Y
2 O GENE-Y
- I None
mediated I None
lymphocyte I None
stimulation I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
SDZ I CHEMICAL
RAD O CHEMICAL
blocks I None
lymphocyte I None
stimulation I None
by I None
other I None
cytokines I GENE-N
( I None
e I None
. I None
g I None
. I None
, I None
IL I GENE-Y
- O GENE-Y
15 O GENE-Y
) I None
that I None
are I None
not I None
inhibited I None
by I None
anti I None
- I None
IL I GENE-Y
- O GENE-Y
2 O GENE-Y
receptor I None
mAb I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Twelve I None
unilateral I None
lung I None
transplants I None
were I None
performed I None
. I None
<eof> I None

<s> O None
Recipients I None
were I None
observed I None
for I None
49 I None
days I None
by I None
daily I None
weight I None
assessment I None
, I None
hemograms I None
, I None
blood I None
chemistries I None
, I None
radiographs I None
, I None
and I None
lung I None
biopsies I None
. I None
<eof> I None

<s> O None
Monkeys I None
were I None
euthanized I None
before I None
day I None
49 I None
in I None
the I None
event I None
of I None
excessive I None
weight I None
loss I None
( I None
> I None
25 I None
% I None
) I None
or I None
organ I None
failure I None
. I None
<eof> I None

<s> O None
Target I None
CsA I CHEMICAL
trough I None
levels I None
were I None
100 I None
- I None
200 I None
ng I None
/ I None
ml I None
. I None
<eof> I None

<s> O None
Target I None
SDZ I CHEMICAL
RAD O CHEMICAL
trough I None
levels I None
in I None
the I None
CTL I None
group I None
( I None
no I None
mAb I None
) I None
were I None
20 I None
- I None
40 I None
ng I None
/ I None
ml I None
, I None
and I None
10 I None
- I None
20 I None
ng I None
/ I None
ml I None
in I None
the I None
CD25 I GENE-Y
group I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
None I None
of I None
the I None
monkeys I None
in I None
the I None
CD25 I GENE-Y
group I None
needed I None
to I None
be I None
euthanized I None
early I None
due I None
to I None
signs I None
of I None
drug I None
toxicity I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
four I None
monkeys I None
in I None
the I None
CTL I None
group I None
were I None
sacrificed I None
on I None
days I None
28 I None
- I None
35 I None
as I None
a I None
result I None
of I None
excessive I None
weight I None
loss I None
( I None
n I None
= I None
3 I None
) I None
and I None
renal I None
functional I None
impairment I None
( I None
n I None
= I None
1 I None
) I None
. I None
<eof> I None

<s> O None
Three I None
recipients I None
in I None
the I None
CD25 I GENE-Y
group I None
were I None
euthanized I None
on I None
days I None
36 I None
, I None
38 I None
, I None
and I None
46 I None
as I None
a I None
result I None
of I None
persistent I None
high I None
fever I None
associated I None
with I None
severe I None
rejection I None
. I None
<eof> I None

<s> O None
The I None
median I None
animal I None
survival I None
in I None
the I None
CTL I None
group I None
was I None
32 I None
vs I None
. I None
46 I None
days I None
in I None
the I None
CD25 I GENE-Y
group I None
( I None
P I None
< I None
0 I None
. I None
04 I None
) I None
. I None
<eof> I None

<s> O None
The I None
only I None
two I None
long I None
- I None
term I None
survivors I None
in I None
the I None
CTL I None
group I None
showed I None
moderate I None
rejection I None
at I None
day I None
49 I None
. I None
<eof> I None

<s> O None
The I None
median I None
rejection I None
scores I None
at I None
day I None
14 I None
( I None
A0 I None
) I None
and I None
day I None
28 I None
( I None
A2 I None
) I None
were I None
identical I None
in I None
the I None
two I None
groups I None
, I None
despite I None
the I None
fact I None
that I None
the I None
mean I None
SDZ I CHEMICAL
RAD O CHEMICAL
trough I None
level I None
was I None
significantly I None
lower I None
in I None
the I None
CD25 I GENE-Y
group I None
( I None
CTL I None
: I None
38 I None
+ I None
/ I None
- I None
3 I None
ng I None
/ I None
ml I None
, I None
CD25 I GENE-Y
: I None
18 I None
+ I None
/ I None
- I None
2 I None
ng I None
/ I None
ml I None
, I None
P I None
< I None
0 I None
. I None
0001 I None
) I None
. I None
<eof> I None

<s> O None
After I None
basiliximab I None
levels I None
fell I None
below I None
the I None
minimum I None
therapeutic I None
level I None
( I None
1 I None
mg I None
/ I None
ml I None
) I None
on I None
day I None
28 I None
, I None
the I None
median I None
rejection I None
score I None
at I None
day I None
49 I None
increased I None
to I None
A4 I None
in I None
the I None
CD25 I GENE-Y
group I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
This I None
is I None
the I None
first I None
study I None
to I None
combine I None
an I None
anti I None
- I None
IL I GENE-N
- O GENE-N
2 O GENE-N
receptor O GENE-N
mAb I None
with I None
a I None
drug I None
from I None
the I None
rapamycin I None
class I None
plus I None
CsA I CHEMICAL
. I None
<eof> I None

<s> O None
Our I None
study I None
shows I None
that I None
induction I None
therapy I None
with I None
basiliximab I None
enabled I None
SDZ I CHEMICAL
RAD O CHEMICAL
blood I None
levels I None
to I None
be I None
significantly I None
reduced I None
, I None
which I None
led I None
to I None
improved I None
tolerability I None
without I None
the I None
penalty I None
of I None
increased I None
rejection I None
. I None
<eof> I None

<s> O None
Carnitine I CHEMICAL
biosynthesis I None
. I None
<eof> I None

<s> O None
Purification I None
of I None
gamma I GENE-Y
- O GENE-Y
butyrobetaine O GENE-Y
hydroxylase O GENE-Y
from I None
rat I None
liver I None
. I None
<eof> I None

<s> O None
gamma I GENE-Y
- O GENE-Y
Butyrobetaine O GENE-Y
hydroxylase O GENE-Y
catalyse I None
the I None
last I None
step I None
in I None
carnitine I CHEMICAL
biosynthesis I None
, I None
the I None
formation I None
of I None
L I CHEMICAL
- O CHEMICAL
carnitine O CHEMICAL
from I None
gamma I CHEMICAL
- O CHEMICAL
butyrobetaine O CHEMICAL
, I None
a I None
reaction I None
dependent I None
on I None
Fe2 I CHEMICAL
+ O CHEMICAL
, I None
alpha I CHEMICAL
- O CHEMICAL
ketoglutarate O CHEMICAL
, I None
ascorbate I CHEMICAL
and I None
oxygen I CHEMICAL
. I None
<eof> I None

<s> O None
Initial I None
attempts I None
to I None
purify I None
the I None
protein I None
from I None
rat I None
liver I None
showed I None
that I None
gamma I GENE-Y
- O GENE-Y
butyrobetaine O GENE-Y
hydroxylase O GENE-Y
is I None
unstable I None
. I None
<eof> I None

<s> O None
We I None
, I None
therefore I None
, I None
determined I None
the I None
influence I None
of I None
various I None
compounds I None
on I None
the I None
stability I None
of I None
gamma I GENE-Y
- O GENE-Y
butyrobetaine O GENE-Y
hydroxylase O GENE-Y
at I None
different I None
storage I None
temperatures I None
. I None
<eof> I None

<s> O None
The I None
enzyme I None
activity I None
was I None
best I None
conserved I None
by I None
storing I None
the I None
protein I None
at I None
4 I None
degrees I None
C I None
in I None
the I None
presence I None
of I None
200 I None
g I None
/ I None
l I None
glycerol I CHEMICAL
and I None
10 I None
mM I None
DTT I CHEMICAL
. I None
<eof> I None

<s> O None
We I None
subsequently I None
purified I None
the I None
enzyme I None
from I None
rat I None
liver I None
to I None
apparent I None
homogeneity I None
by I None
liquid I None
chromatography I None
. I None
<eof> I None

<s> O None
Pharmacological I None
activation I None
of I None
cloned I None
intermediate I GENE-N
- O GENE-N
and O GENE-N
small O GENE-N
- O GENE-N
conductance O GENE-N
Ca O GENE-N
( O GENE-N
2 O GENE-N
+ O GENE-N
) O GENE-N
- O GENE-N
activated O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
channels O GENE-N
. I None
<eof> I None

<s> O None
We I None
previously I None
characterized I None
1 I CHEMICAL
- O CHEMICAL
ethyl O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
benzimidazolinone O CHEMICAL
( I None
1 I CHEMICAL
- O CHEMICAL
EBIO O CHEMICAL
) I None
, I None
as I None
well I None
as I None
the I None
clinically I None
useful I None
benzoxazoles I CHEMICAL
, I None
chlorzoxazone I CHEMICAL
( I None
CZ I CHEMICAL
) I None
, I None
and I None
zoxazolamine I CHEMICAL
( I None
ZOX I CHEMICAL
) I None
, I None
as I None
pharmacological I None
activators I None
of I None
the I None
intermediate I GENE-N
- O GENE-N
conductance O GENE-N
Ca O GENE-N
( O GENE-N
2 O GENE-N
+ O GENE-N
) O GENE-N
- O GENE-N
activated O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
channel O GENE-N
, I None
hIK1 I GENE-Y
. I None
<eof> I None

<s> O None
The I None
mechanism I None
of I None
activation I None
of I None
hIK1 I GENE-Y
, I None
as I None
well I None
as I None
the I None
highly I None
homologous I None
small I GENE-N
- O GENE-N
conductance O GENE-N
, O GENE-N
Ca O GENE-N
( O GENE-N
2 O GENE-N
+ O GENE-N
) O GENE-N
- O GENE-N
dependent O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
channel O GENE-N
, I None
rSK2 I GENE-Y
, I None
was I None
determined I None
following I None
heterologous I None
expression I None
in I None
Xenopus I None
oocytes I None
using I None
two I None
- I None
electrode I None
voltage I None
clamp I None
( I None
TEVC I None
) I None
and I None
excised I None
, I None
inside I None
- I None
out I None
patch I None
- I None
clamp I None
techniques I None
. I None
<eof> I None

<s> O None
1 I CHEMICAL
- O CHEMICAL
EBIO O CHEMICAL
, I None
CZ I CHEMICAL
, I None
and I None
ZOX I CHEMICAL
activated I None
both I None
hIK1 I GENE-Y
and I None
rSK2 I GENE-Y
in I None
TEVC I None
and I None
excised I None
inside I None
- I None
out I None
patch I None
- I None
clamp I None
experiments I None
. I None
<eof> I None

<s> O None
In I None
excised I None
, I None
inside I None
- I None
out I None
patches I None
, I None
1 I CHEMICAL
- O CHEMICAL
EBIO O CHEMICAL
and I None
CZ I CHEMICAL
induced I None
a I None
concentration I None
- I None
dependent I None
activation I None
of I None
hIK1 I GENE-Y
, I None
with I None
half I None
- I None
maximal I None
( I None
K I None
( I None
1 I None
/ I None
2 I None
) I None
) I None
values I None
of I None
84 I None
microM I None
and I None
98 I None
microM I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Similarly I None
, I None
CZ I CHEMICAL
activated I None
rSK2 I GENE-Y
with I None
a I None
K I None
( I None
1 I None
/ I None
2 I None
) I None
of I None
87 I None
microM I None
. I None
<eof> I None

<s> O None
In I None
the I None
absence I None
of I None
CZ I CHEMICAL
, I None
the I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
- I None
dependent I None
activation I None
of I None
hIK1 I GENE-Y
was I None
best I None
fit I None
with I None
a I None
K I None
( I None
1 I None
/ I None
2 I None
) I None
of I None
700 I None
nM I None
and I None
a I None
Hill I None
coefficient I None
( I None
n I None
) I None
of I None
2 I None
. I None
0 I None
. I None
<eof> I None

<s> O None
rSK2 I GENE-Y
was I None
activated I None
by I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
with I None
a I None
K I None
( I None
1 I None
/ I None
2 I None
) I None
of I None
700 I None
nM I None
and I None
an I None
n I None
of I None
2 I None
. I None
5 I None
. I None
<eof> I None

<s> O None
Addition I None
of I None
CZ I CHEMICAL
had I None
no I None
effect I None
on I None
either I None
the I None
K I None
( I None
1 I None
/ I None
2 I None
) I None
or I None
n I None
for I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
- I None
dependent I None
activation I None
of I None
either I None
hIK1 I GENE-Y
or I None
rSK2 I GENE-Y
. I None
<eof> I None

<s> O None
Rather I None
, I None
CZ I CHEMICAL
increased I None
channel I None
activity I None
at I None
all I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
concentrations I None
( I None
V I None
( I None
max I None
) I None
) I None
. I None
<eof> I None

<s> O None
Event I None
- I None
duration I None
analysis I None
revealed I None
hIK1 I GENE-Y
was I None
minimally I None
described I None
by I None
two I None
open I None
and I None
three I None
closed I None
times I None
. I None
<eof> I None

<s> O None
Activation I None
by I None
1 I CHEMICAL
- O CHEMICAL
EBIO O CHEMICAL
had I None
no I None
effect I None
on I None
tau I None
( I None
o1 I None
) I None
, I None
tau I None
( I None
o2 I None
) I None
, I None
or I None
tau I None
( I None
c1 I None
) I None
, I None
whereas I None
tau I None
( I None
c2 I None
) I None
and I None
tau I None
( I None
c3 I None
) I None
were I None
reduced I None
from I None
9 I None
. I None
0 I None
and I None
92 I None
. I None
6 I None
ms I None
to I None
5 I None
. I None
0 I None
and I None
44 I None
. I None
1 I None
ms I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
we I None
define I None
1 I CHEMICAL
- O CHEMICAL
EBIO O CHEMICAL
, I None
CZ I CHEMICAL
, I None
and I None
ZOX I CHEMICAL
as I None
the I None
first I None
known I None
activators I None
of I None
hIK1 I GENE-Y
and I None
rSK2 I GENE-Y
. I None
<eof> I None

<s> O None
Openers I None
of I None
IK I GENE-N
and I None
SK I GENE-N
channels O GENE-N
may I None
be I None
therapeutically I None
beneficial I None
in I None
cystic I None
fibrosis I None
and I None
vascular I None
diseases I None
. I None
<eof> I None

<s> O None
[ I None
Plasminogen I GENE-Y
binding I None
with I None
decapeptide I None
and I None
polypeptide I None
fragments I None
of I None
streptokinase I GENE-N
] I None
. I None
<eof> I None

<s> O None
The I None
plasminogen I GENE-Y
binding I None
with I None
streptokinase I GENE-N
decapeptides I None
, I None
modeling I None
the I None
primary I None
structure I None
of I None
molecule I None
, I None
and I None
chymotryptic I None
fragments I None
of I None
streptokinase I GENE-N
have I None
been I None
investigated I None
. I None
<eof> I None

<s> O None
The I None
immunoenzymatic I None
assay I None
has I None
shown I None
that I None
plasminogen I GENE-Y
binds I None
to I None
all I None
streptokinase I GENE-N
fragments I None
with I None
the I None
decreasing I None
affinity I None
in I None
the I None
set I None
of I None
fragments I None
: I None
36 I None
> I None
30 I None
> I None
17 I None
> I None
7 I None
> I None
11 I None
kDa I None
. I None
<eof> I None

<s> O None
Location I None
of I None
the I None
binding I None
sites I None
in I None
streptokinase I GENE-N
primary I None
structure I None
was I None
performed I None
using I None
the I None
immobilized I None
decapeptides I None
on I None
plastic I None
pins I None
adopted I None
to I None
IEA I None
. I None
<eof> I None

<s> O None
In I None
the I None
presence I None
of I None
10 I None
mM I None
6 I CHEMICAL
- O CHEMICAL
aminohexanoic O CHEMICAL
acid O CHEMICAL
11 I None
sites I None
for I None
human I GENE-N
Glu O GENE-N
- O GENE-N
and O GENE-N
mini O GENE-N
- O GENE-N
plasminogens O GENE-N
, I None
pig I GENE-N
and O GENE-N
bovine O GENE-N
plasminogens O GENE-N
binding I None
have I None
been I None
found I None
. I None
<eof> I None

<s> O None
They I None
were I None
of I None
the I None
same I None
location I None
for I None
human I GENE-N
, O GENE-N
bovine O GENE-N
and O GENE-N
pig O GENE-N
plasminogens O GENE-N
. I None
<eof> I None

<s> O None
3 I None
sites I None
were I None
located I None
in I None
plasminogen I GENE-N
alpha O GENE-N
- O GENE-N
domain O GENE-N
- I None
- I None
T43 I None
- I None
A72 I None
, I None
N113 I None
- I None
T126 I None
, I None
Q133 I None
- I None
V158 I None
, I None
5 I None
sites I None
in I None
beta I None
- I None
domain I None
- I None
- I None
T163 I None
- I None
L188 I None
, I None
A203 I None
- I None
S222 I None
, I None
Q239 I None
- I None
I264 I None
, I None
Y275 I None
- I None
L294 I None
, I None
T315 I None
- I None
L340 I None
, I None
and I None
3 I None
sites I None
in I None
gamma I None
- I None
domain I None
- I None
- I None
T361 I None
- I None
R362 I None
, I None
N377 I None
- I None
E392 I None
, I None
T397 I None
- I None
N410 I None
. I None
<eof> I None

<s> O None
Participation I None
of I None
linear I None
part I None
of I None
streptokinase I GENE-N
polypeptide I None
chain I None
in I None
plasminogen I GENE-Y
- I None
- I None
streptokinase I GENE-N
complex I None
formation I None
is I None
suggested I None
. I None
<eof> I None

<s> O None
Interactions I None
of I None
the I None
human I GENE-N
multidrug O GENE-N
resistance O GENE-N
proteins O GENE-N
MRP1 I GENE-Y
and I None
MRP2 I GENE-Y
with I None
organic I None
anions I None
. I None
<eof> I None

<s> O None
The I None
human I GENE-N
multidrug O GENE-N
resistance O GENE-N
protein O GENE-N
MRP1 I GENE-Y
and I None
its I None
homolog I None
, I None
MRP2 I GENE-Y
, I None
are I None
both I None
suggested I None
as I None
being I None
involved I None
in I None
cancer I None
drug I None
resistance I None
and I None
the I None
transport I None
of I None
organic I None
anions I None
. I None
<eof> I None

<s> O None
We I None
expressed I None
MRP1 I GENE-Y
and I None
MRP2 I GENE-Y
in I None
Spodoptera I None
frugiperda I None
ovarian I None
cells I None
and I None
compared I None
their I None
ATP I CHEMICAL
- I None
dependent I None
transport I None
properties I None
and I None
vanadate I GENE-N
- O GENE-N
sensitive O GENE-N
ATPase O GENE-N
activities I None
in I None
isolated I None
membrane I None
vesicles I None
. I None
<eof> I None

<s> O None
Both I None
MRP1 I GENE-Y
and I None
MRP2 I GENE-Y
actively I None
transported I None
leukotriene I CHEMICAL
C O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
and I None
N I None
- I None
ethylmaleimide I None
glutathione I None
( I None
NEM I None
- I None
GS I None
) I None
, I None
although I None
the I None
relative I None
affinity I None
of I None
MRP2 I GENE-Y
for I None
these I None
substrates I None
was I None
found I None
to I None
be I None
significantly I None
lower I None
than I None
that I None
of I None
MRP1 I GENE-Y
. I None
<eof> I None

<s> O None
Methotrexate I CHEMICAL
was I None
actively I None
transported I None
by I None
both I None
proteins I None
, I None
although I None
more I None
efficiently I None
by I None
MRP2 I GENE-Y
. I None
<eof> I None

<s> O None
ATP I CHEMICAL
- I None
dependent I None
NEM I None
- I None
GS I None
transport I None
by I None
MRP1 I GENE-Y
and I None
MRP2 I GENE-Y
was I None
variably I None
modulated I None
by I None
organic I None
anions I None
. I None
<eof> I None

<s> O None
Probenecid I CHEMICAL
and I None
furosemide I CHEMICAL
inhibited I None
, I None
whereas I None
under I None
certain I None
conditions I None
sulfinpyrazone I CHEMICAL
, I None
penicillin I CHEMICAL
G O CHEMICAL
, I None
and I None
indomethacin I CHEMICAL
greatly I None
stimulated I None
, I None
MRP2 I GENE-Y
- I None
mediated I None
NEM I None
- I None
GS I None
uptake I None
. I None
<eof> I None

<s> O None
Vanadate I GENE-N
- O GENE-N
sensitive O GENE-N
ATPase O GENE-N
activity I None
in I None
isolated I None
membranes I None
containing I None
MRP1 I GENE-Y
or I None
MRP2 I GENE-Y
was I None
significantly I None
stimulated I None
by I None
NEM I None
- I None
GS I None
and I None
reduced I None
GS I None
, I None
although I None
these I None
compounds I None
acted I None
only I None
at I None
higher I None
concentrations I None
in I None
MRP2 I GENE-Y
. I None
<eof> I None

<s> O None
ATP I CHEMICAL
hydrolysis I None
by I None
MRP2 I GENE-Y
was I None
also I None
effectively I None
stimulated I None
by I None
methotrexate I CHEMICAL
. I None
<eof> I None

<s> O None
Probenecid I CHEMICAL
, I None
sulfinpyrazone I CHEMICAL
, I None
indomethacin I CHEMICAL
, I None
furosemide I CHEMICAL
, I None
and I None
penicillin I CHEMICAL
G O CHEMICAL
all I None
significantly I None
increased I None
MRP2 I GENE-Y
- I None
ATPase I GENE-N
activity I None
, I None
whereas I None
these I None
compounds I None
acted I None
more I None
as I None
ATPase I GENE-N
inhibitors I None
on I None
MRP1 I GENE-Y
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
MRP1 I GENE-Y
is I None
a I None
more I None
efficient I None
transporter I None
of I None
glutathione I CHEMICAL
conjugates I None
and I None
free I None
glutathione I CHEMICAL
than I None
MRP2 I GENE-Y
, I None
whereas I None
several I None
anions I None
are I None
preferred I None
substrates I None
for I None
MRP2 I GENE-Y
. I None
<eof> I None

<s> O None
Our I None
data I None
suggest I None
that I None
MRP2 I GENE-Y
may I None
be I None
responsible I None
for I None
the I None
active I None
secretion I None
of I None
pharmacologically I None
relevant I None
organic I None
anions I None
, I None
such I None
as I None
diuretics I None
and I None
antibiotics I None
, I None
and I None
indicate I None
different I None
modulation I None
possibilities I None
for I None
MRP1 I GENE-Y
or I None
MRP2 I GENE-Y
in I None
drug I None
- I None
resistant I None
tumor I None
cells I None
. I None
<eof> I None

<s> O None
Aspirin I CHEMICAL
and I None
sodium I CHEMICAL
salicylate O CHEMICAL
inhibit I None
endothelin I None
ETA I GENE-Y
receptors O GENE-Y
by I None
an I None
allosteric I None
type I None
of I None
mechanism I None
. I None
<eof> I None

<s> O None
Aspirin I CHEMICAL
is I None
a I None
commonly I None
used I None
drug I None
with I None
a I None
wide I None
pharmacological I None
spectrum I None
including I None
antiplatelet I None
, I None
anti I None
- I None
inflammatory I None
, I None
and I None
neuroprotective I None
actions I None
. I None
<eof> I None

<s> O None
This I None
study I None
shows I None
that I None
aspirin I CHEMICAL
and I None
sodium I CHEMICAL
salicylate O CHEMICAL
, I None
its I None
major I None
blood I None
metabolite I None
, I None
reverse I None
contractile I None
actions I None
of I None
endothelin I GENE-N
- O GENE-N
1 O GENE-N
( I None
ET I GENE-N
- O GENE-N
1 O GENE-N
) I None
in I None
isolated I None
rat I None
aorta I None
and I None
human I None
mammary I None
arteries I None
. I None
<eof> I None

<s> O None
They I None
also I None
prevent I None
the I None
intracellular I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
mobilizing I None
action I None
of I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
in I None
cultured I None
endothelial I None
cells I None
but I None
not I None
those I None
of I None
neuromedin I GENE-Y
B O GENE-Y
or I None
UTP I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
the I None
actions I None
of I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
by I None
salicylates I CHEMICAL
is I None
apparently I None
competitive I None
. I None
<eof> I None

<s> O None
Salicylates I CHEMICAL
inhibit I None
( I CHEMICAL
125 O CHEMICAL
) O CHEMICAL
I O CHEMICAL
- I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
binding I None
to I None
recombinant I None
rat I GENE-Y
ETA O GENE-Y
receptors O GENE-Y
. I None
<eof> I None

<s> O None
Salicylic I CHEMICAL
acid O CHEMICAL
promotes I None
dissociation I None
of I None
( I CHEMICAL
125 O CHEMICAL
) O CHEMICAL
I O CHEMICAL
- I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
ETA I GENE-Y
receptor O GENE-Y
complexes I None
both I None
in I None
the I None
absence I None
and I None
the I None
presence I None
of I None
unlabeled I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
. I None
<eof> I None

<s> O None
It I None
has I None
no I None
influence I None
on I None
the I None
rate I None
of I None
association I None
of I None
( I CHEMICAL
125 O CHEMICAL
) O CHEMICAL
I O CHEMICAL
- I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
to I None
ETA I GENE-Y
receptors O GENE-Y
. I None
<eof> I None

<s> O None
Salicylates I CHEMICAL
do I None
not I None
promote I None
dissociation I None
of I None
( I CHEMICAL
125 O CHEMICAL
) O CHEMICAL
I O CHEMICAL
- I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
ETB I GENE-Y
receptor O GENE-Y
complexes I None
. I None
<eof> I None

<s> O None
Salicylates I CHEMICAL
potentiate I None
relaxing I None
actions I None
of I None
receptor I None
antagonists I None
such I None
as I None
bosentan I CHEMICAL
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
salicylates I CHEMICAL
are I None
allosteric I None
inhibitors I None
of I None
ETA I GENE-Y
receptors O GENE-Y
. I None
<eof> I None

<s> O None
The I None
results I None
also I None
suggest I None
that I None
: I None
1 I None
) I None
irreversible I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
binding I None
probably I None
limits I None
actions I None
of I None
receptor I None
antagonists I None
in I None
vivo I None
, I None
and I None
2 I None
) I None
an I None
association I None
of I None
salicylates I CHEMICAL
and I None
ETA I GENE-Y
receptor O GENE-Y
antagonists I None
should I None
be I None
used I None
to I None
evaluate I None
the I None
physiopathological I None
role I None
of I None
ET I GENE-Y
- O GENE-Y
1 O GENE-Y
and I None
may I None
be I None
of I None
therapeutic I None
interest I None
in I None
the I None
treatment I None
of I None
ischemic I None
heart I None
disease I None
. I None
<eof> I None

<s> O None
Nitric I CHEMICAL
oxide O CHEMICAL
, I None
but I None
not I None
vasopressin I GENE-Y
V2 O GENE-Y
receptor O GENE-Y
- I None
mediated I None
vasodilation I None
, I None
modulates I None
vasopressin I CHEMICAL
- I None
induced I None
renal I None
vasoconstriction I None
in I None
rats I None
. I None
<eof> I None

<s> O None
The I None
renal I None
vascular I None
response I None
to I None
vasopressin I CHEMICAL
and I None
its I None
modulation I None
were I None
evaluated I None
in I None
vivo I None
by I None
infusing I None
the I None
peptide I None
directly I None
into I None
the I None
renal I None
artery I None
of I None
anaesthetized I None
rats I None
. I None
<eof> I None

<s> O None
The I None
intra I None
- I None
renal I None
artery I None
( I None
i I None
. I None
r I None
. I None
a I None
) I None
infusion I None
of I None
vasopressin I CHEMICAL
induced I None
a I None
dose I None
- I None
dependent I None
decrease I None
in I None
renal I None
blood I None
flow I None
. I None
<eof> I None

<s> O None
Vasoconstriction I None
was I None
obvious I None
at I None
a I None
dose I None
of I None
3 I None
ng I None
/ I None
kg I None
per I None
min I None
and I None
reached I None
a I None
maximum I None
at I None
100 I None
ng I None
/ I None
kg I None
per I None
min I None
. I None
<eof> I None

<s> O None
The I None
dose I None
required I None
for I None
a I None
half I None
- I None
maximal I None
response I None
( I None
ED50 I None
) I None
was I None
24 I None
+ I None
/ I None
- I None
4 I None
ng I None
/ I None
kg I None
per I None
min I None
( I None
mean I None
+ I None
/ I None
- I None
SEM I None
, I None
n I None
= I None
8 I None
) I None
, I None
corresponding I None
to I None
an I None
estimated I None
concentration I None
in I None
renal I None
arterial I None
blood I None
required I None
for I None
a I None
half I None
- I None
maximal I None
response I None
( I None
EC50 I None
) I None
of I None
1 I None
. I None
9 I None
+ I None
/ I None
- I None
0 I None
. I None
6 I None
nM I None
. I None
<eof> I None

<s> O None
Thiobutabarbitone I CHEMICAL
anaesthesia I None
markedly I None
increased I None
plasma I None
vasopressin I CHEMICAL
concentration I None
. I None
<eof> I None

<s> O None
This I None
increase I None
was I None
prevented I None
partially I None
by I None
hypotonic I None
hydration I None
of I None
the I None
rats I None
without I None
any I None
change I None
in I None
the I None
renal I None
vascular I None
response I None
to I None
exogenous I None
vasopressin I CHEMICAL
. I None
<eof> I None

<s> O None
Vasopressin I CHEMICAL
- I None
induced I None
vasoconstriction I None
dose I None
/ I None
response I None
curves I None
were I None
similar I None
in I None
homozygous I None
and I None
heterozygous I None
Brattleboro I None
rats I None
. I None
<eof> I None

<s> O None
Infusion I None
of I None
desmopressin I CHEMICAL
( I None
1 I None
- I None
1000 I None
ng I None
/ I None
kg I None
per I None
min I None
, I None
i I None
. I None
r I None
. I None
a I None
. I None
) I None
, I None
a I None
vasopressin I GENE-Y
V2 O GENE-Y
receptor O GENE-Y
- I None
selective I None
agonist I None
, I None
failed I None
to I None
induce I None
renal I None
vasodilation I None
or I None
vasoconstriction I None
. I None
<eof> I None

<s> O None
In I None
the I None
presence I None
of I None
SR I CHEMICAL
49059 O CHEMICAL
( I None
1 I None
mg I None
/ I None
kg I None
i I None
. I None
v I None
. I None
) I None
, I None
a I None
vasopressin I GENE-Y
V1A O GENE-Y
receptor O GENE-Y
antagonist I None
that I None
completely I None
abolished I None
the I None
vasopressin I CHEMICAL
- I None
induced I None
renal I None
vasoconstriction I None
, I None
desmopressin I CHEMICAL
again I None
failed I None
to I None
induce I None
vasodilation I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
nitric I GENE-N
oxide O GENE-N
synthase O GENE-N
by I None
N I CHEMICAL
( O CHEMICAL
omega O CHEMICAL
) O CHEMICAL
- O CHEMICAL
nitro O CHEMICAL
- O CHEMICAL
L O CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
( I None
L I CHEMICAL
- O CHEMICAL
NNA O CHEMICAL
, I None
100 I None
microg I None
/ I None
kg I None
for I None
10 I None
min I None
and I None
7 I None
. I None
5 I None
microg I None
/ I None
kg I None
per I None
min I None
, I None
i I None
. I None
r I None
. I None
a I None
. I None
) I None
enhanced I None
vasopressin I CHEMICAL
- I None
induced I None
renal I None
vasoconstriction I None
( I None
EC50 I None
0 I None
. I None
6 I None
+ I None
/ I None
- I None
0 I None
. I None
1 I None
nM I None
, I None
P I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
cyclooxygenase I GENE-N
blockade I None
by I None
indomethacin I CHEMICAL
( I None
5 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
v I None
. I None
) I None
neither I None
modified I None
the I None
vasopressin I CHEMICAL
- I None
induced I None
decrease I None
in I None
renal I None
blood I None
flow I None
nor I None
altered I None
the I None
potentiation I None
of I None
vasoconstriction I None
by I None
L I CHEMICAL
- O CHEMICAL
NNA O CHEMICAL
. I None
<eof> I None

<s> O None
These I None
results I None
show I None
that I None
the I None
constrictor I None
response I None
of I None
the I None
rat I None
renal I None
vascular I None
bed I None
in I None
vivo I None
is I None
observed I None
only I None
with I None
high I None
local I None
concentrations I None
of I None
vasopressin I CHEMICAL
. I None
<eof> I None

<s> O None
This I None
hyporeactivity I None
in I None
vivo I None
was I None
not I None
explained I None
by I None
an I None
anaesthesia I None
- I None
elicited I None
increase I None
in I None
endogenous I None
vasopressin I CHEMICAL
, I None
nor I None
by I None
a I None
modulatory I None
effect I None
linked I None
to I None
V2 I GENE-Y
receptor O GENE-Y
activation I None
or I None
prostanoid I None
release I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
NO I CHEMICAL
release I None
contributed I None
to I None
the I None
attenuation I None
of I None
vasopressin I CHEMICAL
- I None
induced I None
renal I None
vasoconstriction I None
. I None
<eof> I None

<s> O None
N I GENE-N
- O GENE-N
methyl O GENE-N
- O GENE-N
D O GENE-N
- O GENE-N
aspartate O GENE-N
receptor O GENE-N
channel I None
block I None
by I None
meperidine I CHEMICAL
is I None
dependent I None
on I None
extracellular I None
pH I None
. I None
<eof> I None

<s> O None
UNLABELLED I None
: I None
Large I None
concentrations I None
of I None
meperidine I CHEMICAL
inhibit I None
N I GENE-N
- O GENE-N
methyl O GENE-N
- O GENE-N
D O GENE-N
- O GENE-N
aspartate O GENE-N
- O GENE-N
( O GENE-N
NMDA O GENE-N
) O GENE-N
receptor O GENE-N
channels I None
by I None
channel I None
block I None
mechanisms I None
. I None
<eof> I None

<s> O None
Extracellular I None
pH I None
regulates I None
the I None
activity I None
and I None
drug I None
sensitivity I None
of I None
NMDA I GENE-N
- O GENE-N
receptor O GENE-N
channels I None
. I None
<eof> I None

<s> O None
We I None
examined I None
the I None
influence I None
of I None
extracellular I None
pH I None
on I None
sensitivity I None
to I None
meperidine I CHEMICAL
of I None
epsilon I None
/ I None
zeta I None
heteromeric I None
NMDA I GENE-N
- O GENE-N
receptor O GENE-N
channels I None
expressed I None
in I None
Xenopus I None
oocytes I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
epsilon1 I GENE-N
/ O GENE-N
zeta1 O GENE-N
, I None
epsilon2 I GENE-N
/ O GENE-N
zeta1 O GENE-N
, I None
epsilon3 I GENE-N
/ O GENE-N
zeta1 O GENE-N
, I None
and I None
epsilon4 I GENE-N
/ O GENE-N
zeta1 O GENE-N
channels O GENE-N
by I None
meperidine I CHEMICAL
was I None
dependent I None
on I None
pH I None
, I None
with I None
more I None
inhibition I None
at I None
acidic I None
pH I None
and I None
less I None
inhibition I None
at I None
alkaline I None
pH I None
. I None
<eof> I None

<s> O None
The I None
degree I None
of I None
voltage I None
- I None
dependence I None
of I None
meperidine I CHEMICAL
block I None
was I None
only I None
slightly I None
affected I None
by I None
changes I None
in I None
pH I None
, I None
whereas I None
affinity I None
for I None
meperidine I CHEMICAL
was I None
greatly I None
reduced I None
at I None
alkaline I None
pH I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
interaction I None
of I None
meperidine I CHEMICAL
with I None
Mg I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
block I None
was I None
reduced I None
at I None
alkaline I None
pH I None
. I None
<eof> I None

<s> O None
Because I None
the I None
percentage I None
of I None
the I None
protonated I None
form I None
of I None
meperidine I CHEMICAL
is I None
only I None
slightly I None
affected I None
by I None
pH I None
, I None
changes I None
in I None
properties I None
of I None
the I None
meperidine I CHEMICAL
binding I None
site I None
may I None
be I None
involved I None
in I None
mechanisms I None
of I None
alteration I None
of I None
meperidine I CHEMICAL
potency I None
by I None
pH I None
. I None
<eof> I None

<s> O None
IMPLICATIONS I None
: I None
At I None
acidic I None
pH I None
the I None
potency I None
of I None
meperidine I CHEMICAL
for I None
N I GENE-N
- O GENE-N
methyl O GENE-N
- O GENE-N
D O GENE-N
- O GENE-N
aspartate O GENE-N
- O GENE-N
receptor O GENE-N
channels I None
was I None
increased I None
. I None
<eof> I None

<s> O None
Any I None
antinociceptive I None
and I None
neuroprotective I None
benefit I None
from I None
the I None
N I GENE-N
- O GENE-N
methyl O GENE-N
- O GENE-N
D O GENE-N
- O GENE-N
aspartate O GENE-N
- O GENE-N
receptor O GENE-N
antagonist I None
property I None
of I None
meperidine I CHEMICAL
may I None
be I None
pH I None
dependent I None
. I None
<eof> I None

<s> O None
Statins I CHEMICAL
: I None
effective I None
antiatherosclerotic I None
therapy I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Statins I CHEMICAL
are I None
the I None
most I None
effective I None
agents I None
currently I None
available I None
for I None
lowering I None
plasma I None
levels I None
of I None
low I GENE-N
- O GENE-N
density O GENE-N
lipoprotein O GENE-N
cholesterol I CHEMICAL
( I None
LDL I GENE-N
- I None
C I None
) I None
and I None
are I None
the I None
mainstay I None
of I None
therapy I None
for I None
hyperlipidemia I None
. I None
<eof> I None

<s> O None
The I None
statins I CHEMICAL
are I None
highly I None
liver I None
- I None
selective I None
, I None
inhibiting I None
3 I GENE-Y
- O GENE-Y
hydroxy O GENE-Y
- O GENE-Y
3 O GENE-Y
- O GENE-Y
methylglutaryl O GENE-Y
- O GENE-Y
coenzyme O GENE-Y
A O GENE-Y
( O GENE-Y
HMG O GENE-Y
- O GENE-Y
CoA O GENE-Y
) O GENE-Y
reductase O GENE-Y
, I None
a I None
key I None
enzyme I None
in I None
the I None
synthesis I None
of I None
cholesterol I CHEMICAL
. I None
<eof> I None

<s> O None
Several I None
large I None
, I None
controlled I None
clinical I None
trials I None
have I None
confirmed I None
significant I None
reductions I None
in I None
rates I None
of I None
coronary I None
heart I None
disease I None
morbidity I None
and I None
death I None
with I None
long I None
- I None
term I None
statin I None
therapy I None
in I None
patients I None
with I None
mild I None
to I None
severe I None
hypercholesterolemia I None
. I None
<eof> I None

<s> O None
METHODS I None
AND I None
RESULTS I None
: I None
This I None
review I None
article I None
is I None
based I None
on I None
a I None
literature I None
search I None
of I None
more I None
than I None
60 I None
relevant I None
articles I None
from I None
peer I None
- I None
reviewed I None
journals I None
. I None
<eof> I None

<s> O None
Search I None
engines I None
included I None
Medline I None
and I None
Embase I None
. I None
<eof> I None

<s> O None
In I None
surveying I None
clinical I None
and I None
angiographic I None
evidence I None
, I None
we I None
found I None
that I None
statins I None
appear I None
to I None
reduce I None
the I None
incidence I None
of I None
coronary I None
events I None
by I None
slowing I None
the I None
progression I None
of I None
atherosclerosis I None
and I None
preventing I None
atheromatous I None
lesion I None
formation I None
. I None
<eof> I None

<s> O None
We I None
found I None
that I None
the I None
6 I None
statins I CHEMICAL
currently I None
marketed I None
- I None
atorvastatin I CHEMICAL
, I None
cerivastatin I CHEMICAL
, I None
fluvastatin I CHEMICAL
, I None
lovastatin I CHEMICAL
, I None
pravastatin I CHEMICAL
, I None
and I None
simvastatin I CHEMICAL
- I None
differ I None
in I None
their I None
inhibitory I None
action I None
on I None
the I None
HMG I GENE-Y
- O GENE-Y
CoA O GENE-Y
reductase O GENE-Y
enzyme I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
The I None
use I None
of I None
more I None
potent I None
statins I None
such I None
as I None
atorvastatin I CHEMICAL
and I None
simvastatin I CHEMICAL
affords I None
greater I None
lowering I None
of I None
LDL I GENE-N
- I None
C I None
and I None
triglyceride I CHEMICAL
levels I None
, I None
allowing I None
more I None
patients I None
to I None
achieve I None
target I None
goals I None
. I None
<eof> I None

<s> O None
The I None
question I None
of I None
how I None
low I None
LDL I GENE-N
- I None
C I None
levels I None
should I None
be I None
lowered I None
will I None
be I None
answered I None
by I None
ongoing I None
clinical I None
trials I None
. I None
<eof> I None

<s> O None
A I None
unique I None
cytosolic I None
activity I None
related I None
but I None
distinct I None
from I None
NQO1 I GENE-N
catalyses I None
metabolic I None
activation I None
of I None
mitomycin I CHEMICAL
C O CHEMICAL
. I None
<eof> I None

<s> O None
Mitomycin I CHEMICAL
C O CHEMICAL
( I None
MMC I CHEMICAL
) I None
is I None
a I None
prototype I None
bioreductive I None
drug I None
employed I None
to I None
treat I None
a I None
variety I None
of I None
cancers I None
including I None
head I None
and I None
neck I None
cancer I None
. I None
<eof> I None

<s> O None
Among I None
the I None
various I None
enzymes I None
, I None
dicoumarol I CHEMICAL
inhibitable I None
cytosolic I None
NAD I GENE-N
( O GENE-N
P O GENE-N
) O GENE-N
H O GENE-N
: O GENE-N
quinone O GENE-N
oxidoreductase1 O GENE-N
( I None
NQO1 I GENE-N
) I None
was I None
shown I None
to I None
catalyse I None
bioreductive I None
activation I None
of I None
MMC I CHEMICAL
leading I None
to I None
cross I None
- I None
linking I None
of I None
the I None
DNA I None
and I None
cytotoxicity I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
role I None
of I None
NQO1 I GENE-N
in I None
metabolic I None
activation I None
of I None
MMC I CHEMICAL
has I None
been I None
disputed I None
. I None
<eof> I None

<s> O None
In I None
this I None
report I None
, I None
we I None
present I None
cellular I None
and I None
animal I None
models I None
to I None
demonstrate I None
that I None
NQO1 I GENE-N
may I None
play I None
only I None
a I None
minor I None
role I None
in I None
metabolic I None
activation I None
of I None
MMC I CHEMICAL
. I None
<eof> I None

<s> O None
We I None
further I None
demonstrate I None
that I None
bioreductive I None
activation I None
of I None
MMC I CHEMICAL
is I None
catalysed I None
by I None
a I None
unique I None
cytosolic I None
activity I None
which I None
is I None
related I None
but I None
distinct I None
from I None
NQO1 I GENE-N
. I None
<eof> I None

<s> O None
Chinese I None
hamster I None
ovary I None
( I None
CHO I None
) I None
cells I None
were I None
developed I None
that I None
permanently I None
express I None
higher I None
levels I None
of I None
cDNA I None
- I None
derived I None
NQO1 I GENE-N
. I None
<eof> I None

<s> O None
These I None
cells I None
showed I None
significantly I None
increased I None
protection I None
against I None
menadione I CHEMICAL
toxicity I None
. I None
<eof> I None

<s> O None
However I None
, I None
they I None
failed I None
to I None
demonstrate I None
higher I None
cytotoxicity I None
due I None
to I None
exposure I None
to I None
MMC I CHEMICAL
under I None
oxygen I CHEMICAL
( I None
normal I None
air I None
) I None
or I None
hypoxia I None
, I None
as I None
compared I None
to I None
the I None
wild I None
- I None
type I None
control I None
CHO I None
cells I None
. I None
<eof> I None

<s> O None
Disruption I None
of I None
the I None
NQO1 I GENE-N
gene I None
by I None
homologous I None
recombination I None
generated I None
NQO1 I GENE-N
- I None
/ I None
- I None
mice I None
that I None
do I None
not I None
express I None
the I None
NQO1 I GENE-N
gene I None
resulting I None
in I None
the I None
loss I None
of I None
NQO1 I GENE-N
protein I None
and I None
activity I None
. I None
<eof> I None

<s> O None
The I None
cytosolic I None
fractions I None
from I None
liver I None
and I None
colon I None
tissues I None
of I None
NQO1 I GENE-N
- I None
/ I None
- I None
mice I None
showed I None
similar I None
amounts I None
of I None
DNA I None
cross I None
- I None
linking I None
upon I None
exposure I None
to I None
MMC I CHEMICAL
, I None
as I None
observed I None
in I None
NQO1 I GENE-N
+ I None
/ I None
+ I None
mice I None
. I None
<eof> I None

<s> O None
The I None
unique I None
cytosolic I None
activity I None
that I None
activated I None
MMC I CHEMICAL
in I None
cytosolic I None
fractions I None
of I None
liver I None
and I None
colon I None
tissues I None
of I None
NQO1 I GENE-N
- I None
/ I None
- I None
mice I None
was I None
designated I None
as I None
cytosolic I None
MMC I GENE-N
reductase O GENE-N
. I None
<eof> I None

<s> O None
This I None
activity I None
, I None
like I None
NQO1 I GENE-N
, I None
was I None
inhibited I None
by I None
dicoumarol I CHEMICAL
and I None
immunologically I None
related I None
to I None
NQO1 I GENE-N
. I None
<eof> I None

<s> O None
High I None
affinity I None
blockade I None
of I None
the I None
HERG I GENE-Y
cardiac O GENE-Y
K O GENE-Y
( O GENE-Y
+ O GENE-Y
) O GENE-Y
channel O GENE-Y
by I None
the I None
neuroleptic I None
pimozide I CHEMICAL
. I None
<eof> I None

<s> O None
Pimozide I CHEMICAL
is I None
an I None
antipsychotic I None
agent I None
also I None
used I None
to I None
treat I None
facial I None
tics I None
. I None
<eof> I None

<s> O None
Pimozide I CHEMICAL
can I None
cause I None
acquired I None
long I None
QT I None
syndrome I None
and I None
ventricular I None
arrhythmias I None
. I None
<eof> I None

<s> O None
To I None
elucidate I None
the I None
mechanism I None
behind I None
these I None
clinical I None
findings I None
, I None
we I None
examined I None
the I None
effects I None
of I None
pimozide I CHEMICAL
on I None
the I None
cloned I None
human I GENE-Y
cardiac O GENE-Y
K O GENE-Y
( O GENE-Y
+ O GENE-Y
) O GENE-Y
channels O GENE-Y
HERG O GENE-Y
( I None
human I GENE-Y
ether O GENE-Y
- O GENE-Y
a O GENE-Y
- O GENE-Y
go O GENE-Y
- O GENE-Y
go O GENE-Y
- O GENE-Y
related O GENE-Y
gene O GENE-Y
; I None
rapid I None
component I None
of I None
delayed I None
rectifier I None
) I None
, I None
Kv1 I GENE-Y
. O GENE-Y
5 O GENE-Y
( I None
ultra I None
- I None
rapid I None
delayed I None
rectifier I None
) I None
and I None
KvLQT1 I GENE-Y
/ I None
minK I GENE-Y
( I None
slow I None
component I None
of I None
delayed I None
rectifier I None
) I None
. I None
<eof> I None

<s> O None
Using I None
patch I None
clamp I None
electrophysiology I None
, I None
we I None
found I None
that I None
pimozide I CHEMICAL
was I None
a I None
potent I None
inhibitor I None
of I None
HERG I GENE-Y
displaying I None
an I None
IC I None
( I None
50 I None
) I None
value I None
of I None
18 I None
nM I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
pimozide I CHEMICAL
( I None
10 I None
microM I None
) I None
was I None
a I None
weak I None
inhibitor I None
of I None
KvLQT1 I GENE-Y
/ I None
minK I GENE-Y
and I None
Kv1 I GENE-Y
. O GENE-Y
5 O GENE-Y
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
pimozide I CHEMICAL
is I None
a I None
specific I None
, I None
high I None
affinity I None
antagonist I None
of I None
HERG I GENE-Y
, I None
and I None
that I None
this I None
interaction I None
leads I None
to I None
prolongation I None
of I None
cardiac I None
repolarization I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
L I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
- I None
nitric I CHEMICAL
oxide O CHEMICAL
system I None
on I None
the I None
metabolism I None
of I None
essential I CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
in I None
chemical I None
- I None
induced I None
diabetes I None
mellitus I None
. I None
<eof> I None

<s> O None
Several I None
studies I None
have I None
shown I None
that I None
the I None
activities I None
of I None
delta I GENE-Y
- O GENE-Y
6 O GENE-Y
- O GENE-Y
desaturase O GENE-Y
and I None
delta I GENE-Y
- O GENE-Y
5 O GENE-Y
- O GENE-Y
desaturase O GENE-Y
are I None
depressed I None
in I None
experimental I None
diabetes I None
and I None
in I None
humans I None
with I None
insulin I GENE-Y
- I None
and I None
non I None
- I None
insulin I GENE-Y
- I None
dependent I None
diabetes I None
mellitus I None
( I None
type I None
I I None
and I None
type I None
II I None
diabetes I None
mellitus I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
treatment I None
with I None
insulin I GENE-Y
is I None
known I None
to I None
correct I None
the I None
defects I None
in I None
desaturases I GENE-N
in I None
rats I None
and I None
humans I None
with I None
diabetes I None
, I None
especially I None
in I None
type I None
I I None
. I None
<eof> I None

<s> O None
In I None
a I None
recent I None
study I None
, I None
we I None
demonstrated I None
that I None
L I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
and I None
nitric I CHEMICAL
oxide O CHEMICAL
can I None
prevent I None
alloxan I CHEMICAL
- I None
induced I None
beta I None
cell I None
damage I None
, I None
and I None
the I None
severity I None
of I None
diabetes I None
, I None
and I None
restore I None
the I None
antioxidant I None
status I None
to I None
near I None
normal I None
levels I None
. I None
<eof> I None

<s> O None
But I None
, I None
no I None
information I None
is I None
available I None
as I None
to I None
the I None
relationship I None
between I None
L I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
- I None
nitric I CHEMICAL
oxide O CHEMICAL
system I None
and I None
the I None
metabolism I None
of I None
essential I CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
in I None
diabetes I None
mellitus I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
it I None
was I None
noted I None
that I None
the I None
plasma I None
levels I None
of I None
saturated I CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
: I None
stearic I None
and I None
palmitic I None
were I None
increased I None
where I None
as I None
unsaturated I CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
such I None
as I None
oleic I CHEMICAL
, O CHEMICAL
linoleic O CHEMICAL
, O CHEMICAL
gamma O CHEMICAL
- O CHEMICAL
linolenic O CHEMICAL
and O CHEMICAL
eicosapentaenoic O CHEMICAL
acids O CHEMICAL
( I None
OA I CHEMICAL
, I None
LA I CHEMICAL
, I None
GLA I CHEMICAL
and I None
EPA I CHEMICAL
respectively I None
) I None
were I None
decreased I None
in I None
alloxan I CHEMICAL
- I None
induced I None
diabetic I None
rats I None
. I None
<eof> I None

<s> O None
In I None
the I None
liver I None
phospholipid I None
( I None
PL I None
) I None
fraction I None
, I None
GLA I CHEMICAL
, I None
DGLA I None
( I None
dihomo I CHEMICAL
- O CHEMICAL
GLA O CHEMICAL
) I None
and I None
alpha I CHEMICAL
- O CHEMICAL
linolenic O CHEMICAL
acid O CHEMICAL
( I None
ALA I CHEMICAL
) I None
were I None
decreased I None
in I None
the I None
alloxan I CHEMICAL
- I None
treated I None
group I None
; I None
in I None
the I None
muscle I None
PL I None
fraction I None
, I None
LA I CHEMICAL
, I None
GLA I CHEMICAL
and I None
DGLA I None
were I None
low I None
, I None
whereas I None
an I None
increase I None
in I None
the I None
saturated I CHEMICAL
fatty O CHEMICAL
acid O CHEMICAL
content I None
was I None
noted I None
. I None
<eof> I None

<s> O None
L I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
( I None
the I None
precursor I None
of I None
nitric I CHEMICAL
oxide O CHEMICAL
) I None
and I None
sodium I CHEMICAL
nitroprusside O CHEMICAL
( I None
a I None
nitric I CHEMICAL
oxide O CHEMICAL
donor I None
) I None
treatment I None
of I None
alloxan I CHEMICAL
- I None
induced I None
diabetic I None
rats I None
enhanced I None
the I None
levels I None
of I None
LA I CHEMICAL
, I None
GLA I CHEMICAL
and I None
DGLA I None
. I None
<eof> I None

<s> O None
Further I None
, I None
nitric I GENE-N
oxide O GENE-N
synthase O GENE-N
inhibitor I None
, I None
L I CHEMICAL
- O CHEMICAL
NMMA O CHEMICAL
, I None
prevented I None
this I None
beneficial I None
action I None
of I None
L I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
- I None
nitric I CHEMICAL
oxide O CHEMICAL
system I None
on I None
essential I CHEMICAL
fatty O CHEMICAL
acid O CHEMICAL
metabolism I None
. I None
<eof> I None

<s> O None
The I None
abnormalities I None
in I None
the I None
essential I CHEMICAL
fatty O CHEMICAL
acid O CHEMICAL
metabolism I None
observed I None
also I None
reverted I None
to I None
normalcy I None
following I None
control I None
of I None
diabetes I None
with I None
insulin I GENE-N
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
nitric I CHEMICAL
oxide O CHEMICAL
can I None
enhance I None
the I None
activities I None
of I None
delta I GENE-N
- O GENE-N
6 O GENE-N
- O GENE-N
and O GENE-N
delta O GENE-N
- O GENE-N
5 O GENE-N
desaturases O GENE-N
, I None
which I None
are I None
depressed I None
in I None
diabetes I None
, I None
and I None
suggests I None
that I None
there I None
is I None
a I None
close I None
interaction I None
between I None
L I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
- I None
nitric I CHEMICAL
oxide O CHEMICAL
system I None
and I None
the I None
metabolism I None
of I None
essential I CHEMICAL
fatty O CHEMICAL
acids O CHEMICAL
. I None
<eof> I None

<s> O None
Troglitazone I CHEMICAL
reduces I None
plasminogen I GENE-Y
activator O GENE-Y
inhibitor O GENE-Y
- O GENE-Y
1 O GENE-Y
expression I None
and I None
secretion I None
in I None
cultured I None
human I None
adipocytes I None
. I None
<eof> I None

<s> O None
AIMS I None
/ I None
HYPOTHESIS I None
: I None
Increased I None
plasma I GENE-Y
plasminogen O GENE-Y
activator O GENE-Y
inhibitor O GENE-Y
- O GENE-Y
1 O GENE-Y
( I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
concentrations I None
are I None
characteristic I None
for I None
subjects I None
with I None
insulin I GENE-Y
resistance I None
and I None
could I None
contribute I None
to I None
the I None
increased I None
cardiovascular I None
risk I None
in I None
this I None
state I None
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
investigated I None
the I None
effect I None
of I None
troglitazone I CHEMICAL
, I None
a I None
ligand I None
of I None
the I None
nuclear I GENE-N
receptor O GENE-N
peroxisome I GENE-Y
proliferator O GENE-Y
activated O GENE-Y
receptor O GENE-Y
- O GENE-Y
gamma O GENE-Y
, I None
on I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
expression I None
and I None
secretion I None
in I None
human I None
adipocytes I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
We I None
used I None
two I None
models I None
: I None
in I None
vitro I None
differentiated I None
subcutaneous I None
and I None
omental I None
adipocytes I None
cultured I None
under I None
serum I None
- I None
free I None
conditions I None
and I None
isolated I None
subcutaneous I None
and I None
omental I None
fat I None
cells I None
kept I None
in I None
suspension I None
culture I None
. I None
<eof> I None

<s> O None
Plasminogen I GENE-Y
activator O GENE-Y
inhibitor O GENE-Y
- O GENE-Y
1 O GENE-Y
protein I None
was I None
measured I None
by I None
ELISA I None
, I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
mRNA I None
by I None
a I None
semiquantitative I None
RT I None
- I None
PCR I None
technique I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Exposure I None
of I None
in I None
vitro I None
differentiated I None
subcutaneous I None
adipocytes I None
from I None
young I None
normal I None
- I None
weight I None
females I None
to I None
1 I None
microgram I None
/ I None
ml I None
troglitazone I CHEMICAL
for I None
72 I None
h I None
caused I None
a I None
reduction I None
of I None
both I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
secretion I None
( I None
by I None
29 I None
+ I None
/ I None
- I None
5 I None
% I None
; I None
p I None
< I None
0 I None
. I None
01 I None
) I None
and I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
mRNA I None
expression I None
( I None
by I None
26 I None
+ I None
/ I None
- I None
3 I None
% I None
; I None
p I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
In I None
cultures I None
from I None
severely I None
obese I None
subjects I None
, I None
troglitazone I CHEMICAL
induced I None
a I None
decrease I None
of I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
antigen I None
secretion I None
from I None
newly I None
differentiated I None
omental I None
adipocytes I None
by I None
49 I None
+ I None
/ I None
- I None
8 I None
% I None
( I None
p I None
< I None
0 I None
. I None
01 I None
) I None
and I None
from I None
subcutaneous I None
adipocytes I None
by I None
30 I None
+ I None
/ I None
- I None
7 I None
% I None
( I None
p I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
Exposure I None
of I None
freshly I None
isolated I None
subcutaneous I None
and I None
omental I None
adipocytes I None
in I None
suspension I None
culture I None
to I None
troglitazone I CHEMICAL
induced I None
a I None
similar I None
reduction I None
of I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
concentration I None
in I None
the I None
culture I None
medium I None
( I None
by I None
35 I None
+ I None
/ I None
- I None
11 I None
% I None
, I None
p I None
< I None
0 I None
. I None
05 I None
, I None
and I None
33 I None
+ I None
/ I None
- I None
8 I None
% I None
, I None
p I None
< I None
0 I None
. I None
05 I None
compared I None
with I None
control I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
/ I None
INTERPRETATION I None
: I None
This I None
study I None
provides I None
evidence I None
that I None
troglitazone I CHEMICAL
reduces I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
production I None
in I None
human I None
adipocytes I None
, I None
probably I None
at I None
the I None
transcriptional I None
level I None
. I None
<eof> I None

<s> O None
This I None
observation I None
could I None
point I None
to I None
a I None
new I None
beneficial I None
effect I None
of I None
troglitazone I CHEMICAL
, I None
particularly I None
in I None
obese I None
subjects I None
, I None
which I None
could I None
be I None
associated I None
with I None
a I None
reduced I None
cardiovascular I None
risk I None
. I None
<eof> I None

<s> O None
Topiramate I CHEMICAL
as I None
an I None
inhibitor I None
of I None
carbonic I GENE-N
anhydrase O GENE-N
isoenzymes I None
. I None
<eof> I None

<s> O None
PURPOSE I None
: I None
This I None
study I None
investigated I None
the I None
effectiveness I None
of I None
topiramate I CHEMICAL
( I None
TPM I CHEMICAL
) I None
as I None
an I None
inhibitor I None
of I None
six I None
isozymes I None
of I None
carbonic I GENE-N
anhydrase O GENE-N
( I None
CA I GENE-N
) I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
The I None
inhibition I None
constants I None
( I None
Ki I None
) I None
of I None
TPM I CHEMICAL
and I None
acetazolamide I CHEMICAL
( I None
AZM I CHEMICAL
) I None
for I None
CA I GENE-N
I O GENE-N
, I None
CA I GENE-N
II O GENE-N
, I None
CA I GENE-N
III O GENE-N
, I None
CA I GENE-N
IV O GENE-N
, I None
CA I GENE-N
V O GENE-N
, I None
and I None
CA I GENE-N
VI O GENE-N
were I None
determined I None
for I None
human I None
( I None
HCA I GENE-N
) I None
, I None
rat I None
( I None
RCA I GENE-N
) I None
, I None
or I None
mouse I None
( I None
MCA I GENE-N
) I None
. I None
<eof> I None

<s> O None
The I None
activity I None
of I None
CA I GENE-N
was I None
studied I None
by I None
using I None
purified I None
isozymes I None
, I None
erythrocytes I None
, I None
subcellular I None
fractions I None
of I None
kidney I None
or I None
brain I None
, I None
and I None
saliva I None
, I None
and I None
was I None
assayed I None
at I None
37 I None
degrees I None
C I None
or I None
25 I None
degrees I None
C I None
by I None
18O I None
mass I None
spectrometry I None
and I None
/ I None
or I None
by I None
measuring I None
the I None
pH I None
shift I None
at I None
0 I None
degrees I None
C I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Topiramate I CHEMICAL
Ki I None
values I None
for I None
HCA I GENE-Y
I O GENE-Y
, I None
HCA I GENE-Y
II O GENE-Y
, I None
HCA I GENE-Y
IV O GENE-Y
, I None
and I None
HCA I GENE-Y
VI O GENE-Y
were I None
approximately I None
100 I None
, I None
7 I None
, I None
10 I None
, I None
and I None
> I None
100 I None
microM I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
TPM I CHEMICAL
Ki I None
values I None
for I None
RCA I GENE-Y
I O GENE-Y
, I None
RCA I GENE-Y
II O GENE-Y
, I None
RCA I GENE-Y
III O GENE-Y
, I None
RCA I GENE-Y
IV O GENE-Y
, I None
and I None
RCA I GENE-Y
V O GENE-Y
were I None
approximately I None
180 I None
, I None
0 I None
. I None
1 I None
to I None
1 I None
, I None
> I None
100 I None
, I None
0 I None
. I None
2 I None
to I None
10 I None
and I None
18 I None
microM I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
For I None
RCA I GENE-Y
II O GENE-Y
and I None
RCA I GENE-Y
IV O GENE-Y
, I None
the I None
Ki I None
values I None
were I None
temperature I None
dependent I None
. I None
<eof> I None

<s> O None
TPM I CHEMICAL
Ki I None
values I None
for I None
MCA I GENE-Y
II O GENE-Y
and I None
MCA I GENE-Y
IV O GENE-Y
ranged I None
between I None
1 I None
and I None
20 I None
microM I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
These I None
results I None
indicate I None
that I None
TPM I CHEMICAL
is I None
more I None
potent I None
as I None
an I None
inhibitor I None
of I None
CA I GENE-N
II O GENE-N
and I None
CA I GENE-N
IV O GENE-N
than I None
of I None
CA I GENE-N
I O GENE-N
, I None
CA I GENE-N
III O GENE-N
, I None
and I None
CA I GENE-N
VI O GENE-N
. I None
<eof> I None

<s> O None
In I None
all I None
three I None
species I None
, I None
AZM I CHEMICAL
was I None
usually I None
10 I None
to I None
100 I None
times I None
more I None
potent I None
than I None
TPM I CHEMICAL
as I None
an I None
inhibitor I None
of I None
CA I GENE-N
isozymes I None
. I None
<eof> I None

<s> O None
Effect I None
of I None
JTH I None
- I None
601 I None
, I None
a I None
novel I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonist I None
, I None
on I None
prostate I None
function I None
in I None
dogs I None
. I None
<eof> I None

<s> O None
We I None
examined I None
the I None
effect I None
of I None
JTH I CHEMICAL
- O CHEMICAL
601 O CHEMICAL
( I None
3 I None
- I None
inverted I None
question I None
markN I CHEMICAL
- O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
hydroxy O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
isopropyl O CHEMICAL
- O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
methylphenoxy O CHEMICAL
) O CHEMICAL
ethyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
N O CHEMICAL
- O CHEMICAL
methylaminom O CHEMICAL
ethyl I CHEMICAL
inverted I None
question I None
mark I None
- I None
4 I CHEMICAL
- O CHEMICAL
methoxy O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
, O CHEMICAL
6 O CHEMICAL
- O CHEMICAL
trimethylphenol O CHEMICAL
hemifumarate O CHEMICAL
) I None
, I None
a I None
new I None
alpha I GENE-N
( O GENE-N
1L O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonist I None
, I None
on I None
prostatic I None
function I None
in I None
isolated I None
canine I None
prostate I None
and I None
in I None
anesthetized I None
dogs I None
. I None
<eof> I None

<s> O None
In I None
the I None
contraction I None
study I None
, I None
phenylephrine I CHEMICAL
and I None
noradrenaline I CHEMICAL
produced I None
concentration I None
- I None
dependent I None
contractions I None
in I None
canine I None
prostate I None
and I None
carotid I None
artery I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
In I None
these I None
tissues I None
, I None
JTH I CHEMICAL
- O CHEMICAL
601 O CHEMICAL
, I None
prazosin I CHEMICAL
( I None
a I None
non I None
- I None
selective I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonist I None
) I None
, I None
and I None
tamsulosin I CHEMICAL
( I None
an I None
alpha I GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
antagonist I None
) I None
competitively I None
antagonized I None
contraction I None
in I None
a I None
concentration I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
The I None
pA I None
( I None
2 I None
) I None
( I None
pK I None
( I None
B I None
) I None
) I None
values I None
with I None
prostate I None
were I None
8 I None
. I None
49 I None
+ I None
/ I None
- I None
0 I None
. I None
07 I None
for I None
JTH I None
- I None
601 I None
, I None
7 I None
. I None
94 I None
+ I None
/ I None
- I None
0 I None
. I None
04 I None
for I None
prazosin I CHEMICAL
and I None
9 I None
. I None
42 I None
+ I None
/ I None
- I None
0 I None
. I None
22 I None
for I None
tamsulosin I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
ratio I None
of I None
pA I None
( I None
2 I None
) I None
( I None
carotid I None
artery I None
/ I None
prostate I None
) I None
, I None
i I None
. I None
e I None
. I None
prostatic I None
selectivity I None
, I None
was I None
10 I None
. I None
471 I None
for I None
JTH I CHEMICAL
- O CHEMICAL
601 O CHEMICAL
, I None
0 I None
. I None
008 I None
for I None
prazosin I CHEMICAL
and I None
0 I None
. I None
371 I None
for I None
tamsulosin I CHEMICAL
, I None
respectively I None
. I None
<eof> I None

<s> O None
In I None
anesthetized I None
dogs I None
, I None
JTH I CHEMICAL
- O CHEMICAL
601 O CHEMICAL
( I None
1 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
d I None
. I None
) I None
significantly I None
decreased I None
urethral I None
pressure I None
by I None
15 I None
% I None
without I None
affecting I None
blood I None
pressure I None
or I None
heart I None
rate I None
. I None
<eof> I None

<s> O None
Tamsulosin I CHEMICAL
( I None
0 I None
. I None
1 I None
mg I None
/ I None
kg I None
, I None
i I None
. I None
d I None
. I None
) I None
decreased I None
urethral I None
pressure I None
to I None
the I None
same I None
extent I None
as I None
did I None
JTH I CHEMICAL
- O CHEMICAL
601 O CHEMICAL
, I None
but I None
with I None
a I None
significant I None
effect I None
on I None
blood I None
pressure I None
and I None
heart I None
rate I None
. I None
<eof> I None

<s> O None
JTH I CHEMICAL
- O CHEMICAL
601 O CHEMICAL
showed I None
higher I None
selectivity I None
for I None
canine I None
prostate I None
both I None
in I None
vitro I None
and I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
In I None
prostate I None
, I None
an I None
important I None
role I None
of I None
the I None
alpha I GENE-N
( O GENE-N
1L O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
is I None
suggested I None
in I None
the I None
smooth I None
muscle I None
contraction I None
mediated I None
by I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptors O GENE-N
. I None
<eof> I None

<s> O None
JTH I CHEMICAL
- O CHEMICAL
601 O CHEMICAL
is I None
expected I None
to I None
be I None
an I None
effective I None
alpha I GENE-N
( O GENE-N
1 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonist I None
for I None
the I None
treatment I None
of I None
urinary I None
outlet I None
obstruction I None
by I None
benign I None
prostatic I None
hypertrophy I None
with I None
a I None
minimum I None
effect I None
on I None
the I None
cardiovascular I None
system I None
. I None
<eof> I None

<s> O None
Cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
contributes I None
to I None
N I CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
- O CHEMICAL
D O CHEMICAL
- O CHEMICAL
aspartate O CHEMICAL
- I None
mediated I None
neuronal I None
cell I None
death I None
in I None
primary I None
cortical I None
cell I None
culture I None
. I None
<eof> I None

<s> O None
Cyclooxygenase I GENE-N
isozymes I None
( I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
and I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
are I None
found I None
to I None
be I None
constitutively I None
expressed I None
in I None
brain I None
, I None
with I None
neuronal I None
expression I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
being I None
rapidly I None
induced I None
after I None
numerous I None
insults I None
, I None
including I None
cerebral I None
ischemia I None
. I None
<eof> I None

<s> O None
Because I None
overactivation I None
of I None
N I GENE-N
- O GENE-N
methyl O GENE-N
- O GENE-N
D O GENE-N
- O GENE-N
aspartate O GENE-N
( O GENE-N
NMDA O GENE-N
) O GENE-N
receptors O GENE-N
has I None
been I None
implicated I None
in I None
the I None
cell I None
loss I None
associated I None
with I None
ischemia I None
, I None
we I None
characterized I None
the I None
expression I None
of I None
the I None
COX I GENE-N
isozymes I None
in I None
murine I None
mixed I None
cortical I None
cell I None
cultures I None
and I None
used I None
isozyme I None
- I None
selective I None
inhibitors I None
to I None
determine I None
their I None
relative I None
contribution I None
to I None
NMDA I GENE-N
receptor O GENE-N
- I None
stimulated I None
prostaglandin I CHEMICAL
( I None
PG I CHEMICAL
) I None
production I None
and I None
excitotoxic I None
neuronal I None
cell I None
death I None
. I None
<eof> I None

<s> O None
Immunocytochemical I None
analysis I None
of I None
mixed I None
cortical I None
cell I None
cultures I None
revealed I None
that I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
expression I None
was I None
restricted I None
to I None
neurons I None
, I None
whereas I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
was I None
expressed I None
in I None
both I None
neurons I None
and I None
astrocytes I None
. I None
<eof> I None

<s> O None
Brief I None
exposure I None
to I None
NMDA I CHEMICAL
( I None
5 I None
min I None
; I None
100 I None
microM I None
) I None
elicited I None
a I None
time I None
- I None
dependent I None
accumulation I None
of I None
PGs I None
in I None
the I None
culture I None
medium I None
that I None
preceded I None
neuronal I None
cell I None
death I None
and I None
correlated I None
with I None
the I None
induction I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
mRNA I None
. I None
<eof> I None

<s> O None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
expression I None
remained I None
unchanged I None
. I None
<eof> I None

<s> O None
Flurbiprofen I CHEMICAL
, I None
a I None
nonselective I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
/ I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
, I None
blocked I None
NMDA I CHEMICAL
- I None
stimulated I None
PG I CHEMICAL
production I None
and I None
attenuated I None
neuronal I None
death I None
in I None
a I None
concentration I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
Similar I None
results I None
were I None
obtained I None
with I None
the I None
specific I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
( I None
10 I None
- I None
30 I None
microM I None
) I None
but I None
not I None
with I None
the I None
selective I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
inhibitor I None
valeryl I CHEMICAL
salicylate O CHEMICAL
( I None
10 I None
- I None
300 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
total I None
constitutive I None
COX I GENE-N
activity I None
with I None
aspirin I CHEMICAL
( I None
100 I None
microM I None
, I None
1 I None
. I None
5 I None
h I None
) I None
before I None
NMDA I CHEMICAL
exposure I None
did I None
not I None
prevent I None
subsequent I None
NMDA I CHEMICAL
- I None
mediated I None
neuronal I None
cell I None
death I None
. I None
<eof> I None

<s> O None
However I None
, I None
neuronal I None
injury I None
in I None
aspirin I CHEMICAL
- I None
pretreated I None
cultures I None
was I None
attenuated I None
by I None
flurbiprofen I CHEMICAL
administration I None
after I None
NMDA I CHEMICAL
exposure I None
. I None
<eof> I None

<s> O None
Finally I None
, I None
the I None
protection I None
afforded I None
by I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibition I None
was I None
specific I None
for I None
NMDA I CHEMICAL
because I None
neither I None
flurbiprofen I CHEMICAL
nor I None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
protected I None
neurons I None
against I None
kainate I CHEMICAL
- I None
mediated I None
neurotoxicity I None
. I None
<eof> I None

<s> O None
Together I None
, I None
these I None
results I None
support I None
the I None
conclusion I None
that I None
newly I None
synthesized I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
protein I None
contributes I None
to I None
NMDA I CHEMICAL
- I None
induced I None
neuronal I None
injury I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
the I None
human I GENE-Y
intermediate O GENE-Y
conductance O GENE-Y
Ca O GENE-Y
( O GENE-Y
2 O GENE-Y
+ O GENE-Y
) O GENE-Y
- O GENE-Y
activated O GENE-Y
K O GENE-Y
( O GENE-Y
+ O GENE-Y
) O GENE-Y
channel O GENE-Y
, I None
hIK1 I GENE-Y
, I None
by I None
volatile I None
anesthetics I None
. I None
<eof> I None

<s> O None
Ca I GENE-N
( O GENE-N
2 O GENE-N
+ O GENE-N
) O GENE-N
- O GENE-N
activated O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
channels O GENE-N
( I None
K I GENE-N
( O GENE-N
Ca O GENE-N
) O GENE-N
) I None
regulate I None
a I None
wide I None
variety I None
of I None
cellular I None
functions I None
by I None
coupling I None
intracellular I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
concentration I None
to I None
membrane I None
potential I None
. I None
<eof> I None

<s> O None
There I None
are I None
three I None
major I None
groups I None
of I None
K I GENE-N
( O GENE-N
Ca O GENE-N
) O GENE-N
classified I None
by I None
their I None
unit I None
conductances I None
: I None
large I None
( I None
BK I GENE-Y
) I None
, I None
intermediate I None
( I None
IK I GENE-Y
) I None
, I None
and I None
small I None
( I None
SK I GENE-Y
) I None
conductance I None
of I None
channels I None
. I None
<eof> I None

<s> O None
BK I GENE-Y
channel O GENE-Y
is I None
gated I None
by I None
combined I None
influences I None
of I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
and I None
voltage I None
, I None
while I None
IK I GENE-Y
and I None
SK I GENE-Y
channels O GENE-Y
are I None
gated I None
solely I None
by I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
. I None
<eof> I None

<s> O None
Volatile I None
anesthetics I None
inhibit I None
BK I GENE-Y
channel O GENE-Y
activity I None
by I None
interfering I None
with I None
the I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
gating I None
mechanism I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
effects I None
of I None
anesthetics I None
on I None
IK I GENE-Y
and I None
SK I GENE-Y
channels O GENE-Y
are I None
unknown I None
. I None
<eof> I None

<s> O None
Using I None
cloned I None
IK I GENE-Y
and I None
SK I GENE-Y
channels O GENE-Y
, I None
hIK1 I GENE-Y
and I None
hSK1 I GENE-Y
- O GENE-Y
3 O GENE-Y
, I None
respectively I None
, I None
we I None
found I None
that I None
the I None
currents I None
of I None
hIK1 I GENE-Y
were I None
inhibited I None
rapidly I None
and I None
reversibly I None
by I None
volatile I None
anesthetics I None
, I None
whereas I None
those I None
of I None
SK I GENE-Y
channels O GENE-Y
were I None
not I None
affected I None
. I None
<eof> I None

<s> O None
The I None
IC I None
( I None
50 I None
) I None
values I None
of I None
the I None
volatile I None
anesthetics I None
, I None
halothane I CHEMICAL
, I None
sevoflurane I CHEMICAL
, I None
enflurane I CHEMICAL
, I None
and I None
isoflurane I CHEMICAL
for I None
hIK1 I GENE-Y
inhibition I None
were I None
0 I None
. I None
69 I None
, I None
0 I None
. I None
42 I None
, I None
1 I None
. I None
01 I None
and I None
1 I None
. I None
03 I None
mM I None
, I None
respectively I None
, I None
and I None
were I None
in I None
the I None
clinically I None
used I None
concentration I None
range I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
to I None
BK I GENE-Y
channel O GENE-Y
, I None
halothane I CHEMICAL
inhibition I None
of I None
hIK1 I GENE-Y
currents I None
was I None
independent I None
of I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
concentration I None
, I None
suggesting I None
that I None
Ca I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
gating I None
mechanism I None
is I None
not I None
involved I None
. I None
<eof> I None

<s> O None
These I None
results I None
demonstrate I None
that I None
volatile I None
anesthetics I None
, I None
such I None
as I None
halothane I CHEMICAL
, I None
enflurane I CHEMICAL
, I None
isoflurane I CHEMICAL
, I None
and I None
sevoflurane I CHEMICAL
, I None
affect I None
BK I GENE-Y
, I None
IK I GENE-Y
, I None
and I None
SK I GENE-Y
channels O GENE-Y
in I None
distinct I None
ways I None
. I None
<eof> I None

<s> O None
Characterization I None
of I None
phentermine I CHEMICAL
and I None
related I None
compounds I None
as I None
monoamine I GENE-N
oxidase O GENE-N
( I None
MAO I GENE-N
) I None
inhibitors I None
. I None
<eof> I None

<s> O None
Phentermine I CHEMICAL
was I None
shown I None
in I None
the I None
1970s I None
to I None
inhibit I None
the I None
metabolism I None
of I None
serotonin I CHEMICAL
by I None
monoamine I GENE-N
oxidase O GENE-N
( I None
MAO I GENE-N
) I None
, I None
but I None
never I None
was I None
labeled I None
as I None
an I None
MAO I GENE-N
inhibitor I None
; I None
hence I None
, I None
it I None
was I None
widely I None
used I None
in I None
combination I None
with I None
fenfluramine I CHEMICAL
, I None
and I None
continues I None
to I None
be I None
used I None
, I None
in I None
violation I None
of I None
their I None
labels I None
, I None
with I None
other I None
serotonin I CHEMICAL
uptake I None
blockers I None
. I None
<eof> I None

<s> O None
We I None
examined I None
the I None
effects I None
of I None
phentermine I CHEMICAL
and I None
several I None
other I None
unlabeled I None
MAO I GENE-N
inhibitors I None
on I None
MAO I GENE-N
activities I None
in I None
rat I None
lung I None
, I None
brain I None
, I None
and I None
liver I None
, I None
and I None
also I None
the I None
interactions I None
of I None
such I None
drugs I None
when I None
administered I None
together I None
. I None
<eof> I None

<s> O None
Rat I None
tissues I None
were I None
assayed I None
for I None
MAO I GENE-N
- O GENE-N
A O GENE-N
and O GENE-N
- O GENE-N
B O GENE-N
, I None
using I None
serotonin I CHEMICAL
and I None
beta I CHEMICAL
- O CHEMICAL
phenylethylamine O CHEMICAL
as I None
substrates I None
. I None
<eof> I None

<s> O None
Phentermine I CHEMICAL
inhibited I None
serotonin I CHEMICAL
- I None
metabolizing I None
( I None
MAO I GENE-Y
- O GENE-Y
A O GENE-Y
) I None
activity I None
in I None
all I None
three I None
tissues I None
with I None
K I None
( I None
i I None
) I None
values I None
of I None
85 I None
- I None
88 I None
microM I None
. I None
<eof> I None

<s> O None
These I None
potencies I None
were I None
similar I None
to I None
those I None
of I None
the I None
antidepressant I None
MAO I GENE-N
inhibitors I None
iproniazid I CHEMICAL
and I None
moclobemide I CHEMICAL
. I None
<eof> I None

<s> O None
When I None
phentermine I CHEMICAL
was I None
mixed I None
with I None
other I None
unlabeled I None
reversible I None
MAO I GENE-N
inhibitors I None
( I None
e I None
. I None
g I None
. I None
pseudoephedrine I CHEMICAL
, I None
ephedrine I CHEMICAL
, I None
norephedrine I CHEMICAL
; I None
estradiol I CHEMICAL
benzoate O CHEMICAL
) I None
, I None
the I None
degree I None
of I None
MAO I GENE-N
inhibition I None
was I None
additive I None
. I None
<eof> I None

<s> O None
The I None
cardiac I None
valvular I None
lesions I None
and I None
primary I None
pulmonary I None
hypertension I None
that I None
have I None
been I None
reported I None
to I None
be I None
associated I None
with I None
fenfluramine I CHEMICAL
- I None
phentermine I CHEMICAL
use I None
may I None
have I None
resulted I None
from I None
the I None
intermittent I None
concurrent I None
blockage I None
of I None
both I None
serotonin I CHEMICAL
uptake I None
and I None
metabolism I None
. I None
<eof> I None

<s> O None
Comparison I None
of I None
the I None
AT1 I GENE-Y
- O GENE-Y
receptor O GENE-Y
blocker I None
, I None
candesartan I CHEMICAL
cilexetil O CHEMICAL
, I None
and I None
the I None
ACE I GENE-Y
inhibitor I None
, I None
lisinopril I CHEMICAL
, I None
in I None
fixed I None
combination I None
with I None
low I None
dose I None
hydrochlorothiazide I CHEMICAL
in I None
hypertensive I None
patients I None
. I None
<eof> I None

<s> O None
AIM I None
: I None
To I None
compare I None
candesartan I CHEMICAL
cilexetil O CHEMICAL
and I None
lisinopril I CHEMICAL
in I None
fixed I None
combination I None
with I None
hydrochlorothiazide I CHEMICAL
with I None
respect I None
to I None
antihypertensive I None
efficacy I None
and I None
tolerability I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
This I None
was I None
a I None
double I None
- I None
blind I None
( I None
double I None
- I None
dummy I None
) I None
, I None
randomised I None
, I None
parallel I None
group I None
comparison I None
in I None
patients I None
with I None
a I None
mean I None
sitting I None
diastolic I None
blood I None
pressure I None
95 I None
- I None
115 I None
mm I None
Hg I None
on I None
prior I None
antihypertensive I None
monotherapy I None
. I None
<eof> I None

<s> O None
Treatments I None
were I None
candesartan I CHEMICAL
cilexetil O CHEMICAL
/ I None
hydrochlorothiazide I CHEMICAL
8 I None
/ I None
12 I None
. I None
5 I None
mg I None
once I None
daily I None
( I None
n I None
= I None
237 I None
) I None
and I None
lisinopril I CHEMICAL
/ I None
hydrochlorothiazide I CHEMICAL
10 I None
/ I None
12 I None
. I None
5 I None
mg I None
once I None
daily I None
( I None
n I None
= I None
116 I None
) I None
for I None
26 I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
primary I None
efficacy I None
variable I None
was I None
change I None
in I None
trough I None
sitting I None
diastolic I None
blood I None
pressure I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Changes I None
in I None
mean I None
sitting I None
diastolic I None
blood I None
pressure I None
did I None
not I None
differ I None
significantly I None
between I None
the I None
groups I None
( I None
mean I None
difference I None
0 I None
. I None
5 I None
mm I None
Hg I None
; I None
95 I None
% I None
confidence I None
interval I None
- I None
1 I None
. I None
6 I None
, I None
2 I None
. I None
7 I None
, I None
P I None
= I None
0 I None
. I None
20 I None
) I None
. I None
<eof> I None

<s> O None
No I None
significant I None
differences I None
between I None
the I None
groups I None
was I None
found I None
for I None
other I None
haemodynamic I None
variables I None
( I None
sitting I None
systolic I None
blood I None
pressure I None
, I None
standing I None
blood I None
pressure I None
, I None
sitting I None
/ I None
erect I None
heart I None
rate I None
, I None
and I None
proportion I None
of I None
responders I None
and I None
controlled I None
patients I None
) I None
. I None
<eof> I None

<s> O None
Both I None
drugs I None
were I None
well I None
tolerated I None
but I None
the I None
proportion I None
of I None
patients I None
with I None
at I None
least I None
one I None
adverse I None
event I None
was I None
significantly I None
greater I None
in I None
the I None
lisinopril I CHEMICAL
group I None
( I None
80 I None
% I None
vs I None
69 I None
% I None
, I None
P I None
= I None
0 I None
. I None
020 I None
) I None
. I None
<eof> I None

<s> O None
The I None
proportion I None
of I None
patients I None
spontaneously I None
reporting I None
cough I None
( I None
23 I None
. I None
1 I None
% I None
vs I None
4 I None
. I None
6 I None
% I None
) I None
and I None
discontinuing I None
therapy I None
due I None
to I None
adverse I None
events I None
( I None
12 I None
. I None
0 I None
% I None
vs I None
5 I None
. I None
9 I None
% I None
) I None
was I None
also I None
higher I None
in I None
the I None
lisinopril I CHEMICAL
group I None
compared I None
with I None
the I None
candesartan I CHEMICAL
cilexetil O CHEMICAL
group I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
The I None
fixed I None
combinations I None
of I None
candesartan I CHEMICAL
cilexetil O CHEMICAL
and I None
hydrochlorothiazide I CHEMICAL
8 I None
/ I None
12 I None
. I None
5 I None
mg I None
and I None
lisinopril I CHEMICAL
and I None
hydrochlorothiazide I CHEMICAL
10 I None
/ I None
12 I None
. I None
5 I None
mg I None
once I None
daily I None
are I None
equally I None
effective I None
as I None
antihypertensive I None
agents I None
. I None
<eof> I None

<s> O None
The I None
fixed I None
combination I None
containing I None
candesartan I CHEMICAL
cilexetil O CHEMICAL
is I None
better I None
tolerated I None
than I None
that I None
containing I None
lisinopril I CHEMICAL
. I None
<eof> I None

<s> O None
NADH I GENE-N
- O GENE-N
ferric O GENE-N
reductase O GENE-N
activity I None
associated I None
with I None
dihydropteridine I GENE-Y
reductase O GENE-Y
. I None
<eof> I None

<s> O None
In I None
mammals I None
dietary I None
ferric I CHEMICAL
iron O CHEMICAL
is I None
reduced I None
to I None
ferrous I CHEMICAL
iron O CHEMICAL
for I None
more I None
efficient I None
absorption I None
by I None
the I None
intestine I None
. I None
<eof> I None

<s> O None
Analysis I None
of I None
a I None
pig I None
duodenal I None
membrane I None
fraction I None
revealed I None
two I None
NADH I GENE-N
- O GENE-N
dependent O GENE-N
ferric O GENE-N
reductase O GENE-N
activities I None
, I None
one I None
associated I None
with I None
a I None
b I GENE-N
- O GENE-N
type O GENE-N
cytochrome O GENE-N
and I None
the I None
other I None
not I None
. I None
<eof> I None

<s> O None
Purification I None
and I None
characterization I None
of I None
the I None
non I None
- I None
cytochrome I GENE-N
ferric I GENE-N
reductase O GENE-N
identified I None
a I None
31 I None
kDa I None
protein I None
. I None
<eof> I None

<s> O None
MALDI I None
- I None
MS I None
analysis I None
and I None
amino I CHEMICAL
acid O CHEMICAL
sequencing I None
identified I None
the I None
ferric I GENE-N
reductase O GENE-N
as I None
being I None
related I None
to I None
the I None
26 I None
kDa I None
liver I None
NADH I CHEMICAL
- I None
dependent I None
quinoid I GENE-Y
dihydropteridine O GENE-Y
reductase O GENE-Y
( I None
DHPR I GENE-Y
) I None
. I None
<eof> I None

<s> O None
The I None
NADH I CHEMICAL
- I None
dependent I None
DHPR I GENE-Y
ferric I GENE-N
reductase O GENE-N
activity I None
was I None
found I None
to I None
be I None
pteridine I CHEMICAL
- I None
independent I None
since I None
exhaustive I None
dialysis I None
did I None
not I None
reduce I None
activity I None
and I None
heat I None
- I None
inactivation I None
destroyed I None
activity I None
. I None
<eof> I None

<s> O None
In I None
intestinal I None
Caco I None
- I None
2 I None
cells I None
, I None
DHPR I GENE-Y
mRNA I None
levels I None
were I None
found I None
to I None
be I None
regulated I None
by I None
iron I CHEMICAL
. I None
<eof> I None

<s> O None
Thus I None
, I None
DHPR I GENE-Y
appears I None
to I None
be I None
a I None
dual I None
function I None
enzyme I None
, I None
a I None
NADH I CHEMICAL
- I None
dependent I None
dihydopteridine I GENE-Y
reductase O GENE-Y
and I None
an I None
iron I CHEMICAL
- I None
regulated I None
, I None
NADH I CHEMICAL
- I None
dependent I None
, I None
pteridine I CHEMICAL
- I None
independent I None
ferric I GENE-N
reductase O GENE-N
. I None
<eof> I None

<s> O None
Functional I None
evidence I None
that I None
gastroprotection I None
can I None
be I None
induced I None
by I None
activation I None
of I None
central I None
alpha I GENE-Y
( O GENE-Y
2B O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
subtypes I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
Clonidine I CHEMICAL
injected I None
intracerebroventricularly I None
( I None
i I None
. I None
c I None
. I None
v I None
. I None
) I None
( I None
0 I None
. I None
47 I None
nmol I None
/ I None
rat I None
) I None
exerted I None
gastric I None
mucosal I None
protective I None
effect I None
against I None
acidified I None
ethanol I CHEMICAL
. I None
<eof> I None

<s> O None
Evidence I None
was I None
obtained I None
that I None
the I None
gastroprotective I None
effect I None
of I None
clonidine I CHEMICAL
was I None
blocked I None
by I None
i I None
. I None
c I None
. I None
v I None
. I None
injected I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
antagonists I None
yohimbine I CHEMICAL
( I None
non I None
- I None
subtype I None
selective I None
antagonist I None
) I None
, I None
prazosin I CHEMICAL
and I None
2 I CHEMICAL
- O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
O O CHEMICAL
- O CHEMICAL
methoxyphenyl O CHEMICAL
) O CHEMICAL
piperazin O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
yl O CHEMICAL
) O CHEMICAL
ethyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
4 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
dimethyl O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
, O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
H O CHEMICAL
, O CHEMICAL
4H O CHEMICAL
) O CHEMICAL
- O CHEMICAL
isoquinolindione O CHEMICAL
( I None
ARC I CHEMICAL
- O CHEMICAL
239 O CHEMICAL
) I None
( I None
representative I None
alpha I GENE-N
( O GENE-N
2B O GENE-N
/ O GENE-N
2C O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
blocking I None
agents I None
) I None
and I None
opioid I GENE-N
receptor O GENE-N
antagonists I None
naloxone I CHEMICAL
( I None
a I None
non I None
- I None
selective I None
, I None
moderately I None
mu I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
preferring I None
antagonist I None
) I None
, I None
naltrindole I CHEMICAL
and I None
naltriben I CHEMICAL
delta I GENE-Y
- O GENE-Y
opioid O GENE-Y
receptor O GENE-Y
antagonists I None
) I None
. I None
<eof> I None

<s> O None
The I None
centrally I None
injected I None
naltrindole I CHEMICAL
( I None
0 I None
. I None
5 I None
nmol I None
/ I None
rat I None
) I None
antagonised I None
also I None
the I None
gastroprotective I None
effect I None
of I None
clonidine I CHEMICAL
- I None
- I None
but I None
not I None
that I None
of I None
the I None
delta I None
- I None
agonist I None
[ I CHEMICAL
D O CHEMICAL
- O CHEMICAL
Ala O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
, O CHEMICAL
D O CHEMICAL
- O CHEMICAL
Leu O CHEMICAL
( O CHEMICAL
5 O CHEMICAL
) O CHEMICAL
] O CHEMICAL
enkephalin O CHEMICAL
- I None
- I None
administered I None
peripherally I None
. I None
<eof> I None

<s> O None
The I None
results I None
suggest I None
that I None
central I None
alpha I GENE-N
( O GENE-N
2B O GENE-N
/ O GENE-N
2C O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
subtypes I None
and I None
opioid I None
- I None
- I None
particularly I None
delta I GENE-Y
- O GENE-Y
- O GENE-Y
receptors O GENE-Y
are I None
likely I None
to I None
be I None
involved I None
in I None
the I None
gastric I None
mucosal I None
protective I None
effect I None
of I None
clonidine I CHEMICAL
. I None
<eof> I None

<s> O None
Irbesartan I CHEMICAL
: I None
review I None
of I None
pharmacology I None
and I None
comparative I None
properties I None
. I None
<eof> I None

<s> O None
The I None
recently I None
developed I None
and I None
marketed I None
angiotensin I GENE-Y
II O GENE-Y
type O GENE-Y
1 O GENE-Y
( O GENE-Y
AT1 O GENE-Y
) O GENE-Y
receptor O GENE-Y
blockers I None
( I None
ARBs I None
) I None
have I None
demonstrated I None
efficacy I None
equivalent I None
to I None
that I None
of I None
other I None
leading I None
classes I None
of I None
antihypertensive I None
agents I None
, I None
with I None
superior I None
tolerability I None
profiles I None
. I None
<eof> I None

<s> O None
The I None
specific I None
targeting I None
of I None
the I None
AT1 I GENE-Y
receptor I None
afforded I None
by I None
these I None
agents I None
has I None
demonstrated I None
more I None
complete I None
blockade I None
of I None
the I None
renin I GENE-Y
- I None
angiotensin I CHEMICAL
system I None
than I None
that I None
offered I None
by I None
angiotensin I GENE-Y
- O GENE-Y
converting O GENE-Y
enzyme O GENE-Y
inhibitors I None
. I None
<eof> I None

<s> O None
These I None
data I None
notwithstanding I None
, I None
differentiation I None
within I None
the I None
class I None
of I None
ARBs I None
has I None
been I None
limited I None
. I None
<eof> I None

<s> O None
With I None
the I None
accumulation I None
of I None
additional I None
data I None
with I None
ARBs I None
, I None
it I None
has I None
recently I None
become I None
possible I None
to I None
make I None
within I None
- I None
class I None
distinctions I None
, I None
based I None
in I None
large I None
part I None
on I None
the I None
individual I None
pharmacological I None
profiles I None
of I None
the I None
ARBs I None
. I None
<eof> I None

<s> O None
To I None
this I None
end I None
, I None
absorption I None
, I None
distribution I None
, I None
half I None
- I None
life I None
, I None
dose I None
response I None
and I None
level I None
of I None
angiotensin I CHEMICAL
II O CHEMICAL
antagonism I None
are I None
of I None
special I None
note I None
. I None
<eof> I None

<s> O None
When I None
these I None
properties I None
are I None
viewed I None
as I None
a I None
group I None
, I None
the I None
ARB I None
irbesartan I CHEMICAL
appears I None
to I None
offer I None
advantages I None
beyond I None
those I None
attained I None
with I None
other I None
ARBs I None
. I None
<eof> I None

<s> O None
Irbesartan I CHEMICAL
is I None
well I None
absorbed I None
, I None
does I None
not I None
require I None
biotransformation I None
to I None
an I None
active I None
metabolite I None
to I None
exert I None
its I None
antihypertensive I None
activity I None
, I None
offers I None
a I None
large I None
volume I None
of I None
distribution I None
, I None
has I None
a I None
half I None
- I None
life I None
that I None
is I None
sufficient I None
to I None
allow I None
once I None
- I None
daily I None
dosing I None
, I None
is I None
associated I None
with I None
a I None
strong I None
and I None
consistent I None
dose I None
- I None
response I None
and I None
has I None
been I None
demonstrated I None
to I None
provide I None
a I None
level I None
of I None
angiotensin I CHEMICAL
II O CHEMICAL
antagonism I None
that I None
is I None
statistically I None
superior I None
to I None
that I None
offered I None
by I None
some I None
other I None
ARBs I None
. I None
<eof> I None

<s> O None
These I None
pharmacological I None
differences I None
may I None
explain I None
the I None
clinical I None
superiority I None
of I None
irbesartan I CHEMICAL
compared I None
with I None
losartan I CHEMICAL
, I None
the I None
first I None
member I None
of I None
the I None
ARB I None
class I None
. I None
<eof> I None

<s> O None
As I None
even I None
more I None
data I None
on I None
the I None
ARBs I None
become I None
available I None
, I None
the I None
ability I None
to I None
determine I None
the I None
advantages I None
of I None
specific I None
members I None
of I None
this I None
class I None
will I None
be I None
enhanced I None
, I None
distinctions I None
that I None
already I None
have I None
begun I None
to I None
come I None
to I None
light I None
. I None
<eof> I None

<s> O None
Amphetamine I CHEMICAL
- I None
induced I None
loss I None
of I None
human I GENE-Y
dopamine O GENE-Y
transporter O GENE-Y
activity I None
: I None
an I None
internalization I None
- I None
dependent I None
and I None
cocaine I CHEMICAL
- I None
sensitive I None
mechanism I None
. I None
<eof> I None

<s> O None
The I None
dopamine I GENE-Y
transporter O GENE-Y
( I None
DAT I GENE-Y
) I None
is I None
a I None
target I None
of I None
amphetamine I CHEMICAL
( I None
AMPH I CHEMICAL
) I None
and I None
cocaine I CHEMICAL
. I None
<eof> I None

<s> O None
These I None
psychostimulants I None
attenuate I None
DAT I GENE-Y
clearance I None
efficiency I None
, I None
thereby I None
increasing I None
synaptic I None
dopamine I CHEMICAL
( I None
DA I CHEMICAL
) I None
levels I None
. I None
<eof> I None

<s> O None
Re I None
- I None
uptake I None
rate I None
is I None
determined I None
by I None
the I None
number I None
of I None
functional I None
transporters I None
at I None
the I None
cell I None
surface I None
as I None
well I None
as I None
by I None
their I None
turnover I None
rate I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
present I None
evidence I None
that I None
DAT I GENE-Y
substrates I None
, I None
including I None
AMPH I CHEMICAL
and I None
DA I CHEMICAL
, I None
cause I None
internalization I None
of I None
human I GENE-Y
DAT O GENE-Y
, I None
thereby I None
reducing I None
transport I None
capacity I None
. I None
<eof> I None

<s> O None
Acute I None
treatment I None
with I None
AMPH I CHEMICAL
reduced I None
the I None
maximal I None
rate I None
of I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
DA O CHEMICAL
uptake I None
, I None
decreased I None
AMPH I CHEMICAL
- I None
induced I None
currents I None
, I None
and I None
significantly I None
redistributed I None
the I None
immunofluorescence I None
of I None
an I None
epitope I None
- I None
tagged I None
DAT I GENE-Y
from I None
the I None
plasma I None
membrane I None
to I None
the I None
cytosol I None
in I None
human I None
embryonic I None
kidney I None
293 I None
cells I None
. I None
<eof> I None

<s> O None
Conversely I None
, I None
DAT I GENE-Y
inhibitors I None
, I None
such I None
as I None
cocaine I CHEMICAL
, I None
mazindol I CHEMICAL
, I None
and I None
nomifensine I CHEMICAL
, I None
when I None
administered I None
with I None
AMPH I CHEMICAL
, I None
blocked I None
the I None
reduction I None
in I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
DA O CHEMICAL
uptake I None
and I None
the I None
redistribution I None
of I None
DAT I GENE-Y
immunofluorescence I None
to I None
the I None
cytosol I None
. I None
<eof> I None

<s> O None
The I None
reductions I None
of I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
DA O CHEMICAL
uptake I None
and I None
AMPH I CHEMICAL
- I None
induced I None
DAT I GENE-Y
internalization I None
also I None
were I None
inhibited I None
by I None
coexpression I None
of I None
a I None
dominant I None
negative I None
mutant I None
of I None
dynamin I GENE-Y
I O GENE-Y
( I None
K44A I GENE-N
) I None
, I None
indicating I None
that I None
endocytosis I None
modulates I None
transport I None
capacity I None
, I None
likely I None
through I None
a I None
clathrin I GENE-N
- I None
mediated I None
pathway I None
. I None
<eof> I None

<s> O None
With I None
this I None
mechanism I None
of I None
regulation I None
, I None
acute I None
application I None
of I None
AMPH I CHEMICAL
would I None
reduce I None
DA I CHEMICAL
uptake I None
not I None
only I None
by I None
direct I None
competition I None
for I None
uptake I None
, I None
but I None
also I None
by I None
reducing I None
the I None
available I None
cell I None
- I None
surface I None
DAT I GENE-Y
. I None
<eof> I None

<s> O None
Moreover I None
, I None
AMPH I CHEMICAL
- I None
induced I None
internalization I None
might I None
diminish I None
the I None
amount I None
of I None
DAT I GENE-Y
available I None
for I None
DA I CHEMICAL
efflux I None
, I None
thereby I None
modulating I None
the I None
cytotoxic I None
effects I None
of I None
elevated I None
extracellular I None
DA I CHEMICAL
. I None
<eof> I None

<s> O None
Peroxisome I GENE-Y
proliferator O GENE-Y
- O GENE-Y
activated O GENE-Y
receptor O GENE-Y
alpha O GENE-Y
activators I None
improve I None
insulin I GENE-Y
sensitivity I None
and I None
reduce I None
adiposity I None
. I None
<eof> I None

<s> O None
Fibrates I CHEMICAL
and I None
glitazones I CHEMICAL
are I None
two I None
classes I None
of I None
drugs I None
currently I None
used I None
in I None
the I None
treatment I None
of I None
dyslipidemia I None
and I None
insulin I GENE-Y
resistance I None
( I None
IR I None
) I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Whereas I None
glitazones I CHEMICAL
are I None
insulin I GENE-Y
sensitizers I None
acting I None
via I None
activation I None
of I None
the I None
peroxisome I GENE-Y
proliferator O GENE-Y
- O GENE-Y
activated O GENE-Y
receptor O GENE-Y
( O GENE-Y
PPAR O GENE-Y
) O GENE-Y
gamma O GENE-Y
subtype I None
, I None
fibrates I CHEMICAL
exert I None
their I None
lipid I None
- I None
lowering I None
activity I None
via I None
PPARalpha I GENE-Y
. I None
<eof> I None

<s> O None
To I None
determine I None
whether I None
PPARalpha I GENE-Y
activators I None
also I None
improve I None
insulin I GENE-Y
sensitivity I None
, I None
we I None
measured I None
the I None
capacity I None
of I None
three I None
PPARalpha I GENE-N
- I None
selective I None
agonists I None
, I None
fenofibrate I CHEMICAL
, I None
ciprofibrate I CHEMICAL
, I None
and I None
the I None
new I None
compound I None
GW9578 I CHEMICAL
, I None
in I None
two I None
rodent I None
models I None
of I None
high I None
fat I None
diet I None
- I None
induced I None
( I None
C57BL I None
/ I None
6 I None
mice I None
) I None
or I None
genetic I None
( I None
obese I None
Zucker I None
rats I None
) I None
IR I None
. I None
<eof> I None

<s> O None
At I None
doses I None
yielding I None
serum I None
concentrations I None
shown I None
to I None
activate I None
selectively I None
PPARalpha I GENE-N
, I None
these I None
compounds I None
markedly I None
lowered I None
hyperinsulinemia I None
and I None
, I None
when I None
present I None
, I None
hyperglycemia I None
in I None
both I None
animal I None
models I None
. I None
<eof> I None

<s> O None
This I None
effect I None
relied I None
on I None
the I None
improvement I None
of I None
insulin I GENE-N
action I None
on I None
glucose I CHEMICAL
utilization I None
, I None
as I None
indicated I None
by I None
a I None
lower I None
insulin I GENE-N
peak I None
in I None
response I None
to I None
intraperitoneal I None
glucose I CHEMICAL
in I None
ciprofibrate I CHEMICAL
- I None
treated I None
IR I None
obese I None
Zucker I None
rats I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
fenofibrate I CHEMICAL
treatment I None
prevented I None
high I None
fat I None
diet I None
- I None
induced I None
increase I None
of I None
body I None
weight I None
and I None
adipose I None
tissue I None
mass I None
without I None
influencing I None
caloric I None
intake I None
. I None
<eof> I None

<s> O None
The I None
specificity I None
for I None
PPARalpha I GENE-N
activation I None
in I None
vivo I None
was I None
demonstrated I None
by I None
marked I None
alterations I None
in I None
the I None
expression I None
of I None
PPARalpha I GENE-N
target I None
genes I None
, I None
whereas I None
PPARgamma I GENE-N
target I None
gene I None
mRNA I None
levels I None
did I None
not I None
change I None
in I None
treated I None
animals I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
compounds I None
with I None
a I None
selective I None
PPARalpha I GENE-N
activation I None
profile I None
reduce I None
insulin I GENE-N
resistance I None
without I None
having I None
adverse I None
effects I None
on I None
body I None
weight I None
and I None
adipose I None
tissue I None
mass I None
in I None
animal I None
models I None
of I None
IR I None
. I None
<eof> I None

<s> O None
Recent I None
developments I None
in I None
receptor I None
- I None
selective I None
retinoids I CHEMICAL
. I None
<eof> I None

<s> O None
Natural I None
( I None
all I CHEMICAL
trans O CHEMICAL
- O CHEMICAL
retinoic O CHEMICAL
acid O CHEMICAL
, I None
RA I CHEMICAL
) I None
and I None
synthetic I None
retinoids I CHEMICAL
exhibit I None
potent I None
anti I None
- I None
proliferative I None
, I None
normalization I None
of I None
differentiation I None
and I None
anti I None
- I None
inflammatory I None
activities I None
which I None
appear I None
to I None
account I None
for I None
their I None
therapeutic I None
effects I None
in I None
acne I None
, I None
psoriasis I None
, I None
photoaging I None
, I None
precancerous I None
lesions I None
and I None
established I None
cancers I None
. I None
<eof> I None

<s> O None
Although I None
RA I CHEMICAL
has I None
shown I None
considerable I None
promise I None
in I None
dermatologic I None
indications I None
, I None
certain I None
side I None
effects I None
have I None
restricted I None
its I None
use I None
as I None
a I None
choice I None
of I None
agent I None
for I None
chronic I None
administration I None
. I None
<eof> I None

<s> O None
Systematic I None
synthesis I None
of I None
receptor I None
- I None
selective I None
retinoids I CHEMICAL
has I None
resulted I None
in I None
two I None
topical I None
drugs I None
, I None
Tazorac I CHEMICAL
/ I None
Zorac I CHEMICAL
( I None
tazarotene I CHEMICAL
) I None
and I None
Differin I CHEMICAL
( I None
adapalene I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Tazorac I CHEMICAL
is I None
indicated I None
for I None
psoriasis I None
and I None
acne I None
and I None
Differin I CHEMICAL
gel I None
for I None
the I None
treatment I None
of I None
acne I None
. I None
<eof> I None

<s> O None
These I None
drugs I None
bind I None
to I None
the I None
retinoic I GENE-N
acid O GENE-N
receptor O GENE-N
( I None
RAR I GENE-N
) I None
family I None
members I None
. I None
<eof> I None

<s> O None
Various I None
RAR I GENE-N
subtype I None
- I None
specific I None
and I None
function I None
- I None
selective I None
retinoids I CHEMICAL
have I None
been I None
synthesized I None
. I None
<eof> I None

<s> O None
These I None
retinoids I CHEMICAL
, I None
which I None
are I None
in I None
various I None
stages I None
of I None
pre I None
- I None
clinical I None
development I None
for I None
the I None
treatment I None
of I None
cancers I None
, I None
psoriasis I None
and I None
as I None
an I None
antidote I None
to I None
Accutane I None
- I None
mediated I None
mucocutaneous I None
toxicity I None
, I None
will I None
also I None
be I None
discussed I None
in I None
this I None
review I None
. I None
<eof> I None

<s> O None
Discovery I None
of I None
another I None
retinoid I GENE-N
receptor O GENE-N
, I None
retinoid I GENE-N
X O GENE-N
receptor O GENE-N
( I None
RXR I GENE-N
) I None
, I None
revealed I None
that I None
RXR I GENE-N
- I None
specific I None
retinoids I CHEMICAL
already I None
existed I None
in I None
retinoid I CHEMICAL
chemical I None
libraries I None
. I None
<eof> I None

<s> O None
Structure I None
activity I None
relationship I None
studies I None
based I None
upon I None
binding I None
and I None
transactivation I None
assays I None
led I None
to I None
the I None
synthesis I None
of I None
RXR I GENE-N
- I None
specific I None
ligands I None
with I None
high I None
affinities I None
for I None
RXR I GENE-N
subtypes I None
. I None
<eof> I None

<s> O None
These I None
compounds I None
were I None
found I None
to I None
be I None
effective I None
in I None
the I None
treatment I None
of I None
hyperglycemia I None
in I None
animal I None
models I None
of I None
type I None
II I None
diabetes I None
. I None
<eof> I None

<s> O None
The I None
discovery I None
of I None
novel I None
retinoids I CHEMICAL
along I None
with I None
an I None
increased I None
understanding I None
of I None
the I None
biological I None
functions I None
and I None
mechanisms I None
of I None
action I None
of I None
retinoid I GENE-N
receptors O GENE-N
are I None
likely I None
to I None
result I None
in I None
improved I None
treatments I None
for I None
existing I None
responsive I None
indications I None
and I None
identification I None
of I None
new I None
retinoid I CHEMICAL
therapeutic I None
targets I None
. I None
<eof> I None

<s> O None
Severe I None
impairment I None
of I None
salivation I None
in I None
Na I GENE-N
+ O GENE-N
/ O GENE-N
K O GENE-N
+ O GENE-N
/ O GENE-N
2Cl O GENE-N
- O GENE-N
cotransporter O GENE-N
( I None
NKCC1 I GENE-Y
) I None
- I None
deficient I None
mice I None
. I None
<eof> I None

<s> O None
The I None
salivary I None
fluid I None
secretory I None
mechanism I None
is I None
thought I None
to I None
require I None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
2Cl O GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
cotransporter O GENE-N
- I None
mediated I None
Cl I CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
uptake I None
. I None
<eof> I None

<s> O None
To I None
directly I None
test I None
this I None
possibility I None
we I None
studied I None
the I None
in I None
vivo I None
and I None
in I None
vitro I None
functioning I None
of I None
acinar I None
cells I None
from I None
the I None
parotid I None
glands I None
of I None
mice I None
with I None
targeted I None
disruption I None
of I None
Na I GENE-Y
( O GENE-Y
+ O GENE-Y
) O GENE-Y
/ O GENE-Y
K O GENE-Y
( O GENE-Y
+ O GENE-Y
) O GENE-Y
/ O GENE-Y
2Cl O GENE-Y
( O GENE-Y
- O GENE-Y
) O GENE-Y
cotransporter O GENE-Y
isoform O GENE-Y
1 O GENE-Y
( I None
Nkcc1 I GENE-Y
) I None
, I None
the I None
gene I None
encoding I None
the I None
salivary I None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
2Cl O GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
cotransporter O GENE-N
. I None
<eof> I None

<s> O None
In I None
wild I None
- I None
type I None
mice I None
NKCC1 I GENE-Y
was I None
localized I None
to I None
the I None
basolateral I None
membranes I None
of I None
parotid I None
acinar I None
cells I None
, I None
whereas I None
expression I None
was I None
not I None
detected I None
in I None
duct I None
cells I None
. I None
<eof> I None

<s> O None
The I None
lack I None
of I None
functional I None
NKCC1 I GENE-Y
resulted I None
in I None
a I None
dramatic I None
reduction I None
( I None
> I None
60 I None
% I None
) I None
in I None
the I None
volume I None
of I None
saliva I None
secreted I None
in I None
response I None
to I None
a I None
muscarinic I None
agonist I None
, I None
the I None
primary I None
in I None
situ I None
salivation I None
signal I None
. I None
<eof> I None

<s> O None
Consistent I None
with I None
defective I None
Cl I CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
uptake I None
, I None
a I None
loss I None
of I None
bumetanide I CHEMICAL
- I None
sensitive I None
Cl I CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
influx I None
was I None
observed I None
in I None
parotid I None
acinar I None
cells I None
from I None
mice I None
lacking I None
NKCC1 I GENE-Y
. I None
<eof> I None

<s> O None
Cl I GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
/ O GENE-N
HCO O GENE-N
( O GENE-N
3 O GENE-N
) O GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
exchanger O GENE-N
activity I None
was I None
increased I None
in I None
parotid I None
acinar I None
cells I None
isolated I None
from I None
knockout I None
mice I None
suggesting I None
that I None
the I None
residual I None
saliva I None
secreted I None
by I None
mice I None
lacking I None
NKCC1 I GENE-Y
is I None
associated I None
with I None
anion I None
exchanger I None
- I None
dependent I None
Cl I CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
uptake I None
. I None
<eof> I None

<s> O None
Indeed I None
, I None
expression I None
of I None
the I None
Cl I GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
/ O GENE-N
HCO O GENE-N
( O GENE-N
3 O GENE-N
) O GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
exchanger O GENE-N
AE2 I GENE-N
was I None
enhanced I None
suggesting I None
that I None
this I None
transporter I None
compensates I None
for I None
the I None
loss I None
of I None
functional I None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
K O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
/ O GENE-N
2Cl O GENE-N
( O GENE-N
- O GENE-N
) O GENE-N
cotransporter O GENE-N
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
the I None
ability I None
of I None
the I None
parotid I None
gland I None
to I None
conserve I None
NaCl I CHEMICAL
was I None
abolished I None
in I None
NKCC1 I GENE-Y
- I None
deficient I None
mice I None
. I None
<eof> I None

<s> O None
This I None
deficit I None
was I None
not I None
associated I None
with I None
changes I None
in I None
the I None
morphology I None
of I None
the I None
ducts I None
, I None
but I None
transcript I None
levels I None
for I None
the I None
alpha I None
- I None
, I None
beta I None
- I None
, I None
and I None
gamma I None
- I None
subunits I None
of I None
the I None
epithelial I None
Na I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
channel I None
were I None
reduced I None
. I None
<eof> I None

<s> O None
These I None
data I None
directly I None
demonstrate I None
that I None
NKCC1 I GENE-Y
is I None
the I None
major I None
Cl I CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
uptake I None
mechanism I None
across I None
the I None
basolateral I None
membrane I None
of I None
acinar I None
cells I None
and I None
is I None
critical I None
for I None
driving I None
saliva I None
secretion I None
in I None
vivo I None
. I None
<eof> I None

<s> O None
Induction I None
of I None
estrogen I GENE-N
receptor O GENE-N
- O GENE-N
alpha O GENE-N
and O GENE-N
- O GENE-N
beta O GENE-N
activities I None
by I None
synthetic I None
progestins I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
cellular I None
action I None
of I None
steroid I CHEMICAL
hormones I None
is I None
mediated I None
by I None
specific I None
receptors I None
. I None
<eof> I None

<s> O None
Recently I None
, I None
two I None
different I None
estrogen I GENE-N
receptors O GENE-N
( O GENE-N
ER O GENE-N
) O GENE-N
, O GENE-N
alpha O GENE-N
and O GENE-N
beta O GENE-N
, I None
have I None
been I None
cloned I None
with I None
a I None
specific I None
tissue I None
distribution I None
. I None
<eof> I None

<s> O None
Active I None
estrogen I CHEMICAL
as I None
well I None
as I None
active I None
progestin I CHEMICAL
are I None
compounds I None
of I None
oral I None
hormonal I None
contraceptives I None
and I None
hormone I None
replacement I None
therapy I None
. I None
<eof> I None

<s> O None
To I None
examine I None
the I None
regulation I None
of I None
ER I GENE-N
- O GENE-N
alpha O GENE-N
and O GENE-N
- O GENE-N
beta O GENE-N
activities I None
after I None
treatment I None
with I None
synthetic I None
progestins I CHEMICAL
and I None
synthetic I None
and I None
natural I None
estrogens I CHEMICAL
, I None
COS I None
7 I None
cells I None
were I None
transfected I None
with I None
the I None
vector I None
expressing I None
ER I GENE-N
- O GENE-N
alpha O GENE-N
and O GENE-N
- O GENE-N
beta O GENE-N
in I None
combination I None
with I None
a I None
luciferase I None
reporter I None
vector I None
. I None
<eof> I None

<s> O None
ER I GENE-Y
- O GENE-Y
alpha O GENE-Y
activity I None
was I None
upregulated I None
in I None
the I None
presence I None
of I None
synthetic I None
progestins I CHEMICAL
in I None
a I None
dose I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
Norethisterone I CHEMICAL
, I None
norethynodrel I CHEMICAL
and I None
desogestrel I CHEMICAL
proved I None
to I None
be I None
the I None
most I None
potent I None
stimulatory I None
agents I None
of I None
ER I GENE-Y
- O GENE-Y
alpha O GENE-Y
expression I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
not I None
all I None
progestins I CHEMICAL
exhibited I None
a I None
stimulatory I None
action I None
on I None
ER I GENE-Y
- O GENE-Y
beta O GENE-Y
activity I None
. I None
<eof> I None

<s> O None
Only I None
norgestrel I CHEMICAL
, I None
levonorgestrel I CHEMICAL
, I None
norethynodrel I CHEMICAL
and I None
norethisterone I CHEMICAL
induced I None
ER I GENE-Y
- O GENE-Y
beta O GENE-Y
- I None
activating I None
functions I None
in I None
a I None
dose I None
- I None
dependent I None
manner I None
. I None
<eof> I None

<s> O None
Luciferase I None
activity I None
due I None
to I None
estrogen I CHEMICAL
stimulation I None
served I None
as I None
a I None
positive I None
control I None
. I None
<eof> I None

<s> O None
Our I None
results I None
indicate I None
that I None
progestins I CHEMICAL
have I None
different I None
effects I None
on I None
the I None
activities I None
of I None
ER I GENE-N
- O GENE-N
alpha O GENE-N
and O GENE-N
- O GENE-N
beta O GENE-N
. I None
<eof> I None

<s> O None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
- O GENE-N
dependent O GENE-N
transporters O GENE-N
mediate I None
HCO I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
salvage I None
across I None
the I None
luminal I None
membrane I None
of I None
the I None
main I None
pancreatic I None
duct I None
. I None
<eof> I None

<s> O None
To I None
study I None
the I None
roles I None
of I None
Na I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
- O GENE-N
dependent O GENE-N
H O GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
transporters O GENE-N
, I None
we I None
characterized I None
H I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
efflux I None
mechanisms I None
in I None
the I None
pancreatic I None
duct I None
in I None
wild I None
- I None
type I None
, I None
NHE2 I GENE-Y
( I None
- I None
/ I None
- I None
) I None
, I None
and I None
NHE3 I GENE-Y
( I None
- I None
/ I None
- I None
) I None
mice I None
. I None
<eof> I None

<s> O None
The I None
pancreatic I None
duct I None
expresses I None
NHE1 I GENE-Y
in I None
the I None
basolateral I None
membrane I None
, I None
and I None
NHE2 I GENE-Y
and I None
NHE3 I GENE-Y
in I None
the I None
luminal I None
membrane I None
, I None
but I None
does I None
not I None
contain I None
NHE4 I GENE-Y
or I None
NHE5 I GENE-Y
. I None
<eof> I None

<s> O None
Basolateral I None
Na I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
- I None
dependent I None
H I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
efflux I None
in I None
the I None
microperfused I None
duct I None
was I None
inhibited I None
by I None
1 I None
. I None
5 I None
microM I None
of I None
the I None
amiloride I CHEMICAL
analogue I None
HOE I CHEMICAL
694 O CHEMICAL
, I None
consistent I None
with I None
expression I None
of I None
NHE1 I GENE-Y
, I None
whereas I None
the I None
luminal I None
activity I None
required I None
50 I None
microM I None
HOE I CHEMICAL
694 O CHEMICAL
for I None
effective I None
inhibition I None
, I None
suggesting I None
that I None
the I None
efflux I None
might I None
be I None
mediated I None
by I None
NHE2 I GENE-Y
. I None
<eof> I None

<s> O None
However I None
, I None
disruption I None
of I None
NHE2 I GENE-Y
had I None
no I None
effect I None
on I None
luminal I None
transport I None
, I None
while I None
disruption I None
of I None
the I None
NHE3 I GENE-Y
gene I None
reduced I None
luminal I None
Na I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
- I None
dependent I None
H I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
efflux I None
by I None
approximately I None
45 I None
% I None
. I None
<eof> I None

<s> O None
Notably I None
, I None
the I None
remaining I None
luminal I None
Na I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
- I None
dependent I None
H I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
efflux I None
in I None
ducts I None
from I None
NHE3 I GENE-Y
( I None
- I None
/ I None
- I None
) I None
mice I None
was I None
inhibited I None
by I None
50 I None
microM I None
HOE I CHEMICAL
694 O CHEMICAL
. I None
<eof> I None

<s> O None
Hence I None
, I None
approximately I None
55 I None
% I None
of I None
luminal I None
H I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
efflux I None
( I None
or I None
HCO I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
influx I None
) I None
in I None
the I None
pancreatic I None
duct I None
is I None
mediated I None
by I None
a I None
novel I None
, I None
HOE I CHEMICAL
694 O CHEMICAL
- I None
sensitive I None
, I None
Na I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
- I None
dependent I None
mechanism I None
. I None
<eof> I None

<s> O None
H I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
transport I None
by I None
NHE3 I GENE-Y
and I None
the I None
novel I None
transporter I None
is I None
inhibited I None
by I None
cAMP I CHEMICAL
, I None
albeit I None
to I None
different I None
extents I None
. I None
<eof> I None

<s> O None
We I None
propose I None
that I None
multiple I None
Na I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
- I None
dependent I None
mechanisms I None
in I None
the I None
luminal I None
membrane I None
of I None
the I None
pancreatic I None
duct I None
absorb I None
Na I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
) O CHEMICAL
and I None
HCO I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
to I None
produce I None
a I None
pancreatic I None
juice I None
that I None
is I None
poor I None
in I None
HCO I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
and I None
rich I None
in I None
Cl I CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
during I None
basal I None
secretion I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
the I None
transporters I None
during I None
stimulated I None
secretion I None
aids I None
in I None
producing I None
the I None
HCO I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
- I None
rich I None
pancreatic I None
juice I None
. I None
<eof> I None

<s> O None
Improvement I None
of I None
cardiac I None
output I None
in I None
patients I None
with I None
severe I None
heart I None
failure I None
by I None
use I None
of I None
ACE I GENE-Y
- I None
inhibitors I None
combined I None
with I None
the I None
AT1 I GENE-Y
- I None
antagonist I None
eprosartan I CHEMICAL
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
The I None
efficacy I None
of I None
ACE I GENE-Y
- I None
inhibitor I None
therapy I None
is I None
well I None
documented I None
in I None
the I None
treatment I None
of I None
chronic I None
heart I None
failure I None
. I None
<eof> I None

<s> O None
As I None
pharmacological I None
mechanisms I None
of I None
ACE I GENE-Y
- I None
inhibition I None
and I None
angiotensin I CHEMICAL
II O CHEMICAL
AT1 I GENE-Y
- I None
receptor I None
- I None
antagonists I None
differ I None
, I None
an I None
additional I None
positive I None
effect I None
concerning I None
left I None
ventricular I None
function I None
can I None
be I None
expected I None
in I None
combining I None
both I None
classes I None
of I None
drugs I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Twenty I None
patients I None
( I None
64 I None
. I None
9 I None
+ I None
/ I None
- I None
8 I None
. I None
5 I None
years I None
) I None
with I None
advanced I None
chronic I None
heart I None
failure I None
( I None
NYHA I None
class I None
III I None
) I None
receiving I None
long I None
- I None
term I None
medication I None
with I None
digitalis I None
, I None
diuretics I None
and I None
ACE I GENE-Y
- I None
inhibitors I None
were I None
randomized I None
to I None
either I None
eprosartan I CHEMICAL
( I None
540 I None
+ I None
/ I None
- I None
96 I None
mg I None
/ I None
day I None
) I None
or I None
placebo I None
, I None
according I None
to I None
a I None
blinded I None
protocol I None
. I None
<eof> I None

<s> O None
Hemodynamic I None
measurements I None
by I None
impedance I None
cardiography I None
were I None
performed I None
at I None
baseline I None
and I None
after I None
8 I None
. I None
85 I None
+ I None
/ I None
- I None
1 I None
. I None
<eof> I None

<s> O None
5 I None
days I None
of I None
study I None
medication I None
treatment I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Additional I None
treatment I None
with I None
eprosartan I CHEMICAL
resulted I None
in I None
a I None
higher I None
cardiac I None
output I None
than I None
in I None
the I None
control I None
group I None
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
While I None
in I None
the I None
active I None
treatment I None
group I None
cardiac I None
output I None
increased I None
significantly I None
from I None
baseline I None
( I None
2 I None
. I None
27 I None
- I None
3 I None
. I None
24 I None
l I None
/ I None
min I None
, I None
P I None
= I None
0 I None
. I None
039 I None
) I None
, I None
there I None
was I None
no I None
change I None
in I None
the I None
control I None
group I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
The I None
additional I None
treatment I None
with I None
the I None
AT1 I GENE-Y
- I None
receptor I None
antagonist I None
eprosartan I CHEMICAL
, I None
given I None
to I None
severe I None
heart I None
failure I None
patients I None
, I None
who I None
received I None
digitalis I None
, I None
diuretics I None
and I None
ACE I GENE-Y
- I None
inhibitors I None
, I None
resulted I None
in I None
a I None
beneficial I None
effect I None
by I None
increasing I None
cardiac I None
output I None
. I None
<eof> I None

<s> O None
This I None
effect I None
may I None
be I None
due I None
to I None
eprosartan I None
' I None
s I None
additional I None
property I None
of I None
blocking I None
the I None
autocrine I None
interaction I None
of I None
locally I None
and I None
not I None
ACE I GENE-Y
- I None
generated I None
angiotensin I CHEMICAL
II O CHEMICAL
with I None
their I None
respective I None
vascular I None
and I None
myocardial I None
AT1 I GENE-Y
- I None
receptors I None
as I None
well I None
as I None
the I None
influence I None
on I None
prejunctional I None
AT1 I GENE-Y
- I None
receptors I None
located I None
on I None
sympathetic I None
nerve I None
terminals I None
. I None
<eof> I None

<s> O None
Gene I None
expression I None
of I None
the I None
phosphodiesterases I GENE-N
3A O GENE-N
and O GENE-N
5A O GENE-N
in I None
human I None
corpus I None
cavernosum I None
penis I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
The I None
following I None
study I None
was I None
performed I None
to I None
evaluate I None
the I None
importance I None
of I None
phosphodiesterases I GENE-Y
3A O GENE-Y
( I None
PDE3A I GENE-Y
) I None
and I None
5A I None
( I None
PDE5A I GENE-Y
) I None
for I None
the I None
regulation I None
of I None
penile I None
smooth I None
muscle I None
tone I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
indications I None
of I None
side I None
effects I None
of I None
specific I None
inhibitors I None
in I None
certain I None
tissues I None
as I None
well I None
as I None
of I None
a I None
possible I None
relation I None
between I None
the I None
level I None
of I None
PDE3A I GENE-Y
and I None
PDE5A I GENE-Y
gene I None
expression I None
and I None
erectile I None
dysfunction I None
should I None
have I None
been I None
deduced I None
from I None
the I None
results I None
obtained I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
Total I None
ribonucleic I None
acid I None
was I None
isolated I None
from I None
different I None
human I None
tissues I None
( I None
urogenital I None
tract I None
, I None
gastrointestinal I None
tract I None
, I None
cardiovascular I None
system I None
and I None
central I None
nervous I None
system I None
) I None
and I None
subjected I None
to I None
RTPCR I None
analysis I None
and I None
Northern I None
blotting I None
using I None
primers I None
and I None
probes I None
specific I None
for I None
PDE3A I GENE-Y
and I None
PDE5A I GENE-Y
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
As I None
shown I None
by I None
RT I None
- I None
PCR I None
and I None
Northern I None
blotting I None
, I None
PDE3A I GENE-Y
and I None
PDE5A I GENE-Y
mRNAs I None
exhibit I None
a I None
distinct I None
distribution I None
throughout I None
the I None
tissues I None
examined I None
but I None
were I None
2 I None
- I None
fold I None
higher I None
in I None
cavernous I None
tissue I None
than I None
in I None
all I None
other I None
tissues I None
investigated I None
. I None
<eof> I None

<s> O None
However I None
, I None
there I None
were I None
no I None
significant I None
differences I None
in I None
the I None
levels I None
of I None
gene I None
expression I None
between I None
the I None
two I None
subgroups I None
of I None
patients I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Very I None
high I None
expression I None
levels I None
of I None
PDE3A I GENE-Y
and I None
PDE5A I GENE-Y
in I None
human I None
cavernous I None
tissue I None
underscore I None
the I None
physiological I None
importance I None
of I None
these I None
enzymes I None
for I None
the I None
regulation I None
of I None
penile I None
erection I None
, I None
emphasizing I None
their I None
therapeutical I None
and I None
pharmacological I None
relevance I None
. I None
<eof> I None

<s> O None
The I None
distribution I None
pattern I None
of I None
the I None
mRNA I None
for I None
the I None
isoenzymes I None
PDE3A I GENE-Y
and I None
PDE5A I GENE-Y
may I None
explain I None
the I None
pharmacological I None
effects I None
as I None
well I None
as I None
the I None
side I None
effects I None
of I None
milrinone I CHEMICAL
and I None
sidenafil I CHEMICAL
. I None
<eof> I None

<s> O None
Effects I None
of I None
troglitazone I CHEMICAL
on I None
blood I None
concentrations I None
of I None
plasminogen I GENE-Y
activator O GENE-Y
inhibitor O GENE-Y
1 O GENE-Y
in I None
patients I None
with I None
type I None
2 I None
diabetes I None
and I None
in I None
lean I None
and I None
obese I None
normal I None
subjects I None
. I None
<eof> I None

<s> O None
Low I None
plasma I None
fibrinolytic I None
activity I None
in I None
association I None
with I None
increased I None
plasma I None
plasminogen I GENE-Y
activator O GENE-Y
inhibitor O GENE-Y
1 O GENE-Y
( I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
levels I None
has I None
been I None
linked I None
to I None
an I None
increased I None
risk I None
of I None
atherosclerosis I None
in I None
obesity I None
and I None
type I None
2 I None
diabetes I None
. I None
<eof> I None

<s> O None
We I None
tested I None
the I None
hypothesis I None
that I None
troglitazone I CHEMICAL
, I None
which I None
improves I None
insulin I GENE-Y
sensitivity I None
and I None
lowers I None
plasma I None
insulin I GENE-Y
levels I None
in I None
insulin I GENE-Y
- I None
resistant I None
obese I None
subjects I None
and I None
patients I None
with I None
type I None
2 I None
diabetes I None
, I None
would I None
also I None
lower I None
circulating I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
antigen I None
concentrations I None
and I None
activity I None
. I None
<eof> I None

<s> O None
We I None
assessed I None
insulin I GENE-Y
sensitivity I None
( I None
5 I None
- I None
h I None
, I None
80 I None
mU I None
x I None
m I None
( I None
- I None
2 I None
) I None
x I None
min I None
( I None
- I None
1 I None
) I None
hyperinsulinemic I None
- I None
euglycemic I None
clamp I None
) I None
and I None
measured I None
plasma I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
antigen I None
and I None
activities I None
and I None
tissue I GENE-Y
plasminogen O GENE-Y
activator O GENE-Y
( I None
tPA I GENE-Y
) I None
in I None
14 I None
patients I None
with I None
type I None
2 I None
diabetes I None
and I None
20 I None
normal I None
control I None
subjects I None
( I None
10 I None
lean I None
, I None
10 I None
obese I None
) I None
before I None
and I None
after I None
3 I None
months I None
of I None
treatment I None
with I None
troglitazone I CHEMICAL
( I None
600 I None
mg I None
/ I None
day I None
) I None
. I None
<eof> I None

<s> O None
At I None
baseline I None
, I None
plasma I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
antigen I None
levels I None
after I None
an I None
overnight I None
fast I None
were I None
significantly I None
higher I None
in I None
the I None
obese I None
( I None
33 I None
. I None
5 I None
+ I None
/ I None
- I None
4 I None
. I None
7 I None
microg I None
/ I None
l I None
) I None
and I None
type I None
2 I None
diabetic I None
subjects I None
( I None
54 I None
. I None
9 I None
+ I None
/ I None
- I None
6 I None
. I None
3 I None
microg I None
/ I None
l I None
) I None
than I None
in I None
the I None
lean I None
control I None
subjects I None
( I None
16 I None
. I None
3 I None
+ I None
/ I None
- I None
3 I None
. I None
2 I None
microg I None
/ I None
l I None
; I None
P I None
< I None
0 I None
. I None
01 I None
and I None
P I None
< I None
0 I None
. I None
001 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
Troglitazone I CHEMICAL
decreased I None
plasma I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
antigen I None
concentrations I None
in I None
the I None
diabetic I None
patients I None
( I None
36 I None
. I None
8 I None
+ I None
/ I None
- I None
5 I None
. I None
0 I None
microg I None
/ I None
l I None
; I None
P I None
< I None
0 I None
. I None
001 I None
vs I None
. I None
baseline I None
) I None
, I None
but I None
the I None
reduction I None
in I None
the I None
obese I None
subjects I None
did I None
not I None
reach I None
statistical I None
significance I None
( I None
baseline I None
, I None
33 I None
. I None
5 I None
+ I None
/ I None
- I None
4 I None
. I None
7 I None
; I None
after I None
troglitazone I CHEMICAL
, I None
25 I None
. I None
6 I None
+ I None
/ I None
- I None
5 I None
. I None
2 I None
microg I None
/ I None
l I None
) I None
. I None
<eof> I None

<s> O None
Changes I None
in I None
plasma I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
activity I None
paralleled I None
those I None
of I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
antigen I None
. I None
<eof> I None

<s> O None
The I None
extent I None
of I None
the I None
reduction I None
in I None
plasma I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
antigen I None
concentrations I None
in I None
the I None
diabetic I None
patients I None
after I None
troglitazone I CHEMICAL
correlated I None
with I None
the I None
reductions I None
in I None
fasting I None
plasma I None
insulin I GENE-Y
( I None
r I None
= I None
0 I None
. I None
60 I None
, I None
P I None
< I None
0 I None
. I None
05 I None
) I None
, I None
nonesterified I CHEMICAL
fatty O CHEMICAL
acid O CHEMICAL
( I None
r I None
= I None
0 I None
. I None
63 I None
, I None
P I None
< I None
0 I None
. I None
02 I None
) I None
, I None
and I None
glucose I CHEMICAL
concentrations I None
( I None
r I None
= I None
0 I None
. I None
64 I None
, I None
P I None
< I None
0 I None
. I None
02 I None
) I None
but I None
not I None
with I None
the I None
improvement I None
in I None
glucose I CHEMICAL
disposal I None
rates I None
during I None
the I None
glucose I CHEMICAL
clamps I None
. I None
<eof> I None

<s> O None
Three I None
nonresponders I None
to I None
troglitazone I CHEMICAL
with I None
respect I None
to I None
effects I None
on I None
insulin I GENE-Y
sensitivity I None
and I None
fasting I None
glucose I CHEMICAL
and I None
insulin I GENE-Y
levels I None
also I None
had I None
no I None
reduction I None
in I None
circulating I None
PAI I GENE-Y
- O GENE-Y
1 O GENE-Y
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
troglitazone I CHEMICAL
enhances I None
fibrinolytic I None
system I None
activity I None
in I None
insulin I GENE-Y
- I None
resistant I None
type I None
2 I None
diabetic I None
patients I None
. I None
<eof> I None

<s> O None
This I None
effect I None
appears I None
to I None
be I None
intimately I None
linked I None
to I None
its I None
potential I None
to I None
lower I None
plasma I None
insulin I GENE-Y
levels I None
and I None
improve I None
glycemic I None
control I None
through I None
its I None
peripheral I None
tissue I None
insulin I GENE-Y
- I None
sensitizing I None
effects I None
. I None
<eof> I None

<s> O None
Tetrahydropterin I CHEMICAL
- I None
dependent I None
amino I GENE-N
acid O GENE-N
hydroxylases O GENE-N
. I None
<eof> I None

<s> O None
Phenylalanine I GENE-Y
hydroxylase O GENE-Y
, I None
tyrosine I GENE-Y
hydroxylase O GENE-Y
, I None
and I None
tryptophan I GENE-Y
hydroxylase O GENE-Y
constitute I None
a I None
small I None
family I None
of I None
monooxygenases I GENE-N
that I None
utilize I None
tetrahydropterins I CHEMICAL
as I None
substrates I None
. I None
<eof> I None

<s> O None
When I None
from I None
eukaryotic I None
sources I None
, I None
these I None
enzymes I None
are I None
composed I None
of I None
a I None
homologous I None
catalytic I None
domain I None
to I None
which I None
are I None
attached I None
discrete I None
N I GENE-N
- O GENE-N
terminal O GENE-N
regulatory O GENE-N
domains O GENE-N
and I None
short I None
C I GENE-N
- O GENE-N
terminal O GENE-N
tetramerization O GENE-N
domains O GENE-N
, I None
whereas I None
the I None
bacterial I None
enzymes I None
lack I None
the I None
N I CHEMICAL
- I None
terminal I None
and I None
C I CHEMICAL
- I None
terminal I None
domains I None
. I None
<eof> I None

<s> O None
Each I None
enzyme I None
contains I None
a I None
single I None
ferrous I CHEMICAL
iron O CHEMICAL
atom I None
bound I None
to I None
two I None
histidines I CHEMICAL
and I None
a I None
glutamate I CHEMICAL
. I None
<eof> I None

<s> O None
Recent I None
mechanistic I None
studies I None
have I None
begun I None
to I None
provide I None
insights I None
into I None
the I None
mechanisms I None
of I None
oxygen I CHEMICAL
activation I None
and I None
hydroxylation I None
. I None
<eof> I None

<s> O None
Although I None
the I None
hydroxylating I None
intermediate I None
in I None
these I None
enzymes I None
has I None
not I None
been I None
identified I None
, I None
the I None
iron I None
is I None
likely I None
to I None
be I None
involved I None
. I None
<eof> I None

<s> O None
Reversible I None
phosphorylation I None
of I None
serine I CHEMICAL
residues I None
in I None
the I None
regulatory I None
domains I None
affects I None
the I None
activities I None
of I None
all I None
three I None
enzymes I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
phenylalanine I GENE-Y
hydroxylase O GENE-Y
is I None
allosterically I None
regulated I None
by I None
its I None
substrates I None
, I None
phenylalanine I CHEMICAL
and I None
tetrahydrobiopterin I CHEMICAL
. I None
<eof> I None

<s> O None
Protective I None
action I None
of I None
cardiac I None
DT I GENE-Y
- O GENE-Y
diaphorase O GENE-Y
against I None
menadione I CHEMICAL
toxicity I None
in I None
guinea I None
pig I None
isolated I None
atria I None
. I None
<eof> I None

<s> O None
In I None
myocardial I None
preparations I None
isolated I None
from I None
guinea I None
pigs I None
, I None
2 I CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
naphthoquinone O CHEMICAL
( I None
menadione I CHEMICAL
) I None
causes I None
an I None
increase I None
in I None
contractility I None
that I None
is I None
strictly I None
related I None
to I None
the I None
generation I None
of I None
reactive I None
oxygen I CHEMICAL
species I None
( I None
ROS I None
) I None
as I None
a I None
consequence I None
of I None
quinone I CHEMICAL
metabolism I None
. I None
<eof> I None

<s> O None
In I None
heart I None
, I None
menadione I CHEMICAL
undergoes I None
one I None
- I None
electron I None
reduction I None
to I None
semiquinone I CHEMICAL
, I None
a I None
reaction I None
mainly I None
catalysed I None
by I None
mitochondrial I None
NADH I GENE-N
: O GENE-N
ubiquinone O GENE-N
oxidoreductase O GENE-N
. I None
<eof> I None

<s> O None
It I None
is I None
also I None
converted I None
to I None
hydroquinone I CHEMICAL
by I None
the I None
soluble I None
two I None
- I None
electron I None
reductase I None
, I None
DT I GENE-Y
- O GENE-Y
diaphorase O GENE-Y
, I None
and I None
is I None
conjugated I None
with I None
GSH I CHEMICAL
by I None
glutathione I GENE-N
S O GENE-N
- O GENE-N
transferase O GENE-N
. I None
<eof> I None

<s> O None
In I None
order I None
to I None
assess I None
the I None
role I None
of I None
DT I GENE-Y
- O GENE-Y
diaphorase O GENE-Y
in I None
cardiac I None
responses I None
to I None
menadione I CHEMICAL
, I None
we I None
examined I None
the I None
effects I None
of I None
both I None
a I None
specific I None
inhibitor I None
( I None
dicoumarol I CHEMICAL
) I None
and I None
an I None
inducer I None
( I None
beta I CHEMICAL
- O CHEMICAL
naphthoflavone O CHEMICAL
) I None
of I None
the I None
enzyme I None
on I None
the I None
inotropic I None
action I None
of I None
the I None
quinone I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
electrically I None
driven I None
left I None
atria I None
of I None
guinea I None
pig I None
, I None
4 I None
microM I None
dicoumarol I CHEMICAL
significantly I None
enhanced I None
the I None
positive I None
inotropic I None
effect I None
of I None
menadione I CHEMICAL
, I None
especially I None
at I None
the I None
lower I None
concentrations I None
of I None
the I None
quinone I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
myocardial I None
preparations I None
isolated I None
from I None
guinea I None
pigs I None
treated I None
with I None
beta I CHEMICAL
- O CHEMICAL
naphthoflavone O CHEMICAL
( I None
80 I None
mg I None
/ I None
kg I None
i I None
. I None
p I None
. I None
for I None
2 I None
days I None
) I None
, I None
DT I GENE-Y
- O GENE-Y
diaphorase O GENE-Y
activity I None
was I None
enhanced I None
( I None
+ I None
36 I None
% I None
with I None
respect I None
to I None
control I None
animals I None
, I None
P I None
< I None
0 I None
. I None
01 I None
) I None
, I None
whereas I None
the I None
activities I None
of I None
the I None
other I None
enzymes I None
involved I None
in I None
menadione I None
metabolism I None
were I None
not I None
modified I None
. I None
<eof> I None

<s> O None
In I None
these I None
preparations I None
, I None
menadione I CHEMICAL
caused I None
a I None
significantly I None
lower I None
increase I None
in I None
the I None
force I None
of I None
contraction I None
than I None
in I None
atria I None
from I None
untreated I None
animals I None
; I None
moreover I None
, I None
pretreatment I None
with I None
beta I CHEMICAL
- O CHEMICAL
naphthoflavone O CHEMICAL
caused I None
a I None
significant I None
decrease I None
in I None
the I None
menadione I CHEMICAL
- I None
induced I None
oxidative I None
stress I None
, I None
as I None
evaluated I None
from I None
the I None
GSH I CHEMICAL
redox I None
index I None
. I None
<eof> I None

<s> O None
Taken I None
together I None
, I None
these I None
results I None
demonstrate I None
that I None
cardiac I None
DT I GENE-Y
- O GENE-Y
diaphorase O GENE-Y
does I None
not I None
contribute I None
to I None
ROS I None
generation I None
, I None
but I None
represents I None
a I None
detoxification I None
system I None
. I None
<eof> I None

<s> O None
The I None
use I None
of I None
leflunomide I CHEMICAL
in I None
the I None
treatment I None
of I None
rheumatoid I None
arthritis I None
: I None
an I None
experimental I None
and I None
clinical I None
review I None
. I None
<eof> I None

<s> O None
Leflunomide I CHEMICAL
, I None
the I None
newest I None
disease I None
- I None
modifying I None
antirheumatic I None
drug I None
( I None
DMARD I None
) I None
for I None
the I None
treatment I None
of I None
rheumatoid I None
arthritis I None
( I None
RA I None
) I None
, I None
acts I None
by I None
inhibiting I None
dihydroorotate I GENE-Y
dehydrogenase O GENE-Y
, I None
the I None
rate I None
- I None
limiting I None
enzyme I None
in I None
the I None
pathway I None
for I None
pyrimidine I CHEMICAL
production I None
. I None
<eof> I None

<s> O None
The I None
drug I None
thus I None
limits I None
T I None
- I None
cell I None
proliferation I None
, I None
a I None
process I None
thought I None
to I None
be I None
a I None
key I None
step I None
in I None
the I None
pathogenesis I None
of I None
RA I None
. I None
<eof> I None

<s> O None
In I None
placebo I None
- I None
controlled I None
trials I None
, I None
leflunomide I CHEMICAL
was I None
superior I None
to I None
placebo I None
and I None
comparable I None
to I None
sulfasalazine I CHEMICAL
and I None
methotrexate I CHEMICAL
for I None
improving I None
the I None
signs I None
and I None
symptoms I None
of I None
RA I None
; I None
and I None
superior I None
to I None
placebo I None
, I None
sulfasalazine I CHEMICAL
, I None
and I None
methotrexate I CHEMICAL
for I None
improving I None
health I None
- I None
related I None
quality I None
of I None
life I None
. I None
<eof> I None

<s> O None
In I None
the I None
same I None
trials I None
, I None
leflunomide I CHEMICAL
was I None
also I None
superior I None
to I None
methotrexate I CHEMICAL
and I None
comparable I None
to I None
sulfasalazine I CHEMICAL
for I None
slowing I None
radiographically I None
assessed I None
progression I None
of I None
RA I None
. I None
<eof> I None

<s> O None
When I None
used I None
in I None
combination I None
therapy I None
in I None
an I None
open I None
- I None
label I None
trial I None
, I None
leflunomide I CHEMICAL
resulted I None
in I None
improvement I None
for I None
over I None
half I None
of I None
a I None
group I None
of I None
RA I None
patients I None
who I None
had I None
failed I None
to I None
respond I None
to I None
methotrexate I CHEMICAL
alone I None
. I None
<eof> I None

<s> O None
The I None
most I None
common I None
adverse I None
events I None
associated I None
with I None
leflunomide I CHEMICAL
treatment I None
were I None
gastrointestinal I None
symptoms I None
, I None
allergic I None
reactions I None
, I None
alopecia I None
, I None
and I None
elevated I None
liver I None
enzyme I None
levels I None
. I None
<eof> I None

<s> O None
Adverse I None
events I None
were I None
generally I None
mild I None
to I None
moderate I None
in I None
severity I None
and I None
resolved I None
without I None
sequelae I None
. I None
<eof> I None

<s> O None
Clinical I None
trial I None
results I None
indicate I None
that I None
leflunomide I CHEMICAL
is I None
an I None
efficacious I None
and I None
safe I None
addition I None
to I None
the I None
roster I None
of I None
therapeutic I None
agents I None
used I None
to I None
treat I None
RA I None
. I None
<eof> I None

<s> O None
Mechanisms I None
of I None
reduced I None
body I None
growth I None
in I None
the I None
pubertal I None
feminized I None
male I None
rat I None
: I None
unbalanced I None
estrogen I CHEMICAL
and I None
androgen I CHEMICAL
action I None
on I None
the I None
somatotropic I None
axis I None
. I None
<eof> I None

<s> O None
It I None
is I None
well I None
known I None
that I None
the I None
sex I None
difference I None
in I None
body I None
growth I None
at I None
puberty I None
is I None
modulated I None
by I None
a I None
complex I None
interplay I None
between I None
sex I None
steroids I CHEMICAL
and I None
somatotropic I None
axis I None
; I None
however I None
, I None
the I None
exact I None
role I None
played I None
by I None
sex I None
steroids I CHEMICAL
remains I None
a I None
matter I None
of I None
controversy I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
assess I None
the I None
mechanisms I None
by I None
which I None
sex I None
steroids I CHEMICAL
regulate I None
body I None
growth I None
during I None
pubertal I None
development I None
. I None
<eof> I None

<s> O None
Flutamide I CHEMICAL
, I None
a I None
non I None
- I None
steroid I CHEMICAL
- I None
blocking I None
androgen I GENE-Y
receptor O GENE-Y
, I None
was I None
subcutaneously I None
administered I None
to I None
30 I None
- I None
d I None
- I None
old I None
male I None
Wistar I None
rats I None
for I None
4 I None
wk I None
. I None
<eof> I None

<s> O None
The I None
blockade I None
of I None
the I None
androgen I GENE-Y
receptor O GENE-Y
led I None
to I None
a I None
marked I None
elevation I None
in I None
serum I None
testosterone I CHEMICAL
and I None
an I None
increment I None
in I None
serum I None
estradiol I CHEMICAL
. I None
<eof> I None

<s> O None
Flutamide I CHEMICAL
administration I None
decreased I None
body I None
weight I None
gain I None
, I None
serum I None
IGF I GENE-Y
- O GENE-Y
I O GENE-Y
levels I None
, I None
hepatic I None
IGF I GENE-Y
- O GENE-Y
I O GENE-Y
mRNA I None
, I None
and I None
GH I GENE-Y
receptor O GENE-Y
mRNA I None
content I None
. I None
<eof> I None

<s> O None
There I None
were I None
no I None
significant I None
changes I None
in I None
serum I None
GH I GENE-Y
concentration I None
, I None
pituitary I None
GH I GENE-Y
reserve I None
, I None
and I None
pituitary I None
GH I GENE-Y
mRNA I None
content I None
. I None
<eof> I None

<s> O None
Flutamide I CHEMICAL
lowered I None
hypothalamic I None
somatostatin I GENE-Y
mRNA I None
content I None
and I None
augmented I None
hypothalamic I None
immunoreactive I None
somatostatin I GENE-Y
stores I None
, I None
but I None
did I None
not I None
alter I None
hypothalamic I None
immunoreactive I None
GH I GENE-Y
- I None
releasing I None
factor I None
stores I None
. I None
<eof> I None

<s> O None
Our I None
findings I None
indicate I None
that I None
during I None
pubertal I None
development I None
of I None
the I None
male I None
rat I None
, I None
the I None
imbalance I None
between I None
androgen I CHEMICAL
and I None
estrogen I CHEMICAL
actions I None
determines I None
an I None
abnormal I None
somatic I None
growth I None
, I None
which I None
is I None
at I None
least I None
partly I None
exerted I None
through I None
the I None
peripheral I None
or I None
hepatic I None
modification I None
of I None
the I None
somatotropic I None
axis I None
that I None
occurs I None
under I None
the I None
high I None
or I None
exclusive I None
action I None
of I None
estrogens I CHEMICAL
. I None
<eof> I None

<s> O None
Potential I None
implication I None
of I None
coincident I None
sex I None
- I None
specific I None
regulated I None
mode I None
of I None
pulsatile I None
GH I GENE-Y
secretion I None
cannot I None
be I None
excluded I None
from I None
this I None
random I None
serum I None
GH I GENE-Y
sample I None
study I None
. I None
<eof> I None

<s> O None
Clinical I None
pharmacology I None
, I None
therapeutic I None
use I None
and I None
potential I None
of I None
COMT I GENE-Y
inhibitors I None
in I None
Parkinson I None
' I None
s I None
disease I None
. I None
<eof> I None

<s> O None
When I None
peripheral I None
decarboxylation I None
is I None
blocked I None
by I None
carbidopa I CHEMICAL
or I None
benserazide I CHEMICAL
, I None
the I None
main I None
metabolic I None
pathway I None
of I None
levodopa I CHEMICAL
is I None
O I CHEMICAL
- I None
methylation I None
by I None
catechol I GENE-Y
- O GENE-Y
O O GENE-Y
- O GENE-Y
methyltransferase O GENE-Y
( I None
COMT I GENE-Y
) I None
. I None
<eof> I None

<s> O None
Entacapone I CHEMICAL
and I None
tolcapone I CHEMICAL
are I None
new I None
potent I None
, I None
selective I None
and I None
reversible I None
nitrocatechol I CHEMICAL
- I None
type I None
COMT I GENE-Y
inhibitors I None
. I None
<eof> I None

<s> O None
Animal I None
studies I None
have I None
demonstrated I None
that I None
entacapone I CHEMICAL
mainly I None
has I None
a I None
peripheral I None
effect I None
whereas I None
tolcapone I CHEMICAL
also I None
inhibits I None
O I CHEMICAL
- I None
methylation I None
in I None
the I None
brain I None
. I None
<eof> I None

<s> O None
In I None
human I None
volunteers I None
, I None
both I None
entacapone I CHEMICAL
and I None
tolcapone I CHEMICAL
dose I None
- I None
dependently I None
inhibit I None
the I None
COMT I GENE-Y
activity I None
in I None
erythrocytes I None
, I None
improve I None
the I None
bioavailability I None
and I None
decrease I None
the I None
elimination I None
of I None
levodopa I CHEMICAL
, I None
and I None
inhibit I None
the I None
formation I None
of I None
3 I CHEMICAL
- O CHEMICAL
O O CHEMICAL
- O CHEMICAL
methyldopa O CHEMICAL
( I None
3 I CHEMICAL
- O CHEMICAL
OMD O CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Entacapone I CHEMICAL
is I None
administered I None
with I None
every I None
scheduled I None
dose I None
of I None
levodopa I CHEMICAL
whereas I None
tolcapone I CHEMICAL
is I None
administered I None
3 I None
times I None
daily I None
. I None
<eof> I None

<s> O None
The I None
different I None
administration I None
regimens I None
for I None
these I None
agents I None
are I None
based I None
on I None
their I None
different I None
pharmacokinetic I None
and I None
pharmacodynamic I None
profiles I None
. I None
<eof> I None

<s> O None
Both I None
entacapone I CHEMICAL
and I None
tolcapone I CHEMICAL
enhance I None
and I None
extend I None
the I None
therapeutic I None
effect I None
of I None
levodopa I CHEMICAL
in I None
patients I None
with I None
advanced I None
and I None
fluctuating I None
Parkinson I None
' I None
s I None
disease I None
. I None
<eof> I None

<s> O None
They I None
prolong I None
the I None
duration I None
of I None
levodopa I CHEMICAL
effect I None
. I None
<eof> I None

<s> O None
Clinical I None
studies I None
show I None
that I None
they I None
increase I None
the I None
daily I None
ON I None
time I None
by I None
an I None
average I None
1 I None
to I None
3 I None
hours I None
, I None
improve I None
the I None
activities I None
of I None
daily I None
living I None
and I None
allow I None
daily I None
levodopa I CHEMICAL
dosage I None
to I None
be I None
decreased I None
. I None
<eof> I None

<s> O None
Correspondingly I None
, I None
they I None
significantly I None
reduce I None
the I None
daily I None
OFF I None
time I None
. I None
<eof> I None

<s> O None
No I None
comparative I None
studies I None
between I None
entacapone I CHEMICAL
and I None
tolcapone I CHEMICAL
have I None
been I None
performed I None
. I None
<eof> I None

<s> O None
Tolcapone I CHEMICAL
also I None
appears I None
to I None
have I None
a I None
beneficial I None
effect I None
in I None
patients I None
with I None
nonfluctuating I None
Parkinson I None
' I None
s I None
disease I None
. I None
<eof> I None

<s> O None
The I None
main I None
adverse I None
effects I None
of I None
the I None
COMT I GENE-Y
inhibitors I None
are I None
related I None
to I None
their I None
dopaminergic I None
and I None
gastrointestinal I None
effects I None
. I None
<eof> I None

<s> O None
Enhancement I None
of I None
dopaminergic I None
activity I None
may I None
cause I None
an I None
initial I None
worsening I None
of I None
levodopa I CHEMICAL
- I None
induced I None
adverse I None
effects I None
, I None
such I None
as I None
dyskinesia I None
, I None
nausea I None
, I None
vomiting I None
, I None
orthostatic I None
hypotension I None
, I None
sleep I None
disorders I None
and I None
hallucinations I None
. I None
<eof> I None

<s> O None
Levodopa I CHEMICAL
dose I None
adjustment I None
is I None
recommended I None
to I None
avoid I None
these I None
events I None
. I None
<eof> I None

<s> O None
Tolcapone I CHEMICAL
is I None
associated I None
with I None
diarrhoea I None
in I None
about I None
16 I None
to I None
18 I None
% I None
of I None
patients I None
and I None
entacapone I CHEMICAL
in I None
less I None
than I None
10 I None
% I None
of I None
patients I None
. I None
<eof> I None

<s> O None
Diarrhoea I None
has I None
led I None
to I None
discontinuation I None
in I None
5 I None
to I None
6 I None
% I None
of I None
patients I None
treated I None
with I None
tolcapone I CHEMICAL
and I None
in I None
2 I None
. I None
5 I None
% I None
of I None
those I None
treated I None
with I None
entacapone I CHEMICAL
. I None
<eof> I None

<s> O None
Urine I None
discoloration I None
to I None
dark I None
yellow I None
or I None
orange I None
is I None
related I None
to I None
the I None
colour I None
of I None
COMT I GENE-Y
inhibitors I None
and I None
their I None
metabolites I None
. I None
<eof> I None

<s> O None
Elevated I None
liver I GENE-N
transaminase O GENE-N
levels I None
are I None
reported I None
in I None
1 I None
to I None
3 I None
% I None
of I None
patients I None
treated I None
with I None
tolcapone I CHEMICAL
but I None
very I None
rarely I None
, I None
if I None
at I None
all I None
, I None
in I None
patients I None
treated I None
with I None
entacapone I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
descriptions I None
of I None
acute I None
, I None
fatal I None
fulminant I None
hepatitis I None
and I None
potentially I None
fatal I None
neurological I None
reactions I None
, I None
such I None
as I None
neuroleptic I None
malignant I None
syndrome I None
and I None
rhabdomyolysis I None
, I None
in I None
association I None
with I None
tolcapone I CHEMICAL
led I None
to I None
the I None
suspension I None
of I None
its I None
marketing I None
authorisation I None
in I None
the I None
European I None
Community I None
and I None
Canada I None
. I None
<eof> I None

<s> O None
In I None
many I None
other I None
countries I None
, I None
the I None
use I None
of I None
tolcapone I CHEMICAL
is I None
restricted I None
to I None
patients I None
who I None
are I None
not I None
responding I None
satisfactorily I None
to I None
other I None
therapies I None
. I None
<eof> I None

<s> O None
Regular I None
monitoring I None
of I None
liver I None
enzymes I None
is I None
required I None
if I None
tolcapone I CHEMICAL
is I None
used I None
. I None
<eof> I None

<s> O None
No I None
such I None
adverse I None
reactions I None
have I None
so I None
far I None
been I None
described I None
for I None
entacapone I CHEMICAL
and I None
no I None
laboratory I None
monitoring I None
has I None
been I None
proposed I None
. I None
<eof> I None

<s> O None
COMT I GENE-Y
inhibitors I None
added I None
to I None
levodopa I CHEMICAL
therapy I None
are I None
beneficial I None
, I None
particularly I None
in I None
patients I None
with I None
fluctuating I None
disease I None
. I None
<eof> I None

<s> O None
They I None
may I None
be I None
combined I None
with I None
other I None
antiparkinsonian I None
drugs I None
, I None
such I None
as I None
dopamine I CHEMICAL
agonists I None
, I None
selegiline I None
and I None
anticholinergics I None
without I None
adverse I None
interactions I None
. I None
<eof> I None

<s> O None
They I None
provide I None
a I None
new I None
treatment I None
possibility I None
in I None
patients I None
with I None
Parkinson I None
' I None
s I None
disease I None
who I None
have I None
problems I None
with I None
their I None
present I None
levodopa I CHEMICAL
therapy I None
. I None
<eof> I None

<s> O None
The I None
inhibition I None
of I None
cholera I GENE-N
toxin O GENE-N
- I None
induced I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
release I None
by I None
the I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
3 O GENE-Y
) O GENE-Y
receptor O GENE-Y
antagonist I None
, I None
granisetron I CHEMICAL
, I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
1 I None
. I None
<eof> I None

<s> O None
The I None
secretagogue I None
5 I CHEMICAL
- O CHEMICAL
hydroxytryptamine O CHEMICAL
( I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
) I None
is I None
implicated I None
in I None
the I None
pathophysiology I None
of I None
cholera I None
. I None
<eof> I None

<s> O None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
released I None
from I None
enterochromaffin I None
cells I None
after I None
cholera I GENE-N
toxin O GENE-N
exposure I None
is I None
thought I None
to I None
activate I None
non I None
- I None
neuronally I None
( I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
dependent I None
) I None
and I None
neuronally I None
( I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
3 O GENE-Y
) O GENE-Y
dependent I None
) I None
mediated I None
water I None
and I None
electrolyte I None
secretion I None
. I None
<eof> I None

<s> O None
CT I GENE-N
- I None
secretion I None
can I None
be I None
reduced I None
by I None
preventing I None
the I None
release I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
. I None
<eof> I None

<s> O None
Enterochromaffin I None
cells I None
possess I None
numerous I None
receptors I None
that I None
, I None
under I None
basal I None
conditions I None
, I None
modulate I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
release I None
. I None
<eof> I None

<s> O None
2 I None
. I None
<eof> I None

<s> O None
These I None
include I None
basolateral I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
3 O GENE-Y
) O GENE-Y
receptors O GENE-Y
, I None
the I None
activation I None
of I None
which I None
is I None
known I None
to I None
enhance I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
release I None
. I None
<eof> I None

<s> O None
3 I None
. I None
<eof> I None

<s> O None
Until I None
now I None
, I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
3 O GENE-Y
) O GENE-Y
receptor O GENE-Y
antagonists I None
( I None
e I None
. I None
g I None
. I None
granisetron I CHEMICAL
) I None
have I None
been I None
thought I None
to I None
inhibit I None
cholera I GENE-N
toxin O GENE-N
- I None
induced I None
fluid I None
secretion I None
by I None
blockading I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
3 O GENE-Y
) O GENE-Y
receptors O GENE-Y
on I None
secretory I None
enteric I None
neurones I None
. I None
<eof> I None

<s> O None
Instead I None
we I None
postulated I None
that I None
they I None
act I None
by I None
inhibiting I None
cholera I GENE-N
toxin O GENE-N
- I None
induced I None
enterochromaffin I None
cell I None
degranulation I None
. I None
<eof> I None

<s> O None
4 I None
. I None
<eof> I None

<s> O None
Isolated I None
intestinal I None
segments I None
in I None
anaesthetized I None
male I None
Wistar I None
rats I None
, I None
pre I None
- I None
treated I None
with I None
granisetron I CHEMICAL
75 I None
microg I None
kg I None
( I None
- I None
1 I None
) I None
, I None
lidoocaine I CHEMICAL
6 I None
mg I None
kg I None
( I None
- I None
1 I None
) I None
or I None
saline I None
, I None
were I None
instilled I None
with I None
a I None
supramaximal I None
dose I None
of I None
cholera I GENE-N
toxin O GENE-N
or I None
saline I None
. I None
<eof> I None

<s> O None
Net I None
fluid I None
movement I None
was I None
determined I None
by I None
small I None
intestinal I None
perfusion I None
or I None
gravimetry I None
and I None
small I None
intestinal I None
and I None
luminal I None
fluid I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
levels I None
were I None
determined I None
by I None
HPLC I None
with I None
fluorimetric I None
detection I None
. I None
<eof> I None

<s> O None
5 I None
. I None
<eof> I None

<s> O None
Intraluminal I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
release I None
was I None
proportional I None
to I None
the I None
reduction I None
in I None
tissue I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
levels I None
and I None
to I None
the I None
onset I None
of I None
water I None
and I None
electrolyte I None
secretion I None
, I None
suggesting I None
that I None
luminal I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
levels I None
reflect I None
enterochromaffin I None
cell I None
activity I None
. I None
<eof> I None

<s> O None
6 I None
. I None
<eof> I None

<s> O None
Both I None
lidocaine I CHEMICAL
and I None
granisetron I CHEMICAL
inhibited I None
fluid I None
secretion I None
. I None
<eof> I None

<s> O None
However I None
, I None
granisetron I CHEMICAL
alone I None
, I None
and I None
proportionately I None
, I None
reduced I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
release I None
. I None
<eof> I None

<s> O None
7 I None
. I None
<eof> I None

<s> O None
The I None
simultaneous I None
inhibition I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
release I None
and I None
fluid I None
secretion I None
by I None
granisetron I CHEMICAL
suggests I None
that I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
release I None
from I None
enterochromaffin I None
cells I None
is I None
potentiated I None
by I None
endogenous I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
3 O GENE-Y
) O GENE-Y
receptors O GENE-Y
. I None
<eof> I None

<s> O None
The I None
accentuated I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
release I None
promotes I None
cholera I GENE-N
toxin O GENE-N
- I None
induced I None
fluid I None
secretion I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
sustained I None
administration I None
of I None
the I None
serotonin I CHEMICAL
and I None
norepinephrine I CHEMICAL
reuptake I None
inhibitor I None
venlafaxine I CHEMICAL
: I None
I I None
. I None
in I None
vivo I None
electrophysiological I None
studies I None
in I None
the I None
rat I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
a I None
21 I None
- I None
day I None
treatment I None
with I None
the I None
dual I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
and I None
NE I CHEMICAL
reuptake I None
blocker I None
venlafaxine I CHEMICAL
( I None
delivered I None
s I None
. I None
c I None
. I None
by I None
osmotic I None
minipumps I None
) I None
was I None
assessed I None
on I None
the I None
time I None
required I None
for I None
a I None
50 I None
% I None
recovery I None
( I None
RT I None
( I None
50 I None
) I None
) I None
of I None
the I None
firing I None
activity I None
of I None
dorsal I None
hippocampus I None
CA I None
( I None
3 I None
) I None
pyramidal I None
neurons I None
from I None
the I None
suppression I None
induced I None
by I None
microiontophoretic I None
applications I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
and I None
NE I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
RT I None
( I None
50 I None
) I None
values I None
for I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
were I None
increased I None
by I None
both I None
10 I None
and I None
40 I None
mg I None
/ I None
kg I None
/ I None
day I None
regimens I None
of I None
venlafaxine I CHEMICAL
, I None
whereas I None
those I None
for I None
NE I CHEMICAL
were I None
increased I None
only I None
by I None
the I None
40 I None
mg I None
/ I None
kg I None
/ I None
day I None
regimen I None
, I None
indicative I None
of I None
a I None
greater I None
potency I None
of I None
venlafaxine I CHEMICAL
in I None
blocking I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
reuptake I None
. I None
<eof> I None

<s> O None
The I None
sensitivity I None
of I None
the I None
postsynaptic I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
and I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenergic O GENE-N
receptors O GENE-N
was I None
altered I None
by I None
neither I None
regimen I None
of I None
venlafaxine I CHEMICAL
. I None
<eof> I None

<s> O None
Using I None
a I None
paradigm I None
by I None
which I None
the I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
antagonist I None
WAY I CHEMICAL
100635 O CHEMICAL
can I None
induce I None
a I None
disinhibition I None
of I None
firing I None
activity I None
of I None
CA I None
( I None
3 I None
) I None
pyramidal I None
neurons I None
, I None
it I None
was I None
demonstrated I None
that I None
the I None
high I None
, I None
but I None
not I None
the I None
low I None
, I None
dose I None
of I None
venlafaxine I CHEMICAL
led I None
to I None
an I None
enhanced I None
tonic I None
activation I None
of I None
postsynaptic I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
receptors I None
in I None
the I None
dorsal I None
hippocampus I None
. I None
<eof> I None

<s> O None
The I None
duration I None
of I None
the I None
suppressant I None
effect I None
of I None
the I None
firing I None
activity I None
of I None
CA I None
( I None
3 I None
) I None
hippocampus I None
pyramidal I None
neurons I None
produced I None
by I None
the I None
electrical I None
stimulation I None
of I None
the I None
ascending I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
pathway I None
was I None
significantly I None
reduced I None
when I None
the I None
frequency I None
of I None
the I None
stimulation I None
was I None
enhanced I None
from I None
1 I None
Hz I None
to I None
5 I None
Hz I None
in I None
control I None
rats I None
and I None
in I None
rats I None
treated I None
with I None
10 I None
mg I None
/ I None
kg I None
/ I None
day I None
, I None
but I None
not I None
with I None
40 I None
mg I None
/ I None
kg I None
/ I None
day I None
of I None
venlafaxine I CHEMICAL
. I None
<eof> I None

<s> O None
Hence I None
, I None
venlafaxine I CHEMICAL
induced I None
a I None
desensitization I None
of I None
the I None
terminal I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
autoreceptor I None
only I None
at I None
the I None
high I None
dose I None
. I None
<eof> I None

<s> O None
A I None
2 I None
- I None
day I None
treatment I None
with I None
10 I None
mg I None
/ I None
kg I None
/ I None
day I None
of I None
venlafaxine I CHEMICAL
induced I None
a I None
suppression I None
of I None
the I None
firing I None
activity I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
neurons I None
of I None
the I None
dorsal I None
raphe I None
. I None
<eof> I None

<s> O None
The I None
firing I None
activity I None
of I None
these I None
neurons I None
was I None
back I None
to I None
control I None
level I None
in I None
rats I None
that I None
had I None
been I None
treated I None
for I None
21 I None
days I None
with I None
the I None
same I None
dose I None
of I None
venlafaxine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
suppressant I None
effect I None
of I None
the I None
i I None
. I None
v I None
. I None
administration I None
of I None
the I None
5 I GENE-N
- O GENE-N
HT O GENE-N
autoreceptor O GENE-N
agonist I None
LSD I None
on I None
the I None
firing I None
activity I None
of I None
dorsal I None
raphe I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
neurons I None
was I None
reduced I None
in I None
rats I None
that I None
had I None
been I None
treated I None
for I None
21 I None
days I None
with I None
10 I None
mg I None
/ I None
kg I None
/ I None
day I None
of I None
venlafaxine I CHEMICAL
. I None
<eof> I None

<s> O None
A I None
2 I None
- I None
day I None
treatment I None
with I None
40 I None
mg I None
/ I None
kg I None
/ I None
day I None
of I None
venlafaxine I CHEMICAL
, I None
unlike I None
the I None
10 I None
mg I None
/ I None
kg I None
/ I None
day I None
regimen I None
, I None
induced I None
a I None
marked I None
suppression I None
of I None
the I None
firing I None
activity I None
of I None
locus I None
coeruleus I None
NE I CHEMICAL
neurons I None
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
contrast I None
to I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
neurons I None
, I None
NE I CHEMICAL
neurons I None
did I None
not I None
recover I None
their I None
firing I None
activity I None
after I None
a I None
21 I None
- I None
day I None
treatment I None
. I None
<eof> I None

<s> O None
Taken I None
together I None
, I None
the I None
results I None
from I None
this I None
study I None
indicate I None
that I None
the I None
low I None
dose I None
of I None
venlafaxine I CHEMICAL
blocked I None
selectively I None
the I None
reuptake I None
of I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
, I None
whereas I None
the I None
high I None
dose I None
blocked I None
the I None
reuptake I None
of I None
both I None
5 I CHEMICAL
- O CHEMICAL
HT O CHEMICAL
and I None
NE I CHEMICAL
. I None
<eof> I None

<s> O None
Moreover I None
, I None
an I None
enhancement I None
of I None
serotonergic I None
neurotransmission I None
by I None
venlafaxine I CHEMICAL
was I None
only I None
achieved I None
under I None
conditions I None
whereby I None
the I None
desensitization I None
of I None
the I None
terminal I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
autoreceptor I None
is I None
appended I None
to I None
that I None
of I None
the I None
somatodendritic I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1A O GENE-Y
) O GENE-Y
receptor I None
. I None
<eof> I None

<s> O None
Phosphoacetylcholinesterase I GENE-N
: I None
toxicity I None
of I None
phosphorus I CHEMICAL
oxychloride O CHEMICAL
to I None
mammals I None
and I None
insects I None
that I None
can I None
be I None
attributed I None
to I None
selective I None
phosphorylation I None
of I None
acetylcholinesterase I GENE-N
by I None
phosphorodichloridic I CHEMICAL
acid O CHEMICAL
. I None
<eof> I None

<s> O None
Phosphorus I CHEMICAL
oxychloride O CHEMICAL
( I None
POCl I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
) I None
is I None
an I None
intermediate I None
in I None
the I None
synthesis I None
of I None
many I None
organophosphorus I CHEMICAL
insecticides I None
and I None
chemical I None
warfare I None
nerve I None
gases I None
that I None
are I None
toxic I None
to I None
insects I None
and I None
mammals I None
by I None
inhibition I None
of I None
acetylcholinesterase I GENE-N
( I None
AChE I GENE-N
) I None
activity I None
. I None
<eof> I None

<s> O None
It I None
was I None
therefore I None
surprising I None
to I None
observe I None
that I None
POCl I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
, I None
which I None
is I None
hydrolytically I None
unstable I None
, I None
also I None
itself I None
gives I None
poisoning I None
signs I None
in I None
ip I None
- I None
treated I None
mice I None
and I None
fumigant I None
- I None
exposed I None
houseflies I None
similar I None
to I None
those I None
produced I None
by I None
the I None
organophosphorus I CHEMICAL
ester O CHEMICAL
insecticides I None
and I None
chemical I None
warfare I None
agents I None
. I None
<eof> I None

<s> O None
In I None
mice I None
, I None
POCl I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
inhibits I None
serum I None
butyrylcholinesterase I GENE-Y
( I None
BuChE I GENE-Y
) I None
at I None
a I None
sublethal I None
dose I None
and I None
muscle I None
but I None
not I None
brain I None
AChE I GENE-Y
at I None
a I None
lethal I None
dose I None
. I None
<eof> I None

<s> O None
In I None
houseflies I None
, I None
POCl I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
- I None
induced I None
brain I None
AChE I GENE-Y
inhibition I None
is I None
correlated I None
with I None
poisoning I None
and I None
the I None
probable I None
cause I None
thereof I None
. I None
<eof> I None

<s> O None
POCl I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
in I None
vitro I None
is I None
selective I None
for I None
AChE I GENE-Y
( I None
IC I None
( I None
50 I None
) I None
= I None
12 I None
- I None
36 I None
microM I None
) I None
compared I None
with I None
several I None
other I None
serine I GENE-N
hydrolases O GENE-N
( I None
BuChE I GENE-Y
, I None
carboxylesterase I GENE-N
, I None
elastase I GENE-N
, I None
alpha I GENE-N
- O GENE-N
chymotrypsin O GENE-N
, I None
and I None
thrombin I GENE-Y
) I None
( I None
IC I None
( I None
50 I None
) I None
= I None
88 I None
- I None
2000 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
With I None
electric I GENE-Y
eel O GENE-Y
AChE O GENE-Y
, I None
methylcarbamoylation I None
of I None
the I None
active I None
site I None
with I None
eserine I None
reversibly I None
protects I None
against I None
subsequent I None
irreversible I None
inhibition I None
by I None
POCl I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
. I None
<eof> I None

<s> O None
Most I None
importantly I None
, I None
POCl I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
- I None
induced I None
electric I GENE-Y
eel O GENE-Y
AChE O GENE-Y
inhibition I None
prevents I None
postlabeling I None
with I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
diisopropyl O CHEMICAL
phosphorofluoridate O CHEMICAL
; I None
i I None
. I None
e I None
. I None
, I None
both I None
compounds I None
phosphorylate I None
at I None
Ser I CHEMICAL
- I None
200 I None
in I None
the I None
catalytic I None
triad I None
. I None
<eof> I None

<s> O None
Pyridine I CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
aldoxime O CHEMICAL
methiodide O CHEMICAL
does I None
not I None
reactivate I None
POCl I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
- I None
inhibited I None
AChE I GENE-Y
, I None
consistent I None
with I None
an I None
anionic I None
phosphoserine I CHEMICAL
residue I None
at I None
the I None
esteratic I None
site I None
. I None
<eof> I None

<s> O None
The I None
actual I None
phosphorylating I None
agent I None
is I None
formed I None
within I None
seconds I None
from I None
POCl I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
in I None
water I None
, I None
has I None
a I None
half I None
- I None
life I None
of I None
approximately I None
2 I None
min I None
, I None
and I None
is I None
identified I None
as I None
phosphorodichloridic I CHEMICAL
acid O CHEMICAL
[ I None
HOP I CHEMICAL
( O CHEMICAL
O O CHEMICAL
) O CHEMICAL
Cl O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
] I None
by I None
( I CHEMICAL
31 O CHEMICAL
) O CHEMICAL
P O CHEMICAL
NMR I None
and I None
derivatization I None
with I None
dimethylamine I CHEMICAL
to I None
HOP I CHEMICAL
( O CHEMICAL
O O CHEMICAL
) O CHEMICAL
( O CHEMICAL
NMe O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
) O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
. I None
<eof> I None

<s> O None
POCl I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
on I None
reaction I None
with I None
water I None
and I None
HOP I CHEMICAL
( O CHEMICAL
O O CHEMICAL
) O CHEMICAL
Cl O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
have I None
the I None
same I None
potency I None
for I None
inhibition I None
of I None
AChE I GENE-Y
from I None
either I None
electric I None
eel I None
or I None
housefly I None
head I None
as I None
well I None
as I None
the I None
same I None
toxicity I None
for I None
mice I None
. I None
<eof> I None

<s> O None
In I None
summary I None
, I None
the I None
acute I None
toxicity I None
of I None
POCl I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
is I None
attributable I None
to I None
hydrolytic I None
activation I None
to I None
HOP I CHEMICAL
( O CHEMICAL
O O CHEMICAL
) O CHEMICAL
Cl O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
that I None
phosphorylates I None
AChE I GENE-Y
at I None
the I None
active I None
site I None
to I None
form I None
enzymatically I None
inactive I None
[ I None
O I CHEMICAL
- O CHEMICAL
phosphoserine O CHEMICAL
] I None
AChE I GENE-Y
. I None
<eof> I None

<s> O None
Effects I None
of I None
2 I CHEMICAL
, O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
7 O CHEMICAL
, O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
tetrachlorodibenzo O CHEMICAL
- O CHEMICAL
p O CHEMICAL
- O CHEMICAL
dioxin O CHEMICAL
or I None
2 I CHEMICAL
, O CHEMICAL
2 O CHEMICAL
' O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
' O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
hexachlorobiphenyl O CHEMICAL
on I None
vitamin I CHEMICAL
K O CHEMICAL
- I None
dependent I None
blood I None
coagulation I None
in I None
male I None
and I None
female I None
WAG I None
/ I None
Rij I None
- I None
rats I None
. I None
<eof> I None

<s> O None
Newborns I None
are I None
susceptible I None
to I None
hemorrhages I None
( I None
hemorrhagic I None
disease I None
of I None
the I None
newborn I None
or I None
HDN I None
) I None
due I None
to I None
vitamin I CHEMICAL
K O CHEMICAL
deficiency I None
. I None
<eof> I None

<s> O None
Induction I None
of I None
cytochrome I GENE-N
P450 O GENE-N
in I None
the I None
fetal I None
liver I None
by I None
maternal I None
anticonvulsant I None
therapy I None
such I None
as I None
phenobarbital I CHEMICAL
or I None
phenytoin I CHEMICAL
is I None
considered I None
to I None
be I None
a I None
major I None
cause I None
. I None
<eof> I None

<s> O None
An I None
observed I None
increase I None
in I None
late I None
hemorrhagic I None
disease I None
( I None
LHD I None
) I None
in I None
breast I None
fed I None
neonates I None
gave I None
rise I None
to I None
the I None
hypothesis I None
that I None
PCBs I CHEMICAL
and I None
dioxins I CHEMICAL
, I None
P450 I None
- I None
inducing I None
contaminants I None
present I None
in I None
human I None
milk I None
, I None
might I None
effect I None
vitamin I CHEMICAL
K O CHEMICAL
- I None
dependent I None
blood I None
coagulation I None
. I None
<eof> I None

<s> O None
This I None
hypothesis I None
was I None
studied I None
in I None
rats I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
a I None
single I None
oral I None
dose I None
of I None
0 I None
. I None
003 I None
, I None
0 I None
. I None
03 I None
, I None
0 I None
. I None
3 I None
, I None
3 I None
or I None
30 I None
nmol I None
2 I CHEMICAL
, O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
7 O CHEMICAL
, O CHEMICAL
8 O CHEMICAL
- O CHEMICAL
tetrachlorodibenzo O CHEMICAL
- O CHEMICAL
p O CHEMICAL
- O CHEMICAL
dioxin O CHEMICAL
( I None
TCDD I CHEMICAL
) I None
per I None
kg I None
bodyweight I None
or I None
0 I None
. I None
75 I None
, I None
4 I None
, I None
20 I None
, I None
100 I None
or I None
500 I None
micromol I None
2 I CHEMICAL
, O CHEMICAL
2 O CHEMICAL
' O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
' O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
' O CHEMICAL
- O CHEMICAL
hexachlorobiphenyl O CHEMICAL
/ I None
kg I None
bw I None
( I None
HxCB I CHEMICAL
) I None
to I None
female I None
and I None
male I None
rats I None
resulted I None
in I None
dose I None
- I None
related I None
reductions I None
of I None
the I None
vitamin I CHEMICAL
K O CHEMICAL
- I None
dependent I None
coagulation I GENE-Y
factor O GENE-Y
VII O GENE-Y
. I None
<eof> I None

<s> O None
The I None
highest I None
factor I GENE-Y
VII O GENE-Y
reduction I None
in I None
female I None
rats I None
was I None
44 I None
% I None
, I None
observed I None
after I None
TCDD I CHEMICAL
exposure I None
. I None
<eof> I None

<s> O None
The I None
Lowest I None
Observed I None
Adverse I None
Effect I None
Level I None
( I None
LOAEL I None
) I None
of I None
TCDD I CHEMICAL
on I None
female I None
factor I GENE-Y
VII O GENE-Y
levels I None
was I None
0 I None
. I None
3 I None
nmol I None
/ I None
kg I None
bw I None
( I None
96 I None
ng I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
There I None
was I None
a I None
significant I None
inverse I None
correlation I None
between I None
Factor I GENE-Y
VII O GENE-Y
levels I None
and I None
induction I None
of I None
hepatic I None
ethoxyresorufin I CHEMICAL
O I CHEMICAL
- I None
deethylating I None
( I None
EROD I None
) I None
activity I None
, I None
reflecting I None
CYP1A1 I GENE-Y
, I None
and I None
total I None
P450 I GENE-N
content I None
. I None
<eof> I None

<s> O None
HxCB I CHEMICAL
had I None
no I None
effect I None
on I None
female I None
coagulation I GENE-N
factors O GENE-N
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
in I None
male I None
rats I None
only I None
exposure I None
to I None
HxCB I CHEMICAL
, I None
which I None
induces I None
mainly I None
CYP2B1 I GENE-N
and O GENE-N
2B2 O GENE-N
, I None
decreased I None
both I None
coagulation I GENE-N
factors O GENE-N
dramatically I None
up I None
to I None
88 I None
% I None
. I None
<eof> I None

<s> O None
The I None
LOAEL I None
of I None
HxCB I CHEMICAL
on I None
factor I GENE-Y
VII O GENE-Y
in I None
male I None
rats I None
was I None
100 I None
micromol I None
/ I None
kg I None
bw I None
( I None
36 I None
mg I None
/ I None
kg I None
) I None
. I None
<eof> I None

<s> O None
In I None
general I None
, I None
effects I None
on I None
coagulation I None
factors I None
in I None
male I None
rats I None
exceeded I None
those I None
in I None
females I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
sex I None
- I None
dependent I None
differences I None
of I None
TCDD I CHEMICAL
and I None
HxCB I CHEMICAL
were I None
observed I None
on I None
the I None
hepatic I None
vitamin I CHEMICAL
K O CHEMICAL
cycle I None
enzyme I None
activities I None
in I None
female I None
and I None
male I None
rats I None
. I None
<eof> I None

<s> O None
Vitamin I CHEMICAL
K O CHEMICAL
- I None
dependent I None
( I None
gamma I GENE-Y
- O GENE-Y
glutamyl O GENE-Y
carboxylase O GENE-Y
activity I None
was I None
mainly I None
induced I None
in I None
female I None
rats I None
; I None
2 I None
. I None
3 I None
- I None
fold I None
in I None
the I None
highest I None
dose I None
group I None
of I None
TCDD I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
male I None
rats I None
only I None
vitamin I GENE-N
K O GENE-N
2 O GENE-N
, O GENE-N
3 O GENE-N
- O GENE-N
epoxide O GENE-N
reductase O GENE-N
( I None
KO I GENE-N
- O GENE-N
reductase O GENE-N
) I None
activity I None
was I None
induced I None
1 I None
. I None
7 I None
- I None
fold I None
by I None
the I None
highest I None
dose I None
of I None
HxCB I CHEMICAL
. I None
<eof> I None

<s> O None
KO I GENE-N
- O GENE-N
reductase O GENE-N
activity I None
in I None
female I None
rats I None
was I None
also I None
increased I None
by I None
TCDD I CHEMICAL
, I None
however I None
, I None
less I None
pronounced I None
than I None
the I None
carboxylase I GENE-N
activity I None
. I None
<eof> I None

<s> O None
Concluding I None
, I None
the I None
hepatic I None
vitamin I CHEMICAL
K O CHEMICAL
cycle I None
still I None
functions I None
and I None
is I None
not I None
blocked I None
by I None
TCDD I CHEMICAL
or I None
HxCB I CHEMICAL
, I None
thus I None
explaining I None
the I None
observed I None
reduction I None
in I None
factor I GENE-Y
VII O GENE-Y
. I None
<eof> I None

<s> O None
Finally I None
, I None
the I None
possible I None
role I None
of I None
P450 I GENE-N
in I None
vitamin I CHEMICAL
K O CHEMICAL
deficiency I None
is I None
discussed I None
. I None
<eof> I None

<s> O None
Based I None
on I None
these I None
results I None
it I None
is I None
suggested I None
to I None
investigate I None
the I None
possible I None
role I None
of I None
PCBs I CHEMICAL
and I None
dioxin I CHEMICAL
- I None
like I None
compounds I None
in I None
LHD I None
in I None
more I None
detail I None
. I None
<eof> I None

<s> O None
Low I None
grade I None
inflammation I None
and I None
coronary I None
heart I None
disease I None
: I None
prospective I None
study I None
and I None
updated I None
meta I None
- I None
analyses I None
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
To I None
assess I None
associations I None
between I None
baseline I None
values I None
of I None
four I None
different I None
circulating I None
markers I None
of I None
inflammation I None
and I None
future I None
risk I None
of I None
coronary I None
heart I None
disease I None
, I None
potential I None
triggers I None
of I None
systemic I None
inflammation I None
( I None
such I None
as I None
persistent I None
infection I None
) I None
, I None
and I None
other I None
markers I None
of I None
inflammation I None
. I None
<eof> I None

<s> O None
DESIGN I None
: I None
Nested I None
case I None
- I None
control I None
comparisons I None
in I None
a I None
prospective I None
, I None
population I None
based I None
cohort I None
. I None
<eof> I None

<s> O None
SETTING I None
: I None
General I None
practices I None
in I None
18 I None
towns I None
in I None
Britain I None
. I None
<eof> I None

<s> O None
PARTICIPANTS I None
: I None
506 I None
men I None
who I None
died I None
from I None
coronary I None
heart I None
disease I None
or I None
had I None
a I None
non I None
- I None
fatal I None
myocardial I None
infarction I None
and I None
1025 I None
men I None
who I None
remained I None
free I None
of I None
such I None
disease I None
until I None
1996 I None
selected I None
from I None
5661 I None
men I None
aged I None
40 I None
- I None
59 I None
years I None
who I None
provided I None
blood I None
samples I None
in I None
1978 I None
- I None
1980 I None
. I None
<eof> I None

<s> O None
MAIN I None
OUTCOME I None
MEASURES I None
: I None
Plasma I None
concentrations I None
of I None
C I GENE-Y
reactive O GENE-Y
protein O GENE-Y
, I None
serum I GENE-Y
amyloid O GENE-Y
A O GENE-Y
protein O GENE-Y
, I None
and I None
serum I GENE-Y
albumin O GENE-Y
and I None
leucocyte I None
count I None
. I None
<eof> I None

<s> O None
Information I None
on I None
fatal I None
and I None
non I None
- I None
fatal I None
coronary I None
heart I None
disease I None
was I None
obtained I None
from I None
medical I None
records I None
and I None
death I None
certificates I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
Compared I None
with I None
men I None
in I None
the I None
bottom I None
third I None
of I None
baseline I None
measurements I None
of I None
C I GENE-Y
reactive O GENE-Y
protein O GENE-Y
, I None
men I None
in I None
the I None
top I None
third I None
had I None
an I None
odds I None
ratio I None
for I None
coronary I None
heart I None
disease I None
of I None
2 I None
. I None
13 I None
( I None
95 I None
% I None
confidence I None
interval I None
1 I None
. I None
38 I None
to I None
3 I None
. I None
28 I None
) I None
after I None
age I None
, I None
town I None
, I None
smoking I None
, I None
vascular I None
risk I None
factors I None
, I None
and I None
indicators I None
of I None
socioeconomic I None
status I None
were I None
adjusted I None
for I None
. I None
<eof> I None

<s> O None
Similar I None
adjusted I None
odds I None
ratios I None
were I None
1 I None
. I None
65 I None
( I None
1 I None
. I None
07 I None
to I None
2 I None
. I None
55 I None
) I None
for I None
serum I GENE-Y
amyloid O GENE-Y
A O GENE-Y
protein O GENE-Y
; I None
1 I None
. I None
12 I None
( I None
0 I None
. I None
71 I None
to I None
1 I None
. I None
77 I None
) I None
for I None
leucocyte I None
count I None
; I None
and I None
0 I None
. I None
67 I None
( I None
0 I None
. I None
43 I None
to I None
1 I None
. I None
04 I None
) I None
for I None
albumin I None
. I None
<eof> I None

<s> O None
No I None
strong I None
associations I None
were I None
observed I None
of I None
these I None
factors I None
with I None
Helicobacter I None
pylori I None
seropositivity I None
, I None
Chlamydia I None
pneumoniae I None
IgG I None
titres I None
, I None
or I None
plasma I None
total I None
homocysteine I CHEMICAL
concentrations I None
. I None
<eof> I None

<s> O None
Baseline I None
values I None
of I None
the I None
acute I None
phase I None
reactants I None
were I None
significantly I None
associated I None
with I None
one I None
another I None
( I None
P I None
< I None
0 I None
. I None
0001 I None
) I None
, I None
although I None
the I None
association I None
between I None
low I None
serum I GENE-Y
albumin O GENE-Y
concentration I None
and I None
leucocyte I None
count I None
was I None
weaker I None
( I None
P I None
= I None
0 I None
. I None
08 I None
) I None
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
In I None
the I None
context I None
of I None
results I None
from I None
other I None
relevant I None
studies I None
these I None
findings I None
suggest I None
that I None
some I None
inflammatory I None
processes I None
, I None
unrelated I None
to I None
the I None
chronic I None
infections I None
studied I None
here I None
, I None
are I None
likely I None
to I None
be I None
involved I None
in I None
coronary I None
heart I None
disease I None
. I None
<eof> I None

<s> O None
Identification I None
of I None
mu I GENE-N
- O GENE-N
class O GENE-N
glutathione O GENE-N
transferases O GENE-N
M2 O GENE-N
- O GENE-N
2 O GENE-N
and O GENE-N
M3 O GENE-N
- O GENE-N
3 O GENE-N
as I None
cytosolic I None
prostaglandin I GENE-N
E O GENE-N
synthases O GENE-N
in I None
the I None
human I None
brain I None
. I None
<eof> I None

<s> O None
Cytosolic I None
prostaglandin I GENE-N
( O GENE-N
PG O GENE-N
) O GENE-N
E O GENE-N
synthase O GENE-N
was I None
purified I None
from I None
human I None
brain I None
cortex I None
. I None
<eof> I None

<s> O None
The I None
N I CHEMICAL
- O CHEMICAL
terminal O CHEMICAL
amino O CHEMICAL
acid O CHEMICAL
sequence I None
, I None
PMTLGYXNIRGL I CHEMICAL
, I None
was I None
identical I None
to I None
that I None
of I None
the I None
human I GENE-Y
mu O GENE-Y
- O GENE-Y
class O GENE-Y
glutathione O GENE-Y
transferase O GENE-Y
( O GENE-Y
GST O GENE-Y
) O GENE-Y
M2 O GENE-Y
subunit I None
. I None
<eof> I None

<s> O None
Complementary I None
DNAs I None
for I None
human I GENE-Y
GSTM2 O GENE-Y
, I None
GSTM3 I GENE-Y
, I None
and I None
GSTM4 I GENE-Y
subunits I None
were I None
cloned I None
, I None
and I None
recombinant I None
proteins I None
were I None
expressed I None
as I None
homodimers I None
in I None
Escherichia I None
coli I None
. I None
<eof> I None

<s> O None
The I None
recombinant I None
GSTM2 I GENE-N
- O GENE-N
2 O GENE-N
and O GENE-N
3 O GENE-N
- O GENE-N
3 O GENE-N
catalyzed I None
the I None
conversion I None
of I None
PGH2 I CHEMICAL
to I None
PGE2 I CHEMICAL
at I None
the I None
rates I None
of I None
282 I None
and I None
923 I None
nmol I None
/ I None
min I None
/ I None
mg I None
of I None
protein I None
, I None
respectively I None
, I None
at I None
the I None
optimal I None
pH I None
of I None
8 I None
, I None
whereas I None
GSTM4 I GENE-Y
- O GENE-Y
4 O GENE-Y
was I None
inactive I None
; I None
although I None
all I None
three I None
enzymes I None
showed I None
GST I GENE-N
activity I None
. I None
<eof> I None

<s> O None
The I None
PGE I GENE-N
synthase O GENE-N
activity I None
depended I None
on I None
thiols I CHEMICAL
, I None
such I None
as I None
glutathione I CHEMICAL
, I None
dithiothreitol I CHEMICAL
, I None
2 I CHEMICAL
- O CHEMICAL
mercaptoethanol O CHEMICAL
, I None
or I None
L I CHEMICAL
- O CHEMICAL
cysteine O CHEMICAL
. I None
<eof> I None

<s> O None
Michaelis I None
- I None
Menten I None
constants I None
and I None
turnover I None
numbers I None
for I None
PGH2 I CHEMICAL
were I None
141 I None
microM I None
and I None
10 I None
. I None
8 I None
min I None
( I None
- I None
1 I None
) I None
for I None
GSTM2 I GENE-Y
- O GENE-Y
2 O GENE-Y
and I None
1 I None
. I None
5 I None
mM I None
and I None
130 I None
min I None
( I None
- I None
1 I None
) I None
for I None
GSTM3 I GENE-Y
- O GENE-Y
3 O GENE-Y
, I None
respectively I None
. I None
<eof> I None

<s> O None
GSTM2 I GENE-N
- O GENE-N
2 O GENE-N
and O GENE-N
3 O GENE-N
- O GENE-N
3 O GENE-N
may I None
play I None
crucial I None
roles I None
in I None
temperature I None
regulation I None
, I None
nociception I None
, I None
and I None
sleep I None
- I None
wake I None
regulation I None
by I None
producing I None
PGE2 I CHEMICAL
in I None
the I None
brain I None
. I None
<eof> I None

<s> O None
Evaluation I None
of I None
in I None
vivo I None
binding I None
properties I None
of I None
3H I CHEMICAL
- O CHEMICAL
NMPB O CHEMICAL
and I None
3H I CHEMICAL
- O CHEMICAL
QNB O CHEMICAL
in I None
mouse I None
brain I None
. I None
<eof> I None

<s> O None
UNLABELLED I None
: I None
Apparent I None
muscarinic I GENE-N
acetylcholine O GENE-N
( O GENE-N
mAch O GENE-N
) O GENE-N
receptor O GENE-N
occupancy I None
in I None
mouse I None
cerebral I None
cortex I None
, I None
hippocampus I None
, I None
and I None
striatum I None
by I None
scopolamine I CHEMICAL
, I None
an I None
antagonist I None
, I None
and I None
biperiden I CHEMICAL
, I None
a I None
relatively I None
selective I None
M1 I GENE-Y
antagonist I None
, I None
was I None
estimated I None
with I None
competitive I None
binding I None
studies I None
using I None
two I None
different I None
radioligands I None
: I None
3H I CHEMICAL
- O CHEMICAL
N O CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
piperidyl O CHEMICAL
benzilate O CHEMICAL
( I None
3H I CHEMICAL
- O CHEMICAL
NMPB O CHEMICAL
) I None
and I None
3H I CHEMICAL
- O CHEMICAL
quinuclidinyl O CHEMICAL
benzilate O CHEMICAL
( I None
3H I CHEMICAL
- O CHEMICAL
QNB O CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Both I None
radioligands I None
labeled I None
mAch I GENE-N
receptors O GENE-N
in I None
these I None
brain I None
regions I None
, I None
and I None
the I None
relative I None
regional I None
distributions I None
of I None
the I None
specific I None
binding I None
of I None
3H I CHEMICAL
- O CHEMICAL
NMPB O CHEMICAL
in I None
vivo I None
paralleled I None
the I None
distribution I None
of I None
mAch I GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
3H I CHEMICAL
- O CHEMICAL
NMPB O CHEMICAL
binding I None
in I None
vivo I None
was I None
much I None
more I None
sensitive I None
to I None
direct I None
competitive I None
inhibition I None
by I None
scopolamine I CHEMICAL
than I None
was I None
3H I CHEMICAL
- O CHEMICAL
QNB O CHEMICAL
. I None
<eof> I None

<s> O None
A I None
similar I None
discrepancy I None
in I None
sensitivity I None
to I None
competitors I None
between I None
3H I CHEMICAL
- O CHEMICAL
NMPB O CHEMICAL
and I None
3H I CHEMICAL
- O CHEMICAL
QNB O CHEMICAL
was I None
also I None
observed I None
when I None
biperiden I CHEMICAL
was I None
used I None
as I None
a I None
competitor I None
, I None
indicating I None
that I None
binding I None
to I None
different I None
subtypes I None
of I None
the I None
mAch I GENE-N
receptor O GENE-N
could I None
not I None
account I None
for I None
the I None
observed I None
differences I None
in I None
sensitivity I None
to I None
competition I None
. I None
<eof> I None

<s> O None
An I None
in I None
vivo I None
saturation I None
study I None
suggested I None
that I None
the I None
apparent I None
association I None
rate I None
constant I None
( I None
k I None
on I None
) I None
of I None
3H I CHEMICAL
- O CHEMICAL
QNB O CHEMICAL
binding I None
might I None
be I None
changed I None
by I None
ligand I None
concentration I None
. I None
<eof> I None

<s> O None
The I None
heterogeneity I None
of I None
the I None
free I None
ligand I None
concentration I None
in I None
intact I None
brain I None
was I None
assessed I None
in I None
relation I None
to I None
the I None
ligand I None
concentration I None
dependency I None
of I None
the I None
apparent I None
association I None
rate I None
constant I None
( I None
k I None
on I None
) I None
of I None
3H I CHEMICAL
- O CHEMICAL
QNB O CHEMICAL
binding I None
. I None
<eof> I None

<s> O None
This I None
finding I None
, I None
together I None
with I None
the I None
more I None
favorable I None
accumulation I None
of I None
3H I CHEMICAL
- O CHEMICAL
NMPB O CHEMICAL
in I None
cerebral I None
cortex I None
, I None
hippocampus I None
, I None
and I None
striatum I None
, I None
leads I None
us I None
to I None
conclude I None
that I None
3H I CHEMICAL
- O CHEMICAL
NMPB O CHEMICAL
, I None
or I None
its I None
positron I None
emitting I None
counterpart I None
, I None
should I None
be I None
the I None
more I None
favorable I None
radiotracer I None
for I None
the I None
estimation I None
of I None
mAch I GENE-N
receptor O GENE-N
occupancy I None
by I None
cholinergic I None
drugs I None
in I None
the I None
brain I None
. I None
<eof> I None

<s> O None
KEYWORDS I None
: I None
mAch I GENE-N
receptor O GENE-N
, I None
QNB I CHEMICAL
, I None
NMPB I CHEMICAL
, I None
in I None
vivo I None
, I None
mouse I None
. I None
<eof> I None

<s> O None
Modulation I None
of I None
KCNQ2 I GENE-N
/ O GENE-N
3 O GENE-N
potassium I GENE-N
channels O GENE-N
by I None
the I None
novel I None
anticonvulsant I None
retigabine I CHEMICAL
. I None
<eof> I None

<s> O None
Retigabine I CHEMICAL
is I None
a I None
novel I None
anticonvulsant I None
with I None
an I None
unknown I None
mechanism I None
of I None
action I None
. I None
<eof> I None

<s> O None
It I None
has I None
recently I None
been I None
reported I None
that I None
retigabine I CHEMICAL
modulates I None
a I None
potassium I GENE-N
channel O GENE-N
current I None
in I None
nerve I GENE-Y
growth O GENE-Y
factor O GENE-Y
- I None
differentiated I None
PC12 I None
cells I None
( I None
) I None
, I None
however I None
, I None
to I None
date I None
the I None
molecular I None
correlate I None
of I None
this I None
current I None
has I None
not I None
been I None
identified I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
we I None
have I None
examined I None
the I None
effects I None
of I None
retigabine I CHEMICAL
on I None
recombinant I None
human I GENE-Y
KCNQ2 O GENE-Y
and I None
KCNQ3 I GENE-Y
potassium I GENE-N
channels O GENE-N
, I None
expressed I None
either I None
alone I None
or I None
in I None
combination I None
in I None
Xenopus I None
oocytes I None
. I None
<eof> I None

<s> O None
Application I None
of I None
10 I None
microM I None
retigabine I CHEMICAL
to I None
oocytes I None
expressing I None
the I None
KCNQ2 I GENE-N
/ O GENE-N
3 O GENE-N
heteromeric I None
channel I None
shifted I None
both I None
the I None
activation I None
threshold I None
and I None
voltage I None
for I None
half I None
- I None
activation I None
by I None
approximately I None
20 I None
mV I None
in I None
the I None
hyperpolarizing I None
direction I None
, I None
leading I None
to I None
an I None
increase I None
in I None
current I None
amplitude I None
at I None
test I None
potentials I None
between I None
- I None
80 I None
mV I None
and I None
+ I None
20 I None
mV I None
. I None
<eof> I None

<s> O None
Retigabine I CHEMICAL
also I None
had I None
a I None
marked I None
effect I None
on I None
KCNQ I GENE-N
current I None
kinetics I None
, I None
increasing I None
the I None
rate I None
of I None
channel I None
activation I None
but I None
slowing I None
deactivation I None
at I None
a I None
given I None
test I None
potential I None
. I None
<eof> I None

<s> O None
Similar I None
effects I None
of I None
retigabine I CHEMICAL
were I None
observed I None
in I None
oocytes I None
expressing I None
KCNQ2 I GENE-Y
alone I None
, I None
suggesting I None
that I None
KCNQ2 I GENE-Y
may I None
be I None
the I None
molecular I None
target I None
of I None
retigabine I CHEMICAL
. I None
<eof> I None

<s> O None
Membrane I None
potential I None
recordings I None
in I None
oocytes I None
expressing I None
the I None
KCNQ2 I GENE-N
/ O GENE-N
3 O GENE-N
heteromeric I None
channel I None
showed I None
that I None
application I None
of I None
retigabine I CHEMICAL
leads I None
to I None
a I None
concentration I None
- I None
dependent I None
hyperpolarization I None
of I None
the I None
oocyte I None
, I None
from I None
a I None
resting I None
potential I None
of I None
- I None
63 I None
mV I None
under I None
control I None
conditions I None
to I None
- I None
85 I None
mV I None
in I None
the I None
presence I None
of I None
100 I None
microM I None
retigabine I CHEMICAL
( I None
IC I None
( I None
50 I None
) I None
= I None
5 I None
. I None
2 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
In I None
control I None
experiments I None
retigabine I CHEMICAL
had I None
no I None
effect I None
on I None
either I None
resting I None
membrane I None
potential I None
or I None
endogenous I None
oocyte I None
membrane I None
currents I None
. I None
<eof> I None

<s> O None
In I None
conclusion I None
, I None
we I None
have I None
shown I None
that I None
retigabine I CHEMICAL
acts I None
as I None
a I None
KCNQ I GENE-N
potassium I GENE-N
channel O GENE-N
opener I None
. I None
<eof> I None

<s> O None
Because I None
the I None
heteromeric I None
KCNQ2 I GENE-N
/ O GENE-N
3 O GENE-N
channel I None
has I None
recently I None
been I None
reported I None
to I None
underlie I None
the I None
M I None
- I None
current I None
, I None
it I None
is I None
likely I None
that I None
M I None
- I None
current I None
modulation I None
can I None
explain I None
the I None
anticonvulsant I None
actions I None
of I None
retigabine I CHEMICAL
in I None
animal I None
models I None
of I None
epilepsy I None
. I None
<eof> I None

<s> O None
Impaired I None
expression I None
of I None
the I None
uncoupling I GENE-Y
protein O GENE-Y
- O GENE-Y
3 O GENE-Y
gene I None
in I None
skeletal I None
muscle I None
during I None
lactation I None
: I None
fibrates I None
and I None
troglitazone I CHEMICAL
reverse I None
lactation I None
- I None
induced I None
downregulation I None
of I None
the I None
uncoupling I GENE-Y
protein O GENE-Y
- O GENE-Y
3 O GENE-Y
gene I None
. I None
<eof> I None

<s> O None
The I None
expression I None
of I None
uncoupling I GENE-Y
protein O GENE-Y
( O GENE-Y
UCP O GENE-Y
) O GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
in I None
skeletal I None
muscle I None
is I None
dramatically I None
reduced I None
during I None
lactation I None
in I None
mice I None
. I None
<eof> I None

<s> O None
The I None
reduction I None
in I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
levels I None
lowers I None
the I None
amount I None
of I None
the I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
protein I None
in I None
skeletal I None
muscle I None
mitochondria I None
during I None
lactation I None
. I None
<eof> I None

<s> O None
Spontaneous I None
or I None
abrupt I None
weaning I None
reverses I None
the I None
downregulation I None
of I None
the I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
but I None
not I None
the I None
reduction I None
in I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
protein I None
levels I None
. I None
<eof> I None

<s> O None
In I None
lactating I None
and I None
virgin I None
mice I None
, I None
however I None
, I None
fasting I None
increases I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
levels I None
. I None
<eof> I None

<s> O None
Changes I None
in I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
occur I None
in I None
parallel I None
with I None
modifications I None
in I None
the I None
levels I None
of I None
free I None
fatty I CHEMICAL
acids O CHEMICAL
, I None
which I None
are I None
reduced I None
in I None
lactation I None
and I None
are I None
upregulated I None
due I None
to I None
weaning I None
or I None
fasting I None
. I None
<eof> I None

<s> O None
Modifications I None
in I None
the I None
energy I None
nutritional I None
stress I None
of I None
lactating I None
dams I None
achieved I None
by I None
manipulating I None
litter I None
sizes I None
do I None
not I None
influence I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
levels I None
in I None
skeletal I None
muscle I None
. I None
<eof> I None

<s> O None
Conversely I None
, I None
when I None
mice I None
are I None
fed I None
a I None
high I None
- I None
fat I None
diet I None
after I None
parturition I None
, I None
the I None
downregulation I None
of I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
and I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
protein I None
levels I None
due I None
to I None
lactation I None
is I None
partially I None
reversed I None
, I None
as I None
is I None
the I None
reduction I None
in I None
serum I None
free I None
fatty I CHEMICAL
acid O CHEMICAL
levels I None
. I None
<eof> I None

<s> O None
Treatment I None
of I None
lactating I None
mice I None
with I None
a I None
single I None
injection I None
of I None
bezafibrate I CHEMICAL
, I None
an I None
activator I None
of I None
the I None
peroxisome I GENE-N
proliferator O GENE-N
- O GENE-N
activated O GENE-N
receptor O GENE-N
( I None
PPAR I GENE-N
) I None
, I None
raises I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
in I None
skeletal I None
muscle I None
to I None
levels I None
similar I None
to I None
those I None
in I None
virgin I None
mice I None
. I None
<eof> I None

<s> O None
4 I CHEMICAL
- O CHEMICAL
chloro O CHEMICAL
- O CHEMICAL
6 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
, O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
xylidine O CHEMICAL
) O CHEMICAL
- O CHEMICAL
pirimidinylthio O CHEMICAL
] O CHEMICAL
acetic O CHEMICAL
acid O CHEMICAL
( I None
WY I CHEMICAL
- O CHEMICAL
14 O CHEMICAL
, O CHEMICAL
643 O CHEMICAL
) I None
, I None
a I None
specific I None
ligand I None
of I None
the I None
PPAR I GENE-Y
- O GENE-Y
alpha O GENE-Y
subtype I None
, I None
causes I None
the I None
most I None
dramatic I None
increase I None
in I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
, I None
whereas I None
troglitazone I CHEMICAL
, I None
a I None
specific I None
activator I None
of I None
PPAR I GENE-Y
- O GENE-Y
gamma O GENE-Y
, I None
also I None
significantly I None
increases I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
abundance I None
in I None
skeletal I None
muscle I None
of I None
lactating I None
mice I None
. I None
<eof> I None

<s> O None
However I None
, I None
in I None
virgin I None
mice I None
, I None
bezafibrate I CHEMICAL
and I None
WY I CHEMICAL
- O CHEMICAL
14 O CHEMICAL
, O CHEMICAL
643 O CHEMICAL
do I None
not I None
significantly I None
affect I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
mRNA I None
expression I None
, I None
whereas I None
troglitazone I CHEMICAL
is I None
at I None
least I None
as I None
effective I None
as I None
it I None
is I None
in I None
lactating I None
dams I None
. I None
<eof> I None

<s> O None
It I None
is I None
proposed I None
that I None
the I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
gene I None
is I None
regulated I None
in I None
skeletal I None
muscle I None
during I None
lactation I None
in I None
response I None
to I None
changes I None
in I None
circulating I None
free I None
fatty I CHEMICAL
acids O CHEMICAL
by I None
mechanisms I None
involving I None
activation I None
of I None
PPARs I GENE-N
. I None
<eof> I None

<s> O None
The I None
impaired I None
expression I None
of I None
the I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
gene I None
is I None
consistent I None
with I None
the I None
involvement I None
of I None
UCP I GENE-Y
- O GENE-Y
3 O GENE-Y
gene I None
regulation I None
in I None
the I None
reduction I None
of I None
the I None
use I None
of I None
fatty I CHEMICAL
acids O CHEMICAL
as I None
fuel I None
by I None
the I None
skeletal I None
muscle I None
and I None
in I None
impaired I None
adaptative I None
thermogenesis I None
, I None
both I None
of I None
which I None
are I None
major I None
metabolic I None
adaptations I None
that I None
occur I None
during I None
lactation I None
. I None
<eof> I None

<s> O None
Hypertrophic I None
effect I None
of I None
selective I None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
stimulation I None
on I None
ventricular I None
cardiomyocytes I None
from I None
adult I None
rat I None
. I None
<eof> I None

<s> O None
We I None
investigated I None
whether I None
selective I None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
stimulation I None
causes I None
hypertrophic I None
growth I None
on I None
isolated I None
ventricular I None
cardiomyocytes I None
from I None
adult I None
rat I None
. I None
<eof> I None

<s> O None
As I None
parameters I None
for I None
the I None
induction I None
of I None
hypertrophic I None
growth I None
, I None
the I None
increases I None
of I None
[ I CHEMICAL
( O CHEMICAL
14 O CHEMICAL
) O CHEMICAL
C O CHEMICAL
] O CHEMICAL
phenylalanine O CHEMICAL
incorporation I None
, I None
protein I None
and I None
RNA I None
mass I None
, I None
and I None
cell I None
size I None
were I None
determined I None
. I None
<eof> I None

<s> O None
Isoproterenol I CHEMICAL
( I None
Iso I None
, I None
10 I None
microM I None
) I None
alone I None
had I None
no I None
growth I None
effect I None
. I None
<eof> I None

<s> O None
In I None
the I None
presence I None
of I None
the I None
beta I GENE-Y
( O GENE-Y
2 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
antagonist I None
ICI I CHEMICAL
- O CHEMICAL
118551 O CHEMICAL
( I None
ICI I None
, I None
10 I None
microM I None
) I None
, I None
Iso I None
caused I None
an I None
increase I None
in I None
[ I CHEMICAL
( O CHEMICAL
14 O CHEMICAL
) O CHEMICAL
C O CHEMICAL
] O CHEMICAL
phenylalanine O CHEMICAL
incorporation I None
, I None
protein I None
and I None
RNA I None
mass I None
, I None
cell I None
volume I None
, I None
and I None
cross I None
- I None
sectional I None
area I None
. I None
<eof> I None

<s> O None
We I None
showed I None
for I None
phenylalanine I CHEMICAL
incorporation I None
that I None
the I None
growth I None
effect I None
of I None
Iso I None
+ I None
ICI I None
could I None
be I None
antagonized I None
by I None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
blockade I None
with I None
atenolol I CHEMICAL
( I None
10 I None
microM I None
) I None
or I None
metoprolol I CHEMICAL
( I None
10 I None
microM I None
) I None
, I None
indicating I None
that I None
it I None
was I None
caused I None
by I None
selective I None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
stimulation I None
. I None
<eof> I None

<s> O None
The I None
growth I None
response I None
to I None
Iso I None
+ I None
ICI I None
was I None
accompanied I None
by I None
an I None
increase I None
in I None
ornithine I GENE-Y
decarboxylase O GENE-Y
( I None
ODC I GENE-Y
) I None
activity I None
and I None
expression I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
ODC I GENE-Y
by I None
the I None
ODC I GENE-Y
antagonist I None
difluoromethylornithine I CHEMICAL
( I None
1 I None
mM I None
) I None
attenuated I None
this I None
hypertrophic I None
response I None
, I None
indicating I None
that I None
ODC I GENE-Y
induction I None
is I None
causally I None
involved I None
. I None
<eof> I None

<s> O None
The I None
growth I None
response I None
to I None
Iso I None
+ I None
ICI I None
was I None
found I None
to I None
be I None
cAMP I CHEMICAL
independent I None
but I None
was I None
sensitive I None
to I None
genistein I None
( I None
100 I None
microM I None
) I None
or I None
rapamycin I CHEMICAL
( I None
0 I None
. I None
1 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
The I None
reaction I None
was I None
enhanced I None
in I None
the I None
presence I None
of I None
pertussis I GENE-N
toxin O GENE-N
( I None
10 I None
microM I None
) I None
. I None
<eof> I None

<s> O None
We I None
conclude I None
that I None
selective I None
beta I GENE-Y
( O GENE-Y
1 O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
stimulation I None
causes I None
hypertrophic I None
growth I None
of I None
ventricular I None
cardiomyocytes I None
by I None
a I None
mechanism I None
that I None
is I None
independent I None
of I None
cAMP I CHEMICAL
but I None
dependent I None
on I None
a I None
tyrosine I GENE-N
kinase O GENE-N
and I None
ODC I GENE-Y
. I None
<eof> I None

<s> O None
Hyperphenylalaninemia I None
and I None
7 I CHEMICAL
- O CHEMICAL
pterin O CHEMICAL
excretion I None
associated I None
with I None
mutations I None
in I None
4a I GENE-Y
- O GENE-Y
hydroxy O GENE-Y
- O GENE-Y
tetrahydrobiopterin O GENE-Y
dehydratase O GENE-Y
/ I None
DCoH I GENE-Y
: I None
analysis I None
of I None
enzyme I None
activity I None
in I None
intestinal I None
biopsies I None
. I None
<eof> I None

<s> O None
Hyperphenylalaninemia I None
, I None
which I None
can I None
cause I None
neurological I None
disorders I None
and I None
mental I None
retardation I None
, I None
results I None
from I None
a I None
mutation I None
in I None
phenylalanine I GENE-Y
hydroxylase O GENE-Y
or I None
an I None
enzyme I None
required I None
for I None
biosynthesis I None
or I None
regeneration I None
of I None
its I None
cofactor I None
, I None
tetrahydrobiopterin I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
hyperphenylalaninemia I None
variant I None
primapterinuria I None
is I None
characterized I None
by I None
the I None
excretion I None
of I None
7 I CHEMICAL
- O CHEMICAL
biopterin O CHEMICAL
( I None
primapterin I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
This I None
disorder I None
is I None
thought I None
to I None
be I None
due I None
to I None
a I None
deficiency I None
of I None
4a I GENE-Y
- O GENE-Y
hydroxy O GENE-Y
- O GENE-Y
tetrahydrobiopterin O GENE-Y
dehydratase O GENE-Y
( I None
pterin I GENE-Y
- O GENE-Y
4a O GENE-Y
- O GENE-Y
carbinolamine O GENE-Y
dehydratase O GENE-Y
) I None
, I None
but I None
a I None
lack I None
of I None
tissue I None
activity I None
has I None
not I None
been I None
directly I None
demonstrated I None
. I None
<eof> I None

<s> O None
The I None
five I None
mutations I None
so I None
far I None
recognized I None
in I None
patients I None
with I None
primapterinuria I None
are I None
associated I None
with I None
either I None
a I None
single I None
amino I CHEMICAL
acid O CHEMICAL
change I None
or I None
a I None
premature I None
stop I None
codon I None
. I None
<eof> I None

<s> O None
Only I None
C81R I GENE-N
has I None
been I None
successfully I None
expressed I None
in I None
soluble I None
form I None
, I None
and I None
was I None
found I None
to I None
have I None
40 I None
% I None
of I None
normal I None
activity I None
. I None
<eof> I None

<s> O None
Tissues I None
which I None
could I None
be I None
obtained I None
by I None
minimally I None
invasive I None
procedures I None
were I None
analyzed I None
for I None
dehydratase I GENE-N
activity I None
. I None
<eof> I None

<s> O None
None I None
was I None
detected I None
in I None
normal I None
human I None
white I None
cells I None
or I None
fibroblasts I None
. I None
<eof> I None

<s> O None
However I None
, I None
activity I None
was I None
found I None
in I None
intestine I None
of I None
rat I None
, I None
dog I None
, I None
pig I None
, I None
and I None
particularly I None
humans I None
where I None
it I None
was I None
only I None
eight I None
times I None
lower I None
than I None
in I None
liver I None
. I None
<eof> I None

<s> O None
Distribution I None
along I None
the I None
length I None
and I None
across I None
the I None
wall I None
of I None
small I None
intestine I None
was I None
relatively I None
uniform I None
. I None
<eof> I None

<s> O None
Moreover I None
, I None
the I None
dehydratases I GENE-N
from I None
human I None
liver I None
and I None
intestinal I None
mucosa I None
have I None
identical I None
kinetic I None
properties I None
. I None
<eof> I None

<s> O None
A I None
biopsy I None
of I None
duodenal I None
mucosa I None
from I None
a I None
patient I None
with I None
homozygous I None
E96K I GENE-N
dehydratase I GENE-N
had I None
activity I None
of I None
55 I None
nmol I None
. I None
<eof> I None

<s> O None
min I None
( I None
- I None
1 I None
) I None
g I None
( I None
- I None
1 I None
) I None
mucosa I None
compared I None
to I None
329 I None
+ I None
/ I None
- I None
32 I None
nmol I None
. I None
<eof> I None

<s> O None
min I None
( I None
- I None
1 I None
) I None
g I None
( I None
- I None
1 I None
) I None
tissue I None
in I None
controls I None
( I None
n I None
= I None
12 I None
) I None
. I None
<eof> I None

<s> O None
The I None
sixfold I None
lower I None
tissue I None
activity I None
of I None
the I None
E96K I GENE-N
mutant I None
alone I None
may I None
not I None
be I None
sufficient I None
to I None
account I None
for I None
the I None
biochemical I None
symptoms I None
of I None
primapterinuria I None
in I None
this I None
patient I None
. I None
<eof> I None

<s> O None
However I None
, I None
accumulation I None
of I None
a I None
4a I CHEMICAL
- O CHEMICAL
hydroxy O CHEMICAL
- O CHEMICAL
tetrahydrobiopterin O CHEMICAL
degradation I None
product I None
( I None
a I None
side I None
- I None
chain I None
cyclic I None
adduct I None
) I None
, I None
which I None
has I None
been I None
observed I None
in I None
vitro I None
and I None
appears I None
to I None
be I None
a I None
dehydratase I GENE-N
inhibitor I None
, I None
may I None
further I None
exacerbate I None
the I None
problem I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
the I None
inhibition I None
of I None
cyclo I GENE-N
- O GENE-N
oxygenase O GENE-N
1 O GENE-N
or O GENE-N
2 O GENE-N
or I None
5 I GENE-Y
- O GENE-Y
lipoxygenase O GENE-Y
on I None
the I None
activation I None
of I None
the I None
hypothalamic I None
- I None
pituitary I None
- I None
adrenal I None
axis I None
induced I None
by I None
interleukin I GENE-Y
- O GENE-Y
1beta O GENE-Y
in I None
the I None
male I None
Rat I None
. I None
<eof> I None

<s> O None
The I None
limited I None
entry I None
of I None
interleukin I GENE-Y
- O GENE-Y
1beta O GENE-Y
( I None
IL I GENE-Y
- O GENE-Y
1beta O GENE-Y
) I None
into I None
the I None
central I None
nervous I None
system I None
has I None
led I None
to I None
the I None
hypothesis I None
that I None
IL I GENE-Y
- O GENE-Y
1beta O GENE-Y
acts I None
, I None
through I None
IL I GENE-N
- O GENE-N
1beta O GENE-N
receptors O GENE-N
located I None
notably I None
on I None
endothelial I None
cells I None
, I None
on I None
the I None
release I None
of I None
prostaglandins I CHEMICAL
which I None
in I None
turn I None
stimulate I None
the I None
hypothalamic I None
- I None
pituitary I None
- I None
adrenal I None
( I None
HPA I None
) I None
axis I None
. I None
<eof> I None

<s> O None
We I None
used I None
cyclo I GENE-Y
- O GENE-Y
oxygenase O GENE-Y
- O GENE-Y
1 O GENE-Y
( I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
) I None
and I None
cyclo I GENE-Y
- O GENE-Y
oxygenase O GENE-Y
- O GENE-Y
2 O GENE-Y
( I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
and I None
5 I GENE-Y
- O GENE-Y
lipoxygenase O GENE-Y
( I None
5 I GENE-Y
- O GENE-Y
LOX O GENE-Y
) I None
inhibitors I None
, I None
before I None
the I None
injection I None
of I None
IL I GENE-Y
- O GENE-Y
1beta O GENE-Y
, I None
to I None
explore I None
the I None
role I None
of I None
arachidonic I CHEMICAL
acid O CHEMICAL
metabolic I None
pathways I None
on I None
HPA I None
axis I None
activation I None
. I None
<eof> I None

<s> O None
Adult I None
male I None
rats I None
were I None
i I None
. I None
m I None
injected I None
20 I None
min I None
before I None
i I None
. I None
p I None
injection I None
of I None
IL I GENE-Y
- O GENE-Y
1beta O GENE-Y
, I None
with I None
( I None
i I None
) I None
: I None
a I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
/ I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
( I None
ketoprofen I CHEMICAL
) I None
; I None
( I None
ii I None
) I None
a I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
selective I None
inhibitor I None
( I None
NS I CHEMICAL
398 O CHEMICAL
) I None
; I None
or I None
( I None
iii I None
) I None
a I None
5 I GENE-Y
- O GENE-Y
LOX O GENE-Y
inhibitor I None
( I None
BW I CHEMICAL
A4C O CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Following I None
this I None
, I None
rats I None
were I None
killed I None
90 I None
min I None
after I None
i I None
. I None
p I None
. I None
<eof> I None

<s> O None
IL I GENE-Y
- O GENE-Y
1beta O GENE-Y
injection I None
and I None
analysis I None
for I None
plasma I None
adrenocorticotropic I GENE-Y
hormone O GENE-Y
( I None
ACTH I GENE-Y
) I None
and I None
corticosterone I CHEMICAL
concentrations I None
and I None
determination I None
of I None
anterior I None
pituitary I None
pro I GENE-Y
- O GENE-Y
opio O GENE-Y
melanocortin O GENE-Y
( I None
POMC I GENE-Y
) I None
gene I None
transcription I None
was I None
conducted I None
. I None
<eof> I None

<s> O None
Administration I None
of I None
the I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
/ I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
led I None
to I None
a I None
complete I None
blockage I None
of I None
ACTH I GENE-Y
and I None
corticosterone I CHEMICAL
secretion I None
and I None
POMC I GENE-Y
gene I None
transcription I None
. I None
<eof> I None

<s> O None
The I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitor I None
led I None
to I None
a I None
complete I None
blockade I None
of I None
ACTH I GENE-Y
secretion I None
and I None
POMC I GENE-Y
gene I None
transcription I None
but I None
had I None
no I None
effect I None
on I None
corticosterone I CHEMICAL
secretion I None
. I None
<eof> I None

<s> O None
The I None
5 I GENE-Y
- O GENE-Y
LOX O GENE-Y
inhibitor I None
had I None
no I None
significant I None
effect I None
on I None
any I None
parameter I None
. I None
<eof> I None

<s> O None
These I None
results I None
demonstrate I None
the I None
crucial I None
role I None
of I None
eicosanoid I None
pathways I None
in I None
mediating I None
the I None
stimulation I None
of I None
the I None
HPA I None
axis I None
induced I None
by I None
IL I GENE-Y
- O GENE-Y
1beta O GENE-Y
. I None
<eof> I None

<s> O None
Moreover I None
, I None
we I None
found I None
a I None
clear I None
dissociation I None
of I None
the I None
effect I None
of I None
the I None
blockage I None
of I None
COXs I GENE-N
upon I None
ACTH I GENE-Y
and I None
corticosterone I CHEMICAL
secretion I None
, I None
suggesting I None
that I None
IL I GENE-Y
- O GENE-Y
1beta O GENE-Y
may I None
act I None
at I None
the I None
brain I None
as I None
well I None
as I None
at I None
the I None
adrenal I None
cortex I None
to I None
stimulate I None
the I None
secretion I None
of I None
corticosterone I CHEMICAL
. I None
<eof> I None

<s> O None
Drug I None
treatment I None
of I None
obesity I None
. I None
<eof> I None

<s> O None
Drugs I None
to I None
treat I None
obesity I None
can I None
be I None
divided I None
into I None
three I None
groups I None
: I None
those I None
which I None
reduce I None
food I None
intake I None
, I None
those I None
which I None
alter I None
metabolism I None
and I None
those I None
which I None
increase I None
thermogenesis I None
. I None
<eof> I None

<s> O None
Monoamines I CHEMICAL
acting I None
on I None
noradrenergic I GENE-N
receptors O GENE-N
, I None
serotonin I GENE-N
receptors O GENE-N
, I None
dopamine I GENE-N
receptors O GENE-N
and I None
histamine I GENE-N
receptors O GENE-N
can I None
reduce I None
food I None
intake I None
. I None
<eof> I None

<s> O None
A I None
number I None
of I None
peptides I None
also I None
affect I None
food I None
intake I None
. I None
<eof> I None

<s> O None
The I None
noradrenergic I None
drugs I None
phentermine I CHEMICAL
, I None
diethylpropion I CHEMICAL
, I None
mazindol I CHEMICAL
benzphetamine O CHEMICAL
and I None
phendimetrazine I CHEMICAL
are I None
approved I None
only I None
for I None
short I None
- I None
term I None
use I None
. I None
<eof> I None

<s> O None
Sibutramine I CHEMICAL
, I None
a I None
norepinephrine I CHEMICAL
- I None
serotonin I CHEMICAL
re I None
- I None
uptake I None
inhibitor I None
, I None
is I None
approved I None
for I None
long I None
- I None
term I None
use I None
. I None
<eof> I None

<s> O None
Orlistat I CHEMICAL
inhibits I None
pancreatic I GENE-Y
lipase O GENE-Y
and I None
can I None
block I None
30 I None
% I None
of I None
triglyceride I CHEMICAL
hydrolysis I None
in I None
subjects I None
eating I None
a I None
30 I None
% I None
fat I None
diet I None
. I None
<eof> I None

<s> O None
The I None
only I None
thermogenic I None
drug I None
combination I None
that I None
has I None
been I None
tested I None
is I None
ephedrine I CHEMICAL
and I None
caffeine I CHEMICAL
, I None
but I None
this I None
treatment I None
has I None
not I None
been I None
approved I None
by I None
regulating I None
agencies I None
. I None
<eof> I None

<s> O None
Leptin I GENE-Y
is I None
currently I None
in I None
clinical I None
trials I None
and I None
other I None
drugs I None
that I None
may I None
modulate I None
peptide I None
- I None
feeding I None
systems I None
are I None
being I None
developed I None
. I None
<eof> I None

<s> O None
The I None
apoptosome I None
: I None
heart I None
and I None
soul I None
of I None
the I None
cell I None
death I None
machine I None
. I None
<eof> I None

<s> O None
Apoptosis I None
is I None
a I None
fundamental I None
biologic I None
process I None
by I None
which I None
metazoan I None
cells I None
orchestrate I None
their I None
own I None
self I None
- I None
demise I None
. I None
<eof> I None

<s> O None
Genetic I None
analyses I None
of I None
the I None
nematode I None
C I None
elegans I None
identified I None
three I None
core I None
components I None
of I None
the I None
suicide I None
apparatus I None
which I None
include I None
CED I GENE-Y
- O GENE-Y
3 O GENE-Y
, I None
CED I GENE-Y
- O GENE-Y
4 O GENE-Y
, I None
and I None
CED I GENE-Y
- O GENE-Y
9 O GENE-Y
. I None
<eof> I None

<s> O None
An I None
analogous I None
set I None
of I None
core I None
constituents I None
exists I None
in I None
mammalian I None
cells I None
and I None
includes I None
caspase I GENE-Y
- O GENE-Y
9 O GENE-Y
, I None
Apaf I GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
and I None
bcl I GENE-N
- O GENE-N
2 O GENE-N
/ O GENE-N
xL O GENE-N
, I None
respectively I None
. I None
<eof> I None

<s> O None
CED I GENE-Y
- O GENE-Y
3 O GENE-Y
and I None
CED I GENE-Y
- O GENE-Y
4 O GENE-Y
, I None
along I None
with I None
their I None
mammalian I None
counterparts I None
, I None
function I None
to I None
kill I None
cells I None
, I None
whereas I None
CED I GENE-Y
- O GENE-Y
9 O GENE-Y
and I None
its I None
mammalian I None
equivalents I None
protect I None
cells I None
from I None
death I None
. I None
<eof> I None

<s> O None
These I None
central I None
components I None
biochemically I None
intermingle I None
in I None
a I None
ternary I None
complex I None
recently I None
dubbed I None
the I None
" I None
apoptosome I None
. I None
" I None
The I None
C I None
elegans I None
protein I None
EGL I GENE-Y
- O GENE-Y
1 O GENE-Y
and I None
its I None
mammalian I None
counterparts I None
, I None
pro I None
- I None
apoptotic I None
members I None
of I None
the I None
bcl I GENE-N
- O GENE-N
2 O GENE-N
family I None
, I None
induce I None
cell I None
death I None
by I None
disrupting I None
apoptosome I None
interactions I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
EGL I GENE-Y
- O GENE-Y
1 O GENE-Y
may I None
represent I None
a I None
primordial I None
signal I None
integrator I None
for I None
the I None
apoptosome I None
. I None
<eof> I None

<s> O None
Various I None
biochemical I None
processes I None
including I None
oligomerization I None
, I None
adenosine I CHEMICAL
triphosphate O CHEMICAL
ATP I CHEMICAL
/ I None
dATP I None
binding I None
, I None
and I None
cytochrome I GENE-Y
c O GENE-Y
interaction I None
play I None
a I None
role I None
in I None
regulating I None
the I None
ternary I None
death I None
complex I None
. I None
<eof> I None

<s> O None
Recent I None
studies I None
suggest I None
that I None
cell I None
death I GENE-N
receptors O GENE-N
, I None
such I None
as I None
CD95 I GENE-Y
, I None
may I None
amplify I None
their I None
suicide I None
signal I None
by I None
activating I None
the I None
apoptosome I None
. I None
<eof> I None

<s> O None
These I None
mutual I None
associations I None
by I None
core I None
components I None
of I None
the I None
suicide I None
apparatus I None
provide I None
a I None
molecular I None
framework I None
in I None
which I None
diverse I None
death I None
signals I None
likely I None
interface I None
. I None
<eof> I None

<s> O None
Understanding I None
the I None
apoptosome I None
and I None
its I None
cellular I None
connections I None
will I None
facilitate I None
the I None
design I None
of I None
novel I None
therapeutic I None
strategies I None
for I None
cancer I None
and I None
other I None
disease I None
states I None
in I None
which I None
apoptosis I None
plays I None
a I None
pivotal I None
role I None
. I None
<eof> I None

<s> O None
Calicheamicin I CHEMICAL
- I None
conjugated I None
humanized I None
anti I None
- I None
CD33 I GENE-Y
monoclonal I None
antibody I None
( I None
gemtuzumab I None
zogamicin I None
, I None
CMA I None
- I None
676 I None
) I None
shows I None
cytocidal I None
effect I None
on I None
CD33 I GENE-Y
- I None
positive I None
leukemia I None
cell I None
lines I None
, I None
but I None
is I None
inactive I None
on I None
P I GENE-N
- O GENE-N
glycoprotein O GENE-N
- I None
expressing I None
sublines I None
. I None
<eof> I None

<s> O None
Calicheamicin I CHEMICAL
- I None
conjugated I None
humanized I None
anti I None
- I None
CD33 I GENE-Y
mouse I None
monoclonal I None
antibody I None
, I None
CMA I None
- I None
676 I None
, I None
has I None
recently I None
been I None
introduced I None
to I None
clinics I None
as I None
a I None
promising I None
drug I None
to I None
treat I None
patients I None
with I None
acute I None
myeloid I None
leukemia I None
( I None
AML I None
) I None
in I None
relapse I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
mechanism I None
of I None
action I None
of I None
CMA I None
- I None
676 I None
has I None
not I None
been I None
well I None
elucidated I None
. I None
<eof> I None

<s> O None
The I None
cytotoxic I None
effect I None
of I None
CMA I None
- I None
676 I None
on I None
HL60 I None
, I None
NOMO I None
- I None
1 I None
, I None
NB4 I None
, I None
NKM I None
- I None
1 I None
, I None
K562 I None
, I None
Daudi I None
, I None
and I None
the I None
multidrug I None
- I None
resistant I None
sublines I None
, I None
NOMO I None
- I None
1 I None
/ I None
ADR I None
and I None
NB4 I None
/ I None
MDR I None
, I None
was I None
investigated I None
by I None
cell I None
cycle I None
distribution I None
and I None
morphology I None
. I None
<eof> I None

<s> O None
These I None
studies I None
were I None
done I None
by I None
a I None
video I None
- I None
microscopic I None
system I None
, I None
DNA I None
fragmentation I None
, I None
dye I None
exclusion I None
and I None
3H I CHEMICAL
- O CHEMICAL
thymidine O CHEMICAL
uptake I None
after I None
analysis I None
of I None
CD33 I GENE-Y
, I None
CD34 I GENE-Y
, I None
P I GENE-N
- O GENE-N
glycoprotein O GENE-N
( I None
P I GENE-N
- O GENE-N
gp O GENE-N
) I None
, I None
multidrug I GENE-Y
resistance O GENE-Y
( O GENE-Y
MDR O GENE-Y
) O GENE-Y
- O GENE-Y
associated O GENE-Y
protein O GENE-Y
and I None
lung I None
- I None
related I None
protein I None
on I None
these I None
cells I None
. I None
<eof> I None

<s> O None
A I None
dose I None
- I None
dependent I None
, I None
selective I None
cytotoxic I None
effect I None
of I None
CMA I None
- I None
676 I None
was I None
observed I None
in I None
cell I None
lines I None
that I None
expressed I None
CD33 I GENE-Y
, I None
and I None
was I None
dependent I None
on I None
the I None
amount I None
of I None
CD33 I GENE-Y
and I None
the I None
proliferative I None
speed I None
of I None
the I None
cells I None
. I None
<eof> I None

<s> O None
Sensitive I None
cells I None
were I None
temporally I None
arrested I None
at I None
the I None
G2 I None
/ I None
M I None
phase I None
before I None
undergoing I None
morphological I None
changes I None
. I None
<eof> I None

<s> O None
CMA I None
- I None
676 I None
is I None
not I None
effective I None
on I None
P I GENE-N
- O GENE-N
gp O GENE-N
- I None
expressing I None
multidrug I None
- I None
resistant I None
sublines I None
compared I None
with I None
parental I None
cell I None
lines I None
. I None
<eof> I None

<s> O None
MDR I None
modifiers I None
, I None
MS209 I None
and I None
PSC833 I None
, I None
restored I None
the I None
cytotoxic I None
effect I None
of I None
CMA I None
- I None
676 I None
in I None
P I GENE-N
- O GENE-N
gp O GENE-N
- I None
expressing I None
sublines I None
. I None
<eof> I None

<s> O None
CMA I None
- I None
676 I None
is I None
a I None
promising I None
agent I None
in I None
the I None
treatment I None
of I None
patients I None
with I None
AML I None
that I None
expresses I None
CD33 I GENE-Y
. I None
<eof> I None

<s> O None
The I None
combined I None
use I None
of I None
CMA I None
- I None
676 I None
and I None
MDR I None
modifiers I None
may I None
increase I None
the I None
selective I None
cytotoxic I None
effect I None
in I None
multidrug I None
- I None
resistant I None
AML I None
. I None
<eof> I None

<s> O None
Retigabine I CHEMICAL
, I None
a I None
novel I None
anti I None
- I None
convulsant I None
, I None
enhances I None
activation I None
of I None
KCNQ2 I GENE-N
/ O GENE-N
Q3 O GENE-N
potassium I GENE-N
channels O GENE-N
. I None
<eof> I None

<s> O None
Retigabine I CHEMICAL
[ I None
N I CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
amino O CHEMICAL
- O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
fluorobenzylamino O CHEMICAL
] O CHEMICAL
- O CHEMICAL
phenyl O CHEMICAL
) O CHEMICAL
carbamic O CHEMICAL
acid O CHEMICAL
; I None
D I CHEMICAL
- O CHEMICAL
23129 O CHEMICAL
] I None
is I None
a I None
novel I None
anticonvulsant I None
, I None
unrelated I None
to I None
currently I None
available I None
antiepileptic I None
agents I None
, I None
with I None
activity I None
in I None
a I None
broad I None
range I None
of I None
seizure I None
models I None
. I None
<eof> I None

<s> O None
In I None
the I None
present I None
study I None
, I None
we I None
sought I None
to I None
determine I None
whether I None
retigabine I None
could I None
enhance I None
current I None
through I None
M I None
- I None
like I None
currents I None
in I None
PC12 I None
cells I None
and I None
KCNQ2 I GENE-N
/ O GENE-N
Q3 O GENE-N
K I GENE-N
( O GENE-N
+ O GENE-N
) O GENE-N
channels O GENE-N
expressed I None
in I None
Chinese I None
hamster I None
ovary I None
cells I None
( I None
CHO I None
- I None
KCNQ2 I GENE-N
/ O GENE-N
Q3 O GENE-N
) I None
. I None
<eof> I None

<s> O None
In I None
differentiated I None
PC12 I None
cells I None
, I None
retigabine I None
enhanced I None
a I None
linopirdine I CHEMICAL
- I None
sensitive I None
current I None
. I None
<eof> I None

<s> O None
The I None
effect I None
of I None
retigabine I CHEMICAL
was I None
associated I None
with I None
a I None
slowing I None
of I None
M I None
- I None
like I None
tail I None
current I None
deactivation I None
in I None
these I None
cells I None
. I None
<eof> I None

<s> O None
Retigabine I CHEMICAL
( I None
0 I None
. I None
1 I None
to I None
10 I None
microM I None
) I None
induced I None
a I None
potassium I CHEMICAL
current I None
and I None
hyperpolarized I None
CHO I None
cells I None
expressing I None
KCNQ2 I GENE-N
/ O GENE-N
Q3 O GENE-N
cells I None
but I None
not I None
in I None
wild I None
- I None
type I None
cells I None
. I None
<eof> I None

<s> O None
Retigabine I CHEMICAL
- I None
induced I None
currents I None
in I None
CHO I None
- I None
KCNQ2 I GENE-N
/ O GENE-N
Q3 O GENE-N
cells I None
were I None
inhibited I None
by I None
60 I None
. I None
6 I None
+ I None
/ I None
- I None
11 I None
% I None
( I None
n I None
= I None
4 I None
) I None
by I None
the I None
KCNQ2 I GENE-N
/ O GENE-N
Q3 O GENE-N
blocker I None
, I None
linopirdine I CHEMICAL
( I None
10 I None
microM I None
) I None
, I None
and I None
82 I None
. I None
7 I None
+ I None
/ I None
- I None
5 I None
. I None
4 I None
% I None
( I None
n I None
= I None
4 I None
) I None
by I None
BaCl I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
( I None
10 I None
mM I None
) I None
. I None
<eof> I None

<s> O None
The I None
mechanism I None
by I None
which I None
retigabine I CHEMICAL
enhanced I None
KCNQ2 I GENE-N
/ O GENE-N
Q3 O GENE-N
currents I None
involved I None
large I None
, I None
drug I None
- I None
induced I None
, I None
leftward I None
shifts I None
in I None
the I None
voltage I None
dependence I None
of I None
channel I None
activation I None
( I None
- I None
33 I None
. I None
1 I None
+ I None
/ I None
- I None
2 I None
. I None
6 I None
mV I None
, I None
n I None
= I None
4 I None
, I None
by I None
10 I None
microM I None
retigabine I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Retigabine I CHEMICAL
shifted I None
the I None
voltage I None
dependence I None
of I None
channel I None
activation I None
with I None
an I None
EC I None
( I None
50 I None
) I None
value I None
of I None
1 I None
. I None
6 I None
+ I None
/ I None
- I None
0 I None
. I None
3 I None
microM I None
( I None
slope I None
factor I None
was I None
1 I None
. I None
2 I None
+ I None
/ I None
- I None
0 I None
. I None
1 I None
, I None
n I None
= I None
4 I None
to I None
5 I None
cells I None
per I None
concentration I None
) I None
. I None
<eof> I None

<s> O None
Retigabine I CHEMICAL
( I None
0 I None
. I None
1 I None
to I None
10 I None
microM I None
) I None
also I None
slowed I None
the I None
rate I None
of I None
channel I None
deactivation I None
, I None
predominantly I None
by I None
increasing I None
the I None
contribution I None
of I None
a I None
slowly I None
deactivating I None
tail I None
current I None
component I None
. I None
<eof> I None

<s> O None
Our I None
findings I None
identify I None
KCNQ2 I GENE-N
/ O GENE-N
Q3 O GENE-N
channels I None
as I None
a I None
molecular I None
target I None
for I None
retigabine I CHEMICAL
and I None
suggest I None
that I None
activation I None
of I None
KCNQ2 I GENE-N
/ O GENE-N
Q3 O GENE-N
channels I None
may I None
be I None
responsible I None
for I None
at I None
least I None
some I None
of I None
the I None
anticonvulsant I None
activity I None
of I None
this I None
agent I None
. I None
<eof> I None

<s> O None
Interaction I None
of I None
flavodoxin I GENE-N
with I None
cobalamin I CHEMICAL
- I None
dependent I None
methionine I GENE-Y
synthase O GENE-Y
. I None
<eof> I None

<s> O None
Cobalamin I CHEMICAL
- I None
dependent I None
methionine I GENE-Y
synthase O GENE-Y
catalyzes I None
the I None
transfer I None
of I None
a I None
methyl I CHEMICAL
group I None
from I None
methyltetrahydrofolate I CHEMICAL
to I None
homocysteine I CHEMICAL
, I None
forming I None
tetrahydrofolate I CHEMICAL
and I None
methionine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
Escherichia I None
coli I None
enzyme I None
, I None
like I None
its I None
mammalian I None
homologue I None
, I None
is I None
occasionally I None
inactivated I None
by I None
oxidation I None
of I None
the I None
cofactor I None
to I None
cob I CHEMICAL
( O CHEMICAL
II O CHEMICAL
) O CHEMICAL
alamin O CHEMICAL
. I None
<eof> I None

<s> O None
To I None
return I None
to I None
the I None
catalytic I None
cycle I None
, I None
the I None
cob I CHEMICAL
( O CHEMICAL
II O CHEMICAL
) O CHEMICAL
alamin O CHEMICAL
forms I None
of I None
both I None
the I None
bacterial I None
and I None
mammalian I None
enzymes I None
must I None
be I None
reductively I None
remethylated I None
. I None
<eof> I None

<s> O None
Reduced I GENE-N
flavodoxin O GENE-N
donates I None
an I None
electron I None
for I None
this I None
reaction I None
in I None
E I None
. I None
coli I None
, I None
and I None
S I CHEMICAL
- O CHEMICAL
adenosylmethionine O CHEMICAL
serves I None
as I None
the I None
methyl I None
donor I None
. I None
<eof> I None

<s> O None
In I None
humans I None
, I None
the I None
electron I None
is I None
thought I None
to I None
be I None
provided I None
by I None
methionine I GENE-Y
synthase O GENE-Y
reductase O GENE-Y
, I None
a I None
protein I None
containing I None
a I None
domain I None
with I None
a I None
significant I None
degree I None
of I None
homology I None
to I None
flavodoxin I GENE-N
. I None
<eof> I None

<s> O None
Because I None
of I None
this I None
homology I None
, I None
studies I None
of I None
the I None
interactions I None
between I None
E I GENE-N
. O GENE-N
coli O GENE-N
flavodoxin O GENE-N
and I None
methionine I GENE-Y
synthase O GENE-Y
provide I None
a I None
model I None
for I None
the I None
mammalian I None
system I None
. I None
<eof> I None

<s> O None
To I None
characterize I None
the I None
binding I None
interface I None
between I None
E I GENE-N
. O GENE-N
coli O GENE-N
flavodoxin O GENE-N
and I None
methionine I GENE-Y
synthase O GENE-Y
, I None
we I None
have I None
employed I None
site I None
- I None
directed I None
mutagenesis I None
and I None
chemical I None
cross I None
- I None
linking I None
using I None
carbodiimide I CHEMICAL
and I None
N I CHEMICAL
- O CHEMICAL
hydroxysuccinimide O CHEMICAL
. I None
<eof> I None

<s> O None
Glutamate I CHEMICAL
61 I None
of I None
flavodoxin I GENE-N
is I None
identified I None
as I None
a I None
cross I None
- I None
linked I None
residue I None
, I None
and I None
lysine I None
959 I None
of I None
the I None
C I CHEMICAL
- I None
terminal I None
activation I None
domain I None
of I None
methionine I GENE-Y
synthase O GENE-Y
is I None
assigned I None
as I None
its I None
partner I None
. I None
<eof> I None

<s> O None
The I None
mutation I None
of I None
lysine I GENE-N
959 O GENE-N
to O GENE-N
threonine O GENE-N
results I None
in I None
a I None
diminished I None
level I None
of I None
cross I None
- I None
linking I None
, I None
but I None
has I None
only I None
a I None
small I None
effect I None
on I None
the I None
affinity I None
of I None
methionine I GENE-Y
synthase O GENE-Y
for I None
flavodoxin I GENE-N
. I None
<eof> I None

<s> O None
Identification I None
of I None
these I None
cross I None
- I None
linked I None
residues I None
provides I None
evidence I None
in I None
support I None
of I None
a I None
docking I None
model I None
that I None
will I None
be I None
useful I None
in I None
predicting I None
the I None
effects I None
of I None
mutations I None
observed I None
in I None
mammalian I None
homologues I None
of I None
E I GENE-N
. O GENE-N
coli O GENE-N
flavodoxin O GENE-N
and I None
methionine I GENE-Y
synthase O GENE-Y
. I None
<eof> I None

<s> O None
A I None
gene I None
for I None
pyridoxine I CHEMICAL
- I None
dependent I None
epilepsy I None
maps I None
to I None
chromosome I None
5q31 I None
. I None
<eof> I None

<s> O None
Pyridoxine I CHEMICAL
- I None
dependent I None
epilepsy I None
( I None
PDE I None
) I None
is I None
a I None
rare I None
autosomal I None
recessive I None
disorder I None
characterized I None
by I None
generalized I None
seizures I None
in I None
the I None
first I None
hours I None
of I None
life I None
and I None
responding I None
only I None
to I None
pyridoxine I CHEMICAL
hydrochloride O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
pathogenesis I None
of I None
PDE I None
is I None
unknown I None
, I None
but I None
an I None
alteration I None
in I None
the I None
binding I None
of I None
pyridoxal I CHEMICAL
5 O CHEMICAL
- O CHEMICAL
phosphate O CHEMICAL
to I None
glutamic I GENE-N
acid O GENE-N
decarboxylase O GENE-N
( I None
GAD I GENE-N
) I None
has I None
been I None
postulated I None
in I None
patients I None
with I None
PDE I None
. I None
<eof> I None

<s> O None
Results I None
are I None
reported I None
for I None
genetic I None
linkage I None
analyses I None
in I None
four I None
families I None
with I None
consanguineous I None
parents I None
and I None
in I None
one I None
family I None
with I None
nonconsanguineous I None
parents I None
. I None
<eof> I None

<s> O None
The I None
GAD1 I GENE-Y
( I None
2q31 I None
) I None
and I None
GAD2 I GENE-Y
genes I None
( I None
10p23 I None
) I None
were I None
tested I None
and I None
excluded I None
. I None
<eof> I None

<s> O None
A I None
genomewide I None
search I None
was I None
subsequently I None
performed I None
, I None
using I None
microsatellite I None
markers I None
at I None
an I None
average I None
distance I None
of I None
10 I None
cM I None
, I None
and I None
the I None
search I None
revealed I None
linkage I None
of I None
the I None
disease I None
- I None
causing I None
gene I None
to I None
markers I None
on I None
chromosome I None
5q31 I None
. I None
2 I None
- I None
q31 I None
. I None
3 I None
( I None
maximum I None
LOD I None
score I None
[ I None
Z I None
( I None
max I None
) I None
] I None
8 I None
. I None
43 I None
at I None
recombination I None
fraction I None
[ I None
theta I None
] I None
0 I None
and I None
Zmax I None
= I None
7 I None
. I None
58 I None
at I None
straight I None
theta I None
= I None
0 I None
at I None
loci I None
D5S2017 I None
and I None
D5S1972 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
A I None
recombination I None
event I None
, I None
between I None
loci I None
D5S638 I None
and I None
D5S463 I None
, I None
in I None
one I None
family I None
defined I None
the I None
distal I None
boundary I None
, I None
and I None
a I None
second I None
recombination I None
event I None
between I None
loci I None
D5S2011 I None
and I None
D5S2017 I None
in I None
another I None
family I None
defined I None
the I None
proximal I None
boundary I None
of I None
the I None
genetic I None
interval I None
encompassing I None
the I None
PDE I None
gene I None
( I None
5 I None
. I None
1 I None
cM I None
) I None
. I None
<eof> I None

<s> O None
Ongoing I None
studies I None
may I None
lead I None
to I None
the I None
identification I None
of I None
the I None
disease I None
- I None
causing I None
gene I None
. I None
<eof> I None

<s> O None
Serotonin I GENE-Y
transporter O GENE-Y
gene I None
regulatory I None
region I None
polymorphism I None
( I None
5 I GENE-Y
- O GENE-Y
HTTLPR O GENE-Y
) I None
, I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
paroxetine O CHEMICAL
binding I None
in I None
healthy I None
control I None
subjects I None
and I None
alcohol I None
- I None
dependent I None
patients I None
and I None
their I None
relationships I None
to I None
impulsivity I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
investigate I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
paroxetine O CHEMICAL
binding I None
and I None
impulsivity I None
in I None
alcohol I CHEMICAL
- I None
dependent I None
and I None
age I None
- I None
matched I None
control I None
subjects I None
in I None
relation I None
to I None
a I None
5 I None
' I None
- I None
promoter I None
region I None
serotonin I GENE-Y
transporter O GENE-Y
( I None
5 I GENE-Y
- O GENE-Y
HTT O GENE-Y
) I None
polymorphism I None
( I None
5 I GENE-Y
- O GENE-Y
HTTLPR O GENE-Y
) I None
. I None
<eof> I None

<s> O None
Alcohol I None
- I None
dependent I None
subjects I None
were I None
hypothesized I None
to I None
show I None
a I None
decreased I None
number I None
of I None
bindings I None
sites I None
and I None
a I None
lower I None
dissociation I None
constant I None
. I None
<eof> I None

<s> O None
5 I GENE-Y
- O GENE-Y
HTTLPR O GENE-Y
S I None
- I None
genotype I None
carriers I None
in I None
both I None
alcohol I CHEMICAL
- I None
dependent I None
and I None
control I None
subjects I None
were I None
expected I None
to I None
show I None
significantly I None
fewer I None
binding I None
sites I None
and I None
a I None
lower I None
dissociation I None
constant I None
. I None
<eof> I None

<s> O None
Influences I None
of I None
impulsive I None
traits I None
, I None
chronic I None
daily I None
alcohol I CHEMICAL
intake I None
, I None
duration I None
of I None
alcohol I CHEMICAL
dependence I None
, I None
age I None
of I None
onset I None
and I None
age I None
on I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
paroxetine O CHEMICAL
binding I None
were I None
also I None
investigated I None
. I None
<eof> I None

<s> O None
Inpatients I None
meeting I None
DSM I None
IV I None
alcohol I CHEMICAL
dependence I None
criteria I None
and I None
of I None
German I None
descent I None
were I None
recruited I None
to I None
avoid I None
ethnic I None
stratification I None
effects I None
. I None
<eof> I None

<s> O None
One I None
hundred I None
and I None
seventeen I None
control I None
subjects I None
of I None
similar I None
social I None
status I None
were I None
recruited I None
from I None
a I None
town I None
community I None
. I None
<eof> I None

<s> O None
Blood I None
samples I None
were I None
taken I None
from I None
both I None
alcohol I CHEMICAL
- I None
dependent I None
and I None
control I None
subjects I None
to I None
determine I None
5 I GENE-Y
- O GENE-Y
HTTLPR O GENE-Y
genotypes I None
using I None
PCR I None
of I None
lymphocyte I None
DNA I None
, I None
and I None
to I None
perform I None
platelet I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
paroxetine O CHEMICAL
binding I None
( I None
binding I None
capacity I None
: I None
B I None
( I None
max I None
) I None
; I None
and I None
dissociation I None
constant I None
: I None
K I None
( I None
D I None
) I None
) I None
. I None
<eof> I None

<s> O None
Impulsivity I None
was I None
assessed I None
using I None
the I None
Barratt I None
impulsiveness I None
scale I None
version I None
5 I None
( I None
BIS I None
- I None
5 I None
) I None
in I None
alcohol I CHEMICAL
- I None
dependent I None
subjects I None
only I None
. I None
<eof> I None

<s> O None
Alcohol I CHEMICAL
- I None
dependent I None
subjects I None
were I None
subdivided I None
into I None
low I None
or I None
high I None
impulsivity I None
groups I None
using I None
a I None
median I None
- I None
split I None
of I None
the I None
BIS I None
- I None
5 I None
scale I None
. I None
<eof> I None

<s> O None
The I None
control I None
group I None
was I None
slightly I None
older I None
than I None
the I None
alcohol I None
- I None
dependent I None
group I None
( I None
not I None
statistically I None
significant I None
) I None
. I None
<eof> I None

<s> O None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
paroxetine O CHEMICAL
binding I None
was I None
investigated I None
in I None
72 I None
control I None
subjects I None
and I None
72 I None
patients I None
, I None
of I None
which I None
five I None
patients I None
met I None
type I None
2 I None
alcohol I CHEMICAL
dependence I None
criteria I None
. I None
<eof> I None

<s> O None
Genotyping I None
was I None
carried I None
out I None
in I None
all I None
patients I None
and I None
control I None
subjects I None
. I None
<eof> I None

<s> O None
A I None
significant I None
influence I None
of I None
duration I None
of I None
alcohol I CHEMICAL
dependence I None
was I None
found I None
on I None
the I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
paroxetine O CHEMICAL
binding I None
K I None
( I None
D I None
) I None
but I None
not I None
B I None
( I None
max I None
. I None
) I None
Neither I None
alcohol I CHEMICAL
- I None
dependent I None
nor I None
control I None
subjects I None
showed I None
any I None
differences I None
in I None
B I None
( I None
max I None
) I None
or I None
K I None
( I None
D I None
) I None
. I None
<eof> I None

<s> O None
S I None
- I None
allele I None
carriers I None
did I None
not I None
show I None
a I None
decreased I None
binding I None
or I None
lower I None
dissociation I None
constant I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
no I None
significant I None
interaction I None
between I None
B I None
( I None
max I None
) I None
and I None
K I None
( I None
D I None
) I None
with I None
either I None
5 I GENE-Y
- O GENE-Y
HTTLPR O GENE-Y
genotype I None
or I None
impulsivity I None
was I None
revealed I None
. I None
<eof> I None

<s> O None
This I None
was I None
the I None
first I None
study I None
to I None
investigate I None
platelet I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
paroxetine O CHEMICAL
binding I None
in I None
alcohol I CHEMICAL
- I None
dependent I None
and I None
age I None
- I None
matched I None
control I None
subjects I None
in I None
relation I None
to I None
the I None
5 I GENE-Y
- O GENE-Y
HTTLPR O GENE-Y
genotype I None
. I None
<eof> I None

<s> O None
No I None
differences I None
concerning I None
5 I GENE-Y
- O GENE-Y
HTTLPR O GENE-Y
- I None
alleles I None
were I None
found I None
in I None
these I None
groups I None
Furthermore I None
, I None
no I None
significant I None
interaction I None
between I None
these I None
parameters I None
and I None
impulsivity I None
was I None
shown I None
in I None
alcohol I CHEMICAL
- I None
dependent I None
subjects I None
. I None
<eof> I None

<s> O None
These I None
results I None
do I None
not I None
support I None
previous I None
results I None
of I None
altered I None
[ I CHEMICAL
3H O CHEMICAL
] O CHEMICAL
paroxetine O CHEMICAL
binding I None
sites I None
in I None
alcohol I None
- I None
dependent I None
subjects I None
or I None
5 I GENE-Y
- O GENE-Y
HTTLPR O GENE-Y
S I None
- I None
allele I None
carriers I None
. I None
<eof> I None

<s> O None
K I None
( I None
D I None
) I None
might I None
be I None
influenced I None
by I None
duration I None
of I None
alcohol I CHEMICAL
dependence I None
, I None
but I None
not I None
sufficiently I None
to I None
yield I None
differences I None
between I None
alcohol I CHEMICAL
- I None
dependent I None
and I None
control I None
subjects I None
. I None
<eof> I None

<s> O None
Entacapone I CHEMICAL
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
To I None
introduce I None
entacapone I CHEMICAL
, I None
a I None
new I None
catechol I GENE-Y
- O GENE-Y
O O GENE-Y
- O GENE-Y
methyltransferase O GENE-Y
inhibitor I None
, I None
and I None
discuss I None
its I None
pharmacology I None
, I None
pharmacodynamics I None
, I None
pharmacokinetics I None
, I None
clinical I None
efficacy I None
, I None
drug I None
interactions I None
, I None
adverse I None
events I None
, I None
dosage I None
guidelines I None
, I None
and I None
therapeutic I None
and I None
formulary I None
considerations I None
. I None
<eof> I None

<s> O None
DATA I None
SOURCE I None
: I None
A I None
MEDLINE I None
database I None
search I None
( I None
1966 I None
- I None
December I None
1999 I None
) I None
was I None
performed I None
to I None
identify I None
relevant I None
English I None
- I None
language I None
articles I None
including I None
recent I None
studies I None
, I None
abstracts I None
, I None
and I None
reviews I None
. I None
<eof> I None

<s> O None
Search I None
terms I None
included I None
entacapone I CHEMICAL
, I None
OR I CHEMICAL
- O CHEMICAL
611 O CHEMICAL
, I None
catechol I GENE-Y
- O GENE-Y
O O GENE-Y
- O GENE-Y
methyltransferase O GENE-Y
inhibitor I None
, I None
and I None
Parkinson I None
' I None
s I None
disease I None
. I None
<eof> I None

<s> O None
STUDY I None
SELECTION I None
: I None
Relevant I None
published I None
human I None
studies I None
were I None
chosen I None
to I None
summarize I None
the I None
pharmacokinetics I None
, I None
clinical I None
efficacy I None
, I None
adverse I None
effects I None
, I None
and I None
drug I None
interactions I None
. I None
<eof> I None

<s> O None
DATA I None
EXTRACTION I None
: I None
All I None
available I None
human I None
clinical I None
trials I None
were I None
reviewed I None
. I None
<eof> I None

<s> O None
DATA I None
SYNTHESIS I None
: I None
Entacapone I CHEMICAL
is I None
the I None
second I None
medication I None
of I None
a I None
new I None
class I None
of I None
drugs I None
, I None
the I None
catechol I GENE-Y
- O GENE-Y
O O GENE-Y
- O GENE-Y
methyltransferase O GENE-Y
inhibitors I None
, I None
indicated I None
for I None
clinical I None
use I None
as I None
an I None
adjunct I None
to I None
levodopa I CHEMICAL
/ I None
carbidopa I CHEMICAL
to I None
treat I None
patients I None
with I None
idiopathic I None
Parkinson I None
' I None
s I None
disease I None
who I None
experience I None
the I None
signs I None
and I None
symptoms I None
of I None
end I None
- I None
of I None
- I None
dose I None
wearing I None
- I None
off I None
. I None
<eof> I None

<s> O None
Entacapone I CHEMICAL
in I None
combination I None
with I None
levodopa I CHEMICAL
/ I None
dopa I GENE-Y
decarboxylase O GENE-Y
inhibitor I None
has I None
been I None
shown I None
to I None
increase I None
the I None
AUC I None
of I None
levodopa I CHEMICAL
, I None
which I None
leads I None
to I None
less I None
fluctuation I None
of I None
levodopa I CHEMICAL
plasma I None
concentrations I None
. I None
<eof> I None

<s> O None
Clinically I None
, I None
the I None
duration I None
of I None
motor I None
response I None
to I None
levodopa I CHEMICAL
was I None
prolonged I None
as I None
reflected I None
by I None
an I None
increase I None
in I None
the I None
mean I None
on I None
time I None
. I None
<eof> I None

<s> O None
The I None
addition I None
of I None
entacapone I CHEMICAL
resulted I None
in I None
a I None
decrease I None
in I None
the I None
mean I None
daily I None
dosage I None
of I None
levodopa I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
recommended I None
dosage I None
of I None
entacapone I CHEMICAL
is I None
200 I None
mg I None
administered I None
orally I None
with I None
each I None
dose I None
of I None
levodopa I CHEMICAL
/ I None
carbidopa I CHEMICAL
, I None
up I None
to I None
a I None
maximum I None
of I None
eight I None
doses I None
per I None
day I None
. I None
<eof> I None

<s> O None
Common I None
adverse I None
effects I None
include I None
dyskinesia I None
, I None
nausea I None
, I None
diarrhea I None
, I None
and I None
urine I None
discoloration I None
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
Entacapone I CHEMICAL
should I None
be I None
considered I None
as I None
add I None
- I None
on I None
treatment I None
to I None
levodopa I CHEMICAL
/ I None
carbidopa I CHEMICAL
in I None
Parkinson I None
' I None
s I None
disease I None
patients I None
with I None
end I None
- I None
of I None
- I None
dose I None
wearing I None
- I None
off I None
effect I None
. I None
<eof> I None

<s> O None
Bupropion I CHEMICAL
is I None
a I None
nicotinic I None
antagonist I None
. I None
<eof> I None

<s> O None
Neuronal I GENE-N
nicotinic O GENE-N
receptors O GENE-N
are I None
ligand I GENE-N
- O GENE-N
gated O GENE-N
ion O GENE-N
channels O GENE-N
of I None
the I None
central I None
and I None
peripheral I None
central I None
nervous I None
system I None
that I None
regulate I None
synaptic I None
activity I None
from I None
both I None
pre I None
- I None
and I None
postsynaptic I None
sites I None
. I None
<eof> I None

<s> O None
The I None
present I None
study I None
establishes I None
the I None
acute I None
interaction I None
of I None
bupropion I CHEMICAL
, I None
an I None
antidepressant I None
agent I None
that I None
is I None
also I None
effective I None
in I None
nicotine I None
dependence I None
, I None
with I None
nicotine I CHEMICAL
and I None
nicotinic I None
receptors I None
using I None
different I None
in I None
vivo I None
and I None
in I None
vitro I None
tests I None
. I None
<eof> I None

<s> O None
Bupropion I CHEMICAL
was I None
found I None
to I None
block I None
nicotine I None
' I None
s I None
antinociception I None
( I None
in I None
two I None
tests I None
) I None
, I None
motor I None
effects I None
, I None
hypothermia I None
, I None
and I None
convulsive I None
effects I None
with I None
different I None
potencies I None
in I None
the I None
present I None
investigation I None
, I None
suggesting I None
that I None
bupropion I CHEMICAL
possesses I None
some I None
selectivity I None
for I None
neuronal I None
nicotinic I None
receptors I None
underlying I None
these I None
various I None
nicotinic I None
effects I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
bupropion I CHEMICAL
blocks I None
nicotine I CHEMICAL
activation I None
of I None
alpha I GENE-N
( O GENE-N
3 O GENE-N
) O GENE-N
beta O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
, O GENE-N
alpha O GENE-N
( O GENE-N
4 O GENE-N
) O GENE-N
beta O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
, O GENE-N
and O GENE-N
alpha O GENE-N
( O GENE-N
7 O GENE-N
) O GENE-N
neuronal O GENE-N
acetylcholine O GENE-N
nicotinic O GENE-N
receptors O GENE-N
( I None
nAChRs I GENE-N
) I None
with I None
some I None
degree I None
of I None
selectivity I None
. I None
<eof> I None

<s> O None
It I None
was I None
approximately I None
50 I None
and I None
12 I None
times I None
more I None
effective I None
in I None
blocking I None
alpha I None
( I None
3 I None
) I None
beta I None
( I None
2 I None
) I None
and I None
alpha I None
( I None
4 I None
) I None
beta I None
( I None
2 I None
) I None
than I None
alpha I None
( I None
7 I None
. I None
) I None
This I None
functional I None
blockade I None
was I None
noncompetitive I None
, I None
because I None
it I None
was I None
insurmountable I None
by I None
increasing I None
concentration I None
of I None
ACh I None
in I None
the I None
nAChRs I GENE-N
subtypes I None
tested I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
bupropion I CHEMICAL
at I None
high I None
concentration I None
failed I None
to I None
displace I None
brain I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
nicotine O CHEMICAL
binding I None
sites I None
, I None
a I None
site I None
largely I None
composed I None
of I None
alpha I None
( I None
4 I None
) I None
beta I None
( I None
2 I None
) I None
subunit I None
combination I None
. I None
<eof> I None

<s> O None
Given I None
the I None
observation I None
that I None
bupropion I CHEMICAL
inhibition I None
of I None
alpha I GENE-N
( O GENE-N
3 O GENE-N
) O GENE-N
beta O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
and O GENE-N
alpha O GENE-N
( O GENE-N
4 O GENE-N
) O GENE-N
beta O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
receptors O GENE-N
exhibits I None
voltage I None
- I None
independence I None
properties I None
, I None
bupropion I CHEMICAL
may I None
not I None
be I None
acting I None
as I None
an I None
open I None
channel I None
blocker I None
. I None
<eof> I None

<s> O None
These I None
effects I None
may I None
explain I None
in I None
part I None
bupropion I None
' I None
s I None
efficacy I None
in I None
nicotine I None
dependence I None
. I None
<eof> I None

<s> O None
Our I None
present I None
findings I None
suggest I None
that I None
functional I None
blockade I None
of I None
neuronal I GENE-N
nAChRs O GENE-N
are I None
useful I None
in I None
nicotine I CHEMICAL
dependence I None
treatment I None
. I None
<eof> I None

<s> O None
A I None
novel I None
hepatointestinal I None
leukotriene I GENE-N
B4 O GENE-N
receptor O GENE-N
. I None
<eof> I None

<s> O None
Cloning I None
and I None
functional I None
characterization I None
. I None
<eof> I None

<s> O None
Leukotriene I CHEMICAL
B O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
( I None
LTB I CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
) I None
is I None
a I None
product I None
of I None
eicosanoid I None
metabolism I None
and I None
acts I None
as I None
an I None
extremely I None
potent I None
chemotactic I None
mediator I None
for I None
inflammation I None
. I None
<eof> I None

<s> O None
LTB I CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
exerts I None
positive I None
effects I None
on I None
the I None
immigration I None
and I None
activation I None
of I None
leukocytes I None
. I None
<eof> I None

<s> O None
These I None
effects I None
suggest I None
an I None
involvement I None
of I None
LTB I CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
in I None
several I None
diseases I None
: I None
inflammatory I None
bowel I None
disease I None
, I None
psoriasis I None
, I None
arthritis I None
, I None
and I None
asthma I None
. I None
<eof> I None

<s> O None
LTB I CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
elicits I None
actions I None
through I None
interaction I None
with I None
one I None
or I None
more I None
cell I None
surface I None
receptors I None
that I None
lead I None
to I None
chemotaxis I None
and I None
inflammation I None
. I None
<eof> I None

<s> O None
One I None
leukotriene I GENE-N
B O GENE-N
( O GENE-N
4 O GENE-N
) O GENE-N
receptor O GENE-N
has I None
been I None
recently I None
identified I None
( I None
LTB I GENE-Y
( O GENE-Y
4 O GENE-Y
) O GENE-Y
- O GENE-Y
R1 O GENE-Y
) I None
. I None
<eof> I None

<s> O None
In I None
this I None
report I None
we I None
describe I None
cloning I None
of I None
a I None
cDNA I None
encoding I None
a I None
novel I None
358 I None
- I None
amino I CHEMICAL
acid O CHEMICAL
receptor I None
( I None
LTB I GENE-Y
( O GENE-Y
4 O GENE-Y
) O GENE-Y
- O GENE-Y
R2 O GENE-Y
) I None
that I None
possesses I None
seven I None
membrane I GENE-N
- O GENE-N
spanning O GENE-N
domains O GENE-N
and I None
is I None
homologous I None
( I None
42 I None
% I None
) I None
and I None
genetically I None
linked I None
to I None
LTB I GENE-Y
( O GENE-Y
4 O GENE-Y
) O GENE-Y
- O GENE-Y
R1 O GENE-Y
. I None
<eof> I None

<s> O None
Expression I None
of I None
LTB I GENE-Y
( O GENE-Y
4 O GENE-Y
) O GENE-Y
- O GENE-Y
R2 O GENE-Y
is I None
broad I None
but I None
highest I None
in I None
liver I None
, I None
intestine I None
, I None
spleen I None
, I None
and I None
kidney I None
. I None
<eof> I None

<s> O None
In I None
radioligand I None
binding I None
assays I None
, I None
membranes I None
prepared I None
from I None
COS I None
- I None
7 I None
cells I None
transfected I None
with I None
LTB I GENE-Y
( O GENE-Y
4 O GENE-Y
) O GENE-Y
- O GENE-Y
R2 O GENE-Y
cDNA I None
displayed I None
high I None
affinity I None
( I None
K I None
( I None
d I None
) I None
= I None
0 I None
. I None
17 I None
nm I None
) I None
for I None
[ I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
H O CHEMICAL
] O CHEMICAL
LTB O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
. I None
<eof> I None

<s> O None
Radioligand I None
competition I None
assays I None
revealed I None
high I None
affinities I None
of I None
the I None
receptor I None
for I None
LTB I CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
and I None
LTB I CHEMICAL
( O CHEMICAL
5 O CHEMICAL
) O CHEMICAL
, I None
and I None
20 I CHEMICAL
- O CHEMICAL
hydroxy O CHEMICAL
- O CHEMICAL
LTB O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
, I None
and I None
intermediate I None
affinities I None
for I None
15 I CHEMICAL
( O CHEMICAL
S O CHEMICAL
) O CHEMICAL
- O CHEMICAL
HETE O CHEMICAL
and I None
12 I CHEMICAL
- O CHEMICAL
oxo O CHEMICAL
- O CHEMICAL
ETE O CHEMICAL
. I None
<eof> I None

<s> O None
Three I None
LTB I GENE-N
( O GENE-N
4 O GENE-N
) O GENE-N
receptor O GENE-N
antagonists I None
, I None
14 I CHEMICAL
, O CHEMICAL
15 O CHEMICAL
- O CHEMICAL
dehydro O CHEMICAL
- O CHEMICAL
LTB O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
, I None
LTB I CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
aminopropylamide O CHEMICAL
, I None
and I None
U I CHEMICAL
- O CHEMICAL
75302 O CHEMICAL
, I None
had I None
high I None
affinity I None
for I None
LTB I GENE-Y
( O GENE-Y
4 O GENE-Y
) O GENE-Y
- O GENE-Y
R1 O GENE-Y
but I None
not I None
for I None
LTB I GENE-Y
( O GENE-Y
4 O GENE-Y
) O GENE-Y
- O GENE-Y
R2 O GENE-Y
. I None
<eof> I None

<s> O None
No I None
apparent I None
affinity I None
binding I None
for I None
the I None
receptors I None
was I None
detected I None
for I None
the I None
CysLT1 I GENE-Y
- I None
selective I None
antagonists I None
montelukast I None
and I None
zafirlukast I None
. I None
<eof> I None

<s> O None
LTB I CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
functionally I None
mobilized I None
intracellular I None
calcium I None
and I None
inhibited I None
forskolin I None
- I None
stimulated I None
cAMP I CHEMICAL
production I None
in I None
293 I None
cells I None
. I None
<eof> I None

<s> O None
The I None
discovery I None
of I None
this I None
new I None
receptor I None
should I None
aid I None
in I None
further I None
understanding I None
the I None
roles I None
of I None
LTB I CHEMICAL
( O CHEMICAL
4 O CHEMICAL
) O CHEMICAL
in I None
pathologies I None
in I None
these I None
tissues I None
and I None
may I None
provide I None
a I None
tool I None
in I None
identification I None
of I None
specific I None
antagonists I None
/ I None
agonists I None
for I None
potential I None
therapeutic I None
treatments I None
. I None
<eof> I None

<s> O None
Arachidonic I CHEMICAL
acid O CHEMICAL
and I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
induce I None
conformational I None
changes I None
in I None
the I None
human I GENE-Y
prostaglandin O GENE-Y
endoperoxide O GENE-Y
H2 O GENE-Y
synthase O GENE-Y
- O GENE-Y
2 O GENE-Y
( I None
cyclooxygenase I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
. I None
<eof> I None

<s> O None
By I None
using I None
the I None
technique I None
of I None
site I None
- I None
directed I None
spin I None
labeling I None
combined I None
with I None
EPR I None
spectroscopy I None
, I None
we I None
have I None
observed I None
that I None
binding I None
of I None
arachidonic I CHEMICAL
acid O CHEMICAL
and I None
nonsteroidal I None
anti I None
- I None
inflammatory I None
drugs I None
induces I None
conformational I None
changes I None
in I None
the I None
human I GENE-N
prostaglandin O GENE-N
endoperoxide O GENE-N
H O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
synthase O GENE-N
enzyme O GENE-N
( I None
PGHS I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
. I None
<eof> I None

<s> O None
Line I None
shape I None
broadening I None
resulting I None
from I None
spin I None
- I None
spin I None
coupling I None
of I None
nitroxide I CHEMICAL
pairs I None
introduced I None
into I None
the I None
membrane I None
- I None
binding I None
helices I None
of I None
PGHS I GENE-Y
- O GENE-Y
2 O GENE-Y
was I None
used I None
to I None
calculate I None
the I None
inter I None
- I None
helical I None
distances I None
and I None
changes I None
in I None
these I None
distances I None
that I None
occur I None
in I None
response I None
to I None
binding I None
various I None
ligands I None
. I None
<eof> I None

<s> O None
The I None
inter I None
- I None
residue I None
distances I None
determined I None
for I None
the I None
PGHS I GENE-Y
- O GENE-Y
2 O GENE-Y
holoenzyme I None
using I None
EPR I None
were I None
1 I None
- I None
7 I None
. I None
9 I None
A I None
shorter I None
than I None
those I None
of I None
the I None
crystal I None
structure I None
of I None
the I None
PGHS I GENE-Y
- O GENE-Y
2 O GENE-Y
holoenzyme I None
. I None
<eof> I None

<s> O None
However I None
, I None
inter I None
- I None
helical I None
distances I None
calculated I None
and I None
determined I None
by I None
EPR I None
for I None
PGHS I GENE-Y
- O GENE-Y
2 O GENE-Y
complexed I None
with I None
arachidonic I CHEMICAL
acid O CHEMICAL
, I None
flurbiprofen I CHEMICAL
, I None
and I None
SC I CHEMICAL
- O CHEMICAL
58125 O CHEMICAL
were I None
in I None
close I None
agreement I None
with I None
those I None
obtained I None
from I None
the I None
cognate I None
crystal I None
structures I None
. I None
<eof> I None

<s> O None
These I None
results I None
indicate I None
that I None
the I None
structure I None
of I None
the I None
solubilized I None
PGHS I GENE-Y
- O GENE-Y
2 O GENE-Y
holoenzyme I None
measured I None
in I None
solution I None
differs I None
from I None
the I None
crystal I None
structure I None
of I None
PGHS I GENE-Y
- O GENE-Y
2 O GENE-Y
holoenzyme I None
obtained I None
by I None
x I None
- I None
ray I None
analysis I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
binding I None
of I None
ligands I None
induces I None
a I None
conformational I None
change I None
in I None
the I None
holo I None
- I None
PGHS I GENE-Y
- O GENE-Y
2 O GENE-Y
, I None
converting I None
it I None
to I None
a I None
structure I None
similar I None
to I None
those I None
obtained I None
by I None
x I None
- I None
ray I None
analysis I None
. I None
<eof> I None

<s> O None
Proteolysis I None
protection I None
assays I None
had I None
previously I None
provided I None
circumstantial I None
evidence I None
that I None
binding I None
of I None
heme I None
and I None
non I None
- I None
steroidal I CHEMICAL
anti I None
- I None
inflammatory I None
drugs I None
alters I None
the I None
conformation I None
of I None
PGHS I GENE-N
, I None
but I None
the I None
present I None
experiments I None
are I None
the I None
first I None
to I None
directly I None
measure I None
such I None
changes I None
. I None
<eof> I None

<s> O None
The I None
finding I None
that I None
arachidonate I CHEMICAL
can I None
also I None
induce I None
a I None
conformational I None
change I None
in I None
PGHS I GENE-Y
- O GENE-Y
2 O GENE-Y
was I None
unexpected I None
, I None
and I None
the I None
magnitude I None
of I None
changes I None
suggests I None
this I None
structural I None
flexibility I None
may I None
be I None
integral I None
to I None
the I None
cyclooxygenase I GENE-N
catalytic I None
mechanism I None
. I None
<eof> I None

<s> O None
A I None
comparison I None
of I None
the I None
effects I None
of I None
etodolac I CHEMICAL
and I None
ibuprofen I CHEMICAL
on I None
renal I None
haemodynamics I None
, I None
tubular I None
function I None
, I None
renin I GENE-Y
, I None
vasopressin I CHEMICAL
and I None
urinary I None
excretion I None
of I None
albumin I GENE-Y
and I None
alpha I GENE-N
- O GENE-N
glutathione O GENE-N
- O GENE-N
S O GENE-N
- O GENE-N
transferase O GENE-N
in I None
healthy I None
subjects I None
: I None
a I None
placebo I None
- I None
controlled I None
cross I None
- I None
over I None
study I None
. I None
<eof> I None

<s> O None
BACKGROUND I None
: I None
Non I None
- I None
steroidal I CHEMICAL
anti I None
- I None
inflammatory I None
drugs I None
( I None
NSAIDs I None
) I None
are I None
known I None
to I None
be I None
potentially I None
nephrotoxic I None
agents I None
. I None
<eof> I None

<s> O None
NSAIDs I None
inhibit I None
the I None
enzyme I None
cyclo I GENE-N
- O GENE-N
oxygenase O GENE-N
and I None
thereby I None
block I None
the I None
prostaglandin I CHEMICAL
synthesis I None
in I None
the I None
kidneys I None
. I None
<eof> I None

<s> O None
Cyclo I GENE-N
- O GENE-N
oxygenase O GENE-N
exists I None
in I None
two I None
isoforms I None
( I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
and I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
) I None
. I None
<eof> I None

<s> O None
It I None
has I None
been I None
proposed I None
that I None
NSAIDs I None
with I None
preferential I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
selectivity I None
have I None
fewer I None
renal I None
side I None
effects I None
than I None
drugs I None
with I None
preferential I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
selectivity I None
. I None
<eof> I None

<s> O None
Etodolac I CHEMICAL
is I None
a I None
relative I None
selective I None
inhibitor I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
, I None
while I None
ibuprofen I CHEMICAL
has I None
a I None
higher I None
potency I None
against I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
than I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
OBJECTIVE I None
: I None
In I None
this I None
study I None
, I None
we I None
compared I None
the I None
effects I None
of I None
etodolac I CHEMICAL
and I None
ibuprofen I CHEMICAL
on I None
renal I None
function I None
, I None
plasma I None
renin I GENE-Y
, I None
plasma I None
arginine I GENE-Y
vasopressin O GENE-Y
and I None
the I None
urinary I None
excretion I None
of I None
albumin I GENE-Y
and I None
alpha I GENE-N
- O GENE-N
glutathione O GENE-N
- O GENE-N
S O GENE-N
- O GENE-N
transferase O GENE-N
( I None
alpha I GENE-N
- O GENE-N
GST O GENE-N
) I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
In I None
a I None
randomised I None
, I None
double I None
- I None
blind I None
, I None
three I None
- I None
way I None
crossover I None
study I None
with I None
placebo I None
, I None
we I None
compared I None
the I None
effects I None
of I None
2 I None
weeks I None
of I None
treatment I None
with I None
ibuprofen I CHEMICAL
and I None
etodolac I CHEMICAL
on I None
renal I None
haemodynamics I None
[ I None
glomerular I None
filtration I None
rate I None
( I None
GFR I None
) I None
, I None
renal I None
plasma I None
flow I None
( I None
RPF I None
) I None
and I None
filtration I None
fraction I None
( I None
FF I None
) I None
] I None
, I None
tubular I None
function I None
and I None
plasma I None
concentrations I None
of I None
the I None
hormones I None
renin I GENE-Y
( I None
PRC I GENE-Y
) I None
and I None
arginine I CHEMICAL
vasopressin O CHEMICAL
( I None
AVP I CHEMICAL
) I None
in I None
18 I None
healthy I None
subjects I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
we I None
examined I None
the I None
effects I None
on I None
the I None
urinary I None
excretion I None
of I None
albumin I GENE-Y
and I None
alpha I GENE-N
- O GENE-N
GST O GENE-N
as I None
markers I None
of I None
renal I None
injury I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
No I None
differences I None
were I None
found I None
between I None
the I None
three I None
treatments I None
, I None
placebo I None
, I None
ibuprofen I CHEMICAL
and I None
etodolac I CHEMICAL
, I None
in I None
the I None
effects I None
on I None
GFR I None
, I None
RPF I None
, I None
FF I None
, I None
free I None
water I None
clearance I None
, I None
urinary I None
output I None
or I None
fractional I None
excretion I None
of I None
potassium I CHEMICAL
and I None
sodium I CHEMICAL
. I None
<eof> I None

<s> O None
However I None
, I None
ibuprofen I CHEMICAL
, I None
in I None
contrast I None
to I None
etodolac I CHEMICAL
, I None
caused I None
a I None
significant I None
decrease I None
in I None
both I None
lithium I CHEMICAL
clearance I None
( I None
- I None
16 I None
% I None
versus I None
placebo I None
) I None
and I None
the I None
fractional I None
excretion I None
of I None
lithium I CHEMICAL
( I None
- I None
17 I None
% I None
versus I None
placebo I None
) I None
, I None
suggesting I None
an I None
increase I None
in I None
the I None
reabsorption I None
in I None
the I None
proximal I None
tubuli I None
. I None
<eof> I None

<s> O None
PRC I GENE-Y
was I None
reduced I None
significantly I None
by I None
ibuprofen I CHEMICAL
( I None
- I None
32 I None
% I None
versus I None
placebo I None
) I None
but I None
not I None
etodolac I CHEMICAL
. I None
<eof> I None

<s> O None
None I None
of I None
the I None
drugs I None
changed I None
AVP I CHEMICAL
. I None
<eof> I None

<s> O None
Fourteen I None
days I None
of I None
treatment I None
with I None
ibuprofen I CHEMICAL
caused I None
a I None
significant I None
decrease I None
( I None
- I None
47 I None
% I None
versus I None
placebo I None
) I None
in I None
the I None
urinary I None
excretion I None
of I None
alpha I GENE-N
- O GENE-N
GST O GENE-N
, I None
while I None
no I None
changes I None
were I None
seen I None
after I None
etodolac I CHEMICAL
. I None
<eof> I None

<s> O None
None I None
of I None
the I None
drugs I None
changed I None
the I None
urinary I None
excretion I None
of I None
albumin I GENE-Y
. I None
<eof> I None

<s> O None
CONCLUSION I None
: I None
In I None
conclusion I None
, I None
a I None
14 I None
- I None
day I None
administration I None
of I None
etodolac I CHEMICAL
or I None
ibuprofen I CHEMICAL
in I None
therapeutic I None
doses I None
did I None
not I None
affect I None
the I None
renal I None
haemodynamics I None
, I None
the I None
net I None
excretion I None
of I None
electrolytes I None
or I None
the I None
urinary I None
excretion I None
of I None
albumin I GENE-Y
in I None
healthy I None
subjects I None
. I None
<eof> I None

<s> O None
However I None
, I None
ibuprofen I CHEMICAL
, I None
in I None
contrast I None
to I None
etodolac I CHEMICAL
, I None
caused I None
a I None
reduction I None
in I None
PRC I GENE-Y
, I None
suggesting I None
that I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
is I None
involved I None
in I None
basal I None
renin I GENE-Y
release I None
in I None
humans I None
. I None
<eof> I None

<s> O None
Furthermore I None
, I None
ibuprofen I CHEMICAL
decreased I None
lithium I CHEMICAL
excretion I None
suggesting I None
that I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
is I None
involved I None
in I None
the I None
re I None
- I None
absorption I None
of I None
sodium I CHEMICAL
and I None
/ I None
or I None
water I None
in I None
the I None
proximal I None
tubuli I None
. I None
<eof> I None

<s> O None
The I None
reduction I None
in I None
the I None
urinary I None
excretion I None
of I None
alpha I GENE-N
- O GENE-N
GST O GENE-N
by I None
ibuprofen I CHEMICAL
may I None
be I None
caused I None
by I None
an I None
inhibition I None
of I None
the I None
detoxification I None
enzyme I None
by I None
ibuprofen I CHEMICAL
. I None
<eof> I None

<s> O None
Overall I None
the I None
study I None
indicates I None
that I None
only I None
small I None
differences I None
in I None
the I None
effects I None
of I None
the I None
two I None
drugs I None
on I None
renal I None
function I None
in I None
healthy I None
subjects I None
exist I None
during I None
a I None
treatment I None
period I None
of I None
2 I None
weeks I None
. I None
<eof> I None

<s> O None
The I None
active I None
- I None
site I None
residue I None
tyr I CHEMICAL
- I None
175 I None
in I None
human I GENE-Y
glyoxalase O GENE-Y
II O GENE-Y
contributes I None
to I None
binding I None
of I None
glutathione I CHEMICAL
derivatives I None
. I None
<eof> I None

<s> O None
Tyrosine I CHEMICAL
- I None
175 I None
located I None
in I None
the I None
active I None
site I None
of I None
human I GENE-Y
glyoxalase O GENE-Y
II O GENE-Y
was I None
replaced I None
by I None
phenylalanine I CHEMICAL
in I None
order I None
to I None
study I None
the I None
contribution I None
of I None
this I None
residue I None
to I None
catalysis I None
. I None
<eof> I None

<s> O None
The I None
mutation I None
had I None
a I None
marginal I None
effect I None
on I None
the I None
k I None
( I None
cat I None
) I None
value I None
determined I None
using I None
S I CHEMICAL
- O CHEMICAL
D O CHEMICAL
- O CHEMICAL
lactoylglutathione O CHEMICAL
as I None
substrate I None
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
Y175F I GENE-N
mutant I None
had I None
an I None
8 I None
- I None
fold I None
higher I None
K I None
( I None
m I None
) I None
value I None
than I None
the I None
wild I None
- I None
type I None
enzyme I None
. I None
<eof> I None

<s> O None
The I None
competitive I None
inhibitor I None
S I CHEMICAL
- O CHEMICAL
( O CHEMICAL
N O CHEMICAL
- O CHEMICAL
hydroxy O CHEMICAL
- O CHEMICAL
N O CHEMICAL
- O CHEMICAL
bromophenylcarbamoyl O CHEMICAL
) O CHEMICAL
glutathione O CHEMICAL
had I None
a I None
30 I None
- I None
fold I None
higher I None
K I None
( I None
i I None
) I None
value I None
towards I None
the I None
mutant I None
, I None
than I None
that I None
of I None
the I None
wild I None
- I None
type I None
. I None
<eof> I None

<s> O None
Pre I None
- I None
equilibrium I None
fluorescence I None
studies I None
with I None
the I None
inhibitor I None
showed I None
that I None
this I None
was I None
due I None
to I None
a I None
significantly I None
increased I None
off I None
- I None
rate I None
for I None
the I None
mutant I None
enzyme I None
. I None
<eof> I None

<s> O None
The I None
phenolic I CHEMICAL
hydroxyl O CHEMICAL
group I None
of I None
tyrosine I CHEMICAL
- I None
175 I None
is I None
within I None
hydrogen I CHEMICAL
bonding I None
distance I None
of I None
the I None
amide I CHEMICAL
nitrogen O CHEMICAL
of I None
the I None
glycine I CHEMICAL
in I None
the I None
glutathione I CHEMICAL
moiety I None
and I None
the I None
present I None
study I None
shows I None
that I None
this I None
interaction I None
makes I None
a I None
significant I None
contribution I None
to I None
the I None
binding I None
of I None
the I None
active I None
- I None
site I None
ligand I None
. I None
<eof> I None

<s> O None
Beneficial I None
renal I None
and I None
hemodynamic I None
effects I None
of I None
omapatrilat I CHEMICAL
in I None
mild I None
and I None
severe I None
heart I None
failure I None
. I None
<eof> I None

<s> O None
Omapatrilat I CHEMICAL
is I None
a I None
member I None
of I None
the I None
new I None
drug I None
class I None
of I None
vasopeptidase I GENE-N
inhibitors I None
that I None
may I None
offer I None
benefit I None
in I None
the I None
treatment I None
of I None
heart I None
failure I None
( I None
HF I None
) I None
through I None
simultaneous I None
inhibition I None
of I None
angiotensin I GENE-Y
- O GENE-Y
converting O GENE-Y
enzyme O GENE-Y
and I None
neutral I GENE-Y
endopeptidase O GENE-Y
. I None
<eof> I None

<s> O None
We I None
examined I None
the I None
effects I None
of I None
omapatrilat I CHEMICAL
in I None
a I None
placebo I None
- I None
controlled I None
crossover I None
study I None
using I None
a I None
pacing I None
model I None
of I None
HF I None
. I None
<eof> I None

<s> O None
Seven I None
sheep I None
were I None
paced I None
sequentially I None
at I None
180 I None
bpm I None
( I None
mild I None
HF I None
) I None
and I None
then I None
225 I None
bpm I None
( I None
severe I None
HF I None
) I None
for I None
7 I None
days I None
each I None
. I None
<eof> I None

<s> O None
Omapatrilat I CHEMICAL
( I None
0 I None
. I None
005 I None
mg I None
/ I None
kg I None
) I None
or I None
vehicle I None
was I None
administered I None
by I None
intravenous I None
bolus I None
on I None
days I None
4 I None
to I None
7 I None
of I None
each I None
paced I None
period I None
. I None
<eof> I None

<s> O None
Omapatrilat I CHEMICAL
lowered I None
mean I None
arterial I None
and I None
left I None
atrial I None
pressure I None
and I None
increased I None
cardiac I None
output I None
acutely I None
and I None
chronically I None
in I None
both I None
mild I None
and I None
severe I None
HF I None
( I None
P I None
< I None
0 I None
. I None
01 I None
for I None
all I None
) I None
. I None
<eof> I None

<s> O None
Plasma I None
atrial I None
and I None
brain I None
natriuretic I GENE-N
peptide O GENE-N
and I None
cGMP I CHEMICAL
levels I None
were I None
stable I None
acutely I None
( I None
P I None
= I None
NS I None
) I None
, I None
while I None
brain I None
natriuretic I GENE-N
peptide O GENE-N
increased I None
after I None
repeated I None
dosing I None
in I None
severe I None
HF I None
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
Plasma I None
renin I GENE-Y
activity I None
rose I None
, I None
whereas I None
angiotensin I CHEMICAL
II O CHEMICAL
and I None
aldosterone I CHEMICAL
levels I None
fell I None
after I None
acute I None
and I None
repeated I None
dosing I None
in I None
both I None
states I None
( I None
P I None
< I None
0 I None
. I None
01 I None
for I None
all I None
) I None
. I None
<eof> I None

<s> O None
Omapatrilat I CHEMICAL
increased I None
urinary I None
sodium I CHEMICAL
excretion I None
by I None
day I None
7 I None
in I None
both I None
mild I None
and I None
severe I None
HF I None
( I None
P I None
< I None
0 I None
. I None
05 I None
) I None
. I None
<eof> I None

<s> O None
Effective I None
renal I None
plasma I None
flow I None
and I None
glomerular I None
filtration I None
rate I None
increased I None
or I None
were I None
stable I None
after I None
omapatrilat I CHEMICAL
in I None
mild I None
and I None
severe I None
HF I None
after I None
both I None
acute I None
and I None
repeated I None
dosing I None
. I None
<eof> I None

<s> O None
Omapatrilat I CHEMICAL
exhibited I None
pronounced I None
acute I None
and I None
sustained I None
beneficial I None
hemodynamic I None
and I None
renal I None
effects I None
in I None
both I None
mild I None
and I None
severe I None
heart I None
failure I None
. I None
<eof> I None

<s> O None
Pharmacological I None
analysis I None
of I None
contractile I None
effects I None
of I None
eletriptan I CHEMICAL
and I None
sumatriptan I CHEMICAL
on I None
human I None
isolated I None
blood I None
vessels I None
. I None
<eof> I None

<s> O None
Eletriptan I CHEMICAL
, I None
a I None
second I None
- I None
generation I None
triptan I CHEMICAL
with I None
high I None
affinity I None
for I None
5 I GENE-N
- O GENE-N
HT O GENE-N
( O GENE-N
1B O GENE-N
/ O GENE-N
1D O GENE-N
) O GENE-N
receptors I None
, I None
is I None
highly I None
effective I None
in I None
migraine I None
, I None
with I None
or I None
without I None
aura I None
. I None
<eof> I None

<s> O None
We I None
compared I None
the I None
effects I None
of I None
eletriptan I CHEMICAL
and I None
sumatriptan I CHEMICAL
on I None
the I None
human I None
isolated I None
middle I None
meningeal I None
and I None
coronary I None
arteries I None
and I None
saphenous I None
vein I None
, I None
used I None
as I None
models I None
for I None
therapeutic I None
efficacy I None
and I None
potential I None
side I None
effects I None
, I None
and I None
have I None
investigated I None
the I None
role I None
of I None
5 I GENE-N
- O GENE-N
HT O GENE-N
( O GENE-N
1B O GENE-N
/ O GENE-N
1D O GENE-N
) O GENE-N
receptors I None
in I None
contractions I None
induced I None
by I None
these I None
triptans I CHEMICAL
. I None
<eof> I None

<s> O None
Concentration I None
- I None
response I None
curves I None
to I None
eletriptan I CHEMICAL
and I None
sumatriptan I CHEMICAL
were I None
constructed I None
in I None
the I None
absence I None
or I None
presence I None
of I None
a I None
selective I None
5 I GENE-N
- O GENE-N
HT O GENE-N
( O GENE-N
1B O GENE-N
/ O GENE-N
1D O GENE-N
) O GENE-N
receptor I None
antagonist I None
, I None
N I CHEMICAL
- O CHEMICAL
[ O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
methoxy O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
methylpiperazin O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
yl O CHEMICAL
) O CHEMICAL
phenyl O CHEMICAL
] O CHEMICAL
- O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
- O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
py O CHEMICAL
rid O CHEMICAL
yl O CHEMICAL
) O CHEMICAL
benzamide O CHEMICAL
( I None
GR125743 I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
All I None
three I None
blood I None
vessels I None
constricted I None
in I None
response I None
to I None
eletriptan I CHEMICAL
and I None
sumatriptan I CHEMICAL
, I None
but I None
the I None
middle I None
meningeal I None
artery I None
relaxed I None
following I None
the I None
highest I None
concentration I None
( I None
100 I None
microM I None
) I None
of I None
eletriptan I CHEMICAL
. I None
<eof> I None

<s> O None
In I None
the I None
middle I None
meningeal I None
artery I None
, I None
GR125743 I CHEMICAL
antagonised I None
the I None
contractions I None
induced I None
by I None
both I None
eletriptan I CHEMICAL
( I None
pEC I None
( I None
50 I None
) I None
: I None
7 I None
. I None
34 I None
+ I None
/ I None
- I None
0 I None
. I None
13 I None
) I None
and I None
sumatriptan I CHEMICAL
( I None
pEC I None
( I None
50 I None
) I None
: I None
6 I None
. I None
91 I None
+ I None
/ I None
- I None
0 I None
. I None
17 I None
) I None
to I None
a I None
similar I None
degree I None
( I None
pA I None
( I None
2 I None
) I None
: I None
8 I None
. I None
81 I None
+ I None
/ I None
- I None
0 I None
. I None
17 I None
and I None
8 I None
. I None
64 I None
+ I None
/ I None
- I None
0 I None
. I None
21 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
In I None
the I None
human I None
coronary I None
artery I None
and I None
saphenous I None
vein I None
, I None
sumatriptan I CHEMICAL
- I None
induced I None
contractions I None
( I None
pEC I None
( I None
50 I None
) I None
: I None
6 I None
. I None
24 I None
+ I None
/ I None
- I None
0 I None
. I None
14 I None
and I None
6 I None
. I None
19 I None
+ I None
/ I None
- I None
0 I None
. I None
12 I None
, I None
respectively I None
) I None
were I None
also I None
potently I None
antagonised I None
by I None
GR125743 I CHEMICAL
( I None
pA I None
( I None
2 I None
) I None
: I None
8 I None
. I None
18 I None
+ I None
/ I None
- I None
0 I None
. I None
27 I None
and I None
8 I None
. I None
34 I None
+ I None
/ I None
- I None
0 I None
. I None
12 I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
The I None
eletriptan I CHEMICAL
- I None
induced I None
contractions I None
of I None
the I None
human I None
saphenous I None
vein I None
( I None
pEC I None
( I None
50 I None
) I None
: I None
6 I None
. I None
09 I None
+ I None
/ I None
- I None
0 I None
. I None
13 I None
) I None
were I None
antagonised I None
less I None
effectively I None
by I None
GR125743 I CHEMICAL
( I None
pK I None
( I None
B I None
) I None
: I None
7 I None
. I None
73 I None
+ I None
/ I None
- I None
0 I None
. I None
18 I None
) I None
, I None
and I None
those I None
of I None
the I None
human I None
coronary I None
artery I None
( I None
pEC I None
( I None
50 I None
) I None
: I None
5 I None
. I None
54 I None
+ I None
/ I None
- I None
0 I None
. I None
22 I None
) I None
remained I None
unaffected I None
by I None
GR125743 I CHEMICAL
up I None
to I None
a I None
concentration I None
of I None
100 I None
nM I None
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
( I None
i I None
) I None
based I None
on I None
the I None
differences I None
in I None
pEC I None
( I None
50 I None
) I None
values I None
, I None
the I None
cranioselectivity I None
of I None
eletriptan I CHEMICAL
( I None
63 I None
- I None
fold I None
) I None
is I None
higher I None
than I None
that I None
of I None
sumatriptan I CHEMICAL
( I None
5 I None
- I None
fold I None
) I None
in I None
coronary I None
artery I None
, I None
( I None
ii I None
) I None
the I None
contractile I None
effects I None
of I None
sumatriptan I CHEMICAL
and I None
eletriptan I CHEMICAL
( I None
lower I None
concentrations I None
) I None
in I None
the I None
three I None
blood I None
vessels I None
are I None
mediated I None
via I None
the I None
5 I GENE-Y
- O GENE-Y
HT O GENE-Y
( O GENE-Y
1B O GENE-Y
) O GENE-Y
receptor I None
, I None
and I None
( I None
iii I None
) I None
additional I None
mechanisms I None
seem I None
to I None
be I None
involved I None
in I None
coronary I None
artery I None
and I None
saphenous I None
vein I None
contractions I None
and I None
middle I None
meningeal I None
artery I None
relaxation I None
following I None
high I None
concentrations I None
of I None
eletriptan I CHEMICAL
. I None
<eof> I None

<s> O None
A I None
comparison I None
of I None
agonist I None
- I None
specific I None
coupling I None
of I None
cloned I None
human I GENE-N
alpha O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
subtypes I None
. I None
<eof> I None

<s> O None
The I None
agonist I None
- I None
specific I None
coupling I None
properties I None
of I None
the I None
three I None
cloned I None
human I GENE-N
alpha O GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
subtypes I None
have I None
been I None
compared I None
, I None
when I None
expressed I None
at I None
similar I None
levels I None
in I None
Chinese I None
hamster I None
ovary I None
( I None
CHO I None
) I None
cell I None
lines I None
, I None
using I None
noradrenaline I CHEMICAL
and I None
( I CHEMICAL
+ O CHEMICAL
/ O CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
meta O CHEMICAL
- O CHEMICAL
octopamine O CHEMICAL
as I None
agonists I None
. I None
<eof> I None

<s> O None
Noradrenaline I CHEMICAL
can I None
couple I None
the I None
receptor I None
to I None
both I None
the I None
inhibition I None
and I None
stimulation I None
of I None
forskolin I CHEMICAL
- I None
stimulated I None
cyclic I CHEMICAL
AMP O CHEMICAL
production I None
in I None
all I None
three I None
receptor I None
subtypes I None
, I None
with I None
the I None
relative I None
strength I None
of I None
the I None
coupling I None
to I None
the I None
pathways I None
varying I None
for I None
each I None
of I None
the I None
receptor I None
subtypes I None
. I None
<eof> I None

<s> O None
meta I CHEMICAL
- O CHEMICAL
Octopamine O CHEMICAL
selectively I None
couples I None
the I None
alpha I GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
only I None
to I None
the I None
inhibition I None
of I None
forskolin I CHEMICAL
- I None
stimulated I None
cyclic I CHEMICAL
AMP O CHEMICAL
production I None
. I None
<eof> I None

<s> O None
However I None
, I None
meta I CHEMICAL
- O CHEMICAL
octopamine O CHEMICAL
couples I None
the I None
alpha I GENE-N
( O GENE-N
2B O GENE-N
) O GENE-N
- O GENE-N
and O GENE-N
alpha O GENE-N
( O GENE-N
2C O GENE-N
) O GENE-N
- O GENE-N
adrenoceptors O GENE-N
to I None
both I None
the I None
inhibition I None
and I None
stimulation I None
of I None
forskolin I CHEMICAL
- I None
stimulated I None
cyclic I CHEMICAL
AMP O CHEMICAL
production I None
. I None
<eof> I None

<s> O None
The I None
relative I None
potency I None
of I None
meta I CHEMICAL
- O CHEMICAL
octopamine O CHEMICAL
to I None
noradrenaline I CHEMICAL
varies I None
between I None
the I None
different I None
alpha I GENE-N
( O GENE-N
2 O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
subtypes I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
meta I CHEMICAL
- O CHEMICAL
octopamine O CHEMICAL
are I None
around I None
two I None
orders I None
of I None
magnitude I None
less I None
potent I None
than I None
those I None
of I None
noradrenaline I CHEMICAL
on I None
both I None
the I None
alpha I GENE-N
( O GENE-N
2A O GENE-N
) O GENE-N
- O GENE-N
and O GENE-N
alpha O GENE-N
( O GENE-N
2B O GENE-N
) O GENE-N
- O GENE-N
adrenoceptor O GENE-N
subtypes I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
in I None
the I None
case I None
of I None
the I None
alpha I GENE-Y
( O GENE-Y
2C O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptor O GENE-Y
, I None
meta I CHEMICAL
- O CHEMICAL
octopamine O CHEMICAL
is I None
only I None
one I None
order I None
of I None
magnitude I None
less I None
potent I None
than I None
noradrenaline I CHEMICAL
in I None
the I None
stimulation I None
of I None
forskolin I CHEMICAL
- I None
stimulated I None
cyclic I CHEMICAL
AMP O CHEMICAL
production I None
and I None
, I None
in I None
addition I None
, I None
is I None
equipotent I None
with I None
noradrenaline I CHEMICAL
in I None
the I None
inhibition I None
of I None
forskolin I CHEMICAL
- I None
stimulated I None
cyclic I CHEMICAL
AMP O CHEMICAL
production I None
and I None
has I None
an I None
increased I None
maximal I None
response I None
. I None
<eof> I None

<s> O None
This I None
raises I None
the I None
possibility I None
that I None
meta I CHEMICAL
- O CHEMICAL
octopamine O CHEMICAL
may I None
have I None
physiologically I None
important I None
actions I None
via I None
alpha I GENE-Y
( O GENE-Y
2C O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptors O GENE-Y
in I None
vivo I None
. I None
<eof> I None

<s> O None
The I None
results I None
show I None
that I None
the I None
modulation I None
of I None
cyclic I CHEMICAL
AMP O CHEMICAL
production I None
occurs I None
in I None
both I None
a I None
subtype I None
- I None
and I None
agonist I None
- I None
specific I None
manner I None
for I None
alpha I GENE-Y
( O GENE-Y
2A O GENE-Y
) O GENE-Y
- O GENE-Y
adrenoceptors O GENE-Y
and I None
in I None
a I None
subtype I None
specific I None
manner I None
for I None
alpha I GENE-N
( O GENE-N
2B O GENE-N
) O GENE-N
- O GENE-N
and O GENE-N
alpha O GENE-N
( O GENE-N
2C O GENE-N
) O GENE-N
- O GENE-N
adrenoceptors O GENE-N
. I None
<eof> I None

<s> O None
Suppression I None
of I None
NF I GENE-N
- O GENE-N
kappaB O GENE-N
activity I None
by I None
sulfasalazine I CHEMICAL
is I None
mediated I None
by I None
direct I None
inhibition I None
of I None
IkappaB I GENE-N
kinases O GENE-N
alpha O GENE-N
and O GENE-N
beta O GENE-N
. I None
<eof> I None

<s> O None
BACKGROUND I None
& I None
AIMS I None
: I None
Activation I None
of I None
NF I GENE-N
- O GENE-N
kappaB O GENE-N
/ I None
Rel I GENE-Y
has I None
been I None
implicated I None
in I None
the I None
pathogenesis I None
of I None
inflammatory I None
bowel I None
disease I None
( I None
IBD I None
) I None
. I None
<eof> I None

<s> O None
Various I None
drugs I None
used I None
in I None
the I None
treatment I None
of I None
IBD I None
, I None
such I None
as I None
glucocorticoids I None
, I None
5 I CHEMICAL
- O CHEMICAL
aminosalicylic O CHEMICAL
acid O CHEMICAL
, I None
and I None
sulfasalazine I CHEMICAL
, I None
interfere I None
with I None
NF I GENE-N
- O GENE-N
kappaB O GENE-N
/ I None
Rel I GENE-Y
signaling I None
. I None
<eof> I None

<s> O None
The I None
aim I None
of I None
this I None
study I None
was I None
to I None
define I None
the I None
molecular I None
mechanism I None
by I None
which I None
sulfasalazine I CHEMICAL
inhibits I None
NF I GENE-N
- O GENE-N
kappaB O GENE-N
activation I None
. I None
<eof> I None

<s> O None
METHODS I None
: I None
The I None
effects I None
of I None
sulfasalazine I CHEMICAL
and I None
its I None
moieties I None
on I None
NF I GENE-N
- O GENE-N
kappaB O GENE-N
signaling I None
were I None
evaluated I None
using I None
electromobility I None
shift I None
, I None
transfection I None
, I None
and I None
immune I None
complex I None
kinase I None
assays I None
. I None
<eof> I None

<s> O None
The I None
direct I None
effect I None
of I None
sulfasalazine I CHEMICAL
on I None
IkappaB I GENE-N
kinase O GENE-N
( I None
IKK I GENE-N
) I None
activity I None
was I None
investigated I None
using I None
purified I None
recombinant I None
IKK I GENE-N
- O GENE-N
alpha O GENE-N
and O GENE-N
- O GENE-N
beta O GENE-N
proteins I None
. I None
<eof> I None

<s> O None
RESULTS I None
: I None
NF I GENE-N
- O GENE-N
kappaB O GENE-N
/ I None
Rel I GENE-Y
activity I None
induced I None
by I None
tumor I GENE-Y
necrosis O GENE-Y
factor O GENE-Y
alpha O GENE-Y
, I None
12 I CHEMICAL
- O CHEMICAL
O O CHEMICAL
- O CHEMICAL
tetradecanoylphorbol O CHEMICAL
- O CHEMICAL
13 O CHEMICAL
- O CHEMICAL
acetate O CHEMICAL
, I None
or I None
overexpression I None
of I None
NF I GENE-Y
- O GENE-Y
kappaB O GENE-Y
- O GENE-Y
inducing O GENE-Y
kinase O GENE-Y
, I None
IKK I GENE-Y
- O GENE-Y
alpha O GENE-Y
, I None
IKK I GENE-Y
- O GENE-Y
beta O GENE-Y
, I None
or I None
constitutively I None
active I None
IKK I GENE-Y
- O GENE-Y
alpha O GENE-Y
and I None
IKK I GENE-Y
- O GENE-Y
beta O GENE-Y
mutants I None
was I None
inhibited I None
dose I None
dependently I None
by I None
sulfasalazine I CHEMICAL
. I None
<eof> I None

<s> O None
Sulfasalazine I CHEMICAL
inhibited I None
tumor I GENE-Y
necrosis O GENE-Y
factor O GENE-Y
alpha O GENE-Y
- I None
induced I None
activation I None
of I None
endogenous I None
IKK I GENE-N
in I None
Jurkat I None
T I None
cells I None
and I None
SW620 I None
colon I None
cells I None
, I None
as I None
well I None
as I None
the I None
catalytic I None
activity I None
of I None
purified I None
IKK I GENE-Y
- O GENE-Y
alpha O GENE-Y
and I None
IKK I GENE-Y
- O GENE-Y
beta O GENE-Y
in I None
vitro I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
the I None
moieties I None
of I None
sulfasalazine I CHEMICAL
, I None
5 I CHEMICAL
- O CHEMICAL
aminosalicylic O CHEMICAL
acid O CHEMICAL
, I None
and I None
sulfapyridine I CHEMICAL
or I None
4 I CHEMICAL
- O CHEMICAL
aminosalicylic O CHEMICAL
acid O CHEMICAL
had I None
no I None
effect I None
. I None
<eof> I None

<s> O None
Activation I None
of I None
extracellular I GENE-N
signal O GENE-N
- O GENE-N
related O GENE-N
kinase O GENE-N
( O GENE-N
ERK O GENE-N
) O GENE-N
1 O GENE-N
and O GENE-N
2 O GENE-N
, I None
c I GENE-Y
- O GENE-Y
Jun O GENE-Y
- O GENE-Y
N O GENE-Y
- O GENE-Y
terminal O GENE-Y
kinase O GENE-Y
( O GENE-Y
JNK O GENE-Y
) O GENE-Y
1 O GENE-Y
, I None
and I None
p38 I GENE-N
was I None
unaffected I None
by I None
sulfasalazine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
decrease I None
in I None
substrate I None
phosphorylation I None
by I None
IKK I GENE-N
- O GENE-N
alpha O GENE-N
and O GENE-N
- O GENE-N
beta O GENE-N
is I None
associated I None
with I None
a I None
decrease I None
in I None
autophosphorylation I None
of I None
IKKs I GENE-N
and I None
can I None
be I None
antagonized I None
by I None
excess I None
adenosine I CHEMICAL
triphosphate O CHEMICAL
. I None
<eof> I None

<s> O None
CONCLUSIONS I None
: I None
These I None
data I None
identify I None
sulfasalazine I CHEMICAL
as I None
a I None
direct I None
inhibitor I None
of I None
IKK I GENE-N
- O GENE-N
alpha O GENE-N
and O GENE-N
- O GENE-N
beta O GENE-N
by I None
antagonizing I None
adenosine I CHEMICAL
triphosphate O CHEMICAL
binding I None
. I None
<eof> I None

<s> O None
The I None
suppression I None
of I None
NF I GENE-N
- O GENE-N
kappaB O GENE-N
activation I None
by I None
inhibition I None
of I None
the I None
IKKs I GENE-N
contributes I None
to I None
the I None
well I None
- I None
known I None
anti I None
- I None
inflammatory I None
and I None
immunosuppressive I None
effects I None
of I None
sulfasalazine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
reactive I None
oxygen I CHEMICAL
species I None
- I None
- I None
and I None
Michael I None
acceptor I None
- I None
inducible I None
human I GENE-N
aldo O GENE-N
- O GENE-N
keto O GENE-N
reductase O GENE-N
AKR1C1 I GENE-Y
reduces I None
the I None
alpha I CHEMICAL
, O CHEMICAL
beta O CHEMICAL
- O CHEMICAL
unsaturated O CHEMICAL
aldehyde O CHEMICAL
4 I CHEMICAL
- O CHEMICAL
hydroxy O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
nonenal O CHEMICAL
to I None
1 I CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
dihydroxy O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
nonene O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
human I GENE-N
aldo O GENE-N
- O GENE-N
keto O GENE-N
reductase O GENE-N
AKR1C1 I GENE-Y
( I None
20alpha I GENE-Y
( O GENE-Y
3alpha O GENE-Y
) O GENE-Y
- O GENE-Y
hydroxysteroid O GENE-Y
dehydrogenase O GENE-Y
) I None
is I None
induced I None
by I None
electrophilic I None
Michael I None
acceptors I None
and I None
reactive I None
oxygen I CHEMICAL
species I None
( I None
ROS I None
) I None
via I None
a I None
presumptive I None
antioxidant I None
response I None
element I None
( I None
Burczynski I None
, I None
M I None
. I None
E I None
. I None
, I None
Lin I None
, I None
H I None
. I None
K I None
. I None
, I None
and I None
Penning I None
, I None
T I None
. I None
M I None
. I None
( I None
1999 I None
) I None
Cancer I None
Res I None
. I None
59 I None
, I None
607 I None
- I None
614 I None
) I None
. I None
<eof> I None

<s> O None
Physiologically I None
, I None
AKR1C1 I GENE-Y
regulates I None
progesterone I CHEMICAL
action I None
by I None
converting I None
the I None
hormone I None
into I None
its I None
inactive I None
metabolite I None
20alpha I CHEMICAL
- O CHEMICAL
hydroxyprogesterone O CHEMICAL
, I None
and I None
toxicologically I None
this I None
enzyme I None
activates I None
polycyclic I CHEMICAL
aromatic O CHEMICAL
hydrocarbon O CHEMICAL
trans I CHEMICAL
- O CHEMICAL
dihydrodiols O CHEMICAL
to I None
redox I None
- I None
cycling I None
o I CHEMICAL
- O CHEMICAL
quinones O CHEMICAL
. I None
<eof> I None

<s> O None
However I None
, I None
the I None
significance I None
of I None
its I None
potent I None
induction I None
by I None
Michael I None
acceptors I None
and I None
oxidative I None
stress I None
is I None
unknown I None
. I None
<eof> I None

<s> O None
4 I CHEMICAL
- O CHEMICAL
Hydroxy O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
nonenal O CHEMICAL
( I None
HNE I CHEMICAL
) I None
and I None
other I None
alpha I CHEMICAL
, O CHEMICAL
beta O CHEMICAL
- O CHEMICAL
unsaturated O CHEMICAL
aldehydes O CHEMICAL
produced I None
during I None
lipid I None
peroxidation I None
were I None
reduced I None
by I None
AKR1C1 I GENE-Y
with I None
high I None
catalytic I None
efficiency I None
. I None
<eof> I None

<s> O None
Kinetic I None
studies I None
revealed I None
that I None
AKR1C1 I GENE-Y
reduced I None
HNE I CHEMICAL
( I None
K I None
( I None
m I None
) I None
= I None
34 I None
microm I None
, I None
k I None
( I None
cat I None
) I None
= I None
8 I None
. I None
8 I None
min I None
( I None
- I None
1 I None
) I None
) I None
with I None
a I None
k I None
( I None
cat I None
) I None
/ I None
K I None
( I None
m I None
) I None
similar I None
to I None
that I None
for I None
20alpha I CHEMICAL
- O CHEMICAL
hydroxysteroids O CHEMICAL
. I None
<eof> I None

<s> O None
Six I None
other I None
homogeneous I None
recombinant I None
AKRs I GENE-N
were I None
examined I None
for I None
their I None
ability I None
to I None
reduce I None
HNE I CHEMICAL
. I None
<eof> I None

<s> O None
Of I None
these I None
, I None
AKR1C1 I GENE-Y
possessed I None
one I None
of I None
the I None
highest I None
specific I None
activities I None
and I None
was I None
the I None
only I None
isoform I None
induced I None
by I None
oxidative I None
stress I None
and I None
by I None
agents I None
that I None
deplete I None
glutathione I CHEMICAL
( I None
ethacrynic I CHEMICAL
acid O CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Several I None
hydroxysteroid I GENE-N
dehydrogenases O GENE-N
of I None
the I None
AKR1C I GENE-Y
subfamily I None
catalyzed I None
the I None
reduction I None
of I None
HNE I CHEMICAL
with I None
higher I None
activity I None
than I None
aldehyde I GENE-N
reductase O GENE-N
( I None
AKR1A1 I GENE-Y
) I None
. I None
<eof> I None

<s> O None
NMR I None
spectroscopy I None
identified I None
the I None
product I None
of I None
the I None
NADPH I None
- I None
dependent I None
reduction I None
of I None
HNE I CHEMICAL
as I None
1 I CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
dihydroxy O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
nonene O CHEMICAL
. I None
<eof> I None

<s> O None
The I None
K I None
( I None
m I None
) I None
of I None
recombinant I None
AKR1C1 I GENE-Y
for I None
nicotinamide I None
cofactors I None
( I None
K I None
( I None
m I None
) I None
NADPH I CHEMICAL
approximately I None
6 I None
microm I None
, I None
K I None
( I None
m I None
) I None
( I None
app I None
) I None
NADH I CHEMICAL
> I None
6 I None
mm I None
) I None
suggested I None
that I None
it I None
is I None
primed I None
for I None
reductive I None
metabolism I None
of I None
HNE I CHEMICAL
. I None
<eof> I None

<s> O None
Isoform I None
- I None
specific I None
reverse I None
transcription I None
- I None
polymerase I None
chain I None
reaction I None
showed I None
that I None
exposure I None
of I None
HepG2 I None
cells I None
to I None
HNE I CHEMICAL
resulted I None
in I None
elevated I None
levels I None
of I None
AKR1C1 I GENE-Y
mRNA I None
. I None
<eof> I None

<s> O None
Thus I None
, I None
HNE I CHEMICAL
induces I None
its I None
own I None
metabolism I None
via I None
AKR1C1 I GENE-Y
, I None
and I None
this I None
enzyme I None
may I None
play I None
a I None
hitherto I None
unrecognized I None
role I None
in I None
a I None
response I None
mounted I None
to I None
counter I None
oxidative I None
stress I None
. I None
<eof> I None

<s> O None
AKRs I GENE-N
represent I None
alternative I None
GSH I CHEMICAL
- I None
independent I None
/ I None
NADPH I CHEMICAL
- I None
dependent I None
routes I None
for I None
the I None
reductive I None
elimination I None
of I None
HNE I CHEMICAL
. I None
<eof> I None

<s> O None
Of I None
these I None
, I None
AKR1C1 I GENE-Y
provides I None
an I None
inducible I None
cytosolic I None
barrier I None
to I None
HNE I CHEMICAL
following I None
ROS I None
exposure I None
. I None
<eof> I None

<s> O None
Stable I None
expression I None
of I None
varied I None
levels I None
of I None
inducible I GENE-Y
nitric O GENE-Y
oxide O GENE-Y
synthase O GENE-Y
in I None
primary I None
cultures I None
of I None
endothelial I None
cells I None
. I None
<eof> I None

<s> O None
Nitric I CHEMICAL
oxide O CHEMICAL
( I None
NO I CHEMICAL
* I None
) I None
, I None
generated I None
by I None
nitric I GENE-N
oxide O GENE-N
synthase O GENE-N
( I None
NOS I GENE-Y
II O GENE-Y
) I None
from I None
immunostimulated I None
cells I None
during I None
infection I None
, I None
plays I None
an I None
important I None
role I None
in I None
host I None
immune I None
defense I None
against I None
microbial I None
invasion I None
. I None
<eof> I None

<s> O None
The I None
impact I None
of I None
different I None
rates I None
of I None
NO I CHEMICAL
* I None
production I None
on I None
host I None
cell I None
function I None
has I None
not I None
been I None
defined I None
. I None
<eof> I None

<s> O None
Herein I None
, I None
we I None
describe I None
the I None
development I None
of I None
a I None
method I None
to I None
express I None
varied I None
levels I None
of I None
murine I GENE-Y
NOS O GENE-Y
II O GENE-Y
in I None
bovine I None
pulmonary I None
artery I None
endothelial I None
cells I None
. I None
<eof> I None

<s> O None
A I None
retroviral I None
vector I None
( I None
pMFGSNOS I None
) I None
encoding I None
NOS I GENE-Y
II O GENE-Y
was I None
used I None
to I None
transduce I None
primary I None
cultures I None
of I None
endothelial I None
cells I None
. I None
<eof> I None

<s> O None
Bovine I None
endothelial I None
cells I None
were I None
susceptible I None
to I None
this I None
transduction I None
and I None
up I None
to I None
18 I None
% I None
of I None
the I None
cells I None
expressed I None
immunodetectable I None
murine I GENE-Y
NOS O GENE-Y
II O GENE-Y
. I None
<eof> I None

<s> O None
The I None
NOS I GENE-Y
II O GENE-Y
- I None
transduced I None
endothelial I None
cells I None
were I None
cultured I None
on I None
the I None
three I None
- I None
dimensional I None
matrix I None
, I None
Gelfoam I None
, I None
for I None
8 I None
- I None
10 I None
days I None
. I None
<eof> I None

<s> O None
Stable I None
expression I None
of I None
NOS I GENE-Y
II O GENE-Y
was I None
assessed I None
by I None
measuring I None
nitrite I CHEMICAL
accumulation I None
in I None
media I None
every I None
2 I None
days I None
. I None
<eof> I None

<s> O None
By I None
day I None
10 I None
, I None
endothelial I None
cells I None
on I None
Gelfoam I None
were I None
found I None
to I None
secrete I None
NO I CHEMICAL
* I None
at I None
a I None
rate I None
exceeding I None
1 I None
. I None
0 I None
microM I None
/ I None
h I None
/ I None
10 I None
( I None
6 I None
) I None
cells I None
, I None
concomitant I None
with I None
an I None
enhanced I None
level I None
of I None
NOS I GENE-Y
II O GENE-Y
activity I None
. I None
<eof> I None

<s> O None
Argininosuccinate I GENE-Y
synthetase O GENE-Y
, I None
a I None
key I None
enzyme I None
in I None
the I None
metabolism I None
of I None
l I CHEMICAL
- O CHEMICAL
citrulline O CHEMICAL
to I None
l I CHEMICAL
- O CHEMICAL
arginine O CHEMICAL
, I None
increased I None
as I None
well I None
, I None
perhaps I None
in I None
response I None
to I None
dimunition I None
of I None
the I None
intracellular I None
arginine I None
pool I None
corresponding I None
to I None
the I None
observed I None
high I None
output I None
of I None
NO I CHEMICAL
* I None
. I None
<eof> I None

<s> O None
In I None
spite I None
of I None
the I None
continuous I None
flux I None
of I None
NO I CHEMICAL
* I None
, I None
endothelial I None
cell I None
viability I None
was I None
not I None
effected I None
. I None
<eof> I None

<s> O None
This I None
system I None
provides I None
the I None
opportunity I None
to I None
assess I None
the I None
impact I None
of I None
different I None
levels I None
of I None
sustained I None
NO I CHEMICAL
* I None
production I None
on I None
endothelial I None
cell I None
physiology I None
. I None
<eof> I None

<s> O None
Effects I None
of I None
eletriptan I CHEMICAL
on I None
the I None
peptidergic I None
innervation I None
of I None
the I None
cerebral I None
dura I None
mater I None
and I None
trigeminal I None
ganglion I None
, I None
and I None
on I None
the I None
expression I None
of I None
c I GENE-Y
- O GENE-Y
fos O GENE-Y
and I None
c I GENE-Y
- O GENE-Y
jun O GENE-Y
in I None
the I None
trigeminal I None
complex I None
of I None
the I None
rat I None
in I None
an I None
experimental I None
migraine I None
model I None
. I None
<eof> I None

<s> O None
Nociceptive I None
axons I None
and I None
terminals I None
in I None
the I None
supratentorial I None
cerebral I None
dura I None
mater I None
display I None
an I None
intense I None
calcitonin I GENE-N
gene O GENE-N
- O GENE-N
related O GENE-N
peptide O GENE-N
( I None
CGRP I GENE-N
) I None
immunoreactivity I None
. I None
<eof> I None

<s> O None
In I None
an I None
experimental I None
migraine I None
model I None
, I None
it I None
has I None
been I None
shown I None
that I None
electrical I None
stimulation I None
of I None
the I None
rat I None
trigeminal I None
ganglion I None
induced I None
an I None
increase I None
in I None
the I None
lengths I None
of I None
CGRP I GENE-N
- I None
immunoreactive I None
axons I None
, I None
increased I None
size I None
and I None
number I None
of I None
pleomorphic I None
axonal I None
varicosities I None
in I None
the I None
dura I None
mater I None
, I None
and I None
an I None
increased I None
number I None
of I None
c I GENE-Y
- O GENE-Y
jun O GENE-Y
and I None
c I GENE-Y
- O GENE-Y
fos O GENE-Y
protein I None
- I None
expressing I None
nerve I None
cells I None
in I None
the I None
trigeminal I None
complex I None
. I None
<eof> I None

<s> O None
We I None
demonstrate I None
the I None
effect I None
of I None
the I None
highly I None
specific I None
and I None
moderately I None
lipophilic I None
serotonin I CHEMICAL
agonist I None
eletriptan I CHEMICAL
( I None
Pfizer I CHEMICAL
) I None
which I None
prevents I None
the I None
effects I None
of I None
electrical I None
stimulation I None
in I None
the I None
dura I None
mater I None
. I None
<eof> I None

<s> O None
Eletriptan I CHEMICAL
also I None
affected I None
the I None
caudal I None
trigeminal I None
complex I None
; I None
it I None
markedly I None
reduced I None
the I None
numbers I None
of I None
the I None
oncoprotein I None
- I None
expressing I None
cells I None
, I None
mainly I None
after I None
stimulation I None
and I None
to I None
some I None
extent I None
also I None
in I None
nonstimulated I None
animals I None
. I None
<eof> I None

<s> O None
Eletriptan I CHEMICAL
also I None
affected I None
expression I None
of I None
CGRP I GENE-N
in I None
perikarya I None
of I None
trigeminal I None
ganglion I None
cells I None
, I None
insofar I None
as I None
the I None
number I None
of I None
small I None
nerve I None
cells I None
exhibiting I None
a I None
compact I None
CGRP I GENE-N
immunoreaction I None
was I None
decreased I None
to I None
one I None
quarter I None
of I None
the I None
original I None
value I None
. I None
<eof> I None

<s> O None
In I None
all I None
these I None
respects I None
, I None
eletriptan I CHEMICAL
acted I None
in I None
a I None
similar I None
way I None
to I None
sumatriptan I CHEMICAL
, I None
with I None
the I None
notable I None
exception I None
that I None
eletriptan I CHEMICAL
also I None
blocked I None
the I None
stimulation I None
- I None
induced I None
effects I None
in I None
the I None
nucleus I None
caudalis I None
trigemini I None
and I None
the I None
upper I None
cervical I None
spinal I None
cord I None
( I None
trigeminal I None
complex I None
) I None
, I None
whereas I None
sumatriptan I CHEMICAL
did I None
not I None
. I None
<eof> I None

<s> O None
It I None
is I None
concluded I None
that I None
eletriptan I CHEMICAL
, I None
acting I None
on I None
perikarya I None
and I None
both I None
the I None
peripheral I None
and I None
the I None
central I None
axon I None
terminals I None
of I None
primary I None
sensory I None
neurons I None
, I None
exerts I None
its I None
antimigraine I CHEMICAL
effect I None
by I None
an I None
agonist I None
action I None
on I None
5 I GENE-N
- O GENE-N
HT1B O GENE-N
/ O GENE-N
1D O GENE-N
receptors O GENE-N
throughout I None
the I None
entire I None
trigeminal I None
system I None
, I None
probably I None
by I None
passing I None
the I None
blood I None
- I None
brain I None
- I None
barrier I None
because I None
of I None
its I None
lipophilic I None
character I None
. I None
<eof> I None

<s> O None
Human I GENE-Y
peptidylarginine O GENE-Y
deiminase O GENE-Y
type O GENE-Y
III O GENE-Y
: I None
molecular I None
cloning I None
and I None
nucleotide I CHEMICAL
sequence I None
of I None
the I None
cDNA I None
, I None
properties I None
of I None
the I None
recombinant I None
enzyme I None
, I None
and I None
immunohistochemical I None
localization I None
in I None
human I None
skin I None
. I None
<eof> I None

<s> O None
Peptidylarginine I GENE-N
deiminase O GENE-N
catalyzes I None
the I None
post I None
- I None
translational I None
modification I None
of I None
proteins I None
through I None
the I None
conversion I None
of I None
arginine I CHEMICAL
to I None
citrulline I CHEMICAL
in I None
the I None
presence I None
of I None
calcium I CHEMICAL
ions I None
. I None
<eof> I None

<s> O None
In I None
rodents I None
, I None
peptidylarginine I GENE-N
deiminase O GENE-N
has I None
been I None
classified I None
into I None
four I None
isoforms I None
, I None
types I None
I I None
, I None
II I None
, I None
III I None
, I None
and I None
IV I None
, I None
which I None
are I None
distinct I None
in I None
their I None
molecular I None
weights I None
, I None
substrate I None
specificities I None
, I None
and I None
tissue I None
localization I None
. I None
<eof> I None

<s> O None
Of I None
these I None
isoforms I None
, I None
only I None
type I None
III I None
was I None
detected I None
in I None
epidermis I None
and I None
hair I None
follicles I None
. I None
<eof> I None

<s> O None
Although I None
the I None
role I None
of I None
this I None
enzyme I None
in I None
these I None
tissues I None
is I None
not I None
yet I None
clear I None
, I None
indirect I None
data I None
have I None
shown I None
that I None
several I None
structural I None
proteins I None
such I None
as I None
filaggrin I GENE-Y
, I None
trichohyalin I GENE-Y
, I None
and I None
keratin I GENE-N
are I None
substrates I None
for I None
peptidylarginine I GENE-N
deiminase O GENE-N
. I None
<eof> I None

<s> O None
In I None
this I None
study I None
, I None
we I None
cloned I None
the I None
full I None
- I None
length I None
cDNA I None
of I None
human I GENE-Y
peptidylarginine O GENE-Y
deiminase O GENE-Y
type O GENE-Y
III O GENE-Y
( I None
3142 I None
bp I None
) I None
from I None
cultured I None
human I None
keratinocytes I None
by I None
reverse I None
transcription I None
- I None
polymerase I None
chain I None
reaction I None
and I None
by I None
rapid I None
amplification I None
of I None
cDNA I None
ends I None
methods I None
. I None
<eof> I None

<s> O None
This I None
cDNA I None
contained I None
a I None
1995 I None
bp I None
open I None
reading I None
frame I None
encoding I None
664 I None
amino I CHEMICAL
acids O CHEMICAL
( I None
Mr I None
= I None
74 I None
770 I None
) I None
. I None
<eof> I None

<s> O None
To I None
explore I None
the I None
physicochemical I None
and I None
enzymatic I None
properties I None
of I None
human I GENE-Y
peptidylarginine O GENE-Y
deiminase O GENE-Y
type O GENE-Y
III O GENE-Y
, I None
we I None
constructed I None
a I None
plasmid I None
for I None
producing I None
a I None
recombinant I None
human I GENE-Y
peptidylarginine O GENE-Y
deiminase O GENE-Y
type O GENE-Y
III O GENE-Y
in I None
bacteria I None
. I None
<eof> I None

<s> O None
The I None
enzymatic I None
characteristics I None
of I None
the I None
recombinant I None
enzyme I None
were I None
very I None
similar I None
to I None
those I None
of I None
the I None
rodent I GENE-Y
peptidylarginine O GENE-Y
deiminase O GENE-Y
type O GENE-Y
III O GENE-Y
. I None
<eof> I None

<s> O None
The I None
recombinant I None
enzyme I None
showed I None
the I None
catalytic I None
activities I None
toward I None
structural I None
proteins I None
of I None
epidermis I None
and I None
hair I None
follicle I None
, I None
filaggrin I GENE-Y
and I None
trichohyalin I GENE-Y
, I None
in I None
which I None
the I None
deiminations I None
maxima I None
of I None
about I None
60 I None
% I None
and I None
13 I None
% I None
arginine I None
residues I None
were I None
observed I None
in I None
filaggrin I GENE-Y
and I None
trichohyalin I GENE-Y
, I None
respectively I None
. I None
<eof> I None

<s> O None
An I None
immunohistochemical I None
study I None
of I None
human I None
scalp I None
skin I None
with I None
a I None
monospecific I None
anti I None
- I None
peptidyl I GENE-Y
- O GENE-Y
arginine O GENE-Y
deiminase O GENE-Y
type O GENE-Y
III O GENE-Y
antibody I None
revealed I None
that I None
the I None
type I None
III I None
enzyme I None
was I None
localized I None
to I None
the I None
inner I None
root I None
sheath I None
and I None
outer I None
root I None
sheath I None
of I None
hair I None
follicles I None
. I None
<eof> I None

<s> O None
Peptidylarginine I GENE-Y
deiminase O GENE-Y
type O GENE-Y
III O GENE-Y
in I None
the I None
inner I None
root I None
sheath I None
was I None
notable I None
between I None
supramatrix I None
and I None
keratogenous I None
zone I None
and I None
was I None
scarcely I None
detected I None
in I None
cornified I None
hair I None
zone I None
. I None
<eof> I None

<s> O None
The I None
enzyme I None
was I None
also I None
expressed I None
in I None
the I None
cuticle I None
layer I None
of I None
hair I None
. I None
<eof> I None

<s> O None
On I None
the I None
other I None
hand I None
, I None
expression I None
of I None
the I None
enzyme I None
in I None
the I None
epidermis I None
was I None
very I None
low I None
. I None
<eof> I None

<s> O None
These I None
data I None
imply I None
that I None
human I GENE-Y
peptidylarginine O GENE-Y
deiminase O GENE-Y
type O GENE-Y
III O GENE-Y
is I None
the I None
predominant I None
isoform I None
in I None
hair I None
follicles I None
and I None
may I None
function I None
as I None
a I None
modulator I None
of I None
hair I None
structural I None
proteins I None
, I None
including I None
trichohyalin I GENE-Y
during I None
hair I None
and I None
hair I None
follicle I None
formation I None
. I None
<eof> I None

<s> O None
Coinduction I None
of I None
inducible I GENE-Y
nitric O GENE-Y
oxide O GENE-Y
synthase O GENE-Y
and I None
arginine I CHEMICAL
recycling I None
enzymes I None
in I None
cytokine I GENE-N
- I None
stimulated I None
PC12 I None
cells I None
and I None
high I None
output I None
production I None
of I None
nitric I CHEMICAL
oxide O CHEMICAL
. I None
<eof> I None

<s> O None
Nitric I CHEMICAL
oxide O CHEMICAL
( I None
NO I CHEMICAL
) I None
is I None
involved I None
in I None
many I None
physiological I None
and I None
pathological I None
processes I None
in I None
the I None
brain I None
. I None
<eof> I None

<s> O None
NO I CHEMICAL
is I None
synthesized I None
from I None
arginine I CHEMICAL
by I None
nitric I GENE-N
oxide O GENE-N
synthase O GENE-N
( I None
NOS I GENE-N
) I None
, I None
and I None
the I None
citrulline I CHEMICAL
generated I None
as I None
a I None
by I None
- I None
product I None
can I None
be I None
recycled I None
to I None
arginine I CHEMICAL
by I None
argininosuccinate I GENE-Y
synthetase O GENE-Y
( I None
AS I GENE-Y
) I None
and I None
argininosuccinate I GENE-Y
lyase O GENE-Y
( I None
AL I GENE-Y
) I None
via I None
the I None
citrulline I CHEMICAL
- I None
NO I CHEMICAL
cycle I None
. I None
<eof> I None

<s> O None
When I None
neuronal I None
PC12 I None
cells I None
differentiated I None
with I None
nerve I GENE-Y
growth O GENE-Y
factor O GENE-Y
were I None
treated I None
with I None
interferon I GENE-Y
- O GENE-Y
gamma O GENE-Y
( I None
IFNgamma I GENE-Y
) I None
and I None
tumor I GENE-Y
necrosis O GENE-Y
factor O GENE-Y
- O GENE-Y
alpha O GENE-Y
( I None
TNFalpha I GENE-Y
) I None
, I None
iNOS I GENE-Y
and I None
AS I GENE-Y
mRNAs I None
and I None
proteins I None
were I None
markedly I None
induced I None
, I None
with I None
AL I GENE-Y
mRNA I None
and I None
protein I None
being I None
weakly I None
induced I None
. I None
<eof> I None

<s> O None
Cationic I GENE-N
amino O GENE-N
acid O GENE-N
transporter O GENE-N
- O GENE-N
1 O GENE-N
and O GENE-N
- O GENE-N
2 O GENE-N
were I None
not I None
induced I None
. I None
<eof> I None

<s> O None
IFNgamma I GENE-Y
or I None
TNFalpha I GENE-Y
alone I None
was I None
ineffective I None
. I None
<eof> I None

<s> O None
A I None
large I None
amount I None
of I None
NO I CHEMICAL
( I None
190 I None
microM I None
NO I CHEMICAL
( O CHEMICAL
2 O CHEMICAL
) O CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
plus I None
NO I CHEMICAL
( O CHEMICAL
3 O CHEMICAL
) O CHEMICAL
( O CHEMICAL
- O CHEMICAL
) O CHEMICAL
in I None
culture I None
medium I None
in I None
24 I None
h I None
) I None
was I None
produced I None
from I None
arginine I CHEMICAL
by I None
cytokine I GENE-N
- I None
stimulated I None
cells I None
, I None
and I None
arginine I CHEMICAL
could I None
be I None
replaced I None
by I None
citrulline I CHEMICAL
. I None
<eof> I None

<s> O None
iNOS I GENE-Y
induction I None
and I None
NO I CHEMICAL
production I None
were I None
attenuated I None
by I None
dexamethasone I CHEMICAL
and I None
dibutyryl I CHEMICAL
cAMP O CHEMICAL
and I None
even I None
more I None
strongly I None
so I None
when I None
combined I None
. I None
<eof> I None

<s> O None
Therefore I None
, I None
a I None
large I None
amount I None
of I None
NO I CHEMICAL
is I None
produced I None
in I None
cytokine I GENE-N
- I None
stimulated I None
PC12 I None
cells I None
following I None
to I None
induction I None
of I None
iNOS I GENE-Y
and I None
citrulline I CHEMICAL
- I None
arginine I CHEMICAL
recycling I None
is I None
important I None
for I None
NO I None
production I None
. I None
<eof> I None

<s> O None
The I None
new I None
cholinesterase I GENE-Y
inhibitors I None
for I None
Alzheimer I None
' I None
s I None
disease I None
, I None
Part I None
1 I None
: I None
their I None
similarities I None
are I None
different I None
. I None
<eof> I None

<s> O None
Three I None
new I None
cholinesterase I GENE-Y
inhibitors I None
, I None
donepezil I CHEMICAL
, I None
rivastigmine I CHEMICAL
, I None
and I None
galantamine I CHEMICAL
, I None
all I None
inhibit I None
the I None
enzyme I None
AChE I GENE-Y
. I None
<eof> I None

<s> O None
Rivastigmine I CHEMICAL
also I None
inhibits I None
BuChE I GENE-Y
, I None
which I None
could I None
lead I None
to I None
additional I None
benefits I None
in I None
late I None
- I None
stage I None
Alzheimer I None
' I None
s I None
disease I None
, I None
but I None
also I None
cause I None
more I None
GI I None
side I None
effects I None
at I None
initiation I None
of I None
therapy I None
. I None
<eof> I None

<s> O None
Galantamine I CHEMICAL
is I None
also I None
an I None
allosteric I None
modulator I None
of I None
nicotinic I GENE-N
receptors O GENE-N
, I None
which I None
could I None
lead I None
to I None
additional I None
efficacy I None
for I None
attention I None
and I None
for I None
behaviors I None
mediated I None
by I None
neurotransmitters I None
other I None
than I None
ACh I None
. I None
<eof> I None

<s> O None
We I None
are I None
now I None
entering I None
an I None
exciting I None
era I None
where I None
the I None
options I None
for I None
treating I None
the I None
devastating I None
illness I None
Alzheimer I None
' I None
s I None
disease I None
are I None
multiplying I None
and I None
creating I None
a I None
foundation I None
upon I None
which I None
new I None
therapies I None
with I None
new I None
mechanisms I None
of I None
action I None
can I None
be I None
built I None
. I None
<eof> I None

<s> O None
Biochemistry I None
of I None
cyclooxygenase I GENE-Y
( O GENE-Y
COX O GENE-Y
) O GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
and I None
molecular I None
pathology I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
in I None
neoplasia I None
. I None
<eof> I None

<s> O None
Several I None
types I None
of I None
human I None
tumors I None
overexpress I None
cyclooxygenase I GENE-Y
( O GENE-Y
COX O GENE-Y
) O GENE-Y
- O GENE-Y
2 O GENE-Y
but I None
not I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
, I None
and I None
gene I None
knockout I None
transfection I None
experiments I None
demonstrate I None
a I None
central I None
role I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
in I None
experimental I None
tumorigenesis I None
. I None
<eof> I None

<s> O None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
produces I None
prostaglandins I CHEMICAL
that I None
inhibit I None
apoptosis I None
and I None
stimulate I None
angiogenesis I None
and I None
invasiveness I None
. I None
<eof> I None

<s> O None
Selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
reduce I None
prostaglandin I CHEMICAL
synthesis I None
, I None
restore I None
apoptosis I None
, I None
and I None
inhibit I None
cancer I None
cell I None
proliferation I None
. I None
<eof> I None

<s> O None
In I None
animal I None
studies I None
they I None
limit I None
carcinogen I None
- I None
induced I None
tumorigenesis I None
. I None
<eof> I None

<s> O None
In I None
contrast I None
, I None
aspirin I CHEMICAL
- I None
like I None
nonselective I None
NSAIDs I None
such I None
as I None
sulindac I CHEMICAL
and I None
indomethacin I CHEMICAL
inhibit I None
not I None
only I None
the I None
enzymatic I None
action I None
of I None
the I None
highly I None
inducible I None
, I None
proinflammatory I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
but I None
the I None
constitutively I None
expressed I None
, I None
cytoprotective I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
as I None
well I None
. I None
<eof> I None

<s> O None
Consequently I None
, I None
nonselective I None
NSAIDs I None
can I None
cause I None
platelet I None
dysfunction I None
, I None
gastrointestinal I None
ulceration I None
, I None
and I None
kidney I None
damage I None
. I None
<eof> I None

<s> O None
For I None
that I None
reason I None
, I None
selective I None
inhibition I None
of I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
to I None
treat I None
neoplastic I None
proliferation I None
is I None
preferable I None
to I None
nonselective I None
inhibition I None
. I None
<eof> I None

<s> O None
Selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
, I None
such I None
as I None
meloxicam I CHEMICAL
, I None
celecoxib I CHEMICAL
( I None
SC I CHEMICAL
- O CHEMICAL
58635 O CHEMICAL
) I None
, I None
and I None
rofecoxib I CHEMICAL
( I None
MK I CHEMICAL
- O CHEMICAL
0966 O CHEMICAL
) I None
, I None
are I None
NSAIDs I None
that I None
have I None
been I None
modified I None
chemically I None
to I None
preferentially I None
inhibit I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
but I None
not I None
COX I GENE-Y
- O GENE-Y
1 O GENE-Y
. I None
<eof> I None

<s> O None
For I None
instance I None
, I None
meloxicam I CHEMICAL
inhibits I None
the I None
growth I None
of I None
cultured I None
colon I None
cancer I None
cells I None
( I None
HCA I None
- I None
7 I None
and I None
Moser I None
- I None
S I None
) I None
that I None
express I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
but I None
has I None
no I None
effect I None
on I None
HCT I None
- I None
116 I None
tumor I None
cells I None
that I None
do I None
not I None
express I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
NS I CHEMICAL
- O CHEMICAL
398 O CHEMICAL
induces I None
apoptosis I None
in I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
expressing I None
LNCaP I None
prostate I None
cancer I None
cells I None
and I None
, I None
surprisingly I None
, I None
in I None
colon I None
cancer I None
S I None
/ I None
KS I None
cells I None
that I None
does I None
not I None
express I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
. I None
<eof> I None

<s> O None
This I None
effect I None
may I None
due I None
to I None
induction I None
of I None
apoptosis I None
through I None
uncoupling I None
of I None
oxidative I None
phosphorylation I None
and I None
down I None
- I None
regulation I None
of I None
Bcl I GENE-Y
- O GENE-Y
2 O GENE-Y
, I None
as I None
has I None
been I None
demonstrated I None
for I None
some I None
nonselective I None
NSAIDs I None
, I None
for I None
instance I None
, I None
flurbiprofen I CHEMICAL
. I None
<eof> I None

<s> O None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
mRNA I None
and I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
protein I None
is I None
constitutively I None
expressed I None
in I None
the I None
kidney I None
, I None
brain I None
, I None
spinal I None
cord I None
, I None
and I None
ductus I None
deferens I None
, I None
and I None
in I None
the I None
uterus I None
during I None
implantation I None
. I None
<eof> I None

<s> O None
In I None
addition I None
, I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
is I None
constitutively I None
and I None
dominantly I None
expressed I None
in I None
the I None
pancreatic I None
islet I None
cells I None
. I None
<eof> I None

<s> O None
These I None
findings I None
might I None
somewhat I None
limit I None
the I None
use I None
of I None
presently I None
available I None
selective I None
COX I GENE-Y
- O GENE-Y
2 O GENE-Y
inhibitors I None
in I None
cancer I None
prevention I None
but I None
will I None
probably I None
not I None
deter I None
their I None
successful I None
application I None
for I None
the I None
treatment I None
of I None
human I None
cancers I None
. I None
<eof> I None

<s> O None
Sulfonylurea I CHEMICAL
sensitivity I None
of I None
adenosine I GENE-N
triphosphate O GENE-N
- O GENE-N
sensitive O GENE-N
potassium O GENE-N
channels O GENE-N
from I None
beta I None
cells I None
and I None
extrapancreatic I None
tissues I None
. I None
<eof> I None

<s> O None
Sulfonylureas I CHEMICAL
are I None
widely I None
used I None
to I None
stimulate I None
insulin I GENE-Y
secretion I None
in I None
type I None
2 I None
diabetic I None
patients I None
because I None
they I None
close I None
adenosine I GENE-N
triphosphate O GENE-N
- O GENE-N
sensitive O GENE-N
potassium O GENE-N
( O GENE-N
K O GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
) O GENE-N
channels O GENE-N
in I None
the I None
pancreatic I None
beta I None
- I None
cell I None
membrane I None
. I None
<eof> I None

<s> O None
This I None
action I None
is I None
mediated I None
by I None
binding I None
of I None
the I None
drug I None
to I None
the I None
sulfonylurea I GENE-N
receptor O GENE-N
( I None
SUR1 I GENE-Y
) I None
subunit I None
of I None
the I None
channel I None
. I None
<eof> I None

<s> O None
K I GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
channels O GENE-N
are I None
also I None
present I None
in I None
a I None
range I None
of I None
extrapancreatic I None
tissues I None
, I None
but I None
many I None
of I None
these I None
contain I None
an I None
alternative I None
type I None
of I None
SUR I GENE-Y
subunit I None
( I None
SUR2A I GENE-Y
in I None
heart I None
and I None
SUR2B I GENE-Y
in I None
smooth I None
muscle I None
) I None
. I None
<eof> I None

<s> O None
The I None
sulfonylurea I CHEMICAL
- I None
sensitivity I None
of I None
K I GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
channels O GENE-N
containing I None
the I None
different I None
types I None
of I None
SUR I GENE-Y
is I None
variable I None
: I None
gliclazide I CHEMICAL
and I None
tolbutamide I CHEMICAL
block I None
the I None
beta I None
cell I None
, I None
but I None
not I None
the I None
cardiac I None
or I None
smooth I None
muscle I None
types I None
of I None
K I GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
channels O GENE-N
with I None
high I None
affinity I None
. I None
<eof> I None

<s> O None
Glibenclamide I CHEMICAL
and I None
glimepiride I CHEMICAL
, I None
on I None
the I None
other I None
hand I None
, I None
block I None
channels I None
containing I None
SUR1 I GENE-Y
and I None
SUR2 I GENE-Y
with I None
similar I None
affinity I None
. I None
<eof> I None

<s> O None
The I None
reversibility I None
of I None
the I None
different I None
sulfonylureas I CHEMICAL
also I None
varies I None
. I None
<eof> I None

<s> O None
Tolbutamide I CHEMICAL
and I None
gliclazide I CHEMICAL
produce I None
a I None
reversible I None
inhibition I None
of I None
Kir6 I GENE-Y
. O GENE-Y
2 O GENE-Y
/ I None
SUR1 I GENE-Y
and I None
Kir6 I GENE-Y
. O GENE-Y
2 O GENE-Y
/ I None
SUR2 I GENE-Y
channels I None
, I None
whereas I None
glibenclamide I CHEMICAL
has I None
a I None
reversible I None
effect I None
on I None
cardiac I None
, I None
but I None
not I None
beta I None
- I None
cell I None
, I None
K I GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
channels O GENE-N
. I None
<eof> I None

<s> O None
In I None
this I None
article I None
, I None
we I None
summarize I None
current I None
knowledge I None
of I None
how I None
sulfonylureas I CHEMICAL
act I None
on I None
K I GENE-N
( O GENE-N
ATP O GENE-N
) O GENE-N
channels O GENE-N
containing I None
the I None
different I None
types I None
of I None
sulfonylurea I GENE-N
receptor O GENE-N
, I None
and I None
discuss I None
the I None
implications I None
of I None
these I None
findings I None
for I None
the I None
use I None
of I None
sulfonylureas I CHEMICAL
in I None
the I None
treatment I None
of I None
diabetes I None
mellitus I None
. I None
<eof> I None

<s> O None
Determination I None
of I None
residues I None
in I None
the I None
norepinephrine I GENE-Y
transporter O GENE-Y
that I None
are I None
critical I None
for I None
tricyclic I CHEMICAL
antidepressant I None
affinity I None
. I None
<eof> I None

<s> O None
The I None
norepinephrine I GENE-N
( O GENE-N
NET O GENE-N
) O GENE-N
and O GENE-N
dopamine O GENE-N
( O GENE-N
DAT O GENE-N
) O GENE-N
transporters O GENE-N
are I None
highly I None
homologous I None
proteins I None
, I None
displaying I None
many I None
pharmacological I None
similarities I None
. I None
<eof> I None

<s> O None
Both I None
transport I None
dopamine I CHEMICAL
with I None
higher I None
affinity I None
than I None
norepinephrine I CHEMICAL
and I None
are I None
targets I None
for I None
the I None
psychostimulants I None
cocaine I CHEMICAL
and I None
amphetamine I CHEMICAL
. I None
<eof> I None

<s> O None
However I None
, I None
they I None
strikingly I None
contrast I None
in I None
their I None
affinities I None
for I None
tricyclic I CHEMICAL
antidepressants I None
( I None
TCA I None
) I None
. I None
<eof> I None

<s> O None
Previous I None
studies I None
, I None
based I None
on I None
chimeric I None
proteins I None
between I None
DAT I GENE-Y
and I None
NET I GENE-Y
suggest I None
that I None
domains I None
ranging I None
from I None
putative I None
transmembrane I None
domain I None
( I None
TMD I None
) I None
5 I None
to I None
8 I None
are I None
involved I None
in I None
the I None
high I None
affinity I None
binding I None
of I None
TCA I None
to I None
NET I GENE-Y
. I None
<eof> I None

<s> O None
We I None
substituted I None
24 I None
amino I CHEMICAL
acids O CHEMICAL
within I None
this I None
region I None
in I None
the I None
human I GENE-Y
NET O GENE-Y
with I None
their I None
counterparts I None
in I None
the I None
human I GENE-Y
DAT O GENE-Y
, I None
resulting I None
in I None
22 I None
different I None
mutants I None
. I None
<eof> I None

<s> O None
Mutations I None
of I None
residues I None
located I None
in I None
extra I None
- I None
or I None
intracytoplasmic I None
loops I None
have I None
no I None
effect I None
on I None
binding I None
affinity I None
of I None
neither I None
TCA I None
nor I None
cocaine I CHEMICAL
. I None
<eof> I None

<s> O None
Three I None
point I None
mutations I None
in I None
TMD6 I None
( I None
F316C I GENE-N
) I None
, I None
- I None
7 I None
( I None
V356S I GENE-N
) I None
, I None
and I None
- I None
8 I None
( I None
G400L I GENE-N
) I None
induced I None
a I None
loss I None
of I None
TCA I None
binding I None
affinity I None
of I None
8 I None
- I None
, I None
5 I None
- I None
, I None
and I None
4 I None
- I None
fold I None
, I None
respectively I None
, I None
without I None
affecting I None
the I None
affinity I None
of I None
cocaine I CHEMICAL
. I None
<eof> I None

<s> O None
The I None
triple I None
mutation I None
F316C I GENE-N
/ I None
V356S I GENE-N
/ I None
G400L I GENE-N
produced I None
a I None
40 I None
- I None
fold I None
shift I None
in I None
desipramine I CHEMICAL
affinity I None
. I None
<eof> I None

<s> O None
These I None
three I None
residues I None
are I None
strongly I None
conserved I None
in I None
all I None
TCA I None
- I None
sensitive I None
transporters I None
cloned I None
in I None
mammalian I None
and I None
nonmammalian I None
species I None
. I None
<eof> I None

<s> O None
A I None
strong I None
shift I None
in I None
TCA I None
affinity I None
( I None
IC I None
( I None
50 I None
) I None
) I None
was I None
also I None
observed I None
for I None
double I None
mutants I None
F316C I GENE-N
/ I None
D336T I GENE-N
( I None
35 I None
- I None
fold I None
) I None
and I None
S399P I GENE-N
/ I None
G400L I GENE-N
( I None
80 I None
- I None
fold I None
for I None
nortriptyline I CHEMICAL
and I None
1000 I None
- I None
fold I None
for I None
desipramine I CHEMICAL
) I None
. I None
<eof> I None

<s> O None
Reverse I None
mutations I None
P401S I GENE-N
/ I None
L402G I GENE-N
in I None
hDAT I None
did I None
not I None
elicit I None
any I None
gain I None
in I None
TCA I None
affinities I None
, I None
whereas I None
C318F I GENE-N
and I None
S358V I GENE-N
resulted I None
in I None
a I None
3 I None
- I None
and I None
10 I None
- I None
fold I None
increase I None
in I None
affinity I None
, I None
respectively I None
. I None
<eof> I None

<s> O None
Our I None
results I None
clearly I None
indicate I None
that I None
two I None
residues I None
located I None
in I None
TMD6 I None
and I None
- I None
7 I None
of I None
hNET I GENE-Y
may I None
play I None
an I None
important I None
role I None
in I None
TCA I None
interaction I None
and I None
that I None
a I None
critical I None
region I None
in I None
TMD8 I None
is I None
likely I None
to I None
be I None
involved I None
in I None
the I None
tertiary I None
structure I None
allowing I None
the I None
high I None
affinity I None
binding I None
of I None
TCA I None
. I None
<eof> I None

<s> O None
Lyprinol I None
: I None
anti I None
- I None
inflammatory I None
and I None
uterine I None
- I None
relaxant I None
activities I None
in I None
rats I None
, I None
with I None
special I None
reference I None
to I None
a I None
model I None
for I None
dysmenorrhoea I None
. I None
<eof> I None

<s> O None
Lyprinol I None
exhibits I None
anti I None
- I None
inflammatory I None
activity I None
distinct I None
from I None
that I None
of I None
most I None
NSAIDs I None
, I None
controlling I None
chronic I None
but I None
not I None
acute I None
inflammation I None
. I None
<eof> I None

<s> O None
Unlike I None
Cox I GENE-Y
- O GENE-Y
1 O GENE-Y
inhibitors I None
( I None
aspirin I CHEMICAL
, I None
meclofenamic I CHEMICAL
acid O CHEMICAL
) I None
it I None
is I None
not I None
gastro I None
- I None
toxic I None
. I None
<eof> I None

<s> O None
Predosing I None
rats I None
with I None
Lyprinol I None
can I None
modify I None
both I None
( I None
i I None
) I None
the I None
spontaneous I None
and I None
( I None
ii I None
) I None
the I None
oxytocin I CHEMICAL
- I None
induced I None
contractions I None
of I None
the I None
uterus I None
. I None
<eof> I None

<s> O None
In I None
humans I None
there I None
is I None
anecdotal I None
evidence I None
that I None
Lyprinol I None
can I None
relieve I None
dysmenorrhea I None
. I None
<eof> I None

<s> O None
This I None
report I None
explores I None
the I None
concept I None
that I None
the I None
uterotrophic I None
actions I None
of I None
Lyprinol I None
are I None
conditioned I None
by I None
: I None
the I None
intrinsic I None
profile I None
of I None
estrogenic I None
hormones I None
and I None
progestagens I CHEMICAL
and I None
, I None
certain I None
extrinsic I None
stimuli I None
. I None
<eof> I None

<s> O None
Evidence I None
from I None
in I None
vitro I None
studies I None
indicates I None
that I None
Lyprinol I None
is I None
not I None
a I None
smooth I None
muscle I None
relaxant I None
and I None
that I None
its I None
uterotrophic I None
mechanism I None
is I None
not I None
that I None
of I None
a I None
cyclo I GENE-N
- O GENE-N
oxygenase O GENE-N
inhibitor I None
, I None
but I None
may I None
mimic I None
that I None
of I None
a I None
leukotriene I GENE-N
receptor O GENE-N
antagonist I None
. I None
<eof> I None

<s> O None
NMDA I CHEMICAL
and I None
glutamate I CHEMICAL
evoke I None
excitotoxicity I None
at I None
distinct I None
cellular I None
locations I None
in I None
rat I None
cortical I None
neurons I None
in I None
vitro I None
. I None
<eof> I None

<s> O None
The I None
development I None
of I None
cortical I None
neurons I None
in I None
vivo I None
and I None
in I None
vitro I None
is I None
accompanied I None
by I None
alterations I None
in I None
NMDA I GENE-N
receptor O GENE-N
subunit I None
expression I None
and I None
concomitant I None
modifications I None
in I None
the I None
pharmacological I None
profile I None
of I None
NMDA I None
- I None
activated I None
ionic I None
currents I None
. I None
<eof> I None

<s> O None
For I None
example I None
, I None
we I None
observed I None
that I None
with I None
decreasing I None
NR2B I GENE-Y
/ I None
NR2A I GENE-Y
subunit I None
expression I None
ratio I None
, I None
the I None
block I None
of I None
NMDA I GENE-N
receptor O GENE-N
- I None
mediated I None
whole I None
- I None
cell I None
responses I None
by I None
the I None
NR2B I GENE-Y
- I None
selective I None
antagonist I None
haloperidol I CHEMICAL
was I None
also I None
decreased I None
. I None
<eof> I None

<s> O None
In I None
mature I None
cultures I None
( I None
> I None
22 I None
d I None
in I None
vitro I None
) I None
, I None
however I None
, I None
NMDA I CHEMICAL
responses I None
obtained I None
from I None
excised I None
nucleated I None
macropatches I None
, I None
which I None
comprised I None
a I None
large I None
portion I None
of I None
the I None
soma I None
, I None
remained I None
strongly I None
antagonized I None
by I None
haloperidol I CHEMICAL
. I None
<eof> I None

<s> O None
These I None
results I None
suggest I None
that I None
in I None
more I None
mature I None
neurons I None
NR1 I GENE-Y
/ I None
NR2B I GENE-Y
receptors I None
appear I None
to I None
be I None
preferentially I None
expressed I None
in I None
the I None
cell I None
body I None
. I None
<eof> I None

<s> O None
As I None
predicted I None
from I None
the I None
whole I None
- I None
cell I None
recording I None
pharmacological I None
profile I None
, I None
NMDA I CHEMICAL
- I None
induced I None
toxicity I None
was I None
largely I None
unaffected I None
by I None
haloperidol I CHEMICAL
in I None
mature I None
cultures I None
. I None
<eof> I None

<s> O None
However I None
, I None
haloperidol I CHEMICAL
effectively I None
blocked I None
glutamate I CHEMICAL
toxicity I None
in I None
the I None
same I None
cultures I None
, I None
suggesting I None
that I None
the I None
neurotoxic I None
actions I None
of I None
this I None
amino I CHEMICAL
acid O CHEMICAL
were I None
mostly I None
due I None
to I None
the I None
activation I None
of I None
somatic I None
NMDA I GENE-N
receptors O GENE-N
. I None
<eof> I None

<s> O None
In I None
experiments I None
in I None
which I None
the I None
potency I None
of I None
glutamate I None
toxicity I None
was I None
increased I None
by I None
the I None
transport I None
inhibitor I None
l I CHEMICAL
- O CHEMICAL
trans O CHEMICAL
- O CHEMICAL
pyrrolidine O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
, O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
dicarboxylic O CHEMICAL
acid O CHEMICAL
, I None
the I None
neuroprotective I None
effects I None
of I None
haloperidol I CHEMICAL
were I None
significantly I None
diminished I None
. I None
<eof> I None

<s> O None
This I None
was I None
likely I None
because I None
of I None
the I None
fact I None
that I None
glutamate I None
, I None
now I None
toxic I None
at I None
much I None
lower I None
concentrations I None
, I None
was I None
able I None
to I None
reach I None
and I None
activate I None
dendritic I None
receptors I None
under I None
these I None
conditions I None
. I None
<eof> I None

<s> O None
These I None
results I None
strongly I None
argue I None
that I None
exogenous I None
glutamate I CHEMICAL
and I None
NMDA I CHEMICAL
normally I None
induce I None
excitotoxicity I None
at I None
distinct I None
cellular I None
locations I None
in I None
mature I None
mixed I None
neuronal I None
cultures I None
and I None
that I None
NR1 I GENE-Y
/ I None
NR2B I GENE-Y
receptors I None
remain I None
an I None
important I None
component I None
in I None
the I None
expression I None
of I None
glutamate I None
, I None
but I None
not I None
NMDA I CHEMICAL
- I None
induced I None
excitotoxicity I None
. I None
<eof> I None

<s> O None
In I None
- I None
vivo I None
assessment I None
of I None
5 I GENE-Y
- O GENE-Y
HT2A O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
antagonistic I None
properties I None
of I None
newer I None
antipsychotics I None
. I None
<eof> I None

<s> O None
The I None
effects I None
of I None
serotonin I GENE-N
( O GENE-N
5 O GENE-N
- O GENE-N
HT O GENE-N
) O GENE-N
receptor O GENE-N
ligands I None
on I None
the I None
MK I CHEMICAL
212 O CHEMICAL
( I None
6 I CHEMICAL
- O CHEMICAL
chloro O CHEMICAL
- O CHEMICAL
2 O CHEMICAL
[ O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
piperazinyl O CHEMICAL
] O CHEMICAL
pyrazine O CHEMICAL
) I None
discriminative I None
stimulus I None
and I None
quipazine I CHEMICAL
- I None
induced I None
head I None
twitches I None
were I None
studied I None
in I None
rats I None
. I None
<eof> I None

<s> O None
5 I GENE-Y
- O GENE-Y
HT1A O GENE-Y
( I None
8 I CHEMICAL
- O CHEMICAL
OH O CHEMICAL
- O CHEMICAL
DPAT O CHEMICAL
) I None
and I None
preferential I None
5 I GENE-Y
- O GENE-Y
HT2A O GENE-Y
( I None
DOI I None
) I None
receptor I None
agonists I None
did I None
not I None
generalize I None
to I None
the I None
discriminative I None
stimulus I None
. I None
<eof> I None

<s> O None
The I None
5 I GENE-N
- O GENE-N
HT2B O GENE-N
/ O GENE-N
2C O GENE-N
- O GENE-N
receptor O GENE-N
antagonist I None
, I None
SB I CHEMICAL
206553 O CHEMICAL
( I None
5 I CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
pyridylcarbamoyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
, O CHEMICAL
2 O CHEMICAL
, O CHEMICAL
3 O CHEMICAL
, O CHEMICAL
5 O CHEMICAL
- O CHEMICAL
tetrahydropyrrolo O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
, O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
f O CHEMICAL
] O CHEMICAL
indole O CHEMICAL
) I None
, I None
and I None
the I None
5 I GENE-N
- O GENE-N
HT2A O GENE-N
/ O GENE-N
2C O GENE-N
- O GENE-N
receptor O GENE-N
antagonist I None
, I None
ritanserin I CHEMICAL
, I None
acted I None
as I None
potent I None
antagonists I None
, I None
whereas I None
the I None
5 I GENE-Y
- O GENE-Y
HT2A O GENE-Y
- I None
receptor I None
antagonist I None
, I None
MDL I CHEMICAL
100 O CHEMICAL
. O CHEMICAL
151 O CHEMICAL
( I None
[ I CHEMICAL
( O CHEMICAL
+ O CHEMICAL
/ O CHEMICAL
- O CHEMICAL
) O CHEMICAL
- O CHEMICAL
alpha O CHEMICAL
- O CHEMICAL
( O CHEMICAL
2 O CHEMICAL
, O CHEMICAL
3 O CHEMICAL
- O CHEMICAL
dimethoxyphenyl O CHEMICAL
) O CHEMICAL
- O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
[ O CHEMICAL
2 O CHEMICAL
- O CHEMICAL
( O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
fluorophenylethyl O CHEMICAL
) O CHEMICAL
] O CHEMICAL
- O CHEMICAL
4 O CHEMICAL
- O CHEMICAL
piperidine O CHEMICAL
- O CHEMICAL
methanol O CHEMICAL
) I None
, I None
produced I None
minor I None
and I None
inconsistent I None
inhibition I None
. I None
<eof> I None

<s> O None
SB I CHEMICAL
206553 O CHEMICAL
was I None
a I None
weak I None
antagonist I None
against I None
quipazine I CHEMICAL
- I None
induced I None
head I None
twitches I None
, I None
whereas I None
MDL I CHEMICAL
100 O CHEMICAL
. O CHEMICAL
151 O CHEMICAL
and I None
ritanserin I CHEMICAL
were I None
potent I None
antagonists I None
. I None
<eof> I None

<s> O None
This I None
suggests I None
that I None
the I None
MK I CHEMICAL
212 O CHEMICAL
discriminative I None
stimulus I None
is I None
mediated I None
by I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
receptors I None
, I None
while I None
quipazine I CHEMICAL
- I None
induced I None
head I None
twitches I None
are I None
mediated I None
primarily I None
by I None
5 I GENE-Y
- O GENE-Y
HT2A O GENE-Y
receptors I None
. I None
<eof> I None

<s> O None
The I None
effects I None
on I None
quipazine I CHEMICAL
- I None
induced I None
head I None
twitches I None
were I None
comparable I None
to I None
previously I None
published I None
effects I None
on I None
the I None
DOI I None
discriminative I None
stimulus I None
. I None
<eof> I None

<s> O None
5 I GENE-Y
- O GENE-Y
HT2A O GENE-Y
- I None
and I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
- I None
receptor I None
antagonistic I None
potencies I None
of I None
clozapine I CHEMICAL
, I None
olanzapine I CHEMICAL
, I None
risperidone I CHEMICAL
, I None
sertindole I CHEMICAL
and I None
ziprasidone I CHEMICAL
were I None
compared I None
in I None
the I None
same I None
models I None
. I None
<eof> I None

<s> O None
Clozapine I CHEMICAL
showed I None
similar I None
potencies I None
in I None
both I None
models I None
, I None
while I None
sertindole I CHEMICAL
, I None
olanzapine I CHEMICAL
and I None
risperidone I CHEMICAL
inhibited I None
quipazine I CHEMICAL
- I None
induced I None
effects I None
more I None
potently I None
than I None
the I None
MK I CHEMICAL
212 O CHEMICAL
discriminative I None
stimulus I None
. I None
<eof> I None

<s> O None
Ziprasidone I CHEMICAL
exerted I None
a I None
minor I None
preference I None
for I None
5 I GENE-Y
- O GENE-Y
HT2A O GENE-Y
- I None
compared I None
to I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
- I None
receptor I None
- I None
mediated I None
effects I None
. I None
<eof> I None

<s> O None
The I None
ratio I None
between I None
in I None
vivo I None
inhibitory I None
potencies I None
at I None
5 I GENE-Y
- O GENE-Y
HT2A O GENE-Y
and I None
5 I GENE-Y
- O GENE-Y
HT2C O GENE-Y
receptors I None
did I None
not I None
correlate I None
with I None
corresponding I None
ratios I None
from I None
in I None
- I None
vitro I None
affinity I None
and I None
ex I None
- I None
vivo I None
occupancy I None
studies I None
in I None
the I None
literature I None
. I None
<eof> I None

<s> O None
The I None
aromatic I GENE-Y
- O GENE-Y
L O GENE-Y
- O GENE-Y
amino O GENE-Y
acid O GENE-Y
decarboxylase O GENE-Y
inhibitor I None
carbidopa I None
is I None
selectively I None
cytotoxic I None
to I None
human I None
pulmonary I None
carcinoid I None
and I None
small I None
cell I None
lung I None
carcinoma I None
cells I None
. I None
<eof> I None

<s> O None
The I None
carcinoid I None
tumor I None
is I None
an I None
uncommon I None
neuroendocrine I None
neoplasm I None
the I None
hallmark I None
of I None
which I None
is I None
excessive I None
serotonin I CHEMICAL
production I None
. I None
<eof> I None

<s> O None
In I None
studying I None
kinetics I None
of I None
tryptophan I GENE-N
hydroxylase O GENE-N
and I None
aromatic I GENE-Y
- O GENE-Y
L O GENE-Y
- O GENE-Y
amino O GENE-Y
acid O GENE-Y
decarboxylase O GENE-Y
( I None
AAAD I GENE-Y
) I None
in I None
human I None
carcinoid I None
hepatic I None
metastases I None
and I None
adjacent I None
normal I None
liver I None
( I None
J I None
. I None
A I None
. I None
Gilbert I None
et I None
al I None
, I None
Biochem I None
. I None
Pharmacol I None
. I None
, I None
50 I None
: I None
845 I None
- I None
850 I None
, I None
1995 I None
) I None
, I None
we I None
identified I None
one I None
significant I None
difference I None
: I None
the I None
Vmax I None
of I None
carcinoid I None
AAAD I GENE-Y
was I None
50 I None
- I None
fold I None
higher I None
than I None
that I None
in I None
normal I None
liver I None
. I None
<eof> I None

<s> O None
Here I None
, I None
we I None
report I None
Western I None
and I None
Northern I None
analyses I None
detecting I None
large I None
quantities I None
of I None
AAAD I GENE-Y
polypeptide I None
and I None
mRNA I None
in I None
human I None
carcinoid I None
primary I None
as I None
well I None
as I None
metastatic I None
tumors I None
compared I None
with I None
normal I None
surrounding I None
tissues I None
. I None
<eof> I None

<s> O None
To I None
assess I None
the I None
feasibility I None
of I None
targeting I None
these I None
high I None
AAAD I GENE-Y
levels I None
for I None
chemotherapy I None
, I None
AAAD I GENE-Y
inhibitors I None
carbidopa I CHEMICAL
( I None
alpha I CHEMICAL
- O CHEMICAL
methyl O CHEMICAL
- O CHEMICAL
dopahydrazine O CHEMICAL
) I None
, I None
alpha I CHEMICAL
- O CHEMICAL
monofluoromethyldopa O CHEMICAL
( I None
MFMD I CHEMICAL
) I None
, I None
and I None
3 I CHEMICAL
- O CHEMICAL
hydroxybenzylhydrazine O CHEMICAL
( I None
NSD I CHEMICAL
- O CHEMICAL
1015 O CHEMICAL
) I None
were I None
incubated I None
( I None
72 I None
h I None
) I None
with I None
NCI I None
- I None
H727 I None
human I None
lung I None
carcinoid I None
cells I None
. I None
<eof> I None

<s> O None
Carbidopa I CHEMICAL
and I None
MFMD I CHEMICAL
were I None
lethal I None
( I None
IC50 I None
= I None
29 I None
+ I None
/ I None
- I None
2 I None
microM I None
and I None
56 I None
+ I None
/ I None
- I None
6 I None
microM I None
, I None
respectively I None
) I None
; I None
NSD I CHEMICAL
- O CHEMICAL
1015 O CHEMICAL
had I None
no I None
effect I None
on I None
proliferation I None
. I None
<eof> I None

<s> O None
On I None
exposure I None
to I None
other I None
human I None
tumor I None
lines I None
, I None
carbidopa I CHEMICAL
was I None
lethal I None
only I None
to I None
NCI I None
- I None
H146 I None
and I None
NCI I None
- I None
H209 I None
small I None
cell I None
lung I None
carcinoma I None
( I None
SCLC I None
) I None
lines I None
( I None
IC50 I None
= I None
12 I None
+ I None
/ I None
- I None
1 I None
microM I None
and I None
22 I None
+ I None
/ I None
- I None
5 I None
microM I None
, I None
respectively I None
) I None
. I None
<eof> I None

<s> O None
Carbidopa I CHEMICAL
( I None
100 I None
microM I None
) I None
decreased I None
growth I None
of I None
( I None
but I None
did I None
not I None
kill I None
) I None
SK I None
- I None
N I None
- I None
SH I None
neuroblastoma I None
and I None
A204 I None
rhabdomyosarcoma I None
cells I None
and I None
did I None
not I None
affect I None
proliferation I None
of I None
DU I None
145 I None
prostate I None
, I None
MCF7 I None
breast I None
, I None
or I None
NCI I None
- I None
H460 I None
large I None
cell I None
lung I None
carcinoma I None
lines I None
. I None
<eof> I None

<s> O None
The I None
rank I None
order I None
of I None
lines I None
by I None
AAAD I GENE-Y
activity I None
was I None
NCI I None
- I None
H146 I None
> I None
NCI I None
- I None
H209 I None
> I None
SK I None
- I None
N I None
- I None
SH I None
> I None
NCI I None
- I None
H727 I None
, I None
whereas I None
A204 I None
, I None
DU I None
145 I None
, I None
MCF7 I None
, I None
and I None
NCI I None
- I None
H460 I None
had I None
no I None
measurable I None
activity I None
. I None
<eof> I None

<s> O None
For I None
lung I None
tumor I None
lines I None
( I None
carcinoid I None
, I None
two I None
SCLC I None
, I None
and I None
one I None
large I None
cell I None
lung I None
carcinoma I None
) I None
, I None
AAAD I GENE-Y
activity I None
was I None
correlated I None
with I None
the I None
potency I None
of I None
carbidopa I CHEMICAL
- I None
induced I None
cytotoxicity I None
. I None
<eof> I None

<s> O None
However I None
, I None
carcinoid I None
cell I None
death I None
was I None
not I None
solely I None
attributable I None
to I None
complete I None
inhibition I None
of I None
either I None
AAAD I GENE-Y
activity I None
or I None
the I None
serotonin I CHEMICAL
synthetic I None
pathway I None
. I None
<eof> I None

<s> O None
In I None
further I None
evaluating I None
potential I None
applications I None
of I None
these I None
findings I None
with I None
carbidopa I CHEMICAL
, I None
we I None
determined I None
that I None
sublethal I None
doses I None
of I None
carbidopa I CHEMICAL
produced I None
additive I None
cytotoxic I None
effects I None
in I None
carcinoid I None
cells I None
in I None
combination I None
with I None
etoposide I None
and I None
cytotoxic I None
synergy I None
in I None
SCLC I None
cells I None
when I None
coincubated I None
with I None
topotecan I CHEMICAL
. I None
<eof> I None

<s> O None
Role I None
of I None
multidrug I GENE-Y
- O GENE-Y
resistance O GENE-Y
protein O GENE-Y
2 O GENE-Y
in I None
glutathione I GENE-Y
S O GENE-Y
- O GENE-Y
transferase O GENE-Y
P1 O GENE-Y
- O GENE-Y
1 O GENE-Y
- I None
mediated I None
resistance I None
to I None
4 I CHEMICAL
- O CHEMICAL
nitroquinoline O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
oxide O CHEMICAL
toxicities I None
in I None
HepG2 I None
cells I None
. I None
<eof> I None

<s> O None
Previous I None
studies I None
in I None
our I None
laboratory I None
have I None
shown I None
that I None
the I None
phase I None
III I None
efflux I GENE-N
transporter O GENE-N
multidrug I GENE-Y
- O GENE-Y
resistance O GENE-Y
protein O GENE-Y
( O GENE-Y
MRP O GENE-Y
) O GENE-Y
1 O GENE-Y
can I None
act I None
synergistically I None
with I None
the I None
phase I None
II I None
conjugating I None
glutathione I GENE-N
S O GENE-N
- O GENE-N
transferases O GENE-N
( I None
GST I GENE-N
) I None
to I None
confer I None
resistance I None
to I None
the I None
toxicities I None
of I None
some I None
electrophilic I None
drugs I None
and I None
carcinogens I None
. I None
<eof> I None

<s> O None
To I None
determine I None
whether I None
the I None
distinct I None
efflux I GENE-N
transporter O GENE-N
MRP2 I GENE-Y
could I None
also I None
potentiate I None
GST I GENE-N
- I None
mediated I None
protection I None
from I None
electrophilic I None
toxins I None
, I None
we I None
examined I None
the I None
effect I None
of I None
regulatable I None
GSTP1 I GENE-Y
- O GENE-Y
1 O GENE-Y
expression I None
in I None
MRP2 I GENE-Y
- I None
rich I None
HepG2 I None
cells I None
on I None
4 I CHEMICAL
- O CHEMICAL
nitroquinoline O CHEMICAL
1 O CHEMICAL
- O CHEMICAL
oxide O CHEMICAL
( I None
4NQO I CHEMICAL
) I None
- I None
induced I None
cytotoxicity I None
and I None
genotoxicity I None
( I None
nucleic I None
- I None
acid I None
adduct I None
formation I None
) I None
. I None
<eof> I None

<s> O None
Expression I None
of I None
GSTP1 I GENE-Y
- O GENE-Y
1 O GENE-Y
was I None
associated I None
with I None
a I None
fourfold I None
to I None
tenfold I None
protection I None
from I None
4NQO I CHEMICAL
- I None
induced I None
cytotoxicity I None
. I None
<eof> I None

<s> O None
Inhibition I None
of I None
MRP2 I GENE-Y
- I None
mediated I None
efflux I None
activity I None
by I None
sulfinpyrazone I None
or I None
cyclosporin I None
A I None
completely I None
reversed I None
GSTP1 I GENE-Y
- O GENE-Y
1 O GENE-Y
- I None
associated I None
resistance I None
- I None
a I None
result I None
indicating I None
that I None
GSTP1 I GENE-Y
- O GENE-Y
1 O GENE-Y
- I None
mediated I None
cytoprotection I None
is I None
absolutely I None
dependent I None
on I None
MRP2 I GENE-Y
efflux I None
activity I None
. I None
<eof> I None

